(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 October 2004 (28.10.2004)

PCT

(10) International Publication Number
WO 2004/092209 A2

(71) Applicant (for all designated States except US): INTER-
CELL AG [AT/AT]; Campus Vienna Biocenter 6, A-1030
Vienna (AT).

(72) Inventors; and
(75) Inventors/Applicants (for US only): MEINKE, Andreas
[DE/AT]; Piettegasse 26/1, A-3013 Pressbaum (AT).
NAGY, Eszter [HU/AT]; Taborstrasse 9, A-1020 Vienna
(AT). HANNER, Markus [AT/AT]; Jacquingasse 5/6,
A-1030 Vienna (AT). DEWASTHALY, Shailesh [IN/AT];
Anschützgasse 23/10, A-1150 Vienna (AT). STIER-
SCHNEIDER, Ulrike [AT/AT]; Kaiserstrasse 66/2/14,
A-1070 Vienna (AT).

(74) Agent: SONN & PARTNER; Riemergasse 14, A-1010
Vienna (AT).

(54) Title: S. PNEUMONIAE ANTIGENS

(57) Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or
a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. pneumoniae, methods for isolating
such antigens and specific uses thereof.

S.PNEUMONIAE ANTIGENS

The present invention relates to isolated nucleic acid molecules, which encode antigens for *Streptococcus pneumoniae*, which are suitable for use in preparation of pharmaceutical medicaments for the prevention and treatment of bacterial infections caused by *Streptococcus pneumoniae*.

Streptococcus pneumoniae (Pneumococcus) is a lancet-shaped, gram-positive, facultative anaerobic bacterium. It is only the encapsulated organism that is pathogenic for humans and experimental animals. Capsules are antigenic and form the basis for classifying pneumococci by serotypes. Ninety serotypes have been identified, based on their reaction with type-specific antisera. Most *S. pneumoniae* serotypes have been shown to cause serious disease, and the ten most common serotypes are estimated to account for about 62% of invasive disease worldwide. The ranking and serotype prevalence differs by age group and geographic area.

Pneumococci are common inhabitants of the respiratory tract, and may be isolated from the nasopharynx of 5% to 70% of normal adults. Rates of asymptomatic carriage vary with age, environment, and the presence of upper respiratory infections. Only 5%-10% of adults without children are carriers. In schools and orphanages, 27% to 58% of students and residents may be carriers. On military installations, as many as 50% to 60% of service personnel may be carriers. The duration of carriage varies and is generally longer in children than adults (reviewed in Epidemiology and Prevention of Vaccine-Preventable Diseases, 7th Edition-Second Printing, The Pink Book).

The relationship of carriage to the development of natural immunity is poorly understood. In addition, the immunologic mechanism that allows disease to occur in a carrier is poorly understood.

Streptococcus pneumoniae is an important agent of human disease at the extremities of age and in those who have underlying disease. Pneumococcal disease kills more people – in the US 40,000 or more each year – than all other vaccine preventable diseases combined. The major clinical syndromes of pneumococcal disease include pneumonia, bacteremia, and meningitis. The disease most often occurs when a predisposing condition exists, particularly pulmonary disease. It is a common bacterial complication of antecedent viral respiratory infection such as influenza and measles, and of chronic conditions such as chronic obstructive pulmonary disease, diabetes, congestive heart failure, renal failure, smoking and alcoholism. Pneumococcal infections are more common during the winter and in early spring when respiratory diseases are more prevalent. Immunodeficiency (splenic dysfunction, iatrogen, etc.) is a risk factor for development of fatal pneumococcal infections, because of decreased bacterial clearance and lack of antibodies. The incubation period is short, 1-3 days. Symptomes include an abrupt onset of fever and shaking chills or rigor, productive cough, pleuritic chest pain, dyspnoe, tachycardia and hypoxia.

S. pneumoniae is responsible for 88% of bacteremia infections in the US. Pneumonia is the most common form of invasive pneumococcal diseases: 150.000-570.000 cases per year (US). 36% of adult community-acquired and 50% of hospital-acquired pneumonia is caused by *S. pneumoniae* (US). The incidence of disease among adults aged 65 years and older has been reported to be ~60 cases/100.000. Case fatality rates for this disease increase from 1.4% for those aged two or younger to as high as 20.6% among those aged 80 or older. Diseases caused by influenza and *Pneumococcus* are together the fifth leading cause of death for persons aged 65 and older. Mortality attributable to these pathogens is more than 90% in this age group. Bacteremia occurs in about 25-30% of patients with pneumonia. The overall mortality rate of bacteremia is about 20%, but may be as high as 60% in elderly people. In 1998, 51% of all deaths attributable to invasive pneumococcal diseases occurred in age group above 65 years. Pneumococci cause 13%-19% of all cases of bacterial meningitis in the United States. An estimated 3,000 to 6,000 cases of pneumococcal meningitis occur each year. One-quarter of patients with pneumococcal meningitis also have pneumonia. The clinical symptoms, spinal fluid profile and neurologic complications are similar to other forms of purulent bacterial meningitis (reviewed in Epidemiology and Prevention of Vaccine-Preventable Diseases, 7th Edition-Second Printing, The Pink Book).

- 2 -

In children, Pneumococci are a common cause of acute otitis media, and are detected in 28%-55% of middle ear aspirates. By age 12 months, 62% of children have had at least one episode of acute otitis media. Middle ear infections are the most frequent reasons for pediatric office visits in the United States, resulting in over 20 million visits annually. Complications of pneumococcal otitis media may include mastoiditis and meningitis. Bacteremia without a known site of infection is the most common invasive clinical presentation among children <2 years of age, accounting for approximately 70% of invasive disease in this age group. Bacteremic pneumonia accounts for 12%-16% of invasive pneumococcal disease among children <2 years of age. With the decline of invasive Hib disease, *S. pneumoniae* has become the leading cause of bacterial meningitis among children <5 years of age in the United States. Children <1 year have the highest rates of pneumococcal meningitis, approximately 10 cases per 100,000 population. The burden of pneumococcal disease among children <5 years of age is significant. An estimated 17,000 cases of invasive disease occur each year, of which 13,000 are bacteremia without a known site of infection and about 700 are of meningitis. An estimated 200 children die every year as a result of invasive pneumococcal disease. Although not considered invasive disease, an estimated 5 million cases of acute otitis media occur each year among children <5 years of age (reviewed Epidemiology and Prevention of Vaccine-Preventable Diseases, 7th Edition-Second Printing, The Pink Book).

A definitive diagnosis of infection with *Streptococcus pneumoniae* generally relies on isolation of the organism from blood or other normally sterile body sites. Tests are also available to detect capsular polysaccharide antigen in body fluids.

Penicillin is the drug of choice for treatment. However, successful implementation of anti-infective therapy has become increasingly difficult because of widespread antimicrobial resistance. Resistance to penicillin is rising, and according to recent reports it reaches ~ 25% in the US {Whitney, C. et al., 2000}. The proportion of macrolide-resistant strains reached ~ 20 % {Hyde, T. et al., 2001}. Use of antimicrobial agents is highly correlated with the increase in resistance of *S. pneumoniae* to ϴ-lactams and macrolides {McCormick, A. et al., 2003}.

However, even with effective antibiotic therapy (sensitive strains), the case fatality rate of invasive disease is high with an average of 10% in the developed world and can be much higher with certain serotypes, in elderly patients and in cases of bacteremia or meningitis (up to 80%).

Thus, there remains a need for an effective treatment to prevent or ameliorate spneumoococcal infections. A vaccine could not only prevent infections by streptococci, but more specifically prevent or ameliorate colonization of host tissues (esp. in nasopharynx), thereby reducing the incidence of upper respiratory infections and other suppurative infections, such otitis media. Elimination of invasive diseases - pneumonia, bacteremia and meningitis, and sepsis - would be a direct consequence of reducing the incidence of acute infection and carriage of the organism. Vaccines capable of showing cross-protection against the majority of *S. pneumoniae* strains causing human infections would also be useful to prevent or ameliorate infections caused by all other streptococcal species, namely groups A, B, C and G.

A vaccine can contain a whole variety of different antigens. Examples of antigens are whole-killed or attenuated organisms, subfractions of these organisms/tissues, proteins, or, in their most simple form, peptides. Antigens can also be recognized by the immune system in form of glycosylated proteins or peptides and may also be or contain polysaccharides or lipids. Short peptides can be used since for example cytotoxic T-cells (CTL) recognize antigens in form of short usually 8-11 amino acids long peptides in conjunction with major histocompatibility complex (MHC). B-cells can recognize linear epitopes as short as 4-5 amino acids, as well as three-dimensional structures (conformational epitopes). In order to obtain sustained, antigen-specific immune responses, adjuvants need to trigger immune cascades that involve all cells of the immune system. Primarily, adjuvants are acting, but are not restricted in their mode of action, on so-called antigen presenting cells (APCs). These cells usually first

encounter the antigen(s) followed by presentation of processed or unmodified antigen to immune effector cells. Intermediate cell types may also be involved. Only effector cells with the appropriate specificity are activated in a productive immune response. The adjuvant may also locally retain antigens and co-injected other factors. In addition the adjuvant may act as a chemoattractant for other immune cells or may act locally and/or systemically as a stimulating agent for the immune system.

Efforts to develop effective pneumococcal vaccines began as early as 1911. However, with the advent of penicillin in the 1940s, interest in the vaccine declined, until it was observed that many patients still died despite antibiotic treatment. By the late 60s, efforts were again being made to develop a polyvalent vaccine. The first pneumococcal vaccines contained purified capsular polysaccharide antigen from 14 different types of pneumococcal bacteria. In 1983, a 23-valent polysaccharide vaccine (PPV23) was licensed and replaced the 14- valent vaccine, which is no longer produced. PPV23 contains polysaccharide antigen from 23 types of pneumococcal bacteria which cause 88% of bacteremic pneumococcal disease. In addition, cross-reactivity occurs for several capsular types which account for an additional 8% of bacteremic disease. Two polysaccharide vaccines are available in the United States (Pneumovax 23, Merck, and Pnu-Immune 23, Wyeth-Lederle). Both vaccines contain 25 μg of each antigen per dose and include either phenol or thimerosal as a preservative.

The first pneumococcal conjugate vaccine (PCV7, Prevnar) was licensed in the United States in 2000. It includes purified capsular polysaccharide of 7 serotypes of *S. pneumoniae* (4, 9V, 14, 19F, 23F, 18C, and 6B) conjugated to a nontoxic variant of diphtheria toxin known as CRM197. The serotypes included in Prevnar accounted for 86% of bacteremia, 83% of meningitis, and 65% of acute otitis media among children <6 years of age in the United States during 1978-1994 (reviewed in Epidemiology and Prevention of Vaccine-Preventable Diseases, 7th Edition-Second Printing, The Pink Book). Additional pneumococcal polysaccharide conjugate vaccines containing 9 and 11 serotypes of *S. pneumoniae* are being developed. The vaccine is administered intramuscularly. After 4 doses of Prevnar vaccine, virtually all healthy infants develop antibody to all 7 serotypes contained in the vaccine. Prevnar has also been shown to be immunogenic in infants and children, including those with sickle cell disease and HIV infection. In a large clinical trial, Prevnar was shown to reduce invasive disease caused by vaccine serotypes, and reduce invasive disease caused by all serotypes, including serotypes not in the vaccine. Children who received Prevnar had fewer episodes of acute otitis media and underwent fewer tympanostomy tube placements than unvaccinated children. The duration of protection following Prevnar is currently unknown. Immunization with Prevnar reduces the rate of nasopharyngeal carriage of the vaccine serotypes, while the overall carriage rate is unaffected. Unfortunately, it has also been shown to induce serotype redistribution, that is the replacement of vaccine serotypes by strains, which are not covered by Prevnar {Pelton, S. et al., 2003}.

Pneumococcal vaccine is recommended to be administered routinely to i., all children as part of the routine shildhood immunization schedule, ii., adults 65 years of age and older and iii., persons aged >2 years with normal immune systems who have chronic illnesses, including cardiovascular disease, pulmonary disease, diabetes, alcoholism, cirrhosis, or cerebrospinal fluid leaks. In the elderly population the target groups for pneumococcal vaccine and influenza vaccine overlap. These vaccines can be given at the same time at different sites without increased side effects.

High mortality is observed among high-risk individuals (with underlying disease – mainly viral respiratory infection, immunocompromise) even with effective antibiotic therapy. The mAb approach targets patients with serious disease and provides immediate immune enhancement for the clearance of the bacteria. Through opsonization bacteria are killed within phagocytic cells and not lysed in the blood by antibiotics. This mechanism of action can help to eliminate the release of toxins (such as pneumolysin and other cytotoxins), which worsen the clinical condition of septic patients. Recent advances in the technology of monoclonal antibody production provide the means to generate human antibody reagents and reintroduce antibody therapies, while avoiding the toxicities associated with serum therapy.

- 4 -

Immunoglobulins are an extremely versatile class of antimicrobial proteins that can be used to prevent and treat emerging infectious diseases. Antibody therapy has been effective against a variety of diverse microorganisms reviewed in {Burnie, J. et al., 1998}.

Although capsular specific antibodies have been shown to be highly protective, it remains unclear what concentration of these serotype-specific antibodies protect against disease and more recently it has become clear that opsonic activity and avidity of these antibodies are more critical determinants of protection than concentration.

Protein conjugate vaccines are no doubt a great new addition to the amarmatorium in the battle against pneumococcal disease, but the vaccine contains a limited number of pneumococcal serotypes and given adequate ecological pressure, replacement disease by non-vaccine serotypes remains a real threat, particularly in areas with very high disease burden.

During the last decade the immunogenicity and protective capacity of several pneumococcal proteins have been described in animal models and these are now being explored for the development of species-common protein based vaccines. Such proteins are the Pneumococcal surface protein A (PspA, {McDaniel, L. et al., 1991}; {Roche, H. et al., 2003}), Pneumococcal surface adhesin A (PsaA, {Talkington, D. et al., 1996}), Choline binding protein A (CbpA, {Rosenow, C. et al., 1997}), LytB glucosaminidase, LytC muramidase, PrtA serine protease, PhtA (histidine triad A) and Pneumococcal vaccine antigen A (PvaA) {Wizemann, T. et al., 2001}; {Adamou, J. et al., 2001}.

Certain proteins or enzymes displayed on the surface of gram-positive organisms significantly contribute to pathogenesis, and might be involved in the disease process caused by these pathogens. Often, these proteins are involved in direct interactions with host tissues or in conceiling the bacterial surface from the host defense mechanisms {Navarre, W. et al., 1999}. *S. pneumoniae* is not an exception in this regard. Several surface proteins are characterized by as virulence factors, important for pneumococcal pathogenicity reviewed in {Jedrzejas, M., 2001}. If antibodies to these proteins could offer better protection to humans, they could provide the source of a novel, protein-based pneumococcal vaccine to be used in conjunction with or in place of the more traditional capsular polysaccharise vaccine. The use of some of the above-described proteins as antigens for a potential vaccine as well as a number of additional candidates reviewed in {Di Guilmi, A. et al., 2002} resulted mainly from a selection based on easiness of identification or chance of availability. There is a demand to identify relevant antigens for *S. pneumoniae* in a more comprehensive way.

The present inventors have developed a method for identification, isolation and production of hyperimmune serum reactive antigens from a specific pathogen, especially from *Staphylococcus aureus* and *Staphylococcus epidermidis* (WO 02/059148). However, given the differences in biological property, pathogenic function and genetic background, *Streptococcus pneumoniae* is distinctive from *Staphylococcus* strains. Importantly, the selection of sera for the identification of antigens from *S. pneumoniae* is different from that applied to the *S. aureus* screens. Three major types of human sera were collected for that purpose. First, healthy adults below <45 years of age preferably with small children in the household were tested for nasopharyngeal carriage of *S. pneumoniae*. A large percentage of young children are carriers of *S. pneumoniae*, and they are considered to be a source for exposure for their family members. Based on correlative data, protective (colonization neutralizing) antibodies are likely to be present in exposed individuals (children with high carriage rate in the household) who are not carriers of *S. pneumoniae*. To be able to select for relevant serum sources, a series of ELISAs measuring anti-*S. pneumoniae* IgG and IgA antibody levels were performed with bacterial lysates and culture supernatant proteins. Sera from high titer non-carriers were included in the genomic-based antigen identification. This approach for selection of human sera is basically very different from that used for *S. aureus*, where carriage or non-carriage state couldn't be associated with antibody levels. Second, serum samples from

- 5 -

convalescent phase patients with invasive pneumococcal diseases were characterized and selected in the same way. The third group of sera, containing longitudinally collected samples were also obtained from individuals with invasive disease and were used mainly for validation purposes. The main value of this collection is that one can follow the changes in antigen-specific antibody levels before diase (prae-), at the time of onset (acute) and during recovery (convalescent). This latter group helps in the selection of epitopes, which induce antibodies during disease and missing in the prae-disease state.

The genomes of the two bacterial species *S. pneumoniae* and *S. aureus* by itself show a number of important differences. The genome of *S. pneumoniae* contains app. 2.16 Mb, while *S. aureus* harbours 2.85 Mb. They have an average GC content of 39.7 and 33%, respectively and approximately 30 to 45% of the encoded genes are not shared between the two pathogens. In addition, the two bacterial species require different growth conditions and media for propagation. While *S. pneumoniae* is a strictly human pathogen, *S. aureus* can also be found infecting a range of warm-blooded animals. A list of the most important diseases, which can be inflicted by the two pathogens is presented below. *S. aureus* causes mainly nosocomial, opportunistic infections: impetigo, folliculitis, abscesses, boils, infected lacerations, endocarditis, meningitis, septic arthritis, pneumonia, osteomyelitis, scalded skin syndrome (SSS), toxic shock syndrome. *S. pneumoniae* causes mainly community aquired infections: upper (pharyngitis, otitis media) and and lower respiratory infections (pneumonia), as well as bacteremia, sepsis and meningitis.

The complete genome sequence of a capsular serotype 4 isolate of *S. pneumoniae*, designated TIGR4 was determined by the random shotgun sequencing strategy (GenBank accession number AE005672; see www.tigr.org/tigrscripts/CMR2/CMRHomePage.spl). This clinical isolate was taken from the blood of a 30-year-old male patient in Kongsvinger, Norway, and is highly invasive and virulent in a mouse model of infection.

The problem underlying the present invention was to provide means for the development of medicaments such as vaccines against *S. pneumoniae* infection. More particularly, the problem was to provide an efficient, relevant and comprehensive set of nucleic acid molecules or hyperimmune serum reactive antigens from *S. pneumoniae* that can be used for the manufacture of said medicaments.

Therefore, the present invention provides an isolated nucleic acid molecule encoding a hyperimmune serum reactive antigen or a fragment thereof comprising a nucleic acid sequence, which is selected from the group consisting of:

   a) a nucleic acid molecule having at least 70% sequence identity to a nucleic acid molecule selected from Seq ID No 1, 101-144.

   b) a nucleic acid molecule which is complementary to the nucleic acid molecule of a),

   c) a nucleic acid molecule comprising at least 15 sequential bases of the nucleic acid molecule of a) or b)

   d) a nucleic acid molecule which anneals under stringent hybridisation conditions to the nucleic acid molecule of a), b), or c)

   e) a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to the nucleic acid molecule defined in a), b), c) or d).

According to a preferred embodiment of the present invention the sequence identity is at least 80%, preferably at least 95%, especially 100%.

Furthermore, the present invention provides an isolated nucleic acid molecule encoding a hyperimmune serum reactive antigen or a fragment thereof comprising a nucleic acid sequence selected from the group consisting of

   a) a nucleic acid molecule having at least 96% sequence identity to a nucleic acid molecule selected from Seq ID No 2-6, 8, 10-16, 18-23, 25-31, 34, 36, 38-42, 44, 47-48, 51, 53, 55-62, 64, 67, 71-76, 78-79, 81-94, 96-100.

- 6 -

b) a nucleic acid molecule which is complementary to the nucleic acid molecule of a),

c) a nucleic acid molecule comprising at least 15 sequential bases of the nucleic acid molecule of a) or b)

d) a nucleic acid molecule which anneals under stringent hybridisation conditions to the nucleic acid molecule of a), b) or c),

e) a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to the nucleic acid defined in a), b), c) or d).

According to another aspect, the present invention provides an isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of

a) a nucleic acid molecule selected from **Seq ID No** 9, 17, 24, 32, 37, 43, 52, 54, 65-66, 70, 80.

b) a nucleic acid molecule which is complementary to the nucleic acid of a),

c) a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to the nucleic acid defined in a), b), c) or d).

Preferably, the nucleic acid molecule is DNA or RNA.

According to a preferred embodiment of the present invention, the nucleic acid molecule is isolated from a genomic DNA, especially from a S. *pneumoniae* genomic DNA.

According to the present invention a vector comprising a nucleic acid molecule according to any of the present invention is provided.

In a preferred embodiment the vector is adapted for recombinant expression of the hyperimmune serum reactive antigens or fragments thereof encoded by the nucleic acid molecule according to the present invention.

The present invention also provides a host cell comprising the vector according to the present invention.

According to another aspect the present invention further provides a hyperimmune serum-reactive antigen comprising an amino acid sequence being encoded by a nucleic acid molecule according to the present invention.

In a preferred embodiment the amino acid sequence (polypeptide) is selected from the group consisting of **Seq ID No** 145, 245-288.

In another preferred embodiment the amino acid sequence (polypeptide) is selected from the group consisting of **Seq ID No** 146-150, 152, 154-160, 162-167, 169-175, 178, 180, 182-186, 188, 191-192, 195, 197, 199-206, 208, 211, 215-220, 222-223, 225-238, 240-244.

In a further preferred embodiment the amino acid sequence (polypeptide) is selected from the group consisting of **Seq ID No** 153, 161, 168, 176, 181, 187, 196, 198, 209-210, 214, 224.

According to a further aspect the present invention provides fragments of hyperimmune serum-reactive antigens selected from the group consisting of peptides comprising amino acid sequences of column "predicted immunogenic aa" and "location of identified immunogenic region" of Table 1; the serum reactive epitopes of Table 2, especially peptides comprising amino acids 4-11, 35-64, 66-76, 101-108, 111-119 and 57-114 of **Seq ID No** 145; 5-27, 32-64, 92-102, 107-113, 119-125, 133-139, 148-162, 177-187, 195-201, 207-214, 241-251, 254-269, 285-300, 302-309, 317-324, 332-357, 365-404, 411-425, 443-463, 470-477, 479-487, 506-512, 515-520, 532-547, 556-596, 603-610, 616-622, 624-629, 636-642, 646-665, 667-674, 687-692, 708-720, 734-739, 752-757, 798-820, 824-851, 856-865 and 732-763 of **Seq ID No** 146; 14-21, 36-44, 49-66, 102-127, 162-167, 177-196, 45-109 and 145-172 of **Seq ID No** 147; 17-35, 64-75, 81-92, 100-119, 125-172, 174-183, 214-

222, 230-236, 273-282, 287-303, 310-315, 331-340, 392-398, 412-420, 480-505, 515-523, 525-546, 553-575, 592-598, 603-609, 617-625, 631-639, 644-651, 658-670, 681-687, 691-704, 709-716, 731-736, 739-744, 750-763, 774-780, 784-791, 799-805, 809-822, 859-870, 880-885, 907-916, 924-941, 943-949, 973-986, 1010-1016, 1026-1036, 1045-1054, 1057-1062, 1082-1088, 1095-1102, 1109-1120, 1127-1134, 1140-1146, 1152-1159, 1169-1179, 1187-1196, 1243-1251, 1262-1273, 1279-1292, 1306-1312, 1332-1343, 1348-1364, 1379-1390, 1412-1420, 1427-1436, 1458-1468, 1483-1503, 1524-1549, 1574-1588, 1614-1619, 1672-1685, 1697-1707, 1711-1720, 1738-1753, 1781-1787, 1796-1801, 1826-1843, 132-478, 508-592 and 1753-1810 of Seq ID No 148; 15-43, 49-55, 71-77, 104-110, 123-130, 162-171, 180-192, 199-205, 219-227, 246-254, 264-270, 279-287, 293-308, 312-322, 330-342, 349-356, 369-377, 384-394, 401-406, 416-422, 432-439, 450-460, 464-474, 482-494, 501-508, 521-529, 536-546, 553-558, 568-574, 584-591, 602-612, 616-626, 634-646, 653-660, 673-681, 688-698, 705-710, 720-726, 736-749, 833-848, 1-199, 200-337, 418-494 and 549-647 of Seq ID No 149; 9-30, 65-96, 99-123, 170-178 and 1-128 of Seq ID No 150; 7-32, 34-41, 96-106, 127-136, 154-163, 188-199, 207-238, 272-279, 306-312, 318-325, 341-347, 353-360, 387-393, 399-406, 434-440, 452-503, 575-580, 589-601, 615-620, 635-640, 654-660, 674-680, 696-701, 710-731, 1-548 and 660-691 of Seq ID No 151; 4-19, 35-44, 48-59, 77-87, 93-99, 106-111, 130-138, 146-161 and 78-84 of Seq ID No 152; 24-30, 36-43, 64-86, 93-99, 106-130, 132-145, 148-165, 171-177, 189-220, 230-249, 251-263, 293-300, 302-312, 323-329, 338-356, 369-379, 390-412 and 179-193 of Seq ID No 153; 30-39, 61-67, 74-81, 90-120, 123-145, 154-167, 169-179, 182-197, 200-206, 238-244, 267-272 and 230-265 of Seq ID No 154; 14-20, 49-65, 77-86 and 2-68 of Seq ID No 155; 4-9, 26-35, 42-48, 53-61, 63-85, 90-101, 105-111, 113-121, 129-137, 140-150, 179-188, 199-226, 228-237, 248-255, 259-285, 299-308, 314-331, 337-343, 353-364, 410-421, 436-442 and 110-144 of Seq ID No 156; 36-47, 55-63, 94-108, 129-134, 144-158, 173-187, 196-206, 209-238, 251-266, 270-285, 290-295, 300-306, 333-344, 346-354, 366-397, 404-410, 422-435, 439-453, 466-473, 515-523, 529-543, 554-569, 571-585, 590-596, 607-618, 627-643, 690-696, 704-714, 720-728, 741-749, 752-767, 780-799, 225-247 and 480-507 of Seq ID No 157; 16-25, 36-70, 80-93, 100-106 and 78-130 of Seq ID No 158; 18-27, 41-46, 50-57, 65-71, 79-85, 93-98, 113-128, 144-155, 166-178, 181-188, 201-207, 242-262, 265-273, 281-295, 303-309, 318-327 and 36-64 of Seq ID No 159; 7-29, 31-44, 50-59, 91-96, 146-153, 194-201, 207-212, 232-238, 264-278, 284-290, 296-302, 326-353, 360-370, 378-384, 400-405, 409-418, 420-435, 442-460, 499-506, 529-534, 556-562, 564-576, 644-651, 677-684, 687-698, 736-743, 759-766, 778-784, 808-814, 852-858, 874-896, 920-925, 929-935, 957-965, 1003-1012, 1021-1027, 1030-1044, 1081-1087, 1101-1111, 1116-1124, 1148-1159, 1188-1196, 1235-1251, 1288-1303, 1313-1319, 1328-1335, 1367-1373, 1431-1437, 1451-1458, 1479-1503, 1514-1521, 1530-1540, 1545-1552, 1561-1568, 1598-1605, 1617-1647, 1658-1665, 1670-1676, 1679-1689, 1698-1704, 1707-1713, 1732-1738, 1744-1764, 1-70, 154-189, 922-941, 1445-1462 and 1483-1496 of Seq ID No 160; 6-51, 81-91, 104-113, 126-137, 150-159, 164-174, 197-209, 215-224, 229-235, 256-269, 276-282, 307-313, 317-348, 351-357, 376-397, 418-437, 454-464, 485-490, 498-509, 547-555, 574-586, 602-619 and 452-530 of Seq ID No 161; 25-31, 39-47, 49-56, 99-114, 121-127, 159-186, 228-240, 253-269, 271-279, 303-315, 365-382, 395-405, 414-425, 438-453 and 289-384 of Seq ID No 162; 9-24, 41-47, 49-54, 68-78, 108-114, 117-122, 132-140, 164-169, 179-186, 193-199, 206-213, 244-251, 267-274, 289-294, 309-314, 327-333, 209-249 and 286-336 of Seq ID No 163; 9-28, 53-67, 69-82, 87-93, 109-117, 172-177, 201-207, 220-227, 242-247, 262-268, 305-318, 320-325 and 286-306 of Seq ID No 164; 4-10, 26-39, 47-58, 63-73, 86-96, 98-108, 115-123, 137-143, 148-155, 160-176, 184-189, 194-204, 235-240, 254-259, 272-278 and 199-283 of Seq ID No 165; 4-26, 33-39, 47-53, 59-65, 76-83, 91-97, 104-112, 118-137, 155-160, 167-174, 198-207, 242-268, 273-279, 292-315, 320-332, 345-354, 358-367, 377-394, 403-410, 424-439, 445-451, 453-497, 511-518, 535-570, 573-589, 592-601, 604-610 and 202-242 of Seq ID No 166; 8-30, 36-45, 64-71, 76-82, 97-103, 105-112, 134-151, 161-183, 211-234, 253-268, 270-276, 278-284, 297-305, 309-315, 357-362, 366-372, 375-384, 401-407, 409-416, 441-455, 463-470, 475-480, 490-497, 501-513, 524-537, 552-559, 565-576, 581-590, 592-600, 619-625, 636-644, 646-656 and 316-419 of Seq ID No 167; 4-17, 52-58, 84-99, 102-110, 114-120, 124-135, 143-158, 160-173, 177-196, 201-216, 223-250, 259-267, 269-275 and 1-67 of Seq ID No 168; 6-46, 57-67, 69-80, 82-133, 137-143, 147-168, 182-187, 203-209, 214-229, 233-242, 246-280 and 53-93 of Seq ID No 169; 7-40, 50-56, 81-89, 117-123, 202-209, 213-218, 223-229, 248-261, 264-276, 281-288, 303-308, 313-324, 326-332, 340-346, 353-372, 434-443, 465-474, 514-523, 556-564, 605-616, 620-626, 631-636, 667-683, 685-699, 710-719, 726-732, 751-756, 760-771, 779-788, 815-828, 855-867, 869-879, 897-902, 917-924, 926-931, 936-942, 981-1000, 1006-1015, 1017-1028, 1030-1039, 1046-1054, 1060-1066, 1083-1092, 1099-1112, 1122-1130, 1132-1140, 1148-1158, 1161-1171, 1174-1181, 1209-1230, 1236-1244, 1248-1254, 1256-1267, 1269-1276, 1294-1299, 1316-1328, 1332-1354, 1359-1372, 1374-1380, 1384-1390, 1395-1408, 1419-1425, 1434-1446, 1453-1460, 1465-1471, 1474-

- 8 -

1493, 1505-1515, 1523-1537, 1547-1555, 1560-1567, 1577-1605, 1633-1651, 1226-1309, 1455-1536 and 1538-1605 of Seq ID No 170; 4-10, 31-39, 81-88, 106-112, 122-135, 152-158, 177-184, 191-197, 221-227, 230-246, 249-255, 303-311, 317-326, 337-344, 346-362, 365-371, 430-437, 439-446, 453-462, 474-484 and 449-467 of Seq ID No 171; 9-15, 24-35, 47-55, 122-128, 160-177, 188-196, 202-208, 216-228, 250-261, 272-303, 318-324, 327-339, 346-352, 355-361, 368-373, 108-218 and 344-376 of Seq ID No 172; 6-14, 17-48, 55-63, 71-90, 99-109, 116-124, 181-189, 212-223, 232-268, 270-294, 297-304, 319-325, 340-348, 351-370, 372-378, 388-394, 406-415, 421-434 and 177-277 of Seq ID No 173; 21-39, 42-61, 65-75, 79-85, 108-115 and 11-38 of Seq ID No 174; 4-17, 26-39, 61-76, 103-113, 115-122, 136-142, 158-192, 197-203, 208-214, 225-230, 237-251 and 207-225 of Seq ID No 175; 5-11, 27-36, 42-53, 62-70, 74-93, 95-104, 114-119, 127-150, 153-159, 173-179, 184-193, 199-206, 222-241, 248-253, 257-280, 289-295, 313-319, 322-342, 349-365, 368-389, 393-406, 408-413, 426-438, 447-461, 463-470, 476-495, 532-537, 543-550 and 225-246 of Seq ID No 176; 4-29, 68-82, 123-130, 141-147, 149-157, 178-191, 203-215, 269-277, 300-307, 327-335, 359-370, 374-380, 382-388, 393-400, 410-417, 434-442, 483-492, 497-503, 505-513, 533-540, 564-569, 601-607, 639-647, 655-666, 693-706, 712-718, 726-736, 752-758, 763-771, 774-780, 786-799, 806-812, 820-828, 852-863, 884-892, 901-909, 925-932, 943-948, 990-996, 1030-1036, 1051-1059, 1062-1068, 1079-1086, 1105-1113, 1152-1162, 1168-1179, 1183-1191, 1204-1210, 1234-1244, 1286-1295, 1318-1326, 1396-1401, 1451-1460, 1465-1474, 1477-1483, 1488-1494, 1505-1510, 1514-1521, 1552-1565, 1593-1614, 1664-1672, 1677-1685, 1701-1711, 1734-1745, 1758-1770, 1784-1798, 1840-1847, 1852-1873, 1885-1891, 1906-1911, 1931-1939, 1957-1970, 1977-1992, 2014-2020, 2026-2032, 2116-2134, 1-348, 373-490, 573-767, 903-1043, 1155-1198, 1243-1482, 1550-1595, 1682-1719, 1793-1921 and 2008-2110 of Seq ID No 177; 10-35, 39-52, 107-112, 181-188, 226-236, 238-253, 258-268, 275-284, 296-310, 326-338, 345-368, 380-389, 391-408, 410-418, 420-429, 444-456, 489-505, 573-588, 616-623, 637-643, 726-739, 741-767, 785-791, 793-803, 830-847, 867-881, 886-922, 949-956, 961-980, 988-1004, 1009-1018, 1027-1042, 1051-1069, 1076-1089, 1108-1115, 1123-1135, 1140-1151, 1164-1179, 1182-1191, 1210-1221, 1223-1234, 1242-1250, 1255-1267, 1281-1292, 1301-1307, 1315-1340, 1348-1355, 1366-1373, 1381-1413, 1417-1428, 1437-1444, 1453-1463, 1478-1484, 1490-1496, 1498-1503, 1520-1536, 1538-1546, 1548-1570, 1593-1603, 1612-1625, 1635-1649, 1654-1660, 1670-1687, 1693-1700, 1705-1711, 1718-1726, 1729-1763, 1790-1813, 1871-1881, 1893-1900, 1907-1935, 1962-1970, 1992-2000, 2006-2013, 2033-2039, 2045-2051, 2055-2067, 2070-2095, 2097-2110, 2115-2121, 2150-2171, 2174-2180, 2197-2202, 2206-2228 and 1526-1560 of Seq ID No 178; 4-17, 35-48, 54-76, 78-107, 109-115, 118-127, 134-140, 145-156, 169-174, 217-226, 232-240, 256-262, 267-273, 316-328, 340-346, 353-360, 402-409, 416-439, 448-456, 506-531, 540-546, 570-578, 586-593, 595-600, 623-632, 662-667, 674-681, 689-705, 713-724, 730-740, 757-763, 773-778, 783-796, 829-835, 861-871, 888-899, 907-939, 941-955, 957-969, 986-1000, 1022-1028, 1036-1044, 1068-1084, 1095-1102, 1118-1124, 1140-1146, 1148-1154, 1168-1181, 1185-1190, 1197-1207, 1218-1226, 1250-1270, 1272-1281, 1284-1296, 1312-1319, 1351-1358, 1383-1409, 1422-1428, 1438-1447, 1449-1461, 1482-1489, 1504-1510, 1518-1527, 1529-1537, 1544-1551, 1569-1575, 1622-1628, 1631-1637, 1682-1689, 1711-1718, 1733-1740, 1772-1783, 1818-1834, 1859-1872, 1-64 and 128-495 of Seq ID No 179; 8-28, 32-37, 62-69, 119-125, 137-149, 159-164, 173-189, 200-205, 221-229, 240-245, 258-265, 268-276, 287-293, 296-302, 323-329 and 1-95 of Seq ID No 180; 9-18, 25-38, 49-63, 65-72, 74-81, 94-117, 131-137, 139-146, 149-158, 162-188, 191-207, 217-225, 237-252, 255-269, 281-293, 301-326, 332-342, 347-354, 363-370, 373-380, 391-400, 415-424, 441-447 and 75-107 of Seq ID No 181; 4-24, 64-71, 81-87, 96-116, 121-128, 130-139, 148-155, 166-173, 176-184, 203-215, 231-238, 243-248, 256-261, 280-286, 288-306, 314-329 and 67-148 of Seq ID No 182; 4-10, 19-37, 46-52, 62-81, 83-89, 115-120, 134-139, 141-151, 168-186, 197-205, 209-234, 241-252, 322-335, 339-345, 363-379, 385-393, 403-431, 434-442, 447-454, 459-465, 479-484, 487-496 and 404-420 of Seq ID No 183; 10-35, 46-66, 71-77, 84-93, 96-122, 138-148, 154-172, 182-213, 221-233, 245-263, 269-275, 295-301, 303-309, 311-320, 324-336, 340-348, 351-359, 375-381 and 111-198 of Seq ID No 184; 14-25, 30-42, 47-61, 67-75, 81-91, 98-106, 114-122, 124-135, 148-193, 209-227 and 198-213 of Seq ID No 185; 5-18, 45-50, 82-90, 97-114, 116-136, 153-161, 163-171, 212-219, 221-227, 240-249, 267-281, 311-317, 328-337, 375-381, 390-395, 430-436, 449-455, 484-495, 538-543, 548-554, 556-564, 580-586, 596-602 and 493-606 of Seq ID No 186; 9-25, 28-34, 37-44, 61-68, 75-81, 88-96, 98-111, 119-133, 138-150, 152-163, 168-182, 186-194, 200-205, 216-223, 236-245, 257-264, 279-287, 293-304, 311-318, 325-330, 340-346, 353-358, 365-379, 399-409, 444-453 and 303-391 of Seq ID No 187; 16-36, 55-61, 66-76, 78-102, 121-130, 134-146, 150-212, 221-239, 255-276, 289-322, 329-357 and 29-59 of Seq ID No 188; 8-27, 68-74, 77-99, 110-116, 124-141, 171-177, 202-217, 221-228, 259-265, 275-290, 293-303, 309-325, 335-343, 345-351, 365-379, 384-394, 406-414, 423-437, 452-465, 478-507, 525-534, 554-560, 611-624, 628-651, 669-682, 742-747, 767-778, 782-

792, 804-812, 820-836, 79-231 and 359-451 of Seq ID No 189; 5-28, 39-45, 56-62, 67-74, 77-99, 110-117, 124-141, 168-176, 200-230, 237-244, 268-279, 287-299, 304-326, 329-335, 348-362, 370-376, 379-384, 390-406, 420-429, 466-471, 479-489, 495-504, 529-541, 545-553, 561-577, 598-604, 622-630, 637-658, 672-680, 682-688, 690-696, 698-709, 712-719, 724-736, 738-746, 759-769, 780-786, 796-804, 813-818, 860-877, 895-904, 981-997, 1000-1014, 1021-1029, 1-162, 206-224, 254-350, 414-514 and 864-938 of Seq ID No 190; 4-11, 19-49, 56-66, 68-101, 109-116, 123-145, 156-165, 177-185, 204-221, 226-234, 242-248, 251-256, 259-265, 282-302, 307-330, 340-349, 355-374, 377-383, 392-400, 422-428, 434-442, 462-474 and 266-322 of Seq ID No 191; 14-43, 45-57, 64-74, 80-87, 106-127, 131-142, 145-161, 173-180, 182-188, 203-210, 213-219, 221-243, 245-254, 304-311, 314-320, 342-348, 354-365, 372-378, 394-399, 407-431, 436-448, 459-465, 470-477, 484-490, 504-509, 531-537, 590-596, 611-617, 642-647, 723-734, 740-751, 754-762, 764-774, 782-797, 807-812, 824-831, 838-845, 877-885, 892-898, 900-906, 924-935, 940-946, 982-996, 1006-1016, 1033-1043, 1051-1056, 1058-1066, 1094-1108, 1119-1126, 1129-1140, 1150-1157, 1167-1174, 1176-1185, 1188-1201, 1209-1216, 1220-1228, 1231-1237, 1243-1248, 1253-1285, 1288-1297, 1299-1307, 1316-1334, 1336-1343, 1350-1359, 1365-1381, 1390-1396, 1412-1420, 1427-1439, 1452-1459, 1477-1484, 1493-1512, 1554-1559, 1570-1578, 1603-1608, 1623-1630, 1654-1659, 1672-1680, 1689-1696, . 1705-1711, 1721-1738, 1752-1757, 1773-1780, 1817-1829, 1844-1851, 1856-1863, 1883-1895, 1950-1958, 1974-1990, 172-354, 384-448, 464-644, 648-728 and 1357-1370 of Seq ID No 192; 8-27, 68-74, 77-99, 110-116, 124-141, 169-176, 201-216, 220-227, 258-264, 274-289, 292-302, 308-324, 334-342, 344-350, 364-372, 377-387, 399-407, 416-429, 445-458, 471-481, 483-500, 518-527, 547-553, 604-617, 621-644, 662-675, 767-778, 809-816, 15-307, 350-448 and 496-620 of Seq ID No 193; 4-17, 24-29, 53-59, 62-84, 109-126, 159-164, 189-204, 208-219, 244-249, 274-290, 292-302, 308-324, 334-342, 344-350, 378-389, 391-397, 401-409, 424-432, 447-460, 470-479, 490-504, 521-529, 538-544, 549-555, 570-577, 583-592, 602-608, 615-630, 635-647, 664-677, 692-698, 722-731, 733-751, 782-790, 793-799, 56-267, 337-426 and 495-601 of Seq ID No 194; 12-22, 49-59, 77-89, 111-121, 136-148, 177-186, 207-213, 217-225, 227-253, 259-274, 296-302, 328-333, 343-354, 374-383, 424-446, 448-457, 468-480, 488-502, 507-522, 544-550, 553-560, 564-572, 587-596, 604-614, 619-625, 629-635, 638-656, 662-676, 680-692, 697-713, 720-738, 779-786, 833-847, 861-869, 880-895, 897-902, 911-917, 946-951, 959-967, 984-990, 992-1004, 1021-1040, 1057-1067, 1073-1080 and 381-403 of Seq ID No 195; 4-10, 26-31, 46-56, 60-66, 70-79, 86-94, 96-102, 109-118, 132-152, 164-187, 193-206, 217-224 and 81-149 of Seq ID No 196; 4-21, 26-37, 48-60, 71-82, 109-117, 120-128, 130-136, 142-147, 181-187, 203-211, 216-223, 247-255, 257-284, 316-325, 373-379, 395-400, 423-435, 448-456, 479-489, 512-576, 596-625, 641-678, 680-688, 692-715 and 346-453 of Seq ID No 197; 10-16, 25-31, 34-56, 58-69, 71-89, 94-110, 133-176, 186-193, 208-225, 240-250, 259-266, 302-307, 335-341, 376-383, 410-416 and 316-407 of Seq ID No 198; 11-29, 42-56, 60-75, 82-88, 95-110, 116-126, 132-143, 145-160, 166-172, 184-216 and 123-164 of Seq ID No 199; 11-29, 54-63, 110-117, 139-152, 158-166, 172-180, 186-193, 215-236, 240-251, 302-323, 330-335, 340-347, 350-366, 374-381 and 252-299 of Seq ID No 200; 18-27, 35-42, 50-56, 67-74, 112-136, 141-153, 163-171, 176-189, 205-213, 225-234, 241-247, 253-258, 269-281, 288-298, 306-324, 326-334, 355-369, 380-387 and 289-320 of Seq ID No 201; 7-15, 19-41, 56-72, 91-112, 114-122, 139-147, 163-183, 196-209, 258-280, 326-338, 357-363, 391-403, 406-416 and 360-378 of Seq ID No 202; 11-18, 29-41, 43-49, 95-108, 142-194, 204-212, 216-242, 247-256, 264-273 and 136-149 of Seq ID No 203; 18-24, 33-40, 65-79, 89-102, 113-119, 130-137, 155-161, 173-179, 183-203, 205-219, 223-231, 245-261, 267-274, 296-306, 311-321, 330-341, 344-363, 369-381, 401-408, 415-427, 437-444, 453-464, 472-478, 484-508, 517-524, 526-532, 543-548 and 59-180 of Seq ID No 204; 5-13, 52-65, 67-73, 97-110, 112-119, 134-155 and 45-177 of Seq ID No 205; 6-28, 34-43, 57-67, 75-81, 111-128, 132-147, 155-163, 165-176, 184-194, 208-216, 218-229, 239-252, 271-278, 328-334, 363-376, 381-388, 426-473, 481-488, 492-498, 507-513, 536-546, 564-582, 590-601, 607-623, 148-269, 420-450 and 610-648 of Seq ID No 206; 4-12, 20-38, 69-75, 83-88, 123-128, 145-152, 154-161, 183-188, 200-213, 245-250, 266-272, 306-312, 332-339, 357-369, 383-389, 395-402, 437-453, 455-470, 497-503 and 1-112 of Seq ID No 207; 35-59, 74-86, 111-117, 122-137 and 70-154 of Seq ID No 208; 26-42, 54-61, 65-75, 101-107, 123-130, 137-144, 148-156, 164-172, 177-192, 213-221, 231-258 and 157-249 of Seq ID No 209; 29-38, 61-67, 77-87, 94-100, 105-111, 118-158 and 1-97 of Seq ID No 210; 7-21, 30-48, 51-58, 60-85, 94-123, 134-156, 160-167, 169-183, 186-191, 216-229, 237-251, 257-267, 272-282, 287-298 and 220-243 of Seq ID No 211; 6-29, 34-47, 56-65, 69-76, 83-90, 123-134, 143-151, 158-178, 197-203, 217-235, 243-263, 303-309, 320-333, 338-348, 367-373, 387-393, 407-414, 416-427, 441-457, 473-482, 487-499, 501-509, 514-520, 530-535, 577-583, 590-602, 605-612, 622-629, 641-670, 678-690, 37-71 and 238-307 of Seq ID No 212; 7-40, 121-132, 148-161, 196-202, 209-215, 221-235, 248-255, 271-280, 288-295, 330-339, 395-409, 414-420, 446-451, 475-487, 556-563, 568-575, 580-586, 588-595,

633-638, 643-648, 652-659, 672-685, 695-700, 710-716, 737-742, 749-754, 761-767, 775-781, 796-806, 823-835, 850-863, 884-890, 892-900, 902-915, 934-941 and 406-521 of Seq ID No 213; 9-18, 24-46, 51-58, 67-77, 85-108, 114-126, 129-137, 139-146, 152-165, 173-182, 188-195, 197-204, 217-250, 260-274, 296-313, 343-366, 368-384, 427-434, 437-446, 449-455, 478-484, 492-506, 522-527, 562-591, 599-606, 609-618, 625-631, 645-652 and 577-654 of Seq ID No 214; 13-20, 26-37, 41-53, 56-65, 81-100, 102-114, 118-127, 163-188, 196-202, 231-238, 245-252, 266-285, 293-298, 301-306 and 19-78 of Seq ID No 215; 10-23, 32-42, 54-66, 73-91, 106-113, 118-127, 139-152, 164-173, 198-207, 210-245, 284-300, 313-318, 330-337, 339-346, 354-361, 387-393, 404-426, 429-439, 441-453, 467-473, 479-485, 496-509, 536-544, 551-558, 560-566, 569-574, 578-588, 610-615, 627-635, 649-675, 679-690, 698-716, 722-734, 743-754, 769-780, 782-787 and 480-550 of Seq ID No 216; 6-39, 42-50, 60-68, 76-83, 114-129, 147-162, 170-189, 197-205, 217-231, 239-248, 299-305, 338-344, 352-357, 371-377, 380-451, 459-483, 491-499, 507-523, 537-559, 587-613, 625-681, 689-729, 737-781, 785-809, 817-865, 873-881, 889-939, 951-975, 983-1027, 1031-1055, 1063-1071, 1079-1099, 1103-1127, 1151-1185, 1197-1261, 1269-1309, 1317-1333, 1341-1349, 1357-1465, 1469-1513, 1517-1553, 1557-1629, 1637-1669, 1677-1701, 1709-1725, 1733-1795, 1823-1849, 1861-1925, 1933-1973, 1981-2025, 2029-2053, 2061-2109, 2117-2125, 2133-2183, 2195-2219, 2227-2271, 2275-2299, 2307-2315, 2323-2343, 2347-2371, 2395-2429, 2441-2529, 2537-2569, 2577-2601, 2609-2625, 2633-2695, 2699-2737, 2765-2791, 2803-2867, 2889-2913, 2921-2937, 2945-2969, 2977-2985, 2993-3009, 3023-3045, 3073-3099, 3111-3167, 3175-3215, 3223-3267, 3271-3295, 3303-3351, 3359-3367, 3375-3425, 3437-3461, 3469-3513, 3517-3541, 3549-3557, 3565-3585, 3589-3613, 3637-3671, 3683-3747, 3755-3795, 3803-3819, 3827-3835, 3843-3951, 3955-3999, 4003-4039, 4043-4115, 4123-4143, 4147-4171, 4195-4229, 4241-4305, 4313-4353, 4361-4377, 4385-4393, 4401-4509, 4513-4557, 4561-4597, 4601-4718, 4749-4768, 74-171, 452-559 and 2951-3061 of Seq ID No 217; 16-22, 30-51, 70-111, 117-130, 137-150, 171-178, 180-188, 191-196 and 148-181 of Seq ID No 218; 6-19, 21-46, 50-56, 80-86, 118-126, 167-186, 189-205, 211-242, 244-267, 273-286, 290-297, 307-316, 320-341 and 34-60 of Seq ID No 219; 5-26, 33-43, 48-54, 58-63, 78-83, 113-120, 122-128, 143-152, 157-175, 185-192, 211-225, 227-234, 244-256, 270-281, 284-290, 304-310, 330-337, 348-355, 362-379, 384-394, 429-445, 450-474, 483-490, 511-520, 537-546, 548-554, 561-586, 590-604, 613-629, 149-186, 285-431 and 573-659 of Seq ID No 220; 5-26, 49-59, 61-67, 83-91, 102-111, 145-157, 185-192, 267-272, 279-286, 292-298, 306-312, 134-220, 235-251 and 254-280 of Seq ID No 221; 5-19, 72-79, 83-92, 119-124, 140-145, 160-165, 167-182, 224-232, 240-252, 259-270, 301-310, 313-322, 332-343, 347-367, 384-398, 416-429, 431-446, 454-461 and 1-169 of Seq ID No 222; 8-17, 26-31, 56-62, 75-83, 93-103, 125-131, 135-141, 150-194, 205-217, 233-258, 262-268, 281-286 and 127-168 of Seq ID No 223; 6-12, 69-75, 108-115, 139-159, 176-182, 194-214 and 46-161 of Seq ID No 224; 6-13, 18-27, 39-48, 51-59, 66-73, 79-85, 95-101, 109-116, 118-124, 144-164, 166-177, 183-193, 197-204, 215-223, 227-236, 242-249, 252-259, 261-270, 289-301, 318-325 and 12-58 of Seq ID No 225; 4-10, 26-32, 48-60, 97-105, 117-132, 138-163, 169-185, 192-214, 219-231, 249-261, 264-270, 292-308, 343-356, 385-392, 398-404, 408-417, 435-441 and 24-50 of Seq ID No 226; 10-40, 42-48, 51-61, 119-126 and 1-118 of Seq ID No 227; 5-17, 40-58, 71-83, 103-111, 123-140, 167-177, 188-204 and 116-128 of Seq ID No 228; 4-9, 11-50, 57-70, 112-123, 127-138 and 64-107 of Seq ID No 229; 9-39, 51-67 and 1-101 of Seq ID No 230; 5-14, 17-25, 28-46, 52-59, 85-93, 99-104, 111-120, 122-131, 140-148, 158-179, 187-197, 204-225, 271-283, 285-293 and 139-155 of Seq ID No 231; 42-70, 73-90, 92-108, 112-127, 152-164, 166-172, 181-199, 201-210, 219-228, 247-274, 295-302, 322-334, 336-346, 353-358, 396-414, 419-425, 432-438, 462-471, 518-523, 531-536, 561-567, 576-589, 594-612, 620-631, 665-671, 697-710, 718-731, 736-756, 765-771, 784-801 and 626-653 of Seq ID No 232; 8-28, 41-51, 53-62, 68-74, 79-85, 94-100, 102-108, 114-120, 130-154, 156-162, 175-180, 198-204, 206-213, 281-294, 308-318, 321-339, 362-368, 381-386, 393-399, 407-415 and 2-13 of Seq ID No 233; 4-39, 48-65, 93-98, 106-112, 116-129 and 10-36 of Seq ID No 234; 25-32, 35-50, 66-71, 75-86, 90-96, 123-136, 141-151, 160-179, 190-196, 209-215, 222-228, 235-242, 257-263, 270-280 and 209-247 of Seq ID No 235; 5-29, 31-38, 50-57, 62-75, 83-110, 115-132, 168-195, 197-206, 216-242, 249-258, 262-269, 333-340, 342-350, 363-368, 376-392, 400-406, 410-421, 423-430, 436-442, 448-454, 460-466, 471-476, 491-496, 511-516, 531-536, 551-556, 571-576, 585-591, 599-605, 27-70, 219-293, 441-504 and 512-584 of Seq ID No 236; 4-12, 14-34, 47-75, 83-104, 107-115, 133-140, 148-185, 187-196, 207-212, 224-256, 258-265, 281-287, 289-296, 298-308, 325-333, 345-355, 365-371, 382-395, 424-435, 441-457, 465-472, 483-491, 493-505, 528-534, 536-546, 552-558, 575-584, 589-600, 616-623 and 576-591 of Seq ID No 237; 4-76, 78-89, 91-126, 142-148, 151-191, 195-208, 211-223, 226-240, 256-277, 279-285, 290-314, 317-323, 358-377, 381-387, 391-396, 398-411, 415-434, 436-446, 454-484, 494-512, 516-523, 538-552, 559-566, 571-577, 579-596, 599-615, 620-627, 635-644, 694-707, 720-734, 737-759, 761-771 and 313-329 of Seq ID No

238; 7-38, 44-49, 79-89, 99-108, 117-123, 125-132, 137-146, 178-187, 207-237, 245-255, 322-337, 365-387, 398-408, 445-462, 603-608, 623-628, 644-650, 657-671, 673-679 and 111-566 of Seq ID No 239; 6-20, 22-35, 39-45, 58-64, 77-117, 137-144, 158-163, 205-210, 218-224, 229-236, 239-251, 263-277, 299-307, 323-334, 353-384, 388-396, 399-438, 443-448, 458-463, 467-478, 481-495, 503-509, 511-526, 559-576, 595-600, 612-645, 711-721, 723-738, 744-758, 778-807 and 686-720 of Seq ID No 240; 10-33, 35-41, 72-84, 129-138, 158-163, 203-226, 243-252, 258-264, 279-302, 322-329, 381-386, 401-406, 414-435 and 184-385 of Seq ID No 241; 4-9, 19-24, 41-47, 75-85, 105-110, 113-146 and 45-62 of Seq ID No 242; 4-25, 52-67, 117-124, 131-146, 173-180, 182-191, 195-206, 215-221, 229-236, 245-252, 258-279, 286-291, 293-302, 314-320, 327-336, 341-353, 355-361, 383-389 and 1-285 of Seq ID No 243; 14-32, 38-50, 73-84, 93-105, 109-114 and 40-70 of Seq ID No 244; 5-26 and 22-34 of Seq ID No 245; 23-28 and 13-39 of Seq ID No 246; 8-14 and 21-34 of Seq ID No 247; 4-13, 20-29, 44-50, 59-74 and 41-69 of Seq ID No 248; 4-9, 19-42, 48-59, 71-83 and 57-91 of Seq ID No 249; 4-14 and 10-28 of Seq ID No 250; 22-28, 32-42, 63-71, 81-111, 149-156, 158-167, 172-180, 182-203, 219-229 and 27-49 of Seq ID No 251; 17-27 and 23-32 of Seq ID No 252; 18-24 and 28-38 of Seq ID No 253; 9-15 and 13-27 of Seq ID No 254; 13-22 and 18-29 of Seq ID No 255; 17-26 and 2-11 of Seq ID No 256; 4-33 and 16-32 of Seq ID No 257; 4-10, 37-43, 54-84, 92-127 and 15-62 of Seq ID No 258; 4-14, 20-32, 35-60, 69-75, 79-99, 101-109, 116-140 and 124-136 of Seq ID No 259; 2-13 of Seq ID No 260; 4-13, 28-42 and 42-57 of Seq ID No 261; 4-14, 27-44 and 14-35 of Seq ID No 262; 4-12 and 1-27 of Seq ID No 263; 4-18, 39-45, 47-74 and 35-66 of Seq ID No 264; 8-20, 43-77 and 17-36 of Seq ID No 265; 4-30, 35-45, 51-57 and 35-49 of Seq ID No 266; 4-24, 49-57 and 15-34 of Seq ID No 267; 4-22 and 8-27 of Seq ID No 268; 13-25, 32-59, 66-80 and 21-55 of Seq ID No 269; 4-10, 24-33, 35-42, 54-65, 72-82, 98-108 and 15-30 of Seq ID No 270; 8-19 and 17-47 of Seq ID No 271; 12-18, 40-46 and 31-52 of Seq ID No 272; 4-20, 35-78, 83-102, 109-122 and 74-86 of Seq ID No 273; 7-17, 21-41, 46-63 and 2-20 of Seq ID No 274; 30-37 and 2-33 of Seq ID No 275; 4-13, 17-25 and 1-15 of Seq ID No 276; 17-31, 44-51 and 20-51 of Seq ID No 277; 20-30 and 5-23 of Seq ID No 278; 13-33, 48-71 and 92-110 of Seq ID No 279; 4-9, 50-69, 76-88, 96-106, 113-118 and 12-34 of Seq ID No 280; 4-24 and 6-26 of Seq ID No 281; 7-26 and 14-30 of Seq ID No 282; 9-39, 46-68, 75-82, 84-103 and 26-44 of Seq ID No 283; 4-30, 33-107 and 58-84 of Seq ID No 284; 4-12 and 9-51 of Seq ID No 285; 12-18, 29-37 and 6-37 of Seq ID No 286; 4-21, 33-52, 64-71 and 16-37 of Seq ID No 287; 9-19 and 2-30 of Seq ID No 288; 20-37 of Seq ID No 245; 8-27 of Seq ID No 246; 10-27 of Seq ID No 247; 42-59 and 52-69 of Seq ID No 248; 63-80 and 74-91 of Seq ID No 249; 11-28 of Seq ID No 250; 28-49 of Seq ID No 251; 15-32 of Seq ID No 252; 4-20 of Seq ID No 253; 10-27 of Seq ID No 254; 17-34 of Seq ID No 255; 1-18 of Seq ID No 256; 16-33 of Seq ID No 257; 16-36, 30-49 and 43-62 of Seq ID No 258; 122-139 of Seq ID No 259; 1-18 of Seq ID No 260; 41-58 of Seq ID No 261; 15-35 of Seq ID No 262; 2-27 of Seq ID No 263; 18-36 of Seq ID No 265; 34-51 of Seq ID No 266; 9-27 of Seq ID No 268; 22-47 of Seq ID No 269; 18-36 and 29-47 of Seq ID No 271; 32-52 of Seq ID No 272; 72-89 of Seq ID No 273; 3-20 of Seq ID No 274; 3-21 and 15-33 of Seq ID No 275; 1-18 of Seq ID No 276; 6-23 of Seq ID No 278; 93-110 of Seq ID No 279; 13-34 of Seq ID No 280; 7-26 and 9-26 of Seq ID No 281; 16-33 of Seq ID No 282; 27-44 of Seq ID No 283; 67-84 of Seq ID No 284; 10-33 and 26-50 of Seq ID No 285; 7-25 and 19-37 of Seq ID No 286; 17-37 of Seq ID No 287; 3-20 and 13-30 of Seq ID No 288; 62-80 and 75-93 of Seq ID No 145; 92-108 of Seq ID No 147; 332-349, 177-200 and 1755-1777 of Seq ID No 148; 109-133, 149-174, 260-285 and 460-485 of Seq ID No 149; 26-47 and 42-64 of Seq ID No 150; 22-41, 35-54, 115-130, 306-325, 401-420 and 454-478 of Seq ID No 151; 22-45 of Seq ID No 155; 156-174, 924-940, 1485-1496, 1447-1462 and 1483-1498 of Seq ID No 160; 457-475 of Seq ID No 161; 302-325 of Seq ID No 163; 288-305 of Seq ID No 164; 244-266 and 260-282 of Seq ID No 165; 204-225 and 220-241 of Seq ID No 166; 324-345, 340-361, 356-377, 372-393 and 388-408 of Seq ID No 167; 39-64 of Seq ID No 168; 54-76 and 70-92 of Seq ID No 169; 1227-1247, 1539-1559, 1554-1574, 1569-1589, 1584-1604, 1242-1262, 1272-1292, 1287-1308, 1456-1477, 1472-1494, 1488-1510 and 1505-1526 of Seq ID No 170; 351-368 of Seq ID No 172; 179-200, 195-216, 211-232, 227-248 and 243-263 of Seq ID No 173; 13-37 of Seq ID No 174; 208-224 of Seq ID No 175; 42-64, 59-81, 304-328, 323-348, 465-489, 968-992, 1399-1418, 1412-1431 and 2092-2111 of Seq ID No 177; 1528-1547 and 1541-1560 of Seq ID No 178; 184-200, 367-388, 382-403, 409-429, 425-444 and 438-457 of Seq ID No 179; 27-50 and 45-67 of Seq ID No 180; 114-131 and 405-419 of Seq ID No 183; 113-134, 129-150, 145-166, 161-182 and 177-198 of Seq ID No 184; 495-515 of Seq ID No 186; 346-358 of Seq ID No 187; 208-224 of Seq ID No 190; 178-194, 202-223, 217-238, 288-308 and 1355-1372 of Seq ID No 192; 57-78 of Seq ID No 194; 347-369, 364-386, 381-403, 398-420, 415-437 and 432-452 of Seq ID No 197; 347-372 of Seq ID No 198;

147-163 of **Seq ID No** 199; 263-288 of **Seq ID No** 200; 361-377 of **Seq ID No** 202; 82-104, 99-121, 116-138, 133-155 and 150-171 of **Seq ID No** 204; 110-130 and 125-145 of **Seq ID No** 205; 613-631, 626-644 and 196-213 of **Seq ID No** 206; 78-100, 95-117, 112-134 and 129-151 of **Seq ID No** 208; 158-180, 175-197, 192-214, 209-231 and 226-248 of **Seq ID No** 209; 30-50, 45-65 and 60-79 of **Seq ID No** 210; 431-455 and 450-474 of **Seq ID No** 213; 579-601, 596-618, 613-635 and 630-653 of **Seq ID No** 214; 920-927, 98-119, 114-135, 130-151, 146-167 and 162-182 of **Seq ID No** 217; 36-59 of **Seq ID No** 219; 194-216 and 381-404 of **Seq ID No** 220; 236-251 and 255-279 of **Seq ID No** 221; 80-100 and 141-164 of **Seq ID No** 222; 128-154 of **Seq ID No** 223; 82-100, 95-116 and 111-134 of **Seq ID No** 224; 55-76, 71-92 and 87-110 of **Seq ID No** 227; 91-106 of **Seq ID No** 229; 74-96 of **Seq ID No** 230; 140-157 of **Seq ID No** 231; 4-13 of **Seq ID No** 233; 41-65 and 499-523 of **Seq ID No** 236; 122-146, 191-215, 288-313, 445-469 and 511-535 of **Seq ID No** 239; 347-368 of **Seq ID No** 241; 46-61 of **Seq ID No** 242; 15-37, 32-57, 101-121, 115-135, 138-158, 152-172, 220-242 and 236-258 of **Seq ID No** 243.

The present invention also provides a process for producing a *S. pneumoniae* hyperimmune serum reactive antigen or a fragment thereof according to the present invention comprising expressing one or more of the nucleic acid molecules according to the present invention in a suitable expression system.

Moreover, the present invention provides a process for producing a cell, which expresses a *S pneumoniae* hyperimmune serum reactive antigen or a fragment thereof according to the present invention comprising transforming or transfecting a suitable host cell with the vector according to the present invention.

According to the present invention a pharmaceutical composition, especially a vaccine, comprising a hyperimmune serum-reactive antigen or a fragment thereof as defined in the present invention or a nucleic acid molecule as defined in the present invention is provided.

In a preferred embodiment the pharmaceutical composition further comprises an immunostimulatory substance, preferably selected from the group comprising polycationic polymers, especially polycationic peptides, immunostimulatory deoxynucleotides (ODNs), peptides containing at least two LysLeuLys motifs, especially KLKLLLLLKLK, neuroactive compounds, especially human growth hormone, alumn, Freund's complete or incomplete adjuvants or combinations thereof.

In a more preferred embodiment the immunostimulatory substance is a combination of either a polycationic polymer and immunostimulatory deoxynucleotides or of a peptide containing at least two LysLeuLys motifs and immunostimulatory deoxynucleotides.

In a still more preferred embodiment the polycationic polymer is a polycationic peptide, especially polyarginine.

According to the present invention the use of a nucleic acid molecule according to the present invention or a hyperimmune serum-reactive antigen or fragment thereof according to the present invention for the manufacture of a pharmaceutical preparation, especially for the manufacture of a vaccine against *S. pneumoniae* infection, is provided.

Also an antibody, or at least an effective part thereof, which binds at least to a selective part of the hyperimmune serum-reactive antigen or a fragment thereof according to the present invention, is provided herewith.

In a preferred embodiment the antibody is a monoclonal antibody.

In another preferred embodiment the effective part of the antibody comprises Fab fragments.

In a further preferred embodiment the antibody is a chimeric antibody.

In a still preferred embodiment the antibody is a humanized antibody.

The present invention also provides a hybridoma cell line, which produces an antibody according to the present invention.

Moreover, the present invention provids a method for producing an antibody according to the present invention, characterized by the following steps:

- initiating an immune response in a non-human animal by administrating an hyperimmune serum-reactive antigen or a fragment thereof, as defined in the invention, to said animal,
- removing an antibody containing body fluid from said animal, and
- producing the antibody by subjecting said antibody containing body fluid to further purification steps.

Accordingly, the present invention also provides a method for producing an antibody according to the present invention, characterized by the following steps:

- initiating an immune response in a non-human animal by administrating an hyperimmune serum-reactive antigen or a fragment thereof, as defined in the present invention, to said animal,
- removing the spleen or spleen cells from said animal,
- producing hybridoma cells of said spleen or spleen cells,
- selecting and cloning hybridoma cells specific for said hyperimmune serum-reactive antigens or a fragment thereof,
- producing the antibody by cultivation of said cloned hybridoma cells and optionally further purification steps.

The antibodies provided or produced according to the above methods may be used for the preparation of a medicament for treating or preventing *S. pneumoniae* infections.

According to another aspect the present invention provides an antagonist, which binds to a hyperimmune serum-reactive antigen or a fragment thereof according to the present invention.

Such an antagonist capable of binding to a hyperimmune serum-reactive antigen or fragment thereof according to the present invention may be identified by a method comprising the following steps:

a) contacting an isolated or immobilized hyperimmune serum-reactive antigen or a fragment thereof according to the present invention with a candidate antagonist under conditions to permit binding of said candidate antagonist to said hyperimmune serum-reactive antigen or fragment, in the presence of a component capable of providing a detectable signal in response to the binding of the candidate antagonist to said hyperimmune serum reactive antigen or fragment thereof; and

b) detecting the presence or absence of a signal generated in response to the binding of the antagonist to the hyperimmune serum reactive antigen or the fragment thereof.

An antagonist capable of reducing or inhibiting the interaction activity of a hyperimmune serum-reactive antigen or a fragment thereof according to the present invention to its interaction partner may be identified by a method comprising the following steps:

a) providing a hyperimmune serum reactive antigen or a hyperimmune fragment thereof according to the present invention,

b) providing an interaction partner to said hyperimmune serum reactive antigen or a fragment thereof, especially an antibody according to the present invention,

c) allowing interaction of said hyperimmune serum reactive antigen or fragment thereof to said interaction partner to form an interaction complex,

- 14 -

d) providing a candidate antagonist,

e) allowing a competition reaction to occur between the candidate antagonist and the interaction complex,

f) determining whether the candidate antagonist inhibits or reduces the interaction activities of the hyperimmune serum reactive antigen or the fragment thereof with the interaction partner.

The hyperimmune serum reactive antigens or fragments thereof according to the present invention may be used for the isolation and/or purification and/or identification of an interaction partner of said hyperimmune serum reactive antigen or fragment thereof.

The present invention also provides a process for *in vitro* diagnosing a disease related to expression of a hyperimmune serum-reactive antigen or a fragment thereof according to the present invention comprising determining the presence of a nucleic acid sequence encoding said hyperimmune serum reactive antigen or fragment thereof according to the present invention or the presence of the hyperimmune serum reactive antigen or fragment thereof according to the present invention.

The present invention also provides a process for *in vitro* diagnosis of a bacterial infection, especially a *S. pneumoniae* infection, comprising analyzing for the presence of a nucleic acid sequence encoding said hyperimmune serum reactive antigen or fragment thereof according to the present invention or the presence of the hyperimmune serum reactive antigen or fragment thereof according to the present invention.

Moreover, the present invention provides the use of a hyperimmune serum reactive antigen or fragment thereof according to the present invention for the generation of a peptide binding to said hyperimmune serum reactive antigen or fragment thereof, wherein the peptide is an anticaline.

The present invention also provides the use of a hyperimmune serum-reactive antigen or fragment thereof according to the present invention for the manufacture of a functional nucleic acid, wherein the functional nucleic acid is selected from the group comprising aptamers and spiegelmers.

The nucleic acid molecule according to the present invention may also be used for the manufacture of a functional ribonucleic acid, wherein the functional ribonucleic acid is selected from the group comprising ribozymes, antisense nucleic acids and siRNA.

The present invention advantageously provides an efficient, relevant and comprehensive set of isolated nucleic acid molecules and their encoded hyperimmune serum reactive antigens or fragments thereof identified from *S. pneumoniae* using an antibody preparation from multiple human plasma pools and surface expression libraries derived from the genome of *S. pneumoniae*. Thus, the present invention fulfils a widely felt demand for *S. pneumoniae* antigens, vaccines, diagnostics and products useful in procedures for preparing antibodies and for identifying compounds effective against *S. pneumoniae* infection.

An effective vaccine should be composed of proteins or polypeptides, which are expressed by all strains and are able to induce high affinity, abundant antibodies against cell surface components of S. *pneumoniae*. The antibodies should be IgG1 and/or IgG3 for opsonization, and any IgG subtype and IgA for neutralisation of adherence and toxin action. A chemically defined vaccine must be definitely superior compared to a whole cell vaccine (attenuated or killed), since components of S. *pneumoniae*, which cross-react with human tissues or inhibit opsonization can be eliminated, and the individual proteins inducing protective antibodies and/or a protective immune response can be selected.

The approach, which has been employed for the present invention, is based on the interaction of pneumococcal proteins or peptides with the antibodies present in human sera. The antibodies produced against S. *pneumoniae* by the human immune system and present in human sera are indicative of the *in*

vivo expression of the antigenic proteins and their immunogenicity. In addition, the antigenic proteins as identified by the bacterial surface display expression libraries using pools of pre-selected sera, are processed in a second and third round of screening by individual selected or generated sera. Thus the present invention supplies an efficient, relevant, comprehensive set of pneumoococcal antigens as a pharmaceutical composition, especially a vaccine preventing infection by *S. pneumoniae*.

In the antigen identification program for identifying a comprehensive set of antigens according to the present invention, at least two different bacterial surface expression libraries are screened with several serum pools or plasma fractions or other pooled antibody containing body fluids (antibody pools). The antibody pools are derived from a serum collection, which has been tested against antigenic compounds of *S. pneumoniae*, such as whole cell extracts and culture supernatant proteins. Preferably, two distinct serum collections are used: 1. With very stable antibody repertoire: normal adults, clinically healthy people, who are non-carriers and overcame previous encounters or currently carriers of *S. pneumoniae* without acute disease and symptoms, 2. With antibodies induced acutely by the presence of the pathogenic organism: patients with acute disease with different manifestations (e.g. *S. pneumoniae* pharyngitis, pneumonia, bacteraemia, peritonitis, meningitis and sepsis). Sera have to react with multiple Pneumococcus-specific antigens in order to be considered hyperimmune and therefore relevant in the screening method applied for the present invention.

The expression libraries as used in the present invention should allow expression of all potential antigens, e.g. derived from all secreted and surface proteins of *S. pneumoniae*. Bacterial surface display libraries will be represented by a recombinant library of a bacterial host displaying a (total) set of expressed peptide sequences of *S. pneumoniae* on two selected outer membrane proteins (LamB and FhuA) at the bacterial host membrane {Georgiou, G., 1997}; {Etz, H. et al., 2001}. One of the advantages of using recombinant expression libraries is that the identified hyperimmune serum-reactive antigens may be instantly produced by expression of the coding sequences of the screened and selected clones expressing the hyperimmune serum-reactive antigens without further recombinant DNA technology or cloning steps necessary.

The comprehensive set of antigens identified by the described program according to the present invention is analysed further by one or more additional rounds of screening. Therefore individual antibody preparations or antibodies generated against selected peptides, which were identified as immunogenic are used. According to a preferred embodiment the individual antibody preparations for the second round of screening are derived from patients who have suffered from an acute infection with *S. pneumoniae*, especially from patients who show an antibody titer above a certain minimum level, for example an antibody titer being higher than 80 percentile, preferably higher than 90 percentile, especially higher than 95 percentile of the human (patient or healthy individual) sera tested. Using such high titer individual antibody preparations in the second screening round allows a very selective identification of the hyperimmune serum-reactive antigens and fragments thereof from *S. pneumoniae*.

Following the comprehensive screening procedure, the selected antigenic proteins, expressed as recombinant proteins or *in vitro* translated products, in case it can not be expressed in prokaryotic expression systems, or the identified antigenic peptides (produced synthetically) are tested in a second screening by a series of ELISA and Western blotting assays for the assessment of their immunogenicity with a large human serum collection (minimum ~150 healthy and patients sera).

It is important that the individual antibody preparations (which may also be the selected serum) allow a selective identification of the most promising candidates of all the hyperimmune serum-reactive antigens from all the promising candidates from the first round. Therefore, preferably at least 10 individual antibody preparations (i.e. antibody preparations (e.g. sera) from at least 10 different individuals having suffered from an infection to the chosen pathogen) should be used in identifying these antigens in the second screening round. Of course, it is possible to use also less than 10 individual preparations,

- 16 -

however, selectivity of the step may not be optimal with a low number of individual antibody preparations. On the other hand, if a given hyperimmune serum-reactive antigen (or an antigenic fragment thereof) is recognized by at least 10 individual antibody preparations, preferably at least 30, especially at least 50 individual antibody preparations, identification of the hyperimmune serum-reactive antigen is also selective enough for a proper identification. Hyperimmune serum-reactivity may of course be tested with as many individual preparations as possible (e.g. with more than 100 or even with more than 1,000).

Therefore, the relevant portion of the hyperimmune serum-reactive antibody preparations according to the method of the present invention should preferably be at least 10, more preferred at least 30, especially at least 50 individual antibody preparations. Alternatively (or in combination) hyperimmune serum-reactive antigens may preferably be also identified with at least 20%, preferably at least 30%, especially at least 40% of all individual antibody preparations used in the second screening round.

According to a preferred embodiment of the present invention, the sera from which the individual antibody preparations for the second round of screening are prepared (or which are used as antibody preparations), are selected by their titer against S. pneumoniae (e.g. against a preparation of this pathogen, such as a lysate, cell wall components and recombinant proteins). Preferably, some are selected with a total IgA titer above 2,000 U, especially above 4,000 U, and/or an IgG titer above 5,000 U, especially above 12,000 U (U = units, calculated from the OD_{405nm} reading at a given dilution) when the whole organism (total lysate or whole cells) is used as antigen in the ELISA.

The antibodies produced against streptococci by the human immune system and present in human sera are indicative of the *in vivo* expression of the antigenic proteins and their immunogenicity. The recognition of linear epitopes recognized by serum antibodies can be based on sequences as short as 4-5 amino acids. Of course it does not necessarily mean that these short peptides are capable of inducing the given antibody *in vivo*. For that reason the defined epitopes, polypeptides and proteins are further to be tested in animals (mainly in mice) for their capacity to induce antibodies against the selected proteins in vivo.

The preferred antigens are located on the cell surface or are secreted, and are therefore accessible extracellularly. Antibodies against cell wall proteins are expected to serve multiple purposes: to inhibit adhesion, to interfere with nutrient acquisition, to inhibit immune evasion nand to promote phagocytosis (Hornef, M. et al., 2002). Antibodies against secreted proteins are beneficial in neutralisation of their function as toxin or virulence component. It is also known that bacteria communicate with each other through secreted proteins. Neutralizing antibodies against these proteins will interrupt growth-promoting cross-talk between or within streptococcal species. Bioinformatic analyses (signal sequences, cell wall localisation signals, transmembrane domains) proved to be very useful in assessing cell surface localisation or secretion. The experimental approach includes the isolation of antibodies with the corresponding epitopes and proteins from human serum, and the generation of immune sera in mice against (poly)peptides selected by the bacterial surface display screens. These sera are then used in a third round of screening as reagents in the following assays: cell surface staining of S. pneumoniae grown under different conditions (FACS or microscopy), determination of neutralizing capacity (toxin, adherence), and promotion of opsonization and phagocytosis (*in vitro* phagocytosis assay).

For that purpose, bacterial E. coli clones are directly injected into mice and immune sera are taken and tested in the relevant in vitro assay for functional opsonic or neutralizing antibodies. Alternatively, specific antibodies may be purified from human or mouse sera using peptides or proteins as substrate.

Host defence against S. pneumoniae relies mainly on opsonophagocytic killing mechanism. Inducing high affinity antibodies of the opsonic and neutralizing type by vaccination helps the innate immune system to eliminate bacteria and toxins. This makes the method according to the present invention an optimal tool

- 17 -

for the identification of pneumococcal antigenic proteins.

The skin and mucous membranes are formidable barriers against invasion by streptococci. However, once the skin or the mucous membranes are breached the first line of non-adaptive cellular defence begins its co-ordinate action through complement and phagocytes, especially the polymorphonuclear leukocytes (PMNs). These cells can be regarded as the cornerstones in eliminating invading bacteria. As *Streptococcus pneumoniae* is a primarily extracellular pathogen, the major anti-streptococcal adaptive response comes from the humoral arm of the immune system, and is mediated through three major mechanisms: promotion of opsonization, toxin neutralisation, and inhibition of adherence. It is believed that opsonization is especially important, because of its requirement for an effective phagocytosis. For efficient opsonization the microbial surface has to be coated with antibodies and complement factors for recognition by PMNs through receptors to the Fc fragment of the IgG molecule or to activated C3b. After opsonization, streptococci are phagocytosed and killed. Antibodies bound to specific antigens on the cell surface of bacteria serve as ligands for the attachment to PMNs and to promote phagocytosis. The very same antibodies bound to the adhesins and other cell surface proteins are expected to neutralize adhesion and prevent colonization. The selection of antigens as provided by the present invention is thus well suited to identify those that will lead to protection against infection in an animal model or in humans.

According to the antigen identification method used herein, the present invention can surprisingly provide a set of comprehensive novel nucleic acids and novel hyperimmune serum reactive antigens and fragments thereof of *S. pneumoniae*, among other things, as described below. According to one aspect, the invention particularly relates to the nucleotide sequences encoding hyperimmune serum reactive antigens which sequences are set forth in the Sequence listing **Seq ID No:** 1-144, 289-303 and the corresponding encoded amino acid sequences representing hyperimmune serum reactive antigens are set forth in the Sequence Listing **Seq ID No** 145-288 and 304-318.

In a preferred embodiment of the present invention, a nucleic acid molecule is provided which exhibits 70% identity over their entire length to a nucleotide sequence set forth with **Seq ID No 1, 101-144**. Most highly preferred are nucleic acids that comprise a region that is at least 80% or at least 85% identical over their entire length to a nucleic acid molecule set forth with **Seq ID No 1, 101-144**. In this regard, nucleic acid molecules at least 90%, 91%, 92%, 93%, 94%, 95%, or 96% identical over their entire length to the same are particularly preferred. Furthermore, those with at least 97% are highly preferred, those with at least 98% and at least 99% are particularly highly preferred, with at least 99% or 99.5% being the more preferred, with 100% identity being especially preferred. Moreover, preferred embodiments in this respect are nucleic acids which encode hyperimmune serum reactive antigens or fragments thereof (polypeptides) which retain substantially the same biological function or activity as the mature polypeptide encoded by said nucleic acids set forth in the **Seq ID No 1, 101-144**.

Identity, as known in the art and used herein, is the relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, identity also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. Identity can be readily calculated. While there exist a number of methods to measure identity between two polynucleotide or two polypeptide sequences, the term is well known to skilled artisans (e.g. *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987). Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity are codified in computer programs. Preferred computer program methods to determine identity between two sequences include, but are not limited to, GCG program package {Devereux, J. et al., 1984}, BLASTP, BLASTN, and FASTA {Altschul, S. et al., 1990}.

According to another aspect of the invention, nucleic acid molecules are provided which exhibit at least 96% identity to the nucleic acid sequence set forth with **Seq ID No** 2-6, 8, 10-16, 18-23, 25-31, 34, 36, 38-42,

44, 47-48, 51, 53, 55-62, 64, 67, 71-76, 78-79, 81-94, 96-100.

According to a further aspect of the present invention, nucleic acid molecules are provided which are identical to the nucleic acid sequences set forth with **Seq ID No 9, 17, 24, 32, 37, 43, 52, 54, 65-66, 70, 80.**

The nucleic acid molecules according to the present invention can as a second alternative also be a nucleic acid molecule which is at least essentially complementary to the nucleic acid described as the first alternative above. As used herein complementary means that a nucleic acid strand is base pairing via Watson-Crick base pairing with a second nucleic acid strand. Essentially complementary as used herein means that the base pairing is not occurring for all of the bases of the respective strands but leaves a certain number or percentage of the bases unpaired or wrongly paired. The percentage of correctly pairing bases is preferably at least 70 %, more preferably 80 %, even more preferably 90 % and most preferably any percentage higher than 90 %. It is to be noted that a percentage of 70 % matching bases is considered as homology and the hybridization having this extent of matching base pairs is considered as stringent. Hybridization conditions for this kind of stringent hybridization may be taken from Current Protocols in Molecular Biology (John Wiley and Sons, Inc., 1987). More particularly, the hybridization conditions can be as follows:

- Hybridization performed e.g. in 5 x SSPE, 5 x Denhardt's reagent, 0.1% SDS, 100 g/mL sheared DNA at 68°C
- Moderate stringency wash in 0.2xSSC, 0.1% SDS at 42°C
- High stringency wash in 0.1xSSC, 0.1% SDS at 68°C

Genomic DNA with a GC content of 50% has an approximate T_M of 96°C. For 1% mismatch, the T_M is reduced by approximately 1°C.

In addition, any of the further hybridization conditions described herein are in principle applicable as well.

Of course, all nucleic acid sequence molecules which encode the same polypeptide molecule as those identified by the present invention are encompassed by any disclosure of a given coding sequence, since the degeneracy of the genetic code is directly applicable to unambiguously determine all possible nucleic acid molecules which encode a given polypeptide molecule, even if the number of such degenerated nucleic acid molecules may be high. This is also applicable for fragments of a given polypeptide, as long as the fragments encode a polypeptide being suitable to be used in a vaccination connection, e.g. as an active or passive vaccine.

The nucleic acid molecule according to the present invention can as a third alternative also be a nucleic acid which comprises a stretch of at least 15 bases of the nucleic acid molecule according to the first and second alternative of the nucleic acid molecules according to the present invention as outlined above. Preferably, the bases form a contiguous stretch of bases. However, it is also within the scope of the present invention that the stretch consists of two or more moieties, which are separated by a number of bases.

The present nucleic acids may preferably consist of at least 20, even more preferred at least 30, especially at least 50 contiguous bases from the sequences disclosed herein. The suitable length may easily be optimized due to the planned area of use (e.g. as (PCR) primers, probes, capture molecules (e.g. on a (DNA) chip), etc.). Preferred nucleic acid molecules contain at least a contiguous 15 base portion of one or more of the predicted immunogenic amino acid sequences listed in tables 1 and 2, especially the sequences of table 2 with scores of more than 10, preferably more than 20, especially with a score of more than 25. Specifically preferred are nucleic acids containing a contiguous portion of a DNA sequence of any sequence in the sequence protocol of the present application which shows 1 or more, preferably more

- 19 -

than 2, especially more than 5, non-identical nucleic acid residues compared to the published *Streptococcus pneumoniae* strain TIGR4 genome ({Tettelin, H. et al., 2001}; GenBank accession AE005672) and/or any other published *S. pneumoniae* genome sequence or parts thereof, especially of the strain R6 ({Hoskins, J. et al., 2001}; GenBank accession AE007317). Specifically preferred non-identical nucleic acid residues are residues, which lead to a non-identical amino acid residue. Preferably, the nucleic acid sequences encode for polypeptides having at least 1, preferably at least 2, preferably at least 3 different amino acid residues compared to the published *S. pneumoniae* counterparts mentioned above. Also such isolated polypeptides, being fragments of the proteins (or the whole protein) mentioned herein e.g. in the sequence listing, having at least 6, 7, or 8 amino acid residues and being encoded by these nucleic acids are preferred.

The nucleic acid molecule according to the present invention can as a fourth alternative also be a nucleic acid molecule which anneals under stringent hybridisation conditions to any of the nucleic acids of the present invention according to the above outlined first, second, and third alternative. Stringent hybridisation conditions are typically those described herein.

Finally, the nucleic acid molecule according to the present invention can as a fifth alternative also be a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to any of the nucleic acid molecules according to any nucleic acid molecule of the present invention according to the first, second, third, and fourth alternative as outlined above. This kind of nucleic acid molecule refers to the fact that preferably the nucleic acids according to the present invention code for the hyperimmune serum reactive antigens or fragments thereof according to the present invention. This kind of nucleic acid molecule is particularly useful in the detection of a nucleic acid molecule according to the present invention and thus the diagnosis of the respective microorganisms such as *S. pneumoniae* and any disease or diseased condition where this kind of microorganims is involved. Preferably, the hybridisation would occur or be preformed under stringent conditions as described in connection with the fourth alternative described above.

Nucleic acid molecule as used herein generally refers to any ribonucleic acid molecule or deoxyribonucleic acid molecule, which may be unmodified RNA or DNA or modified RNA or DNA. Thus, for instance, nucleic acid molecule as used herein refers to, among other, single-and double- stranded DNA, DNA that is a mixture of single- and double-stranded RNA, and RNA that is a mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single- stranded or, more typically, double-stranded, or triple-stranded, or a mixture of single- and double- stranded regions. In addition, nucleic acid molecule as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The strands in such regions may be from the same molecule or from different molecules. The regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules. One of the molecules of a triple-helical region often is an oligonucleotide. As used herein, the term nucleic acid molecule includes DNAs or RNAs as described above that contain one or more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "nucleic acid molecule" as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples, are nucleic acid molecule as the term is used herein. It will be appreciated that a great variety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art. The term nucleic acid molecule as it is employed herein embraces such chemically, enzymatically or metabolically modified forms of nucleic acid molecule, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including simple and complex cells, *inter alia*. The term nucleic acid molecule also embraces short nucleic acid molecules often referred to as oligonucleotide(s). "Polynucleotide" and "nucleic acid" or "nucleic acid molecule" are often used interchangeably herein.

Nucleic acid molecules provided in the present invention also encompass numerous unique fragments,

both longer and shorter than the nucleic acid molecule sequences set forth in the sequencing listing of the *S. pneumoniae* coding regions, which can be generated by standard cloning methods. To be unique, a fragment must be of sufficient size to distinguish it from other known nucleic acid sequences, most readily determined by comparing any selected *S. pneumoniae* fragment to the nucleotide sequences in computer databases such as GenBank.

Additionally, modifications can be made to the nucleic acid molecules and polypeptides that are encompassed by the present invention. For example, nucleotide substitutions can be made which do not affect the polypeptide encoded by the nucleic acid, and thus any nucleic acid molecule which encodes a hyperimmune serum reactive antigen or fragments thereof is encompassed by the present invention.

Furthermore, any of the nucleic acid molecules encoding hyperimmune serum reactive antigens or fragments thereof provided by the present invention can be functionally linked, using standard techniques such as standard cloning techniques, to any desired regulatory sequences, whether a *S. pneumoniae* regulatory sequence or a heterologous regulatory sequence, heterologous leader sequence, heterologous marker sequence or a heterologous coding sequence to create a fusion protein.

Nucleic acid molecules of the present invention may be in the form of RNA, such as mRNA or cRNA, or in the form of DNA, including, for instance, cDNA and genomic DNA obtained by cloning or produced by chemical synthetic techniques or by a combination thereof. The DNA may be triple-stranded, double-stranded or single-stranded. Single-stranded DNA may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand.

The present invention further relates to variants of the herein above described nucleic acid molecules which encode fragments, analogs and derivatives of the hyperimmune serum reactive antigens and fragments thereof having a deducted *S. pneumoniae* amino acid sequence set forth in the Sequence Listing. A variant of the nucleic acid molecule may be a naturally occurring variant such as a naturally occurring allelic variant, or it may be a variant that is not known to occur naturally. Such non-naturally occurring variants of the nucleic acid molecule may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells or organisms.

Among variants in this regard are variants that differ from the aforementioned nucleic acid molecules by nucleotide substitutions, deletions or additions. The substitutions, deletions or additions may involve one or more nucleotides. The variants may be altered in coding or non-coding regions or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or additions. Preferred are nucleic acid molecules encoding a variant, analog, derivative or fragment, or a variant, analogue or derivative of a fragment, which have a *S. pneumoniae* sequence as set forth in the Sequence Listing, in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no amino acid(s) is substituted, deleted or added, in any combination. Especially preferred among these are silent substitutions, additions and deletions, which do not alter the properties and activities of the *S. pneumoniae* polypeptides set forth in the Sequence Listing. Also especially preferred in this regard are conservative substitutions.

The peptides and fragments according to the present invention also include modified epitopes wherein preferably one or two of the amino acids of a given epitope are modified or replaced according to the rules disclosed in e.g. (Tourdot, S. et al., 2000), as well as the nucleic acid sequences encoding such modified epitopes.

It is clear that also epitopes derived from the present epitopes by amino acid exchanges improving, conserving or at least not significantly impeding the T cell activating capability of the epitopes are covered by the epitopes according to the present invention. Therefore the present epitopes also cover epitopes, which do not contain the original sequence as derived from *S. pneumoniae*, but trigger the same or preferably an improved T cell response. These epitope are referred to as "heteroclitic"; they need to

- 21 -

have a similar or preferably greater affinity to MHC/HLA molecules, and the need the ability to stimulate the T cell receptors (TCR) directed to the original epitope in a similar or preferably stronger manner.

Heteroclitic epitopes can be obtained by rational design i.e. taking into account the contribution of individual residues to binding to MHC/HLA as for instance described by {Rammensee, H. et al., 1999}, combined with a systematic exchange of residues potentially interacting with the TCR and testing the resulting sequences with T cells directed against the original epitope. Such a design is possible for a skilled man in the art without much experimentation.

Another possibility includes the screening of peptide libraries with T cells directed against the original epitope. A preferred way is the positional scanning of synthetic peptide libraries. Such approaches have been described in detail for instance by {Hemmer, B. et al., 1999}and the references given therein.

As an alternative to epitopes represented by the present derived amino acid sequences or heteroclitic epitopes, also substances mimicking these epitopes e.g. "peptidemimetica" or "retro-inverso-peptides" can be applied.

Another aspect of the design of improved epitopes is their formulation or modification with substances increasing their capacity to stimulate T cells. These include T helper cell epitopes, lipids or liposomes or preferred modifications as described in WO 01/78767.

Another way to increase the T cell stimulating capacity of epitopes is their formulation with immune stimulating substances for instance cytokines or chemokines like interleukin-2, -7, -12, -18, class I and II interferons (IFN), especially IFN-gamma, GM-CSF, TNF-alpha, flt3-ligand and others.

As discussed additionally herein regarding nucleic acid molecule assays of the invention, for instance, nucleic acid molecules of the invention as discussed above, may be used as a hybridization probe for RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic clones of other genes that have a high sequence similarity to the nucleic acid molecules of the present invention. Such probes generally will comprise at least 15 bases. Preferably, such probes will have at least 20, at least 25 or at least 30 bases, and may have at least 50 bases. Particularly preferred probes will have at least 30 bases, and will have 50 bases or less, such as 30, 35, 40, 45, or 50 bases.

For example, the coding region of a nucleic acid molecule of the present invention may be isolated by screening a relevant library using the known DNA sequence to synthesize an oligonucleotide probe. A labeled oligonucleotide having a sequence complementary to that of a gene of the present invention is then used to screen a library of cDNA, genomic DNA or mRNA to determine to which members of the library the probe hybridizes.

The nucleic acid molecules and polypeptides of the present invention may be employed as reagents and materials for development of treatments of and diagnostics for disease, particularly human disease, as further discussed herein relating to nucleic acid molecule assays, inter alia.

The nucleic acid molecules of the present invention that are oligonucleotides can be used in the processes herein as described, but preferably for PCR, to determine whether or not the S. pneumoniae genes identified herein in whole or in part are present and/or transcribed in infected tissue such as blood. It is recognized that such sequences will also have utility in diagnosis of the stage of infection and type of infection the pathogen has attained. For this and other purposes the arrays comprising at least one of the nucleic acids according to the present invention as described herein, may be used.

- 22 -

The nucleic acid molecules according to the present invention may be used for the detection of nucleic acid molecules and organisms or samples containing these nucleic acids. Preferably such detection is for diagnosis, more preferable for the diagnosis of a disease related or linked to the present or abundance of *S. pneumoniae*.

Eukaryotes (herein also "individual(s)"), particularly mammals, and especially humans, infected with *S. pneumoniae* may be identifiable by detecting any of the nucleic acid molecules according to the present invention detected at the DNA level by a variety of techniques. Preferred nucleic acid molecules candidates for distinguishing a *S. pneumoniae* from other organisms can be obtained.

The invention provides a process for diagnosing disease, arising from infection with *S. pneumoniae*, comprising determining from a sample isolated or derived from an individual an increased level of expression of a nucleic acid molecule having the sequence of a nucleic acid molecule set forth in the Sequence Listing. Expression of nucleic acid molecules can be measured using any one of the methods well known in the art for the quantitation of nucleic acid molecules, such as, for example, PCR, RT-PCR, Rnase protection, Northern blotting, other hybridisation methods and the arrays described herein.

Isolated as used herein means separated "by the hand of man" from its natural state; i.e., that, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a naturally occurring nucleic acid molecule or a polypeptide naturally present in a living organism in its natural state is not "isolated," but the same nucleic acid molecule or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. As part of or following isolation, such nucleic acid molecules can be joined to other nucleic acid molecules, such as DNAs, for mutagenesis, to form fusion proteins, and for propagation or expression in a host, for instance. The isolated nucleic acid molecules, alone or joined to other nucleic acid molecules such as vectors, can be introduced into host cells, in culture or in whole organisms. Introduced into host cells in culture or in whole organisms, such DNAs still would be isolated, as the term is used herein, because they would not be in their naturally occurring form or environment. Similarly, the nucleic acid molecules and polypeptides may occur in a composition, such as a media formulations, solutions for introduction of nucleic acid molecules or polypeptides, for example, into cells, compositions or solutions for chemical or enzymatic reactions, for instance, which are not naturally occurring compositions, and, therein remain isolated nucleic acid molecules or polypeptides within the meaning of that term as it is employed herein.

The nucleic acids according to the present invention may be chemically synthesized. Alternatively, the nucleic acids can be isolated from *S. pneumoniae* by methods known to the one skilled in the art.

According to another aspect of the present invention, a comprehensive set of novel hyperimmune serum reactive antigens and fragments thereof are provided by using the herein described antigen identification method. In a preferred embodiment of the invention, a hyperimmune serum-reactive antigen comprising an amino acid sequence being encoded by any one of the nucleic acids molecules herein described and fragments thereof are provided. In another preferred embodiment of the invention a novel set of hyperimmune serum-reactive antigens which comprises amino acid sequences selected from a group consisting of the polypeptide sequences as represented in Seq ID No 145, 245-288 and fragments thereof are provided. In a further preferred embodiment of the invention hyperimmune serum-reactive antigens which comprise amino acid sequences selected from a group consisting of the polypeptide sequences as represented in Seq ID No 146-150, 152, 154-160, 162-167, 169-175, 178, 180, 182-186, 188, 191-192, 195, 197, 199-206, 208, 211, 215-220, 222-223, 225-238, 240-244 and fragments thereof are provided. In a still preferred embodiment of the invention hyperimmune serum-reactive antigens which comprise amino acid sequences selected from a group consisting of the polypeptide sequences as represented in Seq ID No 153, 161, 168, 176, 181, 187, 196, 198, 209-210, 214, 224 and fragments thereof are provided.

The hyperimmune serum reactive antigens and fragments thereof as provided in the invention include

any polypeptide set forth in the Sequence Listing as well as polypeptides which have at least 70% identity to a polypeptide set forth in the Sequence Listing, preferably at least 80% or 85% identity to a polypeptide set forth in the Sequence Listing, and more preferably at least 90% similarity (more preferably at least 90% identity) to a polypeptide set forth in the Sequence Listing and still more preferably at least 95%, 96%, 97%, 98%, 99% or 99.5% similarity (still more preferably at least 95%, 96%, 97%, 98%, 99%, or 99.5% identity) to a polypeptide set forth in the Sequence Listing and also include portions of such polypeptides with such portion of the polypeptide generally containing at least 4 amino acids and more preferably at least 8, still more preferably at least 30, still more preferably at least 50 amino acids, such as 4, 8, 10, 20, 30, 35, 40, 45 or 50 amino acids.

The invention also relates to fragments, analogs, and derivatives of these hyperimmune serum reactive antigens and fragments thereof. The terms "fragment", "derivative" and "analog" when referring to an antigen whose amino acid sequence is set forth in the Sequence Listing, means a polypeptide which retains essentially the same or a similar biological function or activity as such hyperimmune serum reactive antigen and fragment thereof.

The fragment, derivative or analog of a hyperimmune serum reactive antigen and fragment thereof may be 1) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or 2) one in which one or more of the amino acid residues includes a substituent group, or 3) one in which the mature hyperimmune serum reactive antigen or fragment thereof is fused with another compound, such as a compound to increase the half-life of the hyperimmune serum reactive antigen and fragment thereof (for example, polyethylene glycol), or 4) one in which the additional amino acids are fused to the mature hyperimmune serum reactive antigen or fragment thereof, such as a leader or secretory sequence or a sequence which is employed for purification of the mature hyperimmune serum reactive antigen or fragment thereof or a proprotein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein.

The present invention also relates to antigens of different *S. pneumoniae* isolates. Such homologues may easily be isolated based on the nucleic acid and amino acid sequences disclosed herein. There are more than 90 serotypes in more than 40 serogroups distinguished to date and the typing is based on serotype specific antisera. The presence of any antigen can accordingly be determined for every serotype. In addition it is possible to determine the variability of a particular antigen in the various serotypes as described for the *S. pyogenes* sic gene {Hoe, N. et al., 2001}. The contribution of the various serotypes to the different pneumococcal infections varies in the different age groups and geographical regions {Gray, B. et al., 1979}; {Gray, B. et al., 1986}; {Orange, M. et al., 1993}, reviewed in Epidemiology and Prevention of Vaccine-Preventable Diseases, 7th Edition-Second Printing, The Pink Book). It is an important aspect that the most valuable protective antigens are expected to be conserved among various clinical strains.

Among the particularly preferred embodiments of the invention in this regard are the hyperimmune serum reactive antigens set forth in the Sequence Listing, variants, analogs, derivatives and fragments thereof, and variants, analogs and derivatives of fragments. Additionally, fusion polypeptides comprising such hyperimmune serum reactive antigens, variants, analogs, derivatives and fragments thereof, and variants, analogs and derivatives of the fragments are also encompassed by the present invention. Such fusion polypeptides and proteins, as well as nucleic acid molecules encoding them, can readily be made using standard techniques, including standard recombinant techniques for producing and expression of a recombinant polynucleic acid encoding a fusion protein.

Among preferred variants are those that vary from a reference by conservative amino acid substitutions. Such substitutions are those that substitute a given amino acid in a polypeptide by another amino acid of like characteristics. Typically seen as conservative substitutions are the replacements, one for another,

among the aliphatic amino acids Ala, Val, Leu and Ile; interchange of the hydroxyl residues Ser and Thr, exchange of the acidic residues Asp and Glu, substitution between the amide residues Asn and Gln, exchange of the basic residues Lys and Arg and replacements among the aromatic residues Phe and Tyr.

Further particularly preferred in this regard are variants, analogs, derivatives and fragments, and variants, analogs and derivatives of the fragments, having the amino acid sequence of any polypeptide set forth in the Sequence Listing, in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no amino acid residues are substituted, deleted or added, in any combination. Especially preferred among these are silent substitutions, additions and deletions, which do not alter the properties and activities of the polypeptide of the present invention. Also especially preferred in this regard are conservative substitutions. Most highly preferred are polypeptides having an amino acid sequence set forth in the Sequence Listing without substitutions.

The hyperimmune serum reactive antigens and fragments thereof of the present invention are preferably provided in an isolated form, and preferably are purified to homogeneity.

Also among preferred embodiments of the present invention are polypeptides comprising fragments of the polypeptides having the amino acid sequence set forth in the Sequence Listing, and fragments of variants and derivatives of the polypeptides set forth in the Sequence Listing.

In this regard a fragment is a polypeptide having an amino acid sequence that entirely is the same as part but not all of the amino acid sequence of the afore mentioned hyperimmune serum reactive antigen and fragment thereof, and variants or derivative, analogs, fragments thereof. Such fragments may be "free-standing", i.e., not part of or fused to other amino acids or polypeptides, or they may be comprised within a larger polypeptide of which they form a part or region. Also preferred in this aspect of the invention are fragments characterised by structural or functional attributes of the polypeptide of the present invention, i.e. fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta-amphipathic regions, flexible regions, surface-forming regions, substrate binding regions, and high antigenic index regions of the polypeptide of the present invention, and combinations of such fragments. Preferred regions are those that mediate activities of the hyperimmune serum reactive antigens and fragments thereof of the present invention. Most highly preferred in this regard are fragments that have a chemical, biological or other activity of the hyperimmune serum reactive antigen and fragments thereof of the present invention, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Particularly preferred are fragments comprising receptors or domains of enzymes that confer a function essential for viability of S. pneumoniae or the ability to cause disease in humans. Further preferred polypeptide fragments are those that comprise or contain antigenic or immunogenic determinants in an animal, especially in a human.

An antigenic fragment is defined as a fragment of the identified antigen, which is for itself antigenic or may be made antigenic when provided as a hapten. Therefore, also antigens or antigenic fragments showing one or (for longer fragments) only a few amino acid exchanges are enabled with the present invention, provided that the antigenic capacities of such fragments with amino acid exchanges are not severely deteriorated on the exchange(s), i.e., suited for eliciting an appropriate immune response in an individual vaccinated with this antigen and identified by individual antibody preparations from individual sera.

Preferred examples of such fragments of a hyperimmune serum-reactive antigen are selected from the group consisting of peptides comprising amino acid sequences of column "predicted immunogenic aa", and "Location of identified immunogenic region" of Table 1; the serum reactive epitopes of Table 2, especially peptides comprising amino acid 4-11, 35-64, 66-76, 101-108, 111-119 and 57-114 of Seq ID No

145; 5-27, 32-64, 92-102, 107-113, 119-125, 133-139, 148-162, 177-187, 195-201, 207-214, 241-251, 254-269, 285-300, 302-309, 317-324, 332-357, 365-404, 411-425, 443-463, 470-477, 479-487, 506-512, 515-520, 532-547, 556-596, 603-610, 616-622, 624-629, 636-642, 646-665, 667-674, 687-692, 708-720, 734-739, 752-757, 798-820, 824-851, 856-865 and 732-763 of Seq ID No 146; 14-21, 36-44, 49-66, 102-127, 162-167, 177-196, 45-109 and 145-172 of Seq ID No 147; 17-35, 64-75, 81-92, 100-119, 125-172, 174-183, 214-222, 230-236, 273-282, 287-303, 310-315, 331-340, 392-398, 412-420, 480-505, 515-523, 525-546, 553-575, 592-598, 603-609, 617-625, 631-639, 644-651, 658-670, 681-687, 691-704, 709-716, 731-736, 739-744, 750-763, 774-780, 784-791, 799-805, 809-822, 859-870, 880-885, 907-916, 924-941, 943-949, 973-986, 1010-1016, 1026-1036, 1045-1054, 1057-1062, 1082-1088, 1095-1102, 1109-1120, 1127-1134, 1140-1146, 1152-1159, 1169-1179, 1187-1196, 1243-1251, 1262-1273, 1279-1292, 1306-1312, 1332-1343, 1348-1364, 1379-1390, 1412-1420, 1427-1436, 1458-1468, 1483-1503, 1524-1549, 1574-1588, 1614-1619, 1672-1685, 1697-1707, 1711-1720, 1738-1753, 1781-1787, 1796-1801, 1826-1843, 132-478, 508-592 and 1753-1810 of Seq ID No 148; 15-43, 49-55, 71-77, 104-110, 123-130, 162-171, 180-192, 199-205, 219-227, 246-254, 264-270, 279-287, 293-308, 312-322, 330-342, 349-356, 369-377, 384-394, 401-406, 416-422, 432-439, 450-460, 464-474, 482-494, 501-508, 521-529, 536-546, 553-558, 568-574, 584-591, 602-612, 616-626, 634-646, 653-660, 673-681, 688-698, 705-710, 720-726, 736-749, 833-848, 1-199, 200-337, 418-494 and 549-647 of Seq ID No 149; 9-30, 65-96, 99-123, 170-178 and 1-128 of Seq ID No 150; 7-32, 34-41, 96-106, 127-136, 154-163, 188-199, 207-238, 272-279, 306-312, 318-325, 341-347, 353-360, 387-393, 399-406, 434-440, 452-503, 575-580, 589-601, 615-620, 635-640, 654-660, 674-680, 696-701, 710-731, 1-548 and 660-691 of Seq ID No 151; 4-19, 35-44, 48-59, 77-87, 93-99, 106-111, 130-138, 146-161 and 78-84 of Seq ID No 152; 24-30, 36-43, 64-86, 93-99, 106-130, 132-145, 148-165, 171-177, 189-220, 230-249, 251-263, 293-300, 302-312, 323-329, 338-356, 369-379, 390-412 and 179-193 of Seq ID No 153; 30-39, 61-67, 74-81, 90-120, 123-145, 154-167, 169-179, 182-197, 200-206, 238-244, 267-272 and 230-265 of Seq ID No 154; 14-20, 49-65, 77-86 and 2-68 of Seq ID No 155; 4-9, 26-35, 42-48, 53-61, 63-85, 90-101, 105-111, 113-121, 129-137, 140-150, 179-188, 199-226, 228-237, 248-255, 259-285, 299-308, 314-331, 337-343, 353-364, 410-421, 436-442 and 110-144 of Seq ID No 156; 36-47, 55-63, 94-108, 129-134, 144-158, 173-187, 196-206, 209-238, 251-266, 270-285, 290-295, 300-306, 333-344, 346-354, 366-397, 404-410, 422-435, 439-453, 466-473, 515-523, 529-543, 554-569, 571-585, 590-596, 607-618, 627-643, 690-696, 704-714, 720-728, 741-749, 752-767, 780-799, 225-247 and 480-507 of Seq ID No 157; 16-25, 36-70, 80-93, 100-106 and 78-130 of Seq ID No 158; 18-27, 41-46, 50-57, 65-71, 79-85, 93-98, 113-128, 144-155, 166-178, 181-188, 201-207, 242-262, 265-273, 281-295, 303-309, 318-327 and 36-64 of Seq ID No 159; 7-29, 31-44, 50-59, 91-96, 146-153, 194-201, 207-212, 232-238, 264-278, 284-290, 296-302, 326-353, 360-370, 378-384, 400-405, 409-418, 420-435, 442-460, 499-506, 529-534, 556-562, 564-576, 644-651, 677-684, 687-698, 736-743, 759-766, 778-784, 808-814, 852-858, 874-896, 920-925, 929-935, 957-965, 1003-1012, 1021-1027, 1030-1044, 1081-1087, 1101-1111, 1116-1124, 1148-1159, 1188-1196, 1235-1251, 1288-1303, 1313-1319, 1328-1335, 1367-1373, 1431-1437, 1451-1458, 1479-1503, 1514-1521, 1530-1540, 1545-1552, 1561-1568, 1598-1605, 1617-1647, 1658-1665, 1670-1676, 1679-1689, 1698-1704, 1707-1713, 1732-1738, 1744-1764, 1-70, 154-189, 922-941, 1445-1462 and 1483-1496 of Seq ID No 160; 6-51, 81-91, 104-113, 126-137, 150-159, 164-174, 197-209, 215-224, 229-235, 256-269, 276-282, 307-313, 317-348, 351-357, 376-397, 418-437, 454-464, 485-490, 498-509, 547-555, 574-586, 602-619 and 452-530 of Seq ID No 161; 25-31, 39-47, 49-56, 99-114, 121-127, 159-186, 228-240, 253-269, 271-279, 303-315, 365-382, 395-405, 414-425, 438-453 and 289-384 of Seq ID No 162; 9-24, 41-47, 49-54, 68-78, 108-114, 117-122, 132-140, 164-169, 179-186, 193-199, 206-213, 244-251, 267-274, 289-294, 309-314, 327-333, 209-249 and 286-336 of Seq ID No 163; 9-28, 53-67, 69-82, 87-93, 109-117, 172-177, 201-207, 220-227, 242-247, 262-268, 305-318, 320-325 and 286-306 of Seq ID No 164; 4-10, 26-39, 47-58, 63-73, 86-96, 98-108, 115-123, 137-143, 148-155, 160-176, 184-189, 194-204, 235-240, 254-259, 272-278 and 199-283 of Seq ID No 165; 4-26, 33-39, 47-53, 59-65, 76-83, 91-97, 104-112, 118-137, 155-160, 167-174, 198-207, 242-268, 273-279, 292-315, 320-332, 345-354, 358-367, 377-394, 403-410, 424-439, 445-451, 453-497, 511-518, 535-570, 573-589, 592-601, 604-610 and 202-242 of Seq ID No 166; 8-30, 36-45, 64-71, 76-82, 97-103, 105-112, 134-151, 161-183, 211-234, 253-268, 270-276, 278-284, 297-305, 309-315, 357-362, 366-372, 375-384, 401-407, 409-416, 441-455, 463-470, 475-480, 490-497, 501-513, 524-537, 552-559, 565-576, 581-590, 592-600, 619-625, 636-644, 646-656 and 316-419 of Seq ID No 167; 4-17, 52-58, 84-99, 102-110, 114-120, 124-135, 143-158, 160-173, 177-196, 201-216, 223-250, 259-267, 269-275 and 1-67 of Seq ID No 168; 6-46, 57-67, 69-80, 82-133, 137-143, 147-168, 182-187, 203-209, 214-229, 233-242, 246-280 and 53-93 of Seq ID No 169; 7-40, 50-56, 81-89, 117-123, 202-209, 213-218, 223-229, 248-261, 264-276, 281-288, 303-308, 313-324, 326-332, 340-346, 353-372, 434-443,

465-474, 514-523, 556-564, 605-616, 620-626, 631-636, 667-683, 685-699, 710-719, 726-732, 751-756, 760-771, 779-788, 815-828, 855-867, 869-879, 897-902, 917-924, 926-931, 936-942, 981-1000, 1006-1015, 1017-1028, 1030-1039, 1046-1054, 1060-1066, 1083-1092, 1099-1112, 1122-1130, 1132-1140, 1148-1158, 1161-1171, 1174-1181, 1209-1230, 1236-1244, 1248-1254, 1256-1267, 1269-1276, 1294-1299, 1316-1328, 1332-1354, 1359-1372, 1374-1380, 1384-1390, 1395-1408, 1419-1425, 1434-1446, 1453-1460, 1465-1471, 1474-1493, 1505-1515, 1523-1537, 1547-1555, 1560-1567, 1577-1605, 1633-1651, 1226-1309, 1455-1536 and 1538-1605 of Seq ID No 170; 4-10, 31-39, 81-88, 106-112, 122-135, 152-158, 177-184, 191-197, 221-227, 230-246, 249-255, 303-311, 317-326, 337-344, 346-362, 365-371, 430-437, 439-446, 453-462, 474-484 and 449-467 of Seq ID No 171; 9-15, 24-35, 47-55, 122-128, 160-177, 188-196, 202-208, 216-228, 250-261, 272-303, 318-324, 327-339, 346-352, 355-361, 368-373, 108-218 and 344-376 of Seq ID No 172; 6-14, 17-48, 55-63, 71-90, 99-109, 116-124, 181-189, 212-223, 232-268, 270-294, 297-304, 319-325, 340-348, 351-370, 372-378, 388-394, 406-415, 421-434 and 177-277 of Seq ID No 173; 21-39, 42-61, 65-75, 79-85, 108-115 and 11-38 of Seq ID No 174; 4-17, 26-39, 61-76, 103-113, 115-122, 136-142, 158-192, 197-203, 208-214, 225-230, 237-251 and 207-225 of Seq ID No 175; 5-11, 27-36, 42-53, 62-70, 74-93, 95-104, 114-119, 127-150, 153-159, 173-179, 184-193, 199-206, 222-241, 248-253, 257-280, 289-295, 313-319, 322-342, 349-365, 368-389, 393-406, 408-413, 426-438, 447-461, 463-470, 476-495, 532-537, 543-550 and 225-246 of Seq ID No 176; 4-29, 68-82, 123-130, 141-147, 149-157, 178-191, 203-215, 269-277, 300-307, 327-335, 359-370, 374-380, 382-388, 393-400, 410-417, 434-442, 483-492, 497-503, 505-513, 533-540, 564-569, 601-607, 639-647, 655-666, 693-706, 712-718, 726-736, 752-758, 763-771, 774-780, 786-799, 806-812, 820-828, 852-863, 884-892, 901-909, 925-932, 943-948, 990-996, 1030-1036, 1051-1059, 1062-1068, 1079-1086, 1105-1113, 1152-1162, 1168-1179, 1183-1191, 1204-1210, 1234-1244, 1286-1295, 1318-1326, 1396-1401, 1451-1460, 1465-1474, 1477-1483, 1488-1494, 1505-1510, 1514-1521, 1552-1565, 1593-1614, 1664-1672, 1677-1685, 1701-1711, 1734-1745, 1758-1770, 1784-1798, 1840-1847, 1852-1873, 1885-1891, 1906-1911, 1931-1939, 1957-1970, 1977-1992, 2014-2020, 2026-2032, 2116-2134, 1-348, 373-490, 573-767, 903-1043, 1155-1198, 1243-1482, 1550-1595, 1682-1719, 1793-1921 and 2008-2110 of Seq ID No 177; 10-35, 39-52, 107-112, 181-188, 226-236, 238-253, 258-268, 275-284, 296-310, 326-338, 345-368, 380-389, 391-408, 410-418, 420-429, 444-456, 489-505, 573-588, 616-623, 637-643, 726-739, 741-767, 785-791, 793-803, 830-847, 867-881, 886-922, 949-956, 961-980, 988-1004, 1009-1018, 1027-1042, 1051-1069, 1076-1089, 1108-1115, 1123-1135, 1140-1151, 1164-1179, 1182-1191, 1210-1221, 1223-1234, 1242-1250, 1255-1267, 1281-1292, 1301-1307, 1315-1340, 1348-1355, 1366-1373, 1381-1413, 1417-1428, 1437-1444, 1453-1463, 1478-1484, 1490-1496, 1498-1503, 1520-1536, 1538-1546, 1548-1570, 1593-1603, 1612-1625, 1635-1649, 1654-1660, 1670-1687, 1693-1700, 1705-1711, 1718-1726, 1729-1763, 1790-1813, 1871-1881, 1893-1900, 1907-1935, 1962-1970, 1992-2000, 2006-2013, 2033-2039, 2045-2051, 2055-2067, 2070-2095, 2097-2110, 2115-2121, 2150-2171, 2174-2180, 2197-2202, 2206-2228 and 1526-1560 of Seq ID No 178; 4-17, 35-48, 54-76, 78-107, 109-115, 118-127, 134-140, 145-156, 169-174, 217-226, 232-240, 256-262, 267-273, 316-328, 340-346, 353-360, 402-409, 416-439, 448-456, 506-531, 540-546, 570-578, 586-593, 595-600, 623-632, 662-667, 674-681, 689-705, 713-724, 730-740, 757-763, 773-778, 783-796, 829-835, 861-871, 888-899, 907-939, 941-955, 957-969, 986-1000, 1022-1028, 1036-1044, 1068-1084, 1095-1102, 1118-1124, 1140-1146, 1148-1154, 1168-1181, 1185-1190, 1197-1207, 1218-1226, 1250-1270, 1272-1281, 1284-1296, 1312-1319, 1351-1358, 1383-1409, 1422-1428, 1438-1447, 1449-1461, 1482-1489, 1504-1510, 1518-1527, 1529-1537, 1544-1551, 1569-1575, 1622-1628, 1631-1637, 1682-1689, 1711-1718, 1733-1740, 1772-1783, 1818-1834, 1859-1872, 1-64 and 128-495 of Seq ID No 179; 8-28, 32-37, 62-69, 119-125, 137-149, 159-164, 173-189, 200-205, 221-229, 240-245, 258-265, 268-276, 287-293, 296-302, 323-329 and 1-95 of Seq ID No 180; 9-18, 25-38, 49-63, 65-72, 74-81, 94-117, 131-137, 139-146, 149-158, 162-188, 191-207, 217-225, 237-252, 255-269, 281-293, 301-326, 332-342, 347-354, 363-370, 373-380, 391-400, 415-424, 441-447 and 75-107 of Seq ID No 181; 4-24, 64-71, 81-87, 96-116, 121-128, 130-139, 148-155, 166-173, 176-184, 203-215, 231-238, 243-248, 256-261, 280-286, 288-306, 314-329 and 67-148 of Seq ID No 182; 4-10, 19-37, 46-52, 62-81, 83-89, 115-120, 134-139, 141-151, 168-186, 197-205, 209-234, 241-252, 322-335, 339-345, 363-379, 385-393, 403-431, 434-442, 447-454, 459-465, 479-484, 487-496 and 404-420 of Seq ID No 183; 10-35, 46-66, 71-77, 84-93, 96-122, 138-148, 154-172, 182-213, 221-233, 245-263, 269-275, 295-301, 303-309, 311-320, 324-336, 340-348, 351-359, 375-381 and 111-198 of Seq ID No 184; 14-25, 30-42, 47-61, 67-75, 81-91, 98-106, 114-122, 124-135, 148-193, 209-227 and 198-213 of Seq ID No 185; 5-18, 45-50, 82-90, 97-114, 116-136, 153-161, 163-171, 212-219, 221-227, 240-249, 267-281, 311-317, 328-337, 375-381, 390-395, 430-436, 449-455, 484-495, 538-543, 548-554, 556-564, 580-586, 596-602 and 493-606 of Seq ID No 186; 9-25, 28-34, 37-44, 61-68, 75-81, 88-96, 98-111, 119-133, 138-150, 152-163, 168-182, 186-194, 200-

205, 216-223, 236-245, 257-264, 279-287, 293-304, 311-318, 325-330, 340-346, 353-358, 365-379, 399-409, 444-453 and 303-391 of Seq ID No 187; 16-36, 55-61, 66-76, 78-102, 121-130, 134-146, 150-212, 221-239, 255-276, 289-322, 329-357 and 29-59 of Seq ID No 188; 8-27, 68-74, 77-99, 110-116, 124-141, 171-177, 202-217, 221-228, 259-265, 275-290, 293-303, 309-325, 335-343, 345-351, 365-379, 384-394, 406-414, 423-437, 452-465, 478-507, 525-534, 554-560, 611-624, 628-651, 669-682, 742-747, 767-778, 782-792, 804-812, 820-836, 79-231 and 359-451 of Seq ID No 189; 5-28, 39-45, 56-62, 67-74, 77-99, 110-117, 124-141, 168-176, 200-230, 237-244, 268-279, 287-299, 304-326, 329-335, 348-362, 370-376, 379-384, 390-406, 420-429, 466-471, 479-489, 495-504, 529-541, 545-553, 561-577, 598-604, 622-630, 637-658, 672-680, 682-688, 690-696, 698-709, 712-719, 724-736, 738-746, 759-769, 780-786, 796-804, 813-818, 860-877, 895-904, 981-997, 1000-1014, 1021-1029, 1-162, 206-224, 254-350, 414-514 and 864-938 of Seq ID No 190; 4-11, 19-49, 56-66, 68-101, 109-116, 123-145, 156-165, 177-185, 204-221, 226-234, 242-248, 251-256, 259-265, 282-302, 307-330, 340-349, 355-374, 377-383, 392-400, 422-428, 434-442, 462-474 and 266-322 of Seq ID No 191; 14-43, 45-57, 64-74, 80-87, 106-127, 131-142, 145-161, 173-180, 182-188, 203-210, 213-219, 221-243, 245-254, 304-311, 314-320, 342-348, 354-365, 372-378, 394-399, 407-431, 436-448, 459-465, 470-477, 484-490, 504-509, 531-537, 590-596, 611-617, 642-647, 723-734, 740-751, 754-762, 764-774, 782-797, 807-812, 824-831, 838-845, 877-885, 892-898, 900-906, 924-935, 940-946, 982-996, 1006-1016, 1033-1043, 1051-1056, 1058-1066, 1094-1108, 1119-1126, 1129-1140, 1150-1157, 1167-1174, 1176-1185, 1188-1201, 1209-1216, 1220-1228, 1231-1237, 1243-1248, 1253-1285, 1288-1297, 1299-1307, 1316-1334, 1336-1343, 1350-1359, 1365-1381, 1390-1396, 1412-1420, 1427-1439, 1452-1459, 1477-1484, 1493-1512, 1554-1559, 1570-1578, 1603-1608, 1623-1630, 1654-1659, 1672-1680, 1689-1696, 1705-1711, 1721-1738, 1752-1757, 1773-1780, 1817-1829, 1844-1851, 1856-1863, 1883-1895, 1950-1958, 1974-1990, 172-354, 384-448, 464-644, 648-728 and 1357-1370 of Seq ID No 192; 8-27, 68-74, 77-99, 110-116, 124-141, 169-176, 201-216, 220-227, 258-264, 274-289, 292-302, 308-324, 334-342, 344-350, 364-372, 377-387, 399-407, 416-429, 445-458, 471-481, 483-500, 518-527, 547-553, 604-617, 621-644, 662-675, 767-778, 809-816, 15-307, 350-448 and 496-620 of Seq ID No 193; 4-17, 24-29, 53-59, 62-84, 109-126, 159-164, 189-204, 208-219, 244-249, 274-290, 292-302, 308-324, 334-342, 344-350, 378-389, 391-397, 401-409, 424-432, 447-460, 470-479, 490-504, 521-529, 538-544, 549-555, 570-577, 583-592, 602-608, 615-630, 635-647, 664-677, 692-698, 722-731, 733-751, 782-790, 793-799, 56-267, 337-426 and 495-601 of Seq ID No 194; 12-22, 49-59, 77-89, 111-121, 136-148, 177-186, 207-213, 217-225, 227-253, 259-274, 296-302, 328-333, 343-354, 374-383, 424-446, 448-457, 468-480, 488-502, 507-522, 544-550, 553-560, 564-572, 587-596, 604-614, 619-625, 629-635, 638-656, 662-676, 680-692, 697-713, 720-738, 779-786, 833-847, 861-869, 880-895, 897-902, 911-917, 946-951, 959-967, 984-990, 992-1004, 1021-1040, 1057-1067, 1073-1080 and 381-403 of Seq ID No 195; 4-10, 26-31, 46-56, 60-66, 70-79, 86-94, 96-102, 109-118, 132-152, 164-187, 193-206, 217-224 and 81-149 of Seq ID No 196; 4-21, 26-37, 48-60, 71-82, 109-117, 120-128, 130-136, 142-147, 181-187, 203-211, 216-223, 247-255, 257-284, 316-325, 373-379, 395-400, 423-435, 448-456, 479-489, 512-576, 596-625, 641-678, 680-688, 692-715 and 346-453 of Seq ID No 197; 10-16, 25-31, 34-56, 58-69, 71-89, 94-110, 133-176, 186-193, 208-225, 240-250, 259-266, 302-307, 335-341, 376-383, 410-416 and 316-407 of Seq ID No 198; 11-29, 42-56, 60-75, 82-88, 95-110, 116-126, 132-143, 145-160, 166-172, 184-216 and 123-164 of Seq ID No 199; 11-29, 54-63, 110-117, 139-152, 158-166, 172-180, 186-193, 215-236, 240-251, 302-323, 330-335, 340-347, 350-366, 374-381 and 252-299 of Seq ID No 200; 18-27, 35-42, 50-56, 67-74, 112-136, 141-153, 163-171, 176-189, 205-213, 225-234, 241-247, 253-258, 269-281, 288-298, 306-324, 326-334, 355-369, 380-387 and 289-320 of Seq ID No 201; 7-15, 19-41, 56-72, 91-112, 114-122, 139-147, 163-183, 196-209, 258-280, 326-338, 357-363, 391-403, 406-416 and 360-378 of Seq ID No 202; 11-18, 29-41, 43-49, 95-108, 142-194, 204-212, 216-242, 247-256, 264-273 and 136-149 of Seq ID No 203; 18-24, 33-40, 65-79, 89-102, 113-119, 130-137, 155-161, 173-179, 183-203, 205-219, 223-231, 245-261, 267-274, 296-306, 311-321, 330-341, 344-363, 369-381, 401-408, 415-427, 437-444, 453-464, 472-478, 484-508, 517-524, 526-532, 543-548 and 59-180 of Seq ID No 204; 5-13, 52-65, 67-73, 97-110, 112-119, 134-155 and 45-177 of Seq ID No 205; 6-28, 34-43, 57-67, 75-81, 111-128, 132-147, 155-163, 165-176, 184-194, 208-216, 218-229, 239-252, 271-278, 328-334, 363-376, 381-388, 426-473, 481-488, 492-498, 507-513, 536-546, 564-582, 590-601, 607-623, 148-269, 420-450 and 610-648 of Seq ID No 206; 4-12, 20-38, 69-75, 83-88, 123-128, 145-152, 154-161, 183-188, 200-213, 245-250, 266-272, 306-312, 332-339, 357-369, 383-389, 395-402, 437-453, 455-470, 497-503 and 1-112 of Seq ID No 207; 35-59, 74-86, 111-117, 122-137 and 70-154 of Seq ID No 208; 26-42, 54-61, 65-75, 101-107, 123-130, 137-144, 148-156, 164-172, 177-192, 213-221, 231-258 and 157-249 of Seq ID No 209; 29-38, 61-67, 77-87, 94-100, 105-111, 118-158 and 1-97 of Seq ID No 210; 7-21, 30-48, 51-58, 60-85, 94-123, 134-156, 160-167, 169-183, 186-191, 216-229, 237-251,

- 28 -

257-267, 272-282, 287-298 and 220-243 of Seq ID No 211; 6-29, 34-47, 56-65, 69-76, 83-90, 123-134, 143-151, 158-178, 197-203, 217-235, 243-263, 303-309, 320-333, 338-348, 367-373, 387-393, 407-414, 416-427, 441-457, 473-482, 487-499, 501-509, 514-520, 530-535, 577-583, 590-602, 605-612, 622-629, 641-670, 678-690, 37-71 and 238-307 of Seq ID No 212; 7-40, 121-132, 148-161, 196-202, 209-215, 221-235, 248-255, 271-280, 288-295, 330-339, 395-409, 414-420, 446-451, 475-487, 556-563, 568-575, 580-586, 588-595, 633-638, 643-648, 652-659, 672-685, 695-700, 710-716, 737-742, 749-754, 761-767, 775-781, 796-806, 823-835, 850-863, 884-890, 892-900, 902-915, 934-941 and 406-521 of Seq ID No 213; 9-18, 24-46, 51-58, 67-77, 85-108, 114-126, 129-137, 139-146, 152-165, 173-182, 188-195, 197-204, 217-250, 260-274, 296-313, 343-366, 368-384, 427-434, 437-446, 449-455, 478-484, 492-506, 522-527, 562-591, 599-606, 609-618, 625-631, 645-652 and 577-654 of Seq ID No 214; 13-20, 26-37, 41-53, 56-65, 81-100, 102-114, 118-127, 163-188, 196-202, 231-238, 245-252, 266-285, 293-298, 301-306 and 19-78 of Seq ID No 215; 10-23, 32-42, 54-66, 73-91, 106-113, 118-127, 139-152, 164-173, 198-207, 210-245, 284-300, 313-318, 330-337, 339-346, 354-361, 387-393, 404-426, 429-439, 441-453, 467-473, 479-485, 496-509, 536-544, 551-558, 560-566, 569-574, 578-588, 610-615, 627-635, 649-675, 679-690, 698-716, 722-734, 743-754, 769-780, 782-787 and 480-550 of Seq ID No 216; 6-39, 42-50, 60-68, 76-83, 114-129, 147-162, 170-189, 197-205, 217-231, 239-248, 299-305, 338-344, 352-357, 371-377, 380-451, 459-483, 491-499, 507-523, 537-559, 587-613, 625-681, 689-729, 737-781, 785-809, 817-865, 873-881, 889-939, 951-975, 983-1027, 1031-1055, 1063-1071, 1079-1099, 1103-1127, 1151-1185, 1197-1261, 1269-1309, 1317-1333, 1341-1349, 1357-1465, 1469-1513, 1517-1553, 1557-1629, 1637-1669, 1677-1701, 1709-1725, 1733-1795, 1823-1849, 1861-1925, 1933-1973, 1981-2025, 2029-2053, 2061-2109, 2117-2125, 2133-2183, 2195-2219, 2227-2271, 2275-2299, 2307-2315, 2323-2343, 2347-2371, 2395-2429, 2441-2529, 2537-2569, 2577-2601, 2609-2625, 2633-2695, 2699-2737, 2765-2791, 2803-2867, 2889-2913, 2921-2937, 2945-2969, 2977-2985, 2993-3009, 3023-3045, 3073-3099, 3111-3167, 3175-3215, 3223-3267, 3271-3295, 3303-3351, 3359-3367, 3375-3425, 3437-3461, 3469-3513, 3517-3541, 3549-3557, 3565-3585, 3589-3613, 3637-3671, 3683-3747, 3755-3795, 3803-3819, 3827-3835, 3843-3951, 3955-3999, 4003-4039, 4043-4115, 4123-4143, 4147-4171, 4195-4229, 4241-4305, 4313-4353, 4361-4377, 4385-4393, 4401-4509, 4513-4557, 4561-4597, 4601-4718, 4749-4768, 74-171, 452-559 and 2951-3061 of Seq ID No 217; 16-22, 30-51, 70-111, 117-130, 137-150, 171-178, 180-188, 191-196 and 148-181 of Seq ID No 218; 6-19, 21-46, 50-56, 80-86, 118-126, 167-186, 189-205, 211-242, 244-267, 273-286, 290-297, 307-316, 320-341 and 34-60 of Seq ID No 219; 5-26, 33-43, 48-54, 58-63, 78-83, 113-120, 122-128, 143-152, 157-175, 185-192, 211-225, 227-234, 244-256, 270-281, 284-290, 304-310, 330-337, 348-355, 362-379, 384-394, 429-445, 450-474, 483-490, 511-520, 537-546, 548-554, 561-586, 590-604, 613-629, 149-186, 285-431 and 573-659 of Seq ID No 220; 5-26, 49-59, 61-67, 83-91, 102-111, 145-157, 185-192, 267-272, 279-286, 292-298, 306-312, 134-220, 235-251 and 254-280 of Seq ID No 221; 5-19, 72-79, 83-92, 119-124, 140-145, 160-165, 167-182, 224-232, 240-252, 259-270, 301-310, 313-322, 332-343, 347-367, 384-398, 416-429, 431-446, 454-461 and 1-169 of Seq ID No 222; 8-17, 26-31, 56-62, 75-83, 93-103, 125-131, 135-141, 150-194, 205-217, 233-258, 262-268, 281-286 and 127-168 of Seq ID No 223; 6-12, 69-75, 108-115, 139-159, 176-182, 194-214 and 46-161 of Seq ID No 224; 6-13, 18-27, 39-48, 51-59, 66-73, 79-85, 95-101, 109-116, 118-124, 144-164, 166-177, 183-193, 197-204, 215-223, 227-236, 242-249, 252-259, 261-270, 289-301, 318-325 and 12-58 of Seq ID No 225; 4-10, 26-32, 48-60, 97-105, 117-132, 138-163, 169-185, 192-214, 219-231, 249-261, 264-270, 292-308, 343-356, 385-392, 398-404, 408-417, 435-441 and 24-50 of Seq ID No 226; 10-40, 42-48, 51-61, 119-126 and 1-118 of Seq ID No 227; 5-17, 40-58, 71-83, 103-111, 123-140, 167-177, 188-204 and 116-128 of Seq ID No 228; 4-9, 11-50, 57-70, 112-123, 127-138 and 64-107 of Seq ID No 229; 9-39, 51-67 and 1-101 of Seq ID No 230; 5-14, 17-25, 28-46, 52-59, 85-93, 99-104, 111-120, 122-131, 140-148, 158-179, 187-197, 204-225, 271-283, 285-293 and 139-155 of Seq ID No 231; 42-70, 73-90, 92-108, 112-127, 152-164, 166-172, 181-199, 201-210, 219-228, 247-274, 295-302, 322-334, 336-346, 353-358, 396-414, 419-425, 432-438, 462-471, 518-523, 531-536, 561-567, 576-589, 594-612, 620-631, 665-671, 697-710, 718-731, 736-756, 765-771, 784-801 and 626-653 of Seq ID No 232; 8-28, 41-51, 53-62, 68-74, 79-85, 94-100, 102-108, 114-120, 130-154, 156-162, 175-180, 198-204, 206-213, 281-294, 308-318, 321-339, 362-368, 381-386, 393-399, 407-415 and 2-13 of Seq ID No 233; 4-39, 48-65, 93-98, 106-112, 116-129 and 10-36 of Seq ID No 234; 25-32, 35-50, 66-71, 75-86, 90-96, 123-136, 141-151, 160-179, 190-196, 209-215, 222-228, 235-242, 257-263, 270-280 and 209-247 of Seq ID No 235; 5-29, 31-38, 50-57, 62-75, 83-110, 115-132, 168-195, 197-206, 216-242, 249-258, 262-269, 333-340, 342-350, 363-368, 376-392, 400-406, 410-421, 423-430, 436-442, 448-454, 460-466, 471-476, 491-496, 511-516, 531-536, 551-556, 571-576, 585-591, 599-605, 27-70, 219-293, 441-504 and 512-584 of Seq ID No 236; 4-12, 14-34, 47-75, 83-104, 107-115, 133-140, 148-185, 187-196, 207-212, 224-256, 258-265, 281-287, 289-296,

298-308, 325-333, 345-355, 365-371, 382-395, 424-435, 441-457, 465-472, 483-491, 493-505, 528-534, 536-546, 552-558, 575-584, 589-600, 616-623 and 576-591 of Seq ID No 237; 4-76, 78-89, 91-126, 142-148, 151-191, 195-208, 211-223, 226-240, 256-277, 279-285, 290-314, 317-323, 358-377, 381-387, 391-396, 398-411, 415-434, 436-446, 454-484, 494-512, 516-523, 538-552, 559-566, 571-577, 579-596, 599-615, 620-627, 635-644, 694-707, 720-734, 737-759, 761-771 and 313-329 of Seq ID No 238; 7-38, 44-49, 79-89, 99-108, 117-123, 125-132, 137-146, 178-187, 207-237, 245-255, 322-337, 365-387, 398-408, 445-462, 603-608, 623-628, 644-650, 657-671, 673-679 and 111-566 of Seq ID No 239; 6-20, 22-35, 39-45, 58-64, 77-117, 137-144, 158-163, 205-210, 218-224, 229-236, 239-251, 263-277, 299-307, 323-334, 353-384, 388-396, 399-438, 443-448, 458-463, 467-478, 481-495, 503-509, 511-526, 559-576, 595-600, 612-645, 711-721, 723-738, 744-758, 778-807 and 686-720 of Seq ID No 240; 10-33, 35-41, 72-84, 129-138, 158-163, 203-226, 243-252, 258-264, 279-302, 322-329, 381-386, 401-406, 414-435 and 184-385 of Seq ID No 241; 4-9, 19-24, 41-47, 75-85, 105-110, 113-146 and 45-62 of Seq ID No 242; 4-25, 52-67, 117-124, 131-146, 173-180, 182-191, 195-206, 215-221, 229-236, 245-252, 258-279, 286-291, 293-302, 314-320, 327-336, 341-353, 355-361, 383-389 and 1-285 of Seq ID No 243; 14-32, 38-50, 73-84, 93-105, 109-114 and 40-70 of Seq ID No 244; 5-26 and 22-34 of Seq ID No 245; 23-28 and 13-39 of Seq ID No 246; 8-14 and 21-34 of Seq ID No 247; 4-13, 20-29, 44-50, 59-74 and 41-69 of Seq ID No 248; 4-9, 19-42, 48-59, 71-83 and 57-91 of Seq ID No 249; 4-14 and 10-28 of Seq ID No 250; 22-28, 32-42, 63-71, 81-111, 149-156, 158-167, 172-180, 182-203, 219-229 and 27-49 of Seq ID No 251; 17-27 and 23-32 of Seq ID No 252; 18-24 and 28-38 of Seq ID No 253; 9-15 and 13-27 of Seq ID No 254; 13-22 and 18-29 of Seq ID No 255; 17-26 and 2-11 of Seq ID No 256; 4-33 and 16-32 of Seq ID No 257; 4-10, 37-43, 54-84, 92-127 and 15-62 of Seq ID No 258; 4-14, 20-32, 35-60, 69-75, 79-99, 101-109, 116-140 and 124-136 of Seq ID No 259; 2-13 of Seq ID No 260; 4-13, 28-42 and 42-57 of Seq ID No 261; 4-14, 27-44 and 14-35 of Seq ID No 262; 4-12 and 1-27 of Seq ID No 263; 4-18, 39-45, 47-74 and 35-66 of Seq ID No 264; 8-20, 43-77 and 17-36 of Seq ID No 265; 4-30, 35-45, 51-57 and 35-49 of Seq ID No 266; 4-24, 49-57 and 15-34 of Seq ID No 267; 4-22 and 8-27 of Seq ID No 268; 13-25, 32-59, 66-80 and 21-55 of Seq ID No 269; 4-10, 24-33, 35-42, 54-65, 72-82, 98-108 and 15-30 of Seq ID No 270; 8-19 and 17-47 of Seq ID No 271; 12-18, 40-46 and 31-52 of Seq ID No 272; 4-20, 35-78, 83-102, 109-122 and 74-86 of Seq ID No 273; 7-17, 21-41, 46-63 and 2-20 of Seq ID No 274; 30-37 and 2-33 of Seq ID No 275; 4-13, 17-25 and 1-15 of Seq ID No 276; 17-31, 44-51 and 20-51 of Seq ID No 277; 20-30 and 5-23 of Seq ID No 278; 13-33, 48-71 and 92-110 of Seq ID No 279; 4-9, 50-69, 76-88, 96-106, 113-118 and 12-34 of Seq ID No 280; 4-24 and 6-26 of Seq ID No 281; 7-26 and 14-30 of Seq ID No 282; 9-39, 46-68, 75-82, 84-103 and 26-44 of Seq ID No 283; 4-30, 33-107 and 58-84 of Seq ID No 284; 4-12 and 9-51 of Seq ID No 285; 12-18, 29-37 and 6-37 of Seq ID No 286; 4-21, 33-52, 64-71 and 16-37 of Seq ID No 287; 9-19 and 2-30 of Seq ID No 288; 20-37 of Seq ID No 245; 8-27 of Seq ID No 246; 10-27 of Seq ID No 247; 42-59 and 52-69 of Seq ID No 248; 63-80 and 74-91 of Seq ID No 249; 11-28 of Seq ID No 250; 28-49 of Seq ID No 251; 15-32 of Seq ID No 252; 4-20 of Seq ID No 253; 10-27 of Seq ID No 254; 17-34 of Seq ID No 255; 1-18 of Seq ID No 256; 16-33 of Seq ID No 257; 16-36, 30-49 and 43-62 of Seq ID No 258; 122-139 of Seq ID No 259; 1-18 of Seq ID No 260; 41-58 of Seq ID No 261; 15-35 of Seq ID No 262; 2-27 of Seq ID No 263; 18-36 of Seq ID No 265; 34-51 of Seq ID No 266; 9-27 of Seq ID No 268; 22-47 of Seq ID No 269; 18-36 and 29-47 of Seq ID No 271; 32-52 of Seq ID No 272; 72-89 of Seq ID No 273; 3-20 of Seq ID No 274; 3-21 and 15-33 of Seq ID No 275; 1-18 of Seq ID No 276; 6-23 of Seq ID No 278; 93-110 of Seq ID No 279; 13-34 of Seq ID No 280; 7-26 and 9-26 of Seq ID No 281; 16-33 of Seq ID No 282; 27-44 of Seq ID No 283; 67-84 of Seq ID No 284; 10-33 and 26-50 of Seq ID No 285; 7-25 and 19-37 of Seq ID No 286; 17-37 of Seq ID No 287; 3-20 and 13-30 of Seq ID No 288; 62-80 and 75-93 of Seq ID No 145; 92-108 of Seq ID No 147; 332-349, 177-200 and 1755-1777 of Seq ID No 148; 109-133, 149-174, 260-285 and 460-485 of Seq ID No 149; 26-47 and 42-64 of Seq ID No 150; 22-41, 35-54, 115-130, 306-325, 401-420 and 454-478 of Seq ID No 151; 22-45 of Seq ID No 155; 156-174, 924-940, 1485-1496, 1447-1462 and 1483-1498 of Seq ID No 160; 457-475 of Seq ID No 161; 302-325 of Seq ID No 163; 288-305 of Seq ID No 164; 244-266 and 260-282 of Seq ID No 165; 204-225 and 220-241 of Seq ID No 166; 324-345, 340-361, 356-377, 372-393 and 388-408 of Seq ID No 167; 39-64 of Seq ID No 168; 54-76 and 70-92 of Seq ID No 169; 1227-1247, 1539-1559, 1554-1574, 1569-1589, 1584-1604, 1242-1262, 1272-1292, 1287-1308, 1456-1477, 1472-1494, 1488-1510 and 1505-1526 of Seq ID No 170; 351-368 of Seq ID No 172; 179-200, 195-216, 211-232, 227-248 and 243-263 of Seq ID No 173; 13-37 of Seq ID No 174; 208-224 of Seq ID No 175; 42-64, 59-81, 304-328, 323-348, 465-489, 968-992, 1399-1418, 1412-1431 and 2092-2111 of Seq ID No 177; 1528-1547 and 1541-1560 of Seq ID No

178; 184-200, 367-388, 382-403, 409-429, 425-444 and 438-457 of Seq ID No 179; 27-50 and 45-67 of Seq ID No 180; 114-131 and 405-419 of Seq ID No 183; 113-134, 129-150, 145-166, 161-182 and 177-198 of Seq ID No 184; 495-515 of Seq ID No 186; 346-358 of Seq ID No 187; 208-224 of Seq ID No 190; 178-194, 202-223, 217- 238, 288-308 and 1355-1372 of Seq ID No 192; 57-78 of Seq ID No 194; 347-369, 364-386, 381-403, 398-420, 415-437 and 432-452 of Seq ID No 197; 347-372 of Seq ID No 198; 147-163 of Seq ID No 199; 263-288 of Seq ID No 200; 361-377 of Seq ID No 202; 82-104, 99-121, 116-138, 133-155 and 150-171 of Seq ID No 204; 110-130 and 125-145 of Seq ID No 205; 613-631, 626-644 and 196-213 of Seq ID No 206; 78-100, 95-117, 112-134 and 129-151 of Seq ID No 208; 158-180, 175-197, 192-214, 209-231 and 226-248 of Seq ID No 209; 30-50, 45-65 and 60-79 of Seq ID No 210; 431-455 and 450-474 of Seq ID No 213; 579-601, 596-618, 613-635 and 630-653 of Seq ID No 214; 920-927, 98-119, 114-135, 130-151, 146-167 and 162-182 of Seq ID No 217; 36-59 of Seq ID No 219; 194-216 and 381-404 of Seq ID No 220; 236-251 and 255-279 of Seq ID No 221; 80-100 and 141-164 of Seq ID No 222; 128-154 of Seq ID No 223; 82-100, 95-116 and 111-134 of Seq ID No 224; 55-76, 71-92 and 87-110 of Seq ID No 227; 91-106 of Seq ID No 229; 74-96 of Seq ID No 230; 140-157 of Seq ID No 231; 4-13 of Seq ID No 233; 41-65 and 499-523 of Seq ID No 236; 122-146, 191-215, 288-313, 445-469 and 511-535 of Seq ID No 239; 347-368 of Seq ID No 241; 46-61 of Seq ID No 242; 15-37, 32-57, 101-121, 115-135, 138-158, 152-172, 220-242 and 236-258 of Seq ID No 243; and fragments comprising at least 6, preferably more than 8, especially more than 10 aa and preferably not more than 70, 50, 40, 20, 15, 11 aa of said sequences. All these fragments individually and each independently form a preferred selected aspect of the present invention.

All linear hyperimmune serum reactive fragments of a particular antigen may be identified by analysing the entire sequence of the protein antigen by a set of peptides overlapping by 1 amino acid with a length of at least 10 amino acids. Subsequently, non-linear epitopes can be identified by analysis of the protein antigen with hyperimmune sera using the expressed full-length protein or domain polypeptides thereof. Assuming that a distinct domain of a protein is sufficient to form the 3D structure independent from the native protein, the analysis of the respective recombinant or synthetically produced domain polypeptide with hyperimmune serum would allow the identification of conformational epitopes within the individual domains of multi-domain proteins. For those antigens where a domain possesses linear as well as conformational epitopes, competition experiments with peptides corresponding to the linear epitopes may be used to confirm the presence of conformational epitopes.

It will be appreciated that the invention also relates to, among others, nucleic acid molecules encoding the aforementioned fragments, nucleic acid molecules that hybridise to nucleic acid molecules encoding the fragments, particularly those that hybridise under stringent conditions, and nucleic acid molecules, such as PCR primers, for amplifying nucleic acid molecules that encode the fragments. In these regards, preferred nucleic acid molecules are those that correspond to the preferred fragments, as discussed above.

The present invention also relates to vectors, which comprise a nucleic acid molecule or nucleic acid molecules of the present invention, host cells which are genetically engineered with vectors of the invention and the production of hyperimmune serum reactive antigens and fragments thereof by recombinant techniques.

A great variety of expression vectors can be used to express a hyperimmune serum reactive antigen or fragment thereof according to the present invention. Generally, any vector suitable to maintain, propagate or express nucleic acids to express a polypeptide in a host may be used for expression in this regard. In accordance with this aspect of the invention the vector may be, for example, a plasmid vector, a single or double-stranded phage vector, a single or double-stranded RNA or DNA viral vector. Starting plasmids disclosed herein are either commercially available, publicly available, or can be constructed from available plasmids by routine application of well-known, published procedures. Preferred among vectors, in certain respects, are those for expression of nucleic acid molecules and hyperimmune serum reactive antigens or fragments thereof of the present invention. Nucleic acid constructs in host cells can

be used in a conventional manner to produce the gene product encoded by the recombinant sequence. Alternatively, the hyperimmune serum reactive antigens and fragments thereof of the invention can be synthetically produced by conventional peptide synthesizers. Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA construct of the present invention.

Host cells can be genetically engineered to incorporate nucleic acid molecules and express nucleic acid molecules of the present invention. Representative examples of appropriate hosts include bacterial cells, such as streptococci, staphylococci, E. coli, Streptomyces and Bacillus subtillis cells; fungal cells, such as yeast cells and Aspergillus cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, Hela, C127, 3T3, BHK, 293 and Bowes melanoma cells; and plant cells.

The invention also provides a process for producing a S. pneumoniae hyperimmune serum reactive antigen and a fragment thereof comprising expressing from the host cell a hyperimmune serum reactive antigen or fragment thereof encoded by the nucleic acid molecules provided by the present invention. The invention further provides a process for producing a cell, which expresses a S. pneumoniae hyperimmune serum reactive antigen or a fragment thereof comprising transforming or transfecting a suitable host cell with the vector according to the present invention such that the transformed or transfected cell expresses the polypeptide encoded by the nucleic acid contained in the vector.

The polypeptide may be expressed in a modified form, such as a fusion protein, and may include not only secretion signals but also additional heterologous functional regions. Thus, for instance, a region of additional amino acids, particularly charged amino acids, may be added to the N- or C-terminus of the polypeptide to improve stability and persistence in the host cell, during purification or during subsequent handling and storage. Also, regions may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to polypeptides to engender secretion or excretion, to improve stability or to facilitate purification, among others, are familiar and routine techniques in the art. A preferred fusion protein comprises a heterologous region from immunoglobulin that is useful to solubilize or purify polypeptides. For example, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobin molecules together with another protein or part thereof. In drug discovery, for example, proteins have been fused with antibody Fc portions for the purpose of high-throughout screening assays to identify antagonists. See for example, {Bennett, D. et al., 1995} and {Johanson, K. et al., 1995}.

The S. pneumoniae hyperimmune serum reactive antigen or a fragment thereof can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, hydroxylapatite chromatography and lectin chromatography.

The hyperimmune serum reactive antigens and fragments thereof according to the present invention can be produced by chemical synthesis as well as by biotechnological means. The latter comprise the transfection or transformation of a host cell with a vector containing a nucleic acid according to the present invention and the cultivation of the transfected or transformed host cell under conditions, which are known to the ones skilled in the art. The production method may also comprise a purification step in order to purify or isolate the polypeptide to be manufactured. In a preferred embodiment the vector is a vector according to the present invention.

The hyperimmune serum reactive antigens and fragments thereof according to the present invention may be used for the detection of the organism or organisms in a sample containing these organisms or

- 32 -

polypeptides derived thereof. Preferably such detection is for diagnosis, more preferable for the diagnosis of a disease, most preferably for the diagnosis of a diseases related or linked to the presence or abundance of Gram-positive bacteria, especially bacteria selected from the group comprising streptococci, staphylococci and lactococci. More preferably, the microorganisms are selected from the group comprising *Streptococcus agalactiae, Streptococcus pyogenes* and *Streptococcus mutans*, especially the microorganism is *Streptococcus pyogenes*.

The present invention also relates to diagnostic assays such as quantitative and diagnostic assays for detecting levels of the hyperimmune serum reactive antigens and fragments thereof of the present invention in cells and tissues, including determination of normal and abnormal levels. Thus, for instance, a diagnostic assay in accordance with the invention for detecting over-expression of the polypeptide compared to normal control tissue samples may be used to detect the presence of an infection, for example, and to identify the infecting organism. Assay techniques that can be used to determine levels of a polypeptide, in a sample derived from a host are well known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays. Among these, ELISAs frequently are preferred. An ELISA assay initially comprises preparing an antibody specific to the polypeptide, preferably a monoclonal antibody. In addition, a reporter antibody generally is prepared which binds to the monoclonal antibody. The reporter antibody is attached to a detectable reagent such as radioactive, fluorescent or enzymatic reagent, such as horseradish peroxidase enzyme.

The hyperimmune serum reactive antigens and fragments thereof according to the present invention may also be used for the purpose of or in connection with an array. More particularly, at least one of the hyperimmune serum reactive antigens and fragments thereof according to the present invention may be immobilized on a support. Said support typically comprises a variety of hyperimmune serum reactive antigens and fragments thereof whereby the variety may be created by using one or several of the hyperimmune serum reactive antigens and fragments thereof according to the present invention and/or hyperimmune serum reactive antigens and fragments thereof being different. The characterizing feature of such array as well as of any array in general is the fact that at a distinct or predefined region or position on said support or a surface thereof, a distinct polypeptide is immobilized. Because of this any activity at a distinct position or region of an array can be correlated with a specific polypeptide. The number of different hyperimmune serum reactive antigens and fragments thereof immobilized on a support may range from as little as 10 to several 1000 different hyperimmune serum reactive antigens and fragments thereof. The density of hyperimmune serum reactive antigens and fragments thereof per cm² is in a preferred embodiment as little as 10 peptides/polypeptides per cm² to at least 400 different peptides/polypeptides per cm² and more particularly at least 1000 different hyperimmune serum reactive antigens and fragments thereof per cm².

The manufacture of such arrays is known to the one skilled in the art and, for example, described in US patent 5,744,309. The array preferably comprises a planar, porous or non-porous solid support having at least a first surface. The hyperimmune serum reactive antigens and fragments thereof as disclosed herein, are immobilized on said surface. Preferred support materials are, among others, glass or cellulose. It is also within the present invention that the array is used for any of the diagnostic applications described herein. Apart from the hyperimmune serum reactive antigens and fragments thereof according to the present invention also the nucleic acid molecules according to the present invention may be used for the generation of an array as described above. This applies as well to an array made of antibodies, preferably monoclonal antibodies as, among others, described herein.

In a further aspect the present invention relates to an antibody directed to any of the hyperimmune serum reactive antigens and fragments thereof, derivatives or fragments thereof according to the present invention. The present invention includes, for example, monoclonal and polyclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, or the product of a Fab expression

library. It is within the present invention that the antibody may be chimeric, i. e. that different parts thereof stem from different species or at least the respective sequences are taken from different species.

Antibodies generated against the hyperimmune serum reactive antigens and fragments thereof corresponding to a sequence of the present invention can be obtained by direct injection of the hyperimmune serum reactive antigens and fragments thereof into an animal or by administering the hyperimmune serum reactive antigens and fragments thereof to an animal, preferably a non-human. The antibody so obtained will then bind the hyperimmune serum reactive antigens and fragments thereof itself. In this manner, even a sequence encoding only a fragment of a hyperimmune serum reactive antigen and fragments thereof can be used to generate antibodies binding the whole native hyperimmune serum reactive antigen and fragments thereof. Such antibodies can then be used to isolate the hyperimmune serum reactive antigens and fragments thereof from tissue expressing those hyperimmune serum reactive antigens and fragments thereof.

For preparation of monoclonal antibodies, any technique known in the art, which provides antibodies produced by continuous cell line cultures can be used (as described originally in {Kohler, G. et al., 1975}.

Techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778) can be adapted to produce single chain antibodies to immunogenic hyperimmune serum reactive antigens and fragments thereof according to this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies to immunogenic hyperimmune serum reactive antigens and fragments thereof according to this invention.

Alternatively, phage display technology or ribosomal display could be utilized to select antibody genes with binding activities towards the hyperimmune serum reactive antigens and fragments thereof either from repertoires of PCR amplified v-genes of lymphocytes from humans screened for possessing respective target antigens or from naïve libraries {McCafferty, J. et al., 1990}; {Marks, J. et al., 1992}. The affinity of these antibodies can also be improved by chain shuffling {Clackson, T. et al., 1991}.

If two antigen binding domains are present, each domain may be directed against a different epitope – termed 'bispecific' antibodies.

The above-described antibodies may be employed to isolate or to identify clones expressing the hyperimmune serum reactive antigens and fragments thereof or purify the hyperimmune serum reactive antigens and fragments thereof of the present invention by attachment of the antibody to a solid support for isolation and/or purification by affinity chromatography.

Thus, among others, antibodies against the hyperimmune serum reactive antigens and fragments thereof of the present invention may be employed to inhibit and/or treat infections, particularly bacterial infections and especially infections arising from S. pneumoniae.

Hyperimmune serum reactive antigens and fragments thereof include antigenically, epitopically or immunologically equivalent derivatives, which form a particular aspect of this invention. The term "antigenically equivalent derivative" as used herein encompasses a hyperimmune serum reactive antigen and fragments thereof or its equivalent which will be specifically recognized by certain antibodies which, when raised to the protein or hyperimmune serum reactive antigen and fragments thereof according to the present invention, interfere with the interaction between pathogen and mammalian host. The term "immunologically equivalent derivative" as used herein encompasses a peptide or its equivalent which when used in a suitable formulation to raise antibodies in a vertebrate, the antibodies act to interfere with the interaction between pathogen and mammalian host.

The hyperimmune serum reactive antigens and fragments thereof, such as an antigenically or

- 34 -

immunologically equivalent derivative or a fusion protein thereof can be used as an antigen to immunize a mouse or other animal such as a rat or chicken. The fusion protein may provide stability to the hyperimmune serum reactive antigens and fragments thereof. The antigen may be associated, for example by conjugation, with an immunogenic carrier protein, for example bovine serum albumin (BSA) or keyhole limpet haemocyanin (KLH). Alternatively, an antigenic peptide comprising multiple copies of the protein or hyperimmune serum reactive antigen and fragments thereof, or an antigenically or immunologically equivalent hyperimmune serum reactive antigen and fragments thereof, may be sufficiently antigenic to improve immunogenicity so as to obviate the use of a carrier.

Preferably the antibody or derivative thereof is modified to make it less immunogenic in the individual. For example, if the individual is human the antibody may most preferably be "humanized", wherein the complimentarity determining region(s) of the hybridoma-derived antibody has been transplanted into a human monoclonal antibody, for example as described in {Jones, P. et al., 1986} or {Tempest, P. et al., 1991}.

The use of a polynucleotide of the invention in genetic immunization will preferably employ a suitable delivery method such as direct injection of plasmid DNA into muscle, delivery of DNA complexed with specific protein carriers, coprecipitation of DNA with calcium phosphate, encapsulation of DNA in various forms of liposomes, particle bombardment {Tang, D. et al., 1992}; {Eisenbraun, M. et al., 1993} and *in vivo* infection using cloned retroviral vectors {Seeger, C. et al., 1984}.

In a further aspect the present invention relates to a peptide binding to any of the hyperimmune serum reactive antigens and fragments thereof according to the present invention, and a method for the manufacture of such peptides whereby the method is characterized by the use of the hyperimmune serum reactive antigens and fragments thereof according to the present invention and the basic steps are known to the one skilled in the art.

Such peptides may be generated by using methods according to the state of the art such as phage display or ribosome display. In case of phage display, basically a library of peptides is generated, in form of phages, and this kind of library is contacted with the target molecule, in the present case a hyperimmune serum reactive antigen and fragments thereof according to the present invention. Those peptides binding to the target molecule are subsequently removed, preferably as a complex with the target molecule, from the respective reaction. It is known to the one skilled in the art that the binding characteristics, at least to a certain extent, depend on the particularly realized experimental set-up such as the salt concentration and the like. After separating those peptides binding to the target molecule with a higher affinity or a bigger force, from the non-binding members of the library, and optionally also after removal of the target molecule from the complex of target molecule and peptide, the respective peptide(s) may subsequently be characterised. Prior to the characterisation optionally an amplification step is realized such as, e. g. by propagating the peptide encoding phages. The characterisation preferably comprises the sequencing of the target binding peptides. Basically, the peptides are not limited in their lengths, however, preferably peptides having a lengths from about 8 to 20 amino acids are preferably obtained in the respective methods. The size of the libraries may be about 10^2 to 10^{18}, preferably 10^8 to 10^{15} different peptides, however, is not limited thereto.

A particular form of target binding hyperimmune serum reactive antigens and fragments thereof are the so-called "anticalines" which are, among others, described in German patent application DE 197 42 706.

In a further aspect the present invention relates to functional nucleic acids interacting with any of the hyperimmune serum reactive antigens and fragments thereof according to the present invention, and a method for the manufacture of such functional nucleic acids whereby the method is characterized by the use of the hyperimmune serum reactive antigens and fragments thereof according to the present invention and the basic steps are known to the one skilled in the art. The functional nucleic acids are

preferably aptamers and spiegelmers.

Aptamers are D-nucleic acids, which are either single stranded or double stranded and which specifically interact with a target molecule. The manufacture or selection of aptamers is, e.g. described in European patent EP 0 533 838. Basically the following steps are realized. First, a mixture of nucleic acids, i. e. potential aptamers, is provided whereby each nucleic acid typically comprises a segment of several, preferably at least eight subsequent randomised nucleotides. This mixture is subsequently contacted with the target molecule whereby the nucleic acid(s) bind to the target molecule, such as based on an increased affinity towards the target or with a bigger force thereto, compared to the candidate mixture. The binding nucleic acid(s) are/is subsequently separated from the remainder of the mixture. Optionally, the thus obtained nucleic acid(s) is amplified using, e.g. polymerase chain reaction. These steps may be repeated several times giving at the end a mixture having an increased ratio of nucleic acids specifically binding to the target from which the final binding nucleic acid is then optionally selected. These specifically binding nucleic acid(s) are referred to as aptamers. It is obvious that at any stage of the method for the generation or identification of the aptamers samples of the mixture of individual nucleic acids may be taken to determine the sequence thereof using standard techniques. It is within the present invention that the aptamers may be stabilized such as, e. g., by introducing defined chemical groups which are known to the one skilled in the art of generating aptamers. Such modification may for example reside in the introduction of an amino group at the 2'-position of the sugar moiety of the nucleotides. Aptamers are currently used as therapeutical agents. However, it is also within the present invention that the thus selected or generated aptamers may be used for target validation and/or as lead substance for the development of medicaments, preferably of medicaments based on small molecules. This is actually done by a competition assay whereby the specific interaction between the target molecule and the aptamer is inhibited by a candidate drug whereby upon replacement of the aptamer from the complex of target and aptamer it may be assumed that the respective drug candidate allows a specific inhibition of the interaction between target and aptamer, and if the interaction is specific, said candidate drug will, at least in principle, be suitable to block the target and thus decrease its biological availability or activity in a respective system comprising such target. The thus obtained small molecule may then be subject to further derivatisation and modification to optimise its physical, chemical, biological and/or medical characteristics such as toxicity, specificity, biodegradability and bioavailability.

Spiegelmers and their generation or manufacture is based on a similar principle. The manufacture of spiegelmers is described in international patent application WO 98/08856. Spiegelmers are L-nucleic acids, which means that they are composed of L-nucleotides rather than D-nucleotides as aptamers are. Spiegelmers are characterized by the fact that they have a very high stability in biological systems and, comparable to aptamers, specifically interact with the target molecule against which they are directed. In the process of generating spiegelmers, a heterogeonous population of D-nucleic acids is created and this population is contacted with the optical antipode of the target molecule, in the present case for example with the D-enantiomer of the naturally occurring L-enantiomer of the hyperimmune serum reactive antigens and fragments thereof according to the present invention. Subsequently, those D-nucleic acids are separated which do not interact with the optical antipode of the target molecule. But those D-nucleic acids interacting with the optical antipode of the target molecule are separated, optionally identified and/or sequenced and subsequently the corresponding L-nucleic acids are synthesized based on the nucleic acid sequence information obtained from the D-nucleic acids. These L-nucleic acids which are identical in terms of sequence with the aforementioned D-nucleic acids interacting with the optical antipode of the target molecule, will specifically interact with the naturally occurring target molecule rather than with the optical antipode thereof. Similar to the method for the generation of aptamers it is also possible to repeat the various steps several times and thus to enrich those nucleic acids specifically interacting with the optical antipode of the target molecule.

In a further aspect the present invention relates to functional nucleic acids interacting with any of the nucleic acid molecules according to the present invention, and a method for the manufacture of such

functional nucleic acids whereby the method is characterized by the use of the nucleic acid molecules and their respective sequences according to the present invention and the basic steps are known to the one skilled in the art. The functional nucleic acids are preferably ribozymes, antisense oligonucleotides and siRNA.

Ribozymes are catalytically active nucleic acids which preferably consist of RNA which basically comprises two moieties. The first moiety shows a catalytic activity whereas the second moiety is responsible for the specific interaction with the target nucleic acid, in the present case the nucleic acid coding for the hyperimmune serum reactive antigens and fragments thereof according to the present invention. Upon interaction between the target nucleic acid and the second moiety of the ribozyme, typically by hybridisation and Watson-Crick base pairing of essentially complementary stretches of bases on the two hybridising strands, the catalytically active moiety may become active which means that it catalyses, either intramolecularly or intermolecularly, the target nucleic acid in case the catalytic activity of the ribozyme is a phosphodiesterase activity. Subsequently, there may be a further degradation of the target nucleic acid, which in the end results in the degradation of the target nucleic acid as well as the protein derived from the said target nucleic acid. Ribozymes, their use and design principles are known to the one skilled in the art, and, for example described in {Doherty, E. et al., 2001} and {Lewin, A. et al., 2001}.

The activity and design of antisense oligonucleotides for the manufacture of a medicament and as a diagnostic agent, respectively, is based on a similar mode of action. Basically, antisense oligonucleotides hybridise based on base complementarity, with a target RNA, preferably with a mRNA, thereby activating RNase H. RNase H is activated by both phosphodiester and phosphorothioate-coupled DNA. Phosphodiester-coupled DNA, however, is rapidly degraded by cellular nucleases with the exception of phosphorothioate-coupled DNA. These resistant, non-naturally occurring DNA derivatives do not inhibit RNase H upon hybridisation with RNA. In other words, antisense polynucleotides are only effective as DNA RNA hybride complexes. Examples for this kind of antisense oligonucleotides are described, among others, in US-patent US 5,849,902 and US 5,989,912. In other words, based on the nucleic acid sequence of the target molecule which in the present case are the nucleic acid molecules for the hyperimmune serum reactive antigens and fragments thereof according to the present invention, either from the target protein from which a respective nucleic acid sequence may in principle be deduced, or by knowing the nucleic acid sequence as such, particularly the mRNA, suitable antisense oligonucleotides may be designed base on the principle of base complementarity.

Particularly preferred are antisense-oligonucleotides, which have a short stretch of phosphorothioate DNA (3 to 9 bases). A minimum of 3 DNA bases is required for activation of bacterial RNase H and a minimum of 5 bases is required for mammalian RNase H activation. In these chimeric oligonucleotides there is a central region that forms a substrate for RNase H that is flanked by hybridising "arms" comprised of modified nucleotides that do not form substrates for RNase H. The hybridising arms of the chimeric oligonucleotides may be modified such as by 2'-O-methyl or 2'-fluoro. Alternative approaches used methylphosphonate or phosphoramidate linkages in said arms. Further embodiments of the antisense oligonucleotide useful in the practice of the present invention are P-methoxyoligonucleotides, partial P-methoxyoligodeoxyribonucleotides or P-methoxyoligonucleotides.

Of particular relevance and usefulness for the present invention are those antisense oligonucleotides as more particularly described in the above two mentioned US patents. These oligonucleotides contain no naturally occurring 5'→3'-linked nucleotides. Rather the oligonucleotides have two types of nucleotides: 2'-deoxyphosphorothioate, which activate RNase H, and 2'-modified nucleotides, which do not. The linkages between the 2'-modified nucleotides can be phosphodiesters, phosphorothioate or P-ethoxyphosphodiester. Activation of RNase H is accomplished by a contiguous RNase H-activating region, which contains between 3 and 5 2'-deoxyphosphorothioate nucleotides to activate bacterial RNase H and between 5 and 10 2'- deoxyphosphorothioate nucleotides to activate eucaryotic and, particularly,

- 37 -

mammalian RNase H. Protection from degradation is accomplished by making the 5' and 3' terminal bases highly nuclease resistant and, optionally, by placing a 3' terminal blocking group.

More particularly, the antisense oligonucleotide comprises a 5' terminus and a 3' terminus; and from position 11 to 59 5'→3'-linked nucleotides independently selected from the group consisting of 2'-modified phosphodiester nucleotides and 2'-modified P-alkyloxyphosphotriester nucleotides; and wherein the 5'-terminal nucleoside is attached to an RNase H-activating region of between three and ten contiguous phosphorothioate-linked deoxyribonucleotides, and wherein the 3'-terminus of said oligonucleotide is selected from the group consisting of an inverted deoxyribonucleotide, a contiguous stretch of one to three phosphorothioate 2'-modified ribonucleotides, a biotin group and a P-alkyloxyphosphotriester nucleotide.

Also an antisense oligonucleotide may be used wherein not the 5' terminal nucleoside is attached to an RNase H-activating region but the 3' terminal nucleoside as specified above. Also, the 5' terminus is selected from the particular group rather than the 3' terminus of said oligonucleotide.

The nucleic acids as well as the hyperimmune serum reactive antigens and fragments thereof according to the present invention may be used as or for the manufacture of pharmaceutical compositions, especially vaccines. Preferably such pharmaceutical composition, preferably vaccine is for the prevention or treatment of diseases caused by, related to or associated with S. *pneumoniae*. In so far another aspect of the invention relates to a method for inducing an immunological response in an individual, particularly a mammal, which comprises inoculating the individual with the hyperimmune serum reactive antigens and fragments thereof of the invention, or a fragment or variant thereof, adequate to produce antibodies to protect said individual from infection, particularly *streptococcal* infection and most particularly S. *pneumoniae* infections.

Yet another aspect of the invention relates to a method of inducing an immunological response in an individual which comprises, through gene therapy or otherwise, delivering a nucleic acid functionally encoding hyperimmune serum reactive antigens and fragments thereof, or a fragment or a variant thereof, for expressing the hyperimmune serum reactive antigens and fragments thereof, or a fragment or a variant thereof *in vivo* in order to induce an immunological response to produce antibodies or a cell mediated T cell response, either cytokine-producing T cells or cytotoxic T cells, to protect said individual from disease, whether that disease is already established within the individual or not. One way of administering the gene is by accelerating it into the desired cells as a coating on particles or otherwise.

A further aspect of the invention relates to an immunological composition which, when introduced into a host capable of having induced within it an immunological response, induces an immunological response in such host, wherein the composition comprises recombinant DNA which codes for and expresses an antigen of the hyperimmune serum reactive antigens and fragments thereof of the present invention. The immunological response may be used therapeutically or prophylactically and may take the form of antibody immunity or cellular immunity such as that arising from CTL or CD4+ T cells.

The hyperimmune serum reactive antigens and fragments thereof of the invention or a fragment thereof may be fused with a co-protein which may not by itself produce antibodies, but is capable of stabilizing the first protein and producing a fused protein which will have immunogenic and protective properties. This fused recombinant protein preferably further comprises an antigenic co-protein, such as Glutathione-S-transferase (GST) or beta-galactosidase, relatively large co-proteins which solubilise the protein and facilitate production and purification thereof. Moreover, the co-protein may act as an adjuvant in the sense of providing a generalized stimulation of the immune system. The co-protein may be attached to either the amino or carboxy terminus of the first protein.

Also, provided by this invention are methods using the described nucleic acid molecule or particular

- 38 -

fragments thereof in such genetic immunization experiments in animal models of infection with S. pneumoniae. Such fragments will be particularly useful for identifying protein epitopes able to provoke a prophylactic or therapeutic immune response. This approach can allow for the subsequent preparation of monoclonal antibodies of particular value from the requisite organ of the animal successfully resisting or clearing infection for the development of prophylactic agents or therapeutic treatments of S. pneumoniae infection in mammals, particularly humans.

The hyperimmune serum reactive antigens and fragments thereof may be used as an antigen for vaccination of a host to produce specific antibodies which protect against invasion of bacteria, for example by blocking adherence of bacteria to damaged tissue. Examples of tissue damage include wounds in skin or connective tissue and mucosal tissues caused e.g. by viral infection (esp. respiratory, such as the flu) mechanical, chemical or thermal damage or by implantation of indwelling devices, or wounds in the mucous membranes, such as the mouth, mammary glands, urethra or vagina.

The present invention also includes a vaccine formulation, which comprises the immunogenic recombinant protein together with a suitable carrier. Since the protein may be broken down in the stomach, it is preferably administered parenterally, including, for example, administration that is subcutaneous, intramuscular, intravenous, intradermal intranasal or tramsdermal. Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the bodily fluid, preferably the blood, of the individual; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials, and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in-water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

According to another aspect, the present invention relates to a pharmaceutical composition comprising such a hyperimmune serum-reactive antigen or a fragment thereof as provided in the present invention for S. pneumoniae.. Such a pharmaceutical composition may comprise one, preferably at least two or more hyperimmune serum reactive antigens or fragments thereof against S. pneumoniae. Optionally, such S. pneumoniae hyperimmune serum reactive antigens or fragments thereof may also be combined with antigens against other pathogens in a combination pharmaceutical composition. Preferably, said pharmaceutical composition is a vaccine for preventing or treating an infection caused by S. pneumoniae and/or other pathogens against which the antigens have been included in the vaccine.

According to a further aspect, the present invention relates to a pharmaceutical composition comprising a nucleic acid molecule encoding a hyperimmune serum-reactive antigen or a fragment thereof as identified above for S. pneumoniae. Such a pharmaceutical composition may comprise one or more nucleic acid molecules encoding hyperimmune serum reactive antigens or fragments thereof against S. pneumoniae. Optionally, such S. pneumoniae nucleic acid molecules encoding hyperimmune serum reactive antigens or fragments thereof may also be combined with nucleic acid molecules encoding antigens against other pathogens in a combination pharmaceutical composition. Preferably, said pharmaceutical composition is a vaccine for preventing or treating an infection caused by S. pneumoniae and/or other pathogens against which the antigens have been included in the vaccine.

The pharmaceutical composition may contain any suitable auxiliary substances, such as buffer substances, stabilisers or further active ingredients, especially ingredients known in connection of pharmaceutical composition and/or vaccine production.

A preferable carrier/or excipient for the hyperimmune serum-reactive antigens, fragments thereof or a

coding nucleic acid molecule thereof according to the present invention is an immunostimulatory compound for further stimulating the immune response to the given hyperimmune serum-reactive antigen, fragment thereof or a coding nucleic acid molecule thereof. Preferably the immunostimulatory compound in the pharmaceutical preparation according to the present invention is selected from the group of polycationic substances, especially polycationic peptides, immunostimulatory nucleic acids molecules, preferably immunostimulatory deoxynucleotides, alum, Freund's complete adjuvants, Freund's incomplete adjuvants, neuroactive compounds, especially human growth hormone, or combinations thereof.

It is also within the scope of the present invention that the pharmaceutical composition, especially vaccine, comprises apart from the hyperimmune serum reactive antigens, fragments thereof and/or coding nucleic acid molecules thereof according to the present invention other compounds which are biologically or pharmaceutically active. Preferably, the vaccine composition comprises at least one polycationic peptide. The polycationic compound(s) to be used according to the present invention may be any polycationic compound, which shows the characteristic effects according to the WO 97/30721. Preferred polycationic compounds are selected from basic polyppetides, organic polycations, basic polyamino acids or mixtures thereof. These polyamino acids should have a chain length of at least 4 amino acid residues (WO 97/30721). Especially preferred are substances like polylysine, polyarginine and polypeptides containing more than 20 %, especially more than 50 % of basic amino acids in a range of more than 8, especially more than 20, amino acid residues or mixtures thereof. Other preferred polycations and their pharmaceutical compositions are described in WO 97/30721 (e.g. polyethyleneimine) and WO 99/38528. Preferably these polypeptides contain between 20 and 500 amino acid residues, especially between 30 and 200 residues.

These polycationic compounds may be produced chemically or recombinantly or may be derived from natural sources.

Cationic (poly)peptides may also be anti-microbial with properties as reviewed in [Ganz, T., 1999]. These (poly)peptides may be of prokaryotic or animal or plant origin or may be produced chemically or recombinantly (WO 02/13857). Peptides may also belong to the class of defensins (WO 02/13857). Sequences of such peptides can be, for example, found in the Antimicrobial Sequences Database under the following internet address:

http://www.bbcm.univ.trieste.it/~tossi/pag2.html

Such host defence peptides or defensives are also a preferred form of the polycationic polymer according to the present invention. Generally, a compound allowing as an end product activation (or down-regulation) of the adaptive immune system, preferably mediated by APCs (including dendritic cells) is used as polycationic polymer.

Especially preferred for use as polycationic substances in the present invention are cathelicidin derived antimicrobial peptides or derivatives thereof (International patent application WO 02/13857, incorporated herein by reference), especially antimicrobial peptides derived from mammalian cathelicidin, preferably from human, bovine or mouse.

Polycationic compounds derived from natural sources include HIV-REV or HIV-TAT (derived cationic peptides, antennapedia peptides, chitosan or other derivatives of chitin) or other peptides derived from these peptides or proteins by biochemical or recombinant production. Other preferred polycationic compounds are cathelin or related or derived substances from cathelin. For example, mouse cathelin is a peptide which has the amino acid sequence NH2-RLAGLLRKGGEKIGEKLKKIGOKIKNFFQKLVPQPE-COOH. Related or derived cathelin substances contain the whole or parts of the cathelin sequence with at least 15-20 amino acid residues. Derivations may include the substitution or modification of the natural

- 40 -

amino acids by amino acids which are not among the 20 standard amino acids. Moreover, further cationic residues may be introduced into such cathelin molecules. These cathelin molecules are preferred to be combined with the antigen. These cathelin molecules surprisingly have turned out to be also effective as an adjuvant for an antigen without the addition of further adjuvants. It is therefore possible to use such cathelin molecules as efficient adjuvants in vaccine formulations with or without further immunactivating substances.

Another preferred polycationic substance to be used according to the present invention is a synthetic peptide containing at least 2 KLK-motifs separated by a linker of 3 to 7 hydrophobic amino acids (International patent application WO 02/32451, incorporated herein by reference).

The pharmaceutical composition of the present invention may further comprise immunostimulatory nucleic acid(s). Immunostimulatory nucleic acids are e. g. neutral or artificial CpG containing nucleic acids, short stretches of nucleic acids derived from non-vertebrates or in form of short oligonucleotides (ODNs) containing non-methylated cytosine-guanine di-nucleotides (CpG) in a certain base context (e.g. described in WO 96/02555). Alternatively, also nucleic acids based on inosine and cytidine as e.g. described in the WO 01/93903, or deoxynucleic acids containing deoxy-inosine and/or deoxyuridine residues (described in WO 01/93905 and PCT/EP 02/05448, incorporated herein by reference) may preferably be used as immunostimulatory nucleic acids for the present invention. Preferablly, the mixtures of different immunostimulatory nucleic acids may be used according to the present invention.

It is also within the present invention that any of the aforementioned polycationic compounds is combined with any of the immunostimulatory nucleic acids as aforementioned. Preferably, such combinations are according to the ones as described in WO 01/93905, WO 02/32451, WO 01/54720, WO 01/93903, WO 02/13857 and PCT/EP 02/05448 and the Austrian patent application A 1924/2001, incorporated herein by reference.

In addition or alternatively such vaccine composition may comprise apart from the hyperimmune serum reactive antigens and fragments thereof, and the coding nucleic acid molecules thereof according to the present invention a neuroactive compound. Preferably, the neuroactive compound is human growth factor as, e.g. described in WO 01/24822. Also preferably, the neuroactive compound is combined with any of the polycationic compounds and/or immunostimulatory nucleic acids as afore-mentioned.

In a further aspect the present invention is related to a pharmaceutical composition. Such pharmaceutical composition is, for example, the vaccine described herein. Also a pharmaceutical composition is a pharmaceutical composition which comprises any of the following compounds or combinations thereof: the nucleic acid molecules according to the present invention, the hyperimmune serum reactive antigens and fragments thereof according to the present invention, the vector according to the present invention, the cells according to the present invention, the antibody according to the present invention, the functional nucleic acids according to the present invention and the binding peptides such as the anticalines according to the present invention, any agonists and antagonists screened as described herein. In connection therewith any of these compounds may be employed in combination with a non-sterile or sterile carrier or carriers for use with cells, tissues or organisms, such as a pharmaceutical carrier suitable for administration to a subject. Such compositions comprise, for instance, a media additive or a therapeutically effective amount of a hyperimmune serum reactive antigen and fragments thereof of the invention and a pharmaceutically acceptable carrier or excipient. Such carriers may include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof. The formulation should suit the mode of administration.

The pharmaceutical compositions may be administered in any effective, convenient manner including, for instance, administration by topical, oral, anal, vaginal, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal, intratracheal or intradermal routes among others.

In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion, preferably isotonic.

Alternatively the composition may be formulated for topical application, for example in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contain appropriate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams. Such topical formulations may also contain compatible conventional carriers, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions. Such carriers may constitute from about 1 % to about 98 % by weight of the formulation; more usually they will constitute up to about 80 % by weight of the formulation.

In addition to the therapy described above, the compositions of this invention may be used generally as a wound treatment agent to prevent adhesion of bacteria to matrix proteins exposed in wound tissue and for prophylactic use in dental treatment as an alternative to, or in conjunction with, antibiotic prophylaxis.

A vaccine composition is conveniently in injectable form. Conventional adjuvants may be employed to enhance the immune response. A suitable unit dose for vaccination is 0.05-5 μg antigen / per kg of body weight, and such dose is preferably administered 1-3 times and with an interval of 1-3 weeks.

With the indicated dose range, no adverse toxicological effects should be observed with the compounds of the invention, which would preclude their administration to suitable individuals.

In a further embodiment the present invention relates to diagnostic and pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention. The ingredient(s) can be present in a useful amount, dosage, formulation or combination. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, reflecting approval by the agency of the manufacture, use or sale of the product for human administration.

In connection with the present invention any disease related use as disclosed herein such as, e. g. use of the pharmaceutical composition or vaccine, is particularly a disease or diseased condition which is caused by, linked or associated with Streptococci, more preferably, S. pneumoniae. In connection therewith it is to be noted that S. pneumoniae comprises several strains including those disclosed herein. A disease related, caused or associated with the bacterial infection to be prevented and/or treated according to the present invention includes besides others bacterial pharyngitis, otitis media, pneumonia, bacteremia, meningitis, peritonitis and sepsis in humans.

In a still further embodiment the present invention is related to a screening method using any of the hyperimmune serum reactive antigens or nucleic acids according to the present invention. Screening methods as such are known to the one skilled in the art and can be designed such that an agonist or an antagonist is screened. Preferably an antagonist is screened which in the present case inhibits or prevents the binding of any hyperimmune serum reactive antigen and fragment thereof according to the present invention to an interaction partner. Such interaction partner can be a naturally occurring interaction partner or a non-naturally occurring interaction partner.

The invention also provides a method of screening compounds to identify those, which enhance (agonist) or block (antagonist) the function of hyperimmune serum reactive antigens and fragments thereof or nucleic acid molecules of the present invention, such as its interaction with a binding molecule. The

- 42 -

method of screening may involve high-throughput.

For example, to screen for agonists or antagonists, the interaction partner of the nucleic acid molecule and nucleic acid, respectively, according to the present invention, maybe a synthetic reaction mix, a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, may be prepared from a cell that expresses a molecule that binds to the hyperimmune serum reactive antigens and fragments thereof of the present invention. The preparation is incubated with labelled hyperimmune serum reactive antigens and fragments thereof in the absence or the presence of a candidate molecule, which may be an agonist or antagonist. The ability of the candidate molecule to bind the binding molecule is reflected in decreased binding of the labelled ligand. Molecules which bind gratuitously, i. e., without inducing the functional effects of the hyperimmune serum reactive antigens and fragments thereof, are most likely to be good antagonists. Molecules that bind well and elicit functional effects that are the same as or closely related to the hyperimmune serum reactive antigens and fragments thereof are good agonists.

The functional effects of potential agonists and antagonists may be measured, for instance, by determining the activity of a reporter system following interaction of the candidate molecule with a cell or appropriate cell preparation, and comparing the effect with that of the hyperimmune serum reactive antigens and fragments thereof of the present invention or molecules that elicit the same effects as the hyperimmune serum reactive antigens and fragments thereof. Reporter systems that may be useful in this regard include but are not limited to colorimetric labelled substrate converted into product, a reporter gene that is responsive to changes in the functional activity of the hyperimmune serum reactive antigens and fragments thereof, and binding assays known in the art.

Another example of an assay for antagonists is a competitive assay that combines the hyperimmune serum reactive antigens and fragments thereof of the present invention and a potential antagonist with membrane-bound binding molecules, recombinant binding molecules, natural substrates or ligands, or substrate or ligand mimetics, under appropriate conditions for a competitive inhibition assay. The hyperimmune serum reactive antigens and fragments thereof can be labelled such as by radioactivity or a colorimetric compound, such that the molecule number of hyperimmune serum reactive antigens and fragments thereof bound to a binding molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagonist.

Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to a hyperimmune serum reactive antigen and fragments thereof of the invention and thereby inhibit or extinguish its acitivity. Potential antagonists also may be small organic molecules, a peptide, a polypeptide such as a closely related protein or antibody that binds to the same sites on a binding molecule without inducing functional activity of the hyperimmune serum reactive antigens and fragments thereof of the invention.

Potential antagonists include a small molecule, which binds to and occupies the binding site of the hyperimmune serum reactive antigens and fragments thereof thereby preventing binding to cellular binding molecules, such that normal biological activity is prevented. Examples of small molecules include but are not limited to small organic molecules, peptides or peptide-like molecules.

Other potential antagonists include antisense molecules (see {Okano, H. et al., 1991}; OLIGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION; CRC Press, Boca Ration, FL (1988), for a description of these molecules).

Preferred potential antagonists include derivatives of the hyperimmune serum reactive antigens and fragments thereof of the invention.

As used herein the activity of a hyperimmune serum reactive antigen and fragment thereof according to the present invention is its capability to bind to any of its interaction partner or the extent of such capability to bind to its or any interaction partner.

In a particular aspect, the invention provides the use of the hyperimmune serum reactive antigens and fragments thereof, nucleic acid molecules or inhibitors of the invention to interfere with the initial physical interaction between a pathogen and mammalian host responsible for sequelae of infection. In particular the molecules of the invention may be used: i) in the prevention of adhesion of S. pneumoniae to mammalian extracellular matrix proteins at mucosal surfaces and on in-dwelling devices or to extracellular matrix proteins in wounds; ii) to block bacterial adhesion between mammalian extracellular matrix proteins and bacterial proteins which mediate tissue damage or invasion iii) or lead to evasion of immune defense; iv) to block the normal progression of pathogenesis in infections initiated other than by the implantation of in-dwelling devices or by other surgical techniques, e.g. through inhibiting nutrient acquisition {Brown, J. et al., 2001}.

Each of the DNA coding sequences provided herein may be used in the discovery and development of antibacterial compounds. The encoded protein upon expression can be used as a target for the screening of antibacterial drugs. Additionally, the DNA sequences encoding the amino terminal regions of the encoded protein or Shine-Delgarno or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the coding sequence of interest.

The antagonists and agonists may be employed, for instance, to inhibit diseases arising from infection with Streptococcus, especially S. pneumoniae, such as sepsis.

In a still further aspect the present invention is related to an affinity device such affinity device comprises as least a support material and any of the hyperimmune serum reactive antigens and fragments thereof according to the present invention, which is attached to the support material. Because of the specificity of the hyperimmune serum reactive antigens and fragments thereof according to the present invention for their target cells or target molecules or their interaction partners, the hyperimmune serum reactive antigens and fragments thereof allow a selective removal of their interaction partner(s) from any kind of sample applied to the support material provided that the conditions for binding are met. The sample may be a biological or medical sample, including but not limited to, fermentation broth, cell debris, cell preparation, tissue preparation, organ preparation, blood, urine, lymph liquid, liquor and the like.

The hyperimmune serum reactive antigens and fragments thereof may be attached to the matrix in a covalent or non-covalent manner. Suitable support material is known to the one skilled in the art and can be selected from the group comprising cellulose, silicon, glass, aluminium, paramagnetic beads, starch and dextrane.

The present invention is further illustrated by the following figures, examples and the sequence listing, from which further features, embodiments and advantages may be taken. It is to be understood that the present examples are given by way of illustration only and not by way of limitation of the disclosure.

In connection with the present invention

Figure 1 shows the characterization of S. pneumoniae specific human sera.

Figure 2 shows the characterization of the small fragment genomic library, LSPn-70, from Streptococcus pneumoniae serotype 4.

Figure 3 shows the selection of bacterial cells by MACS using biotinylated human IgGs.

- 44 -

Figure 4 shows an example for the gene distribution study with the identified antigens.

Figure 5 shows examples of changes in epitope-specific antibody levels in the different age groups and during the course of pneumococcal disease.

Figure 6 shows examples for cell surface staining with epitope-specific antisera by flow cytometry.

Figure 7 shows the determination of bactericidal activity of antibodies induced by selected epitopes in an *in vitro assay*.

Figure 8 shows the protective effect of active immunization with selected *S. pneumoniae* antigens in a murine lethality sepsis model.

Figure 9 shows the protective effect of passive immunization with sera generated with selected *S. pneumoniae* antigens in a murine lethality sepsis model.

Figure 10 shows the identification of the protective domain within the SP2216 antigen.

Figure 11 shows that antibodies induced by protective antigens are cross-reactive with the different *S. pneumoniae* serotypes.

Figure 12 shows the alignment of amino acid sequences of natural SP2216 variants

Figure 13 shows the alignment of amino acid sequences of natural SP1732 variants

Figure 14 shows the alignment of amino acid sequences of natural SP2190 variants

Table 1 shows the summary of all screens performed with genomic *S. pneumoniae* libraries and human serum.

Table 2 shows the summary of epitope serology analysis with human sera.

Table 3 shows the summary of the gene distribution analysis for the identified antigens in 50 *S. pneumoniae* strains.

Table 4 shows the summary of the surface staining and bactericidal activity measurements.

The figures to which it might be referred to in the specification are described in the following in more details.

Figure 1 shows the characterization of human sera for anti-*S. pneumoniae* antibodies ass measured by immune assays. Total anti-*S. pneumoniae* IgG and IgA antibody levels were measured by standard ELISA using total bacterial lysates or culture supernant fractions prepared from *S. pneumoniae* serotype 4 capsule negative mutant strain as coating antigens. 97 serum samples from convalescing patients with inasive diseases or 50 sera from healthy adults without nasopharyngeal carriage of *S. pneumoniae* were analysed at three different serum dilutions. Results of representative experiments are shown with (A) patients' sera with bacterial lysate and (B) healthy adult sera with culture superntant proteins. Data are expressed as ELISA units calculated from absorbance at 405nm at a serum dilution in the linear range of detection (10.000X for IgA, 50,000 for IgG). 2x5 sera from both donor groups were selected and pooled for antigen identification by bacterial surface display. Selected sera included in the two patient (PSPn3-IgG,-IgA and PSPn7-IgG) and two healthy pools (NSPn4-IgG,-IgA and NSPn5-IgG) are indicated by circules. (C) Immunoblot analysis was performed on sera pre-selected by ELISA in order to ensure multiple immune

reactivity with protein antigens. Results of a representative experiment using total bacterial lysate prepared from *S. pneumoniae* serotype 4 capsule negative mutant strain and selected patients' sera at 5.000X dilution are shown. Not selected, low titer sera were included as negative controls. Mw: molecular weigth markers. **(D)** Surface staining of *S. pneumoniae* serotype 4 capsule negative mutant strain was performed by FACS to compare antibody binding to surface located antigens. Human sera were used at different concentrations (0.5-5%). Representative data are shown with patients' sera used at 0.5% final concentration. Signal was detected with FITC-labeled anti-human IgGFab and analysed with the computer program CELLQuest. **(E)** Correlation between IgG titers measured by ELISA using total bacterial lysates and surface staining of whole living *S. pneumoniae* with serum IgGs is shown. IgG titer is expressed as ELISA units, while surface staining is expressed as mean fluorescence of stained bacteria calculated by the computer program CELLQuest .

Figure 2 (A) shows the fragment size distribution of the *Streptococcus pneumoniae* type 4 small fragment genomic library, LSPn-70. After sequencing 609 randomly selected clones sequences were trimmed to eliminate vector residues and the number of clones with various genomic fragment sizes were plotted. **(B)** shows graphic illustration of the distribution of the same set of randomly sequenced clones of LSPn-70 over the *S. pneumoniae* chromosome (according to the TIGR4 genome data). Circles indicate matching sequences to annotated ORFs and rectangles represent fully matched clones to non-coding chromosomal sequences in +/+ or +/- orientation. Diamonds position all clones with chimeric sequences. Numeric distances in base pairs are indicated over the circular genome for orientation. Partitioning of various clone sets within the library is given in numbers and percentage at the bottom of the figure.

Figure 3 (A) shows the MACS selection with biotinylated human IgGs. The LSPn-70 library in pMAL9.1 was screened with 10 μg biotinylated IgG (PSPn3-IgG, purified from human serum). As negative control, no serum was added to the library cells for screening. Number of cells selected after the 1st and 2nd elution are shown for each selection round (upper and lower panel, respectively). **(B)** shows the reactivity of specific clones (1-26) selected by bacterial surface display as analysed by immunoblot analysis with the human serum IgG pool (PSPn7-IgG, 4μg/μl) used for selection by MACS at a dilution of 1:3,000. As a loading control the same blot was also analysed with antibodies directed against the platform protein LamB at a dilution of 1:5,000 of hyperimmune rabbit serum. LB, Extract from a clone expressing LamB without foreign peptide insert.

Figure 4 (A) shows the representation of different serotypes of *S. pneumoniae* clinical isolates analysed for the gene distribution study. **(B)** shows the PCR analysis for the gene distribution of SP1604 with the respective oligonucleotides. The predicted size of the PCR fragments is 470 bp. 1-50, *S. pneumoniae* strains, clinical isolates as listed under A; -, no genomic DNA added; +, genomic DNA from *S. pneumoniae* serotype 4, which served as template for library construction.

Figure 5 shows the ELISA measurement of epitope-specific human serum IgG antibody levels during pneumococcal disease. Three serum samples were collected longitudinally from patients with invasive pneumococcal disease, before disease occurred (pre), in the acute and convalescent phases. Representative experiments are shown with two sets of sera from two different patients, **(A)** P1147 and **(B)** P1150 reacted with peptides representing the identified antigens SP0069, SP0082, SP0117, SP1175, SP1937, SP2190 and SP2216, as indicated. Biotin-labeled peptides were reacted with human serum samples at 200X and 1.000X dilutions and data are expressed as ELISA units.

Figure 6 shows the detection of specific antibody binding on the cell surface of *Streptococcus pneumoniae* by flow cytometry. In Figure 5A preimmune mouse sera and polyclonal sera raised against *S. pneumoniae* serotype 4 lysate were incubated with *S. pneumoniae* strain serotype 4 and analysed by flow cytometry. Control shows the level of non-specific binding of the secondary antibody to the surface of *S. pneumoniae* cells. The histograms in figure 5B indicates the increased fluorescence due to specific binding of anti-SP2216, anti-SP0117, anti-SP0454 and anti-CRF1992 antibodies in comparison to the control sera against

the platform protein LamB.

Figure 7 shows the bactericidal activity of epitope specific antibodies as determined in *in vitro* killing assay. The killing activity of immune sera is measured parallel with and calculated relative to the appropriate control sera. Data are expressed as percentage of killing, that is the reduction on bacterial cfu numbers as a consequence of the presence of antibodies in hyperimmune (HI) polyclonal mouse sera generated with *S. pneumoniae* lysate (A), in immune sera generated with SP0117 epitopes expressed in the LamB platform protein (B), and in mouse immune sera generated with SP1287 epitopes expressed in the FhuA platform protein (C). The control sera represent preimmune sera (PI), sera induced with Lamb or FhuA expressing *E. coli* clones without *S. pneumonia*-derived epitopes. *S. pneumonaie* serotype 4 cells were incubated with mouse phagocytic cells for 60 min, and surviving bacteria were quantified by counting cfus after plating on blood agar.

Figure 8 shows the protection achieved by active immunization with selected *S. pneumoniae* antigens in a mouse lethality model. C3H mice (10 in each test groups) were immunized with recombinant antigens cloned from a serotype 4 *S. pneumoniae* strain and challenged with serotype 6B strain. Survival was monitored for 2 to 3 weeks post-challenge. A: Mice were immunized with SP0368, SP0667, SP2190 and SP2216 antigens and challenged intravenously with 10^4 cfu bacteria. Nonimmunized mice were used as negative controls, while PspA (SP0117) served as positive control. B: Mice were immunized with SP2190 and SP2216 antigens and challenged intraperitonealy with 10^5 cfu bacteria. Mice injected with PBS or mock immunized with the adjuvants only (CFA/IFA) were used as negative controls, while PspA (SP0117) served as positive control. C: Mice were immunized with SP0498 and SP1732 antigens and challenged intraperitonealy with 10^5 cfu bacteria. Mice injected with PBS were used as negative controls, while PspA (SP0117) served as positive control.

Figure 9 shows the protection achieved by passive immunization with hyperimmune mouse sera generated with selected *S. pneumoniae* antigens in a mouse lethality model. C3H mice (10 in each test groups) were given mouse sera intraperitoneally 2 hrs before intraperitoneal challenge with 10^5 cfu *S. pneumoniae* serotype 6B bacteria. Survival was monitored for 3 weeks post-challenge. 150μl immune sera generated with SP2190 or SP2216 were given and supplemented with 150μl serum from naive mice, except for mice receiving 100μl each of anti-SP2190, anti-SP2216 immune sera and 100 μl serum from naive mice. Negative controls were treated either with 300μl sera from PBS injected, noninjected (naive) or nonimmune CFA/IFA injected mice.

Figure 10 shows the identification of the protective domain within the SP2216 antigen. A: Schematic representation of the SP2216 antigen indicating the two subdomains predicted by *in silico* (structural prediction) analysis and the localization of epitopes identified by bacterial surface display (grey bars and arrows). B: C3H mice (10 in each test groups) were immunized with recombinant SP2216 antigens: full-length, N-terminal or C-terminal domains and challenged with *S. pneumoniae* serotype 6B strain given intraperitoneally 10^5 cfus. Survival was monitored for 2 to 3 weeks post-challenge. Nonimmunized (CFA/IFA adjuvant injected) mice were used as negative controls, while PspA (SP0117) served as positive control.

Figure 11 shows the cross-reactivity of antibodies by analysing different *S. pneumoniae* serotypes. Immunoblot analysis was performed with bacterial lysates prepared from 60 clinical isolates of *S. pneumoniae* representing 48 different serotypes and using sera generated with SP1732, SP2190 and SP2216 recombinant antigens cloned from a serotype 4 strain in order to test the cross-reactivity of antibodies. Results with seven different serotypes (Lanes 1-7) are shown as representative data taken from the complete analysis. Mw: molecular weight markers.

Figure 12 shows the amino acid exchanges detected in natural SP2216 variants expressed in different clinical isolates of *S. pneumoniae*. The SP2216 gene from 47 different clinical isolates representing 47 different *S. pneumoniae* serotypes were analysed by DNA sequencing. The translated amino acid

sequences are shown for those serotypes where amino acid exchanges were detected relative to the published TIGR4 genome sequences.

Figure 13 shows the amino acid exchanges detected in natural SP1732 variants expressed in different clinical isolates of *S. pneumoniae*. The SP1732 gene from six different clinical isolates representing six major *S. pneumoniae* serotypes (4, 6B, 9V, 18C, 19F, 23F) were analysed by DNA sequencing. The translated amino acid sequences are shown for those serotypes where amino acid exchanges were detected relative to the published TIGR4 (serotype 4) genome sequences.

Figure 14 shows the amino acid exchanges detected in natural SP2190 variants expressed in different clinical isolates of *S. pneumoniae*. The SP2190 gene from seven different clinical isolates representing seven major *S. pneumoniae* serotypes (4, 6B, 9V, 14, 18C, 19F, 23F) were analysed by DNA sequencing. The translated amino acid sequences are shown for those serotypes where amino acid exchanges were detected relative to the published TIGR4 (serotype 4) genome sequences. Due to missing sequence information from the middle part of some of the genes, the N-terminal and C-terminal aa alignments are shown separately. **A:** N-terminal amino acid sequences; **B:** C-terminal amino acid sequences.

Table 1: Immunogenic proteins identified by bacterial surface display.
A, 300bp library in fhuA with NSPn4-IgA (362), B, 300bp library in fhuA with NSPn4-IgG (832), C, 300bp library in fhuA with NSPn5-IgG (872), D, 300bp library in fhuA with PSPn3-IgA (361), E, 300bp library in fhuA with PSPn3-IgG (575), F, 300bp library in fhuA with PSPn7-IgG (795), G, 70bp library in lamB with NSPn4-IgA (1043), H, 70bp library in lamB with NSPn4-IgG (929), I, 70bp library in lamB with NSPn5-IgG (527), K, 70bp library in lamB with PSPn3-IgA (1121), L, 70bp library in lamB with PSPn3-IgG (1242), M, 70bp library in lamB with PSPn7-IgG (514); *, prediction of antigenic sequences longer than 5 amino acids was performed with the program ANTIGENIC {Kolaskar, A. et al., 1990}.

Table 2: Epitope serology with human sera.
Immune reactivity of individual synthetic peptides representing selected epitopes with individual human sera is shown. Extent of reactivity is pattern/grey coded; white: - (<50U), light grey: + (50-119U), dark gery: ++ (120-199U), black: +++ (200-500U) and vertically crossed: ++++ (> 500U). ELISA units (U) are calculated from OD_{405nm} readings and the serum dilution after correction for background. S stands for score, calculated as the sum of all reactivities (addition of the number of all +); P1 to P13 sera are measured to be high titer and are from patients with invasive penumococcal diseases and N1 to N10 sera are from healthy adults with high anti-*S. pneumoniae* titers. S stands for score. Which is the sum of immune reactivities: - =0; + =1; ++ =2; +++ =3 and ++++ =4. Location of synthetic peptides within the antigenic ORFs according to the genome annotation of TIGR4 strain are given in columns from and to indicating the first and last amino acid residues, respectively. Peptide names: SP0117.1-7 present in annotated ORFSP0117; ARF0408.1, potential novel ORF in alternative reading-frame of SP0408; CRF0129.1, potential novel ORF on complement of SP0129.

Table 3: Gene distribution in *S. pneumoniae* strains.
Fifty *S. pneumoniae* strains as shown in Figure 4A were tested by PCR with oligonucleotides specific for the genes encoding relevant antigens. The PCR fragment of one selected PCR fragment was sequenced in order to confirm the amplification of the correct DNA fragment. *, number of amino acid substitutions in a serotype 14 strain as compared to *S. pneumoniae* TIGR4 (serotype 4). #, alternative strain used for sequencing, because gene was not present in the serotype 14 strain.

Table 4: Surface location of antigenic epitopes and the functionality of the epitope-specific antibodies.
45 *S. pneumoniae* antigens were tested for surface localization in the way described and presented in Figure 6 by using mouse sera generated by immunization with *E. coli* clones harboring plasmids encoding the platform proteins LamB or FhuA fused to a *S. pneumoniae* peptide. Data are summarized in the column labeled **FACS**. The very same immune reagents were used in an *in vitro* killing assay, as

shown in Figure 7 for the examples, and presented for all antigens tested positive by FACS in column **PK** (phagocytic killing). -: negative result, +: not consistently positive in all assays performed, ++ and +++ are consistently positive relative to control reagents.

EXAMPLES

Example 1: Characterization and selection of human sera based anti-*S. pneumoniae* antibodies, preparation of antibody screening reagents

Experimental procedures

Enzyme linked immune assay (ELISA).
ELISA plates (Maxisorb, Millipore) were coated with 5-10 µg/ml total protein diluted in coating buffer (0.1M sodium carbonate pH 9.2). Three dilutions of sera (2,000X, 10,000X, 50,000X) were made in PBS-BSA. Highly specific Horse Radish Peroxidase (HRP)-conjugated anti-human IgG or anti-human IgA secondary antibodies (Southern Biotech) were used according to the manufacturers' recommendations (dilution: 1,000x). Antigen-antibody complexes were quantified by measuring the conversion of the substrate (ABTS) to colored product based on OD_{405nm} readings by automatic ELIAS reader (TECAN SUNRISE).

Preparation of bacterial antigen extracts
Total bacterial lysate: Bacteria were grown overnight in THB (Todd-Hewitt Broth) and lysed by repeated freeze-thaw cycles: incubation on dry ice/ethanol-mixture until frozen (1 min), then thawed at 37ºC (5 min): repeated 3 times. This was followed by sonication and collection of supernatant by centrifugation (3,500 rpm, 15 min, 4ºC).
Culture supernatant: After removal of bacteria by centrifugation, the supernatant of overnight grown bacterial cultures was precipitated with ice-cold ethanol by mixing 1 part supernatant with 3 parts abs. ethanol and incubated overnight at -20°C. Precipitates were collected by centrifugation (2,600 g, for 15 min). Dry pellets were dissolved either in PBS for ELISA, or in urea and SDS-sample buffer for SDS-PAGE and immunoblotting. The protein concentration of samples was determined by Bradford assay.

Immunoblotting
Total bacterial lysate and culture supernatant samples were prepared from *in vitro* grown *S. pneumoniae* serotype 4 uncapsulated mutant strain. 10 to 25µg total protein/lane was separated by SDS-PAGE using the BioRad Mini-Protean 3 Cell electrophoresis system and proteins transferred to nitrocellulose membrane (ECL, Amersham Pharmacia). After overnight blocking in 5% milk, human sera were added at 2,000x dilution, and HRPO labeled anti-human IgG was used for detection.

Surface staining of bacteria
Flow cytometric analysis was carried out as follows. *S. pneumoniae* serotype 4 uncapsulated mutant strain was grown in Todd-Hewitt broth overnight until early stationary phase. Cells were collected and washed twice in Hanks Balanced Salt Solution (HBSS) and the cell density was adjusted to approximately 1 X 10⁶ CFU in 100µl HBSS with 0.5% BSA based on OD600 nm readings. After incubation with human sera at 0,5 and 2% final concentration for 60 min at 4°C, unbound antibodies were washed away by centrifugation in excess HBSS, 0.5% BSA. For detection fluorescein (FITC) labeled secondary goat anti-human IgG (F(ab')₂ fragment specific) was incubated with the cells at 4°C for 30 min. After washing the cells, cells were fixed with 2% paraformaldehyde. Surface staining antibodies were detected using a Becton Dickinson FACScan flow cytometer and data further analyzed with the computer program CELLQuest.

Purification of antibodies for genomic screening. Five sera from both the patient and the healthy group were selected based on the overall anti-streptococcal titers for a serum pool used in the screening procedure.

Antibodies against *E. coli* proteins were removed by incubating the heat-inactivated sera with whole cell *E. coli* cells (DH5alpha, transformed with pHIE11, grown under the same condition as used for bacterial surface display). Highly enriched preparations of IgGs from the pooled, depleted sera were generated by protein G affinity chromatography, according to the manufacturer's instructions (UltraLink Immobilized Protein G, Pierce). IgA antibodies were purified also by affinity chromatography using biotin-labeled anti-human IgA (Southern Biotech) immobilized on Streptavidin-agarose (GIBCO BRL). The efficiency of depletion and purification was checked by SDS-PAGE, Western blotting, ELISA and protein concentration measurements.

Results

The antibodies produced against *S. pneumoniae* by the human immune system and present in human sera are indicative of the *in vivo* expression of the antigenic proteins and their immunogenicity. These molecules are essential for the identification of individual antigens in the approach as described in the present invention, which is based on the interaction of the specific anti-streptococcal antibodies and the corresponding *S. pneumoniae* peptides or proteins. To gain access to relevant antibody repertoires, human sera were collected from

I. convalescent patients with invasive *S. pneumoniae* infections, such as pneumonia, bacteraemia and meningitis. (*S. pneumoniae* was shown to be the causative agent by medical microbiological tests),

II healthy adults without carriage at the time of sampling. *S. pneumoniae* colonization and infections are common, and antibodies are present as a consequence of natural immunization from previous encounters.

97 serum samples from patien and 50 sera from healthy adults were characterized for anti-*S. pneumoniae* antibodies by a series of immune assays. Primary characterization was done by ELISA using two different antigen preparations, such as total bacterial extract and culture supernatant proteins prepared from *S. pneumoniae* serotype 4 uncapsulated mutant strain. It is an important aspect that we analysed uncapsulated strain, since we avoided the reactivities coming from serotype specific abundant anti-capsular polysaccharide antibodies.

Recently it was reported that not only IgG, but also IgA serum antibodies can be recognized by the FcRIII receptors of PMNs and promote opsonization {Phillips-Quagliata, J. et al., 2000}; {Shibuya, A. et al., 2000}. The primary role of IgA antibodies is neutralization, mainly at the mucosal surface. The level of serum IgA reflects the quality, quantity and specificity of the dimeric secretory IgA. For that reason the serum collection was not only analyzed for anti-streptococcal IgG, but also for IgA levels. In the ELISA assays highly specific secondary reagents were used to detect antibodies from the high affinity types, such as IgG and IgA, but avoided IgM. Production of IgM antibodies occurs during the primary adaptive humoral response, and results in low affinity antibodies, while IgG and IgA antibodies had already undergone affinity maturation, and are more valuable in fighting or preventing disease. Antibody titers were compared at given dilutions where the response was linear (Fig. 1A and 1B.). Sera were ranked based on the IgG and IgA reactivity against the two complex antigenic mixtures, and the highest ones were selected for further testing by immunoblotting. This analysis confirmed a high antibody reactivity of the pre-selected sera against multiple pneumococcal proteins, especially when compared to not selected, low-titer sera (Fig 1C). ELISA ranking of sera also correlated very well with surface staining of the same *S. pneumoniae* strain (Fig. 1D and 1E) suggesting that the majority of the antibodies detected by ELISA corresponded to surface antigens. This extensive antibody characterization approach has led to the unambiguous identification of anti-pneumococcal hyperimmune sera.

Selected sera, 2x5 from both the patient and healthy donor groups were pooled to further enrich for abundant antibodies, but still having a representation of antibody repertoires of different individuals. IgG and IgA antibodies were purified from pooled sera by affinity chromatography and depleted of *E. coli* -reactive antibodies to avoid background in the bacterial surface display screen.

Example 2: Generation of highly random, frame-selected, small-fragment, genomic DNA libraries of *Streptococcus pneumoniae*

Experimental procedures

Preparation of streptococcal genomic DNA. 50 ml Todd-Hewitt Broth medium was inoculated with *S. pneumoniae* serotype 4 (clinical isolate, typed with conventional serotyping) bacteria from a frozen stab and grown with aeration and shaking for 18 h at 37°C. The culture was then harvested, centrifuged with 1,600x g for 15 min and the supernatant was removed. Bacterial pellets were washed 3 x with PBS and carefully re-suspended in 0.5 ml of Lysozyme solution (100 mg/ml). 0.1 ml of 10 mg/ml heat treated RNase A and 20 U of RNase T1 were added, mixed carefully and the solution was incubated for 1 h at 37°C. Following the addition of 0.2 ml of 20 % SDS solution and 0.1 ml of Proteinase K (10 mg/ml) the tube was incubated overnight at 55°C. 1/3 volume of saturated NaCl was then added and the solution was incubated for 20 min at 4°C. The extract was pelleted in a microfuge (13,000 rpm) and the supernatant transferred into a new tube. The solution was extracted with PhOH/CHCl₃/IAA (25:24:1) and with CHCl₃/IAA (24:1). DNA was precipitated at room temperature by adding 0.6x volume of Isopropanol, spooled from the solution with a sterile Pasteur pipette and transferred into tubes containing 80% ice-cold ethanol. DNA was recovered by centrifuging the precipitates with 10-12,000x g, then dried on air and dissolved in ddH_2O.

Preparation of small genomic DNA fragments. Genomic DNA fragments were mechanically sheared into fragments ranging in size between 150 and 300 bp using a cup-horn sonicator (Bandelin Sonoplus UV 2200 sonicator equipped with a BB5 cup horn, 10 sec. pulses at 100 % power output) or into fragments of size between 50 and 70 bp by mild DNase I treatment (Novagen). It was observed that sonication yielded a much tighter fragment size distribution when breaking the DNA into fragments of the 150-300 bp size range. However, despite extensive exposure of the DNA to ultrasonic wave-induced hydromechanical shearing force, subsequent decrease in fragment size could not be efficiently and reproducibly achieved. Therefore, fragments of 50 to 70 bp in size were obtained by mild DNase I treatment using Novagen's shotgun cleavage kit. A 1:20 dilution of DNase I provided with the kit was prepared and the digestion was performed in the presence of MnCl₂ in a 60 µl volume at 20°C for 5 min to ensure double-stranded cleavage by the enzyme. Reactions were stopped with 2 µl of 0.5 M EDTA and the fragmentation efficiency was evaluated on a 2% TAE-agarose gel. This treatment resulted in total fragmentation of genomic DNA into near 50-70 bp fragments. Fragments were then blunt-ended twice using T4 DNA Polymerase in the presence of 100 µM each of dNTPs to ensure efficient flushing of the ends. Fragments were used immediately in ligation reactions or frozen at -20°C for subsequent use.

Description of the vectors. The vector pMAL4.31 was constructed on a pASK-IBA backbone {Skerra, A., 1994} with the beta-lactamase (*bla*) gene exchanged with the Kanamycin resistance gene. In addition the *bla* gene was cloned into the multiple cloning site. The sequence encoding mature beta-lactamase is preceded by the leader peptide sequence of *ompA* to allow efficient secretion across the cytoplasmic membrane. Furthermore a sequence encoding the first 12 amino acids (spacer sequence) of mature beta-lactamase follows the *ompA* leader peptide sequence to avoid fusion of sequences immediately after the leader peptidase cleavage site, since e.g. clusters of positive charged amino acids in this region would decrease or abolish translocation across the cytoplasmic membrane {Kajava, A. et al., 2000}. A *Sma*I restriction site serves for library insertion. An upstream FseI site and a downstream NotI site, which were used for recovery of the selected fragment, flank the *Sma*I site. The three restriction sites are inserted after the sequence encoding the 12 amino acid spacer sequence in such a way that the *bla* gene is transcribed in the -1 reading frame resulting in a stop codon 15 bp after the *Not*I site. A +1 bp insertion restores the *bla* ORF so that beta-lactamase protein is produced with a consequent gain of Ampicillin resistance.

The vector pMAL9.1 was constructed by cloning the *lamB* gene into the multiple cloning site of pEH1 {Hashemzadeh-Bonehi, L. et al., 1998}. Subsequently, a sequence was inserted in *lamB* after amino acid

154, containing the restriction sites *FseI*, *SmaI* and *NotI*. The reading frame for this insertion was constructed in such a way that transfer of frame-selected DNA fragments excised by digestion with *FseI* and *NotI* from plasmid pMAL4.31 yields a continuous reading frame of *lamB* and the respective insert.

The vector pMAL10.1 was constructed by cloning the *btuB* gene into the multiple cloning site of pEH1. Subsequently, a sequence was inserted in *btuB* after amino acid 236, containing the restriction sites *FseI*, *XbaI* and *NotI*. The reading frame for this insertion was chosen in a way that transfer of frame-selected DNA fragments excised by digestion with *FseI* and *NotI* from plasmid pMAL4.31 yields a continuous reading frame of *btuB* and the respective insert.

The vector pHIE11 was constructed by cloning the *fhuA* gene into the multiple cloning site of pEH1. Thereafter, a sequence was inserted in *fhuA* after amino acid 405, containing the restriction site *FseI*, *XbaI* and *NotI*. The reading frame for this insertion was chosen in a way that transfer of frame-selected DNA fragments excised by digestion with *FseI* and *NotI* from plasmid pMAL4.31 yields a continuous reading frame of *fhuA* and the respective insert.

Cloning and evaluation of the library for frame selection. Genomic *S. pneumoniae* DNA fragments were ligated into the *SmaI* site of the vector pMAL4.31. Recombinant DNA was electroporated into DH10B electrocompetent *E. coli* cells (GIBCO BRL) and transformants plated on LB-agar supplemented with Kanamycin (50 μg/ml) and Ampicillin (50 μg/ml). Plates were incubated over night at 37°C and colonies collected for large scale DNA extraction. A representative plate was stored and saved for collecting colonies for colony PCR analysis and large-scale sequencing. A simple colony PCR assay was used to initially determine the rough fragment size distribution as well as insertion efficiency. From sequencing data the precise fragment size was evaluated, junction intactness at the insertion site as well as the frame selection accuracy (*3n+1 rule*).

Cloning and evaluation of the library for bacterial surface display. Genomic DNA fragments were excised from the pMAL4.31 vector, containing the *S. pneumoniae* library with the restriction enzymes *FseI* and *NotI*. The entire population of fragments was then transferred into plasmids pMAL9.1 (LamB) or pHIE11 (FhuA), which have been digested with *FseI* and *NotI*. Using these two restriction enzymes, which recognise an 8 bp GC rich sequence, the reading frame that was selected in the pMAL4.31 vector is maintained in each of the platform vectors. The plasmid library was then transformed into *E. coli* DH5alpha cells by electroporation. Cells were plated onto large LB-agar plates supplemented with 50 μg/ml Kanamycin and grown over night at 37°C at a density yielding clearly visible single colonies. Cells were then scraped off the surface of these plates, washed with fresh LB medium and stored in aliquots for library screening at - 80°C.

Results

Libraries for frame selection. Two libraries (LSPn70 and LSPn300) were generated in the pMAL4.31 vector with sizes of approximately 70 and 300 bp, respectively. For each library, ligation and subsequent transformation of approximately 1 μg of pMAL4.31 plasmid DNA and 50 ng of fragmented genomic *S. pneumoniae* DNA yielded 4x 10^5 to 2x 10^6 clones after frame selection. To assess the randomness of the libraries, approximately 600 randomly chosen clones of LSPn70 were sequenced. The bioinformatic analysis showed that of these clones only very few were present more than once. Furthermore, it was shown that 90% of the clones fell in the size range between 25 and 100 bp with an average size of 52 bp (Figure 2). Allmost all sequences followed the 3n+1 rule, showing that all clones were properly frame selected.

Bacterial surface display libraries. The display of peptides on the surface of *E. coli* required the transfer of the inserts from the LSPn libraries from the frame selection vector pMAL4.31 to the display plasmids pMAL9.1 (LamB) or pHIE11 (FhuA). Genomic DNA fragments were excised by *FseI* and *NotI* restriction

and ligation of 5ng inserts with 0.1μg plasmid DNA and subsequent transformation into DH5alpha cells resulted in 2-5x 10^6 clones. The clones were scraped off the LB plates and frozen without further amplification.

Example 3: Identification of highly immunogenic peptide sequences from *S. pneumoniae* using bacterial surface displayed genomic libraries and human serum

Experimental procedures

MACS screening. Approximately 2.5x 10^8 cells from a given library were grown in 5 ml LB-medium supplemented with 50 μg/ml Kanamycin for 2 h at 37°C. Expression was induced by the addition of 1 mM IPTG for 30 min. Cells were washed twice with fresh LB medium and approximately 2x 10^7 cells re-suspended in 100 μl LB medium and transferred to an Eppendorf tube.

10 μg of biotinylated, human IgGs purified from serum was added to the cells and the suspension incubated overnight at 4°C with gentle shaking. 900 μl of LB medium was added, the suspension mixed and subsequently centrifuged for 10 min at 6,000 rpm at 4°C (For IgA screens, 10 μg of purified IgAs were used and these captured with biotinylated anti-human-IgG secondary antibodies). Cells were washed once with 1 ml LB and then re-suspended in 100 μl LB medium. 10 μl of MACS microbeads coupled to streptavidin (Miltenyi Biotech, Germany) were added and the incubation continued for 20 min at 4°C. Thereafter 900 μl of LB medium was added and the MACS microbead cell suspension was loaded onto the equilibrated MS column (Miltenyi Biotech, Germany) which was fixed to the magnet. (The MS columns were equilibrated by washing once with 1 ml 70% EtOH and twice with 2 ml LB medium.)

The column was then washed three times with 3 ml LB medium. After removal of the magnet, cells were eluted by washing with 2 ml LB medium. After washing the column with 3 ml LB medium, the 2 ml eluate was loaded a second time on the same column and the washing and elution process repeated. The loading, washing and elution process was performed a third time, resulting in a final eluate of 2 ml.

A second round of screening was performed as follows. The cells from the final eluate were collected by centrifugation and re-suspended in 1 ml LB medium supplemented with 50 μg/ml Kanamycin. The culture was incubated at 37°C for 90 min and then induced with 1 mM IPTG for 30 min. Cells were subsequently collected, washed once with 1 ml LB medium and suspended in 10 μl LB medium. 10 μg of human, biotinylated IgGs were added again and the suspension incubated over night at 4°C with gentle shaking. All further steps were exactly the same as in the first selection round. Cells selected after two rounds of selection were plated onto LB-agar plates supplemented with 50 μg/ml Kanamycin and grown over night at 37°C.

Evaluation of selected clones by sequencing and Western blot analysis. Selected clones were grown overnight at 37°C in 3 ml LB medium supplemented with 50 μg/ml Kanamycin to prepare plasmid DNA using standard procedures. Sequencing was performed at MWG (Germany) or in collaboration with TIGR (U.S.A.).

For Western blot analysis approximately 10 to 20 μg of total cellular protein was separated by 10% SDS-PAGE and blotted onto HybondC membrane (Amersham Pharmacia Biotech, England). The LamB or FhuA fusion proteins were detected using human serum as the primary antibody at a dilution of approximately 1:5,000 and anti-human IgG or IgA antibodies coupled to HRP at a dilution of 1:5,000 as secondary antibodies. Detection was performed using the ECL detection kit (Amersham Pharmacia Biotech, England). Alternatively, rabbit anti-FhuA or rabbit anti-LamB polyclonal immune sera were used as primary antibodies in combination with the respective secondary antibodies coupled to HRP for the detection of the fusion proteins.

Results

Screening of bacterial surface display libraries by magnetic activated cell sorting (MACS) using biotinylated Igs.
The libraries LSPn70 in pMAL9.1 and LSPn300 in pHIE11 were screened with pools of biotinylated, human IgGs and IgAs from patient sera or sera from healthy individuals (see Example 1: *Preparation of antibodies from human serum*). The selection procedure was performed as described under Experimental procedures. Figure 3A shows a representative example of a screen with the LSPn-70 library and PSPn3-IgGs. As can be seen from the colony count after the first selection cycle from MACS screening, the total number of cells recovered at the end is drastically reduced from 2×10^7 cells to approximately 5×10^4 cells, whereas the selection without antibodies added showed a reduction to about 2×10^3 cells (Figure 3A). After the second round, a similar number of cells was recovered with PSPn3-IgGs, while fewer than 10 cells were recovered when no IgGs from human serum were added, clearly showing that selection was dependent on *S. pneumoniae* specific antibodies. To evaluate the performance of the screen, 26 selected clones were picked randomly and subjected to immunoblot analysis with screening IgG pool (PSPn7) (Figure 3B). This analysis revealed that ~90% of the selected clones showed reactivity with antibodies present in the relevant serum whereas the control strain expressing LamB without a *S. pneumoniae* specific insert did not react with the same serum. In general, the rate of reactivity was observed to lie within the range of 35 to 90%. Colony PCR analysis showed that all selected clones contained an insert in the expected size range.

Subsequent sequencing of a larger number of randomly picked clones (600 to 1200 per screen) led to the identification of the gene and the corresponding peptide or protein sequence that was specifically recognized by the human serum antibodies used for screening. The frequency with which a specific clone is selected reflects at least in part the abundance and/or affinity of the specific antibodies in the serum used for selection and recognizing the epitope presented by this clone. In that regard it is striking that clones derived from some ORFs (e.g. SP2216, SP0117, SP0641, SP2136, SP2190, SP0107, SP0082) were picked more than 100 times, indicating their highly immunogenic property. Table 1 summarizes the data obtained for all 12 performed screens. All clones that are presented in Table 1 have been verified by immunoblot analysis using whole cellular extracts from single clones to show the indicated reactivity with the pool of human serum used in the respective screen. As can be seen from Table 1, distinct regions of the identified ORF are identified as immunogenic, since variably sized fragments of the proteins are displayed on the surface by the platform proteins.

It is further worth noticing that most of the genes identified by the bacterial surface display screen encode proteins that are either attached to the surface of *S. pneumoniae* and/or are secreted. This is in accordance with the expected role of surface attached or secreted proteins in virulence of *S. pneumoniae*.

Example 4: Assessment of the reactivity of highly immunogenic peptide sequences with individual human sera.

Experimental procedures

Peptide synthesis
Peptides were synthesized in small scale (4 mg resin; up to 288 in parallel) using standard F-moc chemistry on a Rink amide resin (PepChem, Tübingen, Germany) using a SyroII synthesizer (Multisyntech, Witten, Germany). After the sequence was assembled, peptides were elongated with Fmoc-epsilon-aminohexanoic acid (as a linker) and biotin (Sigma, St. Louis, MO; activated like a normal amino acid). Peptides were cleaved off the resin with 93%TFA, 5% triethylsilane, and 2% water for one hour. Peptides were dried under vacuum and freeze dried three times from acetonitrile/water (1:1). The presence of the correct mass was verified by mass spectrometry on a Reflex III MALDI-TOF (Bruker,

- 54 -

Bremen Germany). The peptides were used without further purification.

Enzyme linked immune assay (ELISA).

Biotin-labeled peptides (at the N-terminus) were coated on Streptavidin ELISA plates (EXICON) at 10 µg/ml concentration according to the manufacturer's instructions. Highly specific Horse Radish Peroxidase (HRP)-conjugated anti-human IgG secondary antibodies (Southern Biotech) were used according to the manufacturers' recommendations (dilution: 1,000x). Sera were tested at two serum dilutions, 200X and 1,000X. Following manual coating, peptide plates were processed and analyzed by the Gemini 160 ELISA robot (TECAN) with a built-in ELISA reader (GENIOS, TECAN).

Approximately 110 patients and 60 healthy adult sera were included in the analysis. Following the bioinformatic analysis of selected clones, corresponding peptides were designed and synthesized. In case of epitopes with more than 26 amino acid residues, overlapping peptides were made. All peptides were synthesized with a N-terminal biotin-tag and used as coating reagents on Streptavidin-coated ELISA plates.

The analysis was performed in two steps. First, peptides were selected based on their reactivity with the individual sera, which were included in the serum pools used for preparations of IgG and IgA screening reagents for bacterial surface display. A summary for serum reactivity of 224 peptides representing *S. pneumoniae* epitopes from the genomic screen analysed with 20 human sera (representing 4 different pools of five sera) used for the antigen identification is shown in Table 2. The peptides were compared by the score calculated for each peptide based on the number of positive sera and the extent of reactivity. Peptides range from highly and widely reactive to weakly positive ones. Among the most reactive ones there are known antigens, some of them are also protective in animal challenge models for nasopharyngeal carriage or sepsis (e.g. PspA/SP0117, serine protease/SP0641, histidine triad protein/SP1175). Peptides not displaying a positive reaction were not included in further, more detailed studies.

Second, a large number of not pre-selected individual sera from patients with invasive pneumococcal disease or from healthy adults and children were tested against the peptides showing specific and high reactivity with the screening sera. Seroconversion during disease was tested for highly positive peptides by using three serial serum samples collected longitudinally from patients with invasive pneumococcal disease, the first before disease occurred (pre), the second in the acute phase (within 5 days after onset) and the third in the convalescent phase (> 3 weeks after onset) of the disease. Two representative ELISA experiments are shown with two different patients, displaying seroconversion to multiple peptides, suggesting that epitope-specific antibody levels were low before disease occurred, and were induced in the acute and convalescent phase (Fig. 5). The antigens showing this antibody profile are especially valuable for vaccine development (e.g. SP2216, SP2109, SP1175, SP0117, SP0082).

Example 5: Gene distribution studies with highly immunogenic proteins identified from *S. pneumoniae*.

Experimental procedures

Gene distribution of pneumococcal antigens by PCR. An ideal vaccine antigen would be an antigen that is present in all, or the vast majority of strains of the target organism to which the vaccine is directed. In order to establish whether the genes encoding the identified *Streptococcus pneumoniae* antigens occur ubiquitously in *S. pneumoniae* strains, PCR was performed on a series of independent *S. pneumoniae* isolates with primers specific for the gene of interest. *S. pneumoniae* isolates were obtained covering the serotypes most frequently present in patients as shown in Figure 4A. Oligonucleotide sequences as primers were designed for all identified ORFs yielding products of approximately 1,000 bp, if possible

- 55 -

covering all identified immunogenic epitopes. Genomic DNA of all *S. pneumoniae* strains was prepared as described under Example 2. PCR was performed in a reaction volume of 25 µl using Taq polymerase (1U), 200 nM dNTPs, 10 pMol of each oligonucleotide and the kit according to the manufacturers instructions (Invitrogen, The Netherlands). As standard, 30 cycles (1x: 5min. 95°C, 30x: 30sec. 95°C, 30sec. 56°C, 30sec. 72°C, 1x 4min. 72°C) were performed, unless conditions had to be adapted for individual primer pairs.

Results

All identified genes encoding immunogenic proteins were tested by PCR for their presence in 50 different strains of *S. pneumoniae* (Figure 4A). As an example, figure 4B shows the PCR reaction for SP1604 with all indicated 50 strains. As clearly visible, the gene is present in all strains analysed. The PCR fragment from a type 14 strain was sequenced and showed that of 414 bp, 6 bp are different as compared to the *S. pneumoniae* type 4 strain, resulting in three amino acid difference between the two isolates.
From a total of 50 genes analysed, 31 were present in all strains tested, while 9 genes were absent in more than 10 of the tested 50 strains (Table 3). Several genes (SP0667, SP0930) showed variation in size and were not present in all strain isolates. Some genes showed variation in size, but were otherwise conserved in all tested strains. Sequencing of the generated PCR fragment from one strain and subsequent comparison to the type 4 strain confirmed the amplification of the correct DNA fragment and revealed a degree of sequence divergence as indicated in Table 3. Importantly, many of the identified antigens are well conserved in all strains in sequence and size and are therefore novel vaccine candidates to prevent infections by pneumococci.

Example 6: Characterization of immune sera obtained from mice immunized with highly immunogenic proteins/peptides from *S. pneumoniae* displayed on the surface of *E. coli*.

Experimental procedures

Generation of immune sera from mice
E. coli clones harboring plasmids encoding the platform protein fused to a *S. pneumoniae* peptide, were grown in LB medium supplemented with 50µg/ml Kanamycin at 37°C. Overnight cultures were diluted 1:10, grown until an OD_{600} of 0.5 and induced with 0.2 mM IPTG for 2 hours. Pelleted bacterial cells were suspended in PBS buffer and disrupted by sonication on ice, generating a crude cell extract. According to the OD_{600} measurement, an aliquot corresponding to $5x10^7$ cells was injected into NMRI mice i.v., followed by a boost after 2 weeks. Serum was taken 1 week after the second injection. Epitope specific antibody levels were measured by peptide ELISA.

In vitro expression of antigens
Expression of antigens by *in vitro* grown *S. pneumoniae* serotype 4 was tested by immunoblotting. Different growth media and culture conditions were tested to detect the presence of antigens in total lysates and bacterial culture supernatants. Expression was considered confirmed when a specific band corresponding to the predicted molecular weight and electrophoretic mobility was detected.

Cell surface staining
Flow cytometric analysis was carried out as follows. Bacteria were grown under culture conditions, which resulted in expression of the antigen as shown by the immunoblot analysis. Cells were washed twice in Hanks Balanced Salt Solution (HBSS) and the cell density was adjusted to approximately 1×10^6 CFU in 100µl HBSS, 0.5% BSA. After incubation for 30 to 60 min at 4°C with mouse antisera diluted 50 to 100-fold, unbound antibodies were washed away by centrifugation in excess HBSS, 0.5% BSA. Secondary goat anti-mouse antibody (F(ab')₂ fragment specific) labeled with fluorescein (FITC) was incubated with the cells at 4°C for 30 to 60 min. After washing, cells were fixed with 2% paraformaldehyde. Bound antibodies were detected using a Becton Dickinson FACScan flow cytometer and data further analyzed

with the computer program CELLQuest. Negative control sera included mouse pre-immune serum and mouse polyclonal serum generated with lysates prepared from IPTG induced *E. coli* cells transformed with plasmids encoding the genes *lamB* or *fhuA* without *S. pneumoniae* genomic insert.

Bactericidal (killing) assay

Murine macrophage cells (RAW246.7 or P388.D1) and bacteria were incubated and the loss of viable bacteria after 60 min was determined by colony counting. In brief, bacteria were washed twice in Hanks Balanced Salt Solution (HBSS) and the cell density was adjusted to approximately 1X 10^5 CFU in 50μl HBSS. Bacteria were incubated with mouse sera (up to 25%) and guinea pig complement (up to 5%) in a total volume of 100μl for 60min at 4°C. Pre-opsonized bacteria were mixed with macrophages (murine cell line RAW264.7 or P388.D1; 2X 10^6 cells per 100μl) at a 1:20 ratio and were incubated at 37°C on a rotating shaker at 500 rpm. An aliquot of each sample was diluted in sterile water and incubated for 5 min at room temperature to lyse macrophages. Serial dilutions were then plated onto Todd-Hewitt Broth agar plates. The plates were incubated overnight at 37°C, and the colonies were counted with the Countermat flash colony counter (IUL Instruments). Control sera included mouse pre-immune serum and mouse polyclonal serum generated with lysates prepared from IPTG induced *E. coli* transformed with plasmids harboring the genes *lamB* or *fhuA* without *S. pneumoniae* genomic insert.

Results

In vitro expression of antigens. The expression of the antigenic proteins was analyzed *in vitro* in *S. pneumoniae* serotype 4 by using sera raised against *E. coli* clones harboring plasmids encoding the platform protein fused to a *S. pneumoniae* peptide. First, the presence of specific antibodies was determined by peptide ELISA and/or immunoblotting using the *E. coli* clone expressing the given epitope embedded in LamB or FhuA platform proteins. Positive sera were then analysed by immunblotting using total bacterial lysates and culture supernatants prepared from *S. pneumoniae* serotype 4 strain (data not shown). This analysis served as a first step to determine whether a protein is expressed at all, and if, under which growth conditions, in order to evaluate surface expression of the polypeptide by FACS analysis. It was anticipated based on literature data that not all proteins would be expressed under *in vitro* conditions.

Cell surface staining of S. pneumoniae. Cell surface accessibility for several antigenic proteins was subsequently demonstrated by an assay based on flow cytometry. Streptococci were incubated with preimmune and polyclonal mouse sera raised against *S. pneumoniae* lysate or *E. coli* clones harboring plasmids encoding the platform protein fused to a *S. pneumoniae* peptide, follow by detection with fluorescently tagged secondary antibody. As shown in Fig. 6A, antisera raised against *S. pneumoniae* lysate contains antibodies against surface components, demonstrated by a significant shift in fluorescence of the *S. pneumoniae* serotype 4 cell population. Similar cell surface staining of *S. pneumoniae* sertype 4 cells was observed with polyclonal sera raised against peptides of many of the pneumococcal antigens identified (Fig. 6B and Table 4.). In some instancies, a subpopulation of the bacteria was not stained, as indicated by the detection of two peaks in the histograms (Fig. 6B). This phenomenon may be a result of differential expression of the gene products during the growth of the bacterium, insufficient antibody levels or partial inhibition of antibody binding caused by other surface molecules or plasma proteins.

In vitro bactericidal activity. Opsonophagocytic killing is the cornerstone of host defense against extracellular bacteria, such as *S. pneumoniae*. Cell surface binding of antibodies to bacterial antigens are opsonizing and induce killing (bactericidal) by phagocytic cells (macrophages and neutrophil granulocytes) if the antibodies induced by the particular antigens can bind activated complement components (C3bi). It has been shown that anti-pneumococcal bactericidal activity of human sera measured in *in vitro* assays can be correlated with *in vivo* protection of vaccinated individuals {Romero-Steiner, S. et al., 1999}. In Figure 7 examples are shown and in Table 4 a summary is presented on bactericidal activity measured by antigen-specific antibodies generated in mice with corresponding

- 57 -

epitopes. According to these data, several of the novel pneumococcal antigens induce functional antibodies (e.g. SP0082, SP2216, SP2136, SP0454, SP0069, SP0369, etc.). Importantly, a well-known protective pneumoniae antigen, PspA (SP0117) is proved to be strongly positive in the very same assay.

These experiments confirmed the bioinformatic prediction that many of the proteins are exported due to their signal peptide sequence and in addition showed that they are present on the cell surface of *S. pneumoniae* serotype 4. They also confirm that these proteins are available for recognition by human antibodies with functional properties and make them valuable candidates for the development of a vaccine against pneumococcal diseases.

Example 7: Identification of pneumococcal antigens inducing protective immune responses

Experimental procedures

Expression of recombinant pneumococcal proteins

Cloning of genes/DNA fragments: The gene/DNA fragment of interest was amplified from the genomic DNA of S pneumoniae (strain T4, Capsular type 4) by PCR using gene specific primers. Apart from the gene specific part, the primers had restriction sites that aided in a directional cloning of the amplified PCR product. The gene annealing (specific) part of the primer ranged between 15-24 bases in length. The PCR products obtained were digested with the appropriate restriction enzyme and cloned into pET28b(+) vector (NOVAGEN). Once the recombinant plasmid was confirmed to contain the gene of interest, E coli BL21 star® cells (INVITROGEN) that served as expression hosts were transformed. These cells were optimized to efficiently express the gene of interest. Expression and purification of proteins: *E coli* BL21 star® cells harbouring the recombinant plasmid was grown until log phase in a required culture volume. Once the OD600nm of 0.8 was reached the culture was induced with 1 mM IPTG for 3 hours at 37°C. The cells were harvested by centrifugation, lysed by a combination of freeze-thaw method followed by disruption of cells with 'Bug-buster®, NOVAGEN'. The lysate was separated by centrifugation into soluble (supernatant) and insoluble (pellet) fractions. Depending on the location of the protein different purification strategies was followed. In case the protein was in the soluble fraction, purification of the protein was done by binding the above supernatant with Ni-Agarose beads (Ni-NTA-Agarose®, QIAGEN). Due to the presence of the penta Histidine (HIS) at the C or N or both termini of the expressed protein, it bound to the Ni-agarose while the other contaminating proteins were washed from the column by wash buffer. The proteins were eluted by 100 mM immidazole and the eluate was concentrated, assayed by Bradford for protein concentration and checked by PAGE and Western blot. In case the protein was present in the insoluble fraction the pellet was solubilized in buffer containing 8 M Urea. The purification was done under denaturing conditions (in buffer containing 8M Urea) using the same materials and procedure as mentioned above. The eluate was concentrated and dialyzed to remove all the urea in a gradual stepwise manner. The proteins were checked by SDS-PAGE and concentrations measured by Bradford method.

Animal protection studies

Animals: C3H (HeNHsd; A, B, C, D: agouti, wild type, inbred) female mice were used. Active immunization: 50 µg of recombinant proteins were injected subcutaneously and adjuvanted with Complete Freud Adjuvant (CFA). Animals were boosted twice with the same amount of protein, but adjuvanted with Incomplete Freund Adjuvant (IFA) at days 14 and 28. A well-known protective antigen PspA (SP0117) was used as a positive control, while nonimmunized (PBS or CFA/IFA adjuvant injected) mice served as negative controls. Antibody titers were measured at days 35-38 by ELISA using the respective recombinant proteins, and were determined to be in the range of 200.00-1.000.000 (end-point titer). Passive immunization: Näive mice were injected with 150-300µl mouse sera intraperitoneally 2hrs before intraperitoneal inoculation with *S. pneumoniae*. Bacterial challenge: A frozen glycerol stock of *S. pneumoniae* serotype 6B was prepared and used for all experiments. The approximate estimated cell number was determined by OD600nm measurements. In order to determine the real viable cell numbers

- 58 -

present in the inoculum prepared from the frozen glycerol stock cultures, cfus were determined via plating using six serial dilutions. 10^4-10^8 bacteria/mouse was injected either intravenously in the tail vein or intraperitoneally. Protective effect of immunizations was measured by monitoring survival rates for 2 to 3 weeks post-challenge and was expressed in % of total number of animals (10/ group).

Results

In the present invention six different pneumococcal antigens identified by bacterial surface display were determined to have protective effect in a mouse sepsis/lethality model. The best levels of protection were achieved by immunization with recombinant antigens representing the SP2190, SP2216 and SP0667 protein, while SP0368, SP1732 and SP0498 displayed lower levels of protection (Fig. 8). The protective effect was mediated by antibodies as it has been demonstrated by passive serum transfer experiments (Fig. 9). Näive mice receiving specific anti-SP2190 and anti-SP2216 antibodies were protected from death relative to mice from the negative control groups. Importantly, the combination of these antigens resulted in improved protection, as it has been shown in Fig. 9. Passive immunization with 150 µl immune serum generated either with recombinant SP2190 or with recombinant SP2216 (supplemented with 150µl näive serum) resulted in lower survival rate compared to serum therapy with 100µl each of specific antisera (supplemented with 100µl näive serum). These experiments strongly support that combination of these antigens has beneficial effects in vaccination against pneumococcal diseases.

Since the antigens used for immunization were derived from a serotype 4 strain and the challenge strain was a serotype 6B, these experiments established that the antigens were cross-protective.

The SP2216, SP2190 and SP1732 recombinant proteins detected the highest levels of antibodies in sera of patients convalescing from invasive pneumococcal diseases, as well as in those of healthy individuals exposed to Pneumococcus (children in the household) (data not shown). The most frequently identified antigen in bacterial surface display screens was the SP2216 protein. It was a special interest to compare the protectivity of the subdomains of this protein selected (N-terminal amino acid sequences) or not selected (C-terminal amino acid sequences) by human antibodies (Fig. 10A). Upon immunization with the two different domains (expressed as recombinant antigens) it became evident that the immunogenic part of the SP2216 protein carried the protective potential, while the non-selected domain was ineffective and comparable to the negative control (Fig. 10B). Based on this experiment the epitopes detected by bacterial surface display identifies protective epitopes and regions of bacterial proteins and this information can be used for rational design of subunit vaccines based on the antigens described in the present invention.

Example 8: Determination of sequence conservation of protective antigens

Experimental procedures

Immunoblotting
Total bacterial lysate and culture supernatant samples were prepared from *in vitro* grown *S. pneumoniae* strains. 60 (clinical isolates) representing 48 different serotypes were included in the study. Approximately 25µg total protein/lane was separated by SDS-PAGE using the BioRad Mini-Protean 3 Cell electrophoresis system and proteins transferred to nitrocellulose membrane (ECL, Amersham Pharmacia). After overnight blocking in 5% milk, hyperimmune mouse sera generated by immunization with the recombinant proteins SP2216, SP1732 and SP2190 (and SP0117/PspA as internal control) derived from serotype 4 strain were added at 5,000x dilution, and HRPO labeled anti-mouse IgG was used for detection.

DNA sequencing

The genes of SP1732, SP2190 and SP22126 were amplified from the genomic DNA of S. pneumoniae (serotype4, 6B, 9V, 14, 18C, 19F and23F) by PCR using a proofreading polymerase Expand (ROCHE). Gene specific primers, ranging between 27-31 bases in length, were used to amplify the entire open reading frames. The PCR products obtained were cloned into pCR®2.1-TOPO vector (Invitrogen). The recombinant plasmid DNA was purified using a QIAprep® miniprep kit (Qiagen) before the sequence was confirmed (MWG). In addition to the seven serotypes, the gene of SP2216 from other 41 different serotypes was amplified by PCR and the purified PCR products were sequenced.

Results

Identification of conserved antigens inducing antibodies that are cross-reactive with different clinical isolates is crucial for the development effective vaccines. It is especially relevant for protein-based vaccines targeting pneumococcal diseases, since more then 90 different serotypes of *Streptococcus pnuemoniae (Pneumococcus)* have been associated with human infections.

In a thorough analysis it was determined that the antibodies induced by SP2216, SP2190 and SP1732 all derived from a serotype 4 strain broadly cross-reacted with all the different serotypes tested in the immunoblot analysis (Fig. 11). Notably, the SP2190 antigen that showed variation in electrophoretic mobility (indicating different sizes) preserved the antibody reactivity strongly suggesting that immunodominant epitopes are conserved. In contrast, we detected lower cross-reactivity with anti-PspA antibodies that is in accordance with the known differences in immunogenic amino acid sequences of this antigen.

In order to directly address the question whether the identified protective antigens are conserved among the different serotypes of *S. pneumoniae*, DNA sequence analysis was performed on the SP2216, SP1732 and SP2190 genes. SP2216 and SP1732 are highly conserved, only few amino acid changes were detected. The SP2216 gene was sequenced from 47 different clinical isolates representing 47 different *S. pneumoniae* serotypes and only single amino acid exchanges were detected and only in 2 of the analysed strains (Fig. 12). In the SP1732 gene one or two amino acid exchanges were detected in the majority (in four of the six) of strains analysed (Fig. 13). The 2190 antigen showed a great variability in the amino acid sequences of the corresponding genes as it is shown in Fig. 14. The insertions and deletions makes it difficult to calculate an exact amino acid homology among the different SP2190 variants, but it can be estimated to be between approx. 60 and 90%. However, the amino acid identity was sufficient to induce cross-reactive and cross-protective antibodies based on the experiments presented in Fig. 8,9 and 11.

References

Adamou, J., et al. (2001). Infect Immun 69: 949-58.

Altschul, S., et al. (1990). Journal of Molecular Biology 215: 403-10.

Bennett, D., et al. (1995). J Mol Recognit 8: 52-8.

Brown, J., et al. (2001). Infect Immun 69: 6702-6.

Burnie, J., et al. (1998). J Antimicrob Chemother 41: 319-22.

Clackson, T., et al. (1991). Nature 352: 624-8.

Devereux, J., et al. (1984). Nucleic acids research 12: 387-95.

Di Guilmi, A., et al. (2002). EMBO Rep 3: 728-34.

Doherty, E., et al. (2001). Annu Rev Biophys Biomol Struct 30: 457-475.

Eisenbraun, M., et al. (1993). DNA Cell Biol 12: 791-7.

Epidemiology and Prevention of Vaccine-Preventable Diseases, 7 th Edition-Second Printing (The Pink Book). The Pink Book is published by the Centers for Disease Control and Prevention, U.S. Department of Health and Human Services.

Etz, H., et al. (2001). J Bacteriol 183: 6924-35.

Ganz, T. (1999). Science 286: 420-421.

Georgiou, G. (1997). Nature Biotechnology 15: 29-34.

Gray, B., et al. (1979). J Infect Dis 140: 979-83.

Gray, B., et al. (1986). Pediatr Infect Dis 5: 201-7.

Hashemzadeh-Bonehi, L., et al. (1998). Mol Microbiol 30: 676-678.

Hausdorff, W., et al. (2001). Lancet 357: 950-2.

Heinje, von G. (1987) e.g. Sequence Analysis in Molecular Biology, Acedimic Press

Hemmer, B., et al. (1999). Nat Med 5: 1375-82.

Hoe, N., et al. (2001). J Infect Dis 183: 633-9.

Hornef, M., et al. (2002). Nat Immunol 3: 1033-40.

Hoskins, J., et al. (2001). J Bacteriol 183: 5709-17.

Hyde, T., et al. (2001). JAMA 286: 1857-62.

Jedrzejas, M. (2001). Microbiol Mol Biol Rev 65: 187-207.

Johanson, K., et al. (1995). J Biol Chem 270: 9459-71.

Jones, P., et al. (1986). Nature 321: 522-5.

Kajava, A., et al. (2000). J Bacteriol 182: 2163-9.

Kohler, G., et al. (1975). Nature 256: 495-7.

Kolaskar, A., et al. (1990). FEBS Lett 276: 172-4.

Lewin, A., et al. (2001). Trends Mol Med 7: 221-8.

Marks, J., et al. (1992). Biotechnology (N Y) 10: 779-83.

McCafferty, J., et al. (1990). Nature 348: 552-4.

McCormick, A., et al. (2003). Nat Med 9: 424-30.

McDaniel, L., et al. (1991). Infect Immun 59: 222-8.

Navarre, W., et al. (1999). Microbiol Mol Biol Rev 63: 174-229.

Okano, H., et al. (1991). J Neurochem 56: 560-7.

Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression; CRC Press, Boca Tation, FL (1988) for a description of these molecules

Orange, M., et al. (1993). Pediatr Infect Dis J 12: 244-6.

Pelton, S., et al. (2003). Vaccine 21: 1562-71.

Phillips-Quagliata, J., et al. (2000). J Immunol 165: 2544-55.

Rammensee, H., et al. (1999). Immunogenetics 50: 213-9.

Roche, H., et al. (2003). Infect Immun 71: 1033-41.

Romero-Steiner, S., et al. (1999). Clin Infect Dis 29: 281-8.

Rosenow, C., et al. (1997). Mol Microbiol 25: 819-29.

Seeger, C., et al. (1984). Proc Natl Acad Sci U S A 81: 5849-52.

Shibuya, A., et al. (2000). Nature Immunology 1: 441-6.

Skerra, A. (1994). <u>Gene</u> **151**: 131-5.
Talkington, D., et al. (1996). <u>Microb Pathog</u> **21**: 17-22.
Tang, D., et al. (1992). <u>Nature</u> **356**: 152-4.
Tempest, P., et al. (1991). <u>Biotechnology (N Y)</u> **9**: 266-71.
Tettelin, H., et al. (2001). <u>Science</u> **293**: 498-506.
Tourdot, S., et al. (2000). <u>Eur J Immunol</u> **30**: 3411-21.
Whitney, C., et al. (2000). <u>N Engl J Med</u> **343**: 1917-24.
Wiley, J., et al. (1987) Current Protocols in Molecular Biology.
Wizemann, T., et al. (2001). <u>Infect Immun</u> **69**: 1593-8.

Table 1: Immunogenic proteins identified by bacterial surface display.

S. pneumoniae antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
SP0008	hypothetical protein	4-11,35-64,66-76,101-108,111-119	G:15	57-114	1, 145
SP0032	DNA polymerase I (polA)	5-27,32-64,92-102,107-113,119-125,133-139,148-162,177-187,195-201,207-214,241-251,254-269,285-300,302-309,317-324,332-357,365-404,411-425,443-463,470-477,479-487,506-512,515-520,532-547,556-596,603-610,616-622,624-629,636-642,646-665,667-674,687-692,708-720,734-739,752-757,798-820,824-851,856-865	H:39, I:6, L:2	732-763	2, 146
SP0069	Choline binding protein I	14-21,36-44,49-66,102-127,162-167,177-196	G:1, H:2, I:1, K:44, L:3, M:1	45-109 145-172	3, 147
SP0071	immunoglobulin A1 protease (iga-1)	17-35,64-75,81-92,100-119,125-172,174-183,214-222,230-236,273-282,287-303,310-315,331-340,392-398,412-420,480-505,515-523,525-546,553-575,592-598,603-609,617-625,631-639,644-651,658-670,681-687,691-704,709-716,731-736,739-744,750-763,774-780,784-791,799-805,809-822,859-870,880-885,907-916,924-941,943-949,973-986,1010-1016,1026-1036,1045-1054,1057-1062,1082-1088,1095-1102,1109-1120,1127-1134,1140-1146,1152-1159,1169-1179,1187-1196,1243-1251,1262-1273,1279-1292,1306-1312,1332-1343,1348-1364,1379-1390,1412-1420,1427-1436,1458-1468,1483-1503,1524-1549,1574-1588,1614-1619,1672-1685,1697-1707,1711-1720,1738-1753,1781-1787,1796-1801,1826-1843	A:3, C:1, D:9, E:9, F:4, G:21, I:34, K:61, L:20, M:2	132-478 508-592 1753-1810	4, 148
SP0082	Cell wall surface anchor	15-43,49-55,71-77,104-110,123-130,162-171,180-192,199-205,219-227,246-254,264-270,279-287,293-308,312-322,330-342,349-356,369-377,384-394,401-406,416-422,432-439,450-460,464-474,482-494,501-508,521-529,536-546,553-558,568-574,584-591,602-612,616-626,634-646,653-660,673-681,688-698,705-710,720-726,736-749,833-848	C:9, E:4, F:2, I:26, L:4, M:67	1-199 200-337 418-494 549-647	5, 149
SP0107	LysM domain protein	9-30,65-96,99-123,170-178	A :3, B :16, C :15, D :1, E :5, F :178,	1-128	6, 150

S. pneumoniae antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
			M :1		
SP0117	pneumococcal surface protein A (pspA)	7-32,34-41,96-106,127-136,154-163,188-199,207-238,272-279,306-312,318-325,341-347,353-360,387-393,399-406,434-440,452-503,575-580,589-601,615-620,635-640,654-660,674-680,696-701,710-731	A:13, B:11, C:10, D:4, E:31, F:6, G:33, H:13, I:9, K:64, L:32, M:46	1-548 660-691	7, 151
SP0191	hypothetical protein	4-19,35-44,48-59,77-87,93-99,106-111,130-138,146-161	E:1, I:2	78-84	8, 152
SP0197	dihydrofolate synthetase, putative	24-30,36-43,64-86,93-99,106-130,132-145,148-165,171-177,189-220,230-249,251-263,293-300,302-312,323-329,338-356,369-379,390-412	L :9	179-193	9, 153
SP0212	Ribosomal protein L2	30-39,61-67,74-81,90-120,123-145,154-167,169-179,182-197,200-206,238-244,267-272	L:10	230-265	10, 154
SP0222	Ribosomal protein S14	14-20,49-65,77-86	H:14, L:8, M:3	2-68	11, 155
SP0239	Conserved hypothetical protein	4-9,26-35,42-48,53-61,63-85,90-101,105-111,113-121,129-137,140-150,179-188,199-226,228-237,248-255,259-285,299-308,314-331,337-343,353-364,410-421,436-442	L:2, M:1	110-144	12, 156
SP0251	formate acetyltransferase, putative	36-47,55-63,94-108,129-134,144-158,173-187,196-206,209-238,251-266,270-285,290-295,300-306,333-344,346-354,366-397,404-410,422-435,439-453,466-473,515-523,529-543,554-569,571-585,590-596,607-618,627-643,690-696,704-714,720-728,741-749,752-767,780-799	G:2, H:7, I:1, M:5	225-247 480-507	13, 157
SP0295	ribosomal protein S9 (rpsI)	16-25,36-70,80-93,100-106	I:4	78-130	14, 158
SP0330	sugar binding transcriptional regulator RegR	18-27,41-46,50-57,65-71,79-85,93-98,113-128,144-155,166-178,181-188,201-207,242-262,265-273,281-295,303-309,318-327	G:1, H:1, L:4	36-64	15, 159
SP0368	cell wall surface anchor family protein	7-29,31-44,50-59,91-96,146-153,194-201,207-212,232-238,264-278,284-290,296-302,326-353,360-370,378-384,400-405,409-418,420-435,442-460,499-506,529-534,556-562,564-576,644-651,677-684,687-698,736-743,759-766,778-784,808-814,852-858,874-896,920-925,929-935,957-965,1003-1012,1021-1027,1030-1044,1081-1087,1101-1111,1116-1124,1148-1159,1188-	D:1, H:3, I:1, L:1, M:3	1-70 154-189 922-941 1445-1462 1483-1496	16, 160

S. *pneumoniae* antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
		1196,1235-1251,1288-1303,1313-1319,1328-1335,1367-1373,1431-1437,1451-1458,1479-1503,1514-1521,1530-1540,1545-1552,1561-1568,1598-1605,1617-1647,1658-1665,1670-1676,1679-1689,1698-1704,1707-1713,1732-1738,1744-1764			
SP0369	Penicillin binding protein 1A	6-51,81-91,104-113,126-137,150-159,164-174,197-209,215-224,229-235,256-269,276-282,307-313,317-348,351-357,376-397,418-437,454-464,485-490,498-509,547-555,574-586,602-619	B:1, E:1, L:13, M:1	452-530	17, 161
SP0374	hypothetical protein	25-31,39-47,49-56,99-114,121-127,159-186,228-240,253-269,271-279,303-315,365-382,395-405,414-425,438-453	E:4, I:1, L:3	289-384	18, 162
SP0377	Choline binding protein C	9-24,41-47,49-54,68-78,108-114,117-122,132-140,164-169,179-186,193-199,206-213,244-251,267-274,289-294,309-314,327-333	G:5, H:4, I:1, K:88, L:3, M:8	209-249 286-336	19, 163
SP0378	choline binding protein J (cbpJ)	9-28,53-67,69-82,87-93,109-117,172-177,201-207,220-227,242-247,262-268,305-318,320-325	K:47, L:6, M:5	286-306	20, 164
SP0390	choline binding protein G (cbpG)	4-10,26-39,47-58,63-73,86-96,98-108,115-123,137-143,148-155,160-176,184-189,194-204,235-240,254-259,272-278	G:1, K:69, M:6	199-283	21, 165
SP0454	hypothetical protein	4-26,33-39,47-53,59-65,76-83,91-97,104-112,118-137,155-160,167-174,198-207,242-268,273-279,292-315,320-332,345-354,358-367,377-394,403-410,424-439,445-451,453-497,511-518,535-570,573-589,592-601,604-610	H:1, I:1, L:6	202-242	22, 166
SP0463	cell wall surface anchor family protein	8-30,36-45,64-71,76-82,97-103,105-112,134-151,161-183,211-234,253-268,270-276,278-284,297-305,309-315,357-362,366-372,375-384,401-407,409-416,441-455,463-470,475-480,490-497,501-513,524-537,552-559,565-576,581-590,592-600,619-625,636-644,646-656	A:1, B:2, C:4, E:1, F:4,	316-419	23, 167
SP0466	sortase, putative	4-17,52-58,84-99,102-110,114-120,124-135,143-158,160-173,177-196,201-216,223-250,259-267,269-275	E:1, M:2	1-67	24, 168
SP0468	Sortase, putative	6-46,57-67,69-80,82-133,137-143,147-168,182-187,203-209,214-229,233-242,246-280	G:24, H:20, L:1	53-93	25, 169
SP0498	endo-beta-N-acetylglucosaminidase, putative	7-40,50-56,81-89,117-123,202-209,213-218,223-229,248-261,264-276,281-288,303-308,313-324,326-332,340-346,353-372,434-443,465-474,514-523,556-564,605-616,620-626,631-636,667-683,685-699,710-719,726-732,751-756,760-771,779-788,815-828,855-867,869-	B:5, C:1, E:2, F:1, G:2	1226-1309 1455-1536 1538-1605	26, 170

S. pneumoniae antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
		879,897-902,917-924,926-931,936-942,981-1000,1006-1015,1017-1028,1030-1039,1046-1054,1060-1066,1083-1092,1099-1112,1122-1130,1132-1140,1148-1158,1161-1171,1174-1181,1209-1230,1236-1244,1248-1254,1256-1267,1269-1276,1294-1299,1316-1328,1332-1354,1359-1372,1374-1380,1384-1390,1395-1408,1419-1425,1434-1446,1453-1460,1465-1471,1474-1493,1505-1515,1523-1537,1547-1555,1560-1567,1577-1605,1633-1651			
SP0509	type I restriction-modification system, M subunit	4-10,31-39,81-88,106-112,122-135,152-158,177-184,191-197,221-227,230-246,249-255,303-311,317-326,337-344,346-362,365-371,430-437,439-446,453-462,474-484	I:2	449-467	27, 171
SP0519	dnaJ protein (dnaJ)	9-15,24-35,47-55,122-128,160-177,188-196,202-208,216-228,250-261,272-303,318-324,327-339,346-352,355-361,368-373	A:1, D:2, H:2	108-218 344-376	28, 172
SP0529	BlpC ABC transporter (blpB)	6-14,17-48,55-63,71-90,99-109,116-124,181-189,212-223,232-268,270-294,297-304,319-325,340-348,351-370,372-378,388-394,406-415,421-434	A:1, B:3, C:3, D:1, F:4,	177-277	29, 173
SP0564	hypothetical protein	21-39,42-61,65-75,79-85,108-115	H:3	11-38	30, 174
SP0609	amino acid ABC transporter, amino acid-binding protein	4-17,26-39,61-76,103-113,115-122,136-142,158-192,197-203,208-214,225-230,237-251	I:3	207-225	31, 175
SP0613	metallo-beta-lactamase superfamily protein	5-11,27-36,42-53,62-70,74-93,95-104,114-119,127-150,153-159,173-179,184-193,199-206,222-241,248-253,257-280,289-295,313-319,322-342,349-365,368-389,393-406,408-413,426-438,447-461,463-470,476-495,532-537,543-550	I:12	225-246	32, 176
SP0641	Serine protease	4-29,68-82,123-130,141-147,149-157,178-191,203-215,269-277,300-307,327-335,359-370,374-380,382-388,393-400,410-417,434-442,483-492,497-503,505-513,533-540,564-569,601-607,639-647,655-666,693-706,712-718,726-736,752-758,763-771,774-780,786-799,806-812,820-828,852-863,884-892,901-909,925-932,943-948,990-996,1030-1036,1051-1059,1062-1068,1079-1086,1105-1113,1152-1162,1168-1179,1183-1191,1204-1210,1234-1244,1286-1295,1318-1326,1396-1401,1451-1460,1465-1474,1477-1483,1488-1494,1505-1510,1514-1521,1552-1565,1593-1614,1664-1672,1677-1685,1701-1711,1734-1745,1758-1770,1784-1798,1840-	A:19, B:72, C:34, D:5, E:21, F:86, G:26, H:86, I:17, L:130, M:29	1-348 373-490 573-767 903-1043 1155-1198 1243-1482 1550-1595 1682-1719 1793-1921 2008-2110	33, 177

S. pneumoniae antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
		1847,1852-1873,1885-1891,1906-1911,1931-1939,1957-1970,1977-1992,2014-2020,2026-2032,2116-2134			
SP0648	beta-galactosidase (bgaA)	10-35,39-52,107-112,181-188,226-236,238-253,258-268,275-284,296-310,326-338,345-368,380-389,391-408,410-418,420-429,444-456,489-505,573-588,616-623,637-643,726-739,741-767,785-791,793-803,830-847,867-881,886-922,949-956,961-980,988-1004,1009-1018,1027-1042,1051-1069,1076-1089,1108-1115,1123-1135,1140-1151,1164-1179,1182-1191,1210-1221,1223-1234,1242-1250,1255-1267,1281-1292,1301-1307,1315-1340,1348-1355,1366-1373,1381-1413,1417-1428,1437-1444,1453-1463,1478-1484,1490-1496,1498-1503,1520-1536,1538-1546,1548-1570,1593-1603,1612-1625,1635-1649,1654-1660,1670-1687,1693-1700,1705-1711,1718-1726,1729-1763,1790-1813,1871-1881,1893-1900,1907-1935,1962-1970,1992-2000,2006-2013,2033-2039,2045-2051,2055-2067,2070-2095,2097-2110,2115-2121,2150-2171,2174-2180,2197-2202,2206-2228	C:1, E:1, F:1, G:1, H:4, I:1, M:2	1526-1560	34, 178
SP0664	Zinc metalloprotease ZmpB, putative	4-17,35-48,54-76,78-107,109-115,118-127,134-140,145-156,169-174,217-226,232-240,256-262,267-273,316-328,340-346,353-360,402-409,416-439,448-456,506-531,540-546,570-578,586-593,595-600,623-632,662-667,674-681,689-705,713-724,730-740,757-763,773-778,783-796,829-835,861-871,888-899,907-939,941-955,957-969,986-1000,1022-1028,1036-1044,1068-1084,1095-1102,1118-1124,1140-1146,1148-1154,1168-1181,1185-1190,1197-1207,1218-1226,1250-1270,1272-1281,1284-1296,1312-1319,1351-1358,1383-1409,1422-1428,1438-1447,1449-1461,1482-1489,1504-1510,1518-1527,1529-1537,1544-1551,1569-1575,1622-1628,1631-1637,1682-1689,1711-1718,1733-1740,1772-1783,1818-1834,1859-1872	A:9, B:25, C:13, D:7, E:14, F:77, G:12, H:10, K:67, L:13, M:6	1-64 128-495	35, 179
SP0667	pneumococcal surface protein, putative	8-28,32-37,62-69,119-125,137-149,159-164,173-189,200-205,221-229,240-245,258-265,268-276,287-293,296-302,323-329	A:72, B:80, C:90, D:20, E:12, F:53	1-95	36, 180
SP0688	UDP-N-acetylmuramoylalanine--D-glutamate ligase	9-18,25-38,49-63,65-72,74-81,94-117,131-137,139-146,149-158,162-188,191-207,217-225,237-252,255-269,281-293,301-326,332-342,347-354,363-370,373-	L:3	75-107	37, 181

S. pneumoniae antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
		380,391-400,415-424,441-447			
SP0749	branched-chain amino acid ABC transporter	4-24,64-71,81-87,96-116,121-128,130-139,148-155,166-173,176-184,203-215,231-238,243-248,256-261,280-286,288-306,314-329	E:2, I:8, L:8	67-148	38, 182
SP0770	ABC transporter, ATP-binding protein	4-10,19-37,46-52,62-81,83-89,115-120,134-139,141-151,168-186,197-205,209-234,241-252,322-335,339-345,363-379,385-393,403-431,434-442,447-454,459-465,479-484,487-496	L:2	404-420	39, 183
SP0785	conserved hypothetical protein	10-35,46-66,71-77,84-93,96-122,138-148,154-172,182-213,221-233,245-263,269-275,295-301,303-309,311-320,324-336,340-348,351-359,375-381	C:1, E:2, I:1	111-198	40, 184
SP0914	nodulin-related protein, truncation	14-25,30-42,47-61,67-75,81-91,98-106,114-122,124-135,148-193,209-227	L:2	198-213	41, 185
SP0930	choline binding protein E (cbpE)	5-18,45-50,82-90,97-114,116-136,153-161,163-171,212-219,221-227,240-249,267-281,311-317,328-337,375-381,390-395,430-436,449-455,484-495,538-543,548-554,556-564,580-586,596-602	E:4, G:2, H:1, I:2, K:5	493-606	42, 186
SP0943	Gid protein (gid)	9-25,28-34,37-44,61-68,75-81,88-96,98-111,119-133,138-150,152-163,168-182,186-194,200-205,216-223,236-245,257-264,279-287,293-304,311-318,325-330,340-346,353-358,365-379,399-409,444-453	E:2, L:24	303-391	43, 187
SP0952	alanine dehydrogenase, authentic frameshift (ald)	16-36,55-61,66-76,78-102,121-130,134-146,150-212,221-239,255-276,289-322,329-357	G:3, H:4	29-59	44, 188
SP1003	conserved hypothetical protein (PAT)	8-27,68-74,77-99,110-116,124-141,171-177,202-217,221-228,259-265,275-290,293-303,309-325,335-343,345-351,365-379,384-394,406-414,423-437,452-465,478-507,525-534,554-560,611-624,628-651,669-682,742-747,767-778,782-792,804-812,820-836	A:2, B:5, C:8, D:5, E:13, F:3, M:2	79-231 359-451	45, 189
SP1004	Conserved hypothetical protein	5-28,39-45,56-62,67-74,77-99,110-117,124-141,168-176,200-230,237-244,268-279,287-299,304-326,329-335,348-362,370-376,379-384,390-406,420-429,466-471,479-489,495-504,529-541,545-553,561-577,598-604,622-630,637-658,672-680,682-688,690-696,698-709,712-719,724-736,738-746,759-769,780-786,796-804,813-818,860-877,895-904,981-997,1000-1014,1021-1029	A:5, B:4, C:4, D:9, E:12, F:4, H:3, I:1, L:1	1-162 206-224 254-350 414-514 864-938	46, 190

S. pneumoniae antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
SP1124	glycogen synthase (glgA)	4-11,19-49,56-66,68-101,109-116,123-145,156-165,177-185,204-221,226-234,242-248,251-256,259-265,282-302,307-330,340-349,355-374,377-383,392-400,422-428,434-442,462-474	M:1	266-322	47, 191
SP1154	IgA1 protease	14-43,45-57,64-74,80-87,106-127,131-142,145-161,173-180,182-188,203-210,213-219,221-243,245-254,304-311,314-320,342-348,354-365,372-378,394-399,407-431,436-448,459-465,470-477,484-490,504-509,531-537,590-596,611-617,642-647,723-734,740-751,754-762,764-774,782-797,807-812,824-831,838-845,877-885,892-898,900-906,924-935,940-946,982-996,1006-1016,1033-1043,1051-1056,1058-1066,1094-1108,1119-1126,1129-1140,1150-1157,1167-1174,1176-1185,1188-1201,1209-1216,1220-1228,1231-1237,1243-1248,1253-1285,1288-1297,1299-1307,1316-1334,1336-1343,1350-1359,1365-1381,1390-1396,1412-1420,1427-1439,1452-1459,1477-1484,1493-1512,1554-1559,1570-1578,1603-1608,1623-1630,1654-1659,1672-1680,1689-1696,1705-1711,1721-1738,1752-1757,1773-1780,1817-1829,1844-1851,1856-1863,1883-1895,1950-1958,1974-1990	A:6, B:2, C:9, D:3, E:4, F:2, G:6, H:4, I:13, L:12	172-354 384-448 464-644 648-728 1357-1370	48, 192
SP1174	conserved domain protein (PAT)	8-27,68-74,77-99,110-116,124-141,169-176,201-216,220-227,258-264,274-289,292-302,308-324,334-342,344-350,364-372,377-387,399-407,416-429,445-458,471-481,483-500,518-527,547-553,604-617,621-644,662-675,767-778,809-816	B:14, C:17, D:6, E:18, F:16, I:1, K:5, L:1, M:8	15-307 350-448 496-620	49, 193
SP1175	conserved domain protein	4-17,24-29,53-59,62-84,109-126,159-164,189-204,208-219,244-249,274-290,292-302,308-324,334-342,344-350,378-389,391-397,401-409,424-432,447-460,470-479,490-504,521-529,538-544,549-555,570-577,583-592,602-608,615-630,635-647,664-677,692-698,722-731,733-751,782-790,793-799	A:1, B:4, C:3, D:3, E:9, F:2, H:2, M:4	56-267 337-426 495-601	50, 194
SP1221	type II restriction endonuclease	12-22,49-59,77-89,111-121,136-148,177-186,207-213,217-225,227-253,259-274,296-302,328-333,343-354,374-383,424-446,448-457,468-480,488-502,507-522,544-550,553-560,564-572,587-596,604-614,619-625,629-635,638-656,662-676,680-692,697-713,720-738,779-786,833-847,861-869,880-895,897-902,911-917,946-951,959-967,984-990,992-1004,1021-1040,1057-	G:2, H:1, K:1, L:4	381-403	51, 195

S. *pneumoniae* antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
		1067,1073-1080			
SP1227	DNA-binding response regulator	4-10,26-31,46-56,60-66,70-79,86-94,96-102,109-118,132-152,164-187,193-206,217-224	E:1, L:3	81-149	52, 196
SP1241	amino acid ABC transporter, amino acid-binding pro	4-21,26-37,48-60,71-82,109-117,120-128,130-136,142-147,181-187,203-211,216-223,247-255,257-284,316-325,373-379,395-400,423-435,448-456,479-489,512-576,596-625,641-678,680-688,692-715	B:2, C:1, E:2, I:1	346-453	53, 197
SP1287	signal recognition particle protein (ffh)	10-16,25-31,34-56,58-69,71-89,94-110,133-176,186-193,208-225,240-250,259-266,302-307,335-341,376-383,410-416	B :8, G :8, H :3, M :1	316-407	54, 198
SP1330	N-acetylmannosamine-6-P epimerase, putative (nanE)	11-29,42-56,60-75,82-88,95-110,116-126,132-143,145-160,166-172,184-216	L:45	123-164	55, 199
SP1374	Chorismate sythetase (aroC)	11-29,54-63,110-117,139-152,158-166,172-180,186-193,215-236,240-251,302-323,330-335,340-347,350-366,374-381	G:1, L:29, M:14	252-299	56, 200
SP1378	conserved hypothetical protein	18-27,35-42,50-56,67-74,112-136,141-153,163-171,176-189,205-213,225-234,241-247,253-258,269-281,288-298,306-324,326-334,355-369,380-387	H:2	289-320	57, 201
SP1429	peptidase, U32 family	7-15,19-41,56-72,91-112,114-122,139-147,163-183,196-209,258-280,326-338,357-363,391-403,406-416	H:4	360-378	58, 202
SP1478	oxidoreductase, aldo/keto reductase family	11-18,29-41,43-49,95-108,142-194,204-212,216-242,247-256,264-273	H:11	136-149	59, 203
SP1518	conserved hypothetical protein	18-24,33-40,65-79,89-102,113-119,130-137,155-161,173-179,183-203,205-219,223-231,245-261,267-274,296-306,311-321,330-341,344-363,369-381,401-408,415-427,437-444,453-464,472-478,484-508,517-524,526-532,543-548	A:10, E:4, G:5, H:1	59-180	60, 204
SP1522	conserved domain protein	5-13,52-65,67-73,97-110,112-119,134-155	B:4, C:6, E:1, H:7, L:3	45-177	61, 205
SP1527	oligopeptide ABC transporter	6-28,34-43,57-67,75-81,111-128,132-147,155-163,165-176,184-194,208-216,218-229,239-252,271-278,328-334,363-376,381-388,426-473,481-488,492-498,507-513,536-546,564-582,590-601,607-623	A:1, B:1, C:4, F:1, G:26, H:18, I:10, L:2, M:1	148-269 420-450 610-648	62, 206

S. pneumoniae antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
SP1573	lysozyme (lytC)	4-12,20-38,69-75,83-88,123-128,145-152,154-161,183-188,200-213,245-250,266-272,306-312,332-339,357-369,383-389,395-402,437-453,455-470,497-503	A:40, B:27, C:24, D:2, E:6, G:11, K:1	1-112	63, 207
SP1604	hypothetical protein	35-59,74-86,111-117,122-137	A:1, C:3, E:1, G:1, I:1	70-154	64, 208
SP1661	cell division protein DivIVA	26-42,54-61,65-75,101-107,123-130,137-144,148-156,164-172,177-192,213-221,231-258	E :2	157-249	65, 209
SP1664	ylmF protein (ylmF)	29-38,61-67,77-87,94-100,105-111,118-158	B:1, C:42, I:3	1-97	66, 210
SP1676	N-acetylneuraminate lyase, putative	7-21,30-48,51-58,60-85,94-123,134-156,160-167,169-183,186-191,216-229,237-251,257-267,272-282,287-298	H:2	220-243	67, 211
SP1687	neuraminidase B (nanB)	6-29,34-47,56-65,69-76,83-90,123-134,143-151,158-178,197-203,217-235,243-263,303-309,320-333,338-348,367-373,387-393,407-414,416-427,441-457,473-482,487-499,501-509,514-520,530-535,577-583,590-602,605-612,622-629,641-670,678-690	B:3, E:2, L:1, M:2	37-71, 238-307	68, 212
SP1693	neuraminidase A (nanA)	7-40,121-132,148-161,196-202,209-215,221-235,248-255,271-280,288-295,330-339,395-409,414-420,446-451,475-487,556-563,568-575,580-586,588-595,633-638,643-648,652-659,672-685,695-700,710-716,737-742,749-754,761-767,775-781,796-806,823-835,850-863,884-890,892-900,902-915,934-941	C:3, D:5, E:3, F:1, G:7, H:1, I:3, K:20, L:4	406-521	69, 213
SP1732	serine/threonine protein kinase	9-18,24-46,51-58,67-77,85-108,114-126,129-137,139-146,152-165,173-182,188-195,197-204,217-250,260-274,296-313,343-366,368-384,427-434,437-446,449-455,478-484,492-506,522-527,562-591,599-606,609-618,625-631,645-652	E:2, H:1	577-654	70, 214
SP1735	methionyl-tRNA formyltransferase (fmt)	13-20,26-37,41-53,56-65,81-100,102-114,118-127,163-188,196-202,231-238,245-252,266-285,293-298,301-306	K:13, M:13	19-78	71, 215
SP1759	preprotein translocase, SecA subunit (secA-2)	10-23,32-42,54-66,73-91,106-113,118-127,139-152,164-173,198-207,210-245,284-300,313-318,330-337,339-346,354-361,387-393,404-426,429-439,441-453,467-473,479-485,496-509,536-544,551-558,560-566,569-574,578-588,610-615,627-635,649-675,679-690,698-716,722-734,743-754,769-780,782-787	I:6, L:2, M:2	480-550	72, 216

S. pneumoniae antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
SP1772	cell wall surface anchor family protein	6-39,42-50,60-68,76-83,114-129,147-162,170-189,197-205,217-231,239-248,299-305,338-344,352-357,371-377,380-451,459-483,491-499,507-523,537-559,587-613,625-681,689-729,737-781,785-809,817-865,873-881,889-939,951-975,983-1027,1031-1055,1063-1071,1079-1099,1103-1127,1151-1185,1197-1261,1269-1309,1317-1333,1341-1349,1357-1465,1469-1513,1517-1553,1557-1629,1637-1669,1677-1701,1709-1725,1733-1795,1823-1849,1861-1925,1933-1973,1981-2025,2029-2053,2061-2109,2117-2125,2133-2183,2195-2219,2227-2271,2275-2299,2307-2315,2323-2343,2347-2371,2395-2429,2441-2529,2537-2569,2577-2601,2609-2625,2633-2695,2699-2737,2765-2791,2803-2867,2889-2913,2921-2937,2945-2969,2977-2985,2993-3009,3023-3045,3073-3099,3111-3167,3175-3215,3223-3267,3271-3295,3303-3351,3359-3367,3375-3425,3437-3461,3469-3513,3517-3541,3549-3557,3565-3585,3589-3613,3637-3671,3683-3747,3755-3795,3803-3819,3827-3835,3843-3951,3955-3999,4003-4039,4043-4115,4123-4143,4147-4171,4195-4229,4241-4305,4313-4353,4361-4377,4385-4393,4401-4509,4513-4557,4561-4597,4601-4718,4749-4768	B:9, C:1, D:1, F:13, G:1, H:3, I:1, L:1, M:2	74-171 452-559 2951-3061	73, 217
SP1804	general stress protein 24, putative	16-22,30-51,70-111,117-130,137-150,171-178,180-188,191-196	I:4	148-181	74, 218
SP1888	oligopeptide ABC transporter, ATP-binding protein AmiE	6-19,21-46,50-56,80-86,118-126,167-186,189-205,211-242,244-267,273-286,290-297,307-316,320-341	H:1	34-60	75, 219
SP1891	oligopeptide ABC transporter,	5-26,33-43,48-54,58-63,78-83,113-120,122-128,143-152,157-175,185-192,211-225,227-234,244-256,270-281,284-290,304-310,330-337,348-355,362-379,384-394,429-445,450-474,483-490,511-520,537-546,548-554,561-586,590-604,613-629	A:2, B:3, E:1, F:1, G:13, H:8	149-186 285-431 573-659	76, 220
SP1937	Autolysin (lytA)	5-26,49-59,61-67,83-91,102-111,145-157,185-192,267-272,279-286,292-298,306-312	D:3, F:1, G:1, H:2, K:11, M:1	134-220 235-251 254-280	77, 221
SP1954	serine protease, subtilase family, authentic frame	5-19,72-79,83-92,119-124,140-145,160-165,167-182,224-232,240-252,259-270,301-310,313-322,332-343,347-367,384-398,416-429,431-446,454-461	C:43, E:6, I:4, K:21, L:50	1-169	78, 222
SP1980	cmp-binding-factor 1	8-17,26-31,56-62,75-83,93-103,125-131,135-141,150-	H:9	127-168	79, 223

S. pneumoniae antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
	(cbf1)	194,205-217,233-258,262-268,281-286			
SP1992	cell wall surface anchor family protein	6-12,69-75,108-115,139-159,176-182,194-214	B:5, C:1, F:4, I:1	46-161	80, 224
SP1999	catabolite control protein A (ccpA)	6-13,18-27,39-48,51-59,66-73,79-85,95-101,109-116,118-124,144-164,166-177,183-193,197-204,215-223,227-236,242-249,252-259,261-270,289-301,318-325	I:2	12-58	81, 225
SP2021	glycosyl hydrolase	4-10,26-32,48-60,97-105,117-132,138-163,169-185,192-214,219-231,249-261,264-270,292-308,343-356,385-392,398-404,408-417,435-441	L:3	24-50	82, 226
SP2027	Conserved hypothetical protein	10-40,42-48,51-61,119-126	A:1, E:1, G:19, H:12, I:16, L:5	1-118	83, 227
SP2039	conserved hypothetical protein	5-17,40-58,71-83,103-111,123-140,167-177,188-204	G:1, L:3	116-128	84, 228
SP2048	Conserved hypothetical protein	4-9,11-50,57-70,112-123,127-138	I:1, L:4	64-107	85, 229
SP2051	Conpetence protein CglC	9-39,51-67	D:1, G:3, I:8, L:26	1-101	86, 230
SP2092	UTP-glucose-1-phosphate uridylyltransferase (galU)	5-14,17-25,28-46,52-59,85-93,99-104,111-120,122-131,140-148,158-179,187-197,204-225,271-283,285-293	H:2	139-155	87, 231
SP2099	Penicillin binding protein 1B	42-70,73-90,92-108,112-127,152-164,166-172,181-199,201-210,219-228,247-274,295-302,322-334,336-346,353-358,396-414,419-425,432-438,462-471,518-523,531-536,561-567,576-589,594-612,620-631,665-671,697-710,718-731,736-756,765-771,784-801	A:1, B:9, C:11, D:1, E:6, F:1, H:4, K:1	626-653	88, 232
SP2108	Maltose ABC transporter	8-28,41-51,53-62,68-74,79-85,94-100,102-108,114-120,130-154,156-162,175-180,198-204,206-213,281-294,308-318,321-339,362-368,381-386,393-399,407-415	G:10, H:1, L:10, M:1	2-13	89, 233
SP2120	hypothetical protein	4-39,48-65,93-98,106-112,116-129	I:2	10-36	90, 234
SP2128	transketolase, N-terminal subunit	25-32,35-50,66-71,75-86,90-96,123-136,141-151,160-179,190-196,209-215,222-228,235-242,257-263,270-280	H:2	209-247	91, 235
SP2136	choline binding protein PcpA	5-29,31-38,50-57,62-75,83-110,115-132,168-195,197-206,216-242,249-258,262-269,333-340,342-350,363-368,376-392,400-406,410-421,423-430,436-442,448-454,460-466,471-476,491-496,511-516,531-536,551-	C:3, F:1, G:24, H:32, I:13, K:177,	27-70 219-293 441-504 512-584	92, 236

S. pneumoniae antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
		556,571-576,585-591,599-605	L:34, M:18		
SP2141	glycosyl hydrolase-related protein	4-12,14-34,47-75,83-104,107-115,133-140,148-185,187-196,207-212,224-256,258-265,281-287,289-296,298-308,325-333,345-355,365-371,382-395,424-435,441-457,465-472,483-491,493-505,528-534,536-546,552-558,575-584,589-600,616-623	L:3	576-591	93, 237
SP2180	conserved hypothetical protein	4-76, 78-89, 91-126, 142-148, 151-191, 195-208, 211-223, 226-240, 256-277, 279-285, 290-314, 317-323, 358-377, 381-387, 391-396, 398-411, 415-434, 436-446, 454-484, 494-512, 516-523, 538-552, 559-566, 571-577, 579-596, 599-615, 620-627, 635-644, 694-707, 720-734, 737-759, 761-771	L:3	313-329	94, 238
SP2190	choline binding protein A (cbpA)	7-38,44-49,79-89,99-108,117-123,125-132,137-146,178-187,207-237,245-255,322-337,365-387,398-408,445-462,603-608,623-628,644-650,657-671,673-679	A:6, B:12, C:9, D:6, E:30, F:8, G:65, H:72, I:76, K:222, L:99, M:37	111-566	95, 239
SP2194	ATP-dependent Clp protease, ATP-binding subunit	6-20,22-35,39-45,58-64,77-117,137-144,158-163,205-210,218-224,229-236,239-251,263-277,299-307,323-334,353-384,388-396,399-438,443-448,458-463,467-478,481-495,503-509,511-526,559-576,595-600,612-645,711-721,723-738,744-758,778-807	H:1	686-720	96, 240
SP2201	choline binding protein D (cbpD)	10-33,35-41,72-84,129-138,158-163,203-226,243-252,258-264,279-302,322-329,381-386,401-406,414-435	B:4, C:3, D:1, E:7, F:1, G:1, H:2, K:26, M:1	184-385	97, 241
SP2204	ribosomal protein L9	4-9,19-24,41-47,75-85,105-110,113-146	H:3, L:4	45-62	98, 242
SP2216	secreted 45 kd protein - homology to glucan binding protein (GbpB) S.mutant	4-25,52-67,117-124,131-146,173-180,182-191,195-206,215-221,229-236,245-252,258-279,286-291,293-302,314-320,327-336,341-353,355-361,383-389	A:130, B:414, C:450, D:162, E:166, F:284, G:90, H:16, I:4, K:10, L:29,	1-285	99, 243

S. pneumoniae antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
			M:11		
SP-NRF1	Choline binding protein	14-32,38-50,73-84,93-105,109-114	H:1	40-70	100, 244
ARF0408	Hypothetical protein	5-26	L:3	22-34	101, 245
ARF0441	Hypothetical protein	23-28	H:3	13-39	102, 246
ARF0690	Hypothetical protein	8-14	L:2	21-34	103, 247
ARF0878	Hypothetical protein	4-13,20-29,44-50,59-74	H:3	41-69	104, 248
ARF0921	Hypothetical protein	4-9, 19-42, 48-59, 71-83	M:4	57-91	105, 249
ARF1153	Hypothetical protein	4-14	M:7	10-28	106, 250
ARF1515	Hypothetical protein	22-28,32-42,63-71,81-111,149-156,158-167,172-180,182-203,219-229	G:4, H:5	27-49	107, 251
ARF1519	Hypothetical protein	17-27	H:3	23-32	108, 252
ARF1905	Hypothetical protein	18-24	H:2	28-38	109, 253
ARF2044	Hypothetical protein	9-15	G:2, H:5	13-27	110, 254
ARF2155	Hypothetical protein	13-22	H:3	18-29	111, 255
ARF2199	Hypothetical protein	17-26	M:3	2-11	112, 256
CRF0129	Hypothetical protein	4-33	L:4	16-32	113, 257
CRF0200	Hypothetical protein	4-10,37-43,54-84,92-127	H:5, L:1	15-62	114, 258
CRF0236	Hypothetical protein	4-14,20-32,35-60,69-75,79-99,101-109,116-140	L:3	124-136	115, 259
CRF0394	Hypothetical protein	none	H:7	2-13	116, 260
CRF0408	Hypothetical protein	4-13,28-42	L:11	42-57	117, 261
CRF0430	Hypothetical protein	4-14,27-44	G:4, H:8	14-35	118, 262
CRF0498	Hypothetical protein	4-12	H:4	1-27	119, 263
CRF0519	Hypothetical protein	4-18,39-45,47-74	G:5, H:3	35-66	120, 264
CRF0573	Hypothetical protein	8-20,43-77	I:3, L:9	17-36	121, 265
CRF0713	Hypothetical protein	4-30,35-45,51-57	L:3	35-49	122, 266
CRF0722	Hypothetical protein	4-24,49-57	G:18	15-34	123, 267
CRF0764	Hypothetical protein	4-22	L:4	8-27	124, 268
CRF1079	Hypothetical protein	13-25,32-59,66-80	H:5	21-55	125, 269
CRF1248	Hypothetical protein	4-10,24-33,35-42,54-65,72-82,98-108	H:1	15-30	126, 270
CRF1398	Hypothetical protein	8-19	H:1, L:3	17-47	127, 271
CRF1412	Hypothetical protein	12-18,40-46	L:8	31-52	128, 272
CRF1467	Hypothetical protein	4-20,35-78,83-102,109-122	I:4	74-86	129, 273
CRF1484	Hypothetical protein	7-17,21-41,46-63	I:5	2-20	130, 274
CRF1587	Hypothetical protein	30-37	G:3, H:3,	2-33	131, 275

S. pneumoniae antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
			L:4		
CRF1606	Hypothetical protein	4-13,17-25	L:3	1-15	132, 276
CRF1623	Hypothetical protein	17-31,44-51	M:6	20-51	133, 277
CRF1625	Hypothetical protein	20-30	L:10	5-23	134, 278
CRF1640	Hypothetical protein	13-33,48-71	I:5	92-110	135, 279
CRF1702	Hypothetical protein	4-9,50-69,76-88,96-106,113-118	L:6	12-34	136, 280
CRF1825	Hypothetical protein	4-24	L:11	6-26	137, 281
CRF1883	Hypothetical protein	7-26	H:61, L:77	14-30	138, 282
CRF1991	Hypothetical protein	9-39,46-68,75-82,84-103	H:6, L:2	26-44	139, 283
CRF1992	Hypothetical protein	4-30,33-107	M:7	58-84	140, 284
CRF2004	Hypothetical protein	4-12	L:3	9-51	141, 285
CRF2030	Hypothetical protein	12-18,29-37	H:5, L:1, M:1	6-37	142, 286
CRF2065	Hypothetical protein	4-21,33-52,64-71	I:1, M:6	16-37	143, 287
CRF2232	Hypothetical protein	9-19	L:3	2-30	144, 288

Table 2. Immunogenicity of epitopes in peptide ELISA

Peptides	P1	P2	P3	P4	P5	P6	P7	P8	P9	P10	P11	P12	P13	N1	N2	N3	N4	N5	N6	N7	N8	N9	N10	S	from	to	Seq ID
ARF0408.1	nd					nd		nd																15	20	37	245
ARF0441.1	nd					nd		nd																26	8	27	246
ARF0680.1	nd					nd		nd																20	10	27	247
ARF0878.1						nd					nd	nd												22	42	59	248
ARF0878.2						nd					nd	nd												11	52	69	248
ARF0921.1						nd					nd	nd												15	63	80	249
ARF0921.2						nd					nd	nd												14	74	91	249
ARF1153.1	nd					nd		nd																19	11	28	250
ARF1515.1	nd					nd		nd																16	28	49	251
ARF1519.1	nd					nd		nd																15	15	32	252
ARF1905.1	nd					nd		nd																21	4	20	253
ARF2044.1	nd					nd		nd																18	10	27	254
ARF2155.1	nd					nd		nd																15	17	34	255
ARF2199.1	nd					nd		nd																19	1	18	256
CRF0129.1	nd					nd		nd																15	16	33	257
CRF0200.1	nd					nd		nd																12	16	36	258
CRF0200.2	nd					nd		nd																9	30	49	258
CRF0200.3	nd					nd		nd																10	43	62	258
CRF0236.1						nd					nd	nd												19	122	139	259
CRF0394.1	nd					nd		nd																20	1	18	260
CRF0408.1	nd					nd		nd																19	41	58	261
CRF0430.1	nd					nd		nd																15	15	35	262
CRF0498.1	nd					nd		nd																21	2	27	263
CRF0573.1						nd						nd	nd											22	18	36	265
CRF0713.1	nd					nd		nd																20	34	51	266
CRF0764.1	nd					nd		nd																16	9	27	268
CRF1079.1	nd					nd		nd																27	22	47	269
CRF1398.1	nd					nd		nd																24	18	36	271
CRF1398.2	nd					nd		nd																21	29	47	271
CRF1412.1						nd					nd	nd												9	32	52	272
CRF1467.1	nd					nd		nd																	72	89	273
CRF1484.1	nd					nd		nd																	3	20	274
CRF1587.1	nd					nd		nd																23	3	21	275
CRF1587.2	nd					nd		nd																21	15	33	275
CRF1606.1	nd					nd		nd																22	1	18	276
CRF1625.1	nd					nd		nd																23	6	23	278
CRF1640.1	nd					nd		nd																18	93	110	279
CRF1702.1						nd					nd	nd												18	13	34	280
CRF1825.1	nd					nd		nd																24	7	26	281
CRF1825.2	nd					nd		nd																24	9	26	281
CRF1883.1	nd					nd		nd																20	16	33	282
CRF1991.1	nd					nd		nd																24	27	44	283
CRF1992.1	nd							nd		nd														19	67	84	284
CRF2004.1	nd					nd		nd																20	10	33	285
CRF2004.2	nd					nd		nd																22	26	50	285
CRF2030.1	nd					nd		nd																21	7	25	286

ID				
CRF2030.2	20	19	37	286
CRF2065.1	21	17	37	287
CRF2232.1	23	3	20	288
CRF2232.2	19	13	30	288
SP0008.1	28	62	80	145
SP0008.2	21	75	93	145
SP0069.1	17	92	108	147
SP0071.1	15	332	349	148
SP0071.2	13	177	200	148
SP0071.3	4	1755	1777	148
SP0082.1	4	109	133	149
SP0082.2	24	149	174	149
SP0082.3	26	260	285	149
SP0082.4	20	460	485	149
SP0107.1	10	26	47	150
SP0107.2	11	42	64	150
SP0117.1	18	22	41	151
SP0117.2	57	35	54	151
SP0117.3	64	115	130	151
SP0117.4	17	306	325	151
SP0117.5	15	401	420	151
SP0117.6	68	454	478	151
SP0222.1	15	22	45	155
SP0368.1	22	156	174	160
SP0368.2	32	924	940	160
SP0368.2b	12	1485	1496	160
SP0368.3	14	1447	1462	160
SP0368.4	11	1483	1498	160
SP0369.1	16	457	475	161
SP0377.1	11	302	325	163
SP0378.1	17	288	305	164
SP0390.1	11	244	266	165
SP0390.2	24	260	282	165
SP0454.1	64	204	225	166
SP0454.2	38	220	241	166
SP0463.1	20	324	345	167
SP0463.2	26	340	361	167
SP0463.3	19	356	377	167
SP0463.4	9	372	393	167
SP0463.5	13	388	408	167
SP0466.1	22	39	64	168
SP0468.1	21	54	76	169
SP0468.2	24	70	92	169
SP0498.1	13	1227	1247	170
SP0498.2	8	1539	1559	170
SP0498.3	16	1554	1574	170
SP0498.4	13	1569	1589	170
SP0498.5	15	1584	1604	170
SP0498.6	11	1242	1262	170
SP0498.8	24	1272	1292	170

SP0498.9	nd		nd		nd				9	1287	1308	170
SP0498.10	nd		nd		nd				63	1456	1477	170
SP0498.11	nd		nd		nd				59	1472	1494	170
SP0498.12	nd		nd		nd				20	1488	1510	170
SP0498.13	nd		nd		nd				10	1505	1526	170
SP0519.1	nd		nd						25	351	368	172
SP0529.1	nd		nd		nd				6	179	200	173
SP0529.2	nd		nd		nd				23	195	216	173
SP0529.3	nd		nd		nd				7	211	232	173
SP0529.4	nd		nd		nd				8	227	248	173
SP0529.5	nd		nd		nd				18	243	263	173
SP0564.1					nd	nd	nd		63	13	37	174
SP0609.1	nd		nd						16	208	224	175
SP0641.1					nd	nd	nd		34	42	64	177
SP0641.2					nd	nd	nd		61	59	81	177
SP0641.3					nd	nd	nd		0	304	328	177
SP0641.4					nd	nd	nd		36	323	348	177
SP0641.5					nd	nd	nd		76	465	489	177
SP0641.6					nd	nd	nd		64	968	992	177
SP0641.7					nd	nd	nd		52	1399	1418	177
SP0641.8					nd	nd	nd		25	1412	1431	177
SP0641.9	nd		nd		nd				18	2092	2111	177
SP0648.1	nd		nd		nd				11	1528	1547	178
SP0648.2	nd		nd		nd				24	1541	1560	178
SP0664.1	nd		nd		nd				28	184	200	179
SP0664.2	nd		nd		nd				18	367	388	179
SP0664.3	nd		nd		nd				15	382	403	179
SP0664.4	nd		nd		nd				14	409	429	179
SP0664.5	nd		nd		nd				20	425	444	179
SP0664.6	nd		nd		nd				17	438	457	179
SP0667.1	nd		nd		nd				22	27	50	180
SP0667.2	nd		nd		nd				16	45	67	180
SP0749.2	nd		nd		nd				24	114	131	182
SP0770.1	nd		nd		nd				17	405	419	183
SP0785.1	nd		nd		nd				11	113	134	184
SP0785.2	nd		nd		nd				10	129	150	184
SP0785.3	nd		nd		nd				8	145	166	184
SP0785.4	nd		nd		nd				11	161	182	184
SP0785.5	nd		nd		nd				8	177	198	184
SP0930.1	nd		nd		nd				30	495	515	186
SP0943.1	nd		nd		nd				19	346	358	187
SP1004.1	nd		nd		nd				21	208	224	190
SP1154.1	nd		nd		nd				33	178	194	192
SP1154.2	nd		nd		nd				28	202	223	192
SP1154.3	nd		nd		nd				21	217	238	192
SP1154.4	nd		nd		nd				19	288	308	192
SP1154.5	nd		nd		nd				16	1355	1372	192
SP1175.1	nd		nd		nd				56	57	78	194
SP1241.1	nd		nd		nd				26	347	369	197
SP1241.2	nd		nd		nd				18	364	386	197

ID				
SP1241.3	25	381	403	197
SP1241.4	21	398	420	197
SP1241.5	26	415	437	197
SP1241.6	16	432	452	197
SP1287.1	20	347	372	198
SP1330.1	18	147	163	199
SP1374.1	15	263	288	200
SP1429.1	20	361	377	202
SP1518.1	19	82	104	204
SP1518.2	28	99	121	204
SP1518.3	21	116	138	204
SP1518.4	26	133	155	204
SP1518.5	19	150	171	204
SP1522.1	12	110	130	205
SP1522.2	13	125	145	205
SP1527.1	22	613	631	206
SP1527.2	20	626	644	206
SP1527.3	16	196	213	206
SP1604.1	13	78	100	208
SP1604.2	20	95	117	208
SP1604.3	15	112	134	208
SP1604.4	25	129	151	208
SP1661.1	18	158	180	209
SP1661.2	10	175	197	209
SP1661.3	13	192	214	209
SP1661.4	16	209	231	209
SP1661.5	12	226	248	209
SP1664.1	24	30	50	210
SP1664.2	26	45	65	210
SP1664.3	11	60	79	210
SP1693.1	20	431	455	213
SP1693.2	18	450	474	213
SP1732.1	25	579	601	214
SP1732.2	15	596	618	214
SP1732.3	19	613	635	214
SP1732.4	22	630	653	214
SP1772.1	27	920	927	217
SP1772.1b	12	98	119	217
SP1772.2	20	114	135	217
SP1772.3	11	130	151	217
SP1772.4	30	146	167	217
SP1772.5	19	162	182	217
SP1888.1	16	36	59	219
SP1891.1	14	194	216	220
SP1891.2	12	381	404	220
SP1937.1	20	236	251	221
SP1937.2	26	255	279	221
SP1954.1	15	80	100	222
SP1954.2	14	141	164	222
SP1980.1	18	128	154	223

SP1992.1	nd						nd		nd													20	82	100	224
SP1992.2	nd																					23	95	116	224
SP1992.3	nd																					20	111	134	224
SP2027.1	nd																					12	55	76	227
SP2027.2	nd																					16	71	92	227
SP2027.3	nd																					21	87	110	227
SP2048.1																						21	91	106	229
SP2051.1																						25	74	96	230
SP2092.1	nd																					22	140	157	231
SP2108.1	nd																					13	4	13	233
SP2136.1	nd																					5	41	65	236
SP2136.2	nd																					32	499	523	236
SP2190.1	nd																					13	122	146	239
SP2190.2	nd																					29	191	215	239
SP2190.3	nd																					26	288	313	239
SP2190.4	nd																					36	445	469	239
SP2190.5	nd																					24	511	535	239
SP2201.1	nd																					34	347	368	241
SP2204.1	nd																					16	46	61	242
SP2216.1																						16	15	37	243
SP2216.2																						28	32	57	243
SP2216.3																						14	101	121	243
SP2216.4																						31	115	135	243
SP2216.5																						22	138	158	243
SP2216.6																						12	152	172	243
SP2216.7																						46	220	242	243
SP2216.8																						12	236	258	243

Table 3: Gene distribution in *S. pneumoniae* strains.

ORF	Common name	Gene distribution (present of 50)	Amino acid substitutions (in serotype 14 strain)*	Homology ()	Seq. ID (DNA, Prot.)
SP0008	hypothetical protein	n.d.	n.d.		1, 145
SP0032	DNA polymerase I (polA)	n.d.	n.d.		2, 146
SP0069	Choline binding protein I	7	0/166#		3, 147
SP0071	immunoglobulin A1 protease (iga-1)	7	0/477#		4, 148
SP0082	Cell wall surface anchor	50	5/385		5, 149
SP0107	LysM domain protein	50	1/173		6, 150
SP0117	pneumococcal surface protein A (pspA)	n.d.	n.d.		7, 151
SP0191	hypothetical protein	n.d.	n.d.		8, 152
SP0197	dihydrofolate synthetase, putative	n.d.	n.d.		9, 153
SP0212	Ribosomal protein L2	50	0/232		10, 154
SP0222	Ribosomal protein S14	n.d.	n.d.		11, 155
SP0239	Conserved hypothetical protein	n.d.	n.d.		12, 156
SP0251	formate acetyltransferase, putative	n.d.	n.d.		13, 157
SP0295	ribosomal protein S9 (rpsI)	50	1/121		14, 158
SP0330	sugar binding transcriptional regulator RegR	n.d.	n.d.		15, 159
SP0368	cell wall surface anchor family protein	46	4/422#		16, 160
SP0369	Penicillin binding protein 1A	50	1/346		17, 161
SP0374	hypothetical protein	n.d.	n.d.		18, 162
SP0377	Choline binding protein C	29	0/114		19, 163
SP0378	choline binding protein J (cbpJ)	50	2/104		20, 164
SP0390	choline binding protein G (cbpG)	50	3/171#		21, 165
SP0454	hypothetical protein	48	1/303#		22, 166
SP0463	cell wall surface anchor family protein	10	0/298#		23, 167
SP0466	sortase, putative	44	4/243#		24, 168
SP0468	Sortase, putative	18	0/254#		25, 169
SP0498	endo-beta-N-acetylglucosaminidase, putative	50	4/334		26, 170
SP0509	type I restriction-modification system, M subunit	n.d.	n.d.		27, 171
SP0519	dnaJ protein (dnaJ)	50	2/312		28, 172
SP0529	BlpC ABC transporter (blpB)	50	6/306		29, 173
SP0564	hypothetical protein	50	1/127		30, 174

ORF	Common name	Gene distribution (present of 50)	Amino acid substitutions (in serotype 14 strain)*	Homology 0	Seq. ID (DNA, Prot.)
SP0609	amino acid ABC transporter, amino acid-binding pro	50	0/232		31, 175
SP0613	metallo-beta-lactamase superfamily protein	n.d.	n.d.		32, 176
SP0641	Serine protease	n.d.	n.d.		33, 177
SP0648	beta-galactosidase (bgaA)	50	0/304		34, 178
SP0664	Zinc metalloprotease ZmpB, putative	n.d.	n.d.		35, 179
SP0667	pneumococcal surface protein, putative	45	18/297		36, 180
SP0688	UDP-N-acetylmuramoylalanine--D-glutamate ligase	n.d.	n.d.		37, 181
SP0749	branched-chain amino acid ABC transporter	50	4/303		38, 182
SP0770	ABC transporter, ATP-binding protein	50	0/307		39, 183
SP0785	conserved hypothetical protein	50	0/304		40, 184
SP0914	nodulin-related protein, truncation	n.d.	n.d.		41, 185
SP0930	choline binding protein E (cbpE)	47	17/294		42, 186
SP0943	Gid protein (gid)	n.d.	n.d.		43, 187
SP0952	alanine dehydrogenase, authentic frameshift (ald)	n.d.	n.d.		44, 188
SP1003	conserved hypothetical protein (PAT)	n.d.	n.d.		45, 189
SP1004	Conserved hypothetical protein	n.d.	n.d.		46, 190
SP1124	glycogen synthase (glgA)	n.d.	n.d.		47, 191
SP1154	IgA1 protease	28	13/470; 80missing		48, 192
SP1174	conserved domain protein (PAT)	n.d.	n.d.		49, 193
SP1175	conserved domain protein	n.d.	n.d.		50, 194
SP1221	type II restriction endonuclease	n.d.	n.d.		51, 195
SP1227	DNA-binding response regulator	n.d.	n.d.		52, 196
SP1241	amino acid ABC transporter, amino acid-binding protein	50	0/285		53, 197
SP1287	signal recognition particle protein (ffh)	49	0/300		54, 198
SP1330	N-acetylmannosamine-6-P epimerase, putative (nanE)	14	0/211#		55, 199
SP1374	Chorismate sythetase (aroC)	50	0/289		56, 200
SP1378	conserved hypothetical protein	n.d.	n.d.		57, 201
SP1429	peptidase, U32 family	50	8/305		58, 202
SP1478	oxidoreductase, aldo/keto reductase	n.d.	n.d.		59, 203

ORF	Common name	Gene distribution (present of 50)	Amino acid substitutions (in serotype 14 strain)*	Homology ()	Seq. ID (DNA, Prot.)
	family				
SP1518	conserved hypothetical protein	50	4/313; 3 additional		60, 204
SP1522	conserved domain protein	n.d.	n.d.		61, 205
SP1527	oligopeptide ABC transporter	50	0/463		62, 206
SP1573	lysozyme (lytC)	n.d.	n.d.		63, 207
SP1604	hypothetical protein	50	3/138		64, 208
SP1661	cell division protein DivIVA	50	3/236		65, 209
SP1664	ylmF protein (ylmF)	50	0/164		66, 210
SP1676	N-acetylneuraminate lyase, putative	n.d.	n.d.		67, 211
SP1687	neuraminidase B (nanB)	n.d.	n.d.		68, 212
SP1693	neuraminidase A (nanA)	n.d.	n.d.		69, 213
SP1732	serine/threonine protein kinase	49	2/293		70, 214
SP1735	methionyl-tRNA formyltransferase (fmt)	n.d.	n.d.		71, 215
SP1759	preprotein translocase, SecA subunit (secA-2)	n.d.	n.d.		72, 216
SP1772	cell wall surface anchor family protein	23	12/253#		73, 217
SP1804	general stress protein 24, putative	n.d.	n.d.		74, 218
SP1888	oligopeptide ABC transporter, ATP-binding protein AmiE	n.d.	n.d.		75, 219
SP1891	oligopeptide ABC transporter,	n.d.	n.d.		76, 220
SP1937	Autolysin (lytA)	50	0/275		77, 221
SP1954	serine protease, subtilase family, authentic frame	12	0/305#		78, 222
SP1980	cmp-binding-factor 1 (cbf1)	n.d.	n.d.		79, 223
SP1992	cell wall surface anchor family protein	50	4/197		80, 224
SP1999	catabolite control protein A (ccpA)	n.d.	n.d.		81, 225
SP2021	glycosyl hydrolase	n.d.	n.d.		82, 226
SP2027	Conserved hypothetical protein	n.d.	n.d.		83, 227
SP2039	conserved hypothetical protein	n.d.	n.d.		84, 228
SP2048	Conserved hypothetical protein	50	8/134		85, 229
SP2051	Conpetence protein CglC	50	8/92		86, 230
SP2092	UTP-glucose-1-phosphate uridylyltransferase (galU)	n.d.	n.d.		87, 231
SP2099	Penecillin binding protein 1B	n.d.	n.d.		88, 232
SP2108	Maltose ABC transporter	50	1/279		89, 233
SP2120	hypothetical protein	n.d.	n.d.		90, 234

ORF	Common name	Gene distribution (present of 50)	Amino acid substitutions (in serotype 14 strain)*	Homology ()	Seq. ID (DNA, Prot.)
SP2128	transketolase, N-terminal subunit	n.d.	n.d.		91, 235
SP2136	choline binding protein PcpA	45	1/382		92, 236
SP2141	glycosyl hydrolase-related protein	n.d.	n.d.		93, 237
SP2180	conserved hypothetical protein	n.d.	n.d.		94, 238
SP2190	choline binding protein A (cbpA)	47	for: 48,8%; rev: 2 /17#		95, 239
SP2194	ATP-dependent Clp protease, ATP-binding subunit	50	1/262		96, 240
SP2201	choline binding protein D (cbpD)	50	7/384		97, 241
SP2204	ribosomal protein L9	n.d.	n.d.		98, 242
SP2216	secreted 45 kd protein - homology to glucan binding protein (GbpB) S.mutant	50	0/347		99, 243
SP-NRF1	Choline binding protein	n.d.	n.d.		100, 244
ARF0408	Hypothetical protein	n.d.	n.d.		101, 245
ARF0441	Hypothetical protein	n.d.	n.d.		102, 246
ARF0690	Hypothetical protein	n.d.	n.d.		103, 247
ARF0878	Hypothetical protein	n.d.	n.d.		104, 248
ARF0921	Hypothetical protein	n.d.	n.d.		105, 249
ARF1153	Hypothetical protein	n.d.	n.d.		106, 250
ARF1515	Hypothetical protein	n.d.	n.d.		107, 251
ARF1519	Hypothetical protein	n.d.	n.d.		108, 252
ARF1905	Hypothetical protein	n.d.	n.d.		109, 253
ARF2044	Hypothetical protein	n.d.	n.d.		110, 254
ARF2155	Hypothetical protein	n.d.	n.d.		111, 255
ARF2199	Hypothetical protein	n.d.	n.d.		112, 256
CRF0129	Hypothetical protein	n.d.	n.d.		113, 257
CRF0200	Hypothetical protein	n.d.	n.d.		114, 258
CRF0236	Hypothetical protein	n.d.	n.d.		115, 259
CRF0394	Hypothetical protein	n.d.	n.d.		116, 260
CRF0408	Hypothetical protein	n.d.	n.d.		117, 261
CRF0430	Hypothetical protein	n.d.	n.d.		118, 262
CRF0498	Hypothetical protein	n.d.	n.d.		119, 263
CRF0519	Hypothetical protein	n.d.	n.d.		120, 264
CRF0573	Hypothetical protein	n.d.	n.d.		121, 265
CRF0713	Hypothetical protein	n.d.	n.d.		122, 266
CRF0722	Hypothetical protein	n.d.	n.d.		123, 267
CRF0764	Hypothetical protein	n.d.	n.d.		124, 268

ORF	Common name	Gene distribution (present of 50)	Amino acid substitutions (in serotype 14 strain)*	Homology ()	Seq. ID (DNA, Prot.)
CRF1079	Hypothetical protein	n.d.	n.d.		125, 269
CRF1248	Hypothetical protein	n.d.	n.d.		126, 270
CRF1398	Hypothetical protein	n.d.	n.d.		127, 271
CRF1412	Hypothetical protein	n.d.	n.d.		128, 272
CRF1467.1	Hypothetical protein	n.d.	n.d.		129, 273
CRF1484	Hypothetical protein	n.d.	n.d.		130, 274
CRF1587	Hypothetical protein	n.d.	n.d.		131, 275
CRF1606	Hypothetical protein	n.d.	n.d.		132, 276
CRF1623	Hypothetical protein	n.d.	n.d.		133, 277
CRF1625	Hypothetical protein	n.d.	n.d.		134, 278
CRF1640	Hypothetical protein	n.d.	n.d.		135, 279
CRF1702	Hypothetical protein	n.d.	n.d.		136, 280
CRF1825	Hypothetical protein	n.d.	n.d.		137, 281
CRF1883	Hypothetical protein	n.d.	n.d.		138, 282
CRF1991	Hypothetical protein	n.d.	n.d.		139, 283
CRF1992	Hypothetical protein	n.d.	n.d.		140, 284
CRF2004	Hypothetical protein	n.d.	n.d.		141, 285
CRF2030	Hypothetical protein	n.d.	n.d.		142, 286
CRF2065	Hypothetical protein	n.d.	n.d.		143, 287
CRF2232	Hypothetical protein	n.d.	n.d.		144, 288

Table 4.

ORF	Common Name	FACS	PK
ARF0878	hypothetical protein	+	nd
ARF0921	hypothetical protein	+	nd
CRF0236	hypothetical protein	++	-
CRF0573	hypothetical protein	+	nd
CRF1412	hypothetical protein	+	nd
CRF1702	hypothetical protein	+	nd
CRF1992	hypothetical protein	++	++
SP0008	hypothetical protein	+	-
SP0069	Choline binding protein I	++	++
SP0082	Cell wall surface anchor	+	-
SP0117	pneumococcal surface protein A (pspA)	+++	+++
SP0212	Ribosomal protein L2	+	++
SP0295	ribosomal protein S9 (rpsI)	++	+++
SP0368	cell wall surface anchor family protein	++	+++
SP0369	Penecillin binding protein 1A	++	++
SP0377	Choline binding protein C	++	++
SP0378	choline binding protein J (cbpJ)	++	nd
SP0390	choline binding protein G (cbpG)	++	+
SP0454	hypothetical protein	++	+++
SP0463	cell wall surface anchor family protein	+	++
SP0466	sortase, putative	++	++
SP0468	Sortase, putative	++	++
SP0519	dnaJ protein (dnaJ)	++	+
SP0609	amino acid ABC transporter, amino acid-bind	++	+
SP0641	Serine protease	+	-
SP0664	Zinc metalloprotease ZmpB	+	++
SP0749	branched-chain amino acid ABC transporter	+	+
SP0770	ABC transporter, ATP-binding protein	++	++
SP1154	IgA1 protease	++	++
SP1287	signal recognition particle protein (ffh)	+	++
SP1330	N-acetylmannoseamine-6-P	++	-
SP1429	peptidase, U32 family	+	++
SP1527	oligopeptide ABC transporter	+	++
SP1759	preprotein translocase, SecA subunit (wrong clone!!!)	+	-
SP1772	cell wall surface anchor family protein	+	+
SP1891	oligopeptide ABC transporter	+	++
SP1937	Autolysin (lytA)	+	-
SP1954	serine protease, subtilase family, auth frame	+	++
SP1980	cmp-binding-factor 1 (cbf1)	+	-
SP2108	Maltose ABC transporter	+	++
SP2136	choline binding protein PcpA	+	++
SP2190	choline binding protein A (cbpA)	+	++
SP2194	ATP-dependent Clp protease, ATP-bind subu	++	++
SP2201	choline binding protein D (cbpD)	+	++
SP2216	secreted 45 kd protein	+	++

Claims:

1.   An isolated nucleic acid molecule encoding a hyperimmune serum reactive antigen or a fragment thereof comprising a nucleic acid sequence, which is selected from the group consisting of:
    a) a nucleic acid molecule having at least 70% sequence identity to a nucleic acid molecule selected from Seq ID No 1, 101-144.
    b) a nucleic acid molecule which is complementary to the nucleic acid molecule of a),
    c) a nucleic acid molecule comprising at least 15 sequential bases of the nucleic acid molecule of a) or b)
    d) a nucleic acid molecule which anneals under stringent hybridisation conditions to the nucleic acid molecule of a), b), or c)
    e) a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to the nucleic acid molecule defined in a), b), c) or d).

2.   The isolated nucleic acid molecule according to claim 1, wherein the sequence identity is at least 80%, preferably at least 95%, especially 100%.

3.   An isolated nucleic acid molecule encoding a hyperimmune serum reactive antigen or a fragment thereof comprising a nucleic acid sequence selected from the group consisting of
    a) a nucleic acid molecule having at least 96% sequence identity to a nucleic acid molecule selected from Seq ID No 2-6, 8, 10-16, 18-23, 25-31, 34, 36, 38-42, 44, 47-48, 51, 53, 55-62, 64, 67, 71-76, 78-79, 81-94, 96-100.
    b) a nucleic acid molecule which is complementary to the nucleic acid molecule of a),
    c) a nucleic acid molecule comprising at least 15 sequential bases of the nucleic acid molecule of a) or b)
    d) a nucleic acid molecule which anneals under stringent hybridisation conditions to the nucleic acid molecule of a), b) or c),
    e) a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to the nucleic acid defined in a), b), c) or d).

4.   An isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of
    a) a nucleic acid molecule selected from Seq ID No 9, 17, 24, 32, 37, 43, 52, 54, 65-66, 70, 80,
    b) a nucleic acid molecule which is complementary to the nucleic acid of a),
    c) a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to the nucleic acid defined in a), b), c) or d).

5.   The nucleic acid molecule according to any one of the claims 1, 2, 3 or 4, wherein the nucleic acid is DNA.

6.   The nucleic acid molecule according to any one of the claims 1, 2, 3, 4, or 5 wherein the nucleic acid is RNA.

7.   An isolated nucleic acid molecule according to any one of claims 1 to 5, wherein the nucleic acid molecule is isolated from a genomic DNA, especially from a S. pneumoniae genomic DNA.

8.   A vector comprising a nucleic acid molecule according to any one of claims 1 to 7.

9.   A vector according to claim 8, wherein the vector is adapted for recombinant expression of the hyperimmune serum reactive antigens or fragment thereof encoded by the nucleic acid molecule according to any one of claims 1 to 7.

- 88 -

10. A host cell comprising the vector according to claim 8 or 9.

11. A hyperimmune serum-reactive antigen comprising an amino acid sequence being encoded by a nucleic acid molecule according to any one of the claims 1, 2, 5, 6 or 7 and fragments thereof, wherein the amino acid sequence is selected from the group consisting of Seq ID No 145, 245-288.

12. A hyperimmune serum-reactive antigen comprising an amino acid sequence being encoded by a nucleic acid molecule according to any one of the claims 3, 5, 6, or 7 and fragments thereof, wherein the amino acid sueqnece is selected from the group consisting of Seq ID No 146-150, 152, 154-160, 162-167, 169-175, 178, 180, 182-186, 188, 191-192, 195, 197, 199-206, 208, 211, 215-220, 222-223, 225-238, 240-244.

13. A hyperimmune serum-reactive antigen comprising an amino acid sequence being encoded by a nucleic acid molecule according to any one of the claims 4, 5, 6, or 7 and fragments thereof, wherein the amino acid sequence is selected from the group consisting of Seq ID No 153, 161, 168, 176, 181, 187, 196, 198, 209-210, 214, 224.

14. Fragments of hyperimmune serum-reactive antigens selected from the group consisting of peptides comprising amino acid sequences of column "predicted immunogenic aa" and "location of identified immunogenic region" of Table 2; the serum reactive epitopes of Table 2, especially peptides comprising amino acid 4-11, 35-64, 66-76, 101-108, 111-119 and 57-114 of Seq ID No 145; 5-27, 32-64, 92-102, 107-113, 119-125, 133-139, 148-162, 177-187, 195-201, 207-214, 241-251, 254-269, 285-300, 302-309, 317-324, 332-357, 365-404, 411-425, 443-463, 470-477, 479-487, 506-512, 515-520, 532-547, 556-596, 603-610, 616-622, 624-629, 636-642, 646-665, 667-674, 687-692, 708-720, 734-739, 752-757, 798-820, 824-851, 856-865 and 732-763 of Seq ID No 146; 14-21, 36-44, 49-66, 102-127, 162-167, 177-196, 45-109 and 145-172 of Seq ID No 147; 17-35, 64-75, 81-92, 100-119, 125-172, 174-183, 214-222, 230-236, 273-282, 287-303, 310-315, 331-340, 392-398, 412-420, 480-505, 515-523, 525-546, 553-575, 592-598, 603-609, 617-625, 631-639, 644-651, 658-670, 681-687, 691-704, 709-716, 731-736, 739-744, 750-763, 774-780, 784-791, 799-805, 809-822, 859-870, 880-885, 907-916, 924-941, 943-949, 973-986, 1010-1016, 1026-1036, 1045-1054, 1057-1062, 1082-1088, 1095-1102, 1109-1120, 1127-1134, 1140-1146, 1152-1159, 1169-1179, 1187-1196, 1243-1251, 1262-1273, 1279-1292, 1306-1312, 1332-1343, 1348-1364, 1379-1390, 1412-1420, 1427-1436, 1458-1468, 1483-1503, 1524-1549, 1574-1588, 1614-1619, 1672-1685, 1697-1707, 1711-1720, 1738-1753, 1781-1787, 1796-1801, 1826-1843, 132-478, 508-592 and 1753-1810 of Seq ID No 148; 15-43, 49-55, 71-77, 104-110, 123-130, 162-171, 180-192, 199-205, 219-227, 246-254, 264-270, 279-287, 293-308, 312-322, 330-342, 349-356, 369-377, 384-394, 401-406, 416-422, 432-439, 450-460, 464-474, 482-494, 501-508, 521-529, 536-546, 553-558, 568-574, 584-591, 602-612, 616-626, 634-646, 653-660, 673-681, 688-698, 705-710, 720-726, 736-749, 833-848, 1-199, 200-337, 418-494 and 549-647 of Seq ID No 149; 9-30, 65-96, 99-123, 170-178 and 1-128 of Seq ID No 150; 7-32, 34-41, 96-106, 127-136, 154-163, 188-199, 207-238, 272-279, 306-312, 318-325, 341-347, 353-360, 387-393, 399-406, 434-440, 452-503, 575-580, 589-601, 615-620, 635-640, 654-660, 674-680, 696-701, 710-731, 1-548 and 660-691 of Seq ID No 151; 4-19, 35-44, 48-59, 77-87, 93-99, 106-111, 130-138, 146-161 and 78-84 of Seq ID No 152; 24-30, 36-43, 64-86, 93-99, 106-130, 132-145, 148-165, 171-177, 189-220, 230-249, 251-263, 293-300, 302-312, 323-329, 338-356, 369-379, 390-412 and 179-193 of Seq ID No 153; 30-39, 61-67, 74-81, 90-120, 123-145, 154-167, 169-179, 182-197, 200-206, 238-244, 267-272 and 230-265 of Seq ID No 154; 14-20, 49-65, 77-86 and 2-68 of Seq ID No 155; 4-9, 26-35, 42-48, 53-61, 63-85, 90-101, 105-111, 113-121, 129-137, 140-150, 179-188, 199-226, 228-237, 248-255, 259-285, 299-308, 314-331, 337-343, 353-364, 410-421, 436-442 and 110-144 of Seq ID No 156; 36-47, 55-63, 94-108, 129-134, 144-158, 173-187, 196-206, 209-238, 251-266, 270-285, 290-295, 300-306, 333-344, 346-354, 366-397, 404-410, 422-435, 439-453, 466-473, 515-523, 529-543, 554-569, 571-585, 590-596, 607-618, 627-643, 690-696, 704-714, 720-728, 741-749, 752-767, 780-799, 225-247 and 480-507 of Seq ID No 157; 16-25, 36-70, 80-

93, 100-106 and 78-130 of Seq ID No 158; 18-27, 41-46, 50-57, 65-71, 79-85, 93-98, 113-128, 144-155, 166-178, 181-188, 201-207, 242-262, 265-273, 281-295, 303-309, 318-327 and 36-64 of Seq ID No 159; 7-29, 31-44, 50-59, 91-96, 146-153, 194-201, 207-212, 232-238, 264-278, 284-290, 296-302, 326-353, 360-370, 378-384, 400-405, 409-418, 420-435, 442-460, 499-506, 529-534, 556-562, 564-576, 644-651, 677-684, 687-698, 736-743, 759-766, 778-784, 808-814, 852-858, 874-896, 920-925, 929-935, 957-965, 1003-1012, 1021-1027, 1030-1044, 1081-1087, 1101-1111, 1116-1124, 1148-1159, 1188-1196, 1235-1251, 1288-1303, 1313-1319, 1328-1335, 1367-1373, 1431-1437, 1451-1458, 1479-1503, 1514-1521, 1530-1540, 1545-1552, 1561-1568, 1598-1605, 1617-1647, 1658-1665, 1670-1676, 1679-1689, 1698-1704, 1707-1713, 1732-1738, 1744-1764, 1-70, 154-189, 922-941, 1445-1462 and 1483-1496 of Seq ID No 160; 6-51, 81-91, 104-113, 126-137, 150-159, 164-174, 197-209, 215-224, 229-235, 256-269, 276-282, 307-313, 317-348, 351-357, 376-397, 418-437, 454-464, 485-490, 498-509, 547-555, 574-586, 602-619 and 452-530 of Seq ID No 161; 25-31, 39-47, 49-56, 99-114, 121-127, 159-186, 228-240, 253-269, 271-279, 303-315, 365-382, 395-405, 414-425, 438-453 and 289-384 of Seq ID No 162; 9-24, 41-47, 49-54, 68-78, 108-114, 117-122, 132-140, 164-169, 179-186, 193-199, 206-213, 244-251, 267-274, 289-294, 309-314, 327-333, 209-249 and 286-336 of Seq ID No 163; 9-28, 53-67, 69-82, 87-93, 109-117, 172-177, 201-207, 220-227, 242-247, 262-268, 305-318, 320-325 and 286-306 of Seq ID No 164; 4-10, 26-39, 47-58, 63-73, 86-96, 98-108, 115-123, 137-143, 148-155, 160-176, 184-189, 194-204, 235-240, 254-259, 272-278 and 199-283 of Seq ID No 165; 4-26, 33-39, 47-53, 59-65, 76-83, 91-97, 104-112, 118-137, 155-160, 167-174, 198-207, 242-268, 273-279, 292-315, 320-332, 345-354, 358-367, 377-394, 403-410, 424-439, 445-451, 453-497, 511-518, 535-570, 573-589, 592-601, 604-610 and 202-242 of Seq ID No 166; 8-30, 36-45, 64-71, 76-82, 97-103, 105-112, 134-151, 161-183, 211-234, 253-268, 270-276, 278-284, 297-305, 309-315, 357-362, 366-372, 375-384, 401-407, 409-416, 441-455, 463-470, 475-480, 490-497, 501-513, 524-537, 552-559, 565-576, 581-590, 592-600, 619-625, 636-644, 646-656 and 316-419 of Seq ID No 167; 4-17, 52-58, 84-99, 102-110, 114-120, 124-135, 143-158, 160-173, 177-196, 201-216, 223-250, 259-267, 269-275 and 1-67 of Seq ID No 168; 6-46, 57-67, 69-80, 82-133, 137-143, 147-168, 182-187, 203-209, 214-229, 233-242, 246-280 and 53-93 of Seq ID No 169; 7-40, 50-56, 81-89, 117-123, 202-209, 213-218, 223-229, 248-261, 264-276, 281-288, 303-308, 313-324, 326-332, 340-346, 353-372, 434-443, 465-474, 514-523, 556-564, 605-616, 620-626, 631-636, 667-683, 685-699, 710-719, 726-732, 751-756, 760-771, 779-788, 815-828, 855-867, 869-879, 897-902, 917-924, 926-931, 936-942, 981-1000, 1006-1015, 1017-1028, 1030-1039, 1046-1054, 1060-1066, 1083-1092, 1099-1112, 1122-1130, 1132-1140, 1148-1158, 1161-1171, 1174-1181, 1209-1230, 1236-1244, 1248-1254, 1256-1267, 1269-1276, 1294-1299, 1316-1328, 1332-1354, 1359-1372, 1374-1380, 1384-1390, 1395-1408, 1419-1425, 1434-1446, 1453-1460, 1465-1471, 1474-1493, 1505-1515, 1523-1537, 1547-1555, 1560-1567, 1577-1605, 1633-1651, 1226-1309, 1455-1536 and 1538-1605 of Seq ID No 170; 4-10, 31-39, 81-88, 106-112, 122-135, 152-158, 177-184, 191-197, 221-227, 230-246, 249-255, 303-311, 317-326, 337-344, 346-362, 365-371, 430-437, 439-446, 453-462, 474-484 and 449-467 of Seq ID No 171; 9-15, 24-35, 47-55, 122-128, 160-177, 188-196, 202-208, 216-228, 250-261, 272-303, 318-324, 327-339, 346-352, 355-361, 368-373, 108-218 and 344-376 of Seq ID No 172; 6-14, 17-48, 55-63, 71-90, 99-109, 116-124, 181-189, 212-223, 232-268, 270-294, 297-304, 319-325, 340-348, 351-370, 372-378, 388-394, 406-415, 421-434 and 177-277 of Seq ID No 173; 21-39, 42-61, 65-75, 79-85, 108-115 and 11-38 of Seq ID No 174; 4-17, 26-39, 61-76, 103-113, 115-122, 136-142, 158-192, 197-203, 208-214, 225-230, 237-251 and 207-225 of Seq ID No 175; 5-11, 27-36, 42-53, 62-70, 74-93, 95-104, 114-119, 127-150, 153-159, 173-179, 184-193, 199-206, 222-241, 248-253, 257-280, 289-295, 313-319, 322-342, 349-365, 368-389, 393-406, 408-413, 426-438, 447-461, 463-470, 476-495, 532-537, 543-550 and 225-246 of Seq ID No 176; 4-29, 68-82, 123-130, 141-147, 149-157, 178-191, 203-215, 269-277, 300-307, 327-335, 359-370, 374-380, 382-388, 393-400, 410-417, 434-442, 483-492, 497-503, 505-513, 533-540, 564-569, 601-607, 639-647, 655-666, 693-706, 712-718, 726-736, 752-758, 763-771, 774-780, 786-799, 806-812, 820-828, 852-863, 884-892, 901-909, 925-932, 943-948, 990-996, 1030-1036, 1051-1059, 1062-1068, 1079-1086, 1105-1113, 1152-1162, 1168-1179, 1183-1191, 1204-1210, 1234-1244, 1286-1295, 1318-1326, 1396-1401, 1451-1460, 1465-1474, 1477-1483, 1488-1494, 1505-1510, 1514-1521, 1552-1565, 1593-1614, 1664-1672, 1677-1685, 1701-1711, 1734-1745, 1758-1770, 1784-1798, 1840-1847, 1852-1873, 1885-1891, 1906-1911, 1931-1939, 1957-1970, 1977-1992, 2014-2020, 2026-2032, 2116-2134, 1-348, 373-490, 573-767, 903-1043, 1155-1198, 1243-1482, 1550-1595, 1682-1719, 1793-1921 and 2008-2110 of Seq ID No 177; 10-35, 39-52, 107-112, 181-188, 226-236, 238-253,

- 90 -

258-268, 275-284, 296-310, 326-338, 345-368, 380-389, 391-408, 410-418, 420-429, 444-456, 489-505, 573-588, 616-623, 637-643, 726-739, 741-767, 785-791, 793-803, 830-847, 867-881, 886-922, 949-956, 961-980, 988-1004, 1009-1018, 1027-1042, 1051-1069, 1076-1089, 1108-1115, 1123-1135, 1140-1151, 1164-1179, 1182-1191, 1210-1221, 1223-1234, 1242-1250, 1255-1267, 1281-1292, 1301-1307, 1315-1340, 1348-1355, 1366-1373, 1381-1413, 1417-1428, 1437-1444, 1453-1463, 1478-1484, 1490-1496, 1498-1503, 1520-1536, 1538-1546, 1548-1570, 1593-1603, 1612-1625, 1635-1649, 1654-1660, 1670-1687, 1693-1700, 1705-1711, 1718-1726, 1729-1763, 1790-1813, 1871-1881, 1893-1900, 1907-1935, 1962-1970, 1992-2000, 2006-2013, 2033-2039, 2045-2051, 2055-2067, 2070-2095, 2097-2110, 2115-2121, 2150-2171, 2174-2180, 2197-2202, 2206-2228 and 1526-1560 of Seq ID No 178; 4-17, 35-48, 54-76, 78-107, 109-115, 118-127, 134-140, 145-156, 169-174, 217-226, 232-240, 256-262, 267-273, 316-328, 340-346, 353-360, 402-409, 416-439, 448-456, 506-531, 540-546, 570-578, 586-593, 595-600, 623-632, 662-667, 674-681, 689-705, 713-724, 730-740, 757-763, 773-778, 783-796, 829-835, 861-871, 888-899, 907-939, 941-955, 957-969, 986-1000, 1022-1028, 1036-1044, 1068-1084, 1095-1102, 1118-1124, 1140-1146, 1148-1154, 1168-1181, 1185-1190, 1197-1207, 1218-1226, 1250-1270, 1272-1281, 1284-1296, 1312-1319, 1351-1358, 1383-1409, 1422-1428, 1438-1447, 1449-1461, 1482-1489, 1504-1510, 1518-1527, 1529-1537, 1544-1551, 1569-1575, 1622-1628, 1631-1637, 1682-1689, 1711-1718, 1733-1740, 1772-1783, 1818-1834, 1859-1872, 1-64 and 128-495 of Seq ID No 179; 8-28, 32-37, 62-69, 119-125, 137-149, 159-164, 173-189, 200-205, 221-229, 240-245, 258-265, 268-276, 287-293, 296-302, 323-329 and 1-95 of Seq ID No 180; 9-18, 25-38, 49-63, 65-72, 74-81, 94-117, 131-137, 139-146, 149-158, 162-188, 191-207, 217-225, 237-252, 255-269, 281-293, 301-326, 332-342, 347-354, 363-370, 373-380, 391-400, 415-424, 441-447 and 75-107 of Seq ID No 181; 4-24, 64-71, 81-87, 96-116, 121-128, 130-139, 148-155, 166-173, 176-184, 203-215, 231-238, 243-248, 256-261, 280-286, 288-306, 314-329 and 67-148 of Seq ID No 182; 4-10, 19-37, 46-52, 62-81, 83-89, 115-120, 134-139, 141-151, 168-186, 197-205, 209-234, 241-252, 322-335, 339-345, 363-379, 385-393, 403-431, 434-442, 447-454, 459-465, 479-484, 487-496 and 404-420 of Seq ID No 183; 10-35, 46-66, 71-77, 84-93, 96-122, 138-148, 154-172, 182-213, 221-233, 245-263, 269-275, 295-301, 303-309, 311-320, 324-336, 340-348, 351-359, 375-381 and 111-198 of Seq ID No 184; 14-25, 30-42, 47-61, 67-75, 81-91, 98-106, 114-122, 124-135, 148-193, 209-227 and 198-213 of Seq ID No 185; 5-18, 45-50, 82-90, 97-114, 116-136, 153-161, 163-171, 212-219, 221-227, 240-249, 267-281, 311-317, 328-337, 375-381, 390-395, 430-436, 449-455, 484-495, 538-543, 548-554, 556-564, 580-586, 596-602 and 493-606 of Seq ID No 186; 9-25, 28-34, 37-44, 61-68, 75-81, 88-96, 98-111, 119-133, 138-150, 152-163, 168-182, 186-194, 200-205, 216-223, 236-245, 257-264, 279-287, 293-304, 311-318, 325-330, 340-346, 353-358, 365-379, 399-409, 444-453 and 303-391 of Seq ID No 187; 16-36, 55-61, 66-76, 78-102, 121-130, 134-146, 150-212, 221-239, 255-276, 289-322, 329-357 and 29-59 of Seq ID No 188; 8-27, 68-74, 77-99, 110-116, 124-141, 171-177, 202-217, 221-228, 259-265, 275-290, 293-303, 309-325, 335-343, 345-351, 365-379, 384-394, 406-414, 423-437, 452-465, 478-507, 525-534, 554-560, 611-624, 628-651, 669-682, 742-747, 767-778, 782-792, 804-812, 820-836, 79-231 and 359-451 of Seq ID No 189; 5-28, 39-45, 56-62, 67-74, 77-99, 110-117, 124-141, 168-176, 200-230, 237-244, 268-279, 287-299, 304-326, 329-335, 348-362, 370-376, 379-384, 390-406, 420-429, 466-471, 479-489, 495-504, 529-541, 545-553, 561-577, 598-604, 622-630, 637-658, 672-680, 682-688, 690-696, 698-709, 712-719, 724-736, 738-746, 759-769, 780-786, 796-804, 813-818, 860-877, 895-904, 981-997, 1000-1014, 1021-1029, 1-162, 206-224, 254-350, 414-514 and 864-938 of Seq ID No 190; 4-11, 19-49, 56-66, 68-101, 109-116, 123-145, 156-165, 177-185, 204-221, 226-234, 242-248, 251-256, 259-265, 282-302, 307-330, 340-349, 355-374, 377-383, 392-400, 422-428, 434-442, 462-474 and 266-322 of Seq ID No 191; 14-43, 45-57, 64-74, 80-87, 106-127, 131-142, 145-161, 173-180, 182-188, 203-210, 213-219, 221-243, 245-254, 304-311, 314-320, 342-348, 354-365, 372-378, 394-399, 407-431, 436-448, 459-465, 470-477, 484-490, 504-509, 531-537, 590-596, 611-617, 642-647, 723-734, 740-751, 754-762, 764-774, 782-797, 807-812, 824-831, 838-845, 877-885, 892-898, 900-906, 924-935, 940-946, 982-996, 1006-1016, 1033-1043, 1051-1056, 1058-1066, 1094-1108, 1119-1126, 1129-1140, 1150-1157, 1167-1174, 1176-1185, 1188-1201, 1209-1216, 1220-1228, 1231-1237, 1243-1248, 1253-1285, 1288-1297, 1299-1307, 1316-1334, 1336-1343, 1350-1359, 1365-1381, 1390-1396, 1412-1420, 1427-1439, 1452-1459, 1477-1484, 1493-1512, 1554-1559, 1570-1578, 1603-1608, 1623-1630, 1654-1659, 1672-1680, 1689-1696, 1705-1711, 1721-1738, 1752-1757, 1773-1780, 1817-1829, 1844-1851, 1856-1863, 1883-1895, 1950-1958, 1974-1990, 172-354, 384-448, 464-644, 648-728 and 1357-1370 of Seq ID No 192; 8-27, 68-74, 77-99, 110-116, 124-141, 169-

176, 201-216, 220-227, 258-264, 274-289, 292-302, 308-324, 334-342, 344-350, 364-372, 377-387, 399-407, 416-429, 445-458, 471-481, 483-500, 518-527, 547-553, 604-617, 621-644, 662-675, 767-778, 809-816, 15-307, 350-448 and 496-620 of Seq ID No 193; 4-17, 24-29, 53-59, 62-84, 109-126, 159-164, 189-204, 208-219, 244-249, 274-290, 292-302, 308-324, 334-342, 344-350, 378-389, 391-397, 401-409, 424-432, 447-460, 470-479, 490-504, 521-529, 538-544, 549-555, 570-577, 583-592, 602-608, 615-630, 635-647, 664-677, 692-698, 722-731, 733-751, 782-790, 793-799, 56-267, 337-426 and 495-601 of Seq ID No 194; 12-22, 49-59, 77-89, 111-121, 136-148, 177-186, 207-213, 217-225, 227-253, 259-274, 296-302, 328-333, 343-354, 374-383, 424-446, 448-457, 468-480, 488-502, 507-522, 544-550, 553-560, 564-572, 587-596, 604-614, 619-625, 629-635, 638-656, 662-676, 680-692, 697-713, 720-738, 779-786, 833-847, 861-869, 880-895, 897-902, 911-917, 946-951, 959-967, 984-990, 992-1004, 1021-1040, 1057-1067, 1073-1080 and 381-403 of Seq ID No 195; 4-10, 26-31, 46-56, 60-66, 70-79, 86-94, 96-102, 109-118, 132-152, 164-187, 193-206, 217-224 and 81-149 of Seq ID No 196; 4-21, 26-37, 48-60, 71-82, 109-117, 120-128, 130-136, 142-147, 181-187, 203-211, 216-223, 247-255, 257-284, 316-325, 373-379, 395-400, 423-435, 448-456, 479-489, 512-576, 596-625, 641-678, 680-688, 692-715 and 346-453 of Seq ID No 197; 10-16, 25-31, 34-56, 58-69, 71-89, 94-110, 133-176, 186-193, 208-225, 240-250, 259-266, 302-307, 335-341, 376-383, 410-416 and 316-407 of Seq ID No 198; 11-29, 42-56, 60-75, 82-88, 95-110, 116-126, 132-143, 145-160, 166-172, 184-216 and 123-164 of Seq ID No 199; 11-29, 54-63, 110-117, 139-152, 158-166, 172-180, 186-193, 215-236, 240-251, 302-323, 330-335, 340-347, 350-366, 374-381 and 252-299 of Seq ID No 200; 18-27, 35-42, 50-56, 67-74, 112-136, 141-153, 163-171, 176-189, 205-213, 225-234, 241-247, 253-258, 269-281, 288-298, 306-324, 326-334, 355-369, 380-387 and 289-320 of Seq ID No 201; 7-15, 19-41, 56-72, 91-112, 114-122, 139-147, 163-183, 196-209, 258-280, 326-338, 357-363, 391-403, 406-416 and 360-378 of Seq ID No 202; 11-18, 29-41, 43-49, 95-108, 142-194, 204-212, 216-242, 247-256, 264-273 and 136-149 of Seq ID No 203; 18-24, 33-40, 65-79, 89-102, 113-119, 130-137, 155-161, 173-179, 183-203, 205-219, 223-231, 245-261, 267-274, 296-306, 311-321, 330-341, 344-363, 369-381, 401-408, 415-427, 437-444, 453-464, 472-478, 484-508, 517-524, 526-532, 543-548 and 59-180 of Seq ID No 204; 5-13, 52-65, 67-73, 97-110, 112-119, 134-155 and 45-177 of Seq ID No 205; 6-28, 34-43, 57-67, 75-81, 111-128, 132-147, 155-163, 165-176, 184-194, 208-216, 218-229, 239-252, 271-278, 328-334, 363-376, 381-388, 426-473, 481-488, 492-498, 507-513, 536-546, 564-582, 590-601, 607-623, 148-269, 420-450 and 610-648 of Seq ID No 206; 4-12, 20-38, 69-75, 83-88, 123-128, 145-152, 154-161, 183-188, 200-213, 245-250, 266-272, 306-312, 332-339, 357-369, 383-389, 395-402, 437-453, 455-470, 497-503 and 1-112 of Seq ID No 207; 35-59, 74-86, 111-117, 122-137 and 70-154 of Seq ID No 208; 26-42, 54-61, 65-75, 101-107, 123-130, 137-144, 148-156, 164-172, 177-192, 213-221, 231-258 and 157-249 of Seq ID No 209; 29-38, 61-67, 77-87, 94-100, 105-111, 118-158 and 1-97 of Seq ID No 210; 7-21, 30-48, 51-58, 60-85, 94-123, 134-156, 160-167, 169-183, 186-191, 216-229, 237-251, 257-267, 272-282, 287-298 and 220-243 of Seq ID No 211; 6-29, 34-47, 56-65, 69-76, 83-90, 123-134, 143-151, 158-178, 197-203, 217-235, 243-263, 303-309, 320-333, 338-348, 367-373, 387-393, 407-414, 416-427, 441-457, 473-482, 487-499, 501-509, 514-520, 530-535, 577-583, 590-602, 605-612, 622-629, 641-670, 678-690, 37-71 and 238-307 of Seq ID No 212; 7-40, 121-132, 148-161, 196-202, 209-215, 221-235, 248-255, 271-280, 288-295, 330-339, 395-409, 414-420, 446-451, 475-487, 556-563, 568-575, 580-586, 588-595, 633-638, 643-648, 652-659, 672-685, 695-700, 710-716, 737-742, 749-754, 761-767, 775-781, 796-806, 823-835, 850-863, 884-890, 892-900, 902-915, 934-941 and 406-521 of Seq ID No 213; 9-18, 24-46, 51-58, 67-77, 85-108, 114-126, 129-137, 139-146, 152-165, 173-182, 188-195, 197-204, 217-250, 260-274, 296-313, 343-366, 368-384, 427-434, 437-446, 449-455, 478-484, 492-506, 522-527, 562-591, 599-606, 609-618, 625-631, 645-652 and 577-654 of Seq ID No 214; 13-20, 26-37, 41-53, 56-65, 81-100, 102-114, 118-127, 163-188, 196-202, 231-238, 245-252, 266-285, 293-298, 301-306 and 19-78 of Seq ID No 215; 10-23, 32-42, 54-66, 73-91, 106-113, 118-127, 139-152, 164-173, 198-207, 210-245, 284-300, 313-318, 330-337, 339-346, 354-361, 387-393, 404-426, 429-439, 441-453, 467-473, 479-485, 496-509, 536-544, 551-558, 560-566, 569-574, 578-588, 610-615, 627-635, 649-675, 679-690, 698-716, 722-734, 743-754, 769-780, 782-787 and 480-550 of Seq ID No 216; 6-39, 42-50, 60-68, 76-83, 114-129, 147-162, 170-189, 197-205, 217-231, 239-248, 299-305, 338-344, 352-357, 371-377, 380-451, 459-483, 491-499, 507-523, 537-559, 587-613, 625-681, 689-729, 737-781, 785-809, 817-865, 873-881, 889-939, 951-975, 983-1027, 1031-1055, 1063-1071, 1079-1099, 1103-1127, 1151-1185, 1197-1261, 1269-1309, 1317-1333, 1341-1349, 1357-1465, 1469-1513, 1517-1553, 1557-1629, 1637-1669, 1677-1701, 1709-1725,

1733-1795, 1823-1849, 1861-1925, 1933-1973, 1981-2025, 2029-2053, 2061-2109, 2117-2125, 2133-2183, 2195-2219, 2227-2271, 2275-2299, 2307-2315, 2323-2343, 2347-2371, 2395-2429, 2441-2529, 2537-2569, 2577-2601, 2609-2625, 2633-2695, 2699-2737, 2765-2791, 2803-2867, 2889-2913, 2921-2937, 2945-2969, 2977-2985, 2993-3009, 3023-3045, 3073-3099, 3111-3167, 3175-3215, 3223-3267, 3271-3295, 3303-3351, 3359-3367, 3375-3425, 3437-3461, 3469-3513, 3517-3541, 3549-3557, 3565-3585, 3589-3613, 3637-3671, 3683-3747, 3755-3795, 3803-3819, 3827-3835, 3843-3951, 3955-3999, 4003-4039, 4043-4115, 4123-4143, 4147-4171, 4195-4229, 4241-4305, 4313-4353, 4361-4377, 4385-4393, 4401-4509, 4513-4557, 4561-4597, 4601-4718, 4749-4768, 74-171, 452-559 and 2951-3061 of Seq ID No 217; 16-22, 30-51, 70-111, 117-130, 137-150, 171-178, 180-188, 191-196 and 148-181 of Seq ID No 218; 6-19, 21-46, 50-56, 80-86, 118-126, 167-186, 189-205, 211-242, 244-267, 273-286, 290-297, 307-316, 320-341 and 34-60 of Seq ID No 219; 5-26, 33-43, 48-54, 58-63, 78-83, 113-120, 122-128, 143-152, 157-175, 185-192, 211-225, 227-234, 244-256, 270-281, 284-290, 304-310, 330-337, 348-355, 362-379, 384-394, 429-445, 450-474, 483-490, 511-520, 537-546, 548-554, 561-586, 590-604, 613-629, 149-186, 285-431 and 573-659 of Seq ID No 220; 5-26, 49-59, 61-67, 83-91, 102-111, 145-157, 185-192, 267-272, 279-286, 292-298, 306-312, 134-220, 235-251 and 254-280 of Seq ID No 221; 5-19, 72-79, 83-92, 119-124, 140-145, 160-165, 167-182, 224-232, 240-252, 259-270, 301-310, 313-322, 332-343, 347-367, 384-398, 416-429, 431-446, 454-461 and 1-169 of Seq ID No 222; 8-17, 26-31, 56-62, 75-83, 93-103, 125-131, 135-141, 150-194, 205-217, 233-258, 262-268, 281-286 and 127-168 of Seq ID No 223; 6-12, 69-75, 108-115, 139-159, 176-182, 194-214 and 46-161 of Seq ID No 224; 6-13, 18-27, 39-48, 51-59, 66-73, 79-85, 95-101, 109-116, 118-124, 144-164, 166-177, 183-193, 197-204, 215-223, 227-236, 242-249, 252-259, 261-270, 289-301, 318-325 and 12-58 of Seq ID No 225; 4-10, 26-32, 48-60, 97-105, 117-132, 138-163, 169-185, 192-214, 219-231, 249-261, 264-270, 292-308, 343-356, 385-392, 398-404, 408-417, 435-441 and 24-50 of Seq ID No 226; 10-40, 42-48, 51-61, 119-126 and 1-118 of Seq ID No 227; 5-17, 40-58, 71-83, 103-111, 123-140, 167-177, 188-204 and 116-128 of Seq ID No 228; 4-9, 11-50, 57-70, 112-123, 127-138 and 64-107 of Seq ID No 229; 9-39, 51-67 and 1-101 of Seq ID No 230; 5-14, 17-25, 28-46, 52-59, 85-93, 99-104, 111-120, 122-131, 140-148, 158-179, 187-197, 204-225, 271-283, 285-293 and 139-155 of Seq ID No 231; 42-70, 73-90, 92-108, 112-127, 152-164, 166-172, 181-199, 201-210, 219-228, 247-274, 295-302, 322-334, 336-346, 353-358, 396-414, 419-425, 432-438, 462-471, 518-523, 531-536, 561-567, 576-589, 594-612, 620-631, 665-671, 697-710, 718-731, 736-756, 765-771, 784-801 and 626-653 of Seq ID No 232; 8-28, 41-51, 53-62, 68-74, 79-85, 94-100, 102-108, 114-120, 130-154, 156-162, 175-180, 198-204, 206-213, 281-294, 308-318, 321-339, 362-368, 381-386, 393-399, 407-415 and 2-13 of Seq ID No 233; 4-39, 48-65, 93-98, 106-112, 116-129 and 10-36 of Seq ID No 234; 25-32, 35-50, 66-71, 75-86, 90-96, 123-136, 141-151, 160-179, 190-196, 209-215, 222-228, 235-242, 257-263, 270-280 and 209-247 of Seq ID No 235; 5-29, 31-38, 50-57, 62-75, 83-110, 115-132, 168-195, 197-206, 216-242, 249-258, 262-269, 333-340, 342-350, 363-368, 376-392, 400-406, 410-421, 423-430, 436-442, 448-454, 460-466, 471-476, 491-496, 511-516, 531-536, 551-556, 571-576, 585-591, 599-605, 27-70, 219-293, 441-504 and 512-584 of Seq ID No 236; 4-12, 14-34, 47-75, 83-104, 107-115, 133-140, 148-185, 187-196, 207-212, 224-256, 258-265, 281-287, 289-296, 298-308, 325-333, 345-355, 365-371, 382-395, 424-435, 441-457, 465-472, 483-491, 493-505, 528-534, 536-546, 552-558, 575-584, 589-600, 616-623 and 576-591 of Seq ID No 237; 4-76, 78-89, 91-126, 142-148, 151-191, 195-208, 211-223, 226-240, 256-277, 279-285, 290-314, 317-323, 358-377, 381-387, 391-396, 398-411, 415-434, 436-446, 454-484, 494-512, 516-523, 538-552, 559-566, 571-577, 579-596, 599-615, 620-627, 635-644, 694-707, 720-734, 737-759, 761-771 and 313-329 of Seq ID No 238; 7-38, 44-49, 79-89, 99-108, 117-123, 125-132, 137-146, 178-187, 207-237, 245-255, 322-337, 365-387, 398-408, 445-462, 603-608, 623-628, 644-650, 657-671, 673-679 and 111-566 of Seq ID No 239; 6-20, 22-35, 39-45, 58-64, 77-117, 137-144, 158-163, 205-210, 218-224, 229-236, 239-251, 263-277, 299-307, 323-334, 353-384, 388-396, 399-438, 443-448, 458-463, 467-478, 481-495, 503-509, 511-526, 559-576, 595-600, 612-645, 711-721, 723-738, 744-758, 778-807 and 686-720 of Seq ID No 240; 10-33, 35-41, 72-84, 129-138, 158-163, 203-226, 243-252, 258-264, 279-302, 322-329, 381-386, 401-406, 414-435 and 184-385 of Seq ID No 241; 4-9, 19-24, 41-47, 75-85, 105-110, 113-146 and 45-62 of Seq ID No 242; 4-25, 52-67, 117-124, 131-146, 173-180, 182-191, 195-206, 215-221, 229-236, 245-252, 258-279, 286-291, 293-302, 314-320, 327-336, 341-353, 355-361, 383-389 and 1-285 of Seq ID No 243; 14-32, 38-50, 73-84, 93-105, 109-114 and 40-70 of Seq ID No 244; 5-26 and 22-34 of Seq ID No 245; 23-28 and 13-39 of Seq ID No 246; 8-14 and 21-34 of

Seq ID No 247; 4-13, 20-29, 44-50, 59-74 and 41-69 of Seq ID No 248; 4-9, 19-42, 48-59, 71-83 and 57-91 of Seq ID No 249; 4-14 and 10-28 of Seq ID No 250; 22-28, 32-42, 63-71, 81-111, 149-156, 158-167, 172-180, 182-203, 219-229 and 27-49 of Seq ID No 251; 17-27 and 23-32 of Seq ID No 252; 18-24 and 28-38 of Seq ID No 253; 9-15 and 13-27 of Seq ID No 254; 13-22 and 18-29 of Seq ID No 255; 17-26 and 2-11 of Seq ID No 256; 4-33 and 16-32 of Seq ID No 257; 4-10, 37-43, 54-84, 92-127 and 15-62 of Seq ID No 258; 4-14, 20-32, 35-60, 69-75, 79-99, 101-109, 116-140 and 124-136 of Seq ID No 259; 2-13 of Seq ID No 260; 4-13, 28-42 and 42-57 of Seq ID No 261; 4-14, 27-44 and 14-35 of Seq ID No 262; 4-12 and 1-27 of Seq ID No 263; 4-18, 39-45, 47-74 and 35-66 of Seq ID No 264; 8-20, 43-77 and 17-36 of Seq ID No 265; 4-30, 35-45, 51-57 and 35-49 of Seq ID No 266; 4-24, 49-57 and 15-34 of Seq ID No 267; 4-22 and 8-27 of Seq ID No 268; 13-25, 32-59, 66-80 and 21-55 of Seq ID No 269; 4-10, 24-33, 35-42, 54-65, 72-82, 98-108 and 15-30 of Seq ID No 270; 8-19 and 17-47 of Seq ID No 271; 12-18, 40-46 and 31-52 of Seq ID No 272; 4-20, 35-78, 83-102, 109-122 and 74-86 of Seq ID No 273; 7-17, 21-41, 46-63 and 2-20 of Seq ID No 274; 30-37 and 2-33 of Seq ID No 275; 4-13, 17-25 and 1-15 of Seq ID No 276; 17-31, 44-51 and 20-51 of Seq ID No 277; 20-30 and 5-23 of Seq ID No 278; 13-33, 48-71 and 92-110 of Seq ID No 279; 4-9, 50-69, 76-88, 96-106, 113-118 and 12-34 of Seq ID No 280; 4-24 and 6-26 of Seq ID No 281; 7-26 and 14-30 of Seq ID No 282; 9-39, 46-68, 75-82, 84-103 and 26-44 of Seq ID No 283; 4-30, 33-107 and 58-84 of Seq ID No 284; 4-12 and 9-51 of Seq ID No 285; 12-18, 29-37 and 6-37 of Seq ID No 286; 4-21, 33-52, 64-71 and 16-37 of Seq ID No 287; 9-19 and 2-30 of Seq ID No 288; 20-37 of Seq ID No 245; 8-27 of Seq ID No 246; 10-27 of Seq ID No 247; 42-59 and 52-69 of Seq ID No 248; 63-80 and 74-91 of Seq ID No 249; 11-28 of Seq ID No 250; 28-49 of Seq ID No 251; 15-32 of Seq ID No 252; 4-20 of Seq ID No 253; 10-27 of Seq ID No 254; 17-34 of Seq ID No 255; 1-18 of Seq ID No 256; 16-33 of Seq ID No 257; 16-36, 30-49 and 43-62 of Seq ID No 258; 122-139 of Seq ID No 259; 1-18 of Seq ID No 260; 41-58 of Seq ID No 261; 15-35 of Seq ID No 262; 2-27 of Seq ID No 263; 18-36 of Seq ID No 265; 34-51 of Seq ID No 266; 9-27 of Seq ID No 268; 22-47 of Seq ID No 269; 18-36 and 29-47 of Seq ID No 271; 32-52 of Seq ID No 272; 72-89 of Seq ID No 273; 3-20 of Seq ID No 274; 3-21 and 15-33 of Seq ID No 275; 1-18 of Seq ID No 276; 6-23 of Seq ID No 278; 93-110 of Seq ID No 279; 13-34 of Seq ID No 280; 7-26 and 9-26 of Seq ID No 281; 16-33 of Seq ID No 282; 27-44 of Seq ID No 283; 67-84 of Seq ID No 284; 10-33 and 26-50 of Seq ID No 285; 7-25 and 19-37 of Seq ID No 286; 17-37 of Seq ID No 287; 3-20 and 13-30 of Seq ID No 288; 62-80 and 75-93 of Seq ID No 145; 92-108 of Seq ID No 147; 332-349, 177-200 and 1755-1777 of Seq ID No 148; 109-133, 149-174, 260-285 and 460-485 of Seq ID No 149; 26-47 and 42-64 of Seq ID No 150; 22-41, 35-54, 115-130, 306-325, 401-420 and 454-478 of Seq ID No 151; 22-45 of Seq ID No 155; 156-174, 924-940, 1485-1496, 1447-1462 and 1483-1498 of Seq ID No 160; 457-475 of Seq ID No 161; 302-325 of Seq ID No 163; 288-305 of Seq ID No 164; 244-266 and 260-282 of Seq ID No 165; 204-225 and 220-241 of Seq ID No 166; 324-345, 340-361, 356-377, 372-393 and 388-408 of Seq ID No 167; 39-64 of Seq ID No 168; 54-76 and 70-92 of Seq ID No 169; 1227-1247, 1539-1559, 1554-1574, 1569-1589, 1584-1604, 1242-1262, 1272-1292, 1287-1308, 1456-1477, 1472-1494, 1488-1510 and 1505-1526 of Seq ID No 170; 351-368 of Seq ID No 172; 179-200, 195-216, 211-232, 227-248 and 243-263 of Seq ID No 173; 13-37 of Seq ID No 174; 208-224 of Seq ID No 175; 42-64, 59-81, 304-328, 323-348, 465-489, 968-992, 1399-1418, 1412-1431 and 2092-2111 of Seq ID No 177; 1528-1547 and 1541-1560 of Seq ID No 178; 184-200, 367-388, 382-403, 409-429, 425-444 and 438-457 of Seq ID No 179; 27-50 and 45-67 of Seq ID No 180; 114-131 and 405-419 of Seq ID No 183; 113-134, 129-150, 145-166, 161-182 and 177-198 of Seq ID No 184; 495-515 of Seq ID No 186; 346-358 of Seq ID No 187; 208-224 of Seq ID No 190; 178-194, 202-223, 217- 238, 288-308 and 1355-1372 of Seq ID No 192; 57-78 of Seq ID No 194; 347-369, 364-386, 381-403, 398-420, 415-437 and 432-452 of Seq ID No 197; 347-372 of Seq ID No 198; 147-163 of Seq ID No 199; 263-288 of Seq ID No 200; 361-377 of Seq ID No 202; 82-104, 99-121, 116-138, 133-155 and 150-171 of Seq ID No 204; 110-130 and 125-145 of Seq ID No 205; 613-631, 626-644 and 196-213 of Seq ID No 206; 78-100, 95-117, 112-134 and 129-151 of Seq ID No 208; 158-180, 175-197, 192-214, 209-231 and 226-248 of Seq ID No 209; 30-50, 45-65 and 60-79 of Seq ID No 210; 431-455 and 450-474 of Seq ID No 213; 579-601, 596-618, 613-635 and 630-653 of Seq ID No 214; 920-927, 98-119, 114-135, 130-151, 146-167 and 162-182 of Seq ID No 217; 36-59 of Seq ID No 219; 194-216 and 381-404 of Seq ID No 220; 236-251 and 255-279 of Seq ID No 221; 80-100 and

141-164 of Seq ID No 222; 128-154 of Seq ID No 223; 82-100, 95-116 and 111-134 of Seq ID No 224; 55-76, 71-92 and 87-110 of **Seq ID No 227**; 91-106 of **Seq ID No 229**; 74-96 of **Seq ID No 230**; 140-157 of **Seq ID No 231**; 4-13 of **Seq ID No 233**; 41-65 and 499-523 of **Seq ID No 236**; 122-146, 191-215, 288-313, 445-469 and 511-535 of **Seq ID No 239**; 347-368 of **Seq ID No 241**; 46-61 of **Seq ID No 242**; 15-37, 32-57, 101-121, 115-135, 138-158, 152-172, 220-242 and 236-258 of **Seq ID No 243**.

15.   A process for producing a *S. pneumoniae* hyperimmune serum reactive antigen or a fragment thereof according to any one of the claims 11 to 14 comprising expressing the nucleic acid molecule according to any one of claims 1 to 7.

16.   A process for producing a cell, which expresses a *S. pneumoniae* hyperimmune serum reactive antigen or a fragment thereof according to any one of the claims 11 to 14 comprising transforming or transfecting a suitable host cell with the vector according to claim 8 or claim 9.

17.   A pharmaceutical composition, especially a vaccine, comprising a hyperimmune serum-reactive antigen or a fragment thereof, as defined in any one of claims 11 to 14 or a nucleic acid molecule according to any one of claims 1 to 7.

18.   A pharmaceutical composition, especially a vaccine, according to claim 17, characterized in that it further comprises an immunostimulatory substance, preferably selected from the group comprising polycationic polymers, especially polycationic peptides, immunostimulatory deoxynucleotides (ODNs), peptides containing at least two LysLeuLys motifs, neuroactive compounds, especially human growth hormone, alumn, Freund's complete or incomplete adjuvants or combinations thereof.

19.   Use of a nucleic acid molecule according to any one of claims 1 to 7 or a hyperimmune serum-reactive antigen or fragment thereof according to any one of claims 11 to 14 for the manufacture of a pharmaceutical preparation, especially for the manufacture of a vaccine against *S. pneumoniae* infection.

20.   An antibody, or at least an effective part thereof, which binds at least to a selective part of the hyperimmune serum-reactive antigen or a fragment thereof according to any one of claims 11 to 14.

21.   An antibody according to claim 20, wherein the antibody is a monoclonal antibody.

22.   An antibody according to claim 20 or 21, wherein said effective part comprises Fab fragments.

23.   An antibody according to any one of claims 20 to 22, wherein the antibody is a chimeric antibody.

24.   An antibody according to any one of claims 20 to 23, wherein the antibody is a humanized antibody.

25.   A hybridoma cell line, which produces an antibody according to any one of claims 20 to 24.

26.   A method for producing an antibody according to claim 20, characterized by the following steps:
    • initiating an immune response in a non-human animal by administrating an hyperimmune serum-reactive antigen or a fragment thereof, as defined in any one of the claims 11 to 14, to said animal,
    • removing an antibody containing body fluid from said animal, and
    • producing the antibody by subjecting said antibody containing body fluid to further purification steps.

27.   Method for producing an antibody according to claim 21, characterized by the following steps:
- initiating an immune response in a non-human animal by administrating an hyperimmune serum-reactive antigen or a fragment thereof, as defined in any one of the claims 12 to 15, to said animal,
- removing the spleen or spleen cells from said animal,
- producing hybridoma cells of said spleen or spleen cells,
- selecting and cloning hybridoma cells specific for said hyperimmune serum-reactive antigens or a fragment thereof,
- producing the antibody by cultivation of said cloned hybridoma cells and optionally further purification steps.

28.   Use of the antibodies according to any one of claims 20 to 24 for the preparation of a medicament for treating or preventing S. pneumoniae infections.

29.   An antagonist, which binds to the hyperimmune serum-reactive antigen or a fragment thereof according to any one of claims 11 to 14.

30.   A method for identifying an antagonist capable of binding to the hyperimmune serum-reactive antigen or fragment thereof according to any one of claims 11 to 14 comprising:
a)   contacting an isolated or immobilized hyperimmune serum-reactive antigen or a fragment thereof according to any one of claims 11 to 14 with a candidate antagonist under conditions to permit binding of said candidate antagonist to said hyperimmune serum-reactive antigen or fragment, in the presence of a component capable of providing a detectable signal in response to the binding of the candidate antagonist to said hyperimmune serum reactive antigen or fragment thereof; and
b)   detecting the presence or absence of a signal generated in response to the binding of the antagonist to the hyperimmune serum reactive antigen or the fragment thereof.

31.   A method for identifying an antagonist capable of reducing or inhibiting the interaction activity of a hyperimmune serum-reactive antigen or a fragment thereof according to any one of claims 11 to 14 to its interaction partner comprising:
a)   providing a hyperimmune serum reactive antigen or a hyperimmune fragment thereof according to any one of claims 11-14,
b)   providing an interaction partner to said hyperimmune serum reactive antigen or a fragment thereof, especially an antibody according to any one of the claims 20 to 24,
c)   allowing interaction of said hyperimmune serum reactive antigen or fragment thereof to said interaction partner to form a interaction complex,
d)   providing a candidate antagonist,
e)   allowing a competition reaction to occur between the candidate antagonist and the interaction complex,
f)   determining whether the candidate antagonist inhibits or reduces the interaction activities of the hyperimmune serum reactive antigen or the fragment thereof with the interaction partner.

32.   Use of any of the hyperimmune serum reactive antigen or fragment thereof according to any one of claims 11 to 14 for the isolation and/or purification and/or identification of an interaction partner of said hyperimmune serum reactive antigen or fragment thereof.

33.   A process for in vitro diagnosing a disease related to expression of the hyperimmune serum-reactive antigen or a fragment thereof according to any one of claims 11 to 14 comprising determining the presence of a nucleic acid sequence encoding said hyperimmune serum reactive antigen and fragment according to any one of claims 1 to 7 or the presence of the hyperimmune

- 96 -

serum reactive antigen or fragment thereof according to any one of claims 11-14.

34.   A process for *in vitro* diagnosis of a bacterial infection, especially a *S. pneumoniae* infection, comprising analysing for the presence of a nucleic acid sequence encoding said hyperimmune serum reactive antigen and fragment according to any one of claims 1 to 7 or the presence of the hyperimmune serum reactive antigen or fragment thereof according to any one of claims 11 to 14.

35.   Use of the hyperimmune serum reactive antigen or fragment thereof according to any one of claims 11 to 14 for the generation of a peptide binding to said hyperimmune serum reactive antigen or fragment thereof, wherein the peptide is selected from the group comprising anticalines.

36.   Use of the hyperimmune serum-reactive antigen or fragment thereof according to any one of claims 11 to 14 for the manufacture of a functional nucleic acid, wherein the functional nucleic acid is selected from the group comprising aptamers and spiegelmers.

37.   Use of a nucleic acid molecule according to any one of claims 11 to 14 for the manufacture of a functional ribonucleic acid, wherein the functional ribonucleic acid is selected from the group comprising ribozymes, antisense nucleic acids and siRNA.

Fig. 1

Fig.1

Fig.1

Fig. 2

Fig. 3

Fig. 4

Fig. 5

Fig. 6

Fig. 7

Fig. 8

Fig. 8

Fig. 9

Fig. 10

Fig. 11

```
                                                                                     90
    1
TIGR4      MKKKILASLL LSTVMVSQVA VLTTAHAETT DDKIAAQDNK ISNLTAQQQE AQKQVDQIQE QVSAIQAEQS NLQAENDRLQ AESKKLEGEI
   14      MKKKILASLL LSTVMVSQVA VLTTAHAETT DDKIAAQDNK ISNLTAQQQE AQKQVDQIQE QVSAIQAEQS NLQAENDRLQ AESKKLEGEI
  19F      MKKKILASLL LSTVMVSQVA VLTTAHAETT DDKIAAQDNK ISNLTAQQQE AQKQVDQIQE QVSAIQAEQS NLQAENDRLQ AESKKLEGEI
Consensus  mKKKILASLL LSTVMVSQVA VLTTAHAETT DDKIAAQDNK ISNLTAQQQE AQKQVDQIQE QVSAIQAEQS NLQAENDRLQ AESKKLEGEI

                                                                                     180
   91
TIGR4      TELSKNIVSR NQSLEKQARS AQTNGAVTSY INTIVNSKSI TEAISRVAAM SEIVSANNKM LEQQKADKKA ISEKQVANND AINTVIANQQ
   14      TELSKNIVSR NQSLEKQARS AQTNGAVTSY INTIVNSKSI TEAISRVAAM SEIVSANNKM LEQQKADKKA ISEKQVANND AINTVIANQQ
  19F      TELSKNIVSR NQSLEKQARS AQTNGAVTSY INTIVNSKSI TEAISRVAAM SEIVSANNKM LEQQKADKKA ISEKQVANND AINTVIANQQ
Consensus  TELSKNIVSR NQSLEKQARS AQTNGAVTSY INTIVNSKSI TEAISRVAAM SEIVSANNKM LEQQKADKKA ISEKQVANND AINTVIANQQ

                                                                                     270
  181
TIGR4      KLADDAQALT TKQAELKAAE LSLAAEKATA EGEKASLLEQ KAAAEAEARA AAVAEAAYKE KRASQQQSVL ASANTNLTAQ VQAVSESAAA
   14      KLADDAQALT TKQAELKAAE LSLAAEKATA EGEKASLLEQ KAAAEAEARA AAVAEAAYKE KRASQQQSVL ASANTNLTAQ VQAVSESAAA
  19F      KLADDAQALT TKQAELKAAE LSLAAEKATA EGEKASLLEQ KAAAEAEARA AAVAEAAYKE KRAGQQQSVL ASANTNLTAQ VQAVSESAAA
Consensus  KLADDAQALT TKQAELKAAE LSLAAEKATA EGEKASLLEQ KAAAEAEARA AAVAEAAYKE KRAsQQQSVL ASANTNLTAQ VQAVSESAAA

                                                                                     360
  271
TIGR4      PVRAKVRPTY STNASSYPIG ECTWGVKTLA PWAGDYWGNG AQWATSAAAA GFRTGSTPQV GAIACWNDGG YGHVAVVTAV ESTTRIQVSE
   14      PVRAKVRPTY STNASSYPIG ECTWGVKTLA PWAGDYWGNG AQWATSAAAA GFRTGSTPQV GAIACWNDGG YGHVAVVTAV ESTTRIQVSE
  19F      PVRAKVRPTY STNASSYPIG ECTWGVKTLA PWAGDYWGNG AQWATSAAAA GFRTGSTPQV GAIACWNDGG YGHVAVVTAV ESTTRIQVSE
Consensus  PVRAKVRPTY STNASSYPIG ECTWGVKTLA PWAGDYWGNG AQWATSAAAA GFRTGSTPQV GAIACWNDGG YGHVAVVTAV ESTTRIQVSE

                    392
  361
TIGR4      SNYAGNRTIG NHRGWFNPTT TSEGFVTYIY AD
   14      SNYAGNRTIG NHRGWFNPTT TPEGFVTYIY AD
  19F      SNYAGNRTIG NHRGWFNPTT TSEGFVTYIY AD
Consensus  SNYAGNRTIG NHRGWFNPTT TsEGFVTyiy ad
```

Fig. 12

```
                                                                                      90
1
TIGR4  MIQIGKIFAG RYRIVKQIGR GGMADVYLAK DLILDGEEVA VKVLRTNYQT DPIAVARFQR EARAMADLDH PHIVRITDIG EEDGQQYLAM
4      MIQIGKIFAG RYRIVKQIGR GGMADVYLAK DLILDGEEVA VKVLRTNYQT DPIAVARFQR EARAMADLDH PHIVRITDIG EEDGQQYLAM
6B     MIQIGKIFAG RYRIVKQIGR GGMADVYLAK DLILDGEEVA VKVLRTNYQT DPIAVARFQR EARAMADLDH PHIVRITDIG EEDGQQYLAM
9V     MIQIGKIFAG RYRIVKQIGR GGMADVYLAK DLILDGEEVA VKVLRTNYQT DPIAVARFQR EARAMADLDH PHIVRITDIG EEDGQQYLAM
18C    MIQIGKIFAG RYRIVKQIGR GGMADVYLAK DLILDGEEVA VKVLRTNYQT DPIAVARFQR EARAMADLDH PHIVRITDIG EEDGQQYLAM
R6     MIQIGKIFAG RYRIVKQIGR GGMADVYLAK DLILDGEEVA VKVLRTNYQT DPIAVARFQR EARAMADLDH PHIVRITDIG EEDGQQYLAM

                                                                                     180
91
TIGR4  EYVAGLDLKR YIKEHYPLSN EEAVRIMGQI LLAMRLAHTR GIVHRDLKPQ NILLTPDGTA FAETSLTQTN SMLGSVHYLS
4      EYVAGLDLKR YIKEHYPLSN EEAARIMGQI LLAMRLAHTR GIVHRDLKPQ NILLTPDGTA FAETSLTQTN SMLGSVHYLS
6B     EYVAGLDLKR YIKEHYPLSN EEAVRIMGQI LLAMRLAHTR GIVHRDLKPQ NILLTPDGTA FAETSLTQTN SMLGSVHYLS
9V     EYVAGLDLKR YIKEHYPLSN EEAVRIMGQI LLAMRLAHTR GIVHRDLKPQ NILLTPDGTA FAETSLTQTN SMLGSVHYLS
18C    EYVAGLDLKR YIKEHYPLSN EEAVRIMGQI LLAMRLAHTR GIVHRDLKPQ NILLTPDGTA FAETSLTQTN SMLGSVHYLS
R6     EYVAGLDLKR YIKEHYPLSN EEAVRIMGQI LLAMRLAHTR GIVHRDLKPQ NILLTPDGTA FAETSLTQTN SMLGSVHYLS

                                                                                     270
181
TIGR4  PEQARGSKAT VQSDIYAMGI IFYEMLTGHI PYDGDSAVTI ALQHFQKPLP SVIAENPSVP QALENVIIKA TAKKLTNRYR SVSEMYVDLS
4      PEQAGGSKAT VQSDIYAMGI IFYEMLTGHI PYDGDSAVTI ALQHFQKPLP SVIAENPSVP QALENVIIKA TAKKLTNRYR SVSEMYVDLS
6B     PEQARGSKAT VQSDIYAMGI IFYEMLTGHI PYDGDSAVTI ALQHFQKPLP SVIAENPSVP QALENVIIKA TAKKLTNRYR SVSEMYVDLS
9V     PEQARGSKAT VQSDIYAMGI IFYEMLTGHI PYDGDSAVTI ALQHFQKPLP SVIAENPSVP QALENVIIKA TAKKLTNRYR SVSEMYVDLS
18C    PEQARGSKAT VQSDIYAMGI IFYEMLTGHI PYDGDSAVTI ALQHFQKPLP SVIAENPSVP QALENVIIRA TAKKLTNRYR SVSEMYVDLS
R6     PEQARGSKAT VQSDIYAMGI IFYEMLTGHI PYDGDSAVTI ALQHFQNPLP SVIAENSSVP QALENVIIKA TAKKLTNRYR SVSEMYVDLS

                                                                                     360
271
TIGR4  SSLSYNRRNE SKLIFDETSK ADTKTLPKVS QSTLTSIPKV QAQTEHKSIK NPSQAVTEET YQPQAPKKHR FKMRYLILLA SLVIVAASLI
4      SSLSYNRRNE SKLIFDETSK ADTKTLPKVS QSTLTSIPKV QAQTEHKSIK NPSQAVTEET YQPQAPKKHR FKMRYLILLA SLVIVAASLI
6B     SSLSYNRRNE SKLIFDETSK ADTKTLPKVS QSTLTSIPKV QAQTEHKSIK NPSQAVTEET YQPQAPKKHR FKMRYLILLA SLVIVAASLI
9V     SSLSYNRRNE SKLIFDETSK ADTKTLPKVS QSTLTSIPKV QAQTEHKSIK NPSRAVTEET YQPQAPKKHR FKMRYLILLA SLVIVAASLI
18C    SSLSYNRRNE SKLIFDETSK ADTKTLPKVS QSTLTSIPKV QAQTGHKSIK NPSQAVTEET YQPQAPKKHR FKMRYLILLA SLVIVAASLI
R6     SSLSYNRRNE SKLIFDETSK ADTKTLPKVS QSTLTSIPKV QAQTEHKSIK NPSQAVTEET YQPQAPKKHR FKMRYLILLA SLVIVAASLI
```

Fig. 13

```
                                                                                    450
      361
TIGR4 WILSRTPATI AIPDVAGQTV AEAKATLKKA NFEIGEEKTE ASEKVEEGRI IRTDPGAGTG RKEGTKINLV VSSGKQSFQI SNYVGRKSSD
4     WILSRTPATI AIPDVAGQTV AEAKATLKKA NFEIGEEKTE ASEKVEEGRI IRTDPGAGTG RKEGTKINLV VSSGKQSFQI SNYVGRKSSD
6B    WILSRTPATI AIPDVAGQTV AEAKATLKKA NFEIGEEKTE ASEKVEEGRI IRTDPGAGTG RKEGTKINLV VSSGKQSFQI SNYVGRKSSD
9V    WILSRTPATI AIPDVAGQTV AEAKATLKKA NFEIGEEKTE ASEKVEEGRI IRTDPGAGTG RKEGTKINLV VSSGKQSFQI SNYVGRKSSD
18C   WILSRTPATI AIPDVAGQTV AEAKATLKKA NFEIGEEKTE ASEKVEEGRI IRTDPGAGTG RKEGTKINLV VSSGKQSFQI SNYVGRKSSD
R6    WILSRTPATI AIPDVAGQTV AEAKATLKKA NFEIGEEKTE ASEKVEEGRI IRTDPGAGTG RKEGTKINLV VSSGKQSFQI SNYVGRKSSD

                                                                                    540
      451
TIGR4 VIAELKEKKV PDNLIKIEEE ESNESEAGTV LKQSLPEGTT YDLSKATQIV LTVAKKATTI QLGNYIGRNS TEVISELKQK KVPENLIKIE
4     VIAELKEKKV PDNLIKIEEE ESNESEAGTV LKQSLPEGTT YDLSKATQI- ---------- ---------- ---------- ----------
6B    VIAELKEKKV PDNLIKIEEE ESNESEAGTV LKQSLPEGTT YDLSKATQIV LTVAKKATTI QLGNYIGRNS TEVISELKQK KVPENLIKIE
9V    VIAELKEKKV PDNLIKIEEE ESNESEAGTV LKQSLPEGTT YDLSKATQIV LTVAKKATTI QLGNYIGRNS TEVISELKQK KVPENLIKIE
18C   VIAELKEKKV PDNLIKIEEE ESNESEAGTV LKQSLPEGTT YDLSKATQII LTVAKKATTI QLGNYIGRNS TEVISELKQK KVPENLIKIE
R6    VIAELKEKKV PDNLIKIEEE ESNESEAGTV LKQSLPEGTT YDLSKATQIV LTVAKKATTI QLGNYIGRNS TEVISELKQK KVPENLIKIE

                                                                                    630
      541
TIGR4 EEESSESEPG TIMKQSPGAG TTYDVSKPTQ IVLTVAKKVT SVAMPSYIGS SLEFTKNNLI QIVGIKEANI EVVEVTTAPA GSAEGMVVEQ
4     ---------- ---------- ---------- -VLTVAKKVT SVAMPSYIGS SLEFTKNNLI QIVGIKEANI EVVEVTTAPA GSAEGMVVEQ
6B    EEESSESEPG TIMKQSPGAG TTYDVSKPTQ IVLTVAKKVT SVAMPSYIGS SLEFTKNNLI QIVGIKEANI EVVEVTTAPA GSVEGMVVEQ
9V    EEESSESEPG TIMKQSPGAG TTYDVSKPTQ IVLTVAKKVT SVAMPSYIGS SLEFTKNNLI QIVGIKEANI EVVEVTTAPA GSVEGMVVEQ
18C   EEESSESEPG TIMKQSPGAG TTYDVSKPTQ IVLTVAKKVT SVAMPSYIGS SLEFTKNNLI QIVGIKEANI EVVEVTTAPA GSAEGMVVEQ
R6    EEESSESEPG TIMKQSPGAG TTYDVSKPTQ IVLTVAKKVT SVAMPSYIGS SLEFTKNNLI QIVGIKEANI EVVEVTTAPA GSVEGMVVEQ

                 659
      631
TIGR4 SPRAGEKVDL NKTRVKISIY KPKTTSATP
4     SPRAGEKVDL NKTRVKISIY KPKTTSATP
6B    SPRAGEKVDL NKTRVKISIY KPKTTSATP
9V    SPRAGEKVDL NKTRVKTSIY KPKTTSATP
18C   SPRAGEKVDL NKTRVKISIY KPKTTSATP
R6    SPRAGEKVDL NKTRVKISIY KPKTTSATP
```

Fig. 13

```
A
                                                                                              90
            1
TIGR4     MFASKSERKV HYSIRKFSVG VASVVVASLV MGSVVHATEN EGATQVPTSS NRANESQAEQ GEQPKKLDSE RDKARKEVEE YVKKIVGESY
R6        MFASKSERKV HYSIRKFSIG VASVVVASLV MGSVVHATEN EGSTQAATSS NMAKTEH--- ---------- RKAAKQVVDE YIEKMLRE--
4         MFASKSERKV HYSIRKFSVG VASVVVASLV MGSVVHATEN EGATQVPTSS NRANESQAEQ GEQPKKLDSE RDKARKEVEE YVKKIVGESY
9V        MFASKSERKV HYSIRKFSVG VASVAVASLV MGSVVHATEN ERTTQVPTSS NRGKPER--- ---------- RKAAEQF-DE YINKM-----
14        MFASKSERKV HYSIRKFSIG VASVAVASLF LGGVVHA-EG VRSENTPKVT SSGDE----- ---------- ------VDE YIKKMLSE--
18C       MFASKSERKV HYSIRKFSIG VASVAVASLV MGSVVHATEK EVTTQVPTYS NMAKTEH--- ---------- RKAAKQVVDE YIEKMLRE--
19F       MFASKSERKV HYSIRKFSIG VASVAVASLF LGGVVHA-EG VRSENTPKVT SSGDE----- ---------- ------VDE YIKKMLSE--
23F       MFASKSERKV HYSIRKFSIG VASVAVASLF MGSVVHATEK EVTTQVATSS NKANKSQ--- --------TE HMKAAKQVDE YIKKKL----
Consensus MFASKSERKV HYSIRKFSiG VASVaVASLv $GsVVHAtE. e..t#vptss n.a.e..... r..a...v#E Y!kKml.e..
            91                                                                                180
TIGR4     AKSTKKRHTI TVALVNELNN IKNEYLNKI- VESTSESQLQ ILMMESRSKV DEAVSKFEKD SSSSSSSDSS TKPEASDTAK PNKPTEPGEK
R6        IQLDRRKHTQ NVALNIKLSA IKTKYLREL- -NVLEEKSKD ELPSEIKAKL DAAFEKFKKD T--------- ---------- ----LKPGEK
4         AKSTKKRHTI TVALVNELNN IKNEYLNKI- VESTSESQLQ ILMMESRSKV DEAVSKFEKD SPSSSSSDSS TKPE------ ----------
9V        IQLDRKHTQ NLAFNIQLSR IKTEYLNGL- ----KEKSEA ELPSKIKAEL DAAFKQFKKD TLPTEPE--- ---------- --KKVAEAKK
14        IQLDRKHTH NFALNLKLSR IKTEYLYKLK VNVLEEKSKA ELTSKTKKEV DAAFEKFKKD T--------- ---------- ----LKLGEK
18C       IQLDRRKHTQ NFAFNMKLSA IKTEYLIYGL -----KEKSEA ELPSS-EAEL PSEVKA-KLD AAFEQFK--- ---------- -KDTLKLGEK
19F       IQLDRKHTH NFALNLKLSR IKTEYLYKLK VNVLEEKSKA ELTSKTKKEV DAAFEKFKKD T--------- ---------- ----LKLGEK
23F       -QLDRRKHTQ NVGLLITKLGV IKTEYLHGL- -SVSKKKSEA ELPSEIKAKL DAAFBQFKKD TLP------- ---------- ----TEPGKK
Consensus iqldkrkHT. n.aln.kls. IKtEYL.kl. v....eks.a eL.s..k.ev daaf.kfkkD t......... .......... ......gek
            181                                                                               270
TIGR4     VAEAKKKVEE AEKKAKDQKE EDRRNYPTIT YKTLELEIAE SDVEVKKAEL ELVKVKANEP RDEQKIKQAE AEVESKQAEA TRLKKIKTDR
R6        VAEAKKKVEE AKKKAEDQKE EDRRNYPTNT YKTLELBIAE FDVKVKEAEL ELVKEEAKES RNEGTIKQAK BKVESKKAEA TRLENIKTDR
9V        VEEAEKKVAE AKKKAKAQKE EDHRNYPTIT YKTLDLBIAE FDVKVKEAEL ELVKKEADES RNEGTINQAK AKVESEKAEA TRLKKIKTDR
14        VAEAQKKVEE AKKKAKDQKE EDHRNYPTNT YKTLELEIAE SDVKVKEAEL ELLKEEA-KT RNEDTINQAK AKVKSEQAEA TRLKKIKTDR
18C       VAEAEKKVAE AEKKAKAQKE EDRRNYPTIT YKTLELEIAE SDVKVKEAEL ELLKEEA-KT RNKDTIKQAK AKVESKKAEA TKLEEIKTDR
19F       VAEAQKKVEE AKKKAKDQKE EDHRNYPTNT YKTLELEIAE SDVKVKEAEL ELLKEEA-KT RNEDTINQAK AKVKSEQAEA TRLKKIKTDR
23F       VAEABKKVEE AKKKAEDQKE KDLRNYPTNT YKTLELDIAE SDVEVKKAEL ELVKGSYRNL ETRKKLIKQS EKLRIKKLML Q
Consensus vaea.kkvee akkkakdqke ed.rnypt.t yktlelelae sdv.vk.ael el.k.ea... rne.ti.qak akv.s..aea trl..iktdr
            271                                                    360
TIGR4     EEAEEE-AKR RADAK----- ----EQGKPK GRAKRGVPGE ETLPSPSLKP EKKVAEAEKK VEEAKKKAED
R6        KKAEEE-AKR RADAKLKEAN VATSDQGKPK GRAKRGVPGE ETLPSSSLKS GKKVAEAEKK VEEAEKKAKD
9V        EKAEEEEAKR RADAKEQDES
14        EQAEAT
18C       KKAEEEA
19F       EQAEAATRLEN IKTDREK--- ---AEEAKRK AE
Consensus ..ae......
```

Fig. 14

B

```
          361                                                                                    450
TIGR4     QKEEDRRNYP  TNTYKTLELE  IAESDVEVKK  KEPRNEEKVK  QAKAEVESKK  AEATRLEKIK  TDRKKAEEEA  KRKAAEEDKV
R6        QKEEDRRNYP  TNTYKTLDLE  IAESDVKVKE  KEPRDEEKIK  QAKAKVESKK  AEATRLENIK  TDRKKAEEEA  KRKAAEEDKV
4                                 AESDVEVKK   KEPRNEEKVK  QAKAEVESKK  AEATRLEKIK  TDRKKAEEEA  KRRAAEEDKV
6B                     LK  LLSPMWKLKK  RSLTS-KEEA  KKPLNEGTIR  QAKAKVESKK  AEATRLEKIK  TDRKKAEEEA  KRRAAEEDKV
9V                                 IAESDVKVKE  AELELVKEEA  KESRNEEKIK  QAKAEVESKK  AEATRLEKIK  TDRKKAEEEA  KRKAAEEDKV
14                                 IAESDVKVKE  AELELVKEEA  KEPRDEEKIK  QAKAKVESKK  AEATRLEKIK  TDRKKAEEEA  KRKAAEEDKV
18C                                IAESDVKVKE  AELELVKEEA  KESRNEEKVK  QAKAEVESKQ  AEATRLEKIK  TDRKKAEE-A  KRKAAEEDKV
19F                  LE  IAESDVKVKE  AELELVKEEA  KESRNEEKVK  QAKAKVESKQ  AEATRLEKIK  TDRKKAEEEA  KRKAAEEDKV
23F

Consensus  ..........  iaesdvkvke  aelelvkeea  keprneek.k  qaka.veskk  aeatrlekik  tdrkkaeeea  krkaaeedkv


          451                                                                                    540
TIGR4     KEKPAEQPQP  APAPKAEKPA  -------PAP  KPENPAEQPK  AEKPA-----  --?-DQQAEED  YARRSEEEYN  RLTQQQPPKT
R6        KEKPAEQPQP  APATQPEKPA  -------p--  KPEKPAEQPK  AEKTD-----  ----DQQAEED  YARRSEEEYN  RLTQQQPPKT
4         KEKPAEQPQP  APAPKAEKP-  -------APAP  KPENPAEQPK  AEKPA-----  ----DQQAEED  YARRSEEEYN  RLTQQQPPKT
6B        KEKPAEQPQP  APAPQPEKPT  EEPENPVPAP  KPEKPAEQPK  EKPAEQPKAE  KTDDQQAEED  YARRSEEEYN  RLTQQQPQKP
9V        KEKPAEQPQP  APAPKPENPA  EEPENPVPAP  KPENPAEQPK  AEKPA-----  ----DQQAEED  YARRSEEEYN  RLTQQQPPKP
14        KEKPAEQPQP  APAPQPEKPT  PKPEKPAPAP  KPENPAEQPK  AEKPA-----  ----DQQAEED  YARRSEEEYN  RLTQQQPPKT
18C       KEKPAEQPQP  APAPQPEKPT  EEPENPAPAP  KPEKPAEQPK  AEKPA-----  ----DQQAEED  YARRSEEEYN  RLTQQQPPKT
19F       KEKPAEQPQP  APAPQPEKP-  -------APAP  KPENPAEQPK  AEKPA-----  ----DQQAEED  YARRSEEEYN  RLTQQQPPKT
23F                                                             VQNGMW  VYFYNTDGSMA  TGWLQNNGSW

Consensus  kekpaeqpqp  apapqpekp.  ........pap  kpenpaeqpk  aekpa.....  ...dqQaeed  Yarrs#eeyn  rltq#ppkt


          541                                                                            630
TIGR4     EKPAQPSTPK  TGWKQENGMW  YFYNTDGSMA  TGWLQNNGSW  YYLNSNGAMA  TGWLQNNGSW  YYLNANGSMA
R6        EKPAQPSTPK  TGWKQENGMW  YFYNTDGSMA  TGWLQNNGSW  YYLNANGSW   TGWLQNNGSW  YYLNANGAMA
4         EKPAQPSTPK  TGWKQENGMW  YFYNTDGSMA  TGWLQNNGSW  YYLNSNGAMA  TGWLQNNGSW  YYLNANGSMA
6B        EQPAP--APK  IGWKQENGMW  YFYNTDGSMA  TGWLQ-----  ----------  ----------  ----------
9V        EQPAP--APK  IGWKQENGMW  YFYNTDGSMA  TGWLQNNGSW  YYLNSNGAMA  TGWLQNNGSW  YYLNANGDMA
14        EKPAQPSTPK  TGWKQENGMW  YFYNTDGSMA  TGWLQNNGSW  YYLNANGDMA  TGWLQNNGSW  YYLNANG---
18C       EKPAQPSTPK  TGWKQENGMW  YFYNTDGSMA  TGWLQYNGSW  YYLNSNGAMA  TGWLQNNGSW  YYLNANGDMA
19F       EKPAQPSTPK  TGWKQENGMW  YFYNTDGSMA  TGWLQYNGSW  YYLNANGDMA  TGWLQNNGSW  YYLNANG---
23F       YYLNSNGAMA  TGWLQNNGAMA  TGWLQYNGSW  YYLNSNGAMA  TGWFQYNGSW  YYLNANGDMA

Consensus  ekpaqpstpk  tgWkQ#NGmW  Y%yNt#GsMA  TGWLQ.ngsw  yyln.ng.ma  tgwlqnngsw  yylnang.ma
```

Fig. 14

```
           631                                                                                    720
TIGR4      TGWLQYNGSW  YYLN------  ----------  ----------  ---ANGSMA   TGWLQYNGSW  YYLNANGDMA  TGWVKDGDTW
R6         TGWLQYNGSW  YYLNSNGAMA  TGWLQYNGSW  YYLNANGDMA  TGWLQYNGSW  YYLNANGDMA  TGWVKDGDTW
4          TGWLQYNGSW  YYLN------  ----------  ---ANGSMA   TGWLQYNGSW  YYLNANGDMA  TGWVKDGDTW
6B         TGWLQYNGSW  YYLN------  ----------  ----------  ----YNGSW   YYLNANGSMA  TGWVKDGDTW
9V         TGWLQYNGSW  YYLN------  ----------  ---ANGDMA   TGWLQYNGSW  YYLNANGDMA  TGWVKDGDTW
14         ----------  ----------  ----------  -----DMA    TGWLQNNGSW  YYLNANGDMA  TGWVKDGDTW
18C        TGWLQYNGSW  YYLN------  ----------  ---ANGDMA   TGWLQNNGSW  YYLNANGDMA  TGWVKDGDTW
19F        ----------  ----------  ----------  -----DMA    TGWLQNNGSW  YYLNANGDMA  TGWVKDGDTW
23F        TGWFQYNGSW  YYLN------  ----------  ---ANGDMA   TGWLQYNGSW  YYLNSNGAMV  TDWVKDGDTW
Consensus  tgw.qyngsw  yyln        .........   ...ngdma    tgwlqyNGSW  YYLNANGdMA  TgWVKDGDTW


           721                                      769
TIGR4      YYLEASGAMK  ASQWFKVSDK  WYYVNGSGAL  AVNTTVDGYG  VNANGEWVN
R6         YYLEASGAMK  ASQWFKVSDK  WYYVNGSGAL  AVNTTVDGYG  VNANGEWVN
4          YYLEASGAMK  ASQWFKVSDK  WYYVNGSGAL  AVNTTVDGYG  VNANGEWVN
6B         YYLEASGAMK  ASQWFKVSDK  WYYVNGSGAL  AVNTTVDGYG  VNANGEWVN
9V         YYLEASGAMK  ASQWFKVSDK  WYYVNGSGAL  AVNTTVDGYG  VNANGEWVN
14         YYLEASGAMK  ASQWFKASDK  WYYVNGSGAL  AVNTTVDGYG  VNANGEWVN
18C        YYLEASGAMK  ASQWFKVSDK  WYYVNGSGAL  AVNTTVDGYG  VNANGEWVN
19F        YYLEASGAMK  ASQWFKASDK  WYYVNGSGAL  AVNTTVDGYG  VNANGEWVN
23F        YYLEASGAMK  ASQWFKVSDK  WYYVNGSGAL  AVNTTVDSYR  VNANGEWVN
Consensus  YYLEASGAMk  asqwFkvsdk  wyyvngsgal  avnttvdgyg  vnangewvn
```

Fig. 14

SEQUENCE LISTING

SeqID 1
```
atgtctaaaa atattgtaca attgaataat tcttttattc aaaatgaata ccaacgtcgt    60
cgctacctga tgaaagaacg acaaaaacgg aatcgtttta tgggaggggt attgattttg   120
attatgctat tatttatctt gccaactttt aatttagcgc agagttatca gcaattactc   180
caaagacgtc agcaattagc agacttgcaa actcagtatc aaactttgag tgatgaaaag   240
gataaggaga cagcatttgc taccaagttg aaagatgaag attatgctgc taaatataca   300
cgagcgaagt actattattc taagtcgagg gaaaaagttt atacgattcc tgacttgctt   360
caaagg                                                             366
```

SeqID 2
```
atggataaga aaaaattatt attgattgat gggtcttctg tagcttttcg ggcgtttttt    60
gcgctgtatc agcagttgga ccgttttaag aatgtggctg gtttgcatac caatgcgatt   120
tatggttttc agttgatgtt gagtcattta ttggagcggg ttgagccgag tcatattttg   180
gtggcttttg atgcgggaaa gacgaccttc cggacagaga tgtatgcgga ctataagggt   240
ggtcgggcca agactcctga tgagtttcgt gagcaatttc ctttcattcg tgagttgctg   300
gatcatatgg ggattcgtca ctatgatctg gctcagtatg aggcggatga catcattggg   360
acgctggata agctagcaga gcaggatggt tttgatatta ctattgtcag tgggggacaag   420
gatttgattc agctgacgga tgagcatacg gtggttgaaa tttccaagaa aggtgtggct   480
gagtttgagg cctttacgcc agattacctc atggaagaaa tgggcctcac accagctcag   540
tttatcgatc tcaaggcgct catgggtgat aagtcggata atatccctgg ggtgaccaaa   600
gtcggtgaaa agacgggtat taagctcttg ctggagcatg gttcgcttga ggggatttat   660
gaaaatattg atggaatgaa gacttctaag atgaaggaaa tctcatcaa tgacaaggaa    720
caggcctttt tgtctaaaac actagcgacc attgatacca aggcaccgat gcgattggt    780
ttagaggact tggtctatag tggtccagat gttgaaaatc ttgggaaatt ctacgatgag    840
atgggcttca aacagctaaa gcaggcttta aatgtgtcgt cagctgatgt gtctgagagt    900
ttggatttta ctattgttga ccaaatcagt caagatatgc tgagtgaaga gtctatcttc    960
cactttgagc tttttggtga gaattaccat acggataatt tggttggatt tgtctggtct   1020
tgtgggggata agctctatgc cacagacaag cttgagctgt tgcaagaccc gatttttcaag  1080
gatttcttag aaaaaacatc tctgagagtt tatgacttta agaaggttaa agttcttttg   1140
caacgttttg gtgtggattt gcaggcgcct gctttttgaca tccgtttggc taaatacctc   1200
ctttcgactg tggaggacaa tgaaattgcg accatcgcta gtctttatgg tcagacttac   1260
ttggttgatg atgaaacttt ctacggtaag ggtgttaaaa aggccattcc tgaacgtgag   1320
aaattcttgg aacacttagc ttgtaaactt gctgtttttgg tagaaacaga gcctattttta   1380
cttgaaaaac tcagcgaaaa tgggcaatta gagcttcttt atgatatgga gcaacctctg    1440
gctttttgtcc ttgccaagat ggaaattgct gggattatgg tcaagaaaga gaccttgctt   1500
gagatgcagg ctgaaaatga gcttgtcatt gaaaaactga ctcaagagat ttacgagctg   1560
gctggtgagg agtttaatgt caactcgcct aagcagttgg gcgtgcttct cttttgagaaa   1620
ttgggacttc ctctagaata cactaagaaa accaagacag gttattcgac agcagtggat   1680
gttttagagc gtctcgctcc tattgctccg attgttaaga aaatcctgga ttaccgtcaa    1740
attgctaaga ttcaatctac ttatgtaatt ggcttgcagg actggatttt ggctgatgga   1800
aagattcata ctcgctatgt gcaggatttg acccagaccg ggcgtttgtc tagtgtggat    1860
ccaaacttgc aaaatattcc tgcccgattg aacaggggc gcttgattcg gaaggctttt   1920
gtgccagagt gggaggatag tgtgctactc agctctgact attcacagat tgaattgcgc   1980
gttttggcgc atatttctaa ggatgagcac ttgattaagc ccttccaaga ggggcagat   2040
atccatactt cgacagccat gcgggtcttt ggcattgagc gtcctgatga tgtgactgca   2100
aacgaccgtc gcaatgccaa ggcagttaac tttggagtgg tttatgggat ttcagacttt   2160
ggcttgtcta taatttgggg aattagtcgt aaggaagcca aagcctacat tgataccctac   2220
tttgaacgtt ttccaggtat taaaaactac atggatgaag tggtgcggga ggcgcgtgat   2280
aagggctatg tagagacctt ctttaagcgt cgccgtgagt tgccagatat caattcgcgc   2340
aacttcaata ttcgtggttt tgcggagcga actgctatca actcacctat ccagggttcg   2400
gcagcagata ttctcaagat tgccatgatt cagctggata aagccttggt tgcaggtggt   2460
tatcagacta agatgctgtt acaagtgcac gatgaaatcg tccttgaagt gcctaaatct   2520
gaattggtag agatgaaaaa attggtgaaa caaaccatgg aagaagccat tcaactcagt   2580
gttcctctta tcgcagatga gaatgaaggg caacctggt acgaggctaa a            2631
```

SeqID 3
```
atggggatgg cagcttttaa aaatcctaac aatcaataca aagctattac aattgctcaa    60
actctaggtg atgatgcttc ttcagaggaa ttggctggta gatatggttc tgctgttcag   120
tgtacagaag tgactgcctc aaacctttca acagttaaaa ctaaagctac ggttgtagaa   180
aaaccactga agattttag agcgtctacg tctgatcagt ctggttgggt ggaatctaat   240
ggtaaatggt atttctatga gtctggtgat gtgaagacag gttgggtgaa aacagatggt   300
aaatggtact atttgaatga cttaggtgtc atgcagactg gatttgtaaa attttctggt   360
agctggtatt acttgagcaa ttcaggtgct atgtttacga gctggggaac agatgttagc   420
agatggttct actttgacgg ctcaggagct atgaagacag gctggtacaa ggaaaatggc   480
acttggtatt accttgacga agcaggtatc atgaagacag gttggtttaa agtcggacca   540
cactggtact atgcctacgg ttcaggagct ttggctgtga gcacaacaac accagatggt   600
```

CONFIRMATION COPY

```
taccgtgtaa atggtaatgg tgaatgggta aac                              633

SeqID 4
atgagccgaa aaagcattgg tgagaaacgc catagtttct cgatgagaaa gttgtcagtg   60
ggattggtat cagttactgt atctagtttc tttttgatga gtcaagggat tcaatcggta  120
tcggccgata atatggaaag tccaattcat tataagtata tgaccgaggg taaattgaca  180
gacgaggaaa aatccttgct ggtagaggcc cttccacaac tggctgaaga atcagatgat  240
acttattact tggtcatact atctcaacag tttttaccga atacaggttt taacccaact  300
gttggtactt tccttttac tgcaggattg agcttgttag tttattggt ttctaaaagg   360
gaaaatggaa agaaacgact tgttcatttt ctgctgttga ctagcatggg agttcaattg  420
ttgccggcca gtgcttttgg gttgaccagc cagattttat ctgcctataa tagtcagctt  480
tctatcggag tcggggaaca tttaccagag cctctgaaaa tcgaaggtta tcaatatatt  540
ggttatatca aaactaagaa acaggataat acagagcttt caaggacagt tgatgggaaa  600
tactctgctc aaagagatag tcaaccaaac tctacaaaaa catcagatgt agttcattca  660
gctgatttag aatggaacca aggacagggg aaggttagtt tacaaggtga agcatcaggg  720
gatgatggac tttcagaaaa atcttctata gcagcagaca atctatcttc taatgattca  780
ttcgcaagtc aagttgagca gaatccggat cacaaggag aatctgtagt tcgaccaaca  840
gtgccagaac aaggaaatcc tgtgtctgct acaacggtgc agagtgcgga gaggaagta  900
ttggcgacga caaatgatcg accagagtat aaacttccat tggaaaccaa aggcacgcaa  960
gaaccggtc atgagggtga agccgcagtc cgtgaagact taccagtcta cactaagcca 1020
ctagaaacca aaggtacaca aggacccgga catgaaggtg aagctgcagt tcgcgaggaa 1080
gaaccagctt acacagaacc gttagcaacg aaaggcacgc aagagccagg tcatgagggc 1140
aaagctacag tccgcgaaga gactctagag tacacggaac cggtagcgac aaaaggcaca 1200
caagaacccg aacatgaggg cgaagcggca gtagaagaag aacttccggc tttagaggtc 1260
actacacgaa atagaacgga aatccagaat attccttata caacagaaga aattcaggat 1320
ccaacacttc tgaaaaatcg tcgtaagatt gaacgacaaa ggcaagcagg gacacgtaca 1380
attcaatatg aagactacat cgtaaatggt aatgtcgtag aaactaaaga agtgtcacga 1440
actgaagtag ctccggtcaa cgaagtcgtt aaagtaggaa cacttgtgaa agttaaacct 1500
acagtagaaa ttacaaactt aacaaaagtt gagaacaaaa aatctataac tgtaagttat 1560
aacttaatag acactacctc agcatatgtt tctgcaaaaa cgcaagtttt ccatggagac 1620
aagctagtta agaggtgga tatagaaaat cctgccaaag agcaagtaat atcaggttta 1680
gattactaca caccgtatac agttaaaaca cacctaactt ataatttggg tgaaaataat 1740
gaggaaaata ctgaaacatc aactcaagat ttccaattag agtataagaa aatagagatt 1800
aaagatattg attcagtaga attatacggt aaagaaaatg atcgttatcg tagatattta 1860
agtctaagtg aagcgccgac tgatacggct aaatactttg taaaagtaca atcagatcgc 1920
ttcaaagaaa tgtacctacc tgtaaaatct attacagaaa atacggatgg aacgtataaa 1980
gtgacggtag ccgttgatca acttgtcgaa gaaggtacag acggttacaa agatgattac 2040
acatttactg tagctaaatc taaagcagag caaccaggag tttacacatc ctttaaacag 2100
ctggtaacag ccatgcaaag caatctgtct ggtgtctata cattggcttc agatatgacc 2160
gcagatgagg tgagcttagg cgataagcag acaagttatc tcacaggtgc atttacaggg 2220
agcttgatcg gttctgatgg aacaaaatcg tatgccattt atgatttgaa gaaaccatta 2280
tttgatacat taaatggtgc tacagttaga gatttggata ttaaaactgt ttctgctgat 2340
agtaaagaaa atgtcgcagc gctggcgaag gcagcgaata gcgcgaatat taataatgtt 2400
gcagtagaag gaaaaatctc aggtgcgaaa tctgttgcgg gattagtagc gagcgcaaca 2460
aatacagtga tagaaaacag ctcgtttaca gggaaactta tcgcaaatca ccaggacagt 2520
aataaaaatg atactggagg aatagtaggt aatataacag gaaatagttc gagagttaat 2580
aaagttaggg tagatgcctt aatctctact aatgcacgca ataataacca aacagctgga 2640
gggatagtag gtagattaga aaatggtgca ttgatatcta attcggttgc tactggagaa 2700
atacgaaatg gtcaaggata ttctagagtc ggaggaatag taggatctac gtggcaaaac 2760
ggtcgagtaa ataatgttgt gagtaacgta gatgttggag atggttatgt tatcaccggt 2820
gatcaatacg cagcagcaga tgtgaaaaat gcaagtacat cagttgataa tagaaaagca 2880
gacagattcg ctacaaaatt atcaaaagac caaatagacg cgaaagttgc tgattatgga 2940
atcacagtaa ctcttgatga tactgggcaa gatttaaaac gtaatctaag agaagttgat 3000
tatacaagac taaataaagc agaagctgaa agaaaagtag cttatagcaa catagaaaaa 3060
ctgatgccat tctacaataa agacctagta gttcactatg gtaacaaagt agcgacaaca 3120
gataaacttt acactacaga attgttagat gttgtgccga tgaaagatga tgaagtagta 3180
acggatatta ataataagaa aaattcaata aataaagtta tgttacattt caaagataat 3240
acagtagaat acctagatgt aacattcaaa gaaaacttca taaacagtca agtaatcgaa 3300
tacaatgtta caggaaaaga atatatattc acaccagaag catttgtttc agactataca 3360
gcgataacga ataacgtact aagcgacttg caaaatgtaa cacttaactc agaagctact 3420
aaaaaagtac taggagcagc gaatgatgca gccttagata acctatactt agatagacaa 3480
tttgaagaag ttaaagctaa tatagcagaa cacctaagaa aagtattagc gatggataaa 3540
tcaatcaata ctacaggaga cggtgtagtt gaatacgtaa gtgagaaaat caaaaataac 3600
aaagaagcat ttatgctagg tcttacttat atgaaccgtt ggtacgatat taattatggt 3660
aaaatgaata caaaagattt atctacgtac aagtttgact ttaacggaaa taatgagact 3720
tcaacgttgg atactattgt cgcattagga aatagtggac tagataacct gagagcttca 3780
aatactgtag gtttatatgc gaataaactt gcatcggtaa aaggagaaga ttcagtcttt 3840
gacttcgtag aagcgtatag aaaactgttc ttaccaaaca aaacaaataa cgagtggttt 3900
```

```
aaagaaaata caaaggcata tatagtcgaa atgaagtctg atattgcaga agtacgagáa   3960
aaacaagaat caccaacagc cgatagaaaa tattcattag gagtttacga tagaatatca   4020
gcaccaagtt gggggcataa gagtatgtta ttaccactac taactttacc tgaagaatct   4080
gtgtatattt catcgaatat gtctacactt gcattcggtt cgtatgaaag atatcgtgat   4140
agtgtggatg gagttattct ttcaggagat gctttacgaa cttatgtaag aaatagagtt   4200
gatatagcag cgaaaaggca tagagaccat tatgatattt ggtacaatct tcttgacagt   4260
gcttcaaaag aaaaactttt ccgtctgtg atagtttatg atggattcaa tgtaaaagat   4320
gagacaggaa gaacttattg ggcaaggtta acggataaaa acatcggctc tattaaagaa   4380
ttcttcggac ctgttgggaa atggtatgag tataatagta gtgcaggagc gtatgcgaat  ·4440
ggaagtttaa cgcactttgt gttagataga ttattagatg cttatggaac gtcggtttat   4500
actcatgaaa tggttcataa ttctgattct gcaatctact ttgaaggaaa tggtagacgt   4560
gaaggattgg gagcggagtt atacgcactt ggtttactgc aatctgtaga tagtgtaaat   4620
tctcatattt tagctttaaa tacgttatat aaagcagaaa aagatgattt gaatagattg   4680
catacatata atccggtgga acgtttcgat tcggatgagg cgcttcaaag ttatatgcat   4740
ggatcatatg atgtaatgta tacacttgat gcgatggaag caaaagcgat attagctcaa   4800
aataatgatg ttaagaaaaa atggtttaga aaaatagaaa attattacgt tcgtgatact   4860
agacataata aagatacaca tgcaggaaat aaagtccgtc cattaacaga tgaagaagta   4920
gctaacttaa catcgttaaa ctcattaatc gacaacgaca tcataaatag acgtagctat   4980
gatgatagta gagaatataa acgaaatggc tactatacta taagtatgtt ctctcctgta   5040
tacgcagcgc taagcaattc gaaaggtgct cctggagata ttatgtttag aaaaatagct   5100
tatgaattac ttgcggaaaa aggttatcac aaaggattcc taccttatgt ttctaatcag   5160
tacggagcag aagcatttgc cagcggaagc aaaacattct catcatggca tggaagagat   5220
gttgctttag tgacagatga tttagtattt aagaaagtat tcaatggtga gtactcatca   5280
tgggctgatt tcaaaaaagc aatgtttaaa caacgtatag ataaacaaga taatctgaaa   5340
ccaataacaa ttcaatacga attaggtaat cctaatagta caaaagaagt aactataaca   5400
acggctgcac aaatgcaaca attaattaat gaagcggctg cgaaagatat tactaatata   5460
gatcgtgcaa cgagtcatac cccagcaagt tgggtgcatt tattaaaaca aaaaatctat   5520
aatgcatatc ttcgcactac agatgacttt agaaattcta tatataaa             5568
```

SeqID 5

```
atgaaattca atccaaatca aagatatact cgttggtcta ttcgccgtct cagtgtcggt     60
gttgcctcag ttgttgtggc tagtggcttc tttgtcctag ttggtcagcc aagttctgta    120
cgtgccgatg ggctcaatcc aaccccaggt caagtcttac ctgaagagac atcgggaacg    180
aaagagggtg acttatcaga aaaaccagga gacaccgttc tcactcaagc gaaacctgag    240
ggcgttactg gaaatacgaa ttcacttccg acacctacag aaagaactga agtgagcgag    300
gaaacaagcc cttctagtct ggatacactt tttgaaaaag atgaagaagc tcaaaaaaat    360
ccagagctaa cagatgtctt aaaagaaact gtagatacag ctgatgtgaa tgggacacaa    420
gcaagtccag cagaaactac tcctgaacaa gtaaaaggtg gagtgaaaga aaatacaaaa    480
gacagcatcg atgttcctgc tgcttatctt gaaaaagctg aagggaaagg tcctttcact    540
gccggtgtaa accaagtaat tccttatgaa ctattcgctg gtgatggtat gttaactcgt    600
ctattactaa aagcttcgga taatgctcct tggtctgaca atggtactgc taaaaatcct    660
gctttacctc ctcttgaagg attaacaaaa gggaaatact ctatgaagt agacttaaat    720
ggcaatactg ttggtaaaca aggtcaagct ttaattgatc aacttcgcgc taatggtact    780
caaacttata aagctactgt taaagtttac ggaaataaag acggtaaagc tgacttgact    840
aatctagttg ctactaaaa tgtagacatc aacatcaatg gattagttgc taagaaaaca    900
gttcaaaaag ccgttgcaga caacgttaaa gacagtatcg atgttccagc agcctaccta    960
gaaaaagcca agggtgaagg tccattcaca gcaggtgtca accatgtgat tccatacgaa   1020
ctcttcgcag gtgatggcat gttgactcgt ctcttgctca aggcatctga caaggcacca   1080
tggtcagata cggcgacgc taaaaaccca gccctatctc cactaggcga aaacgtgaag   1140
accaaaggtc aatacttcta tcaagtagcc ttggacggaa atgtagctgg caaagaaaaa   1200
caagcgctca ttgaccagtt ccgagcaaat ggtactcaaa cttacagcgc tacagtcaat   1260
gtctatggta caaagacgg taaaccagac ttggacaaca tcgtagcaac taaaaaagtc   1320
actattaaca taaacggttt aatttctaaa gaaacagttc aaaaagccgt tgcagacaac   1380
gttaaagaca gtatcgatgt tccagcagca tacctagaaa aagccaaggg tgaaggtcca   1440
ttcacagcag gtgtcaacca tgtgattcca tacgaactct cgcaggtga tggtatgttg   1500
actcgtctct tgctcaaggc atctgacaag gcaccatggt cagataacgg tgacgctaaa   1560
aacccagccc tatctccact aggtgaaaac gtgaagacca aaggtcaata cttctatcaa   1620
ttagccttgg acggaaatgt agctggcaaa gaaaaacaag cgctcattga ccagttccga   1680
gcaaacggta ctcaaactta cagcgctaca gtcaatgtct atggtaacaa agacggtaaa   1740
ccagacttgg acaacatcgt agcaactaaa aaagtcacta ttaacataaa cggttttaatt  1800
tctaaagaaa cagttcaaaa agccgttgca gacaacgtta aggacagtat cgatgttcca   1860
gcagcctacc tagaaaaggc caagggtgaa ggtccattca cagcaggtgt caaccatgtg   1920
attccatacg aactcttcgc aggtgatggc atgttgactc gtctcttgct caaggcatct   1980
gacaaggcac catggtcaga taacggcgac gctaaaaaacc cagctctatc tccactaggt   2040
gaaacgtga agaccaaagg tcaatacttc tatcaagtag ccttggacgg aaatgtagct   2100
ggcaaagaaa aacaagcgct cattgaccag ttccgagcaa acggtactca aacttacagc   2160
gctacagtca atgtctatgg taacaaagac ggtaaaccag acttggacaa catcgtagca   2220
actaaaaaag tcactattaa gataaatgtt aaagaaacat cagacacagc aaatggttca   2280
```

```
ttatcacctt ctaactctgg ttctggcgtg actccgatga atcacaatca tgctacaggt    2340
actacagata gcatgcctgc tgacaccatg acaagttcta ccaacacgat ggcaggtgaa    2400
aacatggctg cttctgctaa caagatgtct gatacgatga tgtcagagga taaagctatg    2460
ctaccaaata ctggtgagac tcaaacatca atggcaagta ttggtttcct tgggcttgcg    2520
cttgcaggtt tactcggtgg tctaggtttg aaaaacaaaa agaagaaaa c              2571


SeqID 6
atgaaatcaa taactaaaaa gattaaagca actcttgcag gagtagctgc cttgtttgca      60
gtatttgctc catcatttgt atctgctcaa gaatcatcaa cttacactgt taaagaaggt     120
gatacacttt cagaaatcgc tgaaactcac aacacaacag ttgaaaaatt ggcagaaaac     180
aaccacattg ataacattca tttgatttat gttgatcaag agttggttat cgatggccct     240
gtagcgcctg ttgcaacacc agcgccagct acttatgcgg caccagccgc tcaagatgaa     300
actgtttcag ctccagtagc agaaactcca gtagtaagtg aaacagttgt ttcaactgta     360
agcggatctg aagcagaagc caaagaatgg atcgctcaaa agaatcagg tggtagctat      420
acagctacaa atggacgtta tatcggacgt taccaattaa cagattcata cctgaacggt      480
gactactcag ctgaaaacca agaacgtgta gcagatgcct acgttgcagg acgttacggt      540
tcatgactg ctgctaaaaa cttctggctt aacaatggct ggtat                      585


SeqID 7
atgaataaga aaaaaatgat tttaacaagt ctagccagcg tcgctatctt aggggctggt      60
tttgttacgt ctcagcctac tttttgtaaga gcagaagaat ctccacaagt tgtcgaaaaa    120
tcttcattag agaagaaata tgaggaagca aaagcaaaag ctgatactgc caagaaagat    180
tacgaaacgg ctaaaaagaa agcagaagac gctcagaaaa agtatgaaga tgatcagaag    240
agaactgagg agaaagctcg aaaagaagca gaagcatctc aaaaattgaa tgatgtggcg    300
cttgttgttc aaaatgcata taaagagtac cgagaagttc aaaatcaacg tagtaaatat    360
aaatctgacg ctgaatatca gaaaaaatta acagaggtcg actctaaaat agagaaggct    420
aggaaagagc aacaggactt gcaaaataaa tttaatgaag taagagcagt tgtagttcct    480
gaaccaaatg cgttggctga gactaagaaa aaagcagaag aagctaaagc agaagaaaaa    540
gtagctaaga gaaaatatga ttatgcaact ctaaaggtag cactagcgaa gaaagaagta    600
gaggctaagg aacttgaaat tgaaaaactt caatatgaaa tttctacttt ggaacaagaa    660
gttgctactg ctcaacatca agtagataat ttgaaaaaac ttcttgctgg tgcggatcct    720
gatgatggca cagaagttat agaagctaaa ttaaaaaaag gagaagctga gctaaacgct    780
aaacaagctg agttagcaaa aaaacaaaca gaacttgaaa acttcttga cagccttgat    840
cctgaaggta agactcagga tgaattagat aaagaagcag aagaagctga gttggataaa    900
aaagctgatg aacttcaaaa taaagttgct gatttagaa aagaaaattag taaccttgaa    960
atattacttg gaggggctga tcctgaagat gatactgctg ctcttcaaaa taaattagct   1020
gctaaaaaag ctgagttagc aaaaaaacaa acagaacttg aaaaacttct tgacagcctt   1080
gatcctgaag gtaagactca ggatgaatta gataagaag cagaagaagc tgagttggat   1140
aaaaaagctg atgaacttca aaataaagtt gctgatttag aaaaagaaat tagtaacctt   1200
gaaatattac ttggaggggc tgattctgaa gatgatactg ctgctcttca aaataaatta   1260
gctactaaaa aagctgaatt ggaaaaaact caaaagaat tagatgcagc tcttaatgag   1320
ttaggccctg atggagatga agaagaaact ccagcgccgg ctcctcaacc agagcaacca   1380
gctcctgcac caaaaccaga gcaaccagct ccagctccaa aaccagagca accagctcct   1440
gcaccaaaac cagagcaacc agctccagct ccaaaaccag agcaaccagc tccagctcca   1500
aaaccagagc accagctaa gccggagaaa ccagctgaag agcctactca accagaaaaa   1560
ccagccactc caaaaacagg ctggaaacaa gaaaacggta tgtggtattt ctacaatact   1620
gatggttcaa tggcaatagg ttggctccaa aacaacggtt catggtacta cctaaacgct   1680
aacggcgcta tggcaacagg ttgggtgaaa gatggagata cctggtacta tcttgaagca   1740
tcaggtgcta tgaaagcaag ccaatggttc aaagtatcag ataaatggta ctatgtcaac   1800
agcaatggcg ctatggcgac aggctggctc caatacaatg gctcatggta ctacctcaac   1860
gctaatggtg atatggcgac aggatggctc caatacaacg gttcatggta ttacctcaac   1920
gctaatggtg atatggcgac aggatggct aaagtcaacg gttcatggta ctacctaaac   1980
gctaacggtg atatggcta caggtgggct aaagtcaacg gttcatggta ctacctaaac   2040
gctaacggtt ctatggctac aggtgggtg aaagatggag ataccctggta ctatcttgaa   2100
gcatcaggtg ctatgaaagc aagccaatgg ttcaaagtat cagataaatg gtactatgtc   2160
aatggcttag gtgcccttgc agtcaacaca actgtagatg ctataaagt caatgccaat   2220
ggtgaatggg tt                                                        2232


SeqID 8
atgaaaaaaa tagttcttgt tagtctagct ttccttttg tcctggttgg ttgcggacag      60
aaaaaagaaa ctggaccagc tacaaaaaca gaaaaagata cgcttcagtc ggcattgcca     120
gttattggaa atgctgagaa gaatacagtt gtaactaaga cttggtctt gcccaagtca     180
gatgatggta gccagcagac acaaacaatt acttacaaag acaagacttt tttgagtcta    240
gctatccaac aaaaacgtcc agtctctgat gagttgaaga cttatattga ccaacatgga    300
gtggaggaaa ctcaaaaagc tcttcttgaa gcggaggaga aggataagtc tatcattgaa    360
gctcgtaaat tggcaggttt caaacttgaa acaaaactat tgagcgcaac ggaacttcaa    420
acaacgacta gttttgattt tcaagttctg gatgtcaaga aggcttccca gttggaacat    480
ctgaagaata ttggtttgga aaatctttttg aaaaatgaac caagcaaata tatttcagat    540
```

```
agattggcaa  atggcgcgac  agaacaa                                         567

SeqID 9
atgtttgaag  tagaagaatg  gctccatagt  cggattggtt  tgaatttttcg  atcaggtttg      60
ggtcgaatgc  agcaagcggt  ggatttgtta  ggaaatcctg  agcagtctta  ccctattatc     120
cacgtaacag  ggactaatgg  gaaaggatct  accattgctt  ttatgaggga  attatttatg     180
gggcaggca   aaaaagttgc  gacctttacc  tcccctcata  tcgtctctat  caatgaccga     240
atctgcatta  atgggcagcc  tatagcagac  gcagacttta  tccgtttgac  tgatcaggtc     300
aaggagatgg  agaaaacgct  tctgcaaact  cctgcccagt  tgtccttttt  tgaattgctg     360
accttggttg  cttttctttta  ttttagggag  caggaggtgg  atttggtttt  attagaagtg     420
ggaattggtg  gcttacttga  cacgaccaat  gtggtaactg  gagagtttgc  tgtcatcacc     480
tccattgggc  ttgaccatca  agaaaccttg  ggtgatagtc  tagaagcaat  tgcagagcag     540
aaagctggta  ttttcaaggc  tggtaagaag  gcagtgattg  cgaaattgcc  tccagaagct     600
aggcttgcct  gtcagaaaaa  agccgaatct  ttagctgtta  acctttatca  ggcaggtcaa     660
gatttttttaa  tgctgaatgg  tgatttttca  agctctttac  taaatctttc  acagctgaac     720
ataggcttag  aaggagtcta  tcagcaggag  aatgcagcct  ggcgttgca   aacttttctt     780
cttttatga   gagaaagaaa  ggaagctgtt  gatgaacagg  ctgtaagaaa  ggccttggaa     840
cagacccatt  gggctggtcg  cttggagcgt  attcgcccac  agatttattt  ggatggtgct     900
cataacctcc  ctgccttgac  tcgcttggct  gagtttatca  aagaaaaaga  gcaggaaggc     960
tatcgacctc  aaatcctctt  tggatccttg  aaacgtaagg  attatcaagg  gatgttgggt    1020
tatctgactg  aaaaattgcc  tcaggtggaa  ctcaaggtga  ccggcttttga  ctatcagggg    1080
gctttggacg  aaagggatgt  gacaggttac  gatatagttt  cttcttaccg  agaatttatc    1140
agcgattttg  aagaaggggc  agacgctcaa  gacttgctgt  tcgttacagg  gtctctctat    1200
tttatctcag  aagtacgggg  ctacctgctg  gaccgtgagc  agataaaat               1248

SeqID 10
gtgggaattc  gtgtttataa  accaacaaca  aacggtcgcc  gtaatatgac  ttctttggat      60
ttcgctgaaa  tcacaacaag  cactcctgaa  aaatcattgc  ttgttgcatt  gaagagcaag     120
gctggtcgta  acaacaacgg  tcgtatcaca  gttcgtcacc  aaggtggtgg  acacaaacgt     180
ttctaccgtt  tggttgactt  caaacgtaat  aaagacaacg  ttgaagcagt  tgttaaaaca     240
atcgagtacg  atccaaaccg  ttctgcaaac  atcgctcttg  tacactacac  tgacggtgtg     300
aaagcataca  tcatcgctcc  aaaaggtctt  gaagtaggtc  aacgtatcgt  ttcaggtcca     360
gaagcagata  tcaaagtcgg  aaacgctctt  ccacttgcta  acatcccagt  tggtactttg     420
attcacaaca  tcgagttgaa  accaggtcgt  ggtggtgaat  tggtacgtgc  tgctggtgca     480
tctgctcaag  tattgggttc  tgaaggtaaa  tatgttcttg  ttcgtctrca  atcaggtgaa     540
gttcgtatga  ttcttggaac  ttgccgtgct  acagttggtg  ttgtcggaaa  cgaacaacat     600
ggacttgtaa  accttggtaa  agcaggacgt  agccgttgga  aaggtatccg  cccaacagtt     660
cgtggttctg  taatgaaccc  taacgatcac  ccacacggtg  gtggtgaagg  taaagcacca     720
gttggtcgta  aagcaccatc  tactccatgg  ggcaaacctg  ctcttggtct  taaaactcgt     780
aacaagaaag  cgaaatctga  caaacttatc  gttcgtcgtc  gcaacgagaa  a              831

SeqID 11
atggctaaaa  aatcaatggt  agctagagag  gctaaacgcc  aaaaaattgt  tgaccgttat      60
gctgaaaaac  gtgctgcatt  aaaggcggca  ggggactacg  aaggtttatc  taaattacct     120
cgcaacgcct  caccgactcg  tttacataat  cgttgtaggg  ttacggggcg  cccacattca     180
gtttaccgca  aatttggtct  gagtcgtatc  gcttttcgcg  aacttgcgca  taaaggtcaa     240
attcctggtg  taacaaaagc  atcttgg                                           267

SeqID 12
atggatatta  gacaagttac  tgaaaccatc  gccatgattg  aggagcaaaa  cttcgatatt      60
agaaccatta  ccatggggat  ttctcttttg  gactgtatcg  atccagatat  caatcgtgct     120
gcggagaaaa  tctatcaaaa  aattacgaca  aaggcggcta  atttagtagc  tgttggtgat     180
gaaattgcgg  ctgagttggg  aattcctatc  gttaataagc  gtgtatcggt  gacacctatt     240
tctctgattg  gggcagcgac  agatgcgacg  gactacgtgg  ttctggcaaa  agcgcttgat     300
aaggctgcga  aagagattgg  tgtggacttt  attggtggtt  tttctgcctt  agtacaaaaa     360
ggttatcaaa  agggagatga  gattctcatc  aattccattc  ctcgcgcttt  ggctgagacg     420
gataaggtct  gctcgtcagt  caatatcggc  tcaaccaagt  ctggtattaa  tatgacggct     480
gtggcagata  tgggacgaat  tatcaaggaa  acagcaaatc  tttcagatat  gggagtggcc     540
aagttggttg  tattcgctaa  tgctgttgag  gacaatccat  ttatggcggg  tgcctttcat     600
ggtgttgggg  aagcagatgt  tatcatcaat  gtcggagttt  ctggtcctgg  tgttgtgaaa     660
cgtgctttgg  aaaaagttcg  tggacagagc  tttgatgtag  tagccgaaac  agttaagaaa     720
actgcccttta  aaatcactcg  tatcggtcaa  ttggttggtc  aaatggccag  tgagagactg     780
ggtgtggagt  ttggtattgt  ggacttgagt  ttggcaccaa  cccctgcggt  tggagactct     840
gtggcacgtg  tccttgagga  aatggggcta  gaaacagttg  gcacgcatgg  aacgacggct     900
gccttggccc  tcttgaacga  ccaagttaaa  aagggtggag  tgatggcctg  caaccaagtc     960
ggtggtttat  ctggtgcctt  tatccctgtt  tctgaggatg  aaggaatgat  tgctgcagtg    1020
caaaatggct  ctcttaattt  agaaaaacta  gaagctatga  cggctatctg  ttctgttgga    1080
ttggatatga  ttgccatccc  agaagatacg  cctgctgaaa  ctattgcggc  tatgattgcg    1140
```

```
gatgaagcag caatcggtgt tatcaacatg aaaacaacag ctgttcgtat cattcccaaa    1200
ggaaaagaag gcgatatgat tgagtttggt ggtctattag gaactgcacc cgttatgaag    1260
gttaatgggg cttcgtctgt cgacttcatc tctcgcggtg gacaaatccc agcaccaatt    1320
catagtttta aaaat                                                    1335

SeqID 13
atggtaaata cagaagtagc aagaacaaca atcaagacag aatattttgg cagccttact      60
gaaaggatga acaaatatcg agaagatgtt ttaaataaaa aaccttatat tgatgctgag     120
agagcagttc tagcaacacg cgcctatgaa cgatacaagg aacaacctaa tgtcctaaaa     180
cgtgcatata tgctgaaaga aattttggaa aatatgacta tctatattga agaagaatct     240
atgattgcgg gaaatcaagc ttcttccaat aaagatgctc ctatttttcc ggaatatacg     300
ctagaatttg ttctcaatga gttggatctt tttgaaaagc gtgatggaga tgttttctat     360
attacagaag aaacaaaaga caacttaga agtattgctc cgttttggga aaataataat      420
ttacgtgcta gagctggtgc cttattacct gaagaagtgt ctgtttatat ggaaacagga     480
ttcttcggta tggaaggtaa gatgaattct ggagatgctc acttagcagt taactatcag     540
aaacttttgc aatttggttt aagaggtttt gaagagcggg ctcgtaaagc aaaagtagct     600
ctagatttaa cagatccagc aagtattgat aaatatcatt tttacgactc tatatttatc     660
gtaatcgatg ctattaaagt atatgcaaag cgctttgttg ctcttgctaa aagtttagcc     720
gaaaatgcaa atcctaaacg taagaaagaa ttacttgaga ttgcagatat ttgctctaga     780
gtcccatatg aaccggcaac tacttttgca gaagctattc aatcagtttg gtttattcaa     840
tgtatttttac aaaattgaatc taatggccac tctctttcat atggccgttt tgatcaatat     900
atgtatccat atatgaaggc tgatttagaa agtggtaaag aaacagaaga tagcattgtt     960
gaacgtctga caaatctttg gattaagaca attacaatta ataaggttcg cagtcaatca    1020
catacatttt cttcagcagg aagtcctta tatcaaaatg ttacaattgg tggacagact    1080
cgagataaga aggatgctgt taacccatta tcttatttgg tattaaaatc agttgcacaa    1140
acccatctac cgcaacctaa tctaactgta cgttaccatg caggtttaga tgctcgtttc    1200
atgaatgagt gtattgaagt gatgaaactt ggttttggta tgcctgcatt taataatgat    1260
gagattatta ttccttcttt tattgcacaa ggagtattgg aagatgatgc ttatgattac    1320
agtgccattg gatgtgttga aacggcagtt ccaggggaaat ggggctatcg ttgcacaggt    1380
atgagttata tgaacttccc taaggttcta cttatcacga tgaatgatgg aattgatccg    1440
gcttcgggta aacggtttgc accaagcttt ggtcgtttta aggatatgaa gaactttct    1500
gaattagaaa atgcttggga taaaaacacta agatatttga cacgaatgag tgttattgtt    1560
gaaaattcta ttgattatc attggaacga gaagttcctg atattctatg ttcagcattg    1620
actgatgatt gtattggtcg tggaaaaacac cttaaagaag gtggagcagt atatgattat    1680
atatcaggat tgcaagttgg aattgcaaat ttgtcggatt cattagctgc aattaaaaaa    1740
ttggtgtttg aggaagaacg tataagccca agtcagcttt ggcatgcact ggaaacagat    1800
tatgccggag aagaaggtaa ggtcattcaa gaaatggttga ttcatgatgc acctaagtat    1860
ggtaatgatg atgattatgc tgacaaattg gttactgctg cttatgacat ttatgttgat    1920
gaaattgcta aatatcctaa tacacgttat ggaagagggc ctattggagg aattcgttat    1980
tcaggaacat cttctatctc agccaacgta gggcagggac gtggaacatt agcaactcca    2040
gatggacgca acgcgggtac accgttagca gagggttgtt caccatcaca taatatggat    2100
caacacggcc ctacatctgt tttaaaatct gtttcaaaat taccaacaga tgaaatcgta    2160
ggtggggttc tcttaaatca gaaagtaaat cctcaaacgt tagccaaaga agaagataaa    2220
ttaaaactaa ttgctttgtt acgaacattc tttaatcgtt tacatgggta ccatattcaa    2280
tacaatgttg tttccagaga gacgctgatt gacgctcaga aacatcctga aaaacacaga    2340
gacttaattg ttcgtgttgc aggatactct gcattcttca atgttctttc taaggcaacc    2400
caagatgaca ttataggacg tactgagcat actttg                             2436

SeqID 14
atgtcacaag cacaatatgc aggtactgga cgtcgtaaaa acgctgttgc acgcgttcgc      60
cttgttccag gaactggtaa aatcactgtt aacaaaaaag atgttgaaga gtacatccca     120
cacgctgacc ttcgtcttgt catcaaccaa ccattcgcag ttacttcaac tgtaggttca     180
tacgacgttt tcgttaacgt tataggtggt ggatacgctg gtcaatcagg agctatccgt     240
cacggtatcg ctcgtgccct tcttcaagta gacccagact tccgcgattc attgaaacgc     300
gcaggacttc ttacacgtga ctcacgtaaa gttgaacgta agaaaccagg tcttaagaaa     360
gctcgtaaag catcacaatt tagtaaacgt                                    390

SeqID 15
ttggagaaga aactgaccat aaaagacatt gcggaaatgg ctcagacctc gaaaacaacc      60
gtgtcatttt acctaaacgg gaaatatgaa aaaatgtccc aagagacacg tgaaaagatt     120
gaaaaagtta ttcatgaaac aaattacaaa ccgagcattg ttgcgcgtag cttaaactcc     180
aaacgaacaa aattaatcgg tgttttgatt ggtgatatta ccaacagttt ctcaaaccaa     240
attgttaagg gaattgagga tatcgccagc cagaatggct accaggtaat gataggaaat     300
agtaattaca gccaagagag tgaggaccgg tatattgaaa gcatgcttct cttgggagta     360
gacggcttta ttattcagcc gacctctaat ttccgaaaat attctcgtat catcgatgag     420
aaaaagaaga aaatggtctt tttgatagt cagctctatg aacaccggac tagctgggtt     480
aaaaccaata actatgatgc cgtttatgac atgacccagt cctgtatcga aaaaggttat     540
gaacattttc tcttgattac agcggatacg agtcgtttga gtactcggat tgagcgggca     600
```

```
agtggttttg tggatgcttt aacagatgct aatatgcgtc acgccagtct aaccattgaa    660
gataagcata cgaatttgga acaaattaag gaatttttac aaaaagaaat cgatcccgat    720
gaaaaaactc tggtatttat ccctaactgt tgggccctac ctctagtctt taccgttatc    780
aaagagttga attataactt gccacaagtt gggttgattg gttttgacaa tacggagtgg    840
acttgctttt cttctccaag tgtttcgacg ctggttcagc cctcctttga ggaaggacaa    900
caggctacaa agattttgat tgaccagatt gaaggtcgca atcaagaaga aaggcaacaa    960
gtcttggatt gtagtgtgaa ttggaaagag tcgactttc                          999
```

SeqID 16
```
atgaataaag gattatttga aaaacgttgt aaatatagta ttcggaaatt ttcattaggt     60
gttgcttctg ttatgattgg agctgcattc tttgggacaa gtccggttct tgcagatagc    120
gtgcagtctg gttccacggc gaacttacca gctgatttag ctactgctct tgcaacagca    180
aaagagaatg atgggcgtga ttttgaagcg cctaaggtgg gagaagacca aggttctcca    240
gaagttacag atggacctaa gacagaagaa gaactattag cacttgaaaa agaaaaaccg    300
gctgaagaaa aaccaaaaga ggataaacct gcagctgcta aacctgaaac acctaagacg    360
gtaaccctga aatggcaaac ggtagcgaat aaagagcaac agggaacagt cactatccga    420
gaagaaaaag gtgtccgcta caaccaacta tcctcaactg ctcaaaatga taacgcaggc    480
aaaccagccc tgtttgaaaa gaagggcttg accgttgatg ccaatggaaa tgcaactgtt    540
gatttaacct tcaaagatga ttctgaaaag gcaaatcac gcttttggtgt cttttttgaaa    600
tttaaagata ccaagaataa tgttttttgtc ggttatgaca aggatggctg gttctgggag    660
tataaatctc aacaactag cacttggtat agaggtagtc gtgttgctgc tcctgaaaca    720
ggatcaacaa accgtctctc tatcactctc aagtcagacg gtcagctaaa tgccagcaat    780
aatgatgtca atctctttga cacagtgact ctaccagctg cggtcaatga ccatcttaaa    840
aatgagaaga agattcttct caaggcgggc tcttatgacg atgagcgaac agttgttagc    900
gttaaaacgg ataaccaaga ggggtaaaa acagaggata ccctgctagg aaagaaaca    960
ggtcctgaag ttgatgatag caaggtgact tatgacacga ttcagtctaa ggtcctcaaa   1020
gcagtgattg accaagcctt ccctcgtgtc aaggaataca gcttgaacgg gcatactttg   1080
ccaggacagg tgcaacagtt caaccaagtc tttatcaata accaccgaat caccccctgaa   1140
gtcacttata agaaaatcaa tgagacaaca gcagagtact tgatgaagct cgcgatgat   1200
gctcacttaa tcaatgcgga aatgacagta cgcttgcaag ttgtagacaa tcaattgcac   1260
tttgatgtga ctaagattgt caaccacaat caagtcactc caggtcaaaa gattgatgac   1320
gaaagcaaac tactttcttc tattagtttc ctcggcaatg ctttagtctc tgtttctagt   1380
aatcaaactg gtgctaagtt tgatggggca accatgtcaa acaatacgta tgtcagcgga   1440
gatgatcata tcgatgtaac caatccaatg aaggatttgg ctaagggtta catgtatgga   1500
tttgtttcta cagataagct tgctgctggt gtttggagta actctcaaaa cagctatggt   1560
ggtggttcga atgactggac tcgtttgaca gcttataaag aaacagtcgg aaatgccaac   1620
tatgtaggaa tccacagctc tgaatggcaa tgggaaaaag cttataaggg cattgttttc   1680
ccagaataca cgaaggaact tccaagtgct aaggttgtta tcactgaaga tgccaatgca   1740
gacaagaacg ttgattggca agatggtgcc attgcttatc gtagcattat gaacaatcct   1800
caaggttggg aaaaagttaa ggatatcaca gcttaccgta tcgcgatgaa ctttggttct   1860
caagcacaaa acccattcct tatgaccttg gatggtatca agaaaatcaa tctccataca   1920
gatggtcttg ggcaaggtgt tctccttaaa ggatatggta gcgaaggcca tgactctggt   1980
cacttgaact atgctgatat tggtaagcgt atcggtggtg tcgaagactt caagaccccta   2040
attgagaagg ctaagaaata tggagctcat ctaggtatcc acgttaacgc ttcagaaact   2100
tatcctgagt ctaaatactt caatgaaaaa attctccgta agaatccaga tggaagctat   2160
agctatggtt ggaactggct agatcaaggt atcaacattg atgctgccta tgacctagct   2220
catggtcgtt tggcacgttg ggaagatttg aagaaaaaac ttggtgacgg tctcgacttt   2280
atctatgtgg acgtttgggg taatggtcaa tcaggtgata acggtgcctg ggctacccac   2340
gttcttgcta aagaaattaa caaacaaggc tggcgctttg cgatcgagtg gggccatggt   2400
ggtgagtacg actctacctt ccatcactgg gcagctgact tgacctacgg tggctacacc   2460
aataaaggta tcaacagtgc catcacccgc tttatccgta accaccaaaa agatgcttgg   2520
gtaggggact acagaagtta tggtggtgca gccaactatc cactgctagg tggctacacgc   2580
atgaaagact ttgaaggctg gcaggaaga agtgactaca atggctatgt aaccaactta   2640
tttgcccatg acgtcatgac taagtacttc caacacttca ctgtaagtaa atgggaaaat   2700
ggtacaccgg tgactatgac cgataacggt agcacctata atggactcc agaaatgcga   2760
gtggaattgg tagatgctga caataataaa gtagttgtaa ctcgtaagtc aaatgatgtc   2820
aatagtccac aatatcgcga acgtacagta acgctcaacg gacgtgtcat ccaagatggt   2880
tcagcttact tgactccttg gaactgggat gcaaatggta agaaactttc tactgataag   2940
gaaaagatgt actacttcaa tacgcaggcc ggtgcaacaa cttggaccct tccaagcgat   3000
tgggcaaaga gcaaggttta cctttacaag ctaactgacc aaggtaagac agaagagcaa   3060
gaactaactg taaaagatag taaaattacc ctagatcttc tagcaaatca accatacgct   3120
ctctatcgtt cgaaacaaac taatcctgaa atgtcatgga gtgaaggcat gcacatctat   3180
gaccaaggat ttaatagcgg tacccttgaaa cattggacca tttcaggcga tgcttctaag   3240
gcagaaattg tcaagtctca aggggcaaac gatatgcttc gtattcaagg aaacaaagaa   3300
aaagttagtc tcactcagaa attaactggc ttgaaaccaa ataccaagta tgccgtttat   3360
gttggtgtag ataaccgtag taatgccaag gcaagtatca ctgtgaatac tggtgaaaaa   3420
gaagtgacta cttataccaa taagtctctc gcgctcaact atgttaaggc ctacgcccac   3480
aatacacgtc gtgacaatgc tacagttgac gatacaagtt acttccaaaa catgtacgcc   3540
```

```
ttctttacaa ctggagcgga cgtctcaaat gttactctga cattgagtcg tgaagctggt   3600
gatcaagcaa cttactttga tgaaattcgt acctttgaaa acaattcaag catgtacgga   3660
gacaagcatg atacaggtaa aggcaccttc aagcaagact ttgaaaatgt tgctcagggt   3720
atcttcccat ttgtagtggg tggtgtcgaa ggtgttgaag ataaccgcac tcacttgtct   3780
gaaaaacaca atccatatac acaacgtggt tggaatggta agaaagtcga tgatgttatc   3840
gaaggaaatt ggtcactcaa gacaaatgga ctagtgagcc gtcgtaactt ggtttaccaa   3900
accatcccac aaaacttccg ttttgaagca ggtaagacct accgtgtaac ctttgaatac   3960
gaagcaggat cagacaatac ctatgctttt gtagtcggta agggagaatt ccagtcaggt   4020
cgtcgtggta ctcaagcaag caacttggaa atgcatgaat tgccaaatac ttggacagat   4080
tctaagaaag ccaagaaggc aaccttcctt gtgacaggtg cagaaacagg cgatacttgg   4140
gtaggtatct actcaactgg aaatgcaagt aatactcgtg gtgattctgg tggaaatgcc   4200
aacttccgtg gttataacga cttcatgatg gataatcttc aaatcgaaga aattaccccta   4260
acaggtaaga tgttgacaga aaatgctctg aagaactact tgccaacggt tgccatgact   4320
aactacacca aagagtctat ggatgctttg aaagaggcgg tctttaacct cagtcaggcc   4380
gatgatgata tcagtgtgga agaagcgcgt gcagagattg ccaagattga agctttgaag   4440
aatgctttgg ttcagaagaa gacggctttg gtagcagatg actttgcaag tcttacagct   4500
cctgctcagg ctcttgcaaat gcctttgatg gcaatgtgtc tagtctatgg   4560
catacatctt ggaatggtgg agatgtaggc aagcctgcaa ctatggtctt gaaagaacca   4620
actgaaatca caggacttcg ctatgttccg cgtggatcag gttcaaatgg taacttgcga   4680
gatgtgaaac ttgttgtgac agatgagtct ggcaaggagc ataccttttac tgcaactgat   4740
tggccaaata acaacaaacc aaaaagatatt gacttggta agacaatcaa ggctaagaaa   4800
attgtcctta ctggtaccaa gacatacgga gatggtggag ataaatacca atctgcagcg   4860
gaacttatct ttactcgtcc acaggtagca gaaacacctc ttgacttgtc aggctatgaa   4920
gcagctttgg ttaaggctca gaaattaaca gacaaagaca tcaagagga agtagctagc   4980
gttcaggcaa gcatgaaata tgcgacggat aaccatctct tgacggaaag aatggtggaa   5040
tactttgcag attatctcaa ccaattaaaa gattctgta cgaaaccaga tgctccaact   5100
gtagagaaac ctgagtttaa acttagatct ttagcttccg agcaaggtaa gacgccagat   5160
tataagcaag aaatagctag accagaaaca cctgaacaaa tcttgccagc aacaggtgag   5220
agtcaatctg acacagccct catcctagca agtgttagtc tagccctatc tgctctcttt   5280
gtagtaaaaa cgaagaaaga c                                              5301
```

SeqID 17

```
atgaacaaac caacgattct gcgcctaatc aagtatctga gcattagctt cttaagcttg     60
gttatcgcag ccattgtctt aggcggagga gttttttct actacgttag caaggctcct    120
agcctatccg agagtaaact agttgcaaca acttctagta aaatctacga caataaaaat    180
caactcattg ctgacttggg ttctgaacgc cgcgtcaatg cccaagctaa tgatattccc    240
acagatttgg ttaaggcaat cgtttctatc gaagaccatc gcttcttcga ccacaggggg    300
attgatacca tccgtatcct gggagctttc ttgcgcaatc tgcaaagcaa ttccctccaa    360
ggtggatcaa ctctcacccca acagttgatt aagttgactt acttttcaac ttcgacttcc    420
gaccagacta tttctcgtaa ggctcaggaa gcttggttag cgattcagtt agaacaaaaa    480
gcaaccaagc aagaaatctt gacctactat ataaataagg tctacatgtc taatgggaac    540
tatggaatgc agacagcagc tcaaaactac tatggtaaag acctcaataa tttaagttta    600
cctcagttag ccttgctggc tggaatgcct caggcaccaa accaatatga ccccctattca    660
catccagaag cagcccaaga ccgccgaaac ttggtcttat ctgaaatgaa aaatcaaggc    720
tacatctctg ctgaacagta tgagaaagca gtcaatacac caattactga tggactacaa    780
agtctcaaat cagcaagtaa ttaccctgct tacatggata attacctcaa ggaagtcatc    840
aatcaagttg aagaagaaac aggctataac ctactcacaa ctgggatgga tgtctacaca    900
aatgtagacc aagaagctca aaaacatctg tgggatattt acaatacaga cgaatacgtt    960
gcctatccag acgatgaatt gcaagtcgct tctaccattg ttgatgtttc taacggtaaa   1020
gtcattgccc agctaggagc acgccatcag tcaagtaatg tttccttcgg aattaaccaa   1080
gcagtagaaa caaaccgcga ctggggatca actatgaaac cgatcacaga ctatgctcct   1140
gccttggagt acggtgtcta cgattcaact gctacatatg ttcacgatga gccctataac   1200
taccctgggt caaatactcc tgtttataac tgggataggg gctactttgg caacatcacc   1260
ttgcaatacg ccctgcaaca atcgcgaaac gtcccagccg tggaaactct aaacaaggtc   1320
ggactcaacc gcgccaagac tttcctaaat ggtctaggaa tcgactaccc aagtattcac   1380
tactcaaatg ccatttcaag taacacaacc gaatcagaca aaaaatatgg agcaagtagt   1440
gaaaagatgg ctgctgctta cgctgccttt gcaaatggtg gaacttacta taaaccaatg   1500
tatatccata aagtcgtctt tagtgatggg agtgaaaaag agttctctaa tgtcggaact   1560
cgtgccatga aggaaacgac agcctatatg atgaccgaca tgatgaaaac agtcttgact   1620
tatggaactg gacgaaatgc ctatcttgct tggctccctc aggctggtaa aacaggaacc   1680
tctaactata cagacgagga aattgaaaac cacatcaaga cctctcaatt tgtagcacct   1740
gatgaactat ttgctggcta tacgcgtaaa tattcatatgg ctgtatggac aggctgattct   1800
aaccgtctga caccacttgt aggcaatggc cttacggtcg ctgccaaagt ttaccgctct   1860
atgatgacct acctgtctga aggaagcaat ccagaagatt ggaatatacc agaggggctc   1920
tacagaaatg gagaattcgt attaaaaaat ggtgctcgtt acgtggaa ctcacctgct   1980
ccacaacaac ccccatcaac tgaaagttca agctcatcat cagatagttc aacttcacag   2040
tctagctcaa ccactccaag cacaaataat agtacgacta ccaatcctaa caataatacg   2100
caacaatcaa atacaacccc tgatcaacaa aatcagaatc ctcaaccagc acaacca      2157
```

```
SeqID 18
atgagtaaaa aaagacgaaa tcgtcataaa aaagaaggtc aagaaccgca atttgatttt        60
gatgaagcaa aagagctaac agttggtcaa gctattcgta aaaatgaaga agtggaatca       120
ggagtcttgc ctgaggattc cattttggac aagtatgtta agcaacacag agatgaaatt       180
gaggcggata agtttgcgac tcgtcaatac aaaaagagg agttcgttga aactcagagt        240
ctggatgatt taattcaaga gatgcgtgag gctgtagaga agtcagaagc ttcttcggag       300
gaagttccat cttctgaaga catcttacta ccccttgcctc tggacgatga ggagcaaggc      360
ttggatcctc tattgctaga tgatgaaaat ccaacagaaa tgactgaaga agtggaagag       420
gagcaaaacc tttctcgtct ggatcaagag gactcagaaa agaaaagtaa aaaaggcttt       480
atttttgaccg ttttggcgct tgtatcagta attatttgtg tcagtgctta ttatgtctac      540
cgtcaagtgg ctcgttcgac taaggaaatt gaaacttctc aatcaactac agccaatcaa       600
tcggatgtgg atgattttaa tacactttat gacgcctttt acacagatag caataaaacg       660
gctttgaaaa atagccagtt tgataaactg agtcaactca agactttact tgataagctg       720
gaaggtagtc gtgaacatac gcttgccaaa tctaaatatg atagtctagc aacgcaaatc       780
aaggctattc aagatgtcaa tgctcaattt gagaaaccag ctattgtgga tggtgtgttg       840
gataccaatg ccaaagccaa atcggatgct aaatttacgg atattaaaac tggaaatacg       900
gagcttgata aagtgctaga taaggctatc agtcttggta agagccagca aacaagtact       960
tctagctcaa gttcaagtca aactagcagc tcaagttcaa gtcaagcaag ttcaaatacg      1020
actagtgagc caaaaccaag tagttcaaat gagactagaa gtagtcgcag tgaagtcaat      1080
atgggtctct cgagtgcagg ggttgctgtt caaagaagtg ccagtcgtgt tgcctataat      1140
cagtctgcta ttgatgatag taataactct gcctgggatt ttgcggatgg tgtcttggaa      1200
caaattctag cgacttcacg ttcacgtggc tatatcactg gagaccaata tatccttgaa      1260
cgtgtcaata tcgttaacgg caatggttat tacaacctct acaagccaga tggaacctat      1320
ctctttaccc ttaactgtaa gacaggctac tttgtcggaa atggcgctgg tcatgcggat      1380
gacttagatt ac                                                         1392

SeqID 19
atgaagctt tgaaaaaaat gatgcaagtc gcattagcag tcttttttctt tggtttgcta        60
gctacaaata cggtatttgc gaataccaca ggtggccgat ttgttgataa ggataataga       120
aaatattatg taaaagatga tcataaagca atctattggc ataaaatag cggtaaaact        180
tactattttg gtgatattgg agagatggtt gtcggttggc aatacttaga aattcctgga       240
acaggttatc gtgataattt attcgataac caaccagtta atgaaattgg ccttcaggag       300
aagtggtact attttggaca agatggtgct ttgctagaac aaacagataa acaagtacta       360
gaggcaaaaa cgtctgaaaa tacaggaaaa gtatacggtg aacaatatcc tctatctgct       420
gaaaagagaa cttattattt tgataataat tatgctgtaa agacaggctg gatttatgaa       480
gagggtcatt ggtattattt aaataagcta ggaaattttg gcgatgattc ttacaatcca       540
ctaccaattg gtgaagttgc taagggttgg actcaagatt ttcatgttac tattgacatt       600
gatagaagca aacctgctcc atggtactac ctagatgctt caggtaagat gcttacagat       660
tggcaaaaag taaacggaaa atggtattat tttggctcct ctggttctat ggcaacaggt       720
tggaaatatg tacgaggcaa atggtattac ttagataata aaaatggtga tatgaaaaca       780
ggatggcaat accttggtaa caagtggtac tacctccgtt catcaggagc tatggtaact       840
ggctggtatc aagatggttc aacttggtac tatttagatc cttctaatgg agatatgaaa       900
ataggttgga caaaagtaaa tggaaaatgg tattatctca attcaaatgg agcaatggtt       960
acaggtagcc aaactatcga tggtaaagtt tataatttcg cctcatctgg tgagtggatt      1020

SeqID 20
atgaaaattt tgaaaaaaac tatgcaagtt ggactgacag tattttttctt tggtttgcta        60
gggaccagta cagtatttgc agatgattct gaaggatggc agtttgtcca agaaaacgga       120
agaacctact acaaaaaggg ggacctcaaa gaaacctact ggcgagtgat tgatggtaag       180
tactattatt ttgattctct atctggagag atggttgtcg gctggcaata tatcccgttt       240
ccatctaaag gtagtacaat tggtccttac ccaaatggta tcagattaga aggttttcca       300
aagtcagagt ggtactactt cgataaaaat ggagtgctac aagagtttgt tggttggaaa       360
acattagaga ttaaaactaa agacagtgtt ggaagaaagt acggggaaaa acgtgaagat       420
tcagaagata aagaagagaa gcgttattat acgaactatt actttaatca aaatcattct       480
ttagagacag gttggcttta tgatcagtct aactggtatt atctagctaa gacggaaatt       540
aatggagaaa actaccttgg tggtgaaaga cgtgcggggt ggataaacga tgattcgact       600
tggtactacc tagatccaac aactggtatt atgcaaacag gttggcaata tctaggtaat       660
aagtggtact acctccgttc ctcaggagca atggccactg ctggtatcag gaaggtacc       720
acttggtatt atttagacca cccaaatggc gatatgaaaa caggttggca aaaccttggg       780
aacaaatggt actatctccg ttcatcagga gctatggcaa ctggttggta tcaagatggt       840
tcaacttggt actacctaaa tgcaggtaat ggagacatga agacaggttg gttccaggtc       900
aatggcaact ggtactatgc ttatagctca ggtgctttgg cagtgaatac gaccgtagat       960
ggctattctg tcaactataa tggcgaatgg gttcgg                                996

SeqID 21
atggttttat ctaagtatta tggagtagcc gatggaatga atgtagaagg gaggggaagt        60
gcgaattta ttaaagataa tgtgttaatt acagcggctc acaactacta cagacatgac        120
```

```
tatgggaaag aagcggatga tatttatgtt cttccggctg ttagtccaag tcaagaacca    180
tttggaaaga tcaaagtaaa ggaagttcgt tatttgaagg aatttagaaa tttaaattct    240
aaggatgcaa gggaatatga cttggcttta ttaattctag aagagcccat tggtgcaaaa    300
ttagggactt tgggtcttcc tactagtcaa aaaaatttga caggaataac tgtgactatc    360
acaggctatc catcatataa ttttaaaatt catcaaatgt atacagataa aaaacaagtt    420
ttaagtgatg atggcatgtt cttggattac caagttgata ctttagaggg gtctagtgga    480
tctacagttt atgatgctag tcaccgtgta gtaggagtgc atactttagg agatggagct    540
aatcaaatta acagtgcagt taaattaaat gaacgaaatt tgccatttat ttattcggtt    600
cttaaaggtt actctcttga aggatggaag aaaataaatg gtagttggta ccattataga    660
caacatgata aacaaacggg ttggcaggag ataaatgata cttggtatta tttagacagt    720
tccggtaaga tgcttacaga ttggcaaaaa gtaaatggaa aatggtatta tctcaattca    780
aatggagcaa tggttacagg tagccaaact atcgatggta aagtttataa cttcgcttca    840
tctggtgagt ggatt                                                     855
```

SeqID 22
```
ttgatgaaaa aaactttttt cttactggtg ttaggcttgt tttgccttct tccactctct     60
gtttttgcca ttgatttcaa gataaactct tatcaagggg atttgtatat tcatgcagac    120
aatacggcag agtttagaca gaagatagtt taccagtttg aggaggactt taagggccaa    180
atcgtgggac ttggacgtgc tggtaagatg cctagcgggt ttgacattga ccctcatcca    240
aagattcagg ccgcgaaaaa cggtgcagaa ctagcagatg tgactagcga agtaacagaa    300
gaagcggatg gttatactgt gagagtctat aatccaggtc aggagggcga catagttgaa    360
gttgacctcg tctggaactt aaaaaaatta cttttccttt atgatgatat cgctgaatta    420
aattggcaac ctctgacaga tagttcagag tctattgaaa agtttgaatt tcatgtaagg    480
ggagacaagg gggctgaaaa actctttttc catcaggga aactttttag agagggaacg    540
attgaaaaga gtaaccttga ttatactatc cgtttagaca atcttccggc taagcgtgga    600
gttgagttgc atgcctattg gcctcggacc gattttgcta gcgctaggga tcagggattg    660
aaagggaatc gtttagaaga gtttaataag atagaagact cgattgttag agaaaaagat    720
cagagtaaac aactcgttac ttgggtcctc ccttcgatcc tttccatctc cttgttattg    780
agtgtctgct tctatttat ttatagaaga aagaccactc cttcagtcaa atatgccaaa    840
aatcatcgtc tctatgaacc accaatggaa ttagagccta tggttttatc agaagcagtc    900
tactcgacct ccttggagga agtgagtccc ttggtcaagg gagctggaaa attcaccttt    960
gatcaactta ttcaagctac cttgctagat gtgatagacc gtgggaatgt ctctatcatt   1020
tcagaaggag atgcagttgg tttgaggcta gtaaaagaag atggtttgtc aagctttgag   1080
aaagactgcc taaatctagc tttttcaggt aaaaaagaag aaactctttc caatttgttt   1140
gcggattaca aggtatctga tagtctttat cgtagagcca agtttctga tgaaaaacgg   1200
attcaagcaa gagggcttca actcaaatct tcttttgaag aggtattgaa ccagatgcaa   1260
gaaggagtga gaaaacgagt ttccttctgg gggctcccag attattatcg tcctttaact   1320
ggtggggaaa aggccttgca agtgggtatg ggtgccttga ctatcctgcc cctatttatc   1380
ggatttggtt tgttcttgta cagtttagac gttcatggct atctttacct ccctttgcca   1440
atacttggtt ttctagggtt agtttttgtct gtttttctatt attggaagct tcgactagat   1500
aatcgtgatg gtgttctaaa tgaagcggga gctgaggtct actatctctg gaccagtttt   1560
gaaaatatgt tgcgtgagat tgcacgattg gatcaggctg aactggaaag tattgtggtc   1620
tggaatcgcc tcttggtcta tgcgacctta tttggctatg cggacaaggt tagtcatttg   1680
atgaaggttc atcagattca agtggaaaat ccagatatca atctctatgt agcttatggc   1740
tggcacagta cgtttttatca ttcaacagca caaatgagcc attatgctag tgtcgcaaat   1800
acagcaagca cctactctgt atcttctgga agtggaagtt ctggtggtgg cttctctgga   1860
ggcggaggtg cggcagtat cggtgccttt                                     1890
```

SeqID 23
```
atgaaatcaa tcaacaaatt tttaacaatg cttgctgcct tattactgac agcgagtagc     60
ctgttttcag ctgcaacagt ttttgcggct gggacgacaa caacatctgt taccgttcat    120
aaactattgg caacagatgg ggatatggat aaaattgcaa atgagttaga aacaggtaac    180
tatgctggta ataaagtggg tgttctacct gcaaatgcaa aagaaattgc cggtgttatg    240
ttcgtttgga caaatactaa taatgaaatt attgatgaaa atggccaaac tctaggagtg    300
aatattgatc cacaaacatt taaactctca ggggcaatgc cggcaactgc aatgaaaaaa    360
ttaacagaag ctgaaggagc taaaatttaac acggcaaatt taccagctgc taagtataaa    420
atttatgaaa ttcacagttt atcaacttat gtcggtgaag atggagcaac cttaacaggt    480
cctaaagcag ttccaattga aattgaatta ccattgaacg atgttgtgga tgcgcatgtg    540
catccaaaaa atacagaagc aaagccaaaa attgataaag atttcaaagg taaagcaaat    600
ccagatacac cacgtgtaga taagataca cctgtgaacc accaagttgg agatgttgta    660
gagtacgaaa ttgttacaaa aattccagca cttgctaatt atgcaacagc aaactggagc    720
gatagaatga ctgaaggttt ggcattcaac aaaggtacag tgaaagtaac tgttgatgat    780
gttgcacttg aagcaggtga ttatgctcta acagaagtag caactggttt tgatttgaaa    840
ctaacagatg ctggttttagc taaagtgaat gaccaaaacg ctgaaaaaac tgtgaaaatc    900
gcttattcgg caacattgaa tgacaaagca attgtagaag taccagaatc taatgatgta    960
gcatttaact atggtaataa tccagatcac gggaatactc caaagccgaa taagccaaat   1020
gaaaacggcg atttgacatt gaccaagaca tgggtgatg ctacaggtgc accaattccg   1080
gctggagctg aagcaacgtt cgatttggtt aatgctcaga ctggtaaagt tgtacaaact   1140
```

```
gtaactttga caacagacaa aaatacagtt actgttaacg gattggataa aaatacagaa   1200
tataaattcg ttgaacgtag tataaaaggg tattcagcag attatcaaga aatcactaca   1260
gctggagaaa ttgctgtcaa gaactggaaa gacgaaaatc caaaaccact tgatccaaca   1320
gagccaaaag ttgttacata tggtaaaaag tttgtcaaag ttaatgataa agataatcgt   1380
ttagctgggg cagaatttgt aattgcaaat gctgataatg ctggtcaata tttagcacgt   1440
aaagcagata aagtgagtca agaagagaag cagtgggttg ttacaacaaa ggatgcttta   1500
gatagagcag ttgctgctta taacgctctt actgcacaac aacaaactca gcaagaaaaa   1560
gagaaagttg acaaagctca agctgcttat aatgctgctg tgattgctgc caacaatgca   1620
tttgaatggg tggcagataa ggacaatgaa aatgttgtga aattagtttc tgatgcacaa   1680
ggtcgctttg aaattacagg ccttcttgca ggtacatatt acttagaaga aacaaaacag   1740
cctgctggtt atgcattact aactagccgt cagaaatttg aagtcactgc aacttcttat   1800
tcagcgactg gacaaggcat tgagtatact gctggttcag gtaaagatga cgctacaaaa   1860
gtagtcaaca aaaaaatcac tatcccacaa acgggtggta ttggtacaat tatctttgct   1920
gtagcggggg ctgcgattat gggtattgca gtgtacgcat atgttaaaaa caacaaagat   1980
gaggatcaac ttgct                                                    1995
```

SeqID 24
```
atggcggtaa tggccgtatc cgctggtgtct cgcttgtatt atcgagtgga atcaaatcaa    60
caaattgctg actttgataa ggaaaaagca acgttggatg aggctgacat tgatgaacga   120
atgaaattgg cacaagcctt caatgactct ttgaataatg tagtgagtgg cgatccttgg   180
tcggaagaaa tgaagaaaaa agggcgagca gagtatgcac gtatgttaga aatccatgag   240
cggatggggc atgtggaaat ccccgttatt gacgtggatt tgccggttta tgctggtact   300
gctgaagagg tattgcagca aggggctggg catctagagg gaacttctct gccgatcgga   360
ggcaattcga cccatgcggt gattacggca catacaggtt tgccaacagc taagatgttt   420
acggatttga ccaaacttaa agttggggat aagtttatg tgcacaatat caaggaagtg   480
atggcctatc aagtggatca agtaaaggtg attgagccga cgaactttga tgatttattg   540
attgtaccag gtcatgatta tgtgaccttg ctgacttgta cgccatacat gatcaatacc   600
catcgtctat tggttcgggg gcatcggata ccgtacgtag cagaggttga ggaagaattt   660
attgcagcaa acaaactcag tcatctctat cgctacctgt tttatgtggc agttggtttg   720
attgtgattc ttttatggat tattcgacgc ttgcgcaaga agaaaaaaca accggaaaag   780
gctttgaagg cgctgaaagc agcaaggaag gaagtgaagg tggaggatgg acaacag       837
```

SeqID 25
```
atgtcaagga ctaaactacg agccttattg ggatacttgt tgatgttggt agcctgtttg    60
attcctattt attgttttg acagatggtg ttgcagtctc ttggacaggt gaaaggtcat   120
gctacatttg tgaaatccat gacaactgaa atgtaccaag aacaacagaa ccattctctc   180
gcctacaatc aacgcttggc ttcgcaaaat cgcattgtag atcctttttt ggcggaggga   240
tatgaggtca attaccaagt gtctgacgac cctgatgcag tctatggtta cttgtctatt   300
ccaagttgg aaatcatgga gccggtttat ttgggagcag attatcatca tttagggatg   360
ggcttggctc atgtggatgg tacaccgctg cctctggatg gtacagggat tcgctcagtg   420
attgctgggc accgtgcaga gccaagccat gtcttttcc gccatttgga tcagctaaaa   480
gttggagatg ctctttatta tgataatggc caggaaattg tagaatatca gatgatggac   540
acagagatta ttttaccgtc ggaatgggaa aaattagaat cggttagctc taaaaatatc   600
atgaccttga taacctgcga tccgattcct accttaata aacgcttatt agtgaatttt   660
gaacgagtcg ctgtttatca aaaatcagat ccacaaacag ctgcagttgc gagggttgct   720
tttacgaaag aaggacaatc tgtatccgcgt gttgcaacct ctcaatggtt gtaccgtggg   780
ctagtggtac tggcatttct gggaatcctg tttgtttttgt ggaagctagc acgtttacta   840
cgagggaaa                                                            849
```

SeqID 26
```
atgaagaatc cattttttga aagacgttgt cgttacagta ttcgtaagtt atcagtagga    60
gcctgctcgc tgatgattgg tgctgtttta tttgctggtc cagccttggc tgaagaaact   120
gcagttcctg aaaatagcgg agctaataca gagcttgttt caggagagag tgagcattcg   180
accaatgaag ctgataagca gaatgaaggg gaacatgcta gagaaaacaa gctagaaaag   240
gcagaaggag tagcgatagc atctgaaact gcttcgccag caagcaatga agctgcaact   300
actgaaactg cagaagcagc tagcgcagct aaaccagagg aaaaagcaag tgaggtggtt   360
gcagaaacac catctgcaga agcaaaacct aagtctgaca aggaaacaga agcaaagccc   420
gaagcaacta accaagggga tgagtctaaa ccagcagcag aagctaataa gactgaaaaa   480
gaagtccagc cagatgtccc taaaaataca gaaaaaacat taaaccaaa ggaaatcaaa   540
tttaattctt gggaagaatt gttaaaatgg gaaccaggtg ctcgtgaaga tgatgctatt   600
aaccgcggat ctgttgtcct cgcttcacgt cggacaggtc atttagtcaa tgaaaaagct   660
agcaaggaag caaaagttca agccttatca aacaccaatt ctaaagcaaa agaccatgct   720
tctgttggtg agaagagtt caaggcctat gcttttgact attggcaata tctagattca   780
atggtcttct gggaggtct cgtaccaact cctgacgtta ttgatgcagg tcaccgtaac   840
ggggttcctg tatacggtac actcttcttc aactggtcta atagtattgc agatcaagaa   900
agatttgctg aagctttgaa gcaagacgca gatggtagct ccaattgc ccgtaaattg   960
gtagacatgg ccaagtatta tggctatgat ggctatttca tcaaccaaga aacaactgga  1020
gatttggtta aacctcttgg agaaaagatg cgccagttta tgctctatag caaggaatat  1080
```

```
gctgctaagg taaaccatcc aatcaagtat tcttggtacg atgccatgac ctataactat   1140
ggacgttatc atcaagatgg tttgggagaa tacaactacc aattcatgca accagaagga   1200
gataaggttc cggcagataa cttctttgct aactttaact gggataaggc taaaaatgat   1260
tacactattg caactgccaa ctggattggt cgtaatcctt atgatgtatt tgcaggtttg   1320
gaattgcaac agggtggttc ctacaagaca aaggttaagt ggaatgacat tttagacgaa   1380
aatgggaaat tgcgcctttc tcttggttta tttgccccag ataccattac aagtttagga   1440
aaaactggtg aagattatca taaaaatgaa gatatcttct ttacaggtta tcaaggagac   1500
cctactggcc aaaaaccagg tgacaaagat tggtatggta ttgctaacct agttgcggac   1560
cgtacgccag cggtaggtaa tacttttact acttctttta atacaggtca tggtaaaaaa   1620
tggttcgtag atggtaaggt ttctaaggat tctgagtgga attatcgttc agtatcaggt   1680
gttcttccaa catggcgctg tggcagact tcaacagggg aaaaacttcg tgcagaatat   1740
gattttacag atgcctataa tggcggaaat tcccttaaat tctctggtga tgtagccggt   1800
aagacagatc aggatgtgag actttattct actaagttag aagtaactga gaagaccaaa   1860
cttcgtgttg cccacaaggg aggaaaaggt tctaaagttt atatggcatt ctctacaact   1920
ccagactaca aattcgatga tgcagatgca tggaaagagc taaccctttc tgacaactgg   1980
acaaatgaag aatttgatct tagctcacta gcgggtaaaa ccatctatgc agtcaaacta   2040
tttttcgagc atgaaggtgc tgtaaaagat tatcagttta acctaggaca attaactatc   2100
tcggacaatc accaagagcc acaatccgcg acaagcttta ctgtagtgaa acaatctctt   2160
aaaaatgccc aagaagcgga agcagttgtg caatttaaag gcaacaagga tgcagatttc   2220
tatgaagttt atgaaaaaga tggagacagc tggaaattac taactggctc atcttctaca   2280
actatttatc taccaaaagt tagccgctca gcaagtgctc agggtacaac tcaagaactg   2340
aaggttgtag cagtcggtaa aaatggagtt cgttcagaag ctgcaaccac aacctttgat   2400
tggggtatga ctgtaaaaga taccagccta ccaaaaccac tagctgaaaa tatcgttcca   2460
ggtgcaacag ttattgatag tactttccct aagactgaag gtggagaagg tattgaaggt   2520
atgttgaacg gtaccattac tagcttgtca gataaatggt cttcagctca gttgagtggt   2580
agtgtggata ttcgtttgac caagccacgt accgttgtta gatgggtcat ggatcatgca   2640
ggagctggtg gtgagtctgt taacgatggc ttgatgaaca ctaaagactt tgaccttttat   2700
tataaagatg cagatggtga gtggaagcta gctaaggaag tccgtggtaa caaagcacac   2760
gtgacagata tcactcttga taaaccaatc actgctcaag actggcgctt gaatgttgtc   2820
acttctgaca atggaactcc atggaaggct attcgtatct ataactggaa aatgtatgaa   2880
aagcttgata ctgagagtgt caatattccg atggccaagg ctgcagcccg ttctctaggc   2940
aataacaagg tacaagttgg cttttgcagat gtaccggctg gagcaactat taccgtttat   3000
gataatccaa attctcaaac tccgctcgca accttgaaga gcgaagttgg aggagaccta   3060
gcaagtgcac cattggattt gacaaatcaa tctggtcttc tttattatcg tacccagttg   3120
ccaggcaagg aaattagtaa tgtcctagca gtttccgttc caaaagatga cagaagaatc   3180
aagtcagtca gcctagaaac aggacctaag aaaaacaagct acgccgaagg ggaggatttg   3240
gaccttagag gtggtgttct tcgagttcag tatgaaggag gaactgagga cgaactcatt   3300
cgcctaactc acgcaggtgt atcagtatca ggttttgata cgcatcataa gggagaacag   3360
aatcttactc tccaatattt gggacaaccg gtaaatgcta atttgtcagt gactgtcact   3420
ggccaagacg aagcaagtcc gaaaactatt ttgggaattg aagtaagtca ggaaccgaaa   3480
aaagattacc tagttggtga tagcttagac ttgtctgaag gacgctttgc agtggcttat   3540
agcaatgaca ccatggaaga acattccttt actgatgagg gagttgaaat ttctggttac   3600
gatgctcaaa agactggtcg tcaaaccttg acgcttcatt accaaggcca tgaagttagc   3660
tttgatgttt tggtatctcc aaaagcagca ttgaacgatg agtacctcaa acaaaaatta   3720
gcagaagttg aagctgctaa gaacaaggtg gtctataact ttgcttcatc agaagtaaaa   3780
gaagccttct tgaaagcaat tgaagcggcc gaacaagtgt tgaaagacca tgaaactagc   3840
acccaagatc aagtcaatga ccgacttaat aaattgacag aagctcataa agctctgaat   3900
ggtcaagaga aatttacgga agaaaagaca gagcttgatc gcttaacagg tgaggttcaa   3960
gaactcttgg ctgccaaacc aaaccatcct tcaggttctg ccctagctcc gcttcttgag   4020
aaaaacaagg ccttggttga aaaagtagat ttgagtccag aagagcttac aacagcgaaa   4080
cagagtctaa aagatctggt tgctttattg aaagaagaca agccagcagt ctttttctgat   4140
agtaaaacag gtgttgaagt acacttctca aataaagaga agactgtcat caagggtttg   4200
aaagtagagc gtgttcaagc aagtgctgaa gagaagaaat actttgctgg agaagatgct   4260
catgtctttg aaatagaagg tttggatgaa aaaggtcaag atgttgatct ctcttatgct   4320
tctattgtga aaatcccaat tgaaaaagat aagaaagtta agaaagtatt tttcttacct   4380
gaaggcaaag aggcagtaga attggctttt gaacaaacgg atagtcatgt tatctttaca   4440
gcacctcact ttactcatta tgcctttgtt tatgaatctg ctgaaaaacc acaacctgct   4500
aaaccagcac cacaaaacac agtccttcca aaacctactt atcaaccgac ttctgatcaa   4560
caaaaggctc ctaaattgga agttcaagag gaaaaggttg cctttcatcg tcaagagcat   4620
gaaaatactg agatgctagt tggggaacaa cgagtcatca tacagggacg agatggactg   4680
ttaagacatg tctttgaagt tgatgaaaac ggtcagcgtc gtcttcgttc aacagaagtc   4740
atccaagaag cgattccaga aattgttgaa attggaacaa aagtaaaaac agtaccagca   4800
gtagtagcta cacaggaaaa accagctcaa aatacagcag ttaaatcaga agaagcaagc   4860
aaacaattgc caaatacagg aacagctgat gctaatgaag ccctaatagc aggcttagcc   4920
agccttggtc ttgctagttt agccttgacc ttgagacgga aaagagaaga taaagat      4977
```

SeqID 27
```
atgtcaatta catcatttgt aaaaagaatt caagatatca ctcgaaacga tgctggtgtt      60
```

```
aatggtgatg ctcaacgtat tgagcaaatg tcttggttat tattcttaaa aatttatgat    120
agccgtgaaa tggtttggga attagaagaa gacgagtatg agtcaattat cccagaggaa    180
ttaaaatggc gaaattgggc tcatgctcaa aatgggaac gggtattgac aggcgatgaa     240
ttacttgatt ttgtcaataa caagttattc aaaagagttga aagagcttga aataacttca    300
aatatgccta ttcgaaaaac gattgttaaa tcagcttttg aagatgcgaa caactatatg    360
aaaaatggcg tcttgttacg ccaagtcatc aatgttattg atgaagttga tttcaatagc    420
cctgaagatc gtcattcgtt taatgatatt tacgaaaaaa ttcttaaaga tattcaaaat    480
gctgggaact caggagaatt ttatacgcca cgtgcagcga ctgattttat tgccgaagtt    540
cttgacccaa aacttggaga atcaatggca gaccttgctt cgcggaacagg aggcttcttg    600
acttcgactc tgaaccgttt aagtagtcaa cgtaaaacta gtgaagatac caaaaaatat    660
aatacagctg tttttggtat tgaaaagaaa gcatttcctc atcttttagc agttacaaat    720
ctgtttcttc acgaaattga tgaccctaaa attgttcatg gaaatacttt ggagaaaaat    780
gttcgtgaat atacggatga tgaaaaattt gacattatta tgatgaatcc accttttgga    840
gggtcagaat tagaaacaat aaaaaataac tttccagcag aattacggag ttctgaaaca    900
gctgattat ttatggctgt cattatgtat cgtttgaaag aaaatggtcg tgttggagtt      960
attttacctg atggttttct atttggtgaa ggtgtaaaaa ctcgcttgaa acaaaaactg    1020
gtagatgagt tcaacttgca tacgattatt aggttgcctc atagtgtctt tgcaccgtat    1080
acaggaatcc atacgacaca t tcttttcttt gataaaacaa agaaaacaga agaaacttgg  1140
ttttatcgtt tagatatgcc agatggttat aaaaatttct cgaaaactaa gccgatgaag    1200
tcagaacact tcaatcctgt tcgtgactgg tgggaaaatc gtgaagagat tctggaaggt    1260
aagttctaca aatctaaatc atttacacct agtgaattgg ctgagttgaa ttataatta     1320
gaccagtgtg actttccaaa agaggaagag gaaatcttaa atcccttga gttgattcag    1380
aattatcaag cggaaagagc aacttttaaat cataagattg ataatgtatt agctgatatt  1440
ttgcagttgt tggaggacaa a                                             1461


SeqID 28
atgaacaata ctgaattta tgatcgtctg ggggtatcca aaaacgcttc ggcagacgaa     60
atcaaaaagg cttatcgtaa gctttccaaa aaatatcacc cagatatcaa caaggagcct    120
ggtgctgagg acaagtacaa ggaagttcaa gaagcctatg agactttgag tgacgaccaa    180
aaacgtgctg cctatgacca gtatggtgct gcaggcgcca atggtggttt tggtggagct    240
ggtggtttcg gcggtttcaa tggggcaggt ggcttcggtg gttttgagga tattttctca    300
agtttcttcg gcggaggcgg ttcttcgcgc aatccaaacg ctcctcgcca aggagatgat    360
ctccagtatc gtgtcaattt gacctttgaa gaagctatct cggaactga gaaggaagtt      420
aagtatcatc gtgaagctgg ctgtcgtaca tgtaatggat ctggtgctaa gccagggaca    480
agtccagtca cttgtggacg ctgtcatgga gctgttgtca ttaacgtcga tacgcagact    540
cctcttggta tgatgcgtcg ccaagtaacc tgtgatgtct gtcacggtcg aggaaaagaa    600
atcaaatatc catgtacaac ctgtcatgga acaggtcatg agaaacaagc tcatagcgta    660
catgtgaaaa tccctgctgg tgtggaaaca ggtcaacaaa ttcgcctcgc tggtcaaggt    720
gaagcaggct ttaacggtgg accttatggt gacttgtatg tagtagtttc tgtggaagct    780
agcgacaagt ttgaacgtga aggaacgact atcttctaca atctcaacct caactttgtc    840
caagcggctc ttggtgatac agtagatatt ccaactgttc acggtgatgt tgaattggtt    900
attccagagg gaactcagac tggtaagaag ttccgcctac gtagtaaggg ggcaccgagc    960
cttcgtggcg gtgcagttgg tgaccaatac gttactgtta atgtcgtaac accgacaggc    1020
ttgaacgacc gccaaaaagt agccttgaaa gaattcgcgg ctgctggtga cttgaaagta    1080
aatccaaaga aaaaaggctt ctttgaccat attaaagatg cctttgatgg agaa          1134


SeqID 29
atgaatccta atctttttag aagcgtcgag ttttatcaga gacgttacca taactatgcg     60
acagtgttaa ttatacctct ttcattacta tttactttca tcttgatttt ctcccttgtt    120
gccacaaaag aaattactgt tacttcccaa ggagaaatcg cccctacaag tgtcattgcc    180
tccattcagt caaccagtga taatcctatc ctagctaatc atttagtggc aaatcaagta    240
gttgaaaaag gggacttact catcaaatac tctgaaacaa tggaagaaag tcagaaaact    300
gcccttagcaa ctcaattaca aagacttgag aagcaaaaag aaggacttgg aattttgaaa    360
caaagcttag aaaaagcgac tgatcttttt tctggcgagg atgaatttgg ctaccataat    420
accttatga attttactaa acaatcccat gatattgaac tgggtatcac aaagactaac   .480
accgaagttt caaatcaagc taatctttcc aatagcagtt catcagctat tgaacaagaa    540
attacaaaag ttcaacaaca aattggagaa tatcaagagt tgagagatgc tatcataaat    600
aacagagcac gcttaccaac tggcaatccg caccagtcaa ttttgaatcg ttatcttgta    660
gcctcacaag acaaacaca aggaactgca gaggagccat ttttatctca aattaatcaa      720
agtattgcag gtcttgaatc atctatcgca agcctcaaaa ttcagcaagc tggtatcgga    780
agtgtagcaa cttatgataa cagtttagca accaaaaattg aagtactccg cactcagttt    840
ttacagacag cctcacagca acaactaact gtggagaatc aattaacaga attaaaagta    900
caactagatc aagccacaca gcgtttggaa aacaatacct taacctcccc aagtaaaggt    960
atcgttcatc tgaacagcga atttgaaggt aaaaatagaa ttccaactgg tacagaaatt    1020
gctcaaatat tccctgtcat cacagataca agagaagtac taatcactta ctacgtatct    1080
tctgactatc tacctctact agataaagga caaactgtaa gattaaaact ggagaagatt    1140
ggaaatcacg gcaccaccat catcggccaa cttcagacaa ttgatcaaac tcctaccaga    1200
acagagcaag gaaatctctt taaattaacc gctcttgcaa aactatctaa cgaggatagt    1260
```

```
aaactcatcc aatatggctt acaaggtcgc gtcactagtg taactacaaa gaaaacatat   1320
tttgattatt tcaaagataa aattttaaca cattctgat                          1359


SeqID 30
atgtcaaaga aactcaatcg taaaaaacaa ttacgaaatg gcctccgtcg cgcaggtgcc     60
ttttcaagta cggtgactaa ggttgtagat gagacaaaaa aagtcgtgaa gcgtgcagaa    120
cagtcagcaa gcgcagctgg taaggctgtt tctaaaaaag ttgaacaagc agtagaagct    180
accaaagagc aagctcaaaa agtagctaat tctgtagaag attttgcagc aaatttgggt    240
ggacttccac ttgatcgtgc caagactttc tatgatgaag gaatcaagtc tgcttcagat    300
ttcaaaaact ggactgaaaa agaactcctt gccttgaaag gaatcggccc agctaccatc    360
aagaaattga agaaaatgg catcaagttc aag                                  393


SeqID 31
ttgattagcc ttttcggcct tgctgctgcc aaaccagtcc aggctgatac aagtatcgca    .60
gacattcaaa aaagaggcga actggttgtc ggtgtcaaac aagacgttcc caattttggt    120
tacaaagatc ccaagaccgg tacttattct ggtatcgaaa ccgacttggc caagatggta    180
gctgatgaac tcaaggtcaa gattcgctat gtgccggtta cagcacaaac ccgcggcccc    .240
cttctagaca tgaacaggt cgatatggat atcgcgacct ttaccatcac ggacgaacgc    300
aaaaaactct acaactttac cagtccctac tacacagacg cttctggatt tttggtcaat    360
aaatctgcca aaatcaaaaa gattgaggac ctaaacggca aaaccatcgg agtcgcccaa    420
ggttctatca cccaacgcct gattactgaa ctgggtaaaa agaaaggtct gaagtttaaa    480
ttcgtcgaac ttggttccta cccagaattg attacttccc tgcacgctca tcgtatcgat    540
acctttccg ttgaccgctc tattctatct ggctacacta gtaaacggac agcactacta    600
gatgatagtt tcaagccatc tgactacggt attgttacca agaaatcaaa tacagagctc    660
aacgactatc ttgataactt ggttactaaa tggagcaagg atggtagttt gcagaaactt    720
tatgaccgtt acaagctcaa accatctagc catactgcag at                      762


SeqID 32
atgagtaata tcagtttaac aacacttggt ggtgtgcgtg agaatggaaa aaatatgtac     60
attgctgaaa ttggagagtc cattttgtt ttgaatgtag ggttaaaata tcctgaaaat    120
gaacaattag gggtcgatgt ggtgattcca aacatggatt accttttga aaatagcgac    180
cgtattgctg gggttttctt gacccacggg catgcggatg ccattggtgc tctaccgtat    240
ctcttggcag aggctaaagt tcctgtattt gggtctgagt tgaccattga gttggcaaag    300
ctctttgtca aaggaaatga tgccgttaag aaatttaatg atttccatgt cattgatgag    360
aatacggaga ttgattttgg tgggacagtg gtttccttct tccctacgac ttactccgtt    420
ccagagagtc tgggaattgt cttgaagaca tcggaaggaa gcatcgtta tacaggtgac    480
ttcaaatttg accaaacggc tagtgaatct tatgcaactg attttgctcg tttggcagag    540
attggtcgtg acggcgtcct ggctctcctc agtgattcgg ccaatgcaga cagcaatatt    600
caggtggcta gtgaaagtga agttagggat gaaattaccc aaactattgc tgactgggaa    660
ggtcgtatca tcgttgcagc tgtttccagt aatctttctc gtattcagca gatttttgac    720
gctgcggata aaacaggtcg acgtatcgtc ttgacaggat ttgatattga aaatatcgtc    780
cgcacagcga ttcgtcttaa gaagttgtct ttagccaacg aaattctttt gattaagcct    840
aaagatatgt ctcgctttga agaccatgag ttgattattc ttgagacagg tcgtatgggt    900
gagcctatca atggacttcg taagatgtcg attggtcgcc atcgttatgt agaaatcaag    960
gatggggacc tagtctatat tgctacggct ccgtctattg ctaaagaagc ctttgttgcg   1020
cgtgtggaaa atatgatta tcaggcaggt ggggttgtca aattgattac ccaaagttta   1080
catgtatcag ggcacggaaa tgtgcgtgat ttgcagctga tgatcaatct tttgcaacct   1140
aagtacctct tccctgtcca aggggagtat cgtgagttgg atgctcacgc taaggctgcc   1200
atggcagttg ggatgttgcc agaacgcatc ttcattccta aaaaggggac gaccatggct   1260
tacgagaatg gagactttgt tccagctgga tcggtttcag caggagatat cttgattgat   1320
gggaatgcca ttggtgatgt tggaaatgtt gttcttcgtg accgtaaggt cttgtcagag   1380
gatggaatt tcatcgtggc tattacagtc aaccgtcgtg agaagaaaat tgtggctagg   1440
gctcgtgttc acacgcgtgg atttgtttat ctcaagaaga gtcgcgatat tctccgtgaa   1500
agttcagaat tgattaacca aacggtagaa gagtatcttc aaggagatga ctttgactgg   1560
gcagatctca aaggtaaggt tcgtgacaat ctgaccaagt acctctttga tcaaaccaag   1620
cgtcgcccag ccatttttacc agtagtcatg gaagcaaaa                          1659


SeqID 33
atgaaaaaaa gtacagtatt gtcattaacc acagctgcag ttattttagc agccctatgc     60
cctaatgagg tagtcttagc agacacatct agctctgaag atgctttaaa catctctgat    120
aaagaaaaag tagcagaaaa taaagagaaa catgaaaata tccatagtgc tatggaaact    180
tcacaggatt ttaaagagaa gaaaacagca gtcattaagg aaaaagaagt tgttagtaaa    240
aatcctgtga tagacaataa cactagcaat gaagaagcaa aaatcaaaga agaaaattcc    300
aataaatccc aaggagatta tacggactca tttgtgaata aaaacacaga aaatcccaaa    360
aagaagata aagttgtcta tattgctgaa tttaaagata agaatctgg agaaaaagca    420
atcaaggaac tatccagtct taagaataca aaagtttttat atacttatga tagaattttt    480
aacggtagtg ccatagaaac aactccagat aacttggaca aaattaaaca aatagaaggt    540
atttcatcgg ttgaaagggc acaaaaagtc caacccatga tgaatcatgc cagaaaggaa    600
```

```
attggagttg aggaagctat tgattaccta aagtctatca atgctccgtt tgggaaaaat    660
tttgatggta gaggtatggt catttcaaat atcgatactg gaacagatta tagacataag    720
gctatgagaa tcgatgatga tgccaaagcc tcaatgagat ttaaaaaaga agacttaaaa    780
ggcactgata aaaattattg gttgagtgat aaaatccctc atgcgttcaa ttattataat    840
ggtggcaaaa tcactgtaga aaaatatgat gatggaaggg attattttga cccacatggg    900
atgcatattg cagggattct tgctggaaat gatactgaac aagacatcaa aaactttaac    960
ggcatagatg gaattgcacc taatgcacaa attttctctt acaaaatgta ttctgacgca   1020
ggatctgggt ttgcgggtga tgaaacaatg tttcatgcta ttgaagattc tatcaaacac   1080
aacgttgatg ttgtttcggt atcatctggt tttacaggaa caggtcttgt aggtgagaaa   1140
tattggcaag ctattcgggc attaagaaaa gcaggcattc caatggttgt cgctacgggt   1200
aactatgcga cttctgcttc aagttcttca tgggatttag tagcaaataa tcatctgaaa   1260
atgaccgaca ctggaaatgt aacacgaact gcagcacatg aagatgcgat agcggtcgct   1320
tctgctaaaa atcaaacagt tgagtttgat aaagttaaca taggtggaga aagtttaaaa   1380
tacagaaata taggggcctt tttcgataag agtaaaatca caacaaatga agatggaaca   1440
aaagctccta gtaaattaaa atttgtatat ataggcaagg ggcaagacca agatttgata   1500
ggtttggatc ttaggggcaa aattgcagta atggatagaa tttatacaaa ggatttaaaa   1560
aatgctttta aaaaagctat ggataagggt gcacgcgcca ttatggttgt aaatactgta   1620
aattactaca atagagataa ttggacagag cttccagcta tgggatatga agcggatgaa   1680
ggtactaaaa gtcaagtgtt ttcaatttca ggagatgatg gtgtaaagct atggaacatg   1740
attaatcctg ataaaaaaac tgaagtcaaa agaaataata agaagagatt taaagataaa   1800
ttggagcaat actatccaat tgatatggaa agtttaatt ccaacaaacc gaatgtaggt    1860
gacgaaaaag agattgactt taagtttgca cctgacacag acaaagaact ctataagaa    1920
gatatcatcg ttccagcagg atctacatct tgggggccaa gaatagattt acttttaaaa   1980
cccgatgttt cagcacctgg taaaaatatt aaatccacgc ttaatgttat taatggcaaa   2040
tcaacttatg gctatatgtc aggaactagt atggcgactc caatcgttgg agcttctact   2100
gtttgatta gaccgaaatt aaaggaaatg cttgaaagac ctgtattgaa aatatttaag   2160
ggagatgaca aaaatagatct tacaagtctt acaaaaattg ccctacaaaa tactgcgcga   2220
cctatgatgg atgcaacttc ttggaaagaa aaaagtcaat actttgcatc acctagacaa   2280
caggagcag gcctaattaa tgtggccaat gctttgagaa atgaagttgt agcaactttc   2340
aaaaacactg attctaaagg tttggtaaac tcatatggtt ccattctct aaagaaata    2400
aaaggtgata aaaaatactt tacaatcaag cttcacaata catcaaacag acctttgact   2460
tttaaagttt cagcatcagc gataactaca gattctctaa ctgacagatt aaaacttgat   2520
gaaacatata aagatgaaaa atctccagat ggtaagcaaa ttgttccaga aattcaccca   2580
gaaaaagtca aaggagcaaa tatccactt gagcatgata cttcactat aggcgcaaat    2640
tctagctttg atttgaatgc ggttataaat gttggagagg ccaaaaacaa aaataaattt   2700
gtagaatcat ttattcattt tgagtcagtg gaagaaatgg aagctctaaa ctccaacggg   2760
aagaaaataa acttccaacc ttctttgtcg atgcctctaa tgggatttgc tgggaattgg   2820
aaccacgaac caatccttga taaatgggct tgggaagaag ggtcaagatc aaaaacactg   2880
ggaggttatg atgatgatgg taaaccgaaa attccaggaa ccttaaataa gggaattggt   2940
ggagaacatg gtatagataa atttaatcca gcaggagtta tacaaaatag aaaagataaa   3000
aatacaacat ccctggatca aaatccagaa ttatttgctt tcaataacga agggatcaac   3060
gctccatcat caagtggttc taagattgct aacatttatc ctttagattc aaatggaaat   3120
cctcaagatg ctcaagttga aagaggatta acaccttctc cacttgtatt aagaagtgca   3180
gaagaaggat tgatttcaat agtaaataca aataaagagg gagaaaatca aagagactta   3240
aaagtcattt cgagagaaca ctttattaga ggaattttaa attctaaaag caatgatgca   3300
aagggaatca aatcatctaa actaaaagtt tggggtgact tgaagtggga tggactcatc   3360
tataatccta gaggtagaga agaaaatgca ccagaaagta aggataatca agatcctgct   3420
actaagataa gaggtcaatt tgaaccgatt gcggaaggtc aatatttcta taaatttaaa   3480
tatagattaa ctaaagatta cccatggcag gtttcctata ttcctgtaaa aattgataac   3540
accgcccta agattgtttc ggttgatttt tcaaatcctg aaaaaattaa gttgattaca   3600
aaggatactt atcataaggt aaaaagatcag tataagaatg aaacgctatt tgcgagagat   3660
caaaaagaac atcctgaaaa atttgacgag attgcgaacg aagtttggta tgctggcgcc   3720
gctcttgtta atgaagatgg agaggttgaa aaaaatcttg aagtaacttca cgcaggtgag   3780
ggtcaaggaa gaaatagaaa acttgataaa gacggaaata ccatttatga aattaaaggt   3840
gcgggagatt taaggggaaa aatcattgaa gtcattgcat tagatggttc tagcaatttc   3900
acaaagattc atagaattaa atttgctaat caggctgatg aaaaggggat gatttcctat   3960
tatctagtag atcctgatca agattcatct aaatatcaaa agcttggcga gattgcagaa   4020
tctaaatttta aaaatttagg aaatggaaaa gagggtagtc taaaaaaaga tacaactggg   4080
gtagaacatc atcatcaaga aaatgaagag tctattaaag aaaaatctag ttttactatt   4140
gatagaaata tttcaacaat tagagacttt gaaaataaag acttaaagaa actcattaaa   4200
aagaaattta gagaagttga tgattttaca agtgaaactg gtaagaacaat ggaggaatac   4260
gattataaat acgatgataa aggaaatata atagcctacg atgatgggac tgatctagaa   4320
tatgaaactg agaaacttga cgaaatcaaa tcaaaaattt atggtgttct aagtccgtct   4380
aaagatggac actttgaaat tcttggaaag ataagtaatg tttctaaaaa tgccaaggta   4440
tattatggga ataactataa atctatagaa atcaaagcga ccaagtatga tttccactca   4500
aaaacgatga catttgatct atacgctaat attaatgata ttgtggatgg attagctttt   4560
gcaggagata tgagattatt tgttaaagat aatgatcaga aaaagctga aattaaaatt   4620
agaatgcctg aaaaaattaa ggaaactaaa tcagaatatc cctatgtatc aagttatggg   4680
```

```
aatgtcatag aattagggga aggagatctt tcaaaaaaca aaccagacaa tttaactaaa    4740
atggaatctg gtaaaatcta ttctgattca gaaaaacaac aatatctgtt aaaggataat    4800
atcattctaa gaaaaggcta tgcactaaaa gtgactacct ataatcctgg aaaaacggat    4860
atgttagaag gaaatggagt ctatagcaag gaagatatag caaaaataca aaaggccaat    4920
cctaatctaa gagcccttttc agaaacaaca atttatgctg atagtagaaa tgttgaagat    4980
ggaagaagta cccaatctgt attaatgtcg gctttgaacg gctttaacat tataaggtat    5040
caagtgttta catttaaaat gaacgataaa ggggaagcta tcgataaaga cggaaatctt    5100
gtgacagatt cttctaaact tgtattattt ggtaaggatg ataaagaata cactggagag    5160
gataagttca atgtagaagc tat_aaagaa gatggctcca tgttatttat tgataccaaa    5220
ccagtaaacc tttcaatgga taagaactac tttaatccat ctaaatctaa taaaatttat    5280
gtacgaaatc cagaatttta tttaagaggt aagatttctg ataagggtgg ttttaactgg    5340
gaattgagag ttaatgaatc ggttgtagat aattatttaa tctacggaga tttacacatt    5400
gataacacta gagattttaa tattaagctg aatgttaaag acggtgacat catggactgg    5460
ggaatgaaag actataaagc aaacggattt ccagataagg taacagatat ggatggaaat    5520
gtttatcttc aaactggcta tagcgatttg aatgctaaag cagttggagt ccactatcag    5580
tttttatatg ataatgttaa acccgaagta aacattgatc ctaaggtaa tactagtatc    5640
gaatatgctg atggaaaatc tgtagtctttt aacatcaatg ataaaagaaa taatggattc    5700
gatggtgaga ttcaagaaca acatatttat ataaatggaa aagaatatac atcatttaat    5760
gatattaaac aaataataga caagacacta aacattaaga ttgttgtaaa agattttgca    5820
agaaatacaa ccgtaaaaga attcattttta aataaagata cgggagaggt aagtgaatta    5880
aaacctcata gggtaactgt gaccattcaa aatggaaaag aaatgagttc aacgatagtg    5940
tcggaagaag atttttatttt acctgtttat aagggtgaat tagaaaaagg ataccaattt    6000
gatggtttggg aaatttctgg tttcgaaggt aaaaaagacg ctggctatgt tattaatcta    6060
tcaaaagata cctttataaa acctgtattc aagaaaatag aggagaaaaa ggaggaagaa    6120
aataaaccta cttttgatgt atcgaaaaag aaagataacc cacaagtaaa ccatagtcaa    6180
ttaaatgaaa gtcacagaaa agaggattta caaagagaag agcattcaca aaaatctgat    6240
tcaactaagg atgttacagc tacagttctt gataaaaaca atatcagtag taaatcaact    6300
actaacaatc ctaataagtt gccaaaaact ggaacagcaa gcggagccca gacactatta    6360
gctgccggaa taatgtttat agtaggaatt tttcttggat tgaagaaaaa aaatcaagat    6420
```

SeqID 34
```
atggggaaag gccattggaa tcggaaaaga gtttatagca ttcgtaagtt tgctgtggga     60
gcttgctcag taatgattgg gacttgtgca gtttattag gaggaaatat agctggagaa    120
tctgtagttt atgcggatga aacacttatt actcatactg ctgagaaacc taaagaggaa    180
aaaatgatag tagaagaaaa ggctgataaa gctttggaaa ctaaaaatat agttgaaagg    240
acagaacaaa gtgaacctag ttcaactgag gctattgcat ctgagaagaa agaagatgaa    300
gccgtaactc caaaagagga aaaagtgtct gctaaaccgg aagaaaaagc tccaaggata    360
gaatcacaag cttcaaatca agaaaaaccg ctcaaggaag atgctaaagc tgtaacaaat    420
gaagaagtga atcaaatgat tgaagacagg aaagtggatt ttaatcaaaa ttggtacttt    480
aaactcaatg caaattctaa ggaagccatt aaacctgatg cagacgtatc tacgtggaaa    540
aaattagatt taccgtatga ctggagtatc tttaacgatt tcgatcatga atctcctgca    600
caaatgaag gtggacagct caacggtggg gaagcttggt atcgcaagac tttcaaacta    660
gatgaaaaag acctcaagaa aaatgttcgc cttacttttg atggcgtcta catggattct    720
caagtttatg tcaatggtca gttagtgggg cattatccaa atggttataa·ccagttctca    780
tatgatatca ccaaataccct tcaaaaagat ggtcgtgaga atgtgattgc tgtccatgca    840
gtcaacaaac agccaagtag ccgttggtat tcaggaagtg gtatctatcg tgatgtgact    900
ttacaagtga cagataaggt gcatgttgag aaaaatggga caactatttt aacaccaaaa    960
cttgaagaac aacaacatgg caaggttgaa actcatgtga ccagcaaaat cgtcaatacg   1020
gacgacaaag accatgaact tgtagccgaa tatcaaatcg ttgaacgagg tggtcatgct   1080
gtaacaggct tagttcgtac agcgagtcgt accttaaaag cacatgaatc aacaagccta   1140
gatgcgattt tagaagttga aagaccaaaa·ctctggactt ttttaaatga caaacctgcc   1200
ttgtacgaat tgattacgcg cgtttaccgt gacggtcaat tggttgatgc taagaaggat   1260
ttgtttggtt accgttacta tcactggact ccaaatgaag gtttctcttt gaatggtgaa   1320
cgtattaaat tccatggagt atccttgcac cacgaccatg gggcgcttgg agcagaagaa   1380
aactataaag cagaatatcg ccgtctcaaa caaatgaagg agatggggagt taactccatc   1440
cgtacaaccc acaaccctgc tagtgagcaa accttgcaaa tcgcagcaga actaggttta   1500
ctcgttcagg aagaggcctt tgatacgtgg tatggtggca agaaacctta tgactatgga   1560
cgtttctttg aaaaagatgc cactcaccca gaagctcgaa aggtgaaaa atggtctgat   1620
tttgacctac gtaccatggt cgaaagaggc aaaaacaacc ctgctatctt catgtggtca   1680
attggtaatg aaataggtga agctaatggt gatgccacct ctttagcaac tgtttaaacgt   1740
ttggttaagg ttatcaagga tgttgataag actcgctatg ttaccatggg agcagataaa   1800
ttccgtttcg gtaatggtag cggagggcat gagaaaattg ctgatgaact cgatgctgtt   1860
ggatttaact attctgaaga taattacaaa gcccttagag ctaagcatcc aaaatggttg   1920
atttatggat cagaaacatc ttcagctacc cgtacacgtg gaagttacta tcgccctgaa   1980
cgtgaattga acatagcaa tggacctgag cgtaattatg aacagtcaga ttatggaaat   2040
gatcgtgtgg gttgggggaa aacagcaacc gcttcatgga cttttgaccg tgacaacgct   2100
ggctatgctg acagtttat ctggacaggt acggactata ttggtgaacc tacaccatgg   2160
cacaaccaaa atcaaactcc tgttaagagc tcttactttg gtatcgtaga tacagccggc   2220
```

```
attccaaaac atgacttcta tctctaccaa agccaatggg tttctgttaa gaagaaaccg  2280
atggtacacc ttcttcctca ctggaactgg gaaaacaaag aattagcatc caaagtagct  2340
gactcagaag gtaagattcc agttcgtgct tattcgaatg cttctagtgt agaattgttc  2400
ttgaatggaa aatctcttgg tcttaagact ttcaataaaa aacaaaccag cgatgggcgg  2460
acttaccaag aaggtgcaaa tgctaatgaa ctttatcttg aatggaaagt tgcctatcaa  2520
ccaggtacct tggaagcaat tgctcgtgat gaatctggca aggaaattgc tcgagataag  2580
attacgactg ctggtaagcc agcggcagtt cgtcttatta aggaagacca tgcgattgca  2640
gcagatggaa aagacttgac ttacatctac tatgaaattg ttgacagcca ggggaatgtg  2700
gttccaactg ctaataatct ggttcgcttc caattgcatg gccaaggtca actggtcggt  2760
gtagataacg gagaacaagc cagccgtgaa cgctataagg cgcaagcaga tggttcttgg  2820
attcgtaaag catttaatgg taaaggtgtt gccattgtca aatcaactga caagcaggg  2880
aaattcaccc tgactgccca ctctgatctc ttgaaatcga accaagtcac tgtctttact  2940
ggtaagaaag aaggacaaga gaagactgtt ttggggacag aagtgccaaa agtacagacc  3000
attattggag aggcacctga aatgcctacc actgttccgt ttgtatacag tgatggtagc  3060
cgtgcagaac gtcctgtaac ctggtcttca gtagatgtga gcaagcctgg tattgtaacg  3120
gtgaaaggta tggctgacgg acgagaagta gaagctcgtg tagaagtgat tgctcttaaa  3180
tcagagctac cagttgtgaa acgtattgct ccaaatactg acttgaattc tgtagacaaa  3240
tctgtttcct atgtttttgat tgatggaagt gttgaagagt atgaagtgga caagtgggag  3300
attgccgaag aagataaagc taagttagca attccaggtt ctcgtattca agcgaccggt  3360
tatttagaag gtcaaccaat tcatgcaacc cttgtggtag aagaaggcaa tcctgcggca  3420
cctgcagtac caactgtaac ggttggtggt gaggcagtaa caggtcttac tagtcaaaaa  3480
ccaatgcaat accgcactct tgcttatgga gctaagttgc cagaagtcac agcaagtgct  3540
aaaaatgcag ctgttacagt tcttcaagca agcgcagcaa acggcatgcg tgcgagcatc  3600
tttattcagc ctaaagatgg tggccctctt caaacctatg caattcaatt ccttgaagaa  3660
gcgccaaaaa ttgctcactt gagcttgcaa gtggaaaaag ctgacagtct caaagaagac  3720
caaactgtca aattgtcggt tcgagctcac tatcaagatg gaacgcaagc tgtattacca  3780
gctgataaag taaccttctc tacaagtggt gaaggggaag tcgcaattcg taaaggaatg  3840
cttgagttgc ataagccagg agcagtcact ctgaacgctg aatatgaggg agctaaagac  3900
caagttgaac tcactatcca agccaatact gagaagaaga ttgcgcaatc catccgtcct  3960
gtaaatgtag tgacagattt gcatcaggaa ccaagtcttc agcaacagt aacagttgag  4020
tatgacaaag gtttccctaa aactcataaa gtcacttggc aagctattcc gaaagaaaaa  4080
ctagactcct atcaaacatt tgaagtacta ggtaaagttg aaggaattga ccttgaagcg  4140
cgtgcaaaag tctctgtaga aggtatcgtt tcagttgaag aagtcagtgt gacaactcca  4200
atcgcagaag caccacaatt accagaaagt gttcggacat atgattcaaa tggtcacgtt  4260
tcatcagcta aggttgcatg ggatgcgatt cgtccagagc aatacgctaa ggaaggtgtc  4320
tttacagtta atggtcgctt agaaggtacg caattaacaa ctaaacttca tgttcgcgta  4380
tctgctcaaa ctgagcaagg tgcaaacatt tctgaccaat ggaccggttc agaattgcca  4440
cttgcctttg cttcagactc aaatccaagc gacccagttt caaatgttaa tgacaagctc  4500
atttcctaca ataaccaacc agccaatcgt tggacaaact ggaatcgtac taatccagaa  4560
gcttcagtcg gtgttctgtt tggagattca ggtatcttga gcaaacgctc cgttgataat  4620
ctaagtgtcg gattccatga agaccatgga gttggtgtac cgaagtctta tgtgattgag  4680
tattatgttg gtaagactgt cccaacagct cctaaaaacc ctagttttgt tggtaatgag  4740
gaccatgtct ttaatgattc tgccaactgg aaaccagtta ctaatctaaa agcccctgct  4800
caactcaagg ctggagaaat gaaccacttt agctttgata aagttgaaac ctatgctgtt  4860
cgtattcgca tggttaaagc agataacaag cgtggaacgt ctatcacaga ggtacaaatc  4920
tttgcgaaac aagttgcggc agccaagcaa ggacaaacaa gaatccaagt tgacggcaaa  4980
gacttagcaa acttcaaccc tgatttgaca gactactacc ttgagtctgt agatggaaaa  5040
gttccggcag tcacagcaag tgttagcaac aatggtctcg ctaccgtcgt tccaagcgtt  5100
cgtgaaggtg agccagttcg tgtcatcgcg aaagctgaaa atggcgacat cttaggagaa  5160
taccgtctgc acttcactaa ggataagagc ttactttctc ataaaccagt tgctgcggtt  5220
aaacaagctc gcttgctaca agtaggtcaa gcacttgaat tgccgactaa ggttccagtt  5280
tacttcacag gtaaagacgg ctacgaaaca aaagacctga cagttgaatg ggaagaagtt  5340
ccagcggaaa atctgacaaa agcaggtcaa tttactgttc gaggccgtgt ccttggtagt  5400
aaccttgttg ctgagatcac tgtacgagtg acagacaaac ttggtgagac tctttcagat  5460
aaccctaact atgatgaaaa cagtaaccag gcctttgctt cagcaaccaa tgatattgac  5520
aaaaactctc atgaccgcgt tgactatctc aatgacggag atcattcaga aaatcgtcgt  5580
tggacaaact ggtcaccaac accatcttct aatccagaag tatcagcggg tgtgattttc  5640
cgtgaaaatg gtaagattgt agaacggact gttacacaag aaaagttca gttctttgca  5700
gatagtggta cggatgcacc atctaaactc gttttagaac gctatgtcgg tccagagttt  5760
gaagtgccaa cctactattc aaactaccaa gcctacgacg cagaccatcc attcaacaat  5820
ccagaaaatt gggaagctgt tccttatcgt gcggataaag acattgcagc tggtcatgaa  5880
atcaacgtaa catttaaagc tatcaaagcc aaagctatga gatggcgtat ggagcgtaaa  5940
gcagataaga gcggtgttgc gatgattgag atgaccttcc ttgcaccaag tgaattgcct  6000
caagaaagca ctcaatcaaa gattcttgta gatggaaaag aacttgctga tttcgctgaa  6060
aatcgtcaag actatcaaat tacctataaa ggtcaacggc caaaagtctc agttgaagaa  6120
aacaatcaag tagcttcaac tgtggtagat agtggagaag atagctttcc agtacttgtt  6180
cgcctcgttt cagaaagtgg aaaacaagtc aaggaatacc gtatccactt gactaaggaa  6240
aaaccagttt ctgagaagac agttgctgct gtacaagaag atcttccaaa aatcgaattt  6300
```

```
gttgaaaaag atttggcata caagacagtt gagaaaaaag attcaacact gtatctaggt   6360
gaaactcgtg tagaacaaga aggaaaagtt ggaaaagaac gtatctttac agcgattaat   6420
cctgatggaa gtaaggaaga aaaactccgt gaagtggtag aagttccgac agaccgcatc   6480
gtcttggttg gaaccaaacc agtagctcaa gaagctaaaa aaccacaagt gtcagaaaaa   6540
gcagatacaa aaccaattga ttcaagtgaa gctagtcaaa ctaataaagc ccagttacca   6600
agtacaggta gtgcggcaag ccaagcagca gtagcagcag gtttaactct tctaggtttg   6660
agtgcaggat tagtagttac taaaggtaaa aaagaagac                          6699
```

SeqID 35
```
atggctcctt ctgtagtgga cgcagccacc tatcactatg taaataaaga gattatttca     60
caagaagcta aagatttaat tcagacagga aagcctgaca ggaatgaagt tgtatatggt    120
ttggtgtatc aaaaagatca gttgcctcaa acaggacag aagcatctgt tttgacagct     180
tttggtttgc tgactgttgg gagcttgctt ttaatctaca agagaaagaa aattgctagc    240
gtctttctag ttggagctat gggattggta gttcttccta gtgcagggc tgtagaccca     300
gttgcgaccc tagcgctggc tagtcgagag ggtgttgttg aaatggaggg ctatcgctat    360
gttggttatc tatcaggtga catcctcaaa acgcttggct tggacactgt tttagaagaa    420
acctcagcaa aacctggaga ggtgactgtg gtcgaagttg agactcctca atcaataaca    480
aatcaggagc aagctaggac agaaaaccaa gtagtagaga cagaggaagc tccaaaagaa    540
gaagcaccta aaacagaaga aagtccaaag gaagaaccaa aatcggaggt aaaacctact    600
gacgacaccc ttcctaaagt agaagagggg aaagaagatt cagcagaacc agctccagtt    660
gaagaagtag gtggagaagt tgagtcaaaa ccagaggaaa aagtagcagt taagccagaa    720
agtcaaccat cagacaaacc agctgaggaa tcaaaagttg aacaagcagg tgaaccagtc    780
gcgccaagag aagacgaaaa ggcaccagtc gagccagaaa agcaaccaga agctcctgaa    840
gaagagaagg ctgtagagga aacaccgaaa caagaagagt caactccaga taccaaggct    900
gaagaaactg tagaaccaaa agaggagact gttaatcaat ctattgaaca accaaaagtt    960
gaaacgcctg ctgtagaaaa acaaacagaa ccaacaaaag aaccaaaagt tgaacaagca   1020
ggtgaaccag tcgcgccaag agaagacgaa caggcaccaa cggcaccagt tgagccagaa   1080
aagcaaccag aagttcctga agaagagaag gctgtagagg aaacaccgaa accagaagat   1140
aaaataaagg gtattggtac taaagaacca gttgataaaa gtgagttaaa taatcaaatt   1200
gataaagcta gttcagtttc tcctactgat tattctacag caagttacaa tgctcttgga   1260
cctgttttag aaactgcaaa aggtgtctat gcttcagagc ctgtaaaaca gcctgaggta   1320
aatagcgaga caaataaact taaaacggct attgacgctc taaacgttga taaaactgaa   1380
ttaaacaata cgattgcaga tgcaaaaaca aaggtaaaag aacattacag tgatagaagt   1440
tggcaaaacc tccaaactga agttacaaag gctgaaaaag ttgcagctaa tacagatgct   1500
aaacaaagtg aagttaacga agctgttgaa aaattaactg caactattga aaaattggtt   1560
gaattatctg aaaagccaat attaacattg actagtaccg ataagaaaat attggaacgt   1620
gaagctgttg ctaagtatac tctagaaaat caaaacaaaa caaaaatcaa atcaatcaca   1680
gctgaattga aaaaaggaga agaagttatt aatactgtag tccttacaga tgacaaggta   1740
acaacagaaa ctataagcgc tgcatttaag aacctagagt actacaaaga atacacccta   1800
tctacaacta tgatttacga cagaggtaac ggtgaagaaa ctgaaactct agaaaatcaa   1860
aatattcaat tagatcttaa aaaagttgag cttaaaaata ttaaacgtac agatttaatc   1920
aaatacgaaa atggaaaaga aactaatgaa tcactgataa caactattcc tgatgataag   1980
agcaattatt atttaaaaat aacttcaaat aatcagataaa ctacattact agctgttaaa   2040
aatatagaag aaactacggt taacggaaca cctgtatata aagttacagc aatcgcagac   2100
aatttagtct ctagaactgc tgataataaa tttgaagaag aatacgttca ctatattgaa   2160
aaacctaaag tccacgaaga taatgtatat tataatttca aagaattagt ggaagctatt   2220
caaaacgatc cttcaaaaga atatcgtctg ggacaatcaa tgagcgctag aaatgttgtt   2280
cctaatggaa aatcatatat cactaaagaa ttcacaggaa aactttaag ttctgaagga    2340
aaacaatttg ctattactga attggaacat ccattattta atgtgataac aaacgcaacg   2400
ataaataatg tgaattttga aaatgtagag atagaacgtt ctggtcaaga taatattgca   2460
tcattagcca atactatgaa aggttcttca gttattacaa atgtcaaaat tacaggcaca   2520
ctttcaggtc gtaataatgt tgctggattt gtaaataata tgaatgatgg aactcgtatt   2580
gaaaatgttg ctttctttgg caaactacac tctacaagtg gaaatggctc tcatacaggg   2640
ggaattgcag gtacaaacta tagaggaatt gttagaaaag catatgttga tgctactatt   2700
acaggaaaca aaacacgcgc cagcttgtta gttcctaaag tagattatgg attaactcta   2760
gaccatctta ttggtacaaa agctctccta actgagtcgg ttgtaaaagg taaaatagat   2820
gtttcaaatc cagtagaagt tggagcaata gcaagtaaga cttggcctgt aggtacggta   2880
agtaattctg tcagctatgc taagattatc cgtggagagg agttattcgg ctctaacgac   2940
gttgatgatt ctgattatgc tagtgctcat ataaaagatt tatatgcggt agagggatat   3000
tcgtcaggta atagatcatt taggaaatct aaaacatta ctaaattaac taaagaacaa    3060
gctgatgcta aagttactac tttcaatatt actgctgata aattagaaag tgatctatct   3120
cctcttgcaa aacttaatga agaaaaagcc tattctagta ttcaagatta taacgctgaa   3180
tataaccaag cctataaaaa tcttgaaaaa ttaataccat tctacaataa agattatatt   3240
gtatatcaag gtaataaatt aaataaagaa caccatctaa atactaaaga agttctttct   3300
gttaccgcga tgaacaacaa tgagtttatc acaaacctag atgaagctaa taaaattatt   3360
gttcactatg cggacggtac aaaaagattac tttaacttgt cttctagcag tgaaggttta   3420
agtaatgtaa aagaatatac tataactgac ttaggaatta aatatacacc taatatcgtt   3480
caaaaagata acactactct tgttaatgat ataaatctaa ttttagaatc agtagagctt   3540
```

```
cagtctcaaa cgatgtatca gcatctaaat cgattaggtg actatagagt taatgcaatc     3600
aaagatttat atttagaaga aagcttcaca gatgttaaag aaaacttaac aaacctaatc     3660
acaaaattag ttcaaaacga agaacatcaa ctaaatgatt ctccagctgc tcgtcaaatg     3720
attcgtgata aagtcgagaa aaacaaagca gctttattac taggtttaac ttacctaaat     3780
cgttactatg gagttaaatt tggtgatgtt aatattaaag aattaatgct attcaaacca     3840
gatttctatg gtgaaaaagt tagcgtatta gacagattaa ttgaaatcgg ttctaaagag     3900
aacaacatta aaggttcacg tacattcgac gcattcggtc aagtattggc taaatatact     3960
aaatcaggta atttagatgc atttttaaat tataatagac aattgttcac aaatatagac     4020
aatatgaacg attggtttat tgatgctaca gaagaccatg tctacatcgc agaacgcgct     4080
tctgaggtcg aagaaattaa aaattctaaa catcgtgcat tcgataattt aaaacgaagt     4140
caccttagaa atactatact cccactactg aatattgata aagcacatct ttatttaatt     4200
tcaaattata atgcaattgc ctttggtagt gcagagcgat taggtaaaaa atcattagaa     4260
gatattaaag atatcgttaa caaagctgca gatggttata gaaactatta tgatttctgg     4320
tatcgtctag cgtctgataa cgttaaacaa cgactactaa gagatgctgt tattcctatt     4380
tgggaaggtt ataacgctcc tggtggatgg gttgaaaaat atggccgcta taataccgac     4440
aaagtatata ctcctcttag agaattcttt ggtcctatgg ataagtatta taattataat     4500
ggaacaggag cttatgctgc tatatatcct aactctgatg atattagaac tgatgtaaaa     4560
tatgttcatt tagaaatggt tggtgaatac ggtatttcag tttacacaca tgaaacaaca     4620
cacgtcaacg accgtgcgat ttacttaggt ggctttggac accgtgaagg tactgatgct     4680
gaagcatatg ctcagggtat gctacaaact cctgttactg gtagtggatt tgatgagttt     4740
ggttctttag gtattaatat ggtatttaaa cgcaaaaatg atgggaatca gtggtatatt     4800
acagatccaa aaactctaaa aacacgagaa gatattaata gatatatgaa gggttataat     4860
gacactttaa ctcttcttga tgaaattgag gctgaatctg tgatttctca acaaaataaa     4920
gatttaaata gtgcatggtt caaaaaaata gatagagaat accgtgataa caataaatta     4980
aatcaatggg ataaaattcg aaatctaagt caagaagaga aaatgaatt aaatattcaa     5040
tctgttaatg atttagttga tcaacaatta atgactaatc gcaatccagg taatggtatc     5100
tataaacccg aagcaattag ctataacgat caatcacctt atgtaggtgt tagaatgatg     5160
accggtatct acggaggtaa tactagtaaa ggtgctcctg gagctgtttc attcaaacat     5220
aatgctttta gattatgggg ttactacgga tacgaaaatg ggttcttagg ttatgcttca     5280
aataaatata aacaacaatc taaaacagat ggtgagtctg ttctaagtga tgaatatatt     5340
atcaagaaaa tatctaacaa tacatttaat actattgaag aatttaaaaa agcttacttc     5400
aaagaagtta aagataaagc aacgaaagga ttaacaacat tcgaagtaaa tggttcttcc     5460
gtttcatcat acgatgattt actgacattg tttaaagaag ctgttaaaaa agatgccgaa     5520
actcttaaac aagaagcaaa cggtaataaa acagtatcta tgaataatac agttaaatta     5580
aaagaagctg tttataagaa acttcttcaa caaacaaata gctttaaaac ttcaatcttt     5640
aaa                                                                    5643

SeqID 36
atgaataaac gtctattttc aaaaatgagt ctggtgacgt tgccaatttt agccttgttt       60
tcacaatcag ttttggcgga agaaaacatc catttttcga gctgtaagga agcttgggcg      120
aatggctatt cggatattca cgagggagaa cctggttatt ctgccaagtt agaccgtgat      180
catgatggtg tggcttgcga attgaaaaat gctcctaagg gtgcttttaa agcaaaacag      240
tcaacggcta ttccaaatcaa cacaagttca gcaacaacaa gtggttgggt taagcaggac      300
ggcgcttggt actactttga tggaaatgga aatctagtga aaaatgcatg gcagggaagc      360
tattacctga aagctgatgg taaaatggca cagagtgaat ggatttatga ctcttcttat      420
caagcttggt attatttgaa atcagatggt tcttatgcaa aaaatgcatg gcaaggagct      480
tattacctta aatcaaacgg taaaatggca caaggtgagt gggtttatga ttcttcttac      540
caagcatggt attacttgaa atcagatggt tcatatgctc gcaatgcatg gcaaggaaac      600
tactatttga aatcagatgg taaaatggct aaaggtgaat gggtttatga tgccacctat      660
caagcttggt attatttgac atcagatggt tcttatgctt acagtacatg gcaaggaaat      720
tactatctaa aatcagatgg taaaatggct gtcaatgaat gggttgatgg tggacgttat      780
catgttggcg ctgacggagt tggaaggaa gttcaagcaa gtacagcttc ttctagtaat      840
tatagcaata gtgaatattc tgctgcttta ggaaaggcaa aaagttataa ttcgttattc      900
cacatgtcaa aaaaacgtat gtatagacaa ttaacttctg attttgataa attttcaaat      960
tatgcagctc aatatgccat tgatcattta gatgat                                996

SeqID 37
atgaaagtaa tagatcaatt taaaaataag aaagtccttg ttttaggttt ggccaagtct       60
ggtgaatctg cagctcgttt gttggacaag ctaggtgcca ttgtgacagt aaatgatggg      120
aacctttcg aggacaatcc agctgcccaa agtttgctgg aagaagggat caaggtcatt      180
caggtggcc atcctttgga actcttggat gaagagtttg cccttatggt gaaaaatcca      240
gtatcccct acaacaatcc catgattgaa aaggctttgg ccaaggaat tccagtcttg      300
ctgaggtgg aattggctta tttgatttca gaagcaccga ttattggtat cacaggatcg      360
acggtaaga caaccacaac gactatgatt ggggaagttt tgactgctgc tggccaacat      420
gtcttttat cagggaatat cggctatcca gctagtcagg ttgctcaaat agcatcagat      480
aggacacgc ttgttatgga acttcttct ttccaactca tgggtgttca agaattccat      540
cagagattg cggttattac caacctcatg ccaactcata tcgactacca tgggtcattt      600
cggaatatg tagcagccaa gtggaatatc cagaacaaga tgacagcagc tgatttcctt      660
```

```
gtcttgaact ttaatcaaga cttggcaaaa gacttgactt ccaagacaga agccactgtt      720
gtaccatttt caacacttga aaaggttgat ggagcttatc tggaagatgg tcaactctac      780
ttccgtggtg aagtagtcat ggcagcgaat gaaatcggtg ttccaggtag ccacaatgtg      840
gaaaatgccc ttgcgactat tgctgtagcc aagcttcgtg atgtggacaa tcaaaccatc      900
aaggaaactc tttcagcctt cggtggtgtc aaacaccgtc tccagtttgt ggatgacatc      960
aaggtgttaa aattctataa cgacagtaaa tcaactaata tcttggctac tcaaaaagcc     1020
ttgtcaggat ttgacaacag caaggtcgtc ttgattgcag gtggtttgga ccgtggcaat     1080
gagtttgacg aattggtgcc agacattact ggactcaaga agatggtcat cctgggtcaa     1140
tctgcagaac gtgtcaaacg ggcagcagac aaggctggtg tcgcttatgt ggaggcgaca     1200
gatattgcag atgcgacccg caaggcctat gagcttgcga ctcaaggaga tgtggttctt     1260
cttagtcctg ccaatgctag ctgggatatg tatgctaact ttgaagtacg tggcgacctc     1320
tttatcgaca cagtagcgga gttaaaagaa                                      1350

SeqID 38
atgaagaaaa aatttgccct atcgtttgtg gcgcttgcaa gtgtagcact tcttgcagcc       60
tgtggagaag tgaagtctgg agcagtcaac actgctggta actcagtaga ggaaaagaca      120
attaaaatcg ggtttaactt tgaagaatca ggttctttag ctgcatacgg aacagctgaa      180
caaaaaggtg cccaattggc tgttgatgaa atcaatgccg caggtggtat cgatggaaaa      240
caaatcgaag tagtcgataa agataataag tctgaaacag ctgaggctgc ttcagttaca      300
actaaccttg taacccaatc taaagtatca gcagtcgtag gacctgcgac atctggtgcg      360
actgcagctg cggtagcgaa cgctacaaaa gcaggtgttc cattgatctc accaagtgcg      420
actcaagatg gattgactaa aggtcaagat tacctctta ttggaacttt ccaagatagc       480
ttccaaggaa aaattatctc aaactatgtt tctgaaaaat aaatgctaa gaaagttgtt       540
ctttacactg acaatgccag tgactatgct aaagggattg caaaatcttt ccgcgagtca      600
tacaagggtg aaatcgttgc agatgaaact ttcgtagcag gtgacacaga cttccaagca      660
gcccttacaa aaatgaaagg gaaagacttt gatgctatcg ttgttcctgg ttactataat      720
gaggctggta aaattgtaaa ccaagcgcgt ggcatgggaa ttgacaaacc aatcgttggt      780
ggtgatggat tcaacggtga ggagtttgta caacaagcaa ctgctgaaaa agcatcaaac      840
atctacttta tctcaggctt ctcaactact gtagaagttt cagctaaagc taaagccttc      900
cttgacgctt accgtgctaa gtacaatgaa gagccttcaa catttgcagc cttggcttat      960
gattcagttc accttgtagc aaacgcagca aaaggtgcta aaaattcagg tgaaatcaag     1020
aataaccttg ctaaaacaaa agattttgaa ggtgtaactg gtcaaacaag cttcgatgca     1080
gaccacaaca cagtcaaaac tgcttacatg atgaccatga acaatggtaa agttgaagca     1140
gcagaagttg taaaaccca                                                 1158

SeqID 39
atgagtattt tagaagttaa aaatctgagt cacggttttg gtgaccgtgc aatttttgaa       60
gatgtgtcct tccgtctcct caagggagaa catatcggcc tggtcggtgc caatggtgaa      120
ggaaaatcaa ccttttatga gtatcgtgact ggtaaaatgc tgccagatga aggaaaggtt      180
gagtggtcca aatatgtgac ggctggttac ttggatcagc actctgtcct tgctgaaaga      240
cagtcggtgc gtgatgttct ccgtacggct tttgatgagc tttttcaaagc tgaagctcgt      300
atcaatgacc tctatatgaa aatggctgaa gacggcgcgg atgttgatgc tctcatggaa      360
gaagtaggag aacttcaaga ccgtctggag agtcgtgatt tctataccct ggatgctaag      420
attgacgaag tagcgcgtgc tcttggtgtt atggactttg gcatggatac ggatgtaact      480
tctttgtcag gtgggcaaag aaccaaggtg cttttggcaa aacttctcct tgaaaagcct      540
gatatcttgc tgttggacga gccgaccaac tacttggatg ctgagcatat tgattggctc      600
aagcgctatc tccaaaacta tgagaatgcc tttgttctca tttcgcacga tattccattc      660
ctcaatgacg ttattaatat tgtctatcat gtggaaaatc aacagctgac gcgttactct      720
ggtgactact accagttcca agaagtttat gctatgaaga atctcagct agaggcagcc       780
tacgaacgcc agcagaaaga gattgcagac ctcaaggact ttgtggctcg taataaagcc      840
cgtgttgcaa ctcgtaatat ggctatgtct cgtcaaaaga aattggataa gatggatatt      900
atcgaactcc aaagtgagaa accaaaacca tcctttgatt tcaaaccagc tcgtacacca      960
gggcgcttta tcttccaagc caagaacttg caaattggtt acgaccgtcc tcttactaag     1020
cctttaaatc ttaccttcga acgcaatcaa aaggttgcga ttattggtgc taatggtatt     1080
ggaaaaacaa ctctcttgaa gagtctcttg ggcattatct cgccaatcgc tggggaagtg     1140
gagcgtggag attatttaga acttggttat tttgagcagg aagtagaagg cggtaatcgc     1200
caaactcctc ttgaagctgt ctggaatgcc tttcctgccc ttaatcaagc agaagtccgt     1260
tcagcccttg ccgttgtgg tttgacaacc aaacatattg aaagccagat tcaagtatta     1320
tcaggggg agcaagccaa ggttcgtttc tgtctcttga tgaatcgtga aaacaacgtt     1380
tagtgctgg acgagccgac caaccatttg gatgtggatg caaaggatga gctcaaacgc     1440
ctctcaaag aatataggg atctatcctt atggtctgcc acgagccaga cttttatgaa      1500
tgctggatag accaaatatg ggattttaat aatttaact                           1539

SeqID 40
atgaagaaaa agaatggtaa agctaaaaag tggcaactgt atgcagcaat cggtgctgcg       60
agtgtagttg tattgggtgc tgggggggatt ttactcttta gacaaccttc tcagactgct      120
ataaagatg agcctactca tcttgttgtt gccaaggaag gaagcgtggc ctcctctgtt       180
ctattgtcag ggacagtaac agcaaaaaat gaacaatatg tttattttga tgctagtaag      240
```

```
ggtgatttag atgaaatcct tgtttctgtg ggcgataagg tcagcgaagg gcaggcttta    300
gtcaagtaca gtagttcaga agcgcaggcg gcctatgatt cagctagtcg agcagtagct    360
agggcagatc gtcatatcaa tgaactcaat caagcacgaa atgaagccgc ttcagctccg    420
gctccacagt taccagcgcc agtaggagga gaagatgcaa cggtgcaaag cccaactcca    480
gtggctggaa attctgttgc ttctattgac gctcaattgg gtgatgcccg tgatgcgcgt    540
gcagatgctg cggcgcaatt aagcaaggct caaagtcaat tggatgcaac aactgttctc    600
agtaccctag agggaactgt ggtcgaagtc aatagcaatg tttctaaatc tccaacaggg    660
gcgagtcaag ttatggttca tattgtcagc aatgaaaatt tacaagtcaa gggagaattg    720
tctgagtaca atctagccaa cctttctgta ggtcaagaag taagctttac ttctaaagtg    780
tatcctgata aaaaatggac tgggaaatta agctatattt ctgactatcc taaaaacaat    840
ggtgaagcag ctagtccagc agccgggaat aatacaggtt ctaaataccc ttatactatt    900
gatgtgacag gcgaggttgg tgatttgaaa caaggttttt ctgtcaacat tgaggttaaa    960
agcaaaacta aggctattct tgttcctgtt agcagtctag taatggatga tagtaaaaat   1020
tatgtctgga ttgtggatga acaacaaaag gctaaaaaag ttgaggtttc attgggaaat   1080
gctgacgcag aaaatcaaga aatcacttct ggtttaacga acggtgctaa ggtcatcagt   1140
aatccaacat cttccttgga agaaggaaaa gaggtgaagg ctgatgaagc aactaat      1197


SeqID 41
tcagaaacaa atcacgaaat tgattcaaat tttgcaggtc gtttaaatat cctgcgtgcg     60
ggtgttcttg atgctaacga tggaattatt tccattgctg gtgtggttat cggagttgcc    120
agtgccacga ccaatatctg gattatcttt ttatcaggtt ttacggctat cttagctggt    180
gcctttttcaa tggctggtgg agaatatgta tccgtttcaa ctccaaaaga taccgaggaa    240
gctgccgttt cgcgagaaaa actcttgcta gaccaagata gggaactagc caaaaaatcc    300
ctctatgctg cttatatcca aaatggagaa ttcaaaactt ctgcccaact cttgaccaat    360
aagatctttc ttaaaaatcc actcaaggct ctggtagagg aaaatatgtg gattgagtat    420
gaagaattta ccaatccttg gcacgctgcc atttctagct tcgttgcctt tttccttaga    480
agtttgcctc caatgctgtc agtgaccatt tttccaagtg attaccgcat ccctgctacc    540
gtccttattg tcggtgtggc ccttcttctc actggttaca caagtgctag acttggaaaa    600
gccccaacca aaacagctat gattcggaac cttgctattg gtctcttgac catgggagtt    660
accttcctgc tcggacaact tttcagcatt                                     690


SeqID 42
atgaaaaaga aattaactag tttagcactt gtaggcgctt tttaggtttt gtcatggtat     60
gggaatgttc aggctcaaga aagttcagga aataaaatcc actttatcaa tgttcaagaa    120
ggtggcagtg atgcgattat tcttgaaagc aatggacatt ttgccatggt ggatacagga    180
gaagattatg atttcccaga tggaagtgat tctcgctatc catggagaga aggaattgaa    240
acgtcttata agcatgttct aacagaccgt gtctttcgtc gtttgaagga attgggtgtc    300
caaaaacttg attttatttt ggtgacccat acccacagtg atcatattgg aaatgttgat    360
gaattactgt ctacctatcc agttgaccga gtctatctta agaaatatag tgatagtcgt    420
attactaatt ctgaacgtct atgggataat ctgtatggct atgataaggt tttacagact    480
gctgcagaaa aaggtgtttc agttattcaa aatatcacac aaggggatgc tcattttcag    540
tttggggaca tggatattca gctctataat tatgaaaaatg aaactgattc atcgggtgaa    600
ttaaagaaaa tttgggatga caattccaat tccttgatta gcgtggttgaa agtcaatggc    660
aagaaaattt accttggggg cgatttagat aatgttcatg gagcagaaga caagtatggt    720
cctctcattg aaaagttga tttgatgaag tttaatcatc accatgatac caacaaatca    780
aataccaagg atttcattaa aaatttgagt ccgagtttga ttgttcaaac ttcggatagt    840
ctaccttgga aaaatggtgt tgatagtgag tatgttaatt ggctcaaaga acgaggaatt    900
gagagaatca acgcagccag caaagactat gatgcaacag ttttttgatat tcgaaaagac    960
ggttttgtca atatttcaac atcctacaag ccgattccaa gtttttcaagc tggttggcat   1020
aagagtgcat atgggaactg gtggtatcaa gcgcctgatt ctacaggaga gtatgctgtc   1080
ggttggaatg aaaatcgaagg tgaatggtat tactttaacc aaacgggtat cttgttacag   1140
aatcaatgga aaaaatggaa caatcattgg ttctatttga cagactctgg tgcttctgct   1200
aaaaattgga agaaaatcgc tggaatctgt tattattta acaaagaaaa ccagatggaa   1260
attggttgga ttcaagataa agagcagtgg tattatttgg atgttgatgg ttctatgaag   1320
acaggatggc ttcaatatat ggggcaatgg tattactttg ctccatcagg ggaaatgaaa   1380
atgggctggg taaaagataa agaaacctgg tactatatgg attctactgg tgtcatgaag   1440
acaggtgaga tagaagttgc tggtcaacat tattatctgg aagattcagg agctatgaag   1500
caaggctggc ataaaaaggc aaatgattgg tatttctaca agacagacgg ttcacgagct   1560
gtgggttgga tcaaggacaa ggataaatgg tacttcttga agaaaatgg tcaattactt   1620
gtgaacggta agacaccaga aggttatact gtggattcaa gtggtgcctg gttagtggat   1680
gtttcgatcg agaaatctgc tacaattcaa tacaagtc attcagaaat aaaagaatcc   1740
aaagaagtag tgaaaatgca tcttgaaaat aaagaaacga gtcaacatga aagtgttaca   1800
aatttttcaa ctagtcaaga tttgacatcc tcaacttcac aaagctctga aacgagtgta   1860
aacaaatcgg aatcagaaca g                                            1881


SeqID 43
atggacttag gtcccacccaa aagaggtatt agtgtcgtgt ctcaatctta tatcaatgtt     60
atcggtgctg gtttggcagg ttctgaagca gcttaccaaa tcgcagagcg tggtattcca    120
```

```
gttaaactat atgaaatgcg tggtgtcaag tctacacccc agcataaaac agacaatttt    180
gctgagttgg tttgttccaa ttctttgcgt ggggatgctt tgacaaatgc agttggtctt    240
ctcaaggaag aaatgcgtcg cttgggttct gttatcttgg aatctgctga ggctacacgt    300
gttcctgcag gtggtgccct tgcagtggac cgtgatggtt tctctcaaat ggtgaccgaa    360
aaagttgcca accacccctt gattgaagtg gttcgtgatg aaattacaga attgccgaca    420
gatgttatta cggttatcgc tactggtcct ttgacaagtg atgccttggc tgaaaagatt    480
catgctctta atgacggtgc tggttttttat ttctacgatg cggcagcgcc tattatcgat    540
gtcaacacta tcgatatgag caaggtctac ctcaaatcac gttatgataa gggagaagcg    600
gcctacctca atgcccctat gaccaagcaa gaatttatgg atttccatga agctttggtc    660
aatgcagaag aagcaccgct tagttctttt gaaaaagaaa agtactttga aggatgtatg    720
cctatcgaag tcatggccaa acgtggcatt aaaactatgc tttatgcccc tatgaagcca    780
gtcggtcttg agtacccaga cgactataca ggacctcgtg atggagaatt taaaacacct    840
tatgcggttg tgcaacttcg tcaggataat gcagctggta gcctctacaa tattgttggt    900
ttccagaccc acctcaaatg gggagaacaa aagcgtgtct tccaaatgat tccgggtctt    960
gaaaatgcgg agtttgtccg ttatggtgtg atgcatcgca attcttacat ggattcacca   1020
aatcttcttg agcagactta ccgttctaag aaacaaccaa atctcttctt tgctggtcaa   1080
atgacgggtg tggaaggcta tgttgagtcg gcggcttcag gcttagttgc gggaattaac   1140
gcagctcgtc tcttcaagga agaaagcgag gctattttcc ccgagacgac agcgattgga   1200
agcttagctc attacattac ccatgccgac agcaaacatt tccaaccaat gaatgtcaat   1260
tttgggatca tcaaggagtt ggaaggcgag cgtatccgtg ataagaaggc tcgttatgaa   1320
aaaattgcag agcgtgccct tgccgactta gaggaatttt tgactgtc               1368


SeqID 44
atgttaatcg gaatcccaaa agaaattaaa aataacgaaa accgtgtcgc cctcacacct     60
gcaggtgttc atagcttagt tagtcgtggt catcgtgtcc ttatcgaaac aaatgctggt    120
ctcggttctg gctttactga tgctgactat caaaagcaag gagctgagat tgtcgctact    180
gctggtgaag cttgggcagc agagttggtt gtgaaagtaa aagaatcttt aagttctgaa    240
tacggttact tgcgcgacga tcttcttctc ttcacctact tgcacatggc cgctgctcca    300
gaattagcag atgctatgtt aacagcaaaa acaactgaaa ctgttcgtga caatcaagga    360
caactaccgc tcctcgttcc tatgagtgag gttgcaggtc gtatggctgt tcaaatcgga    420
gctcacttcc ttactaagca agctggtggc tctggtgttc tacttggtgg tgtaccaggt    480
gttccaaaag aaaaagtaac tatcatcggt ggtggtgtcg tcggtacaca tgctgcccgc    540
atcgcccttg gtcttggtgc tcaagtgact attttagata ttagttccaa gcgtctctca    600
gttctagaag aagtctttgg aagtcaaatt caaactctta tgtctaattc attcaacatt    660
gaagcaagtg tgagagatgc tgatgtggtg attggagcca ttctcatccc tggtgcaaaa    720
gcaccggaat tggtgacaga tgagatggtc aaacaaatgc gtccaggctc tgtatcgttg    780
acgttgctgt tgaccaaggt ggcgttatcg aaacagctga ccgtgtgaca acgcacgatg    840
aacccgtcta tgaaaaacac ggtgttctcc actatgccgt tgccaatatc cctggtgcgg    900
ttgctcgcac ttcaaccatc gccctaacca atgtcactct tccttatatc gaagctttgg    960
ctggcaaagg attcgcacaa gcaatctctg aagatgaagg cttgcgtcaa ggtgtgacta   1020
cttatcaagg ttacttgact aacctaccag ttgctcaagg acttaatcgt gactacactg   1080
atatcaatga tttagta                                                  1097


SeqID 45
atgaaaatta ataaaaaata tctagcaggt tcagtggcag tccttgccct aagtgtttgt     60
tcctatgaac ttggtcgtca ccaagctggt caggttaaga aagagtctaa tcgagtttct    120
tatatagatg gtgatcaggc tggtcaaaag gcagaaaact tgacaccaga tgaagtcagt    180
aagagggagg ggatcaacgc cgaacaaatc gtcatcaaga ttacggatca aggttatgtg    240
acctctcatg gagaccatta tcattactat aatggcaagg tcccttatga tgccatcatc    300
agtgaagagc tcctcatgaa agatccgaat tatcagttga aggattcaga cattgtcaat    360
gaaatcaagg gtggttatgt tatcaaggta gatggaaaat actatgttta ccttaaggat    420
gcagctcatg cggataatat tcggacaaaa gaagagatta aacgtcagaa gcaggaacac    480
agtcataatc acggggtgg ttctaacgat caagcagtag ttgcagccag agcccaagga    540
cgctatacaa cggatgatgg ttatatcttc aatgcatctg atatcattga agacacgggt    600
gatgcttata tcgttcctca cggcgaccat taccattaca ttcctaagaa tgagttatca    660
gctagcgagt tagctgctgc agaagcctat tggaatggga agcagggatc tcgtccttct    720
tcaagttcta gttataatgc aaatccagct caaccaagat tgtcagagaa ccacaatctg    780
actgtcactc caacttatca tcaaaatcaa ggggaaaaca tttcaagcct tttacgtgaa    840
ttgtatgcta aaccettatc agaacgccat gtggaatctg atggccttat tttcgaccca    900
gcgcaaatca caagtcgaac cgccagaggt gtagctgtcc ctcatggtaa ccattaccac    960
tttatccctt atgaacaaat gtctgaattg gaaaaacgaa ttgctcgtat tattcccctt   1020
cgttatcgtt caaaccattg ggtaccagat tcaagaccag aacaaccaag tccacaatcg   1080
actccggaac ctagtccaag tccgcaacct gcaccaaaatc ctcaaccagc tccaagcaat   1140
ccaattgatg agaaattggt caaagaagct gttcgaaaag taggcgatgg ttatgtcttt   1200
gaggagaatg gagtttctcg ttatatccca gccaaggatc tttcagcaga aacagcagca   1260
ggcattgata gcaaactggc caagcaggaa agtttatctc ataagctagg agctaagaaa   1320
actgacctcc catctagtga tcgagaattt tacaataagg cttatgactt actagcaaga   1380
attcaccaag atttacttga taataaaggt cgacaagttg attttgaggc tttggataac   1440
```

```
ctgttggaac gactcaagga tgtcccaagt gataaagtca agttagtgga tgatattctt   1500
gccttcttag ctccgattcg tcatccagaa cgtttaggaa aaccaaatgc gcaaattacc   1560
tacactgatg atgagattca agtagccaag ttggcaggca agtacacaac agaagacggt   1620
tatatctttg atcctcgtga tataaccagt gatgagggggg atgcctatgt aactccacat   1680
atgacccata gccactggat taaaaaagat agtttgtctg aagctgagag agcggcagcc   1740
caggcttatg ctaaagagaa aggtttgacc cctccttcga cagaccatca ggattcagga   1800
aatactgagg caaaaggagc agaagctatc tacaaccgcg tgaaagcagc taagaaggtg   1860
ccacttgatc gtatgcctta caatcttcaa tatactgtag aagtcaaaaa cggtagttta   1920
atcatacctc attatgacca ttaccataac atcaaatttg agtggtttga cgaaggcctt   1980
tatgaggcac ctaaggggta tactcttgag gatcttttgg cgactgtcaa gtactatgtc   2040
gaacatccaa acgaacgtcc gcattcagat aatggttttg gtaacgctag cgaccatgtt   2100
cgtaaaaata aggtagacca agacagtaaa cctgatgaag ataaggaaca tgatgaagta   2160
agtgagccaa ctcaccctga atctgatgaa aaagagaatc acgctggttt aaatccttca   2220
gcagataatc tttataaacc aagcactgat acggaagaga cagaggaaga agctgaagat   2280
accacagatg aggctgaaat tcctcaagta gagaattctg ttattaacgc taagatagca   2340
gatgcggagg ccttgctaga aaaagtaaca gatcctagta ttagacaaaa tgctatggag   2400
acattgactg gtctaaaaag tagtcttctt ctcggaacga aagataataa cactatttca   2460
gcagaagtag atagtctctt ggctttgtta aaagaaagtc aaccggctcc tatacag      2517


SeqID 46
atgaaattta gtaaaaaata tatagcagct ggatcagctg ttatcgtatc cttgagtcta     60
tgtgcctatg cactaaacca gcatcgttcg caggaaaata aggacaataa tcgtgtctct    120
tatgtggatg gcagccagtc aagtcagaaa agtgaaaact tgacaccaga ccaggttagc    180
cagaaagaag gaattcaggc tgagcaaatt gtaatcaaaa ttacagatca gggctatgta    240
acgtcacacg gtgaccacta tcattactat aatgggaaag ttccttatga tgccctcttt    300
agtgaagaac tcttgatgaa ggatccaaac tatcaactta aagacgctga tattgtcaat    360
gaagtcaagg gtggttatat catcaaggtc gatggaaaat attatgtcta cctgaaagat    420
gcagctcatg ctgataatgt tcgaactaaa gatgaaatca atcgtcaaaa acaagaacat    480
gtcaaagata atgagaaggt taactctaat gttgctgtag caaggtctca gggacgatat    540
acgacaaatg atggttatgt ctttaatcca gctgatatta tcgaagatac gggtaatgct    600
tatatcgttc ctcatggagg tcactatcac tacattccca aaagcgattt atctgctagt    660
gaattagcag cagctaaagc acatctggct ggaaaaaata tgcaaccgag tcagttaagc    720
tattcttcaa cagctagtga caataacacg caatctgtag caaaaggatc aactagcaag    780
ccagcaaata aatctgaaaa tctccagagt cttttgaagg aactctatga ttcacctagc    840
gcccaacgtt acagtgaatc agatggcctg gtctttgacc ctgctaagat tatcagtcgt    900
acaccaaatg gagttgcgat tccgcatggc gaccattacc actttattcc ttacagcaag    960
ctttctgcct tagaagaaaa gattgccaga atggtgccta tcagtggaac tggttctaca   1020
gtttctacaa atgcaaaacc taatgaagta gtgtctagtc taggcagtct ttcaagcaat   1080
ccttcttctt taacgacaag taaggagctc tcttcagcat ctgatggtta tattttaat   1140
ccaaaagata tcgttgaaga aacggctaca gcttatattg taagacatgg tgatcatttc   1200
cattacattc caaaatcaaa tcaaattggg caaccgactc ttccaaacaa tagtctagca   1260
acaccttctc catctcc aatcaatcca ggaacttcac atgagaaaca tgaagaagat   1320
ggatacggat ttgatgctaa tcgtattatc gctgaagatg aatcaggttt tgtcatgagt   1380
cacggagacc acaatcatta tttcttcaag aaggacttga cagaagagca aattaaggct   1440
gcgcaaaaac atttagagga agttaaaact agtcataatg gattagattc tttgtcatct   1500
catgaacagg attatccaag taatgccaaa gaaatgaaag atttagataa aaaaatcgaa   1560
gaaaaaattg ctggcattat gaaacaatat ggtgtcaaac gtgaaagtat tgtcgtgaat   1620
aaagaaaaaa atgcgattat ttatccgcat ggagatcacc atcatgcaga tccgattgat   1680
gaacataaac cggttggaat tggtcattct cacagtaact atgaactgtt taaaccgaa   1740
gaaggagttg ctaaaaaaga agggaataaa gtttatactg gagaagaatt aacgaatgtt   1800
gttaatttgt taaaaaatag tacgtttaat aatcaaaact ttactctagc caatggtcaa   1860
aaacgcgttt ctttagttt tccgcctgaa ttggagaaaa aattaggtat caatatgcta   1920
gtaaaattaa taacaccaga tggaaaagta ttggagaaag tatctggtaa agtatttgga   1980
gaaggagtag ggaatattgc aaactttgaa ttagatcaac cttatttacc aggacaaaca   2040
tttaagtata ctatcgcttc aaaagattat ccagaagtaa gttatgatgg tacatttaca   2100
gttccaacct ctttagctta caaaatggcc agtcaaacga ttttctatcc tttccatgca   2160
ggggatactt atttaagagt gaaccctcaa tttgcagtgc ctaaaggaac tgatgctttta   2220
gtcagagtgt ttgatgaatt tcatggaaat gcttatttag aaaataacta aaagttggt   2280
gaaatcaaat taccgattcc gaaattaaac caaggaacaa ccagaacggc cggaaataaa   2340
attcctgtaa cctccatggc aaatgcttat ttggacaatc aatcgactta tattgtggaa   2400
gtacctatct tggaaaaaga aaatcaaact gataaaccaa gtattctacc acaatttaaa   2460
aggaataaag cacaagaaaa cttaaaactt gatgaaaagg tagaagaacc aaagactagt   2520
gagaaggtag aaaaagaaaa actttctgaa actgggaata gtactagtaa ttcaacgtta   2580
gaagaagttc ctacagtgga tcctgtacaa gaaaaagtag caaaatttgc tgaaagttat   2640
gggatgaagc tagaaaatgt cttgtttaat atggacggaa caattgaatt atatttacca   2700
tcggagaag tcattaaaaa gaatatggca gattttacag gagaagcacc tcaaggaaat   2760
ggtgaaaata aaccatctga aaatggaaaa gtatctactg gaacagttga gaaccaacca   2820
acagaaaata aaccagcaga ttctttacca gaggcaccaa acgaaaaacc tgtaaaacca   2880
```

```
gaaaactcaa cggataatgg aatgttgaat ccagaaggga atgtggggag tgaccctatg   2940
ttagatccag cattagagga agctccagca gtagatcctg tacaagaaaa attagaaaaa   3000
tttacagcta gttacggatt aggcttagat agtgttatat tcaatatgga tggaacgatt   3060
gaattaagat tgccaagtgg agaagtgata aaaaagaatt tatctgatct catagcg      3117


SeqID 47
atgaaaattt tatttgtagc agcagagggt gcacccttt caaaaacagg tggtttggga      60
gacgtcattg gcgctcttcc aaaatcactg gtaaaagctg ggcacgaagt tgcagtgatt     120
ttaccctact atgatatggt agaggctaaa tttggaaatc agattgaaga tgtgcttcat     180
tttgaggtga gcgttggttga gcgcagacag tattgtgaa ttaagaaaac agtattaaat     240
ggtgtaacct tctactttat tgacaatcaa tattattct tccgtggtca tgtttacggt     300
gattttgatg acggagaacg ctttgccttt ttccaactgg ctgccattga ggctatggaa     360
aggattgact ttattcctga tcttctccat gttcatgact accatacagc tatgattcct     420
ttcttgttga aggaaaaata ccgttggatt caagcctatg aggacattga aacagtttta     480
accattcata atttagaatt ccaaggacaa ttttcagaag gaatgttggg tgatttgttt     540
ggagttggct ttgaacgtta cgctgatggc acccttcgat ggaacaactg tctgaactgg     600
atgaaggcag gtattctcta tgcgaaccgt gtttcaaccg tttcacctag ctatgctcat     660
gaaattatga ctagtcagtt tggatgtaat ttggatcaga ttcttaaaat ggagtctggt     720
aaagtatctg gtatcgtgaa tgggattgat gctgatcttt ataatcctca gacggatgct     780
cttttagact atcatttcaa tcaggaagat ttgtctggga aagccaaaaa taaggcaaaa     840
ttgcaagaaa gagttggctt gcctgttaga gcagacgttc cactggtggg aattgtttct     900
cgtttgacac gtcaaaaagg ttttgatgtg gtggtcgaaa gtcttcacca tatcttgcaa     960
gaagatgttc agattgttct tttgggaact ggcgatccag cctttgaagg agctttctca    1020
tggtttgctc agatttaccc agacaagcta tcaacaaata tcacttttga tgtcaaactt    1080
gctcaggaaa tctacgctgc ttgtgacctc ttcctcatgc caagtcgttt tgaaccgtgt    1140
ggcttgtctc aaatgatggc tatgcgttat ggaaccttgc cattggtcca tgaagttgga    1200
ggcttgcgag atacagtcg cgcttttcaat ccaatcgaag gaagcggtac tggctttagc    1260
tttgacaatc tatctcctta ttggttaaat tggactttcc aaacagcatt ggacttgtat    1320
agaaaccatc cagacatttg gagaaaccta caaaaacaag ctatggagag tgacttctca    1380
tgggatacag cctgcaagtc ataccttgac ttgtaccata gtttagttaa t             1431


SeqID 48
atggaaaagt attttggtga aaaacaagag cgttttttcat ttagaaaatt atcagtagga      60
cttgtatctg caacgatttc aagtttattt tttatgtctg tattagctag ttcatctgtg     120
gatgctcaag aaactgcggg agttcactat aaatatgtgg cagattcaga gctatcatca     180
gaagaaaaga agcagcttgt ctatgatatt ccgagaatga tgataaact tgatgaaact     240
tattatcttg tttataagtt aaattctcaa aatcaactgc cggaattgcc aaatactgga     300
agcaagaatg agaggcaagc cctagttgct ggtgctagct tagctgctat gggaatttta     360
attttttgctg tttccaagaa aaaggttaag aataaaacgg tattacattt agtattggtt     420
gcagggatag aaatggtgt cttagtttca gtccatgctt tagaaaatca tcttttgcta     480
aattacaata cggactatga attgacctct ggagaaaaat tacctcttcc taaagagatt     540
tcaggttaca cttatattgg atatatcaaa gaggggaaaa cgacttctga gtctgaagta     600
agtaatcaaa agagttcagt tgccactcct acaaaacaac aaaaggtgga ttataatgtt     660
acaccgaatt ttgtagacca tccatcaaca gtacaagcta ttcaggaaca aacacctgtt     720
tcttcaacta agccgacaga agttcaagta gttgaaaaac ctttctctac tgaattaatc     780
aatccaagaa aagaagagaa acaatcttca gattctcaag aacaattagc cgaacataag     840
aatctagaaa cgaagaaaga ggagaagatt tctccaaaag aaaagactgg ggtaaataca     900
ttaaatccac aggatgaagt tttatcaggt caattgaaca aacctgaact cttatatcgt     960
gaggaaacta tggagacaaa aatagatttt caagaagaaa ttcaagaaaa tcctgattta    1020
gctgaaggaa ctgtaagagt aaaaacaagaa ggtaaattag gtaagaaagt tgaaatcgtc    1080
agaatattct ctgtaaacaa ggaagaagtt tcgcgagaaa ttgtttcaac ttcaacgact    1140
gcgcctagtc caagaatagt cgaaaaaggt actaaaaaaa ctcaagttat aaaggaacaa    1200
cctgagactg gtgtagaaca taaggacgta cagtctggag ctattgttga acccgcaatt    1260
cagcctgagt tgcccgaagc tgtagtaagt gacaaaggcg aaccagaagt tcaacctaca    1320
ttacccgaag cagttgtgac cgacaaaggt gagactgagg ttcaaccaga gtcgccagat    1380
actgtggtaa gtgataaagg tgaaccagag caggtagcac cgcttccaga atataagggt    1440
aatattgagc aagtaaaacc tgaaactccg gttgagaaga ccaaagaaca aggtccagaa    1500
aaaactgaag aagttccagt aaaaccaaca gaagaaacac cagtaaatcc aaatgaaggt    1560
actacagaag aacctcaat tcaagaagca gaaaatccag ttcaacctgc agaagaatca    1620
acaacgaatt cagagaaagt atcaccagat acatctagca aaaatactgg ggaagtgtcc    1680
agtaatccta gtgattcgac aacctcagtt ggagaatcaa ataaaccaga acataatgac    1740
tctaaaaatg aaaattcaga aaaaactgta gaagaagttc cagtaaatcc aaatgaaggc    1800
acagtagaag gtacctcaaa tcaagaaaca gaaaaaccag ttcaacctgc agaagaaaca    1860
caaacaaact ctgggaaaat agctaacgaa aatactggag aagtatccaa taaacctagt    1920
gattcaaaac caccagttga agaatcaaat caaccagaaa aaacggaac tgcaacaaaa    1980
ccagaaaatt caggtaatac aacatcagag aatggacaaa cagaaccaga accatcaaac    2040
ggaaattcaa ctgaggatgt ttcaaccgaa tcaaacacat ccaattcaaa tggaaacgaa    2100
gaaattaaac aagaaaatga actagaccct gataaaaagg tagaagaacc agagaaaaca    2160
```

```
cttgaattaa gaaatgtttc cgacctagag ttatacagtt tgtcaaatgg tacttataaa    2220
caacacattt cgttagagca agttccaagc aatccaaata gctacttgt taaagtgaaa      2280
tcttcttcat tcaaagatgt atacctacca gtagcatcaa tatcagagga aagaaaaaat    2340
gataaaatcc tttataaaat cacagcaaaa gtagagaagc ttcagcagga gatagaaagc    2400
agatataaag ataattttac cttctatcta gctaagaagg gaacagaaga aacaacaaac    2460
tttacttcct ttagtaatct ggtcaaagct ataaaccaaa atccctctgg aacctatcat    2520
ttagcggcca gcctgaatgc taacgaagtg gagcttggtc ctgatgaaag atcctatatc    2580
aaggacacct ttactggtcg tttaatcggt gaaaaagatg gcaagaatta tgctatctat    2640
aatttgaaaa aacctctgtt tgaaaacttg agtggtgcta cagtagaaaa actgagtcta    2700
aaaaatgttg ctatttcagg gaaagatgat atcggttcac tggcaaatga agctcagaat    2760
aacacaaaaa ttaagcaagt tcacgtcgat ggtgttctgg ctggtgaacg tggtatcggt    2820
ggtttgctgg ctaaggctga gcaatcaagc atcacagaga gcagtttcaa gggaagaatt    2880
atcaacactt atgaaacgac tgctgcctac aatatcggtg gtatggtcgg tcatttgaca    2940
ggtgacaagg ctttacttac taagtcaaaa gcgacagtag ccattcatc taacacaaat      3000
acttcagatc agactgtggg tggacttgca ggcctagtag accgagatgc acagatccaa    3060
gatagctatg ctgaaggtga tatcaacaat gtcaagcact ttggtagagt cgctggagtg    3120
gcaggcaatt tgtgggatcg aacttctggt gatgttaggc atgctggaag tttgaccaat    3180
gttctcagcg atgttaatgt aaccaacgga aatgccatca ctggttacca ctataacgaa    3240
atgaaggtaa aggacacatt cagcagcaag gccaacgagg tctacaatgt cacccttggtc   3300
aaggatgagg tcgtcagcaa ggaatccttt gaagaagag gaacaatgct agatgcttct     3360
caaattgcaa gcaaaaaagc agaaatcaat cctctcattt taccaacagt ggagccactt    3420
tcaacaagtg gcaaaaaaga cagtgatttt tctaaggtgg cctattatca agctaagcgc    3480
aacttgactt ataaaaacat tgaaaaattg ctacctttct acaacaaggc aaccatcgtc    3540
aaatacggaa acctggtcaa tgagaacagt cttttatatc aaaaagaact cttgtcagca    3600
gtcatgatga aggacaacca agtcatcaca gacattgttt ctaacaaaca gactgcaaac    3660
aaactcttgc ttcactacaa ggatgattta tctgagaagc tggatctcaa ataccagaat    3720
gatttcgcca aattagcaga atatagtctg ggcaatactg gacttctcta tacgccaaac    3780
caattcctgt atgaccaaac ctctatcatc aagcaagtct tacctgactt acaaaaaggtt   3840
gactatcatt cagaagccat cagaaagacg ctgggtattt ctccaaacgt caagcaaact    3900
gagctctatc tagaagacca gttcgccaaa acaaaacaac aactggaaga cagtttgaaa    3960
aaactcttgt cagcggatgc tggactggct agtgctaacc ccgtcactga aggttatctt    4020
gtagataaaa tcaaacgcaa caaggaagcc ttgctacttg gcttgaccta tctggaacgg    4080
tggtataact ttagctatgg tcaggtgaat gtcaaagacc tagttctgta ccatttggac    4140
ttctttggta aggggaaatgc ttcaccatta gatactctga ttgagttggg taaatctggc   4200
tttaacaatc ttctagctaa gaataatgtc gatacttatg gtatcagtct tgccagtcaa    4260
catggaacga cagatttgtt tagcacgctg gaacattacc gaaaagtctt tttaccaaat    4320
acaagcaata atgactggtt taaatcagag actaaggctt acattgtcga agaaaaatcc    4380
actatcgaag aggtgaaaac gaagcaaggg ttagctggca ccaagtattc tatcggtgtt    4440
tatgatcgta tcacgagtgc cacatggaaa taccgcaata tggtcttgcc tctcctgacc    4500
ttgccagaga gatccgtatt tgtcatctcg accatgtcta gtctaggatt tggagcttat    4560
gatcgctacc gcagtagtga ccataaagcg ggcaaggctc tcaatgattt tgttgaagaa    4620
aatgcgcgtg aaacagccaa acgtcagcga gatcactacg attattggta tcgtattta    4680
gacgacaatg cacgtgaaaa acttttataga aatattttgc tttacgatgc ttataaattt    4740
ggcgatgata ataccgtagg gaaagctaca gaagtggcag attttgataa tccaaatcct    4800
gcaatgcaac atttctttgg acctgttgga aataaagttg ggcataatca acacggtgct    4860
tatgctacag gtgatgcagt ttattatatg ggttatcgaa tgttggataa ggatggagct    4920
attacttata cgcatgagat gacacatgac tcagatcagg acatttatct tggaggatat    4980
ggtcgaagaa gtggcttggg accagagttc tttgctaaag gattattaca agcaccagac    5040
catccagatg atgcgaccat taccatcaac tccatcttga aacattcaaa atctgatagt    5100
acagaaagtc gacgattaca agtacttgat ccaactacaa gatttaataa tgcagatgat    5160
ttgaagcaat atgtccacaa catgtttgac gttgtttata tgttggaata tctcgaagga    5220
aattcaattc ttaaattgga tacgaatcaa aaacaacaac ttcttagaaa agttacaaat    5280
gagtaccatc ctgatcctga tggaaataag gtctatgcaa caaatgttgt cagaaatcta    5340
acagtagaag aagttgaaag actacgttca ttcaatgatt tgattgataa taatattctt    5400
tcgtctaggg aatatgcctc aggtaaatac gaaagaaatg gctacttcac tattaagtta    5460
tttgcaccga tttatgctgc attaagtaat gatataggaa caccaggtga cctgatggga    5520
cgtcgtatag cctatgaact actagctgct aaaggcttta agatggtat ggtaccatat     5580
atctcaaacc aatacgaaga agaagccaaa caaaagggca agacaatcaa tctctacggt    5640
aaaacaagag gtttggttac agatgacttg gttttggaaa aggtatttaa taaccaatat    5700
catacttgga gtgagtttaa gaaagctatg tatcaagaac gacaagatca gtttgataga    5760
ttgaacaaag ttactttta tgatacaca cagccttggc aaacatttgc caagaaaact     5820
acaagcagtg tagatgaatt acagaaatta atggacgttg ctgttcgtaa ggatgcagaa    5880
cacaattact accattggaa taactacaat ccagacatag atagtgaagt ccacaagctc    5940
aagagagcaa tctttaaagc ctatcttgac caaacaaatg attttagaag ttcaattttt    6000
gagaataaaa aa                                                        6012
```

SeqID 49
```
atgaaaatta ataaaaaata tctagcaggt tcagtggcag tccttgccct aagtgtttgt      60
```

```
tcctatgagc ttggacgtta ccaagctggt caggataaga aagagtctaa tcgagttgct      120
tatatagatg gtgatcaggc tggtcaaaag gcagaaaact tgacaccaga tgaagtcagt      180
aagagggagg ggatcaacgc cgaacaaatt gttatcaaga ttacggatca aggttatgtg      240
acctctcatg gagaccatta tcattactat aatggcaagg ttccttatga tgccatcatc      300
agtgaagagc tcctcatgaa agatccgaat tatcagttga aggattcaga cattgtcaat      360
gaaatcaagg gtggttatgt cattaaggta aacggtaaat actatgttta ccttaaggat      420
gcagctcatg cggataatat tcggacaaaa gaagagatta aacgtcagaa gcaggaacgc      480
agtcataatc ataactcaag agcagataat gctgttgctg cagccagagc ccaaggacgt      540
tatacaacgg atgatgggta tatcttcaat gcatctgata tcattgagga cacgggtgat      600
gcttatatcg ttcctcacgg cgaccattac cattacattc ctaagaatga gttatcagct      660
agcgagttag ctgctgcgca agcctattgg aatgggaagc agggatctcg tccttcttca      720
agttctagtt ataatgcaaa tccagctcaa ccaagattgt cagagaacca caatctgact      780
gtcactccaa cttatcatca aaatcaaggg gaaaacattt caagcctttt acgtgaattg      840
tatgctaaac ccttatcaga acgccatgtg gaatctgatg cccttatttt cgacccagcg      900
caaatcacaa gtcgaaccgc cagaggtgta gctgtccctc atggtaacca ttaccacttt      960
atcccttatg aacaaatgtc tgaattggaa aaacgaattg ctcgtattat tcccccttcgt     1020
tatcgttcaa accattgggt accagattca agaccagaag aaccaagtcc acaaccgact     1080
ccagaaccta gtccaagtcc gcaaccagct ccaagcaatc caattgatga gaaattggtc     1140
aaagaagctg ttcgaaaagt aggcgatggt tatgtctttg aggagaatgg agtttctcgt     1200
tatatcccag ccaaggatct ttcagcagaa acagcagcag gcattgatag caaactggcc     1260
aagcaggaaa gtttatctca taagctagga actaagaaaa ctgacctccc atctagtgat     1320
cgagaatttt acaataaggc ttatgactta ctagcaagaa ttcaccaaga tttacttgat     1380
aataaaggtc gacaagttga ttttgaggct ttggataacc tgttggaacg actcaaggat     1440
gtctcaagtg ataaagtcaa gttagtggaa gatattcttg ccttcttagc tccgattcgt     1500
catccagaac gtttaggaaa accaaatgcg caaattacct acactgatga tgagattcaa     1560
gtagccaagt tggcaggcaa gtacacaaca gaagacggtt atatctttga tcctcgtgat     1620
ataaccagtg atgaggggga tgcctatgta actccacata tgacccatag ccactggatt     1680
aaaaaagata gtttgtctga agctgagaga gcggcagccc aggcttatgc taaagagaaa     1740
ggtttgaccc ctccttcgac agaccatcag gattcaggaa atactgaggc aaaaggagca     1800
gaagctatct acaaccgcgt gaaaagcagc aagaaggtgc cacttgatcg tatgccttac     1860
aatcttcaat atactgtaga agtcaaaaac ggtagtttaa tcatacctca ttatgaccat     1920
taccataaca tcaaatttga gtggtttgac gaaggccttt atgaggcacc taaggggtat     1980
actcttgagg atcttttggc gactgtcaag tactatgtcg aacatccaaa cgaacgtccg     2040
cattcagata atggttttgg taacgctagc gaccatgttc aaagaaacaa aaatggtcaa     2100
gctgatacca atcaaacgga aaaaccaagc gaggagaaac ctcagacaga aaaacctgag     2160
gaagaaaccc ctcgagaaga gaaaccgcaa agcgagaaac cagagtctcc aaaaaccaaca     2220
gaggaaccag aagaatcacc agaggaatca gaagaacctc aggtcgagac tgaaaaggtt     2280
gaagaaaaac tgagcaggac tgaagattta cttggaaaaa tccaggatcc aattatcaag     2340
tccaatgcca aagagactct cacacaggatta aaaaataatt tactatttgg caccccaggac     2400
aacaatacta ttatggcaga agctgaaaaa ctattggctt tattaaggga gagtaag         2457
```

SeqID 50

```
ttgattttaa gtgtttgttc ttacgagttg ggactgtatc aagctagaac ggttaaggaa       60
aataatcgtg tttcctatat agatggaaaa caagcgacgc aaaaaacgga gaatttgact      120
cctgatgagg ttagcaagcg tgaaggaatc aatgctgagc aaatcgtcat caagataaca      180
gaccaaggct atgtcacttc acatgggaat cactatcatt attacaatgg taaggttcct      240
tatgacgcta tcatcagtga agaattactc atgaaagatc caaactataa gctaaaagat      300
gaggatattg ttaatgaggt caagggtgga tatgttatca aggtagatgg aaaaatactat      360
gtttaccttta aggatgctgc ccacgcggat aacgtccgta caaaagagga aatcaatcga      420
caaaaacaag agcatagtca acatcgtgaa ggtggaactc caagaaacga tggtgctgtt      480
gccttggcac gttcgcaagg acgctatact acagatgatg gttatatctt taatgcttct      540
gatatcatag aggatactgg tgatgcttat atcgttcctc atggagatca ttaccattac      600
attcctaaga atgagttatc agctagcgag ttggctgctg cagaagcctt cctatctggt      660
cgaggaaatc tgtcaaattc aagaacctat cgccgacaaa atagcgataa cacttcaaga      720
acaaactggg taccttctgt aagcaatcca ggaactacaa atactaacac aagcaacaac      780
agcaacacta acagtcaagc aagtcaaagt aatgacattg atagtctctt gaaacagctc      840
tacaaactgc ctttgagtca acgacatgta gaatctgatg ccttgtctt tgatccagca      900
caaatcacaa gtcgaacagc tagaggtgtt gcagtgccac acggagatca ttaccacttc      960
atcccttact ctcaaatgtc tgaattggaa gaacgaatcg ctcgtattat tccccttcgt     1020
tatcgttcaa accattgggt accagattca aggccagaac aaccaagtcc acaaccgact     1080
ccggaaccta gtccaggccc gcaacctgca ccaaatctta aatagactc aaattcttct     1140
ttggttagtc agctggtacg aaaagttggg gaaggatatg tattcgaaga aaagggcatc     1200
tctcgttatg tctttgcgaa agatttacca tctgaaactg ttaaaaatct tgaaagcaag     1260
ttatcaaaac aagagagtgt ttcacacact ttaactgcta aaaagaaaa tgttgctcct     1320
cgtgaccaag aatttttatga taaagcatat aatctgttaa ctgaggctca taagccttg     1380
tttgaaaata agggtcgtaa ttctgatttc caagccttag acaaattatt agaacgcttg     1440
aatgatgaat cgactaataa agaaaaattg gtagatgatt tattggcatt cctagcacca     1500
attacccatc cagagcgact tggcaaacca aattctcaaa ttgagtatac tgaagacgaa     1560
```

```
gttcgtattg ctcaattagc tgataagtat acaacgtcag atggttacat ttttgatgaa      1620
catgatataa tcagtgatga aggagatgca tatgtaacgc ctcatatggg ccatagtcac      1680
tggattggaa aagatagcct ttctgataag gaaaaagttg cagctcaagc ctatactaaa      1740
gaaaaaggta tcctacctcc atctccagac gcagatgtta aagcaaatcc aactggagat      1800
agtgcagcag ctatttacaa tcgtgtgaaa ggggaaaaac gaattccact cgttcgactt      1860
ccatatatgg ttgagcatac agttgaggtt aaaaacggta atttgattat tcctcataag      1920
gatcattacc ataatattaa atttgcttgg tttgatgatc acacatacaa agctccaaat      1980
ggctatacct tggaagattt gtttgcgacg attaagtact acgtagaaca ccctgacgaa      2040
cgtccacatt ctaatgatgg atggggcaat gccagtgagc atgtgttagg caagaaagac      2100
cacagtgaag atccaaataa gaacttcaaa gcggatgaag agccagtaga ggaaacacct     .2160
gctgagccag aagtccctca agtagagact gaaaaagtag aagcccaact caaagaagca      2220
gaagttttgc ttgcgaaagt aacggattct agtctgaaag ccaatgcaac agaaactcta      2280
gctggtttac gaaataattt gactcttcaa attatggata acaatagtat catggcagaa      2340
gcagaaaaat tacttgcgtt gttaaaagga agtaatcctt catctgtaag taaggaaaaa      2400
ataaac                                                                 2406


SeqID 51
atgccagtag aaattaaaac cactaaagaa attcatccta aaatctatgc ctacaccaca        60
ccgacagtaa ccagtaatga aggctggatt aagattgggt atacagaacg tgatgtcaca       120
caacgtatca aggagcaaac gcatacagct catatagcta cagatgtctt atggactggt       180
gatgcagctt atacagaaga gcctgataag gggaaaactt tcaaggacca tgatttccac       240
catttccttt ctttccatga tgtagaacgt cgtcccaaga cggaatggtt ctattttaat       300
ggaactcctg aaaaatcaaa aaatcttttt gataagtttg ttcagcatga tttgtctggt       360
tatcagcctg aaaaaggaca ggactatact ctgcgacaag agcaagaaga agcagttgct       420
aagacattag cttatttcca agaacatgct ggaggcaagt ttctctggaa tgccaagcca       480
cgctttggta aaaccttgtc tacctatgac ctagctcgac ggatggaagc tgtcaatgtc       540
ctaattgtaa caaaccgccc tgccattgct aactcatggt atgatgattt tgaaacattc       600
atagcaggtc aaacgactta caagttgtt tctgaatcag atagccttaa gagtcgtcca        660
atcttgtcac gacaagaatt tcttggtatt ttagctgacg atgtaagaca acttgctttt       720
atcagtctcc aagacttgaa aggatctgtt tatttaggtg gagagcacga taaactcaaa       780
tgggtaactg atctgcattg ggacttgttg gttattgacg aggctcatga aggagttgat       840
accttcaaga ctgaccaagc ctttaataag attcgacgaa attttactct gcatttgtca       900
ggtacatcat ttaaagcatt ggctaaagga gattttacag aggaacaaat ctacaactgg       960
tcttatgctg atgagcaggc tgctaagtat tcgtggtctc ttgagcaaga agaggaaaat      1020
ccttatgaaa gcttgcctca gttgaatctc tttacctatc aaatgtctca gatgattggc      1080
gaaaagttag aaaaaggcgc tcagatcgat ggtgaaaata ttgactatgt ttttgactta      1140
agtgaatttt tcgctacaga tgataaaggg aaatttattc atgagcatga tgtcagaaat      1200
tggttagata ctctatcaag caatgaaaaa tatccatttt caaccaaaga actccgtaat      1260
gaactcaagc atacttttg gcttttagaa cgtgtcgctt cggccaaagc attaaaagcc      1320
ctactagaag aacacccaat ctatgaaaac tatgagatcg ttctagctgc tggtgacgga      1380
cgtatgtccg aagaagacga taaagtcaaa ctcaaatcct tggacttggt tagaaaagcg      1440
atagcagaga atgacaaaac cattaccccta tccgttggtc agctgacgac aggtgtcact      1500
atccctgaat ggacaggtgt attgatgtta tcaaatttga aatcaccagc tctttatatg      1560
caggccgcct ccgtgctca aaatccttac tcatggagcg ataacaaagg aaatcacttt       1620
cgcaaagaaa gagcctatgt atttgacttt gcgccggaaa gaaccttgat tctctttgat      1680
gagtttgcca caacttatt gcttgtaact gcagctggta gaggaacttc agctacacgc      1740
gaagaaaata ttagagaatt attaaacttc tttccaatta ttgccgaaga ccgtgctggt      1800
aagatggttg aaattgatgc aaaggcagtt ctaaccactc ctcgccagat aaaagctaga      1860
gaagttctta acgaggttt tatgtccaat ctcttatttg ataatattag tggtattttc      1920
caagcaagtc aaacagtttt agatatttta aatgagctgc cagttgaaaa ggaagggaag      1980
gtacaagata gttctgattt attagatttt tcagatcgtta cagtcgatga tgagggaaat      2040
gcagtagtag accatgaaat tgtagttaat cagcaaatgc gacttttttg tgaaaaagtt      2100
tatggacttg gtgaatctgt tgctgagtta gtcacaaaag atgaggaacg aactcaaaaa -    2160
cagctggtca atgacttgag taagaccgtt tcttcagtga ttgtagagga attgaaagca      2220
gattattctc taaaaacaag ggaaactgag caaattaaga aacaaattac agcaacactt      2280
gagaatgaaa ttcgaaaaaa tgatatcgaa agaaaaattt ctgaagctca tatcaagcaa      2340
gagttgcaac agcagctcaa agaagcaaat gataaagcgc aaaaagataa gattcaagaa      2400
gatttggaaa aacgtttaga agaaataaaa ctcattcata agaaaaact agaacaaaca      2460
ctcaaaaaag aagtggaaaa aatgcctgag aaatttatcg aacaggttga gataaaacgt      2520
gtggaacagt gaaacaatc agctcaagat gaaattcgtg accatttacg agggtttgca      2580
agaacaattc caagttttat tatggcttac ggtgatcaaa ctctaacact tgataatttt      2640
gatgcctttg ttcctgaaca tgttttttat gaagtaacag ggattacgat tgatcagttt      2700
agatatttgc gagatggtgg gcaggatttt gcaggcatc tctttgataa agcaacattt      2760
gacgaagcta ttcaagaatt tcttcgcaag aaaaaggagt tggcggatta ttttaaagat      2820
caaaaagaag acatttttga ctatattcca ccgcagaaga ccaaccaaat tttcactcct      2880
aaacgagtgg tgaaaaggat ggtagatgat ttggaaaagg aaaatccagg gattttttgat      2940
gatccatcta agacttttat tgatttatat atgaagtcag gcctctatat tgcagaactt      3000
gtgaagcggt tatataatag caatggcttg aaagaggcct ttccaaatcc tgaagaacgc      3060
```

```
ttaaaacata ttttggaaaa gcaagtttat ggatttgctc cgtctgagat tatctataac   3120
atttccacta attttatatt tggcaatctt tctaaagata tcagtaggaa gaattttgtt   3180
ttagcagata ccattccagc ggctaaagaa gggagcattc aaaagttggt tgattcctat   3240
tttgaaaata at                                                       3252
```

SeqID 52
```
atgaaaaaaa tactaattgt agatgatgag aaaccaatct cggatattat caagtttaat   60
atgaccaagg aaggttacga agttgtaact gcttttaatg gtcgtgaagc gctagagcaa   120
tttgaagcag agcaaccaga tattattatt ctggatttga tgcttccaga aattgatggt   180
ttagaagttg ctaagaccat tcgtaagaca agcagtgtgc ccattcttat gctttcagcc   240
aaagatagtg aatttgataa ggttatcggt ttggaacttg gggcagatga ctatgtaaca   300
aaacccttct ccaatcgtga gttgcaggcg cgtgttaaag ctcttctgcg tcgttctcaa   360
cctatgccag tagatggtca ggaagcagat agtaaacctc aacctatcca aattggggat   420
ttagaaattg ttccagacgc ctacgtggct aaaaaatatg gcgaagaact agacttaacc   480
catcgtgaat ttgagctttt gtatcattta gcatcgcata caggtcaagt catcacgcgc   540
gaacacttgc ttgagactgt ctggggttat gactattttg gtgatgtccg tacagttgat   600
gtgactgtac gacgtctgcg tgagaagatt gaagatacgc ccagccgacc agagtatatc   660
ttgacgcgcc gtggtgtagg gtattacatg agaaataatg ct                     702
```

SeqID 53
```
atgaagaaaa aatttctagc attttttgcta attttattcc caattttctc attaggtatt   60
gccaaagcag aaacgattaa gattgtttct gataccgcct atgcaccttt tgagtttaaa   120
gattcagatc aaacttataa aggaattgat gttgacatta ttaacaaagt cgctgagatt   180
aaaggctgga acattcagat gtcctatcct ggatttgacg cagcagtcaa tgcggttcaa   240
gctgggcaag ccgacgctat catggcaggg atgacaaaga ctaaagaacg tgaaaaagtc   300
ttcaccatgt ctgatactta ctatgataca aaagttgtca ttgctactac aaagtcacac   360
aaaattagca agtacgacca attaactggc aaaaccgttg gtgttaaaaa cggaactgcc   420
gctcaacgtt tccttgaaac aatcaaagat aaatacggct ttactattaa aacatttgac   480
actggtgatt taatgaacaa cagcttgagt gctggtgcca tcgatgccat gatggatgac   540
aaacctgtta tcgaatatgc cattaaccaa ggtcaagacc tccatattga aatggatggt   600
gaagctgtag gaagtttttgc tttcggtgtg aaaaaggaa gtaaatacga gcacctggtt   660
actgaattta ccaagcctt gtctgaaatg gtagtcttga taaaattatc               720
aagaaatgga ctgcttcatc atcttcagca gtgccaacta caactactct cgcaggatta   780
aaagctattc ctgttaaggc taaatatatc attgccagcg attcttcttt tgccccttttt   840
gtttttccaaa attcaagcaa ccaatacact ggtattgata tggaattgat taaggcaatc   900
gctaaagacc aaggtttttga aattgaaatc accaacccctg gtttttgatgc tgctatcagt   960
gctgtccaag ctggtcaagc cgatggtatc atcgctggta tgtctgtcac agatgctcgt   1020
aaggcaactt ttgacttctc agaatcatac tacactgcta ataccattct tggtgtcaaa   1080
gaatcaagca atattgcttc ttatgaagat ctaaaaggaa agacagtcgg tgttaaaaac   1140
ggaactgctt ctcaaacctt cctaacagaa aatcaaagca aatacggcta caaaatcaaa   1200
accttttgcg atggttcttc aatgtatgac agtttaaaca ctggtgccat tgatgccgtt   1260
atggatgatg aacctgttct caaatattct atcagccaag gtcaaaaatt gaaaactcca   1320
atctctggaa ctccaatcgg tgaaacagcc tttgccgtta aaaaaggagc aaatccagaa   1380
ctgattgaaa tgttcaacaa cggacttgca aaccttaaag caaacggtga attccaaaag   1440
attcttgaca atacctagc tagcgaatct tcaactgctt caacaagtac tgttgacgaa   1500
acaacgctct gggccttgct tcaaaacaac tacaaacaac tccttagcgg tcttggtatc   1560
actcttgctc tagctcttat ctcatttgct attgccattg tcatcggaat tatcttcggt   1620
atgtttagcg ttagcccata caaatctctt cgcgtcatct ctgagatttt cgttgacgtt   1680
attcggtgta ttccatttgat gattcttgca gccttcatct tctgggacat tccaaacttc   1740
atcgagtcta tcacaggcca acaaagccca attaacgact ttgtagctgg aaccattgcc   1800
ctctcactca atgcggctgc ttatatcgct gaaatcgttc gtggtggtat tcaggccgtt   1860
ccagttggcc aaatggaagc cagccgaagc ttgggtatct cttatggaaa aaccatgcgt   1920
aagattatct tgccacaagc aactaaattg atgttgccaa actttgtcaa ccaattcgtt   1980
atcgctctta agatacaac tatcgtatct gctatcggtt tggttgaact cttccaaact   2040
ggtaagatta tcattgctcg taactaccaa agtttcaaga tgtatgcaat ccttgctatc   2100
ttctatcttg taattatcac acttttgact agactagcga aacgcttaga aaagaggatt   2160
cgt                                                                 2163
```

SeqID 54
```
atggcatttg aaagtttaac agaacgtttg cagaacgtct ttaaaaatct acgtaaaaaa   60
ggaaaaatct ctgaatctga tgtccaagag gcaaccaaag aaattcgctt ggccttgctc   120
gaggccgacg ttgccttgcc tgttgtaaag gactttatca agaaagttcg tgagcgtgca   180
gtcgggcatg aggtcattga tacacttaat cctgcgcaac agattattaa aatcgttgat   240
gaggaattga cagccgtttt aggttctgat acggcagaaa ttatcaagtc acctaagatt   300
ccaaccatca tcatgatggt tggtttacaa ggggctggta aaacaacctt gctggtaaa   360
ttggccaaca aactcaagaa agaagaaaat gctcgtcctt gatgattgc ggcggatatt   420
tatcgtccag ctgccattga ccagcttaag accttgggac aacagattga gtgcctgtc   480
tttgcacttg gaacagaagt accagctgtt gagattgtac gtcaaggttt ggagcaagcc   540
```

```
caaactaatc ataacgacta tgtcttgatt gatactgcgg gtcgtttgca gattgatgag    600
ctcctcatga atgagcttcg tgatgtgaaa gcattggctc aaccaaatga aatcttgctt    660
gtcgttgatg ctatgattgg tcaggaagca gccaatgttg cgcgtgagtt taatgctcag    720
ttggaagtga ctggggtcat ccttaccaag attgatggcg atactcgtgg tggtgctgct    780
ctgtctgttc gtcacattac tggaaaacca atcaagttca ctggtacagg tgaaaagatt    840
acggacattg aaaccttcca cccagaccgc atgtctagcc gtatccttgg tatgggggat    900
atgctcactt tgattgagaa agcttctcag gaatacgatg aacaaaaagc ccttgaaatg    960
gctgagaaga tgcgcgaaaa caccttttgat tttaatgatt tcatcgatca attagatcag   1020
gtgcaaaata tggggccgat ggaagacttg ctcaagatga ttccaggtat ggccaacaat   1080
ccagcccttc aaaacatgaa ggtggatgaa cgccagattg ctcgtaaacg tgccattgtg   1140
tcttcgatga cacctgaaga gcgtgaaaac ccagatttgt taaatccaag ccgtcgccgt   1200
cgtattgctg ctggttctgg aaatacattc gtcgaagtca ataaattcat caaggacttt   1260
aaccaggcta aacagctcat gcagggtgtt atgtctgggg atatgaataa aatgatgaag   1320
caaatgggga ttaatccaaa taaccttcct aaaaatatgc caaatatggg aggaatggat   1380
atgtctgccc ttgaaggaat gatgggacca ggcggtatgc ctgacttatc agctctcgga   1440
ggagcaggaa tgccagatat gagccagatg tttggtggcg gtttgaaagg taaaattggt   1500
gaatttgcca tgaaacagtc catgaaacgt atggctaaca aaatgaagaa agcgaagaag   1560
aaacgcaag                                                           1569
```

SeqID 55
```
atgagccaaa tttggactaa agaaaaattt ataagccaag ttcaaggtgg agtcattgtt     60
tcttgtcaag ctttacctgg tgaagccctt tataatgaag aatttagctt gatgcctttt    120
atggctaaag cagctttaga ggcaggagca gtgggcattc gcgcaaattc tgtgcgtgat    180
attaaagcaa ttcagaaagt agtagattta ccaataattg gaattatcaa aagggattat    240
ccacctcaag aaccatatat tactgctacg atgaaagaag tagatgaact tgtagaatgc    300
ggaacaacag tcattgcatt tgatgcaact ttaagaccaa gatatgatgg cttagttgtc    360
agtgaattta tcaaaaaaat aaaagaaaaa tatccgaatc aattgctgat ggcggatgta    420
agtaatttag atgaaggtct ctatgcattt aaatcaggcg ttgattttgt tggtacaaca    480
ttatcaggtt acacaagtac aagtgtacaa tcagatgagc ctgattttga actaatgaaa    540
aaattggctg attttaatat tccggtaatt gccgaaggaa aaattcatta tccagaacaa    600
ttaaaaaaag cttatagttt aggtgttacc agtgtagtca ttggtggagc gattacacgt    660
ccaaaagaaa ttgctcagcg atttattaat gtcatcaaa                           699
```

SeqID 56
```
atgagatatt taactgcagg agaatcacac ggcccccgtc taacagctat tattgaggga     60
attccagctg gacttccatt gacagctgag gatatcaatg aggaccttag acgccgtcag    120
ggtggctacg gtcgtggtgg tcgtatgaag attgagaatg accaggttgt ctttacttcg    180
ggcgttcgcc acgggaagac gacaggggcg cctattacta tggatgtcat caataaggac    240
caccagaaat ggctggacat catgtctgcg gaggacattg aagaccgcct taaaagcaag    300
cggaaaatta ctcatcctcg cccaggtcat gccgatttgg ttggggggat taagtaccgt    360
tttgatgatt tgcgaaattc tttggagcgt tcatcagctc gtgaaaccac catgcgggtg    420
gcagttggtg cagtagccaa acgcctcttg gctgagctgg atatggagat tgccaaccat    480
gtcgtggtct ttggtggcaa ggaaatcgat gttcctgaaa atctgacagt cgctgaaatt    540
aagcaaaagag ctgcccagtc tgaagtttct attgtcaacc aagaacgaga acaggaaatc    600
aaggactata ttgaccaaat caaacgtgat ggtgataccа tcggtggggt tgtggagaca    660
gtcgtcggag gcgttccagt tggtcttggt tcctatgtcc aatgggatag aaaattggat    720
gcaagattgg ctcaagctgt tgtctctatc aatgccttta aaggggtgga atttggtctt    780
ggctttgagg ctggttatcg taaaggcagc caagttatgg atgaaattct ctggtctaaa    840
gaagacggtt atactcgccg taccaataat ctaggtggtt ttgaaggtgg tatgactaat    900
gggcaaccca tcgttgttcg tggggtcatg aaacccattc ctactcttta taaacctctt    960
atgagtgtgg atatcgaaac ccacgaacct tacaaggcaa ccgtggagag aagtgatccg   1020
actgctcttc cagctgcagg aatggtcatg gaagcagttg tagcaacggt tctggcgcaa   1080
gaaatcctcg aaaaattctc atcagataat cttgaggaac taaaagaagc ggtagccaaa   1140
caccgagact atacaaagaa ctat                                          1164
```

SeqID 57
```
atggtagtta tgaatagaat aagagtcagc aaaagggttg aaaagaagct tgctaagggg     60
ctagttttac tagaagccag tgatcttgag aatgtcaatc ttaaggatca ggaagtagag    120
gtgcaggtc aggaaggaaa ctttcttggg actgcctacc tttctcagca aaacaagggc    180
ttgggctggt ttatcagcaa agacaaggtg gccttcaatc aagctttctt tgaaacgttg    240
tttagaaaag ccaaagaaaa gagaaacgtt cc tactatcaag atgattgac aactgccttt    300
cgtctcttta atcaagaggg agatggcttt gggggtctga cagtcggacct ttatggcgac    360
tacgccgtct tttcttggta taactcttat gtttatcaga ttcgtcagac tatatcagaa    420
gcctttagac aggttttccc tgaggtttta ggagcttatg agaaaatccg cctttaagggt    480
ttggactatg aatctgccca tgtttatggt caagaagcac ctgacttttt caatgtttta    540
gaaaatggtg tcctgtatca agtctttatg aatgatggct tgatgacagg aatttttccta    600
gaccagcatg aggttcgcgg tagtttagtt gacggcttgg ctatgggtaa atcccttactc    660
aatatgtttt cctacacagc ggctttttca gtagctgcgg ccatgggagg agctagccat    720
```

```
acaacttctg ttgatctagc caaacgttca cgagaattgt ctcaagcgca ttttcaggca      780
aatgggctca gcacagacga gcatcgtttt atagtcatgg atgtctttga gtatttcaaa      840
tatgccaaac gcaaagactt gacctacgat gtgattgtcc tagatccgcc tagctttgct      900
cggaataaaa aacaaacttt ctctgtggcc aaggattatc acaagttgat ttcccagagt      960
cttgagattt aaatccgggg agggattatc attgccagta ccaatgctgc caatgtttcc     1020
cgtcagaaat ttacagaaca aattgataaa ggttttgcag gaagaagtta ccagatttta     1080
aacaaatatg gtcttccagc agattttgcc tataataaaa aagatgaaag tagtaattac     1140
ctcaaggtga ttagtatgaa ggttagtaaa                                      1170
```

SeqID 58
```
atgacaaaaa cattaaaacg tcctgaggtt ttatcacctg cagggacttt agagaagcta       60
aaggtagctg ttcagtatgg agcagatgct gtctttatcg gtggtcaggc ctatggtctt      120
cgtagccgtg cgggaaactt tactttcgaa cagatggaag aaggcgtgca gtttgcggcc      180
aagtatggtg ccaaggtcta tgtagcggct aatatggtta tgcacgaagg aaatgaagct      240
ggtgctggtg agtggttccg taaactgcgt gatatcggga ttgcagcagt tatcgtatct      300
gacccagcct tgattatgat tgcagtgact gaagcaccag gccttgaaat ccacctttct      360
acccaagcca gtgccactaa ctatgaaacc cttgagttct ggaaagagct aggcttgact      420
cgtgtcgttt tagcgcgtga ggtttccatg gaagaattag ctgagatccg caaacgtaca      480
gatgttgaaa ttgaagcctt tgtccatgga gctatgtgta tttcatactc tggacgttgt      540
actctttcaa accacatgag tatgcgtgat gccaaccgtg tgggatgttc tcagtcatgc      600
cgttggaaat acgaccttta cgatatgcca tttgggaaag aacgtaagag tttgcagggt      660
gagattccag aagaattttc aatgtcagcc gttgacatgt ctatgattga ccacattcca      720
gatatgattg aaaatggtgt ggacagtcta aaaatcgaag gacgtatgaa gtctattcac      780
tacgtatcaa cagtaaccaa ctgctacaag gcggctgtgg atgcctatct tgaaagtcct      840
gaaagtttg aagctatcaa acaagacttg gtggacgaga tgtggaaggt tgcccaacgt      900
gaactggcta caggatttta ctatggtaca ccatctgaaa atgagcagtt gttggtgct      960
cgccgtaaaa ttcctgagta caagttgtc gctgaagtgg tttcttatga tgatgcggca     1020
caaacagcaa caattcgtca acgaaatgtc attaacgaag gggaccaagt tgagttttat     1080
ggtccaggtt tccgtcattt tgaaacctat attgaagatt tgcatgatgc caaaggcaat     1140
aaaatcgacc gcgctccaaa tccaatggaa ctattgacta ttaaggtgcc tcaacccgtt     1200
caatcaggag atatggttcg tgcattaaaa gaaggactca tcaatctttta taaggaagat     1260
ggaaccagcg tcacagttcg agct                                            1284
```

SeqID 59
```
atgaatacct atcaattaaa taatggagta gaaattccag tattgggatt tggaactttt       60
aaggctaagg atggagaaga agcctatcgt gcagtgttag aagccttgaa ggctggttat      120
cgtcatattg atacggcggc gatttatcag aatgaagaaa gtgttggtca agcaatcaaa      180
gatagcggag ttccacgtga agaaatgttc gtaactacca agctttggaa tagtcagcaa      240
acctatgagc aaactcgtca agctttggaa aaatctatag aaaaactggg cttggattat      300
ttggatttgt atttgattca ttggccgaac ccaaaaccgc tcagagaaaa tgacgcatgg      360
aaaactcgca atgcggaagt ttggagagcg atggaagacc tctatcaaga agggaaaatc      420
cgtgctatcg gcgttagcaa ttttcttccc catcatttgg atgccttgct tgaaactgca      480
actatcgttc ctgcggtcaa tcaagttcgc ttggcgccag gtgtgtatct agatcaagtc      540
gtagcttact gtcgtgaaaa gggaatttta ttggaagctt gggggccttt tggacaagga      600
gaactgtttg atagcaagca agtccaagaa atagcagcaa atcacgtgaaa atcggttgct      660
cagatagcct ggcctggag cttggcagaa ggattttttac cacttccaaa atctgtcaca      720
acctctcgta ttcaagctaa tcttgattgc tttggaattg aactgagtca tgaggagaga      780
gaaaccttaa aaacgattgc tgttcaatcg ggtgctccac gagttgatga tgtggatttc      840
```

SeqID 60
```
ttgagtgaaa agtcaagaga agaagagaaa ttaagctttta aagagcagat tctgagagat       60
ttagaaaaag taaaaggcta tgatgaagtt ctgaaagaag atgaggcagt agttcgcact      120
cctgcaaatg aaccttcaac tgaagaactc atggctgatt ccttgtcaac aaggtgtacc      180
attatgagaa aagctctatc cgtgcctact caccccaagtc aaggtgtacc agcttctcca      240
gcagatgaga ttcaaagaga aactcctggt gttccaagtc atccaagtca agatgtacct      300
tcttctccag cggaagaaag tggatcaaga ccaggtccag gtcctgttag acctaagaaa      360
cttgaaagag aatacaatga aaccccaaca agggtagctg tttcctatac gacggcagag      420
aaaaaagcag aacaagcagg tccagaaaca cctacgcctg ctacagaaac agtggatatc      480
atcagagata catcacgtcg tagccgtaga gaaggagcaa aacccgttaa gcctaagaaa      540
gagaagaagt cacatgtgaa agcttttgtg atttcattcc ttgtattcct tgccttgctc      600
tcagcaggtg gttactttgg ttaccagtac gtgctagatt ccttattacc tatcgatgct      660
aattctaaga aatatgtgac ggttggaatt ccagaaggtt caaacgttca agaaatcggt      720
acgacgcttg aaaaagctgg tttggtaaag catggtctga ttttttagttt ttatgccaag      780
tataaaaatt ataccgactt gaaagcaggt tactacaatt tgcaaaagag tatgagtaca      840
gaagacttac tcaaagagtt gcaaaaaggt ggaacagatg aaccgcaaga acctgtactt      900
gcgactttga caattccaga aggttatacc ttggatcaga ttgctcaagc tgtgggtcaa      960
ttgcaaggtg acttcaaaga gtctttgaca gcggaggctt cttggctaa agttcaagat      1020
gagacgttta tcagtcaagc agtagcgaaa tatcctactt tactggaaag tttgcctgta     1080
```

```
aaagacagcg gtgcgcgtta tcgtttggaa ggataccttt tcccagctac atactctatc   1140
aaggaaagca caactattga gagcttgatt gatgagatgt tagctgctat ggataagaac   1200
ctatctcctt actatagtac tatcaaatct aaaaacttga ctgtcaatga gttgttgacc   1260
attgcttcct tggtcgaaaa agaaggtgcc aagacagaag atcgtaagct cattgcaggt   1320
gtattctaca atcgtttgaa tcgtgatatg ccacttcaaa gtaatattgc aatcttgtat   1380
gcccaaggaa aactggggca aaatatcagt ctagctgagg atgttgcgat tgataccaac   1440
attgattcac cttataatgt ttataaaaat gtaggtctca tgcctggtcc agtcgatagt   1500
ccaagtctgg atgcgattga gtcaagcatc aatcaaacta agagcgataa cctctacttt   1560
gtagcagatg tcacagaagg caaggtctac tatgctaaca atcaagaaga ccacgaccgc   1620
aatgtcgctg aacatgtcaa cagcaaatta aac                               1653
```

SeqID 61
```
atgaaacaag aacgatttcc attggtgtca gatgacgagg tcatgttgac tgaaatgcca     60
gtcatgaatc tctatgatga gtctgatctg atcagtaata tcaagggtga gtatcgagat    120
aaaaattatt tagaatgggc tcctattgct gaagaaaaac cagtaaaacc gattgaaaag    180
caagtcgaaa aacctaaaaa ggctcctta ggggttaaaa agaaggaaa gagctatgcg    240
gaggtggcgc gtgaagaagc gcgtggcggac ttgaaaaga aacgctctgc taactaccta    300
actcaggatt tcagccttgc gagacgtcat tctcagccca gtctagttag acagggcaat    360
caaccgacag ctcctttcca aaaggaaaat cctggtgaat ttgtcaaata tagccaaaaa    420
ttgacccagt ctcattatat cttggcggaa gaagttcatt ctatccctac caagaatgaa    480
gaagtgtcag cacctgctcc aaagaaaaac aattatgatt ttctaaagaa gagccaaatc    540
tacaataaaa aaagtaaaca aacagaacaa gaacgtcggg ttgcccaaga gttgaatctg    600
accagaatga cagaa                                                     615
```

SeqID 62
```
atgaaaaagt ctaagagcaa atatctaacc ttggcaggtc ttgtcctggg tacaggagtt     60
ttattgagcg cgtgtggaaa ttctagcacg gcgtcaaaaa cctacaacta tgtttattca    120
agtgatccat ctagcttgaa ctatctagca gaaaaccgcg cagcaacatc cgatattgtt    180
gcaaatttgg tagacgggtt attagaaaat gaccaatatg ggaatattat tccatcatta    240
gcagaggatt ggactgtttc tcaggacggt ttgacctata cctacaaact tcgtaaggat    300
gccaagtggt ttacttctga gggagaagaa tatgcgcctg taactgccca ggattttgtg    360
acaggtttgc aatatgcagc tgataaaaaa tcagaagcct tgtatctagt gcaggactct    420
gttgctggtt tggatgacta tatcactggt aaaaacaagcg acttttcaac tgtcggtgtc    480
aaggcacttg atgaccaaac ggttcaatat actttggtta aaccagaact ttactggaat    540
tcaaaaacac ttgcaacgat acttttttcct gttaatgcag atttcctgaa atcaaaaggg    600
gatgattttg ggaaggcgga tccatctagt attttgtaca atggaccttt cttgatgaaa    660
gcacttgtct caaaatctgc tattgaatat aagaaaaacc ctaattactg ggatgctaag    720
aatgtctttg tagacgatgt gaaattgacc tactatgatg gtagcgacca agaatcactg    780
gaacgtaatt ttacagctgg tgcttatact acggctcgtc tttttcctaa cagctccagc    840
tatgaaggga ttaaagaaaa atacaaaaac aatatcatct atagtatgca aaattcaact    900
tcatatttct ttaatttttaa cctagatagg aagtcttaca attatacttc taaaacaagt    960
gacattgaaa agaaatcgac tcaggaagca gttctcaata aaaacttccg tcaggctatc   1020
aattttgctt ttgacagaac atcttatggg gctcagtctg aagggaaaga aggtgcaaca   1080
aagattttgc gtaacctagt ggttcctcca aactttgtca gtatcaaggg aaaagacttt   1140
ggtgaagttg tagcctctaa gatggtcaac tatggtaagg aatggcaagg tatcaacttt   1200
gcggatggtc aagacccta ctacaatcct gagaaagcca aggctaagtt tgcggaagct   1260
aagaaagaac tcgaagcaaa gggtgttcaa ttcccaatcc acttggataa gactgtggaa   1320
gtaacagata aagtaggcat acaaggagtt agttctatca acaatcaat tgaatctgtt   1380
ttaggttctg ataatgtagt gattgacatt cagcaattaa catcagatga gtttgacagt   1440
tcaggctact ttgctcaaac agctgctcag aaagattatg atttatatca tggcggttgg   1500
ggacctgatt atcaagaccc gtcaacctat ctcgatattt ttaatactaa tagtggagga   1560
tttctgcaaa atcttggact agagcctggt gaggccaatg acaaggctaa ggcagttgga   1620
ctggatgtct atactcaaat gttggaagaa gctaataacg aacaaatcc ggcaaaacgt   1680
tatgagaaat atgctgatat tcaagcttgg ttgattgata gttctttagt tcttccaagt   1740
gtttcgcgtg ggggaacacc atcattgaga agaaccgtac catttgctgc tgcctatggt   1800
ttaaccggta caaaaggggt tgaatcatat aaatacctca agtacaaga taagattgtc   1860
acaacagacg aatatgcaaa agccagagaa aaatggttga agaaaaaga agaatccaat   1920
aaaaaagccc aagaagaatt ggcaaaacat gtcaaa                              1956
```

SeqID 63
```
gtggaacagc attcagatgt ctgttacatt ttttatagga gagaaagatt gaaaacaaaa     60
attggattag caagtatctg tttactaggc ttggcaacta gtcatgtcgc tgcaaatgaa    120
actgaagtag caaaaacttc gcaggataca acgacagctt caagtagttc agagcaaaat    180
cagtcttcta ataaaacgca aacgagcgca gaagtacaga ctaatgctgc tgcccactgg    240
gatggggatt attatgtaaa ggatgatggt tctaaagctc aaagtgaatg gattttttgac    300
aactactata aggcttggtt ttatattaat tcagatggtc gttactcgca gaatgaatgg    360
catggaaatt actacctgaa atcaggtgga tatatggccc aaaacgagtg gatctatgac    420
agtaattaca agagttggtt ttatctcaag tcagatgggg cttatgctca tcaagaatgg    480
```

```
caattgattg gaaataagtg gtactacttc aagaagtggg gttacatggc taaaagccaa     540
tggcaaggaa gttatttctt gaatggtcaa ggagctatga tgcaaaatga atggctctat     600
gatccagcct attctgctta tttttatcta aaatccgatg gaacttatgc taaccaagag     660
tggcaaaaag tgggcggcaa atggtactat ttcaagaagt ggggctatat ggctcggaat     720
gagtggcaag gcaactacta tttgactgga agtggtgcca tggcgactga cgaagtgatt     780
atggatggta ctcgctatat ctttgcggcc tctggtgagc tcaaagaaaa aaaagatttg     840
aatgtcggct gggttcacag agatggtaag cgctatttct ttaataatag agaagaacaa     900
gtgggaaccg aacatgctaa gaaagtcatt gatattagtg agcacaatgg tcgtatcaat     960
gattggaaaa aggttattga tgagaacgaa gtggatggtg tcattgttcg tctaggttat    1020
agcggtaaag aagacaagga attggcgcat aacattaagg agttaaaccg tctgggaatt    1080
ccttatggtg tctatctcta tacctatgct gaaaatgaga ccgatgctga gagtgacgct    1140
aaacagacca ttgaacttat aaagaaatac aatatgaacc tgtcttaccc tatctattat    1200
gatgttgaga attgggaata tgtaaataag agcaagagag ctccaagtga tacaggcact    1260
tgggttaaaa tcatcaacaa gtacatggac acgatgaagc aggcgggtta tcaaaatgtg    1320
tatgtctata gctatcgtag tttattacag acgcgtttaa aacacccaga tattttaaaa    1380
catgtaaact gggtagcggc ctatacgaat gctttagaat gggaaaaccc tcattattca    1440
ggaaaaaaag gttggcaata tacctcttct gaatacatga aaggaatcca agggcgcgta    1500
gatgtcagcg tttgggtat                                                  1518
```

SeqID 64

```
atggcaaaag aaccgtggca agaagatatc tatgatcaag aagaatcaag agcagagcgt      60
cggcatcgaa accacggagg ggctgatagg atggctaatc gtattttgac gatcctagct     120
agtattttct ttgtaattgt ggtggtgatg gtcatcgttc tcatctatct atcatcgggg     180
gggagtaatc gcacagcagc cttaaaaggc tttcatgatt ctgatgccag tgtagtacaa     240
atctcatctt caagtagttc tcagcctgag cagagttcag agccagaatc tacttctagt     300
agttcagaag aagctgctaa tcctgaagga acgattaaag ttctcgcagg agaaggggaa     360
gcagctattg ccgctcgtgc aggaatctcc attgctcagt tagaggcctt gaatcctggg     420
cacatggcta caggatcttg gtttgctaat ccaggtgatg ttataaaaat aaaa           474
```

SeqID 65

```
atgccaatta catcattaga aataaaggac aagacttttg gaactcgatt cagaggtttt      60
gatccagaag aagtcgatga atttttagat attgtggttc gtgattacga agatcttgtg     120
cgtgcgaatc atgataaaaa tttgcgtatt aagagtttag aagagcgttt gtcttacttt     180
gatgaaataa aagattcatt gagccagtct gtattgattg ctcaggatac agctgagaga     240
gtgaaacagg cggcgcataa acgttcaaac aatatcattc atcaagcaga gcaagatgcg     300
caacgcttgt tggaagaagc taaatataag gcaaacgaga ttcttcgtca agcaactgat     360
aatgctaaga aagtcgctgt tgaaacagaa gaattgaaga acaagagccg tgtcttccac     420
caacgtctca aatctacaat tgagagtcag ttggctattg ttgaatcttc agattgggaa     480
gatattctcc gtccaacagc tacttatctt caaaccagtg atgaagcctt taaagaagtg     540
gttagcgaag tacttggaga accgattcca gctccaattg aagaagaacc aattgatatg     600
acacgtcagt tctctcaagc agaaatggca gaattacaag ctcgtattga ggtagccgat     660
aaagaattgt ctgaatttga agctcagatt aaacaggaag tggaagctcc aactcctgta     720
gtgagtcctc aagttgaaga agagcctctg ctcatccagt ggcccaatg tatgaagaac     780
cagaag                                                              786
```

SeqID 66

```
atgtctttaa aagatagatt cgatagattt atagattatt ttacggagga tgaggattca      60
agtctccctt atgaaaaaag agatgagcct gtgtttactt cagtaaattc ttcacaggaa     120
ccggctctcc caatgaatca accttacag tcggctggca caaaagagaa caatatcacc     180
agacttcatg caagacaaca ggaattggca aatcagagtc agcgtgcaac ggataaggtc     240
attatagatg ttcgttatcc tagaaaatat gaggatgcaa cagaaattgt tgatttattg     300
gcaggaaacg aaagtatctt gattgatttt cagtatatga cagaggtgca ggctcgtcgt     360
tgtttggact atttggatgg agcttgtcat gttttagctg gaaatttgaa aaaggtagct     420
tctaccatgt atttgttgac accagtgaac gttattgtaa atgttgaaga tatccgttta     480
ccagatgaag atcaacaggg tgagttcggt tttgatatga gcgaaatag agtacga         537
```

SeqID 67

```
atgtcagatt tgaaaaaata cgaaggtgtc attccagcct tctacgcatg ttatgatgat      60
caaggagaag taagcccaga acgtacgcgt gccttggttc aatacttcat tgataaaggt     120
gttcaaggtc tttatgtcaa tggttcttct ggtgaatgta tctaccaaag cgttgaagat     180
cgcaagttca ttttggagga agtcatggcg gtagccaaag gtaaattgac cattattgcc     240
catgttgctt gcaataatac taaagatagt atggaacttg ctcgccatgc tgaaagcttg     300
ggagtagatg ctattgcaac gattccacca atttatttcc gcttgccaga atactcagtt     360
gccaaatact ggaacgatat cagttctgca gctccaaaca cagactacgt gatttacaac     420
attcctcaat ggcagggggt gctttgact ccaagccttt acacagaaat gttgaaaaat     480
cctcgtgtta tcggtgtgaa gaactcttct atgccagttc aagatatcca aacctttgtc     540
agccttggtg gagaagacca tatcgtcttt aatggtcctg atgagcagtt cctaggagga     600
cgcctcatgg gggctagggc tggtatcggt ggtacttatg gtgctatgcc agaactcttc     660
```

```
ttgaaactca  atcagttgat  tgcggataag  gacctagaaa  cagcgcgtga  attgcagtat      720
gctatcaacg  caatcattgg  taaactcact  tctgctcatg  gaaatatgta  cggtgtcatc      780
aaagaagtct  tgaaaatcaa  tgaaggcttg  aatattggat  ctgttcgttc  accattgaca      840
ccagtgactg  aagaagatcg  tccagttgta  gaagcggctg  ctgccttgat  tcgtgaaacc      900
aaggagcgct  tcctc                                                          915


SeqID 68
atgaataaaa  gaggtcttta  ttcaaaacta  ggaatttccg  ttgtaggcat  tagtctttta       60
atgggagtcc  ccactttgat  tcatgcgaat  gaattaaact  atggtcaact  gtccatatct      120
cctatttttc  aaggaggttc  atatcaactg  aacaataaga  gtatagatat  cagctctttg      180
ttattagata  aattgtctgg  agagagtcag  acagtagtaa  tgaaatttaa  agcagataaa      240
ccaaactctc  ttcaagcttt  gtttggccta  tctaatagta  aagcaggctt  taaaaataat      300
tacttttcaa  ttttcatgag  agattctggt  gagataggtg  tagaaataag  agacgcccaa      360
aagggaataa  attatttatt  ttccagacca  gcttcattat  ggggaaaaca  taaaggacag      420
gcagttgaaa  atacactagt  atttgtatct  gattctaaag  ataaaacata  cacaatgtat      480
gttaatggaa  tagaagtgtt  ctctgaaaca  gttgatacat  ttttgccaat  ttcaaatata      540
aatggtatag  ataaggcaac  actaggagct  gttaatgtg   aaggtaagga  acattacctc      600
gcaaaaggaa  gtattgatga  aatcagtcta  tttaacaaag  caattagtga  tcaggaagtt      660
tcaactattc  ccttgtcaaa  tccatttcag  ttaattttcc  aatcaggaga  ttctactcaa      720
gctaactatt  ttagaatacc  gacactatat  acattaagta  gtggaagagt  tctatcaagt      780
attgatgcac  gttatggtgg  gactcatgat  tctaaaagta  agattaatat  tgccacttct      840
tatagtgatg  ataatgggaa  aacgtggagt  gagccaattt  ttgctatgaa  gtttaatgac      900
tatgaggagc  agttagttta  ctggccacga  gataaataat  taaagaatag  tcaaattagt      960
ggaagtgctt  cattcataga  ttcatccatt  gttgaagata  aaaaatctgg  gaaaacgata     1020
ttactagctg  atgttatgcc  tgcgggtatt  ggaaataata  atgcaaataa  agccgactca     1080
ggttttaaag  aaataaatgg  tcattattat  ttaaaactaa  agaagaatgg  agataacgat     1140
ttccgttata  cagttagaga  aaatggtgtc  gtttataatg  aaacaactaa  taaacctaca     1200
aattatacta  taaatgataa  gtatgaagtt  ttggagggag  gaaagtcttt  aacagtcgaa     1260
caatattcgg  ttgattttga  tagtggctct  ttaagagaaa  ggcataatgg  aaaacaggtt     1320
cctatgaatg  ttttctacaa  agattcgtta  tttaaagtga  ctcctactaa  ttatatagca     1380
atgacaacta  gtcagaatag  aggagagagt  tgggaacaat  ttaagttgtt  gcctccgttc     1440
ttaggagaaa  aacataatgg  aacttactta  tgtcccggac  aaggtttagc  attaaaatca     1500
agtaacagat  tgattttgc   aacatatact  agtggagaac  taacctatct  catttctgat     1560
gatagtggtc  aaacatggaa  gaaatcctca  gcttcaattc  cgtttaaaaa  tgcaacagca     1620
gaagcacaaa  tggttgaact  gagagatgat  gtgattagaa  cattcttag   aaccactaca     1680
ggtaagatag  cttatatgac  tagtagagat  tctggagaaa  catggtcgaa  agtttcgtat     1740
attgatggaa  tccaacaaac  ttcatatggc  acacaagtat  ctgcaattaa  atactctcaa     1800
ttaattgatg  gaaaagaagc  agtcattttg  agtacaccaa  attctagaag  tggccgcaag     1860
ggaggccaat  tagttgtcgg  tttagtcaat  aaagaagatg  atagtattga  ttggaaatac     1920
cactatgata  ttgatttgcc  ttcgtatggt  tatgcctatt  ctgcgattac  agaattgcca     1980
aatcatcaca  taggtgtact  gtttgaaaaa  tatgattcgt  ggtcgagaaa  tgaattgcat     2040
ttaagcaatg  tagttcagta  tatagatttg  gaaattaatg  atttaacaaa  a              2091


SeqID 69
atgaatcgga  gtgttcaaga  acgtaagtgt  cgttatagca  ttaggaaact  atcggtagga       60
gcggtttcta  tgattgtagg  agcagtggta  tttggaacgt  ctcctgtttt  agctcaagaa      120
ggggcaagtg  agcaacctct  ggcaaatgaa  actcaacttt  cgggggagag  ctcaacccta      180
actgatacag  aaaagagcca  gccttcttca  gagactgaac  tttctggcaa  taagcaagaa      240
caagaaagga  aagataagca  agaagaaaaa  attccaagag  attactatgc  acgagatttg      300
gaaaatgtcg  aaacagtgat  agaaaagaa   gatgttgaaa  ccaatgcttc  aaatggtcag      360
agagttgatt  tatcaagtga  actagataaa  ctaaagaaac  ttgaaaacgc  aacagttcac      420
atggagttta  agccagatgc  caaggcccca  gcattctata  atctcttttc  tgtgtcaagt      480
gctactaaaa  aagatgagta  cttcactatg  gcagtttaca  ataatactgc  tactctagag      540
gggcgtggtt  cggatgggaa  acagttttac  aataattaca  acgatgcacc  cttaaaagtt      600
aaaccaggtc  agtggaattc  tgtgactttc  acagttgaaa  aaccgacagc  agaactacct      660
aaaggccgag  tgcgcctcta  cgtaaacggg  gtattatctc  gaacaagtct  gagatctggc      720
aatttcatta  agatatgcc   agatgtaacg  catgtgcaaa  tcggagcaac  caagcgtgcc      780
aacaatacgg  tttggggggtc  aaatctacag  attcggaatc  tcactgtgta  taatcgtgct      840
ttaacaccag  aagaggtaca  aaaacgtagt  caactttta   aacgctcaga  tttagaaaaa      900
aaactacctg  aaggagcggc  tttaacagag  aaaacggaca  tattcgaaag  cgggcgtaac      960
ggtaacccaa  ataaagatgg  aatcaagagt  tatcgtattc  cagcacttct  caagacagat     1020
aaaggaactt  tgatcgcagg  tgcagatgaa  cgccgtctcc  attcggagtga  ctgggggtgat     1080
atcggtatgg  tcatcagacg  tagtgaagat  aatggtaaaa  cttggggtga  ccgagtaacc     1140
attaccaact  tacgtgacaa  tccaaaagct  tctgaccc    atcgatcggttc  accagtgaat     1200
atcgatatgg  tgttggttca  agatcctgaa  accaaacgaa  tcttttctat  ctatgacatg     1260
ttcccagaag  ggaagggaat  ctttggaatg  tcttcacaaa  aagaagaagc  ctacaaaaaa     1320
atcgatggaa  aaacctatca  aatcctctac  cgtgaaggag  aaaaggagc   ttataccatt     1380
cgagaaaatg  gtactgtcta  tacaccagat  ggtaaggcga  cagactatcg  cgttgttgta     1440
```

```
gatcctgtta aaccagccta tagcgacaag ggtgatctat acaagggtga ccaattacta   1500
ggaaatatct acttcacaac aaacaaaact tctccattta gaattgccaa ggatagctat   1560
ctatggatgt cctacagtga tgacgacggg aagacatggt cagctcctca agatattact   1620
ccgatggtca aagccgattg gatgaaattc ttgggtgtag gtcctggaac aggaattgta   1680
cttcggaatg ggcctcacaa gggacggatt ttgataccgg tttatacgac taataatgta   1740
tctcacttag atggctcgca atcttctcgt gtcatctatt cagatgatca tggaaaaact   1800
tggcatgctg gagaagcggt caacgataac cgtcaggtag acggtcaaaa gatccactct   1860
tctacgatga acaatagacg tgcgcaaaat acagaatcaa cggtggtaca actaaacaat   1920
ggagatgtta aactctttat gcgtggtttg actggagatc ttcaggttgc tacaagtaaa   1980
gacggaggag tgacttggga gaaggatatc aaacgttatc cacaggttaa agatgtctat   2040
gttcaaatgt ctgctatcca tacgatgcac gaaggaaaag aatacatcat cctcagtaat   2100
gcaggtggac cgaaacgtga aaatgggatg gtccacttgg cacgtgtcga agaaaatggt   2160
gagttgactt ggctcaaaca caatccaatt caaaaaggag agtttgccta taattcgctc   2220
caagaattag gaaatgggga gtatggcatc ttgtatgaac atactgaaaa aggacaaaat   2280
gcctataccc tatcatttag aaaatttaat tgggaatttt tgagcaaaaa tctgatttct   2340
cctaccgaag cgaactagag agatgggcaa aggagagatg ggcaaaggag ttattggctt   2400
ggagttcgac tcagaagtat tggtcaacaa ggctccaacc cttcaattgg caaatggtaa   2460
aacagcgact ttcctaaccc agtatgatag caagaccttg ttgtttgcag tagataagga   2520
agatatcgga caggaaatta ttggtatagc taaaggaagc atcgaaagta tgcataatct   2580
tcctgtaaat ctagcaggtg ccagagttcc tggcggagta aatggtagca aagcagcggt   2640
gcatgaagtt ccagaattta caggggggagt taatggtaca gagccagctg ttcatgaaat   2700
cgcagagtat aagggatctg attcgcttgt aactcttact acaaaaaaag attatactta   2760
caaagctcct cttgctcagc aggcacttcc tgaaacagga aacaaggaga gtgacctcct   2820
agcttcacta ggactaacag ctttcttcct tggtctgttt acgctaggga aaagagaga   2880
acaa                                                                  2884
```

SeqID 70
```
atgatccaaa tcggcaagat ttttgccgga cgctatcgga ttgtcaaaca gattggtcga   60
ggaggtatgg cggatgtcta cctagccaaa gacttaatct tagatgggga agaagtggca   120
gtgaaggttc tgaggaccaa ctaccagacg gacccgatag ctgtagctcg tttttcagcgt   180
gaagcgagag ctatggcaga tctagaccat cctcatatcg ttcggataac agatattggc   240
gaggaagacg gtcaacagta cctagctatg gagtatgtgg ctggactgga cctcaaacgc   300
tatatcaagg aacattatcc tctttctaat gaagaagcag tccgtatcat gggacaaatt   360
ctcttggcta tgcgcttggc ccatactcga ggaattgttc acagggactt gaaacctcaa   420
aatatcctct tgacaccaga tgggactgcc aaggtcacag actttgggat tgctgtagcc   480
tttgcagaga caagtctgac ccagactaac tcgatgttgg gctcagttca ttacttgtca   540
ccagagcagg cgcgtggttc gaaggcgact gtgcagagtg atatctatgc catggggatt   600
attttctatg agatgctgac aggccatatc ccttatgacg gggatagcgc ggtgaccatt   660
gccctccagc atttccagaa accctgccg tccgttattg cagaaaatcc atctgtacct   720
caggctttag aaaatgttat tatcaaggca actgctaaaa agttgaccaa tcgctaccgc   780
tcggtttcag agatgtatgt ggacttgtct agtagcttgt cctacaatcg tagaaatgaa   840
agtaagttaa tctttgatga aacgagcaag gcagatacca agaccttgcc gaaggtttct   900
cagagtacct tgacatctat tcctaaggtt caagcgcaaa cagaacacaa atcaatcaaa   960
aacccaagcc aggctgtgac agaggaaact taccaaccac aagcaccgaa aaaacataga   1020
tttaagatgc gttacctgat tttgttggcc agccttgtat tggtggcagc ttctcttatt   1080
tggatactat ccagaactcc tgcaaccatt gccattccag atgtggcagg tcagacagtt   1140
gcagaggcca aggcaacgct caaaaaagcc aattttgaga ttggtgagga gaagacagag   1200
gctagtgaaa aggtggaaga agggcggatt atccgtacag atcctggcgc tggaactggt   1260
cgaaaagaag gaacgaaaat caatttggtt gtctcatcag gcaagcaatc tttccaaatt   1320
agtaattatg tcggtcggaa atcctctgat gtcattgcgg aattaaaaga gaaaaaagtt   1380
ccagataatt tgattaaaat tgaggaagaa gagtcgaatg agagtgaggc tggaacggtc   1440
ctgaagcaaa gtctaccaga aggtacgacc tatgacttga gcaaggcaac tcaaattgtt   1500
ttgacagtag ctaaaaaagc tacgacgatt caattaggga actatattgg acggaactct   1560
acagaagtaa tctcagaact caagcgagag aaggttcctg agaatttgat taagatagag   1620
gaagaagagt ccagcgaaag cgaaccagga acgattatga aacaaagtcc aggtgccgga   1680
acgacttatg atgtgagtaa acctactcaa attgtcttga cagtagctaa aaaagttaca   1740
agtgttgcca tgccgagtta cattggttct agcttggagt ttactaagaa caatttgatt   1800
caaattgttg ggattaagga agctaatata gaagttgtag aagtgacgac agcgcctgca   1860
ggtagtgcag aaggcatggt tgttgaacaa agtcctagag caggtgaaaa ggtagacctc   1920
aataagacta gagtcaagat ttcaatctac aaacctaaaa caacttcagc tactcct     1977
```

SeqID 71
```
atgacaaaac taatctttat ggggaccccc gacttttcag caacagtctt aaaaggactt   60
ttgacagatg accgttacga aattctagcc gttgtgaccc agccagaccg tgctgttggt   120
cgtaaaaaag ttatccaaga aaccccagtc aagcaggctg ccaaggaagc aggactatct   180
atctaccaac ctgaaaaatt atctggaagt ccagagatgg aagatcttat gaagctagga   240
gcagatggaa ttgtgactgc tgcttttggg cagtttctcc caagcaaact ccttgatagc   300
atggactttg ctgtcaacgt tcatgcctcc ctccttccta gacaccgtgg tggtgcgcct   360
```

```
atccattatg ccttgattca aggggatgag gaagctggtg tgaccatcat ggaaatggtt     420
aaggaaatgg atgcaggaga tatgatttct cgtcgcagca ttccgatcac agatgaggac     480
aatgttggca ccttgtttga aaaattggcg ctagttggtc gtgatttgct tttggacact     540
ctgcctgcct atattgctgg tgatatcaaa cctgaaccgc aggatacgag tcaggttacc     600
ttctctccaa atataaagcc agaggaagaa aaactggact ggaacaaaac caatcgtcaa     660
ctctttaacc aaaattcgtgg aatgaacccc tggcctgttg cccatacttt ccttaagggc     720
gaccgcttta agatttatga agccctacca gtagaaggtc agggaaatcc aggtgagatt     780
ctctctatcg gcaagaaaga attgattgtc gcaacggctg aaggggctct atccctcaaa     840
caagtgcagc cagctggtaa gcctaagatg gacattgctt ccttcctcaa cggagttgga     900
cgtacattga ctgtaggaga acgatttggt gac                                  933
```

SeqID 72
```
gtgtttagac gtttaggtca agatttccag cttaggaaag tgaaaaagat tttaaagcag    60
attaatgccc tgaaaggcaa gatgtcctct ctttcggatc aagaattagt agctaaaaca   120
gtagagtttc gtcagcgtct ttccgaggga gaaagtctag acgatatttt ggttgaagct   180
tttgctgtgg tgcgtgaagc agataagcgg attttaggga tgtttcctta tgatgttcaa   240
gtcatgggag ctattgtcat gcactatgga aatgttgctg agatgaatac gggggaaggt   300
aagaccttga cagctaccat gcctgtctat ttgaacgctt tttcaggaga aggagtgatg   360
gttgtgactc ctaatgagta tttatcaaag cgtgatgccg aggaaatggg tcaagtttat   420
cgttttctag gattgaccat tggtgtacca tttacggaag atccaaagaa ggagatgaaa   480
gctgaagaaa agaagcttat ctatgcttcg gatatcatct acacaaccaa tagtaattta   540
ggttttgatt atctaaatga taacctagcc tcgaatgaag aaggtaagtt tttacgaccg   600
tttaactatg tgattattga tgaaattgat gatatcttgc ttgatagtgc acaaactcct   660
ctgattattg cgggttctcc tcgtgttcag tctaattact atgcgatcat tgatacactt   720
gtaacaacct tggtcgaagg agaggattat atctttaaag aggagaaaga ggaggtttgg   780
ctcactacta aggggggccaa gtctgctgaa aatttcctag ggattgataa tttatacaag   840
gaagagcatg cgtcttttgc tcgtcatttg gtttatgcga ttcgagctca taagctcttt   900
actaaagata aggactatat cattcgtgga aatgagatgg tactggttga taagggaaca   960
gggcgtctaa tggaaatgac taaacttcaa ggaggtctcc atcaggctat tgaagccaag  1020
gaacatgtca aattatctcc tgagacgcgg gctatggcct cgatcaccta tcagagtctt  1080
tttaagatgt ttaataagat atctggtatg acagggacag gtaaggtcgc ggaaaaagag  1140
tttattgaaa cttacaatat gtctgtagta cgcattccaa ccaatcgtcc gagacaacgg  1200
attgactatc cagataatct atatatcact ttacctgaaa aagtgtatgc atccttggag  1260
tacatcaagc aataccatgc taagggaaat cctttactcg tttttgtagg ctcagttgaa  1320
atgtctcaac tctattcgtc tctcttgttt cgtgaaggga ttgcccataa tgtcctaaat  1380
gctaataatg cggcgcgtga ggctcagatt atctccgagt caggtcagat gggggctgtg  1440
acagtggcta cctctatggc aggacgtggt acggatatca agcttggtaa aggagtcgca  1500
gagcttgggg gcttgattgt tattgggact gagcggatgg aaagtcagcg gatcgaccta  1560
caaattcgtg gccgttctgg tcgtcaggga gatcctggta tgagtaaatt ttttgtatcc  1620
ttagaggatg atgttatcaa gaaatttggt ccatcttggg tgcataaaaa gtacaaagac  1680
tatcaggttc aagatatgac tcaaccggaa gtattgaaag tcgtaaata ccggaaacta  1740
gtcgaaaagg ctcagcatgc cagtgatagt gctggacgtt cagcacgtcg tcagactctg  1800
gagtatgctg aaagtatgaa tatacaacgg gatatagtct ataaagagag aaatcgtcta  1860
atagatggt ctcgtgactt agaggatgtt gttgtgataa tcattgagag atatacagaa  1920
gaggtagcgg ctgatcacta tgctagtcgt gaattattgt ttcactttat tgtgaccaat  1980
attagttttc atgttaaaga ggttccagat tatatagatg taactgacaa aactgcagtt  2040
cgtagcttta tgaagcaggt gattgataaa gaactttctg aaaagaaaga attacttaat  2100
caacatgact tatatgaaca gttttttcga ctttcactgc ttaaagccat tgatgacaac  2160
tgggtagagc aggtagacta tctacaacag ctatccatgg ctatcggtgg tcaatctgct  2220
agtcagaaaa atccaatcgt agagtactat caagaagcct acgcgggctt tgaagctatg  2280
aaagaacaga ttcatgcgga tatggtgcgt aatctcctga tggggctggt tgaggtcact  2340
ccaaaaggtg aaatcgtgac tcatttccca                                     2370
```

SeqID 73
```
atgaccgaaa cggtagaaga taaagtaagt cattcaatta ctgggcttga tatcctcaag    60
gggatagttg ctgcgggagc tgtcataagt ggaaccgttg caactcaaac gaaggtattt   120
acaaatgagt cagcagtact tgaaaaaact gtagagaaaa cggatgcttt ggcaacaaat   180
gatacagtag ttctaggtac gatatctaca agtaattcag cgagttcaac tagtttgtca   240
gcttcagagt cggcaagtac atctgcatct gagtcagcct caaccagcgc ttcgacctca   300
gcaagtacaa gtgcatcaga atcagcaagt acatcggctt cgacaagtat ttctgcatca   360
tctactgtgg taggttcaca aacagctgcc gctacagaag caactgctaa gaaggtcgaa   420
gaagatcgta agaaaccagc tagtgattat gtagcatcag ttacaaatgt caatctccaa   480
tcttatgcta gcgacgcaa gcgttcagtg gattccatcg agcaattgct ggcttctata   540
aaaaatgctg ctgtttttttc tggcaatacg attgtaaatg gcgcccctgc aattaatgca   600
agtctaaaca ttgctaaaag tgagacaaaa gtttatacag gtgaaggtgt agattcggta   660
tatcgtgttc caatttacta taaattgaaa gtgacaaatg atggttcaaa attgaccttt   720
acctatacgg ttacgtatgt gaatcctaaa acaaatgatc ttggtaatat atcaagtatg   780
cgtcctggat attctatcta taattcaggt acttcaacac aaacaatgtt aacccttggc   840
```

```
agtgatcttg gtaaaccttc aggtgtaaag aactacatta ctgacaaaaa tggtagacag    900
gttctatcct ataatacatc tacaatgacg acgcagggta gtgggtatac ttggggaaat    960
ggtgcccaaa tgaatggttt ctttgctaag aaaggatatg gattaacatc atcttggact   1020
gtaccaatta ctggaacgga tacatccttt acatttaccc cttacgctgc tagaacagat   1080
agaattggaa ttaactactt caatggtgga ggaaaggtag ttgaatctag cacgaccagt   1140
cagtcacttt cacagtctaa gtcactctca gtaagtgcta gtcaaagcgc ctcagcttca   1200
gcatcaacaa gtgcgtcggc ttcagcatca accagtgcct cggcttcagc gtcaaccagt   1260
gcgtcagctt cagcaagtac cagtgcttca gtctcagcat caacaagtgc ttcagcctca   1320
gcatcgacaa gtgcctcggc ttcagcaagc acatcagcat ctgaatcagc gtcaaccagt   1380
gcttcggctt cagcaagtac cagtgcttca gcttcagcat caaccagcgc ctcggcctca   1440
gcaagcacct cagcttctga atcggcctca accagcgcct cggcctcagc aagcacctca   1500
gcttctgaat cggcctcaac cagcgcctca gcctcagcat caacgagtgc ttcggcttca   1560
gcaagcacaa gcgcctcggg ttcagcatca acgagtacgt cagcttcagc gtcaaccagt   1620
gcttcagcct cagcatcaac aagtgcgtca gcctcagcaa gtatctcagc gtctgaatcg   1680
gcatcaacga gtgcgtctga gtcagcatca acgagtacgt cagcctcagc aagcacctca   1740
gcttctgaat cggcctcaac cagtgcgtca gcctcagcat cgacaagcgc ctcagcttca   1800
gcaagtacca gtgcttcagc ctcagcgtcg acaagtgcgt cggcctcaac cagtgcatct   1860
gaatcggcat caaccagtgc gtcagcctca gcaagtacta gtgcatcggc ttcagcatca   1920
accagtgcct cggcttcagc gtcaaccagt gcgtcagctt cagcaagtac cagtgcttca   1980
gtctcagcat caacaagtgc ttcagcctca gcatcgacaa gtgcctcggc ttcagcaagc   2040
acatcagcat ctgaatcagc gtcgacaagc gcctcagctt cagcaagtac cagtgcgtca   2100
gcctcagcgt cgacaagtgc gtcagcctca gcaagtacta gtgcatcagc ttcagcatca   2160
acgagtgcat cggcttcggc gtcaaccagt gcatcagagt cagcaagtac cagtgcgtca   2220
gcttccgcat caacaagtgc ctcggcttca gcaagcacca gtgcgtcggc ttcagcaagt   2280
actagcgcct cagcctcagc ctcaaccagt gcgtcagcct cagcaagtat ctcagcgtct   2340
gaatcggcat caacgagtgc gtccgcttca gcaagtacta gcgcctcagc ctcagcgtca   2400
acaagtgcat cggcttcagc gtcaacgagt gcgtctgaat cggcatcaac gagtgcgtcc   2460
gcttcagcaa gtactagcgc ctcagcctca gcgtcaacaa gtgcatcggc ttcagcatca   2520
acgagtgcgt ccgcttcagc aagtactagc gcctcagcct cagcgtcaac aagtgcatcg   2580
gcttcagcgt caacgagtgc gtctgagtca gcatcaacga gtgcgtcagc ctcagcaagc   2640
acatcagctt ctgaatctgc atcaaccagt gcgtcagcct cagcatcgac aagcgcctca   2700
gcttcagcaa gtaccagtgc gtcagcctca gcgtcgacaa gtgcgtcggc ttcagcaagt   2760
accagtgcgt cagcctcagc aagtaccagt gcgtcagcct cagcgtcgac aagtgcgtcg   2820
gcctcaacca gtgcatctga atcggcatca accagtgcgt cagcctcagc aagtactagt   2880
gcatcagctt cagcatcaac gagtgcggtt gcttcagcat caaccagtgc atcagagtca   2940
gcaagtacca gtgcgtcagc ttccgcatca acaagtgcct cggcttcagc aagtactagc   3000
gcctcagcct cagcgtcaac aagtgcttca gcttccgcgt caaccagcgc ctcggcctca   3060
gcaagtatct cagcgtctga atcggcatca acaagtgcct cggcttcagc atcaacgagt   3120
gcatcagtct cagcaagcac cagtgcgtcg gcctcagcaa gcaccagcgc gtctgaatcc   3180
gcatcaacca gtgcctcagc ttcagcaagt acctcagcat ctgaatcagc atcaacaagt   3240
gcctcggctt cagcaagcac aagtgcttca gcctcagcaa gtatctcagc gtctgaatcg   3300
gcatcaacga gtgcgtccgc ttcagcaagt actagcgcct cagcatcagc gtcaacaagt   3360
gcttcggctt cagcgtcaac gagtgcgtct gagtcagcat caacgagtac gtcagcctca   3420
gcaagcacat cagcttctga atctgcatca accagtgcgt cagcctcagc atcgacaagc   3480
gcctcagctt cagcaagtac cagtgcgtca gcctcagcaa gtaccagtgc ttcagcctca   3540
gcgtcgacaa gtgcgtcggc ctcaaccagt gcatctgaat cggcatcaac cagtgcgtca   3600
gcctcagcaa gtactagcgc ctcagcctca gcatcaacga gtgcgtccgc ttcagcaagt   3660
actagtgcat cagcttcagc aagtactagc gcctcagcct cagcgtcgac aagcgcctca   3720
gcttcagcaa gtaccagtgc gtcagcctca gcgtcgacaa gtgcgtcggc ttcagcaagt   3780
acctcagcgt ctgaatcagc atcaacaagt gcgtcggctt cagcatcaac gagtgcatca   3840
gcttcagcat caacaagtgc ttcagcttca gcaagtacca gtgcgtcggc ttcagcatca   3900
acgagtgctt cagtctcagc gtcaaccagt gcctctgaat ccgcatcaac aagtgcctcg   3960
gcttcagcaa gcaccagtgc ttcggcttca gcgtcaacga gtgcgtctga gtcagcatca   4020
acgagtgcgt cagcctcagc aagcacatca gcttctgaat ctgcatcaac cagtgcgtca   4080
gcttccgcat caacaagcgc ctcggcctca gcaagtacaa gtgcttcagc ctcagcatca   4140
accagtgcat cagcttcagc ctcaacaagt gcttcagcct cagcgtcaac cagtgcctcg   4200
gcttcagcaa gtaccagtgc gtcagcttca gcaagcacaa gtgcgtcagc ttcagcatca   4260
accagtgctt cggcttcggc atcaacaagt gcctcagcat cagcatcaac gagtgcgtca   4320
gcctcagcaa gtactagtgc atcagcatca gcatcaacca gtgcatcagc ctcagcaagt   4380
atctcagcgt ctgaatcggc atcaacgagt gcatcagcat cagcatcaac gagtgcatcg   4440
gcttcagcgt caaccagtgc atcagtctca gcaagcacca gtgcgtcggc ttcagcatca   4500
acgagtgcct cagcctcagc aagtatctca gcgtctgaat cggcatcaac gagtgcgtca   4560
gcctcagcaa gtactagtgc atcggcttca gcaagcacca gtgcgtcggc ttcagcatca   4620
accagtgcct cagcctcagc aagtatctca gcgtctgaat cggcatcaac gagtgcgtca   4680
gcctcagcaa gtactagtgc atcagcatca gcatcaacga gtgcatcggc ttcagcaagt   4740
accagcgcct cagcttcagc aagcaccagt gcgtcagcct cagcaagtac cagcgcctca   4800
gcctcagcaa gcaccagtgc ctcagcttca gcaagtacca gtgcgtcagc ctcagcgtcg   4860
acaagtgcgt cggcttcagc aagtacctca gcgtctgaat cagcatcaac gagtgcatca   4920
```

```
gcttcagcat caacaagtgc ttcagcttca gcaagtacca gtgcgtcggc ttcagcatca    4980
acgagtgctt cagtctcagc gtcaaccagt gcctctgaat cagcatcaac aagtgcctcg    5040
gcttcagcaa gcaccagtgc gtcggcttca gcaagtacta gtgcatcggc ttcagcatcg    5100
acaagtgcgt ctgaatcggc atcaacgagt gcttcggctt cagcatcaac gagtgcgtca    5160
gcctcagcaa gcacatcagc ttctgaatct gcatcaacca gtgcgtccgc ttcagcgtca    5220
accagtgcgt cggcttcagc gtcgacaagt gcttcggctt cagcatcaac gagtgcgtcg    5280
gcctcagcaa gcgcaagtac ctcagcgtca gcttccgcct caaccagtgc gtcggcttca    5340
gcaagcacaa gtgcgtcagc ctcagcaagt atctcagcgt ctgaatcggc atcaacgagt    5400
gcgtctgagt cagcatcaac gagtacgtca gcctcagcaa gcacatcagc ttctgaatct    5460
gcatcaacca gtgcgtcagc ctcagcatcg acaagcgcct cagcttcagc aagtaccagt    5520
gcttcagcct cagcgtcgac aagtgcgtcg gcctcaacca gtgcatctga atcggcatca    5580
accagtgcgt cagcctcagc aagtactagt gcatcagctt cagcatcaac gagtgcatcg    5640
gcttcagcat caaccagtgc ctcggcttca gcgtcaacca gtgcgtcagc ttcagcaagt    5700
accagtgctt cagtctcagc atcaacaagt gcttcagcct cagcatcgac aagtgcctcg    5760
gcttcagcaa gcacatcagc atctgaatca gcgtcgacaa gcgcctcagc ttcagcaagt    5820
accagtgcgt cagcctcagc gtcgacaagt gcgtcagcct cagcaagtac tagtgcatca    5880
gcttcagcat caacgagtgc atcggcttcg gcgtcaacca gtgcatcaga gtcagcaagt    5940
accagtgcgt cagctccggc atcaacaagt gcctccggct cagcaagcac cagtgcgtcg    6000
gcttcagcaa gtactagcgc ctcagcctca gcctcaacca gtgcgtcagc ctcagcaagt    6060
atctcagcgt ctgaatcggc atcaacgagt gcgtccgctt cagcaagtac tagcgcctca    6120
gcctcagcgt caacaagtgc atcggcttca gcgtcaacga gtgcgtctga atcggcatca    6180
acgagtgcgt ccgcttcagc aagtactagc gcctcagcct cagcgtcaac aagtgcatcg    6240
gcttcagcat caacgagtgc gtccgcttca gcaagtacta gcgcctcagc ctcagcgtca    6300
acaagtgcat cggcttcagc gtcaacgagt gcgtctgagt cagcatcaac gagtgcgtca    6360
gcctcagcaa gcacatcagc ttctgaatct gcatcaacca gtgcgtcagc ctcagcatcg    6420
acaagcgcct cagcttcagc aagtaccagt gcgtcagccg cagcgtcagc aagtgcgtcg    6480
gcttcagcaa gtaccagtgc gtcagcctca gcaagtacca gtgcgtcagc ctcagcgtcg    6540
acaagtgcgt cggcctcaac cagtgcatct gaatcggcat caaccagtgc gtcagcctca    6600
gcaagtacta gtgcatcagc ttcagcatca acgagtgcat cggcttcagc atcaaccagt    6660
gcatcagagt cagcaagtac cagtgcgtca gcttccgcat caacaagtgc ctcggcttca    6720
gcaagtacta gcgcctcagc ctcagcgtca acaagtgctt cagcttccgc gtcaaccagc    6780
gcctcggcct cagcaagtat ctcagcgtct gaatcggcat caacaagtgc ctcggcttca    6840
gcatcaacga gtgcatcagt ctcagcaagc accagtgcgt cggcctcagc aagcaccagc    6900
gcgtctgaat ccgcatcaac cagtgcctca gcttcagcaa gtacctcagc atctgaatca    6960
gcatcaacga gtgcatcggc ttcagcaagc acaagtgctt cagcctcagc aagtatctca    7020
gcgtctgaat cggcatcaac gagtgcgtcc gcttcagcaa gtactagcgc ctcagcatca    7080
gcgtcaacaa gtgcttcggc ttcagcgtca acgagtgcgt ctgagtcagc atcaacgagt    7140
acgtcagcct cagcaagcac atcagcttct gaatctgcat caaccagtgc gtcagcctca    7200
gcatcgacaa gcgcctcagc ttcagcaagt accagtgcgt cagcctcagc aagtaccagt    7260
gcttcagcct cagcgtcgac aagtgcgtcg gcctcaacca gtgcatctga atcggcatca    7320
accagtgcgt cagcctcagc aagtactagc gcctcagcct cagcatcaac gagtgcgtcc    7380
gcttcagcaa gtactagtgc atcagcatca gcatcaacga gtgcatcggc ttcagcaagt    7440
accagcgcct cagcttcagc aagcaccagt gcgtcagcct cagcaagtac cagcgcctca    7500
gcctcagcaa gcaccagtgc ctcagcttca gcaagtacca gtgcgtcagc ctcagcgtcg    7560
acaagtgcgt cggcttcagc aagtacctca gcgtctgaat cagcatcaac gagtgcatca    7620
gcttcagcat caacaagtgc ttcagcttca gcaagtacca gtgcgtcggc ttcagcatca    7680
acgagtgctt cagtctcagc gtcaaccagt gcctctgaat cagcatcaac aagtgcctcg    7740
gcttcagcaa gcaccagtgc gtcggcttca gcaagtacta gtgcatcggc ttcagcatcg    7800
acaagtgcgt ctgaatcggc atcaacgagt gcttcggctt cagcatcaac gagtgcgtca    7860
gcctcagcaa gcacatcagc ttctgaatct gcatcaacca gtgcgtccgc ttcagcgtca    7920
accagtgcgt cggcttcagc gtcgacaagt gcttcggctt cagcatcaac gagtgcgtcg    7980
gcctcagcaa gcgcaagtac ctcagcgtca gcttccgcct caaccagtgc gtccgcttca    8040
gcaagcacaa gtgcgtcagc ctcagcaagt atctcagcgt ctgaatcggc atcaacgagt    8100
gcgtcggcct cagcaagcgc aagtacctca gcgtcagctt ccgcctcaac cagtcgtcg     8160
gcttcagcaa gcacaagtgc gtcagcctca gcaagtatct cagcgtctga atcggcatca    8220
acgagtgcgt ctgagtcagc atcaacgagt acgtcagcct cagcaagcac atcagcttct    8280
gaatcggcat caaccagtgc gtcagcctca gcatcgacaa gcgcctcagc ttcagcaagt    8340
accagtgctt cagcctcagc gtcgacaagt gcgtcggcct caaccagtgc atctgaatcg    8400
gcatcaacca gtgcgtcagc ctcagcaagt actagtgcat cagcttcagc atcaacgagt    8460
gcatcggctt cagcatcaac cagtgcctcg gcttcagcgt caaccagtgc gtcagcttca    8520
gcaagtacca gtgcttcagt ctcagcatca acaagtgctt cagcctcagc atcgacaagt    8580
gcctcggctt cagcaagcac atcagcatct gaatctgcat cgacaagtac tagtgcatca    8640
accagtgcat ctgaatcggc atcaaccagt gcgtcagcct cagcaagtac tagtgcatca    8700
gcttcagcat caacgagtgc atcggcttcg gcgtcaacca gtgcatcaga gtcagcaagt    8760
accagtgcgt cagcttccgc atcaacaagt gcctcggctt cagcaagcac atcagcatct    8820
gaatcagcgt caaccagtgc ttcggcttca gcaagtacca gtgcttcagc ttcagcatca    8880
accagcgcct cggcctcagc aagcacctca gcttctgaat cggcctcaac cagcgcctcg    8940
gcctcagcaa gcacctcagc ttctgaatcg gcctcaacca gcgcctcagc ctcagcatca    9000
```

```
acgagtgctt cggcttcagc aagcacaagc gcctcgggtt cagcatcaac gagtacgtca   9060
gcttcagcgt caaccagtgc ttcagcctca gcatcaacaa gtgcgtcagc ctcagcaagt   9120
atctcagcgt ctgaatcggc atcaacgagt gcgtctgagt cagcatcaac gagtacgtca   9180
gcctcagcaa gcacctcagc ttctgaatcg gcctcaacca gtgcgtcagc ctcagcatcg   9240
acaagcgcct cagcttcagc aagtaccagt gcttcagcct cagcgtcgac aagtgcgtcg   9300
gcctcaacca gtgcatctga atcggcatca accagtgcgt cagcctcagc aagtactagt   9360
gcatcggctt cagcatcaac cagtgcctcg gcttcagcgt caaccagtgc gtcagcttca   9420
gcaagtacca gtgcttcagt ctcagcatcc acaagtgctt cagcctcagc atcgacaagt   9480
gcctcggctt cagcaagcac atcagcatct gaatcagcgc cgacaagcgc ctcagcttca   9540
gcaagtacca gtgcgtcagc ctcagcgtcg acaagtgcgt cagcctcagc aagtactagt   9600
gcatcagctt cagcatcaac gagtgcatcg gcttcggcgt caaccagtgc atcagagtca   9660
gcaagtacca gtgcgtcagc ttccgcatca acaagtgcct cggcttcagc aagcaccagt   9720
gcgtcggctt cagcaagtac tagcgcctca gcctcagcct caaccagtgc gtcagcctca   9780
gcaagtatct cagcgtctga atcggcatca acgagtgcgt ccgcttcagc aagtactagc   9840
gcctcagcct cagcgtcaac aagtgcatcg gcttcagcgt caacgagtgc gtctgaatcg   9900
gcatcaacga gtgcgtccgc ttcagcaagt actagcgcct cagcctcagc gtcaacaagt   9960
gcatcggctt cagcatcaac gagtgcgtcc gcttcagcaa gtactagcgc ctcagcctca  10020
gcgtcaacaa gtgcatcggc ttcagcgtca acgagtgcgt ctgagtcagc atcaacgagt  10080
gcgtcagcct cagcaagcac atcagcttct gaatctgcat caaccagtgc gtcagcctca  10140
gcatcgacaa gcgcctcagc ttcagcaagt accagtgcgt cagcctcagc gtcgacaagt  10200
gcgtcggctt cagcaagtac cagtgcgtca gcctcagcaa gtaccagtgc gtcagcctca  10260
gcgtcgacaa gtgcgtcggc ctcaaccagt gcatctgaat cggcatcaac cagtgcgtca  10320
gcctcagcaa gtactagtgc atcagcttca gcatcaacga gtgcatcggc ttcagcatca  10380
accagtgcat cagagtcagc aagtaccagt gcgtcagctt ccgcatcaac aagtgcctcg  10440
gcttcagcaa gtactagcgc ctcagcctca gcgtcaacaa gtgcttcagc ttccgcgtca  10500
accagcgcct cggcctcagc aagtatctca gcgtctgaat cggcatcaac aagtgcctcg  10560
gcttcagcat catcagtctg atcagctcaa gcaagcacaa gtgcgtcgcg gctcagcaagc  10620
accagcgcgt ctgaatccgc atcaaccagt gcctcagctt cagcaagtac ctcagcatct  10680
gaatcagcat caacaagtgc ctcggcttca gcaagcacaa gtgcttcagc ctcagcaagt  10740
atctcagcgt ctgaatcggc atcaacgagt gcgtccgctt cagcaagtac tagcgcctca  10800
gcatcagcgt caacaagtgc ttcggcttca gcgtcaacga gtgcgtctga gtcagcatca  10860
acgagtacgt cagcctcagc aagcacatca gcttctgaat ctgcatcaac cagtgcgtca  10920
gcctcagcat cgacaagcgc ctcagcttca gcaagtacca gtgcgtcagc ctcagcaagt  10980
accagtgctt cagcctcagc gtcgacaagt gcgtcggcct caaccagtgc atctgaatcg  11040
gcatcaacca gtgcgtcagc ctcagcaagt actagcgcct cagcctcagc atcaacgagt  11100
gcgtccgctt cagcaagtac tagtgcatca gcttcagcaa gtactagcgc ctcagcctca  11160
gcgtcgacaa gcgcctcagc ttcagcaagt accagtgcgt cagcctcagc gtcgacaagt  11220
gcgtcggctt cagcaagtac ctcagcgtct gaatcagcat caacaagtgc gtcggcttca  11280
gcatcaacga gtgcatcagc ttcagcatca acaagtgctt cagcttcagc aagtaccagt  11340
gcgtcggctt cagcatcaac gagtgcttca gtctcagcgt caaccagtgc ctctgaatcc  11400
gcatcaacaa gtgcctcggc ttcagcaagc accagtgctt cggcttcagc gtcaacgagt  11460
gcgtctgagt cagcatcaac gagtgcgtca gcctcagcaa gcacatcagc ttctgaatct  11520
gcatcaacca gtgcgtcagc ttccgcatca acaagcgcct cggcctcagc aagtacaagt  11580
gcttcagcct cagcatcaca gtgcatca gcttcagcct caacaagtgc ttcagcctca  11640
gcgtcaacca gtgcctcggc ttcagcaagt accagtgcgt cagcttcagc aagcacaagt  11700
gcgtcagctt cagcatcaac cagtgcttcg gcttcggcat caacaagtgc ctcagcatca  11760
gcatcaacga gtgcgtcagc ctcagcaagt actagtgcat cagcatcagc atcaaccagt  11820
gcatcagcct cagcaagtat ctcagcgtct gaatcggcat caacgagtgc atcagcatca  11880
gcatcaacga gtgcatcggc ttcagcgtca accagtgcat cagtctcagc aagcaccagt  11940
gcgtcggctt cagcatcaac gagtgcctca gcctcagcaa gtatctcagc gtctgaatcg  12000
gcatcaacga gtgcgtcagc ctcagcaagt actagtgcat cggcttcagc aagcaccagt  12060
gcgtcggctt cagcatcaac cagtgcctca gcctcagcaa gtatctcagc gtctgaatcg  12120
gcatcaacga gtgcgtcagc ctcagcaagt actagtgcat cagcatcagc atcaacgagt  12180
gcatcggctt cagcaagtac cagcgcctca gcttcagcaa gcaccagtgc gtcagcctca  12240
gcaagtacca gcgcctcagc ctcagcaagc accagtgcct cagcttcagc aagtaccagt  12300
gcgtcagcct cagcgtcgac aagtgcgtcg gcttcagcaa gtacctcagc gtctgaatca  12360
gcatcaacga gtgcatcagc ttcagcatca acaagtgctt cagcttcagc aagtatctca  12420
gcgtctgaat cggcatcaac gagtgcgtcc gcttcagcaa gtactagcgc ctcagcatca  12480
gcgtcaacaa gtgcttcggc ttcagcgtca acgagtgcgt ctgagtcagc atcaacgagt  12540
acgtcagcct cagcaagcac atcagcttct gaatctgcat caaccagtgc gtcagcctca  12600
gcatcgacaa gcgcctcagc ttcagcaagt accagtgcgt cagcctcagc aagtaccagt  12660
gcttcagcct cagcgtcgac aagtgcgtcg gcctcaacca gtgcatctga atcggcatca  12720
accagtgcgt cagcctcagc aagtactagc gcctcagcaa cagtgcgtcc gagtgcgtcc  12780
gcttcagcaa gtactagtgc atcagcttca gcaagtacta gcgcctcagc ctcagcgtcg  12840
acaagcgcct cagcttcagc aagtaccagt gcgtcagcct cagcgtcgac aagtgcgtcg  12900
gcttcagcaa gtacctcagc gtctgaatca gcatcaacaa gtgcgtcggc ttcagcatca  12960
acgagtgcat cagcttcagc atcaacaagt gcttcagctt cagcaagtac cagtgcgtcg  13020
gcttcagcat caacgagtgc ttcagtctca gcgtcaacca gtgcctctga atccgcatca  13080
```

```
acaagtgcct cggcttcagc aagcaccagt gcttcggctt cagcgtcaac gagtgcgtct   13140
gagtcagcat caacgagtgc gtcagcctca gcaagcacat cagcttctga atctgcatca   13200
accagtgcgt cagcttccgc atcaacaagc gcctcggcct cagcaagtac aagtgcttca   13260
gcctcagcat caaccagtgc atcagcttca gcctcaacaa gtgcttcagc ctcagcgtca   13320
accagtgcct cggcttcagc aagtaccagt gcgtcagctt cagcaagcac aagtgcgtca   13380
gcttcagcat caaccagtgc ttcggcttcg gcatcaacaa gtgcctcagc atcagcatca   13440
acgagtgcgt cagcctcagc aagtactagt gcatcagcat cagcatcaac cagtgcatca   13500
gcctcagcaa gtatctgaatcg gcatcaacga gtgcatcagc atcagcatca   13560
acgagtgcat cggcttcagc gtcaaccagt gcatcagtct cagcaagcac cagtgcgtcg   13620
gcttcagcat caacgagtgc ctcagcctca gcaagtatct cagcgtctga atcggcatca   13680
acgagtgcgt cagcctcagc aagtactagt gcatcggctt cagcaagcac cagtgcgtcg   13740
gcttcagcat caaccagtgc ctcagcctca gcaagtatct cagcgtctga atcggcatca   13800
acgagtgcgt cagcctcagc aagtactagt gcatcagcct cagcatcaac gagtgcatcg   13860
gcttcagcaa gtaccagcgc ctcagcttca gcaagcacca gtgcgtcagc ctcagcaagt   13920
accagcgcct cagcctcagc aagcaccagt gcctcagctt cagcaagtac cagtgcgtca   13980
gcctcagcat caacaagtgc ttcagcttcg gcctcaacaa gtgcgtcagc ttcagcatca   14040
acgagtgcgt cggcttcagc aagcaccagt gcctcggccct cagcaagcac cagtgcttca   14100
gcttcagcat caacaagtgc gtcagcttca gcaagtacat cagtttcaaa ttcagcaaac   14160
cattcgaact cacaagttgg aaatacttct ggatcgacag gtaaatccca aaaagaattg   14220
cctaatacag gtactgagtc gtcaattgga tctgtgttac ttggagttct agcagctgtt   14280
acaggtattg gattggttgc gaaacgccgt aaacgtgatg aagaagag                14328
```

SeqID 74
```
atgtcaaacg aaaaaaacac aaacactaac gtagaaaaga aagatgctac tgttgtagct    60
cacgaaatca aaggggaact tacttacgaa gataaagtta tccaaaaaat cattggtctt   120
tcactagaaa acgtttcagg tcttttggga atcgatggtg gtttcttctc aaatcttaaa   180
gaaaaaatcg ttaacagcga tgacgtaaca agtgtgtta acgtagaagt tggtaaaaca   240
caagttgcag ttgacttaaa cgttattgtt gagtaccaaa aaaatgttcc agctttatat   300
tcagaaatca gagaaatcgt atcttcagaa gttgctaaaa tgactgactt ggaaattgtt   360
gaaatcaacg taaacgttgt cgacatcaaa actaaagaac agcatgaagc agactcagta   420
agccttcaag atcgcgtatc tgacgttgct gaatcaacag gagaattcac ttcagaacaa   480
ttcgaaaaag ctaaatctgg tcttggatct ggtttctcaa ctgttcaaga aaaagttagc   540
gaaggtgtag aagctgttaa aggtgcagca aatggtgtag tatctcacga aaacactcgt   600
gtaaac                                                              606
```

SeqID 75
```
atgacaaaag aaaaaaatgt aattttgact gctcgcgata ttgtcgtgga atttgacgtt    60
cgtgacaaag tattgacagc cattcgcggc gtttcccttg aactagtcga aggagaagta   120
ttagccttgg taggtgagtc aggatcaggt aaatctgttt tgacaaagac cttcacaggt   180
atgctcgaag aaaatggtcg tattgcccaa ggtagtattg actaccgtgg tcaggacttg   240
acagctttat cttctcacaa ggattgggaa caaattcgtg gtgctaagat tgcgactatc   300
ttccaggacc caatgactag tttggacccc attaaaacaa ttggtagtca gattacagaa   360
gttattgtaa aacaccaagg aaaaacagct aaagaagcga aagaattggc cattgactac   420
atgaataagg ttggcattcc agacgcagat agacgtttta atgataccc attccaatat   480
tctggaggca tgcgtcaacg tatcgttatt gctattgccc ttgcctgccg acctgatgtc   540
ttgatctgtg atgagccaac aactgccttg gatgtaacta ttcaagctca gattattgat   600
ttgctaaaat ctttacaaaa cgagtatcat ttcacaacaa tctttattac ccacgacctt   660
ggtgtggtgg caagtattgc ggataaggta gcggttatgt atgcaggaga aatcgttgag   720
tatggaacgg ttgaggaagt cttctatgac cctcgccatc catatacatg gagtctcttg   780
tctagcttgc ctcagcttgc tgatgataaa ggggatcttt actcaatccc aggaacacct   840
ccgtcacttt atactgacct gaaaggggat gcttttgcct tgcgttctga ctacgcaatg   900
cagattgact tcgaacaaaa agctcctcaa ttctcagtat cagagacaca ttgggctaaa   960
acttggcttc ttcatgagga tgctccgaaa gtagaaaaac cagctgtgat tgcaaatctc  1020
catgataaga tccgtgaaaa aatgggattt gcccatctgg ctgac                  1065
```

SeqID 76
```
atgaaaaaaa atcgtgtatt tgctacagca ggtcttgttt tattagcagc aggtgtactt    60
gcagcatgca gttcttcaaa atcatctgat tcatcagccc ctaaagctta tggctatgtt   120
tatacagcag acccagaaac cttggactac ctgatttcaa gtaaaaatag tacaacagta   180
gtgacttcaa atgggattga tggtttattc actaacgata attacggtaa tcttgctcct   240
gcagttgcag aggattggga agtctctaag gatggtttga cctacactta taagattcgt   300
aaaggggtta aatgtttac ctctgatgga gaagaatatg cagaggtgac ggctaaagat   360
ttcgtgaacg gtttaaaaca cgcagcagat aaaaaaatcag aagctatgta tttagctgaa   420
aattcggtta aaggcttggc agattatcta tcaggaactt caacagattt ttccaacagtt   480
ggtgtcaagg cggttgatga ttatacgtta caatacactt gaaccagcc tgaaccgttc   540
tggaactcta agttgaccta ttctattttc tggcctctga atgaagaatt cgaaacatca   600
aaaggaagcg atttgctaa accaacagat ccgacatcct tgctttataa tggtccattc   660
ttgttgaaag ggttgactgc aaaatcttct gtagagtttg taaaaaatga gcaatattgg   720
```

```
gataaagaaa atgtccacct agatactatc aatctagctt actatgatgg atcagatcag     780
gagtcgctag agcgtaactt cactagtgga gcttatagtt atgcccgtct ttaccctacc     840
agctccaact attctaaggt tgcagaagaa tacaaggaca atatctatta cacacaatca     900
ggctctggga ttgctggtct gggtgtgaat attgatcgcc aaagttacaa ctatacttct     960
aaaactacag attcagagaa agtagctact aagaaggcat tgcttaacaa agatttccgt    1020
caagccttga attttgctct tgatcgctca gcttactcag ctcaaatcaa tggtaaagat    1080
ggagcagctt tagcagttcg taatttattt gtaaaaccag actttgtttc agctggtgag    1140
aagacctttg gtgatttagt cgctgctcaa cttcctgctt atggtgatga gtggaaaggt    1200
gtgaatttag ctgatgggca ggatggttta ttcaatgctg acaaggccaa ggcagagttt    1260
gcgaaagcta agaaagcttt agaagcagac ggcgttcagt ttcctattca tctggacgtt    1320
ccagtagacc aagcatcaaa aaactacata tctcgtattc agtcctttaa acaatctgta    1380
gaaacagttc ttggtgttga aaatgtcgtt gttgatattc aacaaatgac aagtgatgaa    1440
ttccttaata ttacttacta tgctgccaat gcttcatctg aggattggga tgtatcagga    1500
ggagtttcat gggggccaga ctatcaagac ccatctactt acctggatat tttaaaaaca    1560
actagcagtg aaactacaaa aacatattta ggatttgata tccaaatag cccttcagta    1620
gttcaagttg gtttgaaaga atacgataaa ttagttgatg aagctgccag agagacaagc    1680
gacttgaatg tccgttatga aaaatatgga gcggctcaag catggttgac agatagttca    1740
ctctttattc ctgctatggc ttcttctggt gcagcaccag tgctttcacg aattgttcca    1800
tttactggag cttctgcgca aacaggctct aagggggtcag atgtttactt caaatatttg    1860
aaatcacaag ataaagtggt gactaaggaa gagtatgaaa aagctcgtga aaaatggttg    1920
aaagaaaaag ctgaatcaaa tgagaaagct caaaaagaat tggcaagtca tgtgaag      1977
```

SeqID 77
```
atggaaatta atgtgagtaa attaagaaca gatttgcctc aagtcggcgt gcaaccatat     60
aggcaagtac acgcacactc aactgggaat ccgcattcaa ccgtacagaa tgaagcggat    120
tatcactggc ggaaagaccc agaattaggt tttttctcgc acattgttgg gaacggttgc    180
atcatgcagg taggacctgt tgataatggt gcctgggacg ttggggggcgg ttggaatgct    240
gagacctatg cagcggttga actgattgaa agccattcaa ccaaagaaga gttcatgacg    300
gactaccgcc tttatatcga actcttacgc aatctagcag atgaagcagg tttgccgaaa    360
acgcttgata cagggagttt agctggaatt aaaacgcacg agtattgcac gaataaccaa    420
ccaaacaacc actcagacca cgttgaccct tatccatatc ttgctaaatg gggcattagc    480
cgtgagcagt ttaagcatga tattgagaac ggcttgacga ttgaaacagg ctggcagaag    540
aatgacactg gctactggta cgtacattca gacggctctt atccaaaaga caagtttgag    600
aaaatcaatg gcacttggta ctactttgac agttcaggct atatgcttgc agaccgctgg    660
aggaagcaca cagacggcaa ctggtactgg ttcgacaact caggcgaaat ggctacaggc    720
tggaagaaaa tcgctgataa gtggtactat ttcaacgaag aaggtgccat gaagacaggc    780
tgggtcaagt acaaggacac ttggtactac ttagacgcta aagaaggcgc catggtatca    840
aatgccttta tccagtcagc ggacggaaca ggctggtact acctcaaacc agacggaaca    900
ctggcagaca agccagaatt cacagtagag ccagatggct tgattacagt aaaa         954
```

SeqID 78
```
atgaaaaaaa aatattggac tttagcgata ttattctttt gtttgttcaa taattctgtt     60
actgctcaag aaaataccta aaaatcttga tggcaatataa ctcacactca gactagcgaa    120
agttttttctg aatctgatga aaaacaggtt gactattcta ataaaaatca agaagaagta    180
gaccaaaaata aatttcgtat tcaaatcgat aagacagaat tatttgtaac aacagataaa    240
catttagaaa aaaactgttg taaattggaa cttgaaccac aaataaataa cgatattgtt    300
aactctgaaa gtaataattt actaggcgaa gataatttag ataataaaat taaggaaaat    360
gtttctcatc tagataatag aggaggaaat atagagcatg acaaagataa cttagaatcg    420
tcgattgtaa gaaaatatga atgggatata gataaagtta ctggtggagg cgaaagttat    480
aaattatatt ctaaaagtaa ttctaaagtt tcaattgcta ttttagattc aggagtcgat    540
ttacaaaata ctggattact gaaaaatctt tcaaatcact caaaaaacta tgtccccaat    600
aaaggatatt taggaaaaga ggaggagag gaaggaataa tatcagatat tcaagataga    660
ttaggtcatg gtacggctgt tgtagctcaa attgtaggg atgacaatat taatggagta    720
aatcctcacg ttaatattaa cgtctctaga atatttggta agtcgtcagc tagtccagat    780
tggattgtaa aagcaatttt tgatgctgta gatgatggca atgatattat caatcttagt    840
actggacaat atttaatgat tgatggagaa tatgaggacg gaacaaatga tttttgaaaca    900
tttttgaagt ataaaaaggc tattgattac gcgaatcaaa aaggagtaat tatagtagct    960
gcattaggga atgactccct aaatgtatca aatcagtcag atttattgaa acttattagt    1020
tcacgcaaaa aagtaagaaa accaggatta gtagttgatg ttccaagtta tttctcatct    1080
acaatttcgg tcggaggcat agatcgctta ggtaatttat cagattttag caataaaggg    1140
gattctgatg caatatatgc gcctgcaggc tcaacattat ctctttcaga attaggactt    1200
aataactttta ttaatgaacaa aaaatataaa gaagattgga ttttttcgga acactagga   1260
ggatatacgt atctttatgg aaaactcattt gctgctccta agtttctgg tgcgattgca    1320
atgattattg ataaatacaa attaaaagat cagccctata attatatgtt tgtaaaaaaa    1380
ttctggaaga aacattacca g                                             1401
```

SeqID 79
```
atgaaaaaag atgagttatt tgaaggcttt tacctaatca aatcagctga cctgaggcaa     60
```

```
actcgagctg ggaaaaacta cctagccttt accttccaag atgatagtgg cgagattgat    120
gggaagctct gggatgccca acctcataac attgaggcct ttaccgcagg taaggttgtc    180
cacatgaaag gacgccgaga agtttataac aatacccctc aagtcaatca aattactctc    240
cgcctgcctc aagctggtga acccaatgac ccagctgatt tcaaggtcaa gtcaccagtt    300
gatgtcaagg aaattcgtga ctacatgtcg caaatgattt tcaaaattga aaatcctgtc    360
tggcaacgga ttgtccgaaa tctctacacc aagtatgata aggaattcta ctcctatcca    420
gctgccaaga ccaaccacca tgcctttgaa acgggcttgg cctatcatac ggcgaccatg    480
gtgcgtttgg cagacgctat tagcgaagtt tatcctcagc tcaataagag cctgctctat    540
gcggggatta tgttgcatga cttagctaag gtcatcgagt tgacggggcc agaccagaca    600
gagtacacag tgcgaggtaa tcttcttgga catatcgctc tcattgatag cgaaattacc    660
aagacagtta tggaactcgg catcgatgat accaaggaag aagtcgtttt gcttcgtcat    720
gtcatcctca gtcaccacgg cttgcttgag tatggaagcc cagtccgtcc acgcattatg    780
gaagcagaga ttatccatat gattgacaat ctggatgcaa gcatgatgat gatgtcaaca    840
gctcttgctt tggtggataa aggagagatg accaataaaa tcttcgctat ggataatcgt    900
tccttctata aaccagattt agat                                          924
```

SeqID 80
```
gtgacgattc taggaaaaga tacagttcaa caatctgcga aaggtgaatc tgtaactcaa    60
gaagctacac cagagtataa gctagaaaat acaccaggtg gagataaggg aggcaatact    120
ggaagctcag atgctaatgc gaatgaaggc ggtggtagcc aggcgggtgg atcagctcac    180
acaggttcac aaaactcagc tcaatcacaa gcttctaagc aattagctac tgaaaaagaa    240
tcagctaaaa atgccattga aaaagcagcc aaggacaagc aggatgaaat caaaggcgca    300
ccgctttctg ataaagaaaa agcagaactt ttagcaagag tggaagcaga aaaacaagca    360
gctctcaaag agattgaaaa tgcgaaaact atggaagatg tgaaggaagc agaaacgatt    420
ggagtgcaag ccattgccat ggttacagtt cctaagagac cagtggctcc taatgctgct    480
cctaagacaa caagtgcacc gcaagcaact gcaggaacaa tgcaagatgt tacctaccag    540
tcacctgctg gcaaacaatt acctaacaca ggttcagcat caagtgcagc acttgctagt    600
cttggtctag tggtggcaac aagtggtttt gctttgctag gaagaaagac tagacgtaga    660
aaa                                                                 663
```

SeqID 81
```
atgaatgcag atgatacagt aaccatttat gatgtcgctc gtgaagcagg tgtttccatg    60
gcgacggtca gccgtgtggt caatggcaat aaaaatgtaa aagagaatac ccgtaaaaaa    120
gtgctagagg taattgatcg tttggattat cgtccaaatg cagttgcgcg tggtcttgca    180
agtaaaaaga caaccactgt cggtgtcgtg attccaaata ttaccaatgg ttattttcga    240
agtttggcta aggggattga tgatattgca gaaatgtaca agtacaatat tgtcctagct    300
aatagcgatg aagataacga gaaagaagtt tctgttgtca ataccctctt ttcaaagcag    360
gtagatggca ttatctatat ggggtatcac ttgacagata aaattcgctc agaatttttcg    420
cgttcacgta ctccgattgt tctcgcagga actgtcgatg ttgagcacca gttgccaagt    480
gtcaatattg actataagca agcaacaatt gatgcagtga gttaccttgc taaagaaaat    540
gagcgtattg ctttcgttag cggtccgcta gtggatgaca tcaatggtaa ggttcgttta    600
gttggctaca aggaaacctt gaaaaaagca ggaatcactt atagtgaggg tttggtattt    660
gaatctaaat atagctatga tgatggttac gccttagcag acgtttgat ttcatcaaat    720
gcaactgcag cagttgtgac aggtgatgag ttggcagcag gagtcttgaa cggttttggct    780
gataagggtg tttctgtgcc agaagatttt gaaattatta ctagtgatga ttcacaaatc    840
tcacgcttta cccgtccaaa cttgacaacg attgcccaac ctctctttatga ccttggtgcc    900
attagtatgc gtatgttgac caagattatg cataaggaag agttggaaga acgtgaagtt    960
ctcttacctc atggtttgac agaacgtagc tcaacacgaa aacgtaaa                1008
```

SeqID 82
```
atgaaaaaaa agttagtatt tcctaatctg ttttggtggg gagctgcttc tagcggacct    60
cagacagaag gtcaatatgg aaaagtacat gaaaatgtga tggactactg gttcaaaacg    120
catccagaga attttttcga taatgtcgga cctcttgtag ccagtaactt ttttcatact    180
tacaccgaag atttccactt gatgaaggaa attggagtta attcttttccg cacttccatc    240
caatggagtc gactcatcaa gaatttagag acaggtgagc ctgatccaaa aggtattgct    300
ttctacaatg ccatcattga agaagctaaa aagaaccaga tggatcttgt gatgaattta    360
catcattttg atttaccagt ggaacttctt caaaaatacg gtggttggga aagcaaacat    420
gtagtggagt tattcgtgaa gtttgccaag actgctttca catgctttgg agataaggtt    480
cattactgga caactttcaa tgagccaatg gtcattccag aagcaggata cttatatgct    540
ttccattatc caaatctaaa aggaaaggga aaagaggccg tacaagtcat ctataatcta    600
aaccttgcta gtgcaaaagt gattcaacta tatcgctcat tagaacttga tggaaagatt    660
gggattattt taaacctgac acctgttat ccaagaagta attctccaga agacttagaa    720
gcaagtcgat ttacagatga cttctttaac aaagtcttct tgaatccagc tgttaaagga    780
actttcccag aaagattggt aaaacagcta gagagagatg gcgtgttatg gagtcatacc    840
gaaaaagagc ttcaactgat gaaatcaaat acggttgatt ttcttggagt aaactactac    900
catccaaaac gtgttcaagc acaagcaaat cctgaggaat atcagacgcc ctggatgcca    960
gaccaatact tcaaagagta tgaatggctg gagcgtcgca tgaatccata tcgtggttgg    1020
gaaatttttc cgaaagccat ttatgatatt gctatgattg tgaaggaaga atatggtaat    1080
```

```
atcccatggt ttatcagtga aaacggaatg ggtgttgaaa acgaagcacg gtttatcgat    1140
gaaaatggag ttatcgatga cgtgtatcgt attgaatttt atgaagaaca tttaagatgg    1200
ctacataaag ccattgaaga gggaagtcac tgttttggat accacgcttg gaccgcattt    1260
gattgctggt cttggaataa tgcatataag aatcgttacg gatttatctc cgttgattta    1320
gaaacgcaaa agagaaccat caagagctca ggaagatggt atcgcaaagt aagtgacaat    1380
aacggttttg aagtagaaat tgaggag                                        1407


SeqID 83
gtggaaaatc ttacgaattt ttacgaaaag tatcgtgtct atctgactcg tccacgttta      60
gagcttttgg cagtagttac cattgttttc tgtgctgtac tcgtcttttt tctaaatatt     120
ccaggaaaag gtgtcttaaa actcgataat ggaacgattg tttatgatgg cagtcttgtc     180
cgcggtaaaa tgaatggcca aggtaccatt accttccaaa atggagacca atatacaggt     240
ggcttcaaca atggagcctt caacggaaaa ggtacctttc aatctaaaga aggctggacc     300
tacgaaggtg attttgtaaa tggtcaggct gaaggaaaag ggaaactaac aacagaacaa     360
gaagtcgttt atgaaggaac tttaaacaa ggcgtttttc aacaaaaa                   408


SeqID 84
atgttgaata agataagaga ctatttagac tttgctggtt tgcagtaccg taatcctgat      60
aaagcgggag cagagcgaga gaagatgctg gcattccgcc acaaaggaca agaggcccga     120
aaggttttta cagaactggc caaagccttt caagcaagcc atccagaatg gcaactccaa     180
cagactagcc agtggatgaa tcaggcccag cgtttgagac cacatttttg ggtttatcta     240
cagagagacg gacaagtgac agaacctatg atggccttac gtttgtatgg gacatctact     300
gactttggaa tttctttgga agtcagtttc atcgaacgta agaaggatga gcaaacactg     360
ggcaagcagg ccaaagtttt agacattcca accgttaaag ggatttatta tctaacctac     420
tctaatggtc aaagtcaacg gtgggaggcg aatgaagaaa agcgtcgtac tttacgcgag     480
aaggtgagaa gtcaagaagt tcgaaaagtt ttagtgaagg tagatgttcc tatgacagaa     540
aattcgtctg aagaagaaat cgtagaaggc ttattgaagt cttattctaa aattcttccc     600
tattatctag ctacgagaaa a                                               621


SeqID 85
atggttcaga acagttgttg gcaatcaaag agccataagg tcaaggcttt taccttgtta      60
gaatccctgc ttgccctcat tgtcatcagt gggggattac tccttttttca agctatgagt    120
cagctcctca tttcagaagt tcgctaccag caacaaagcg agcaaaagga gtggctcttg     180
tttgtggacc aacttgaggt agaattagac cgttcgcagt tcgaaaaagt agaaggcaat     240
cgcctataca tgaagcaaga tggcaaggac atcgccatcg gtaagtcaaa gtcagatgat     300
ttccgtaaaa cgaatgctcg tggtcgaggt tatcagccta tggtttatgg actcaaatct     360
gtacggatta cagaggacaa tcaactggtt cgctttcatt tccagttcca aaaaggctta     420
gaaagggagt tcatctatcg tgtggaaaaa gaaaaaagt                            459


SeqID 86
atgaaaaaaa tgatgacatt cttgaaaaaa gctaaggtta aagcttttac attggtggag      60
atgttggtgg tcttgctgat tatcagcgtg cttttcttgc tctttgtacc taatctgacc     120
aagcaaaaag aagcagtcaa tgacaaagga aaagcagctg ttgttaaggt ggtggaaagc     180
caggcagaac tttatagctt agaaaagaat gaagatgcta gcctaagaaa gttacaagca     240
gatggacgca tcacggaaga acaggctaaa gcttataaag aatacaatga taaaaatgga     300
ggagcaaatc gtaaagtcaa tgat                                            324


SeqID 87
atgacatcaa aagttagaaa ggcagtcatc cctgctgctg gactaggaac tcgattttta      60
ccagcaacca aggcccttgc caaagaaatg ttgccaatcg tagacaaacc aactatccag     120
tttatcgtgg aagaagctct caaatcaggt attgaagata ttctagttgt cactggtaaa     180
tcaaaacgtt ctattgagga ccactttgat tcaaacttcg aattggaata taacctcaaa     240
gaaaaaggga aaacagatct tttgaagcta gttgataaaa caactgacat gcgtctgcat     300
tttatccgcc aaactcatcc acgcggtctc ggagatgctg tttttgcaagc caaggctttc    360
gtcggaaatg aaccttttgt cgttatgctt ggtgatgact tgatggatat cacagacgaa     420
aaggctgttc cacttaccaa acaactcatg gatgactacg agcgtaccca cgcgtctact     480
atcgctgtca tgccagtccc tcatgacgaa gtatctgctt acggggttat tgctccgcaa     540
ggcgaaggaa aagatggtct ttacagtgtt gaaacctttg ttgaaaaacc agctccagag     600
gacgctccta gcgaccttgc tattatcgga cgctacctcc tcacgcctga aatttttgag     660
attctcgaaa agcaagctcc aggtgcagga atgaaaattc agctgacaga tgcaatcgac     720
accctcaata aaacacaacg tgtatttgct cgtgagttca agggggctcg ttacgatgtc     780
ggagacaagt ttggcttcat gaaaaacatcc atcgactacg ccctcaaaca cccacaagtc    840
aaagatgatt tgaagaatta cctcatccaa cttggaaaag aattgactga gaaggaa        897


SeqID 88
atgcaaaatc aattaaatga attaaaacga aaaatgctgg aattttttcca gcaaaaacaa    60
aaaaataaaa aatcagctag acctggcaag aaaggttcaa gtaccaaaaa atctaaaacc    120
ttagataagt cagtcatttt cccagctatt ttactgagta taaaagcctt attaacttaa   180
```

```
ctctttgtac tcggttttct aggaggaatg ttgggagctg ggattgcttt gggatacgga    240
gtggccttat ttgacaaggt tcgggtgcct cagacagaag aattggtgaa tcaggtcaag    300
gacatctctt ctatttcaga gattacctat tcggacggga cggtgattgc ttccatagag    360
agtgatttgt tgcgcacttc tatctcatct gagcaaattt cggaaaatct gaagaaggct    420
atcattgcga cagaagatga acactttaaa gaacataagg gtgtagtacc caaggcggtg    480
attcgtgcga ccttggggaa atttgtaggt ttgggttcct ctagtggggg ttcaaccttg    540
acccagcaac taattaaaca gcaggtggtt ggggatgcgc cgaccttggc tcgtaaggcg    600
gcagagattg tggatgctct tgccttggaa cgcgccatga ataaagatga gattttaacg    660
acctatctca atgtggctcc ctttggccga aataataagg gacagaatat tgcagggget    720
cggcaagcag ctgagggaat tttcggtgta gatgccagtc agttgactgt tcctcaagca    780
gcattttag caggacttcc acagagtccc attacttact ctccttatga aaatactggg    840
gagttgaaga gtgatgaaga cctagaaatt ggcttaagac gggctaaggc agttctttac    900
agtatgtatc gtacaggtgc attaagcaaa gacgagtatt ctcagtacaa ggattatgac    960
cttaaacagg acttttacc atcgggcacg gttacaggaa tttcacgaga ctatttatac   1020
tttacaactt tggcagaagc tcaagaacgt atgtatgact atctagctca gagagacaat   1080
gtctccgcta aggagttgaa aaatgaggca actcagaagt tttatcgaga tttggcagcc   1140
aaggaaattg aaatggtgtgg ttataagatt actaccacca tagatcagaa aattcattct   1200
gccatgcaaa gtgcggttgc tgattatggc tatctttttag acgatggaac aggtcgtgta   1260
gaagtaggga atgtcttgat ggataaccaa acaggtgcta ttctaggctt tgtaggtggt   1320
cgtaattatc aagaaaatca aaataatcat gcctttgata ccaaacgttc gccagcttct   1380
actaccaagc ccttgctggc ctacggtatt gctattgacc agggcttgat gggaagtgaa   1440
acgattctat ctaactatcc aacaaacttt gctaatggca atccgattat gtatgctaat   1500
agcaagggaa caggaatgat gaccttggga gaagctctga actattcatg gaatatccct   1560
gcttactgga cctatcgtat gctccgtgaa aagggtgttg atgtcaaggg ttatatggaa   1620
aagatgggtt acgagattcc tgagtacggt attgagagct gccaatggg tggtggtatt   1680
gaagtcacgt tgcccagca taccaaccct catccgaccc tagctaataa tggagtttat   1740
catcagaagc atgtgatttc aaagattgaa gcagcagatg gtagagtggt gtatgagtat   1800
caggataaac cggttcaagt ctattcaaaa gctactgcga cgattatgca gggattgcta   1860
cgagaagttc tatcctctcg tgtgacaaca accttcaagt ctaacctgac ttctttaaat   1920
cctactctgg ctaatgcaga ttggattggg aagactggta caaccaacca agacgaaaat   1980
atgtggctca tgctttcgac acctagatta accctaggtg gctggattgg gcatgatgat   2040
aatcattcat tgtcacgtag agcaggttat tctaataact ctaattacat ggctcatctg   2100
gtaaatgcga ttcagcaagc ttccccaagc atttggggga acgagcgctt tgctttagat   2160
cctagtgtag tgaaatcgga agtcttgaaa tcaacaggtc aaaaaccaga gaaggtttct   2220
gttgaaggaa aagaagtaga ggtcacaggt tcgactgtta ccagctattg ggctaataag   2280
tcaggagcgc cagcgacaag ttatcgcttt gctattggcg gaagtgatgc ggattatcag   2340
aatgcttggt ctagtattgt ggggagtcta ccaactccat ccagctccag cagttcaagt   2400
agtagttcta gcgatagcag taactcaagt actacacgac cttcttcttc aagggcgaga   2460
cga                                                                 2463
```

SeqID 89
```
atgtcatcta aatttatgaa gagcgctgcg gtgcttggaa ctgctacact tgctagcttg     60
ctttggtag cttgcggaag caaaactgct gataagcctg ctgattctgg ttcatctgaa    120
gtcaaagac tcactgtata tgtagacgag ggataataga gctataatga agaggttgt    180
aaagcttatg aaaaagaagc tggagtaaaa gtcactctta aaactggtga tgctctagga   240
ggtcttgata aacttctct tgacaaccaa tctggtaatg tccctgatgt tatgatggct   300
ccatacgacc gtgtaggtag ccttggttct gacgacaac tttcagaagt gaaattgagc   360
gatggtgcta aaacagacga cacaactaaa tctcttgtaa cagctgctaa tggtaaagtt   420
tacggtgctc ctgccgttat cgagtcactt gttatgtact acaacaaaga cttggtgaaa   480
gatgctccaa aaacatttgc tgacttggaa aaccttgcta agatagcaa atacgcattc   540
gctggtgaag atggtaaaac tactgccttc ctagctgact ggacaaactt ctactataca   600
tatggacttc ttgccggtaa cggtgcttac gtctttggcc aaaacggtaa agacgctaaa   660
gacatcggtc ttgcaaacga cggttctatc gtaggtatca actacgctaa atcttggtac   720
gaaaaatggc ctaaaggtat gcaagataca gaaggtgctg gaaacttaat ccaaactcaa   780
ttccaagaag gtaaaacagc tgctatcatc gacgggacctt ggaaagctca agcctttaaa   840
gatgctaaag taaactacgg agttgcaact atcccaactc ttccaaatgg aaaagaatat   900
gctgcattcg gtggtggtaa agcttgggtc attcctcaag ccgttaagaa ccttgaagct   960
tctcaaaaat ttgtagactt ccttgttgca actgaacaac aaaaagtatt atatgataag  1020
actaacgaaa tcccagctaa tactgaggct cgttcatacg ctgaaggtaa aaacgatgag  1080
ttgacaacag ctgttatcaa acagttcaag aacactcaac cactgccaaa catctctcaa  1140
atgtctgcag tttgggatcc agcgaaaaat atgctctttg atgctgtaag tggtcaaaaa  1200
gatgctaaaa cagctgctaa cgatgctgta acattgatca agaaacaat caaacaaaaa  1260
tttggtgaa                                                          1269
```

SeqID 90
```
atgatagata aagtggtcag gaacctactc ctgacctttt tcttttgcaa aatgacaaaa     60
atcataattt ttttgacaac tatacttgtc aaaaagaaaa agatatgtta caatgaattc    120
aagttaagaa ataggaagca gaaaggagtt ataatgtggg tactaggatt tatactattt    180
```

```
atgattttct tttattctaa taattctaaa aaaatcaaga aactagagaa taaaatcaaa    240
agacttgagc gaaaagagaa aggaaacgca gaaatgtcga gattattaca agaaatgatt    300
ggaaaggaac caattataac gggagtgtat attgggccag ataactggga agttgtggat    360
gttgatgagg aatgggtaaa gctacgacgt gtagataata cgggaaaaga aaaattcaag    420
ttgcaacgta ttgaggatat ccaaaccgtt gaatttgacg gagag                   465
```

SeqID 91
```
atgattttaa gtaaaaatag agaagatggg ttaagaaaat ttgcgactaa catccgatta     60
aatactctta gaacattgaa tcatcttgga ttcggacatt acggaggaag tctgtctatc    120
gtagaagttt tagcggtgct ttatggtgaa ataatgccaa tgactccaga aatatttgca    180
gcacgagata gagattattt catattatca aaaggtcacg gaggaccagc tctatacagt    240
acactctatt tgaatggttt ctttgacaaa gaattcttat attctttaaa tacaaatgga    300
accaaattac cgtctcatcc tgatagaaat ctaacgccag gcatagatat gacaacgggc    360
tctttaggac aaggaattag tgttgcaact ggacttgcat atggtcagag aataagaaag    420
agtccctttt atacttacgc tattgttgga gatggtgagt taaatgaggg acaatgttgg    480
gaggctatac agtttgcttc tcatcaacag ttatccaact taattgtatt tgttgatgat    540
aacaaaaaac aattagatgg ttttacaaag gatatttgta atccaggtga tttcgtagaa    600
aaattttcag catttggatt tgaatccatt agggtcaagg gttcagatat tagagaaatt    660
tatgaaggga ttgtccaatt aaaacagtca aataattcat cacctaagtg cattgtatta    720
gatactatta aaggtcaagg ggttcaagag ctggaagaaa tgaaatccaa tcatcatctt    780
cgccctactg tagaggagaa acaaatgtta acttcagttg tagaaagatt aagtcaggaa    840
ttggaggaaa cagaa                                                     855
```

SeqID 92
```
atgaaaaaaa ctacaatatt atcattaact acagctgcgg ttattttagc agcatatgtc     60
cctaatgaac caatcctagc agatactcct agttcggaag taatcaaaga gactaaagtt    120
ggaagtatta ttcaacaaaa taatatcaaa tataaggttc taactgtaga aggtaacata    180
ggaactgttc aagtgggtaa tggagttact cctgtagagt ttgaagctgg tcaagatgga    240
aaaccattca cgattcctac aaaaatcaca gtaggtgata aagtatttac cgttactgaa    300
gtagctagtc aagcttttag ttattatcca gatgaaacag gtagaattgt ctactatcct    360
agctctatta ctatcccatc aagcataaaa aaaatacaaa aaaaaggctt ccatggaagt    420
aaagctaaaa ctattatttt tgacaaaggc agtcagctgg agaaaattga agatagagct    480
tttgattttt ctgaattaga agagattgaa ttgcctgcat ctctagaata tattggaaca    540
agtgcatttt cttttagtca aaaattgaaa aagctaacct tttcctcaag ttcaaaatta    600
gaattaatat cacatgaggc ttttgctaat ttatcaaatt tagagaaact aacattacca    660
aaatcggtta aaacattagg aagtaatcta tttagactca ctactagctt aaaacatgtt    720
gatgttgaag aaggaaatga atcgtttgcc tcagttgatg gtgttttgtt ttcaaaagat    780
aaaacccaat taatttatta tccaagtcaa aaaaatgacg aaagttataa aacgcctaag    840
gagacaaaag aacttgcatc atattcgttt aataaaaatt cttacttgaa aaaactcgaa    900
ttgaatgaag gtttagaaaa aatcggtact tttgcatttg cagatgcgat taaacttgaa    960
gaaattagct taccaaatag tttagaaact attgaacgtt tagccttta cggtaattta   1020
gaattaaaag aacttatatt accagataat gttaaaaatt ttggtaaaca cgttatgaac   1080
ggtttaccaa aattaaaaag tttaacaatt ggtaataata tcaactcatt gccgtccttc   1140
ttcctaagtg gcgtcttaga ttcattaaag gaaattcata ttaagaataa aagtacagag   1200
ttttctgtga aaaaagatac atttgcaatt cctgaaactg ttaagttcta tgtaacatca   1260
gaacatataa aagatgttct taaatcaaat ttatctacta gtaatgatat cattgttgaa   1320
aaagtagata atataaaaca agaaactgat gtagctaaac ctaaaaagaa ttctaatcag   1380
ggagtagttg gttgggttaa agacaaaggt ttatggtatt acttaaacga atcaggttca   1440
atggctactg gttgggttaa agacaaaggt ttatggtatt acttaaacga atcaggttca   1500
atggctactg gttgggttaa agacaaaggc ttatggtact acttaaatga atcaggttca   1560
atggctactg gttgggttaa agacaaaggc ttatggtatt acttaaacga atcaggttca   1620
atggctactg gttgggttaa agacaaaggc ttatggtact acttaaatga atcaggttca   1680
atggctactg gttgggttaa agacaaaggc ttatggtatt acttaaatga atcaggttca   1740
atggctactg gttgggttac agtttctggt aaatggtact atacctataa ttcaggagat   1800
ttattagtaa acacgactac acccgatggc tatcgagtca atgctaacgg tgagtgggta   1860
gga                                                                 1863
```

SeqID 93
```
atggtaagat ttacaggact tagtctcaaa caaacgcaag ctattgaggt tttaaaaggt     60
cacatttctc taccagatgt ggaagtggct gtcactcagt ctgaccaagc atctatctct    120
atcgagggtg aggaaggtca ctatcaattg acctaccgca aacctcacca actttatcgt    180
gccttgtcct tgttggtaac agttctagca gaagctgata agtagagat tgaggaacaa    240
gcagcttacg aagatttggc ttacatggtt gactgttctc gaaatgcggt gctgaatgtg    300
gcttctgcca agcagatgat tgagatattg gctctcatgg gctactcaac ctttgagctt    360
tacatggaag acacttacca gattgaaggg cagccttact ttggctattt ccgtggagct    420
tattcagcag aggagttgca ggaaatcgaa gcctatgccc aacagtttga cgtgaccttt    480
gtaccatgca tccagacctt ggcccacttg tcggcctttg tcaaatgggg tgtcaaggaa    540
gtgcaggagc tccgtgatgt agaggacatt cttctcattg cgaagaaaa ggtttatgac    600
```

```
ttgattgatg gcatgtttgc cacgttgtct aaactgaaga ctcgcaaggt caatatcggg    660
atggacgaag cccacttggt tggtttggga cgctacctga ttctgaacgg tgttgtggat    720
cgtagtctcc tcatgtgcca acacttggag cgcgtgctgg atattgctga caaatatggt    780
ttccactgcc agatgtggag tgatatgttc ttcaaactca tgtcagcgga tggccagtac    840
gaccgtgatg tggaaattcc agaggaaact cgtgtctacc tagaccgtct caaagaccgt    900
gtgactctgg tttactggga ttattatcag gatagcgagg aaaaatacaa ccgtaatttc    960
cgcaatcatc acaagattag ccatgacctt gcatttgcag ggggagcttg gaagtggatt   1020
ggctttacac ctcacaacca ttttagccgt ctagtggcta tcgaggctaa taaagcctgc   1080
cgtgccaatc agattaaaga agtcatcgta acgggttggg gagacaatgg tggtgaaact   1140
gcccagttct ctatcctacc aagcttgcaa atctgggcag aactcagcta tcgcaatgac   1200
ctagatggtt tgtctgcgca cttcaagacc aatactggtc taacggttga ggatttatg    1260
cagattgacc ttgccaacct cttaccagac ctaccaggca atctcagcgg tatcaatccc   1320
aaccgctatg tttttatca ggatattctt tgtccgattc ttgatcaaca catgacacct  · 1380
gaacaggaca aaccgcactt cgctcaggct gctgagacgc ttgctaacat taaagaaaaa   1440
gctggaaact atgcctatct ctttgaaact caggcccagt tgaatgctat tttaagtagc   1500
aaagtagatg tgggacgacg cattcgtcag gcctaccaag cggatgataa agaaagttta   1560
caacaaatcg ccagacaaga attaccagaa cttaagcac aaatttgaagc cttccatgcc   1620
ctctttagcc accaatggct gaaagaaaac aaggtctttg gtttggatac agttgacatc   1680
cgtatgggcg gactcttgca acgcatcaaa cgagcagaaa gccgtatcga ggtttatctg   1740
gctggtcagc ttgaccgcat cgacgagctg gaagttgaaa tcctaccatt tactgacttc   1800
tacgcagaca aggatttcgc agcaactaca gccaaccagt ggcataccat tgcgacagcg   1860
tcgacgattt atacgact                                                  1878


SeqID 94
atgtctaatt catttgtcaa gttgttagtc tctcaattat ttgcaaattt agcagatatt     60
ttctttagag taacaatcat tgctaacata tacattattt caaaatcagt aattgccaca    120
tcactagttc ctatcttaat aggaatatcc tcttttgttg cgagtctttt agttccgttg    180
gttactaaaa ggttagcgct aaatagggtt ttatctttat ctcaatttgg aaaagactata    240
ttattggcga tactggtagg aatgtttacc gtaatgcaat ccgtagcgcc tttggtgacc    300
tatctatttg ttgttgcaat ttccatacta gatggttttg cagcaccgt ttcctatgct     360
attgtgccac gctatgcgac cgatttgggt aaggctaatt cagccttatc aatgactggt    420
gaagctgttc aattgatagg ttggggatta ggtggactct tgtttgcaac aattggtctg    480
ttacctacca cgtgtatcaa tttagtcttg tatatcattt ctagctttct gatgttattt    540
cttcctaacg ctgaagtgga ggtgttagag tcagaaacta atcttgaaat tttgctcaaa    600
ggttggaagt tagttgctag aaatcctaga ttaagacttt ttgtatcagc aaatttattg    660
gaaattttt caaatacgat ttgggtttct tccattatac ttgttttgt aacggagtta     720
ttaaataaaa cggaaagtta ctggggatat tctaatacag catactctat tggtattata    780
attagtggct taattgcttt taggctatct gaaaagttcc ttgctgctaa a            831


SeqID 95
atgtttgcat caaaaagcga aagaaaagta cattattcaa ttcgtaaatt tagtgttgga     60
gtagctagtg tagttgttgc cagtcttgtt atgggaagtg tggttcatgc gacagagaac    120
gagggagcta cccaagtacc cacttcttct aatagggcaa atgaaagtca ggcagaacaa    180
ggagaacaac ctaaaaaact cgattcagaa cgagataagg caaggaaaga ggtcgaggaa    240
tatgtaaaaa aaatagtggg tgagagctat gcaaaatcaa ctaaaaagcg acatacaatt    300
actgtagctc tagttaacga gttgaacaac attaagaacg agtatttgaa taaaatagtt    360
·gaatcaacct cagaaagcca actacagata ctgatgatgg agagtcgatc aaaagtagat    420
gaagctgtgt ctaagtttga aaaggactca tcttcttcgt caagttcaga ctcttccact    480
aaaccggaag cttcagatac agcgaagcca aacaagccga cagaaccagg agaaaaggta ·   540
gcagaagcta agaagaaggt tgaagaagct gagaaaaaag ccaaggatca aaaagaagaa    600
gatcgtcgta actacccaac cattacttac aaaacgcttg aacttgaaat tgctgagtcc    660
gatgtggaag· ttaaaaaagc ggagcttgaa ctagtaaaag tgaaagctaa cgaacctcga    720
gacgagcaaa aaattaagca agcagaaagcg gaagttgaga gtaaacaagc tgaggctaca  ·   780
aggttaaaaa aaatcaagac agatcgtgaa gagcaagaag aagagctaca acgaagagca    840
gatgctaaag agcaaggtaa accaaagggg cgggcaaaac gaggagttcc tggagagcta    900
gcaacacctg ataaaaaaga aaatgatgcg aagtcttcag attctagcgt aggtgaagaa    960
actcttccaa gcccatccct gaaaccagaa aaaaaggtag cagaagctga gaagaaggtt   1020
gaagaagcta agaaaaaagc cgaggatcaa aagaagaag atcgccgtaa ctacccaacc   1080
aatacttaca aaacgcttga acttgaaatt gctgagtccg atgtggaagt taaaaaagcg   1140
gagcttgaac tagtaaaaga ggaagctaag gaacctcgaa cgaggaaaa agttaagcaa   1200
gcaaaagcgg aagttgagag taaaaaagct gaggctacaa ggttagaaaa aatcaagaca   1260
gatcgtaaaa agcaaggtaa accaaagggg cgggcaaaac gaggagttcc tggagagcta   1320
gcaacacctg ataaaaaaga aaatgatgcg aagtcttcag attctagcgt aggtgaagaa   1380
actcttccaa gcccatccct gaaaccagaa aaaaaggtag cagaagctga gaagaaggtt   1440
gaagaagct actatgctcg tagatcagaa gaagaatata atcgcttgac tcaacagcaa   1500
ccgccaaaaa ctgaaaaacc agcacaacca tctactccaa aaacaggctg gaaacaagaa   1560
aacggtatgt ggtacttcta caatactgat ggttcaatgg cgacaggatg ctccaaaac   1620
aatggctcat ggtactacct caacagcaat ggcgctatgg cgacaggatg ctccaaaac   1680
```

```
aatggttcat ggtactatct aaacgctaat ggttcaatgg caacaggatg gctccaaaac   1740
aatggttcat ggtactacct aaacgctaat ggttcaatgg cgacaggatg gctccaatac   1800
aatggctcat ggtactacct aaacgctaat ggttcaatgg cgacaggatg gctccaatac   1860
aatggctcat ggtactacct aaacgctaat ggtgatatgg cgacaggttg ggtgaaagat   1920
ggagatacct ggtactatct tgaagcatca ggtgctatga aagcaagcca atggttcaaa   1980
gtatcagata aatggtacta tgtcaatggc tcaggtgccc ttgcagtcaa cacaactgta   2040
gatggctatg gagtcaatgc caatggtgaa tgggtaaac                          2079
```

SeqID 96
```
atgaactatt caaaagcatt gaatgaatgt atcgaaagtg cctacatggt tgctggacat    60
tttggagctc gttatctaga gtcgtggcac ttgttgattg ccatgtctaa tcacagttat   120
agtgtagcag gggcaacttt aaatgattat ccgtatgaga tggaccgttt agaagaggtg   180
gctttggaac tgactgaaac ggactatagc caggatgaaa cctttacgga attgccgttc   240
tcccgtcgtt tgcaggttct ttttgatgaa gcagagtatg tagcgtcagt ggtccatgct   300
aaggtactag ggacagagca cgtcctctat gcgattttgc atgatagcaa tgccttggcg   360
actcgtatct tggagagggc tggttttttct tatgaagaca agaaagatca ggtcaagatt   420
gctgctcttc gtcgaaattt agaagaacgg gcaggctgga ctcgtgaaga tctcaaggct   480
ttacgccaac gccatcgtac agtagctgac aagcaaaatt ctatggccaa tatgatgggc   540
atgccgcaga ctcctagtgg tggtctcgag gattatacgc atgatttgac agagcaagcg   600
cgttctggca agttagaacc agtcatcggt cgggacaagg aaatctcacg tatgattcaa   660
atcttgagcc ggaagactaa gaacaaccct gtcttggttg gggatgctgg tgtcgggaaa   720
acagctctgg cgcttggtct tgcccagcgt attgctagtg gtgacgtgcc tgcggaaatg   780
gctaagatgc gcgtgttaga acttgatcg ttgcaggac acgcttccgt   840
ggtgactttg aagaacgcat gaataatatc atcaaggata ttgaagaaga tggccaagtc   900
atcctctttta tcgatgaact ccacaccatc atgggttctg tagcgggat tgattcgact   960
ctggatgcgg ccaatatctt gaaaccagcc ttggcgcgtg gaactttgag aacggttggt   1020
gccactactc aggaagaata tcaaaaacat atcgaaaaag atgcggcact ttctcgtcgt   1080
ttcgctaaag tgacgattga agaaccaagt gtggcagata gtatgactat tttacaaggt   1140
ttgaaggcga cttatgagaa acatcaccgt gtacaaatca cagatgaagc ggttgaaaca   1200
gcggttaaga tggctcatcg ttatttaacc agtcgtcact tgccagactc tgctatcgat   1260
ctcttggatg aggcggcagc aacagtgcaa aataaggcaa agcatgtaaa agcagacgat   1320
tcagatttga gtccagctga caaggccctg atggatggca agtggaaaca ggcagcccag   1380
ctaatcgcaa aagaagagga agtacctgtc tacaaagact tggtgacaga gtctgatatt   1440
ttgaccacct tgagtcgctt gtcaggaatc ccagttcaaa aactgactca aacggatgct   1500
aagaagtatt taaatcttga agcagaactc cataaacggg ttatcggtca agatcaagct   1560
gtttcaagca ttagccgtgc cattcgccgc aaccagtcag ggattcgcag tcataagcgt   1620
ccgattggtt cctttatgtt cctagggcct acaggtgtcg ggaaaactga attagccaag   1680
gctctggcag aagttctttt tgacgacgaa tcagcccctta tccgctttga tatgagtgag   1740
tatatggaga aatttgcagc tagtcgtctc aacggagctc ctccaggcta tgtaggatat   1800
gaagaaggtg gggagttgac agagaaggtt cgcaataaac cctattccgt tctcctcttt   1860
gatgaggtag agaaggcccca cccagatatc tttaatgtcc tcttgcaggt tctggatgac   1920
ggtgtcttga cagatagcaa gggacgcaag gtcgattttt caaataccat tatcattatg   1980
acatcgaatc taggtgcgac tgcccttcgt gatgataaga ctgttggttt tggggctaag   2040
gatattcgtt ttgaccagga aaatatggaa aaacgcatgt ttgaagaact gaaaaaagct   2100
tatagaccgg aattcatcaa ccgtattgat gagaaggtgg tcttccatag cctatctagt   2160
gatcatatgc aggaagtggt gaagattatg gtcaagcctt agtggcaag tttgactgaa   2220
aaaggcattg acttgaaatt acaagcttca gctctgaaat tgttagcaaa tcaaggatat   2280
gacccagaga tgggagctcg cccacttcgc agaaccctgc aaacagaagt ggaggacaag   2340
ttggcagaac ttcttctcaa gggagattta gtggcaggca gcacacttaa gattggtgtc   2400
aaagcaggcc agttaaaatt tgatattgca                                    2430
```

SeqID 97
```
atgaaaattt taccgtttat agcaagagga acaagttatt acttgaagat gtcagttaaa    60
aagcttgttc cttttttagt agtaggattg atgctagcag ctggtgatag tgtctatgcc   120
tattccagag gaaatggatc gattgcgcgt ggggatgatt atcctgctta ttataaaaat   180
gggagccagg agattgatca gtggcgcatg tattctcgtc agtgtacttc ttttgtagcc   240
tttcgtttga gtaatgtcaa tggttttgaa attccggcag cttatggaaa tgcgaatgaa   300
tggggacatc gtgctcgtcg ggaaggttat cgtgtagata atacaccgac gattggttcc   360
attacttagt ctactgcagg aacttatgct catgttgcct gggtgtcaaa tgtaatggga   420
gatcagattg agattgagga atataactat ggttatacag aatcctataa taaacgagtt   480
ataaaagcaa acacgatgac aggatttatt cattttaaag atttggatgg tggcagtgtt   540
gggaatagtc aatcctcaac ttcaacaggc ggaactcatt attttaagac caagtctgct   600
attaaaactg aacctctagc tagcgggaact gtgattgatt actattatcc tggggagaag   660
gttcattatg atcagatact tgaaaaagac ggctataagt ggttgagtta tactgcctat   720
aatggaagct atcgttatgt tcaattggag gctgtgaata aaaatcctct aggtaattct   780
gttctttctt caacaggtgg aactcattat tttaagacca agtctgctat caaaactgaa   840
cccctagtta gtgcaactgt gattgattac tattatcctg agagaaggt tcattatgat   900
caaattctcg aaaaagacgg ctacaagtgg ttgagttata cggcttataa cggaagtcgt   960
```

```
cgctatatac agctagaggg agtgacttct tcacaaaatt atcagaatca atcaggaaac    1020
atctctagct atggatccca tagtagttca actgtcggtt ggaagaaaat aaatggtagt    1080
tggtatcatt tcaaatcaaa tggttctaaa tcaacaggat ggctgaaaga cggttctagc    1140
tggtattatt tgaaattatc tggtgaaatg cagacaggat ggttaaagga aaatggtttg    1200
tggtattatc tgggtagttc aggggcaatg aaaacaggct ggtaccaggt ctctggtaag    1260
tggtattatt cttactcttc aggcgcctta gctgttaata cgacggtgga tggctacaga    1320
gtaaacagtg atggagaacg agta                                          1344
```

SeqID 98
```
atgaaagtaa tctttttagc agatgttaaa ggaaaaggta aaaaaggcga aattaaggaa     60
gtaccaacag ggtatgcgca aaactttctt atcaaaaaga atctagccaa agaagcgact    120
gctcaagctg taggtgaact tcgtggtaaa caaaaatcgg aagaaaaagc tcacgctgag    180
atgattgcag aaggaaaagc aattaaagca caacttgaag cagaagaaac tgttgtagaa    240
tttgttgaaa aagttggtcc agatggtcgt acctttggtt ctattaccaa taagaagatt    300
gcagaagaat tgcaaaagca atttggaatt aagattgata acgtcatat tcaagtacaa    360
gctccgattc gagcggttgg tttgattgat gtgccagtga aaatctatca agatatcaca    420
agtgtaatca atcttcgtgt gaaagaagga                                    450
```

SeqID 99
```
atgaagaaaa aaatcttagc gtcactttta ttaagtacag taatggtttc tcaagtagct     60
gttttaacaa ctgcgcatgc agaaacgact gatgacaaaa ttgctgctca agataataaa    120
attagtaact taacagcaca acaacaagaa gcccaaaaac aagttgacca aattcaggag    180
caagtatcag ctattcaag tgagcagtct aacttgcaag ctgaaaatga tagattacaa    240
gcagaatcta agaaactcga gggtgagatt acagaacttt ctaaaaacat tgtttctcgt    300
aaccaatcgt tggaaaaaca agctcgtagt gctcaaacaa atggagccgt aactagctat    360
atcaatacca ttgtaaactc aaaatcaatt acagaagcta tttcacgtgt tgctgcaatg    420
agtgaaatcg tatctgcaaa caacaaaatg ttagaacaac aaaaggcaga taaaaaagct    480
atttctgaaa aacaagtagc aaataatgat gctatcaata ctgtaattgc taatcaacaa    540
aaattggctg atgatgctca agcattgact acgaaacagg cagaactaaa agctgctgaa    600
ttaagtcttg ctgctgagaa agcgacagct gaagggaaa aagcaagtct attagagcaa    660
aaagcagcag ctgaggcaga ggctcgtgca gctgcggtag cagaagcagc ttataaagaa    720
aaacgagcta gccaacaaca atcagtactt gcttcagcaa acactaactt aacagctcaa    780
gtgcaagcag tatctgaatc tgcagcagca cctgtccgtg caaaagttcg tccaacatac    840
agtacaaacg cttcaagtta tccaattgga gaatgtacat ggggagtaaa aacattggca    900
cctgggctg gagactactg gggtaatgga gcacagtggg ctacaagtgc agcagcagca    960
ggtttccgta caggttcaac acctcaagtt ggagcaattg catgttggaa tgatggtgga    1020
tatggtcacg tagcggttgt tacagctgtt gaatcaacaa cacgtatcca agtatcagaa    1080
tcaaattatg caggtaatcg tacaattgga aatcaccgtg gatggttcaa tccaacaaca    1140
acttctgaag gttttgttac atatatttat gcagat                             1176
```

SeqID 100
```
atggtaaaaa gacgtataag gagagggacg agagaacctg aaaaagttgt tgttcctgag     60
caatcatcta ttccttcgta tcctgtatct gttacatcta accaaggaac agatgtagca    120
gtagaaccag ctaaagcagt tgctccaaca acagactgga aacaagaaaa tggtatgtgg    180
tattttttata atactgatgg ttccatggca acaggttggg tacaagttaa tagttcatgg    240
tactacctca acagcaacgg ttctatgaaa gtcaatcaat ggttccaagt tggtggtaaa    300
tggtattatg taaatacatc gggtgagtta gcggtcaata caagtataga tggctataga    360
gtcaatgata atggtgaatg ggtgcgt                                       387
```

SeqID 101
```
gagttgcgac ggctatcaag gttggtggac caggagctct attttggatg tggatggcgg     60
ctttctttgg aatggctacc aagtatgcgg aaggactctt ggccatcaaa taccgcacca    120
aggacgacca tggtgcag                                                 138
```

SeqID 102
```
gactgtatca ggaaacaacc gttcacacgc gatgaaccaa acaaaacgtg ccgtaaaacc     60
aaaccttcaa aaagttactg ttcttatcga tgg                                 93
```

SeqID 103
```
ggacaaagaa accctcgaag aattgaaaga gttatcagaa tggcagaaac gaaaccaaga     60
atatctaaaa aagaaggc                                                 78
```

SeqID 104
```
cagaggaagc tgttcaaaat cttccaccta ttccagaaga aaagtgggtg gaaccagaaa     60
tcatcctgcc tcaagctgaa cttaaattcc ctgaacagga agatgactca gatgacgaag    120
atgttcaggt cgattttttca gccaaagaag cccttgaata caaacttcca agcttacaac    180
tctttgcacc agataaacca aaagatcagt ctaaagagaa gaaaattgtc agagaaaata    240
tcaaaatct                                                          249
```

```
SeqID 105
ttggtgatta tagttttgaa aatccagtcc aaatcggaga cagactttat tttcaagaca     60
tggccatttta ttcttttgtc aaaaataata cctttaatgg tattggattg ccaagtctct    120
atctcatgga cgaacaggga gactgtagct tactcaaagc ttttggctat caagacttta    180
aagggagatt atcatgatgg acagtccaaa aaaattaggc tatcacatgc cagcagagta    240
cgaaccccat catggtaccc tcatgatatg gccgactcga ccaggatcat ggccttttca    300
aggaaaggct gc                                                        312


SeqID 106
gagagactac cagctttttcc tagaagtctt tcagggagga agttggacca aggcggaacc     60
aaagaaaaag gctcggatgg aagaagtcct                                      90


SeqID 107
agaaattgcc tctctacttg gaaaagctcc tcaaactatc acactgaaat caagcgtggg     60
acagtccgac aatgtcttgg aaaagggcgc ttcaaagagg tttattctgc cgactacgct    120
caacagtctt atgaaaacaa tcgcaagcgc tcggtcaaga aatcaagctt gaccaaggaa    180
ctaaaggaaa agattctcca ctatcataac caaaaatttt cgcctgaaat gatggttatg    240
gctaaagggg ttaacgtggg aatttcaacc atttactatt ggattcatca tggaaaattg    300
gggttaagca agcaggattt gctttaccct agaaaaggaa aagcgcttaa gaaacaggct    360
agcaccaact ttaaacctgc tggtcaatcc atcgaacagc ggcctgaagc tatcaatctt    420
cgcttggaga atgggcatta tgagattgat acggttctac ttacgagatc gaaaaactac    480
tgcttgattg tcttgacgga tcgaaagagt agacatcaga tcatccgatt gattccaaat    540
aaaagtgctg aggtggtcaa tcaggctcta aaactcatct taaaacaaca caagattctt    600
tccatcacgg cagataatgg aacggaattc aatcgcttgt ttgatatatt ttctgaggag    660
cacatctatt atgcgcaccc ctatgcctct tgggaaaggg gaactaatga gaatcacaac    720
aggctcattc gtagatagtt acctaaggga accaagaaaa tgactcccaa agaagtcgca    780
ttcatcgaaa agtggattaa caactatcct aaaaaatgct tggactacaa gtcacccaga    840
gaagacttct ggatggctaa cttgaacttg aaatttagca aaatggaaat aattttttatt    900
aaacgcttcc aa                                                        912


SeqID 108
cctgtcatga ctatctcatc gcctactatg aaaaacatgg atttgtcaac gaaggccagt     60
cccagtcaac ctttgcaggg gaaacatggt atgatatggt ctgggaaa                 108


SeqID 109
acatcatcaa taaggataca cacaaggaaa tcatcgccaa actggactac gacgccccat     60
cttgccctga gtgcggaaac caat                                            84


SeqID 110
tacttccttc cacacaagta tgccagagaa agcttatcgc taccctctac caacaaaata     60
ttacacagaa aacaaggttc g                                               81


SeqID 111
gcagccttca aaaaagatca aattaatgag cgtgtcgaga aattaggtaa gttaaaacct     60
attacaataa attacaacgg aaaatcagaa gtaattgata gtaaagaaaa attacaagag    120
cttatgaata aagccgttaa agacgaagtg gctcaaata                           159


SeqID 112
gcttatgcgc attctaaaag aagcgctgga agtggcaggg caggaggcag acaatgtctt     60
tgccaatgtc aaaataaatg taggagagat tttaagtat                            99


SeqID 113
cacggccgac cttatcataa gcctcaccaa ccgcatcatc acgggtttcc ccaacaatct     60
tataatctcc tgcctccgaa acataaacca actctgtgtg tccgccgc                 108


SeqID 114
aaaggaaaaa tcctcctgct accaaggcta accactcaaa gatggcaaag aaaaatccgc     60
cctgactcac gtaagtcagc aaataataaa gcaaaccttg acttccataa tagtcgctgt    120
aaatcttccc tgtctgatga agcgcccaac ctgcataaaa atcctgcact tcttgtgcac    180
tcattaagtc gagtaatagc ggtactccta gagttatccc cgttacaagc gtactccata    240
gtaaaatttt caccaaagga agacgacttg attcacgatg atgcgattct tgttcgattt    300
ggtattctag aggttcacga ttctccttat gaacttcttc tactctacca tacacactca    360
tatcgtttct cctgttcaat ttatctgtct                                     390


SeqID 115
tttacggtaa gccatgtatt cctcctttat ttatctttta atccaagacc caaatcaatg     60
agtttgagtt tcacttcttc caaactcttg cgtccaagat ttcgtacttt catcatctct    120
```

```
gcttcagatt tttctgtcaa atcatgcaca gtattgatac cggcacgttt taaacagttg      180
tatgaacgca cagacaagtc cagttcctca atcgtacgat ctaaaatacg gtcgtcagat      240
tcagtatcag cttctttcat cacttcagtt gacttagcaa tctcagtaag atttgtaaac      300
aaatcaagat gttctgtcaa aatacgtgct gaaagcccta aagcatcttc tggaataatt      360
gttccatttg tcaagatttc aagggttaat ttgtcgaaac catcattgct acctacacga      420
gcaggttcca ct                                                         432
```

SeqID 116
```
cttgtctgca tgaagaataa gggctgctac aaggaaagaa acaactgctg ccac            54
```

SeqID 117
```
ttccattatt tgtcaaaata ctttttagtt tcagcaataa cgactggcga caagaccaag      60
agggcaatca agtttggcag agccatcaag gcgttaacga tatctgcgat aatccagacc      120
atatccaact cgataaatcc tcctaacaag accatgagca caaaaaccac acgg            174
```

SeqID 118
```
ggaaagaagg tattcataaa ataccctcta tcaagagtct cctcaaaaac aggaccgatg      60
attacaggca ggacaaaaga taagatagtc gataaaaagg ttggttgtcc atttgaaaaa      120
agcacggtaa aatactcatc a                                               141
```

SeqID 119
```
tcttcaccag tttttcctaa acttgtaatg gtatctgggg caaataaacc aagagaaagg      60
cgcaatttcc cattttcgtc taaaatgtca ttccacttaa cctttgtctt g              111
```

SeqID 120
```
tacttaactt ccttctcagt tccgaagata gcttcttcaa aggtcaaatt gacacgatac      60
tggagatcat ctccttggcg aggagcgttt ggattgcgcg aagaaccgcc tccgccgaag      120
aaacttgaga aaatatcctc aaaaccaccg aagccacctg ccccattgaa accgccgaaa      180
ccaccagctc caccaaaacc accattggcg cctgcagcac catactggtc a              231
```

SeqID 121
```
cagtcatggc gtcctattcc agattcaaaa tgctatacac aagaaaaact cactatcccc      60
attaaaagaa gaaaagacat caaggacttc taccacaatt ccatccaaag acacaaaaac      120
agccataaga gtcacctcct tgattcctat aggctgatta taacaagact ggctgaaatt      180
gtacatgaaa ataaaatcct aatagtactc attttgtatg tgactaatat tccgtctcgc      240
tccagaaggt acgaagtaaa tagagtt                                         267
```

SeqID 122
```
ctgtttcgtt tttatcgtgt aattgttctt tatcgaggtt ggcatattta tcttttaatt      60
cttgtgaatt tgcagtacgt tcaaaacgtt ttccgaaagg atcgattcct tgttcgcgga      120
gcgcagccat tttttcacgg cgaacgatct gctggtcatt tagttcttcc atatgttctg      180
```

SeqID 123
```
ataactcacc ctccactaaa ccctgagcat tttgtttcaa gagtctttttc atctcttggt      60
ttgaagtctt atcagccaaa agatgataga tttctgagaa agccttcaga tagtaggcat      120
cctgaatcag gtaatagcgg aaaatggcag gttctaaatt ccctcttgt aattgtaaaa      180
```

SeqID 124
```
acattggcta aagcagtcgg tttgatgtat tctccaccaa ttccaccaaa accattctta      60
ggccgaataa cgacagattc gtcttctata                                      90
```

SeqID 125
```
cctggttctc cattttcaga gattccggt gcaggatttt ttggtgtcgc gaaacgaata      60
tttccacgtc caccacgacc accgtgggca acgataaatt cttgcccatg ttcaatcaaa      120
tctgttaaaa ccttgccagt ctccgcatca cgaacagtcg taccttgtgg tactcgaact      180
ctaaggtcct cagcaccacg accatgcatc cctttggtca tcccttttttc accagaatca      240
gccttgaaa                                                            249
```

SeqID 126
```
ataaattcct tgaccttggc cacatcctta tccaaaagaa gggcaccaag aaaggcttca      60
aaggcatcac caagaatggt gtcacgattg cgaccacctg attttttcttc cccttttaccc      120
aacttgataa actggtcaaa ctggcaatca cgcgcaaaac cagctaaact ctcctcacgg      180
acaatcatag cacggagttt tgataggtca ccttcaggct tttttaggata ttttttatat      240
agatattctg aaatcaataa ctgtagaaca gcgtctccta aaaattccaa gcgttcattg      300
tgtgaaattt ttaagaggcg gtgctcattg gca                                  333
```

SeqID 127
```
ccaataggaa aaaggaattg taaagctgaa tgccaatccc accacctgct tgaaaagcag      60
```

```
aagaccttcc agtcaagaaa gaccaagaga tatggggcaa gccccgaacc aagatatAga    120
gaatcaagga agccaagatt gtcacaa                                        147


SeqID 128
cagccattgg gacactcgaa agccgaagaa catgagacta tctgttcgca taccttcgat     60
aaccatacga ccgaaaccat accaaatcaa gtaaaaggcc gtgatatgac ctcgtctgag    120
actcttccat ttccgtctaa aaatcagaat caaggcaaag ccaagcagat tcca          174


SeqID 129
ccttgctctt tacctgatta tgggctggtt ggttctggct atcattcctg ccattatcag     60
tcaaacgaca cccgtttttct ggagtctcat ggtaactggc ggactctgtt atacagttgg    120
agctggattt tatgccaaga aaaaacctta tttccacatg atttggcatc tctttatcct    180
agctgcgtcc gcacttcaat acatcgctat tgtttattac atgtaaaaaa gttgagaaat    240
tcaatctcaa cttttttctt tacacatatt gataaagtac tggtgcaagc gcacatcatc    300
agtcaattct ggatgaaaag aacttaccaa catatttttt tcttgggctg caacaatttg    360
attgttcact gttgc                                                    375


SeqID 130
cgagtaaaag ataatcatct ggataagctt gtgaaagctc ttctaaaaag gcgttcatcc     60
actcagtatt acatccacca gctattaaga aaaatgattc gcctgtatgg gcatcaacag    120
ctccataaca atagcgaaat tctcgtatat agtgactatg gacatgtgga cctactccta    180
ttggagacca acaagatccc agtttac                                        207


SeqID 131
caagtcatca aaatagacat agcaactaca aataaaacgg aatctgtaaa gagccaaagt     60
gagagagaaa agaaaagatt gacaagcagt aatatactaa aggttagagg gcgaccgata    120


SeqID 132
gcctttaaga gttccaaggt cccatcactt gatccatcat cgacaaagac atactcgatt     60
tctgtttcca aatctggaag taaagcttcc agagcc                              96


SeqID 133
gataaaactg acccactggc taggaaactt cctgacaaaa gtaagccgtc aacttccttt     60
tgcaccaaat cactttctcc cgttaacatg gcttcattga cttccgcaaa gccttccaaa    120
accaaggcat cactaggaat ctgctctcct gcagacaaac gaatgacatc tcctagcact    180
aattcttcag gattaagagc aacttcc                                        207


SeqID 134
ttatgccgat tacaaacaca agcaaggcca cgagggtctg tgaccaatct aacgaagcaa     60
aataaggtat atagatacct aaattatctc cgccagacgc aattgtcagc aatg          114


SeqID 135
tgcattcaaa gcattggcaa tgagggacag tgcaaaggca atagttgtta cgtaggcaag     60
gagattcatc ttgcccccat atccgatata gttggtcaca aaggcaaaga ggaaggcgat    120
gatggaaatg atgatggccg ccaattttac ctgttttttgg ctcatttggt tgggtctgcc    180
ttcttgcgaa gcttcccact tctttatagc aaaggtataa atgaggaagg tgacgggata    240
ggtaatgatg gccgccttat ttccaaggat ataatcaata gcaccggaca aaatggtatt    300
aacaatacca aagtaatttc cccatttgct                                     330


SeqID 136
acgtccacga agctggttat cgatacgacg actttcatga cgttctgtac caataacaca     60
aagtcctcca agttcacgaa caccttcacc aagcttgatg tcggtaccac gacccgccat    120
gttggttgcg atggtaacgg caccacgttg accagcattc atgatgattt gggcttctct    180
atagtggttt ttggcattca agacttcgtg aggaacacca gctgcaacca atttcttaga    240
aatgtagtca ctagtttcaa ccgctactgt accaaccaag acaggttgac ccttttggta    300
acgagcctta acgtcttcga caaccgcttt aaacttagat tcgatacttg cataaagaag    360
gtc                                                                 363


SeqID 137
atctctactg gtgtaccgac ctgttcgatg tatccattgt taaagactgc aattctatca     60
gataaagtca aggcttcctc t                                              81


SeqID 138
ttaagtacca tgtccagcat aaagtcaatc ttgtgctctt taccgacaca caccattttc     60
tcaaaatcag ccatatcacc aaaaagagga tccactgcca ta                        102


SeqID 139
agctgctcat actcatctac caactccaag gcatgctcaa tcgtcggttt atcaaaacca     60
```

```
acaatattca tctgtgtcac acccatctca gcagccaagg caattcttc tgcctcacga    120
.cctgcaaatt cttctacatt caagtgtgta tgtgtatcaa aaatcatctc ttctaacctc    180
gttttctatc ttctattata ccaaaaaaga ggaggggcac ctaatttttc ggtttcccct    240
cctctcttca atagagagct attctgctat cttttctatc cgatattgcc catctcctat    300
tccacagtta gagacagaag agattggcta cat                                 333
```

SeqID 140
```
gtaacatctt gcattgttcc tgcagttgct tgcggtgcac ttgttgtctt aggagcagca    60
ttaggagcca ctggtctctt aggaactgta accatggcaa tggcttgcac tccaatcgtt    120
tctgcttcct tcacatcttc catagttttc gcattttcaa tctctttgag agctgcttgt    180
ttttctgctt ccactcttgc taaaagttct gcttttctt tatcagaaag cggtgcgcct    240
ttgattcat cctgcttgtc cttggctgct ttttcaatgg cattttagc tgattctttt    300
tcagtagcta attgcttaga agcttgtgat                                     330
```

SeqID 141
```
tattctcctt tcaaccactc cattctcata aggaaaacga cgaaaatcat aaatccaaac    60
cccaaagcac cacgaatgaa ttggcgaagc aaggtttggt caaaccaacc tgtaaacatt    120
tccactaacc ataccaagag tgacaggccg ataaagaaa                           159
```

SeqID 142
```
gattattca agtttcgaac aacttttaca agattttcta cagtaaagcc atattctgcc    60
aatacttttg gtgctggggc agaggctccg aaggtatcaa tacctagaac ggcaccatcg    120
agaccaacat atttgtacca gttt                                           144
```

SeqID 143
```
agaggcagac gtggattatg cgttgcacga atcaaggctc ctagactagt cattaaacct    60
aagagaacaa tcgatccgcc taccaaagat agatacagtc caccactctc agctacatcc    120
ctctccgtcc ccaaaagtcc tatcatctct ttcccagcga agatggacaa aaatcctaaa    180
aggaaactta atagtaaggt aatcttcaac gcctcagtca ca                       222
```

SeqID 144
```
actcctccat ataccaaaat tcctgccaaa acagctataa taccatttat ttcagctcaa    60
gatttcaacc aagcccaacg gctctctgga                                     90·
```


SeqID 145
MSKNIVQLNNSFIQNEYQRRRYLMKERQKRNRFMGGVLILIMLLFILPTFNLAQSYQQLLQRRQQLADLQTQYQTLSDEKDKE
TAFATKLKDEDYAAKYTRAKYYYSKSREKVYTIPDLLQR

SeqID 146
MDKKKLLLIDGSSVAFRAFFALYQQLDRFKNVAGLHTNAIYGFQLMLSHLLERVEPSHILVAFDAGKTTFRTEMYADYKGGRA
KTPDEFREQFPFIRELLDHMGIRHYDLAQYEADDIIGTLDKLAEQDGFDITIVSGDKDLIQLTDEHTVVEISKKGVAEFEAFI
PDYLMEEMGLTPAQFIDLKALMGDKSDNIPGVTKVGEKTGIKLLLEHGSLEGIYENIDGMKTSKMKENLINDKEQAFLSKTLA
TIDTKAPIAIGLEDLVYSGPDVENLGKFYDEMGFKQLKQALNVSSADVSESLDFTIVDQISQDMLSEESIFHFELFGENYHTD
NLVGFVWSCGDKLYATDKLELLQDPIFKDFLEKTSLRVYDFKKVKVLLQRFGVDLQAPAFDIRLAKYLLSTVEDNEIATIASI
YGQTYLVDDETFYGKGVKKAIPEREKFLEHLACKLAVLVETEPILLEKLSENGQLELLYDMEQPLAFVLAKMEIAGIMVKKEI
LLEMQAENELVIEKLTQEIYELAGEEFNVNSPKQLGVLLFEKLGLPLEYTKKTKTGYSTAVDVLERLAPIAPIVKKILDYRQI
AKIQSTYVIGLQDWILADGKIHTRYVQDLTQTGRLSSVDPNLQNIPARLEQGRLIRKAFVPEWEDSVLLSSDYSQIELRVLAH
ISKDEHLIKAFQEGADIHTSTAMRVFGIERPDDVTANDRRNAKAVNFGVVYGISDFGLSNNLGISRKEAKAYIDTYFERFPGI
KNYMDEVVREARDKGYVETLFKRRRELPDINSRNFNIRGFAERTAINSPIQGSAADILKIAMIQLDKALVAGGYQTKMLLQVH
DEIVLEVPKSELVEMKKLVKQTMEEAIQLSVPLIADENEGATWYEAK

SeqID 147
MGMAAFKNPNNQYKAITIAQTLGDDASSEELAGRYGSAVQCTEVTASNLSTVKTKATVVEKPLKDFRASTSDQSGWVESNGKW
YFYESGDVKTGWVKTDGKWYYLNDLGVMQTGFVKFSGSWYYLSNSGAMFTGWGTDGSRWFYFDGSGAMKTGWYKENGTWYYLD
EAGIMKTGWFKVGPHWYYAYGSGALAVSTTTPDGYRVNGNGEWVN

SeqID 148
MSRKSIGEKRHSFSMRKLSVGLVSVTVSSFFLMSQGIQSVSADNMESPIHYKYMTEGKLTDEEKSLLVEALPQLAEESDDTYY
LVYRSQQFLPNTGFNPTVGTFLFTAGLSLLVLLVSKRENGKKRLVHFLLLTSMGVQLLPASAFGLTSQILSAYNSQLSIGVGE
HLPEPLKIEGYQYIGYIKTKKQDNTELSRTVDGKYSAQRDSQPNSTKTSDVVHSADLEWNQGQGKVSLQGEASGDDGLSEKSS
IAADNLSSNDSFASQVEQNPDHKGESVVRPTVPEQGNPVSATTVQSAEEEVLATTNDRPEYKLPLETKGTQEPGHEGEAAVRE
DLPVYTKPLETKGTQGPGHEGEAAVREEEPAYTEPLATKGTQEPGHEGKATVREETLEYTEPVATKGTQEPEHEGEAAVEEEL
PALEVTTRNRTEIQNIPYTTEEIQDPTLLKNRRKIERQGQAGTRTIQYEDYIVNGNVVETKEVSRTEVAPVNEVVKVGTLVKV
KPTVEITNLTKVENKKSITVSYNLIDTTSAYVSAKTQVPHGDKLVKEVDIENPAKEQVISGLDYYTPYTVKTHLTYNLGENNE
ENTETSTQDFQLEYKKIEIKDIDSVELYGKENDRYRRYLSLSEAPTDTAKYFVKVKSDRFKEMYLPVKSITENTDGTYKVTVA
VDQLVEEGTDGYKDDYTFTVAKSKAEQPGVYTSFKQLVTAMQSNLSGVYTLASDMTADEVSLGDKQTSYLTGAFTGSLIGSDG
TKSYAIYDLKKPLFDTLNGATVRDLDIKTVSADSKENVAALAKAANSANINNVAVEGKISGAKSVAGLVASATNTVIENSSFT

GKLIANHQDSNKNDTGGIVGNITGNSSRVNKVRVDALISTNARNNNQTAGGIVGRLENGALISNSVATGEIRNGQGYSRVGGI
VGSTWQNGRVNNVVSNVDVGDGYVITGDQYAAADVKNASTSVDNRKADRFATKLSKDQIDAKVADYGITVTLDDTGQDLKRNL
REVDYTRLNKAEAERKVAYSNIEKLMPFYNKDLVVHYGNKVATTDKLYTTELLDVVPMKDDEVVTDINNKKNSINKVMLHFKD
NTVEYLDVTFKENFINSQVIEYNVTGKEYIFTPEAFVSDYTAITNNVLSDLQNVTLNSEATKKVLGAANDAALDNLYLDRQFE
EVKANIAEHLRKVLAMDKSINTTGDGVVEYVSEKIKNNKEAFMLGLTYMNRWYDINYGKMNTKDLSTYKFDFNGNNETSTLDT
IVALGNSGLDNLRASNTVGLYANKLASVKGEDSVFDFVEAYRKLFLPNKTNNEWFKENTKAYIVEMKSDIAEVREKQESPTAD
RKYSLGVYDRISAPSWGHKSMLLPLLTLPEESVYISSNMSTLAFGSYERYRDSVDGVILSGDALRTYVRNRVDIAAKRHRDHY
DIWYNLLDSASKEKLFRSVIVYDGFNVKDETGRTYWARLTDKNIGSIKEFFGPVGKWYEYNSSAGAYANGSLTHFVLDRLLDA
YGTSVYTHEMVHNSDSAIYFEGNGRRREGLGAELYALGLLQSVDSVNSHILALNTLYKAEKDDLNRLHTYNPVERFDSDEALQS
YMHGSYDVMYTLDAMEAKAILAQNNDVKKKWFRKIENYYVRDTRHNKDTHAGNKVRPLTDEEVANLTSLNSLIDNDIINRRSY
DDSREYKRNGYYTISMFSPVYAALSNSKGAPGDIMFRKIAYELLAEKGYHKGFLPYVSNQYGAEAFASGSKTFSSWHGRDVAL
VTDDLVFKKVFNGEYSSWADFKKAMFKQRIDKQDNLKPITIQYELGNPNSTKEVTITTAAQMQQLINEAAAKDITNIDRATSH
TPASWVHLLKQKIYNAYLRTTDDFRNSIYK

SeqID 149
MKFNPNQRYTRWSIRRLSVGVASVVVASGFFVLVGQPSSVRADGLNPTPGQVLPEETSGTKEGDLSEKPGDTVLTQAKPEGVT
GNTNSLPTPTERTEVSEETSPSSLDTLFEKDEEAQKNPELTDVLKETVDTADVDGTQASPAETTPEQVKGGVKENTKDSIDVP
AAYLEKAEGKGPFTAGVNQVIPYELFAGDGMLTRLLLKASDNAPWSDNGTAKNPALPPLEGLTKGKYFYEVDLNGNTVGKQGQ
ALIDQLRANGTQTYKATVKVYGNKDGKADLTNLVATKNVDININGLVAKETVQKAVADNVKDSIDVPAAYLEKAKGEGPFTAG
VNHVIPYELFAGDGMLTRLLLKASDKAPWSDNGDAKNPALSPLGENVKTKGQYFYQVALDGNVAGKEKQALIDQFRANGTQTY
SATVNVYGNKDGKPDLDNIVATKKVTININGLISKETVQKAVADNVKDSIDVPAAYLEKAKGEGPFTAGVNHVIPYELFAGDG
MLTRLLLKASDKAPWSDNGDAKNPALSPLGENVKTKGQYFYQVALDGNVAGKEKQALIDQFRANGTQTYSATVNVYGNKDGKP
DLDNIVATKKVTININGLISKETVQKAVADNVKDSIDVPAAYLEKAKGEGPFTAGVNHVIPYELFAGDGMLTRLLLKASDKAP
WSDNGDAKNPALSPLGENVKTKGQYFYQVALDGNVAGKEKQALIDQFRANGTQTYSATVNVYGNKDGKPDLDNIVATKKVTIK
INVKETSDTANGSLSPSNSGSGVTPMNHNHATGTTDSMPADTMTSSTNTMAGENMAASANKMSDTMMSEDKAMLPNTGETQTS
MASIGFLGLALAGLLGGLGLKNKKEEN

SeqID 150
MKSITKKIKATLAGVAALFAVFAPSFVSAQESSTYTVKEGDTLSEIAETHNTTVEKLAENNHIDNIHLIYVDQELVIDGPVAP
VATPAPATYAAPAAQDETVSAPVAETPVVSETVVSTVSGSEAEAKEWIAQKESGGSYTATNGRYIGRYQLTDSYLNGDYSAEN
QERVADAYVAGRYGSWTAAKNFWLNNGWY

SeqID 151
MNKKKMILTSLASVAILGAGFVTSQPTFVRAEESPQVVEKSSLEKKYEEAKAKADTAKKDYETAKKKAEDAQKKYEDDQKRTE
EKARKEAEASQKLNDVALVVQNAYKEYREVQNQRSKYKSDAEYQKKLTEVDSKIEKARKEQQDLQNKFNEVRAVVVPEPNALA
ETKKKAEEAKAEEKVAKRKYDYATLKVALAKKEVEAKELEIEKLQYEISTLEQEVATAQHQVDNLKKLLAGADPDDGTEVIEA
KLKKGEAELNAKQAELAKKQTELEKLLDSLDPEGKTQDELDKEAEEAELDKKADELQNKVADLEKEISNLEILLGGADPEDDT
AALQNKLAAKKAELAKKQTELEKLLDSLDPEGKTQDELDKEAEEAELDKKADELQNKVADLEKEISNLEILLGGADSEDDTAA
LQNKLATKKAELEKTQKELDAALNELGPDGDEEETPAPAPQPEQPAPAPKPEQPAPAPKPEQPAPAPKPEQPAPAPKPEQPAP
APKPEQPAKPEKPAEEPTQPEKPATPKTGWKQENGMWYFYNTDGSMAIGWLQNNGSWYYLNANGAMATGWVKDGDTWYYLEAS
GAMKASQWFKVSDKWYYVNSNGAMATGWLQYNGSWYYLNANGDMATGWLQYNGSWYYLNANGDMATGWAKVNGSWYYLNANGA
MATGWAKVNGSWYYLNANGSMATGWVKDGDTWYYLEASGAMKASQWFKVSDKWYYVNGLGALAVNTTVDGYKVNANGEWV

SeqID 152
MKKIVLVSLAFLFVLVGCGQKKETGPATKTEKDTLQSALPVIENAEKNTVVTKTLVLPKSDDGSQQTQTITYKDKTFLSLAIQ
QKRPVSDELKTYIDQHGVEETQKALLEAEEKDKSIIEARKLAGFKLETKLLSATELQTTTSFDFQVLDVKKASQLEHLKNIGL
ENLLKNEPSKYISDRLANGATEQ

SeqID 153
MFEVEEWLHSRIGLNFRSGLGRMQQAVDLLGNPEQSYPIIHVTGTNGKGSTIAFMRELFMGHGKKVATFTSPHIVSINDRICI
NGQPIADADFIRLTDQVKEMEKTLLQTPAQLSFFELLTLVAFLYFREQEVDLVLLEVGIGGLLDTTNVVTGEFAVITSIGLDH
QETLGDSLEAIAEQKAGIFKAGKKAVIAKLPPEARLACQKKAESLAVNLYQAGQDFLMLNGDFSSSLLNLSQLNIGLEGVYQQ
ENAALALQTFLLFMRERKEAVDEQAVRKALEQTHWAGRLERIRPQIYLDGAHNLPALTRLAEFIKEKEQEGYRPQILFGSLKR
KDYQGMLGYLTEKLPQVELKVTGFDYQGALDERDVTGYDIVSSYREFISDFEERADAQDLLFVTGSLYFISEVRGYLLDREQI
N

SeqID 154
VGIRVYKPTTNGRRNMTSLDFAEITTSTPEKSLLVALKSKAGRNNNGRITVRHQGGGHKRFYRLVDFKRNKDNVEAVVKTIEY
DPNRSANIALVHYTDGVKAYIIAPKGLEVGQRIVSGPEADIKVGNALPLANIPVGTLIHNIELKPGRGGELVRAAGASAQVLG
SEGKYVLVRLQSGEVRMILGTCRATVGVVGNEQHGLVNLGKAGRSRWKGIRPTVRGSVMNPNDHPHGGGEGKAPVGRKAPSTP
WGKPALGLKTRNKKAKSDKLIVRRRNEK

SeqID 155
MAKKSMVAREAKRQKIVDRYAEKRAALKAAGDYEGLSKLPRNASPTRLHNRCRVTGRPHSVYRKFGLSRIAFRELAHKGQIPG
VTKASW

SeqID 156

MDIRQVTETIAMIEEQNFDIRTITMGISLLDCIDPDINRAAEKIYQKITTKAANLVAVGDEIAAELGIPIVNKRVSVTPISLI
GAATDATDYVVLAKALDKAAKEIGVDFIGGFSALVQKGYQKGDEILINSIPRALAETDKVCSSVNIGSTKSGINMTAVADMGR
IIKETANLSDMGVAKLVVFANAVEDNPFMAGAFHGVGEADVIINVGVSGPGVVKRALEKVRGQSFDVVAETVKKTAFKITRIG
QLVGQMASERLGVEFGIVDLSLAPTPAVGDSVARVLEEMGLETVGTHGTTAALALLNDQVKKGGVMACNQVGGLSGAFIPVSE
DEGMIAAVQNGSLNLEKLEAMTAICSVGLDMIAIPEDTPAETIAAMIADEAAIGVINMKTTAVRIIPKGKEGDMIEFGGLLGT
APVMKVNGASSVDFISRGGQIPAPIHSFKN

SeqID 157
MVNTEVARTTIKTEYFGSLTERMNKYREDVLNKKPYIDAERAVLATRAYERYKEQPNVLKRAYMLKEILENMTIYIEEESMIA
GNQASSNKDAPIFPEYTLEFVLNELDLFEKRDGDVFYITEETKEQLRSIAPFWENNNLRARAGALLPEEVSVYMETGFFGMEG
KMNSGDAHLAVNYQKLLQFGLRGFEERARKAKVALDLTDPASIDKYHFYDSIFIVIDAIKVYAKRFVALAKSLAENANPKRKK
ELLEIADICSRVPYEPATTFAEAIQSVWFIQCILQIESNGHSLSYGRFDQYMYPYMKADLESGKETEDSIVERLTNLWIKTIT
INKVRSQSHTFSSAGSPLYQNVTIGGQTRDKKDAVNPLSYLVLKSVAQTHLPQPNLTVRYHAGLDARFMNECIEVMKLGFGMP
AFNNDEIIIPSFIAKGVLEDDAYDYSAIGCVETAVPGKWGYRCTGMSYMNFPKVLLITMNDGIDPASGKRFAPSFGRFKDMKN
FSELENAWDKTLRYLTRMSVIVENSIDLSLEREVPDILCSALTDDCIGRGKHLKEGGAVYDYISGLQVGIANLSDSLAAIKKL
VFEEERISPSQLWHALETDYAGEEGKVIQEMLIHDAPKYGNDDDYADKLVTAAYDIYVDEIAKYPNTRYGRGPIGGIRYSGTS
SISANVGQGRGTLATPDGRNAGTPLAEGCSPSHNMDQHGPTSVLKSVSKLPTDEIVGGVLLNQKVNPQTLAKEEDKLKLIALL
RTFFNRLHGYHIQYNVVSRETLIDAQKHPEKHRDLIVRVAGYSAFFNVLSKATQDDIIGRTEHTL

SeqID 158
MSQAQYAGTGRRKNAVARVRLVPGTGKITVNKKDVEEYIPHADLRLVINQPFAVTSTVGSYDVFVNVIGGGYAGQSGAIRHGI
ARALLQVDPDFRDSLKRAGLLTRDSRKVERKKPGLKKARKASQFSKR

SeqID 159
LEKKLTIKDIAEMAQTSKTTVSFYLNGKYEKMSQETREKIEKVIHETNYKPSIVARSLNSKRTKLIGVLIGDITNSFSNQIVK
GIEDIASQNGYQVMIGNSNYSQESEDRYIESMLLLGVDGFIIQPTSNFRKYSRIIDEKKKKMVFFDSQLYEHRTSWVKTNNYD
AVYDMTQSCIEKGYEHFLLITADTSRLSTRIERASGFVDALTDANMRHASLTIEDKHTNLEQIKEFLQKEIDPDEKTLVFIPN
CWALPLVFTVIKELNYNLPQVGLIGFDNTEWTCFSSPSVSTLVQPSFEEGQQATKILIDQIEGRNQEERQQVLDCSVNWKEST
F

SeqID 160
MNKGLFEKRCKYSIRKFSLGVASVMIGAAFFGTSPVLADSVQSGSTANLPADLATALATAKENDGRDFEAPKVGEDQGSPEVT
DGPKTEEELLALEKEKPAEEKPKEDKPAAAKPETPKTVTPEWQTVANKEQQGTVTIREEKGVRYNQLSSTAQNDNAGKPALFE
KKGLTVDANGNATVDLTFKDDSEKGKSRFGVFLKFKDTKNNVFWYGYDKDGWFWEYKSPTTSTWYRGSRVAAPETGSTNRLSIT
LKSDGQLNASNNDVNLFDTVTLPAAVNDHLKNEKKILLKAGSYDDERTVVSVKTDNQEGVKTEDTPAEKETGPEVDDSKVTYD
TIQSKVLKAVIDQAFPRVKEYSLNGHTLPGQVQQFNQVFINNHRITPEVTYKKINETTAEYLMKLRDDAHLINAEMTVRLQVV
DNQLHFDVTKIVNHNQVTPGQKIDDESKLLSSISFLGNALVSVSSNQTGAKFDGATMSNNTHVSGDDHIDVTNPMKDLAKGYM
YGFVSTDKLAAGVWSNSQNSYGGGSNDWTRLTAYKETVGNANYVGIHSSEWQWEKAYKGIVFPEYTKELPSAKVVITEDANAD
KNVDWQDGAIAYRSIMNNPQGWEKVKDITAYRIAMNFGSQAQNPFLMTLDGIKKINLHTDGLGQGVLLKGYGSEGHDSGHLNY
ADIGKRIGGVEDFKTLIEKAKKYGAHLGIHVNASETYPESKYFNEKILRKNPDGSYSYGWNWLDQGINIDAAYDLAHGRLARW
EDLKKKLGDGLDFIYVDVWGNGQSGDNGAWATHVLAKEINKQGWRFAIEWGHGGEYDSTFHHWAADLTYGGYTNKGINSAITR
FIRNHQKDAWVGDYRSYGGAANYPLLGGYSMKDFEGWQGRSDYNGYVTNLFAHDVMTKYFQHFTVSKWENGTPVTMTDNGSTY
KWTPEMRVELVDADNNKVVVTRKSNDVNSPQYRERTVTLNGRVIQDGSAYLTPWNWDANGKKLSTDKEKMYYFNTQAGATTWT
LPSDWAKSKVYLYKLTDQGKTEEQELTVKDGKITLDLLANQPYVLYRSKQTNPEMSWSEGMHIYDQGFNSGTLKHWTISGDAS
KAEIVKSQGANDMLRIQGNKEKVSLTQKLTGLKPNTKYAVYVGVDNRSNAKASITVNTGEKEVTTYTNKSLALNYVKAYAHNT
RRDNATVDDTSYFQNMYAFFTTGADVSNVTLTLSREAGDQATYFDEIRTFENNSSMYGDKHDTGKGTFKQDFENVAQGIFPFV
VGGVEGVEDNRTHLSEKHNPYTQRGWNGKKVDDVIEGNWSLKTNGLVSRRNLVYQTIPQNFRPEAGKTYRVTFEYEAGSDNTY
AFVVGKGEFQSGRRGTQASNLEMHELPNTWTDSKKAKKATFLVTGAETGDTWVGIYSTGNASNTRGDSGGNANFRGYNDFMMD
NLQIEEITLTGKMLTENALKNYLPTVAMTNYTKESMDALKEAVFNLSQADDDISVEEARAEIAKIEALKNALVQKKTALVADD
FASLTAPAQAQEGLANAFDGNVSSLWHTSWNGGDVGKPATMVLKEPTEITGLRYVPRGSGSNGNLRDVKLVVTDESGKEHTFT
ATDWPNNNKPKDIDFGKTIKAKKIVLTGTKTYGDGGDKYQSAAELIFTRPQVAETPLDLSGYEAALVKAQKLTDKDNQEEVAS
VQASMKYATDNHLLTERMVEYFADYLNQLKDSATKPDAPTVEKPEFKLRSLASEQGKTPDYKQEIARPETPEQILPATGESQS
DTALILASVSLALSALFVVKTKKD

SeqID 161
MNKPTILRLIKYLSISFLSLVIAAIVLGGGVFFYYVSKAPSLSESKLVATTSSKIYDNKNQLIADLGSERRVNAQANDIPTDL
VKAIVSIEDHRFFDHRGIDTIRILGAFLRNLQSNSLQGGSTLTQQLIKLTYFSTSTSDQTISRKAQEAWLAIQLEQKATKQEI
LTYYINKVYMSNGNYGMQTAAQNYYGKDLNNLSLPQLALLAGMPQAPNQYDPYSHPEAAQDRRNLVLSEMKNQGYISAEQYEK
AVNTPITDGLQSLKSASNYPAYMDNYLKEVINQVEEETGYNLLTTGMDVYTNVDQEAQKHLWDIYNTDEYVAYPDDELQVAST
IVDVSNGKVIAQLGARHQSSNVSFGINQAVETNRDWGSTMKPITDYAPALEYGVYDSTATIVHDEPYNYPGTNTPVYNWDRGY
FGNITLQYALQQSRNVPAVETLNKVGLNRAKTFLNGLGIDYPSIHYSNAISSNTTESDKKYGASSEKMAAAYAAFANGGTYYK
PMYIHKVVFSDGSEKEFSNVGTRAMKETTAYMMTDMMKTVLTYGTGRNAYLAWLPQAGKTGTSNYTDEEIENHIKTSQFVAPD
ELFAGYTRKYSMAVWTGYSNRLTPLVGNGLTVAAKVYRSMMTYLSEGSNPEDWNIPEGLYRNGEFVFKNGARSTWNSPAPQQP
PSTESSSSSSDSSTSQSSSTTPSTNNSTTTNPNNNTQQSNTTPDQQNQNPQPAQP

SeqID 162
MSKKRRNRHKKEGGQEPQFDFDEAKELTVGQAIRKNEEVESGVLPEDSILDKYVKQHRDEIEADKFATRQYKKEEFVETQSLDD
LIQEMREAVEKSEASSEEVPSSEDILLPLPLDDEEQGLDPLLLDDENPTEMTEEVEEEQNLSRLDQEDSEKKSKKGFILTVLA

LVSVIICVSAYYVYRQVARSTKEIETSQSTTANQSDVDDFNTLYDAFYTDSNKTALKNSQFDKLSQLKTLLDKLEGSREHTLA
KSKYDSLATQIKAIQDVNAQFEKPAIVDGVLDTNAKAKSDAKFTDIKTGNTELDKVLDKAISLGKSQQTSTSSSSSSQTSSSS
SSQASSNTTSEPKPSSSNETRSSRSEVNMGLSSAGVAVQRSASRVAYNQSAIDDSNNSAWDFADGVLEQILATSRSRGYITGD
QYILERVNIVNGNGYYNLYKPDGTYLFTLNCKTGYFVGNGAGHADDLDY

SeqID 163
MKLLKKMMQVALAVFFFGLLATNTVFANTTGGRFVDKDNRKYYVKDDHKAIYWHKIDGKTYYFGDIGEMVVGWQYLEIPGTGY
RDNLFDNQPVNEIGLQEKWYYFGQDGALLEQTDKQVLEAKTSENTGKVYGEQYPLSAEKRTYYFDNNYAVKTGWIYEEGHWYY
LNKLGNFGDDSYNPLPIGEVAKGWTQDFHVTIDIDRSKPAPWYYLDASGKMLTDWQKVNGKWYYFGSSGSMATGWKYVRGKWY
YLDNKNGDMKTGWQYLGNKWYYLRSSGAMVTGWYQDGSTWYYLDPSNGDMKIGWTKVNGKWYYLNSNGAMVTGSQTIDGKVYN
FASSGEWI

SeqID 164
MKILKKTMQVGLTVFFFGLLGTSTVFADDSEGWQFVQENGRTYYKKGDLKETYWRVIDGKYYYFDSLSGEMVVGWQYIPFPSK
GSTIGPYPNGIRLEGFPKSEWYYFDKNGVLQEFVGWKTLEIKTKDSVGRKYGEKREDSEDKEEKRYYTNYYFNQNHSLETGWL
YDQSNWYYLAKTEINGENYLGGERRAGWINDDSTWYYLDPTTGIMQTGWQYLGNKWYYLRSSGAMATGWYQEGTTWYYLDHPN
GDMKTGWQNLGNKWYYLRSSGAMATGWYQDGSTWYYLNAGNGDMKTGWFQVNGNWYYAYSSGALAVNTTVDGYSVNYNGEWVR

SeqID 165
MVLSKYYGVADGMNVEGRGSANFIKDNVLITAAHNYYRHDYGKEADDIYVLPAVSPSQEPFGKIKVKEVRYLKEFRNLNSKDA
REYDLALLILEEPIGAKLGTLGLPTSQKNLTGITVTITGYPSYNFKIHQMYTDKKQVLSDDGMFLDYQVDTLEGSSGSTVYDA
SHRVVGVHTLGDGANQINSAVKLNERNLPFIYSVLKGYSLEGWKKINGSWYHYRQHDKQTGWQEINDTWYYLDSSGKMLTDWQ
KVNGKWYYLNSNGAMVTGSQTIDGKVYNFASSGEWI

SeqID 166
LMKKTFFLLVLGLFCLLPLSVFAIDFKINSYQGDLYIHADNTAEFRQKIVYQFEEDFKGQIVGLGRAGKMPSGFDIDPHPKIQ
AAKNGAELADVTSEVTEEADGYTVRVYNPGQEGDIVEVDLVWNLKNLLFLYDDIAELNWQPLTDSSESIEKFEFHVRGDKGAE
KLFFHTGKLFREGTIEKSNLDYTIRLDNLPAKRGVELHAYWPRTDFASARDQGLKGNRLEEFNKIEDSIVREKDQSKQLVTWV
LPSILSISLLLSVCFYFIYRRKTTPSVKYAKNHRLYEPPMELEPMVLSEAVYSTSLEEVSPLVKGAGKFTFDQLIQATLLDVI
DRGNVSIISEGDAVGLRLVKEDGLSSFEKDCLNLAFSGKKEETLSNLFADYKVSDSLYRRAKVSDEKRIQARGLQLKSSFEEV
LNQMQEGVRKRVSFWGLPDYYRPLTGGEKALQVGMGALTILPLFIGFGLFLYSLDVHGYLYLPLPILGFLGLVLSVFYYWKLR
LDNRDGVLNEAGAEVYYLWTSFENMLREIARLDQAELESIVVWNRLLVYATLFGYADKVSHLMKVHQIQVENPDINLYVAYGW
HSTFYHSTAQMSHYASVANTASTYSVSSGSGSSGGGFSGGGGGGSIGAF

SeqID 167
MKSINKFLTMLAALLLTASSLFSAATVFAAGTTTTSVTVHKLLATDGDMDKIANELETGNYAGNKVGVLPANAKEIAGVMFVW
TNTNNEIIDENGQTLGVNIDPQTFKLSGAMPATAMKKLTEAEGAKFNTANLPAAKYKIYEIHSLSTYVGEDGATLTGSKAVPI
EIELPLNDVVDAHVYPKNTEAKPKIDKDFKGKANPDTPRVDKDTPVNHQVGDVVEYEIVTKIPALANYATANWSDRMTEGLAF
NKGTVKVTVDDVALEAGDYALTEVATGFDLKLTDAGLAKVNDQNAEKTVKITYSATLNDKAIVEVPESNDVTFNYGNNPDHGN
TPKPNKPNENGDLTLTKTWVDATGAPIPAGAEATFDLVNAQTGKVVQTVTLTTDKNTVTVNGLDKNTEYKFVERSIKGYSADY
QEITTAGEIAVKNWKDENPKPLDPTEPKVVTYGKKFVKVNDKDNRLAGAEFVIANADNAGQYLARKADKVSQEEKQLVVTTKD
ALDRAVAAYNALTAQQQTQQEKEKVDKAQAAYNAAVIAANNAFEWVADKDNENVVKLVSDAQGRFEITGLLAGTYYLEETKQP
AGYALLTSRQKFEVTATSYSATGQGIEYTAGSGKDDATKVVNKKITIPQTGGIGTIIFAVAGAAIMGIAVYAYVKNNKDEDQL
A

SeqID 168
MAVMAYPLVSRLYYRVESNQQIADFDKEKATLDEADIDERMKLAQAFNDSLNNVVSGDPWSEEMKKKGRAEYARMLEIHERMG
HVEIPVIDVDLPVYAGTAEEVLQQGAGHLEGTSLPIGGNSTHAVITAHTGLPTAKMFTDLTKLKVGDKFYVHNIKEVMAYQVD
QVKVIEPTNFDDLLIVPGHDYVTLLTCTPYMINTHRLLVRGHRIPYVAEVEEEFIAANKLSHLYRYLFYVAVGLIVILLWIIR
RLRKKKQPEKALKALKAARKEVKVEDGQQ

SeqID 169
MSRTKLRALLGYLLMLVACLIPIYCFGQMVLQSLGQVKGHATFVKSMTTEMYQEQQNHSLAYNQRLASQNRIVDPFLAEGYEV
NYQVSDDPDAVYGYLSIPSLEIMEPVYLGADYHHLGMGLAHVDGTPLPLDGTGIRSVIAGHRAEPSHVFFRHLDQLKVGDALY
YDNGQEIVEYQMMDTEIILPSEWEKLESVSSKNIMTLITCDPIPTFNKRLLVNFERVAVYQKSDPQTAAVARVAFTKEGQSVS
RVATSQWLYRGLVVLAFLGILFVLWKLARLLRGK

SeqID 170
MKNPFFERRCRYSIRKLSVGACSLMIGAVLFAGPALAEETAVPENSGANTELVSGESEHSTNEADKQNEGEHARENKLEKAEG
VAIASETASPASNEAATTETAEAASAAKPEEKASEVVAETPSAEAKPKSDKETEAKPEATNQGDESKPAAEANKTEKEVQPDV
PKNTEKTLKPKEIKFNSWEELLKWEPGAREDDAINRGSVVLASRRTGHLVNEKASKEAKVQALSNTNSKAKDHASVGGEEFKA
YAFDYWQYLDSMVFWEGLVPTPDVIDAGHRNGVPVYGTLFFNWSNSIADQERFAEALKQDADGSFPIARKLVDMAKYYGYDGY
FINQETTGDLVKPLGEKMRQFMLYSKEYAAKVNHPIKYSWYDAMTYNYGRYHQDGLGEYNYQFMQPEGDKVPADNFFANFNWD
KAKNDYTIATANWIGRNPYDVFAGLELQQGGSYKTKVKWNDILDENGKLRLSLGLFAPDTITSLGKTGEDYHKNEDIFFTGYQ
GDPTGQKPGDKDWYGIANLVADRTPAVGNTFTTSFNTGHGKKWFVDGKVSKDSEWNYRSVSGVLPTWRWWQTSTGEKLRAEYD
FTDAYNGGNSLKFSGDVAGKTDQDVRLYSTKLEVTEKTKLRVAHKGGKGSKVYMAFSTTPDYKFDDADAWKELTLSDNWTNEE
FDLSSLAGKTIYAVKLFFEHEGAVKDYQFNLGQLTISDNHQEPQSPTSFSVVKQSLKNAQEAEAVVQFKGNKDADFYEVYEKD
GDSWKLLTGSSSTTIYLPKVSRSASAQGTTQELKVVAVGKNGVRSEAATTTFDWGMTVKDTSLPKPLAENIVPGATVIDSTFP

KTEGGEGIEGMLNGTITSLSDKWSSAQLSGGSVDIRLTKPRTVVRWVMDHAGAGGESVNDGLMNTKDFDLYYKDADGEWKLAKE
VRGNKAHVTDITLDKPITAQDWRLNVVTSDNGTPWKAIRIYNWKMYEKLDTESVNIPMAKAAARSLGNNKVQVGFADVPAGAT
ITVYDNPNSQTPLATLKSEVGGDLASAPLDLTNQSGLLYYRTQLPGKEISNVLAVSVPKDDRRIKSVSLETGPKKTSYAEGED
LDLRGGVLRVQYEGGTEDELIRLTHAGVSVSGFDTHHKGEQNLTLQYLGQPVNANLSVTVTGQDEASPKTILGIEVSQEPKKD
YLVGDSLDLSEGRFAVAYSNDTMEEHSFTDEGVEISGYDAQKTGRQTLTLHYQGHEVSFDVLVSPKAALNDEYLKQKLAEVEA
AKNKVVYNFASSEVKEAFLKAIEAAEQVLKDHETSTQDQVNDRLNKLTEAHKALNGQEKFTEEKTELDRLTGEVQELLAAKPN
HPSGSALAPLLEKNKALVEKVDLSPEELTTAKQSLKDLVALLKEDKPAVFSDSKTGVEVHFSNKEKTVIKGLKVERVQASAEE
KKYFAGEDAHVFEIEGLDEKGQDVDLSYASIVKIPIEKDKKVKKVFFLPEGKEAVELAFEQTDSHVIFTAPHFTHYAFVYESA
EKPQPAKPAPQNTVLPKPTYQPTSDQQKAPKLEVQEEKVAFHRQEHENTEMLVGEQRVIIQGRDGLLRHVFEVDENGQRRLRS
TEVIQEAIPEIVEIGTKVKTVPAVVATQEKPAQNTAVKSEEASKQLPNTGTADANEALIAGLASLGLASLALTLRRKREDKD

SeqID 171
MSITSFVKRIQDITRNDAGVNGDAQRIEQMSWLLFLKIYDSREMVWELEEDEYESIIPEELKWRNWAHAQNGERVLTGDELLD
FVNNKLFKELKELEITSNMPIRKTIVKSAFEDANNYMKNGVLLRQVINVIDEVDFNSPEDRHSFNDIYEKILKDIQNAGNSGE
FYTPRAATDFIAEVLDPKLGESMADLACGTGGFLTSTLNRLSSQRKTSEDTKKYNTAVFGIEKKAFPHLLAVTNLFLHEIDDP
KIVHGNTLEKNVREYTDDEKFDIIMMNPPFGSGSELETIKNNFPAELRSSETADLFMAVIMYRLKENGRVGVILPDGFLFGEGV
KTRLKQKLVDEFNLHTIIRLPHSVFAPYTGIHTNILFFDKTKKTEETWFYRLDMPDGYKNFSKTKPMKSEHFNPVRDWWENRE
EILEGKFYKSKSFTPSELAELNYNLDQCDFPKEEEEILNPFELIQNYQAERATLNHKIDNVLADILQLLEDK

SeqID 172
MNNTEFYDRLGVSKNASADEIKKAYRKLSKKYHPDINKEPGAEDKYKEVQEAYETLSDDQKRAAYDQYGAAGANGGFGGAGGF
GGFNGAGGFGGFEDIFSSFFGGGGSSRNPNAPRQGDDLQYRVNLTFEEAIFGTEKEVKYHREAGCRTCNGSGAKPGTSPVTCG
RCHGAGVINVDTQTPLGMMRRQVTCDVCHGRGKEIKYPCTTCHGTGHEKQAHSVHVKIPAGVETGQQIRLAGQGEAGFNGGPY
GDLYVVVSVEASDKFEREGTTIFYNLNLNFVQAALGDTVDIPTVHGDVELVIPEGTQTGKKFRLRSKGAPSLRGGAVGDQYVT
VNVVTPTGLNDRQKVALKEFAAAGDLKVNPKKKGFFDHIKDAFDGE

SeqID 173
MNPNLFRSVEFYQRRYHNYATVLIIPLSLLFTFILIFSLVATKEITVTSQGEIAPTSVIASIQSTSDNPILANHLVANQVVEK
GDLLIKYSETMEESQKTALATQLQRLEKQKEGLGILKQSLEKATDLFSGEDEFGYHNTFMNFTKQSHDIELGITKTNTEVSNQ
ANLSNSSSSAIEQEITKVQQQIGEYQELRDAIINNRARLPTGNPHQSILNRYLVASQGQTQGTAEEPFLSQINQSIAGLESSI
ASLKIQQAGIGSVATYDNSLATKIEVLRTQFLQTASQQQLTVENQLTELKVQLDQATQRLENNTLTSPSKGIVHLNSEFEGKN
RIPTGTEIAQIFPVITDTREVLITYYVSSDYLPLLDKGQTVRLKLEKIGNHGTTIIGQLQTIDQTPTRTEQGNLFKLTALAKL
SNEDSKLIQYGLQGRVTSVTTKKTYFDYFKDKILTHSD

SeqID 174
MSKKLNRKKQLRNGLRRAGAFSSTVTKVVDETKKVVKRAEQSASAAGKAVSKKVEQAVEATKEQAQKVANSVEDFAANLGGLP
LDRAKTFYDEGIKSASDFKNWTEKELLALKGIGPATIKKLKENGIKFK

SeqID 175
LISLFGLAAAKPVQADTSIADIQKRGELVVGVKQDVPNFGYKDPKTGTYSGIETDLAKMVADELKVKIRYVPVTAQTRGPLLD
NEQVDMDIATFTITDERKKLYNFTSPYYTDASGFLVNKSAKIKKIEDLNGKTIGVAQGSITQRLITELGKKKGLKFKFVELGS
YPELITSLHAHRIDTFSVDRSILSGYTSKRTALLDDSFKPSDYGIVTKKSNTELNDYLDNLVTKWSKDGSLQKLYDRYKLKPS
SHTAD

SeqID 176
MSNISLTTLGGVRENGKNMYIAEIGESIFVLNVGLKYPENEQLGVDVVIPNMDYLFENSDRIAGVFLTHGHADAIGALPYLLA
EAKVPVFGSELTIELAKLFVKGNDAVKKFNDFHVIDENTEIDFGGTVVSFFPTTYSVPESLGIVLKTSEGSIVYTGDFKFDQT
ASESYATDFARLAEIGRDGVLALLSDSANADSNIQVASESEVRDEITQTIADWEGRIIVAAVSSNLSRIQQIFDAADKTGRRI
VLTGFDIENIVRTAIRLKKLSLANEILLIKPKDMSRFEDHELIILETGRMGEPINGLRKMSIGRHRYVEIKDGDLVYIATAPS
IAKEAFVARVENMIYQAGGVVKLITQSLHVSGHGNVRDLQLMINLLQPKYLFPVQGEYRELDAHAKAAMAVGMLPERIFIPKK
GTTMAYENGDFVPAGSVSAGDILIDGNAIGDVGNVVLRDRKVLSEDGIFIVAITVNRREKKIVARARVHTRGFVYLKKSRDIL
RESSELINQTVEEYLQGDDFDWADLKGKVRDNLTKYLFDQTKRRPAILPVVMEAK

SeqID 177
MKKSTVLSLTTAAVILAAYAPNEVVLADTSSSEDALNISDKEKVAENKEKHENIHSAMETSQDFKEKKTAVIKEKEVVSKNPV
IDNNTSNEEAKIKEENSNKSQGDYTDSFVNKNTENPKKEDKVVYIAEFKDKESGEKAIKELSSLKNTKVLYTYDRIFNGSAIE
TTPDNLDKIKQIEGISSVERAQKVQPMMNHARKEIGVEEAIDYLKSINAPFGKNFDGRGMVISNIDTGTDYRHKAMRIDDDAK
ASMRFKKEDLKGTDKNYWLSDKIPHAFNYYNGGKITVEKYDDGRDYFDPHGMHIAGILAGNDTEQDIKNFNGIDGIAPNAQIF
SYKMYSDAGSGFAGDETMFHAIEDSIKHNVDVVSVSSGFTGTGLVGEKYWQAIRALRKAGIPMVVATGNYATSASSSSWDLVA
NNHLKMTDTGNVTRTAAHEDAIAVASAKNQTVEFDKVNIGGESFKYRNIGAFFDKSKITTNEDGTKAPSKLKFVYIGKGQDQD
LIGLDLRGKIAVMDRIYTKDLKNAFKKAMDKGARAIMVVNTVNYYNRDNWTELPAMGYEADEGTKSQVFSISGDDGVKLWNMI
NPDKKTEVKRNNKEDFKDKLEQYYPIDMESFNSNKPNVGDEKEIDFKFAPDTDKELYKEDIIVPAGSTSWGPRIDLLLKPDVS
APGKNIKSTLNVINGKSTYGYMSGTSMATPIVAASTVLIRPKLKEMLERPVLKNLKGDDKIDLTSLTKIALQNTARPMMDATS
WKEKSQYFASPRQQGAGLINVANALRNEVVATFKNTDSKGLVNSYGSISLKEIKGDKKYFTIKLHNTSNRPLTFKVSASAITT
DSLTDRLKLDETYKDEKSPDGKQIVPEIHPEKVKGANITFEHDTFTIGANSSFDLNAVINVGEAKNKNKFVESFIHFESVEEM
EALNSNGKKINFQPSLSMPLMGFAGNWNHEPILDKWAWEEGSRSKTLGGYDDDGKPKIPGTLNKIGGEHGIDKFNPAGVIQN
RKDKNTTSLDQNPELFAFNNEGINAPSSSGSKIANIYPLDSNGNPQDAQLERGLTPSPLVLRSAEEGLISIVNTNKEGENQRD
LKVISREHFIRGILNSKSNDAKGIKSSKLKVWGDLKWDGLIYNPRGREENAPESKDNQDPATKIRGQFEPIAEGQYFYKFKYR

LTKDYPWQVSYIPVKIDNTAPKIVSVDFSNPEKIKLITKDTYHKVKDQYKNETLFARDQKEHPEKFDEIANEVWYAGAALVNE
DGEVEKNLEVTYAGEGQGRNRKLDKDGNTIYEIKGAGDLRGKIIEVIALDGSSNFTKIHRIKFANQADEKGMISYYLVDPDQD
SSKYQKLGEIAESKFKNLGNGKEGSLKKDTTGVEHHHQENEESIKEKSSFTIDRNISTIRDFENKDLKKLIKKKFREVDDFTS
ETGKRMEEYDYKYDDKGNIIAYDDGTDLEYETEKLDEIKSKIYGVLSPSKDGHFEILGKISNVSKNAKVYYGNNYKSIEIKAT
KYDFHSKTMTFDLYANINDIVDGLAFAGDMRLFVKDNDQKKAEIKIRMPEKIKETKSEYPYVSSYGNVIELGEGDLSKNKPDN
LTKMESGKIYSDSEKQQYLLKDNIILRKGYALKVTTYNPGKTDMLEGNGVYSKEDIAKIQKANPNLRALSETTIYADSRNVED
GRSTQSVLMSALDGFNIIRYQVFTFKMNDKGEAIDKDGNLVTDSSKLVLFGKDDKEYTGEDKFNVEAIKEDGSMLFIDTKPVN
LSMDKNYFNPSKSNKIYVRNPEFYLRGKISDKGGFNWELRVNESVVDNYLIYGDLHIDNTRDFNIKLNVKDGDIMDWGMKDYK
ANGFPDKVTDMDGNVYLQTGYSDLNAKAVGVHYQFLYDNVKPEVNIDPKGNTSIEYADGKSVVFNINDKRNNGFDGEIQEQHI
YINGKEYTSFNDIKQIIDKTLNIKIVVKDFARNTTVKEFILNKDTGEVSELKPHRVTVTIQNGKEMSSTIVSEEDFILPVYKG
ELEKGYQFDGWEISGFEGKKDAGYVINLSKDTFIKPVFKKIEEKKEEENKPTFDVSKKKDNPQVNHSQLNESHRKEDLQREEH
SQKSDSTKDVTATVLDKNNISSKSTTNNPNKLPKTGSASGAQTLLAAGIMPIVGIFLGLKKKNQD

SeqID 178

MGKGHWNRKRVYSIRKFAVGACSVMIGTCAVLLGGNIAGESVVYADETLITHTAEKPKEEKMIVEEKADKALETKNIVERTEQ
SEPSSTEAIASEKKEDEAVTPKEEKVSAKPEEKAPRIESQASNQEKPLKEDAKAVTNEEVNQMIEDRKVDFNQNWYFKLNANS
KEAIKPDADVSTWKKLDLPYDWSIFNDFDHESPAQNEGGQLNGGEAWYRKTFKLDEKDLKKNVRLTFDGVYMDSQVYVNGQLV
GHYPNGYNQFSYDITKYLQKDGRENVIAVHAVNKQPSSRWYSGSGIYRDVTLQVTDKVHVEKNGTTILTPKLEEQQHGKVETE
VTSKIVNTDDKDHELVAEYQIVERGGHAVTGLVRTASRTLKAHESTSLDAILEVERPKLWTVLNDKPALYELITRVYRDGQLV
DAKKDLFGYRYYHWTPNEGFSLNGERIKFHGVSLHHDHGALGAEENYKAEYRRLKQMKEMGVNSIRTTHNPASEQTLQIAAEI
GLLVQEEAFDTWYGGKKPYDYGRFFEKDATHPEARKGEKWSDFDLRTMVERGKNNPAIFMWSIGNEIGEANGDAHSLATVKRI
VKVIKDVDKTRYVTMGADKFRFGNGSGGHEKIADELDAVGFNYSEDNYKALRAKHPKWLIYGSETSSATRTRGSYYRPERELK
HSNGPERNYEQSDYGNDRVGWGKTATASWTFDRDNAGYAGQFIWTGTDYIGEPTPWHNQNQTPVKSSYFGIVDTAGIPKHDFY
LYQSQWVSVKKKPMVHLLPHWNWENKELASKVADSEGKIPVRAYSNASSVELFLNGKSLGLKTFNKKQTSDGRTYQEGANANE
LYLEWKVAYQPGTLEAIARDESGKEIARDKITTAGKPAAVRLIKEDHAIAADGKDLTYIIYYEIVDSQGNVVPTANNLVRFQLK
GQGQLVGVDNGEQASRERYKAQADGSWIRKAFNGKGVAIVKSTEQAGKFTLTAHSDLLKSNQVTVFTGKKEGQEKTVLGTEVE
KVQTIIGEAPEMPTTVPFVYSDGSRAERPVTWSSVDVSKPGIVTVKGMADGREVEARVEVIALKSELPVVKRIAPNTDLNSVE
KSVSYVLIDGSVEEYEVDKWEIAEEDKAKLAIPGSRIQATGYLEGQPIHATLVVEEGNPAAPAVPTVTGGEAVTGLTSQKPM
QYRTLAYGAKLPEVTASAKNAAVTVLQASAANGMRASIFIQPKDGGPLQTYAIQFLEEAPKIAHLSLQVEKADSLKEDQTVKI
SVRAHYQDGTQAVLPADKVTFSTSGEGEVAIRKGMLELHKPGAVTLNAEYEGAKDQVELTIQANTEKKIAQSIRPVNVVTDLK
QEPSLPATVTVEYDKGFPKTHKVTWQAIPKEKLDSYQTFEVLGKVEGIDLEARAKVSVEGIVSVEEVSVTTPIAEAPQLPES\
RTYDSNGHVSSAKVAWDAIRPEQYAKEGVFTVNGRLEGTQLTTKLHVRVSAQTEQGANISDQWTGSELPLAFASDSNPSDPVS
NVNDKLISYNNQPANRWTNWNRTNPEASVGVLFGDSGILSKRSVDNLSVGFHEDHGVGVPKSYVIEYYVGKTVPTAPKNPSF\
GNEDHVFNDSANWKPVTNLKAPAQLKAGEMNHFSFDKVETYAVRIRMVKADNKRGTSITEVQIFAKQVAAAKQGQTRIQVDGI
DLANFNPDLTDYYLESVDGKVPAVTASVSNNGLATVVPSVREGEPVRVIAKAENGDILGEYRLHFTKDKSLLSHKPVAAVKQA
RLLQVGQALELPTKVPVYFTGKDGYETKDLTVEWEEVPAENLTKAGQFTVRGRVLGSNLVAEITVRVTDKLGETLSDNPNYDE
NSNQAFASATNDIDKNSHDRVDYLNDGDHSENRRWTNWSPTPSSNPEVSAGVIFRENGKIVERTVTQGKVQFFADSGTDAPSE
LVLERYVGPEFEVPTYYSNYQAYDADHPFNNPENWEAVPYRADKDIAAGDEINVTFKAIKAKAMRWRMERKADKSGVAMIEM1
FLAPSELPQESTQSKILVDGKELADFAENRQDYQITYKGQRPKVSVEENNQVASTVVDSGEDSFPVLVRLVSESGKQVKEYR1
HLTKEKPVSEKTVAAVQEDLPKIEFVEKDLAYKTVEKKDSTLYLGETRVEQEGKVGKERIFTAINPDGSKEEKLREVVVEVPTI
RIVLVGTKPVAQEAKKPQVSEKADTKPIDSSEASQTNKAQLPSTGSAASQAAVAAGLTLLGLSAGLVVTKGKKED

SeqID 179

MAPSVVDAATYHYVNKEIISQEAKDLIQTGKPDRNEVVYGLVYQKDQLPQTGTEASVLTAFGLLTVGSLLLIYKRKKIASVFI
VGAMGLVVLPSAGAVDPVATLALASREGVVEMEGYRYVGYLSGDILKTLGLDTVLEETSAKPGEVTVVEVETPQSITNQEQAI
TENQVVETEEAPKEEAPKTEESPKEEPKSEVKPTDDTLPKVEEGKEDSAEPAPVEEVGGEVESKPEEKVAVKPESQPSDKPAI
ESKVEQAGEPVAPREDEKAPVEPEKQPEAPEEEKAVEETPKQEESTPDTKAEETVEPKEETVNQSIEQPKVETPAVEKQTEP1
EEPKVEQAGEPVAPREDEQAPTAPVEPEKQPEVPEEEKAVEETPKPEDKIKGIGTKEPVDKSELNNQIDKASSVSPTDYSTAS
YNALGPVLETAKGVYASEPVKQPEVNSETNKLKTAIDALNVDKTELNNTIADAKTKVKEHYSDRSWQNLQTEVTKAEKVAAN1
DAKQSEVNEAVEKLTATIEKLVELSEKPILTLTSTDKKILEREAVAKYTLENQNKTKIKSITAELKKGEEVINTVVLTDDKV1
TETISAAFKNLEYYKEYTLSTTMIYDRGNGEETETLENQNIQLDLKKVELKNIKRTDLIKYENGKETNESLITTIPDDKSNY\
LKITSNNQKTTLLAVKNIEETTVNGTPVYKVTAIADNLVSRTADNKFEEEYVHYIEKPKVHEDNVYYNFKELVEAIQNDPSKI
YRLGQSMSARNVVPNGKSYITKEFTGKLLSSEGKQFAITELEHPLFNVITNATINNVNFENVEIERSGQDNIASLANTMKGSS
VITNVKITGTLSGRNNVAGFVNNMNDGTRIENVAFFGKLHSTSGNGSHTGGIAGTNYRGIVRKAYVDATITGNKTRASLLVPI
VDYGLTLDHLIGTKALLTESVVKGKIDVSNPVEVGAIASKTWPVGTVSNSVSYAKIIRGEELFGSNDVDDSDYASAHIKDLY1
VEGYSSGNRSFRKSKTFTKLTKEQADAKVTTFNITADKLESDLSPLAKLNEEKAYSSIQDYNAEYNQAYKNLEKLIPFYNKD\
IVYQGNKLNKEHHLNTKEVLSVTAMNNNEFITNLDEANKIIVHYADGTKDYFNLSSSSEGLSNVKEYTITDLGIKYTPNIVQI
DNTTLVNDIKSILESVELQSQTMYQHLNRLGDYRVNAIKDLYLEESFTDVKENLTNLITKLVQNEEHQLNDSPAARQMIRDKV
EKNKAALLLGLTYLNRYYGVKFGDVNIKELMLFKPDFYGEKVSVLDRLIEIGSKENNIKGSRTFDAFGQVLAKYTKSGNLDAI
LNYNRQLFTNIDNMNDWFIDATEDHVYIAERASEVEEIKNSKHRAFDNLKRSHLRNTILPLLNIDKAHLYLISNYNAIAFGSJ
ERLGKKSLEDIKDIVNKAADGYRNYYDFWYRLASDNVKQRLLRDAVIPIWEGYNAPGGWVEKYGRYNTDKVYTPLREFFGPMI
KYYNYNGTGAYAAIYPNSDDIRTDVKYVHLEMVGEYGISVYTHETTHVNDRAIYLGGFGHREGTDAEAYAQGMLQTPVTGSGI
DEFGSLGINMVFKRKNDGNQWYITDPKTLKTREDINRYMKGYNDTLTLLDEIEAESVISQQNKDLNSAWFKKIDREYRDNNKI
NQWDKIRNLSQEEKNELNIQSVNDLVDQQLMTNRNPGNGIYKPEAISYNDQSPYVGVRMMTGIYGGNTSKGAPGAVSFKHNAI
RLWGYYGYENGFLGYASNKYKQQSKTDGESVLSDEYIIKKISNNTFNTIEEFKKAYFKEVKDKATKGLTTFEVNGSSVSSYDI
LLTLFKEAVKKDAETLKQEANGNKTVSMNNTVKLKEAVYKKLLQQTNSFKTSIFK

SeqID 180

MNKRLFSKMSLVTLPILALFSQSVLAEENIHFSSCKEAWANGYSDIHEGEPGYSAKLDRDHDGVACELKNAPKGAFKAKQSTA
IQINTSSATTSGWVKQDGAWYYFDGNGNLVKNAWQGSYYLKADGKMAQSEWIYDSSYQAWYYLKSDGSYAKNAWQGAYYLKSN
GKMAQGEWVYDSSYQAWYYLKSDGSYARNAWQGNYYLKSDGKMAKGEWVYDATYQAWYYLTSDGSYAYSTWQGNYYLKSDGKM
AVNEWVDGGRYYVGADGVWKEVQASTASSSNDSNSEYSAALGKAKSYNSLFHMSKKRMYRQLTSDFDKFSNDAAQYAIDHLDD

SeqID 181
MKVIDQFKNKKVLVLGLAKSGESAARLLDKLGAIVTVNDGKPFEDNPAAQSLLEEGIKVITGGHPLELLDEEFALMVKNPGIP
YNNPMIEKALAKGIPVLTEVELAYLISEAPIIGITGSNGKTTTTTMIGEVLTAAGQHGLLSGNIGYPASQVAQIASDKDTLVM
ELSSFQLMGVQEFHPEIAVITNLMPTHIDYHGSFSEYVAAKWNIQNKMTAADFLVLNFNQDLAKDLTSKTEATVVPFSTLEKV
DGAYLEDGQLYFRGEVVMAANEIGVPGSHNVENALATIAVAKLRDVDNQTIKETLSAFGGVKHRLQFVDDIKGVKFYNDSKST
NILATQKALSGFDNSKVVLIAGGLDRGNEFDELVPDITGLKKMVILGQSAERVKRAADKAGVAYVEATDIADATRKAYELATQ
GDVVLLSPANASWDMYANFEVRGDLFIDTVAELKE

SeqID 182
MKKKFALSFVALASVALLAACGEVKSGAVNTAGNSVEEKTIKIGPNFEESGSLAAYGTAEQKGAQLAVDEINAAGGIDGKQIE
VVDKDNKSETAEAASVTTNLVTQSKVSAVVGPATSGATAAAVANATKAGVPLISPSATQDGLTKGQDYLFIGTFQDSFQGKII
SNYVVSEKLNAKKVVLYTDNASDYAKGIAKSFRESYKGEIVADETFVAGDTDFQAALTKMKGKDFDAIVVPGYYNEAGKIVNQP
RGMGIDKPIVGGDGFNGEEFVQQATAEKASNIYFISGFSTTVEVSAKAKAFLDAYRAKYNEEPSTFAALAYDSVHLVANAAKG
AKNSGEIKNNLAKTKDFEGVTGQTSFDADHNTVKTAYMMTMNNGKVEAAEVVKP

SeqID 183
MSILEVKNLSHGFGDRAIFEDVSFRLLKGEHIGLVGANGEGKSTFMSIVTGKMLPDEGKVEWSKYVTAGYLDQHSVLAERQSV
RDVLRTAFDELFKAEARINDLYMKMAEDGADVDALMEEVGELQDRLESRDFYTLDAKIDEVARALGVMDFGMDTDVTSLSGGQ
RTKVLLAKLLLEKPDILLLDEPTNYLDAEHIDWLKRYLQNYENAFVLISHDIPFLNDVINIVYHVENQQLTRYSGDYYQFQEV
YAMKKSQLEAAYERQQKEIADLKDFVARNKARVATRNMAMSRQKKLDKMDIIELQSEKPKPSFDFKPARTPGRFIFQAKNLQI
GYDRPLTKPLNLTFERNQKVAIIGANGIGKTTLLKSLLGIISPIAGEVERGDYLELGYFEQEVEGGNRQTPLEAVWNAFPALM
QAEVRAALARCGLTTKHIESQIQVLSGGEQAKVRFCLLMNRENNVLVLDEPTNHLDVDAKDELKRALKEYRGSILMVCHEPDF
YEGWIDQIWDFNNLT

SeqID 184
MKKKNGKAKKWQLYAAIGAASVVVLGAGGILLFRQPSQTALKDEPTHLVVAKEGSVASSVLLSGTVTAKNEQYVYFDASKGDI
DEILVSVGDKVSEGQALVKYSSSEAQAAYDSASRAVARADRHINELNQARNEAASAPAPQLPAPVGGEDATVQSPTPVAGNSV
ASIDAQLGDARDARADAAAQLSKAQSQLDATTVLSTLEGTVVEVNSNVSKSPTGASQVMVHIVSNENLQVKGELSEYNLANLS
VGQEVSFTSKVYPDKKWTGKLSYISDYPKNNGEAASPAAGNNTGSKYPYTIDVTGEVGDLKQGFSVNIEVKSKTKAILVPVSS
LVMDDSKNYVWIVDEQQKAKKVEVSLGNADAENQEITSGLTNGAKVISNPTSSLEEGKEVKADEATN

SeqID 185
SETNHEIDSNFAGRLNILRAGVLDANDGIISIAGVVIGVASATTNIWIIFLSGFTAILAGAFSMAGGEYVSVSTPKDTEEAAV
SREKLLLDQDRELAKKSLYAAYIQNGEFKTSAQLLTNKIFLKNPLKALVEEKYGIEYEEFTNPWHAAISSFVAFFLRSLPPMI
SVTIFPSDYRIPATVLIVGVALLLTGYTSARLGKAPTKTAMIRNLAIGLLTMGVTFLLGQLFSI

SeqID 186
MKKKLTSLALVGAFLGLSWYGNVQAQESSGNKIHFINVQEGGSDAIILESNGHFAMVDTGEDYDFPDGSDSRYPWREGIETSY
KHVLTDRVFRRLKELGVQKLDFILVTHTHSDHIGNVDELLSTYPVDRVYLKKYSDSRITNSERLWDNLYGYDKVLQTAAEKGV
SVIQNITQGDAHFQFGDMDIQLYNYENETDSSGELKKIWDDNSNSLISVVKVNGKKIYLGGDLDNVHGAEDKYGPLIGKVDLN
KFNHHHDTNKSNTKDFIKNLSPSLIVQTSDSLPWKNGVDSEYVNWLKERGIERINAASKDYDATVFDIRKDGFVNISTSYKPI
PSFQAGWHKSAYGNWWYQAPDSTGEYAVGWNEIEGEWYYFNQTGILLQNQWKKWNNHWFYLTDSGASAKNWKKIAGIWYYFNF
ENQMEIGWIQDKEQWYYLDVDGSMKTGWLQYMGQWYYFAPSGEMKMGWVKDKETWYYMDSTGVMKTGEIEVAGQHYYLEDSGA
MKQGWHKKANDWYFYKTDGSRAVGWIKDKDKWYFLKENGQLLVNGKTPEGYTVDSSGAWLVDVSIEKSATIKTTSHSEIKESF
EVVKKDLENKETSQHESVTNFSTSQDLTSSTSQSSETSVNKSESEQ

SeqID 187
MDLGPTQRGISVVSQSYINVIGAGLAGSEAAYQIAERGIPVKLYEMRGVKSTPQHKTDNFAELVCSNSLRGDALTNAVGLLKF
EMRRLGSVILESAEATRVPAGGALAVDRDGFSQMVTEKVANHPLIEVVRDEITELPTDVITVIATGPLTSDALAEKIHALNDG
AGFYFYDAAAPIIDVNTIDMSKVYLKSRYDKGEAAYLNAPMTKQEFMDFHEALVNAEEAPLSSFEKEKYFEGCMPIEVMAKRG
IKTMLYGPMKPVGLEYPDDYTGPRDGEFKTPYAVVQLRQDNAAGSLYNIVGFQTHLKWGEQKRVFQMIPGLENAEFVRYGVMF
RNSYMDSPNLLEQTYRSKKQPNLFFAGQMTGVEGYVESAASGLVAGINAARLFKEESEAIFPETTAIGSLAHYITHADSKHFQ
PMNVNFGIIKELEGERIRDKKARYEKIAERALADLEEFLTV

SeqID 188
MLIGIPKEIKNNENRVALTPAGVHSLVSRGHRVLIETNAGLGSGFTDADYQKQGAEIVATAGEAWAAELVVKVKESLSSEYGY
LRDDLLLLFTYLHMAAAPELADAMLTAKTTETVRDNQGQLPLLVPMSEVAGRMAVQIGAHFLTKQAGGSGVLLGGVPGVPKGKV
TIIGGGVVGTHAARIALGLGAQVTILDISSKRLSVLEEVFGSQIQTLMSNSFNIEASVRDADVVIGAILIPGAKAPELVTDEM
VKQMRPGSVSLTLLLTKVALSKQLTVQRTMNPSMKNTVFSTMPLPISLVRLLALQPSPPMSLFLISKLWLAKDSHKQSLKMKP
CVKVLLIKVTLTYQLLKDLIVTTLISMI

SeqID 189

MKINKKYLAGSVAVLALSVCSYELGRHQAGQVKKESNRVSYIDGDQAGQKAENLTPDEVSKREGINAEQIVIKITDQGYVTSH
GDHYHYYNGKVPYDAIISEELLMKDPNYQLKDSDIVNEIKGGYVIKVDGKYYVYLKDAAHADNIRTKEEIKRQKQEHSHNHGG
GSNDQAVVAARAQGRYTTDDGYIFNASDIIEDTGDAYIVPHGDHYHYIPKNELSASELAAAEAYWNGKQGSRPSSSSSYNANP
AQPRLSENHNLTVTPTYHQNQGENISSLLRELYAKPLSERHVESDGLIFDPAQITSRTARGVAVPHGNHYHFIPYEQMSELEK
RIARIIPLRYRSNHWVPDSRPEQPSPQSTPEPSPSPQPAPNPQPAPSNPIDEKLVKEAVRKVGDGYVFEENGVSRYIPAKDLS
AETAAGIDSKLAKQESLSHKLGAKKTDLPSSDREFYNKAYDLLARIHQDLLDNKGRQVDFEALDNLLERLKDVPSDKVKLVDD
ILAFLAPIRHPERLGKPNAQITYTDDEIQVAKLAGKYTTEDGYIFDPRDITSDEGDAYVTPHMTHSHWIKKDSLSEAERAAAC
AYAKEKGLTPPSTDHQDSGNTEAKGAEAIYNRVKAAKKVPLDRMPYNLQYTVEVKNGSLIIPHYDHYHNIKPEWFDEGLYEAP
KGYTLEDLLATVKYYVEHPNERPHSDNGFGNASDHVRKNKVDQDSKPDEDKEHDEVSEPTHPESDEKENHAGLNPSADNLYKP
STDTEETEEEAEDTTDEAEIPQVENSVINAKIADAEALLEKVTDPSIRQNAMETLTGLKSSLLLGTKDNNTISAEVDSLLALL
KESQPAPIQ

SeqID 190
MKFSKKYIAAGSAVIVSLSLCAYALNQHRSQENKDNNRVSYVDGSQSSQKSENLTPDQVSQKEGIQAEQIVIKITDQGYVTSH
GDHYHYYNGKVPYDALFSEELLMKDPNYQLKDADIVNEVKGGYIIKVDGKYYVYLKDAAHADNVRTKDEINRQKQEHVKDNEK
VNSNVAVARSQGRYTTNDGYVFNPHGGHYHYIPKSDLSASELAAAKAHLAGKNMQPSQLSYSSTASDNN
TQSVAKGSTSKPANKSENLQSLLKELYDSPSAQRYSESDGLVFDPAKIISRTPNGVAIPHGDHYHFIPYSKLSALEEKIARMV
PISGTGSTVSTNAKPNEVVSSLGSLSSNPSSLTTSKELSSASDGYIFNPKDIVEETATAYIVRHGDHFHYIPKSNQIGQPTLF
NNSLATPSPSLPINPGTSHEKHEEDGYGFDANRIIAEDESGFVMSHGDHNHYFFKKDLTEEQIKAAQKHLEEVKTSHNGLDSI
SSHEQDYPSNAKEMDLDKKIEEKIAGIMKQYGVKRESIVVNKEKNAIIYPHGDHHHADPIDEHKPVGIGHSHSNYELFKPEE
GVAKKEGNKVYTGEELTNVVNLLKNSTFNNQNFTLANGQKRVSFSFPPELEKKLGINMLVKLITPDGKVLEKVSGKVFGEGVG
NIANFELDQPYLPGQTFKYTIASKDYPEVSYDGTFTVPTSLAYKMASQTIFYPFHAGDTYLRVNPQFAVPKGTDALVRVFDEE
HGNAYLENNYKVGEIKLPIPKLNQGTTRTAGNKIPVTFMANAYLDNQSTYIVEVPILEKENQTDKPSILPQFKRNKAQENLKI
DEKVEEPKTSEKVEKEKLSETGNSTSNSTLEEVPTVDPVQEKVAKFAESYGMKLENVLFNMDGTIELYLPSGEVIKKNMADFT
GEAPQGNGENKPSENGKVSTGTVENQPTENKPADSLPEAPNEKPVKPENSTDNGMLNPEGNVGSDPMLDPALEEAPAVDPVQE
KLEKFTASYGLGLDSVIFNMDGTIELRLPSGEVIKKNLSDLIA

SeqID 191
MKILFVAAEGAPFSKTGGLGDVIGALPKSLVKAGHEVAVILPYYDMVEAKFGNQIEDVLHFEVSVGWRRQYCGIKKTVLNGVI
FYFIDNQYYFFRGHVYGDFDDGERFAFFQLAAIEAMERIDFIPDLLHVHDYHTAMIPFLLKEKYRWIQAYEDIETVLTIHNLE
FQGQFSEGMLGDLFGVGFERYADGTLRWNNCLNWMKAGILYANRVSTVSPSYAHEIMTSQFGCNLDQILKMESGKVSGIVNGI
DADLYNPQTDALLDYHFNQEDLSGKAKNKAKLQERVGLPVRADVPLVGIVSRLTRQKGFDVVVESLHHILQEDVQIVLLGTGE
PAFEGAFSWFAQIYPDKLSTNITFDVKLAQEIYAACDLFLMPSRFEPCGLSQMMAMRYGTLPLVHEVGGLRDTVRAFNPIEGS
GTGFSFDNLSPYWLNWTFQTALDLYRNHPDIWRNLQKQAMESDFSWDTACKSYLDLYHSLVN

SeqID 192
MEKYFGEKQERFSFRKLSVGLVSATISSLFFMSVLASSSVDAQETAGVHYKYVADSELSSEEKKQLVYDIPTYVENDDETYYI
VYKLNSQNQLAELPNTGSKNERQALVAGASLAAMGILIFAVSKKKVKNKTVLHLVLVAGIGNGVLVSVHALENHLLLNYNTDY
ELTSGEKLPLPKEISGYTYIGYIKEGKTTSESEVSNQKSSVATPTKQQKVDYNVTPNFVDHPSTVQAIQEQTPVSSTKPTEVG
VVEKPFSTELINPRKEEKQSSDSQEQLAEHKNLETKKEEKISPKEKTGVNTLNPQDEVLSGQLNKPELLYREETMETKIDFQE
EIQENPDLAEGTVRVKQEGKLGKKVEIVRIFSVNKEEVSREIVSTSTTAPSPRIVEKGTKKTQVIKEQPETGVEHKDVQSGAI
VEPAIQPELPEAVVSDKGEPEVQPTLPEAVVTDKGETEVQPESPDTVVSDKGEPEQVAPLPEYKGNIEQVKPETPVEKTKEQG
PEKTEEVPVKPTEETPVNPNEGTTEGTSIQEAENPVQPAEESTTNSEKVSPDTSSKNTGEVSSNPSDSTTSVGESNKPEHNDS
KNENSEKTVEEVPVNPNEGTVEGTSNQETEKPVQPAEETQTNSGKIANENTGEVSNKPSDSKPPVEESNQPEKNGTATKPENS
GNTTSENGQTEPEPSNGNSTEDVSTESNTSNSNGNEEIKQENELDPDKKVEEPEKTLELRNVSDLELYSLSNGTYKQHISLEG
VPSNPNSYFVKVKSSSFKDVYLPVASISEERKNDKILYKITAKVEKLQQEIESRYKDNFTFYLAKKGTEETTNFTSFSNLVKA
INQNPSGTYHLAASLNANEVELGPDERSYIKDTFTGRLIGEKDGKNYAIYNLKKPLFENLSGATVEKLSLKNVAISGKDDIGS
LANEAQNNTKIKQVHVDGVLAGERGIGGLLAKAEQSSITESSFKGRIINTYETTAAYNIGGMVGHLTGDKALLTKSKATVAIS
SNTNTSDQTVGGLAGLVDRDAQIQDSYAEGDINNVKHFGRVAGVAGNLWDRTSGDVRHAGSLTNVLSDVNVTNGNAITGYHYN
EMKVKDTFSSKANRVYNVTLVKDEVVSKESFEERGTMLDASQIASKKAEINPLILPTVEPLSTSGKKDSDFSKVAYYQAKRNI
TYKNIEKLLPFYNKATIVKYGNLVNENSLLYQKELLSAVMMKDNQVITDIVSNKQTANKLLLHYKDDLSEKLDLKYQNDFAKI
AEYSLGNTGLLYTPNQFLYDQTSIIKQVLPDLQKVDYHSEAIRKTLGISPNVKQTELYLEDQFAKTKQQLEDSLKKLLSADAG
LASANPVTEGYLVDKIKRNKEALLLGLTYLERWYNFSYGQVNVKDLVLYHLDFFGKGNASPLDTLIELGKSGFNNLLAKNNVI
TYGISLASQHGTTDLFSTLEHYRKVFLPNTSNNDWFKSETKAYIVEEKSTIEEVKTKQGLAGTKYSIGVYDRITSATWKYRNM
VLPLLTLPERSVFVISTMSSLGFGAYDRYRSSDHKAGKALNDFVEENARETAKRQRDHYDYWYRILDDNAREKLYRNILLYDA
YKFGDDNTVGKATEVADFDNPNPAMQHFFGPVGNKVGHNQHGAYATGDAVYYMGYRMLDKDGAITYTHEMTHDSDQDIYLGGY
GRRSGLGPEFFAKGLLQAPDHPDDATITINSILKHSKSDSTESRRLQVLDPTTRFNNADDLKQYVHNMFDVVYMLEYLEGNSI
LKLDTNQKQQLLRKVTNEYHPDPDGNKVYATNVVRNLTVEEVERLRSFNDLIDNNILSSREYASGKYERNGYFTIKLFAPIYA
ALSNDIGTPGDLMGRRIAYELLAAKGFKDGMVPYISNQYEEEAKQKGKTINLYGKTRGLVTDDLVLEKVFNNQYHTWSEFKKA
MYQERQDQFDRLNKVTFNDTTQPWQTFAKKTTSSVDELQKLMDVAVRKDAEHNYYHWNNYNPDIDSEVHKLKRAIFKAYLDQI
NDFRSSIFENKK

SeqID 193
MKINKKYLAGSVAVLALSVCSYELGRYQAGQDKKESNRVAYIDGDQAGQKAENLTPDEVSKREGINAEQIVIKITDQGYVTSH
GDHYHYYNGKVPYDAIISEELLMKDPNYQLKDSDIVNEIKGGYVIKVNGKYYVYLKDAAHADNIRTKEEIKRQKQERSHNHNS
RADNAVAAARAQGRYTTDDGYIFNASDIIEDTGDAYIVPHGDHYHYIPKNELSASELAAAEAYWNGKQGSRPSSSSSYNANPA
QPRLSENHNLTVTPTYHQNQGENISSLLRELYAKPLSERHVESDGLIFDPAQITSRTARGVAVPHGNHYHFIPYEQMSELEKR
IARIIPLRYRSNHWVPDSRPEEPSPQPTPEPSPSPQPAPSNPIDEKLVKEAVRKVGDGYVFEENGVSRYIPAKDLSAETAAGI

DSKLAKQESLSHKLGTKKTDLPSSDREFYNKAYDLLARIHQDLLDNKGRQVDFEALDNLLERLKDVSSDKVKLVEDILAFLAF
IRHPERLGKPNAQITYTDDEIQVAKLAGKYTTEDGYIFDPRDITSDEGDAYVTPHMTHSHWIKKDSLSEAERAAAQAYAKEKG
LTPPSTDHQDSGNTEAKGAEAIYNRVKAAKKVPLDRMPYNLQYTVEVKNGSLIIPHYDHYHNIKFEWFDEGLYEAPKGYTLED
LLATVKYYVEHPNERPHSDNGFGNASDHVQRNKNGQADTNQTEKPSEEKPQTEKPEEETPREEKPQSEKPESPKPTEEPEESF
EESEEPQVETEKVEEKLREAEDLLGKIQDPIIKSNAKETLTGLKNNLLFGTQDNNTIMAEAEKLLALLKESK

SeqID 194
LILSVCSYELGLYQARTVKENNRVSYIDGKQATQKTENLTPDEVSKREGINAEIVIKITDQGYVTSHGDHYHYYNGKVPYDA
IISEELLMKDPNYKLKDEDIVNEVKGGYVIKVDGKYYVYLKDAAHADNVRTKEEINRQKQEHSQHREGGTPRNDGAVALARSC
GRYTTDDGYIFNASDIIEDTGDAYIVPHGDHYHYIPKNELSASELAAAEAFLSGRGNLSNSRTYRRQNSDNTSRTNWVPSVSM
PGTTNTNTSNNSNTNSQASQSNDIDSLLKQLYKLPLSQRHVESDGLVFDPAQITSRTARGVAVPHGDHYHFIPYSQMSELEER
IARIIPLRYRSNHWVPDSRPEQPSPQPTPEPSPGPQPAPNLKIDSNSSLVSQLVRKVGEGYVFEEKGISRYVFAKDLPSETVK
NLESKLSKQESVSHTLTAKKENVAPRDQEFYDKAYNLLTEAHKALFENKGRNSDFQALDKLLERLNDESTNKEKLVDDLLAFL
APITHPERLGKPNSQIEYTEDEVRIAQLADKYTTSDGYIFDEHDIISDEGDAYVTPHMGHSHWIGKDSLSDKEKVAAQAYTKE
KGILPPSPDADVKANPTGDSAAAIYNRVKGEKRIPLVRLPYMVEHTVEVKNGNLIIPHKDHYHNIKFAWFDDHTYKAPNGYTL
EDLFATIKYYVEHPDERPHSNDGWGNASEHVLGKKDHSEDPNKNFKADEEPVEETPAEPEVPQVETEKVEAQLKEAEVLLAKV
TDSSLKANATETLAGLRNNLTLQIMDNNSIMAEAEKLLALLKGSNPSSVSKEKIN

SeqID 195
MPVEIKTTKEIHPKIYAYTTPTVTSNEGWIKIGYTERDVTQRIKEQTHTAHIATDVLWTGDAAYTEEPDKGKTFKDHDFHHFL
SFHDVERRPKTEWFYFNGTPEKSKNLFDKFVQHDLSGYQPGKGQDYTLRQEQEEAVAKTLAYFQEHAGGKFLWNAKPRFGKTL
STYDLARRMEAVNVLIVTNRPAIANSWYDDFETFIAGQTTYKFVSESDSLKSRPILSRQEFLGILADDVRQLAFISLQDLKGS
VYLGGEHDKLKWVTDLHWDLLVIDEAHEGVDTPKTDQAFNKIRRNFTLHLSGTSFKALAKGDFTEEQIYNWSYADEQAAKYSW
SLEQEEENPYESLPQLNLFTYQMSQMIGEKLEKGAQIDGENIDYVFDLSEFFATDDKGKFIHEHDVRNWLDTLSSNEKYPFST
KELRNELKHTFWLLERVASAKALKALLEEHPIYENYEIVLAAGDGRMSEEDDKVKLKSLDLVRKAIAENDKTITLSVGQLTTG
VTIPEWTGVLMLSNLKSPALYMQAAFRAQNPYSWSDNKGNHFRKERAYVFDFAPERTLILFDEFANNLLLVTAAGRGTSATRE
ENIRELLNFFPIIAEDRAGKMVEIDAKAVLTTPRQIKAREVLKRGFMSNLLFDNISGIFQASQTVLDILNELPVEKEGKVQDS
SDLLDFSDVTVDDEGNAVVDHEIVVNQQMRLFGEKVYGLGESVAELVTKDEERTQKQLVNDLSKTVSSVIVEELKADYSLKTR
ETEQIKKQITATLENEIRKNDIERKISEAHIKQELQQQLKEANDKAQKDKIQEDLEKRLEENKLIHKEKLEQTLKKEVEKMPE
KFIEQVEIKRVEQLKQSAQDEIRDHLRGFARTIPSFIMAYGDQTLTLDNFDAFVPEHVFYEVTGITIDQFRYLRDGGQDFAGH
LFDKATFDEAIQEFLRKKKELADYFKDQKEDIFDYIPPQKTNQIFTPKRVVKRMVDDLEKENPGIFDDPSKTFIDLYMKSGLY
IAELVKRLYNSNGLKEAFPNPEERLKHILEKQVYGFAPSEIIYNISTNFIFGNLSKDISRKNFVLADTIPAAKEGSIQKLVDS
YFENN

SeqID 196
MKKILIVDDEKPISDIIKFNMTKEGYEVVTAFNGREALEQFEAEQPDIIILDLMLPEIDGLEVAKTIRKTSSVPILMLSAKDS
EFDKVIGLELGADDYVTKPFSNRELQARVKALLRRSQPMPVDGQEADSKPQPIQIGDLEIVPDAYVAKKYGEELDLTHREFEL
LYHLASHTGQVITREHLLETVWGYDYFGDVRTVDVTVRRLREKIEDTPSRPEYILTRRGVGYYMRNNA

SeqID 197
MKKKFLAFLLILFPIFSLGIAKAETIKIVSDTAYAPFEFKDSDQTYKGIDVDIINKVAEIKGWNIQMSYPGFDAAVNAVQAGQ
ADAIMAGMTKTKEREKVFTMSDTYYDTKVVIATTKSHKISKYDQLTGKTVGVKNGTAAQRFLETIKDKYGFTIKTFDTGDLMN
NSLSAGAIDAMMDDKPVIEYAINQGQDLHIEMDGEAVGSFAFGVKKGSKYEHLVTEFNQALSEMKKDGSLDKIIKKWTASSSS
AVPTTTTLAGLKAIPVKAKYIIASDSSFAPFVFQNSSNQYTGIDMELIKAIAKDQGFEIEITNPGFDAAISAVQAGQADGIIA
GMSVTDARKATFDFSESYYTANTILGVKESSNIASYEDLKGKTVGVKNGTASQTFLTENQSKYGYKIKTFADGSSMYDSLNTG
AIDAVMDDEPVLKYSISQGQKLKTPISGTPIGETAFAVKKGANPELIEMFNNGLANLKANGEFQKILDKYLASESSTASTSTV
DETTLWGLLQNNYKQLLSGLGITLALALISFAIAIVIGIIFGMFSVSPYKSLRVISEIFVDVIRGIPLMILAAFIFWGIPNFI
ESITGQQSPINDFVAGTIALSLNAAAYIAEIVRGGIQAVPVGQMEASRSLGISYGKTMRKIILPQATKLMLPNFVNQFVIALK
DTTIVSAIGLVELFQTGKIIIARNYQSFKMYAILAIFYLVIITTLLTRLAKRLEKRIR

SeqID 198
MAFESLTERLQNVFKNLRKKGKISESDVQEATKEIRLALLEADVALPVVKDFIKKVRERAVGHEVIDTLNPAQQIIKIVDEEL
TAVLGSDTAEIIKSPKIPTIIMMVGLQGAGKTTFAGKLANKLKKEENARPLMIAADIYRPAAIDQLKTLGQQIDVPVFALGTE
VPAVEIVRQGLEQAQTNHNDYVLIDTAGRLQIDELLMNELRDVKALAQPNEILLVVDAMIGQEAANVAREFNAQLEVTGVILT
KIDGDTRGGAALSVRHITGKPIKFTGTGEKITDIETFHPDRMSSRILGMGDMLTLIEKASQEYDEQKALEMAEKMRENTFDFN
DFIDQLDQVQNMGPMEDLLKMIPGMANNPALQNMKVDERQIARKRAIVSSMTPEERENPDLLNPSRRRIAAGSGNTFVEVNK
FIKDFNQAKQLMQGVMSGDMNKMMKQMGINPNNLPKNMPNMGGMDMSALEGMMGQGGMPDLSALGGAGMPDMSQMFGGGLKGK
IGEFAMKQSMKRMANKMKKAKKKRK

SeqID 199
MSQIWTKEKFISQVQGGVIVSCQALPGEALYNEEFSLMPFMAKAALEAGAVGIRANSVRDIKAIQKVVDLPIIGIIKRDYPPQ
EPYITATMKEVDELVECGTTVIAFDATLRPRYDGLVVSEFIKKIKEKYPNQLLMADVSNLDEGLYAFKSGVDFVGTTLSGYTS
TSVQSDEPDFELMKKLADFNIPVIAEGKIHYPEQLKKAYSLGVTSVVIGGAITRPKEIAQRFINVIK

SeqID 200
MRYLTAGESHGPRLTAIIEGIPAGLPLTAEDINEDLRRRQGGYGRGGRMKIENDQVVFTSGVRHGKTTGAPITMDVINKDHQK
WLDIMSAEDIEDRLKSKRKITHPRPGHADLVGGIKYRFDDLRNSLERSSARETTMRVAVGAVAKRLLAELDMEIANHVVVFGG
KEIDVPENLTVAEIKQRAAQSEVSIVNQEREQEIKDYIDQIKRDGDTIGGVVETVVGGVPVGLGSYVQWDRKLDARLAQAVVS

INAFKGVEFGLGFEAGYRKGSQVMDEILWSKEDGYTRRTNNLGGFEGGMTNGQPIVVRGVMKPIPTLYKPLMSVDIETHEPYK
ATVERSDPTALPAAGMVMEAVVATVLAQEILEKFSSDNLEELKEAVAKHRDYTKNY

SeqID 201
MVVMNRIRVSKRVEKKLAKGLVLLEASDLENVNLKDQEVEVQGQEGNFLGTAYLSQQNKGLGWFISKDKVAFNQAFFETLFRK
AKEKRNAYYQDDLTTAFRLFNQEGDGFGGLTVDLYGDYAVFSWYNSYVYQIRQTISEAFRQVFPEVLGAYEKIRFKGLDYESA
HVYGQEAPDFFNVLENGVLYQVFMNDGLMTGIFLDQHEVRGSLVDGLAMGKSLLNMFSYTAAFSVAAAMGGASHTTSVDLAKR
SRELSQAHFQANGLSTDEHRFIVMDVFEYFKYAKRKDLTYDVIVLDPPSFARNKKQTFSVAKDYHKLISQSLEILNPGGIIIA
STNAANVSRQKFTEQIDKGFAGRSYQILNKYGLPADFAYNKKDESSNYLKVISMKVSK

SeqID 202
MTKTLKRPEVLSPAGTLEKLKVAVQYGADAVFIGGQAYGLRSRAGNFTFEQMEEGVQFAAKYGAKVYVAANMVMHEGNEAGAG
EWFRKLRDIGIAAVIVSDPALIMIAVTEAPGLEIHLSTQASATNYETLEFWKELGLTRVVLAREVSMEELAEIRKRTDVEIEA
FVHGAMCISYSGRCTLSNHMSMRDANRGGCSQSCRWKYDLYDMPFGKERKSLQGEIPEEFSMSAVDMSMIDHIPDMIENGVDS
LKIEGRMKSIHYVSTVTNCYKAAVDAYLESPEKFEAIKQDLVDEMWKVAQRELATGFYYGTPSENEQLFGARRKIPEYKFVAE
VVSYDDAAQTATIRQRNVINEGDQVEFYGPGFRHFETYIEDLHDAKGNKIDRAPNPMELLTIKVPQPVQSGDMVRALKEGLIN
LYKEDGTSVTVRA

SeqID 203
MNTYQLNNGVEIPVLGFGTFKAKDGEEAYRAVLEALKAGYRHIDTAAIYQNEESVGQAIKDSGVPREEMFVTTKLWNSQQTYE
QTRQALEKSIEKLGLDYLDLYLIHWPNPKPLRENDAWKTRNAEVWRAMEDLYQEGKIRAIGVSNFLPHHLDALLETATIVPAV
NQVRLAPGVYQDQVVAYCREKGILLEAWGPFGQGELFDSKQVQEIAANHGKSVAQIALAWSLAEGFLPLPKSVTTSRIQANLD
CFGIELSHEERETLKTIAVQSGAPRVDDVDF

SeqID 204
LSEKSREEEKLSFKEQILRDLEKVKGYDEVLKEDEAVVRTPANEPSTEELMADSLSTVEEIMRKAPTVPTHPSQGVPASPADE
IQRETPGVPSHPSQDVPSSPAEESGSRPGPGPVRPKKLEREYNETPTRVAVSYTTAEKKAEQAGPETPTPATETVDIIRDTSR
RSRREGAKPVKPKKEKKSHVKAFVISFLVFLALLSAGGYFGYQYVLDSLLPIDANSKKYVTVGIPEGSNVQEIGTTLEKAGLV
KHGLIFSFYAKYKNYTDLKAGYYNLQKSMSTEDLLKELQKGGTDEPQEPVLATLTIPEGYTLDQIAQAVGQLQGDFKESLTAE
AFLAKVQDETFISQAVAKYPTLLESLPVKDSGARYRLEGYLFPATYSIKESTTIESLIDEMLAAMDKNLSPYYSTIKSKNLTV
NELLTIASLVEKEGAKTEDRKLIAGVFYNRLNRDMPLQSNIAILYAQGKLGQNISLAEDVAIDTNIDSPYNVYKNVGLMPGPV
DSPSLDAIESSINQTKSDNLYFVADVTEGKVYYANNQEDHDRNVAEHVNSKLN

SeqID 205
MKQERFPLVSDDEVMLTEMPVMNLYDESDLISNIKGEYRDKNYLEWAPIAEEKPVKPIEKQVEKPKKAPLGVKKEGKSYAEVA
REEARADLKKKRSANYLTQDFSLARRHSQPSLVRQGNQPTAPFQKENPGEFVKYSQKLTQSHYILAEEVHSIPTKNEEVSAPA
PKKNNYDFLKKSQIYNKKSKQTEQERRVAQELNLTRMTE

SeqID 206
MKKSKSKYLTLAGLVLGTGVLLSACGNSSTASKTYNYVYSSDPSSLNYLAENRAATSDIVANLVDGLLENDQYGNIIPSLAED
WTVSQDGLTYTYKLRKDAKWFTSEGEEYAPVTAQDFVTGLQYAADKKSEALYLVQDSVAGLDDYITGKTSDFSTVGVKALDDQ
TVQYTLVKPELYWNSKTLATILFPVNADFLKSKGDDFGKADPSSILYNGPFLMKALVSKSAIEYKKNPNYWDAKNVFVDDVKL
TYYDGSDQESLERNFTAGAYTTARLFPNSSSYEGIKEKYKNNIIYSMQNSTSYFFNFNLDRKSYNYTSKTSDIEKKSTQEAVL
NKNFRQAINFAFDRTSYGAQSEGKEGATKILRNLVVPPNFVSIKGKDFGEVVASKMVNYGKEWQGINFADGQDPYYNPEKAKA
KFAEAKKELEAKGVQFPIHLDKTVEVTDKVGIQGVSSIKQSIESVLGSDNVVIDIQQLTSDEFDSSGYFAQTAAQKDYDLYHG
GWGPDYQDPSTYLDIFNTNSGGFLQNLGLEPGEANDKAKAVGLDVYTQMLEEANKEQDPAKRYEKYADIQAWLIDSSLVLPSV
SRGGTPSLRRTVPFAAAYGLTGTKGVESYKYLKVQDKIVTTDEYAKAREKWLKEKEESNKKAQEELAKHVK

SeqID 207
VEQHSDVCYIFYRRERLKTKIGLASICLLGLATSHVAANETEVAKTSQDTTTASSSSEQNQSSNKTQTSAEVQTNAAAHWDGD
YYVKDDGSKAQSEWIFDNYYKAWFYINSDGRYSQNEWHGNYYLKSGGYMAQNEWIYDSNYKSWFYLKSDGAYAHQEWQLIGNK
WYYFKKWGYMAKSQWQGSYFLNGQGAMMQNEWLYDPAYSAYFYLKSDGTYANQEWQKVGGKWYYFKKWGYMARNEWQGNYYLT
GSGAMATDEVIMDGTRYIFAASGELKEKKDLNVGWVHRDGKRYFFNNREEQVGTEHAKKVIDISEHNGRINDWKKVIDENEVD
GVIVRLGYSGKEDKELAHNIKELNRLGIPYGVYLYTYAENETDAESDAKQTIELIKKYNMNLSYPIYYDVENWEYVNKSKRAP
SDTGTWVKIINKYMDTMKQAGYQNVYVYSYRSLLQTRLKHPDILKHVNWVAAYTNALEWENPHYSGKKGWQYTSSEYMKGIQG
RVDVSVWY

SeqID 208
MAKEPWQEDIYDQEESRAERRHRNHGGADRMANRILTILASIFFVIVVVMVIVLIYLSSGGSNRTAALKGFHDSDASVVQISS
SSSSQPEQSSEPESTSSSSEEAANPEGTIKVLAGEGEAAIAARAGISIAQLEALNPGHMATGSWFANPGDVIKIK

SeqID 209
MPITSLEIKDKTFGTRFRGFDPEEVDEFLDIVVRDYEDLVRANHDKNLRIKSLEERLSYFDEIKDSLSQSVLIAQDTAERVKQ
AAHERSNNIIHQAEQDAQRLLEEAKYKANEILRQATDNAKKVAVETEELKNKSRVFHQRLKSTIESQLAIVESSDWEDILRPT
ATYLQTSDEAFKEVVSEVLGEPIPAPIEEEPIDMTRQFSQAEMAELQARIEVADKELSEFEAQIKQEVEAPTPVVSPQVEEEP
LLIQLAQCMKNQK

SeqID 210

MSLKDRFDRFIDYFTEDEDSSLPYEKRDEPVFTSVNSSQEPALPMNQPSQSAGTKENNITRLHARQQELANQSQRATDKVIID
VRYPRKYEDATEIVDLLAGNESILIDFQYMTEVQARRCLDYLDGACHVLAGNLKKVASTMYLLTPVNVIVNVEDIRLPDEDQQ
GEFGFDMKRNRVR

SeqID 211
MSDLKKYEGVIPAFYACYDDQGEVSPERTRALVQYFIDKGVQGLYVNGSSGECIYQSVEDRKLILEEVMAVAKGKLTIIAHVA
CNNTKDSMELARHAESLGVDAIATIPPIYFRLPEYSVAKYWNDISSAAPNTDYVIYNIPQLAGVALTPSLYTEMLKNPRVIGV
KNSSMPVQDIQTFVSLGGEDHIVFNGPDEQFLGGRLMGARAGIGGTYGAMPELFLKLNQLIADKDLETARELQYAINAIIGKL
TSAHGNMYGVIKEVLKINEGLNIGSVRSPLTPVTEEDRPVVEAAAALIRETKERFL

SeqID 212
MNKRGLYSKLGISVVGISLLMGVPTLIHANELNYGQLSISPIFQGGSYQLNNKSIDISSLLLDKLSGESQTVVMKFKADKPNS
LQALFGLSNSKAGFKNNYFSIFMRDSGEIGVEIRDAQKGINYLFSRPASLWGKHKGQAVENTLVFVSDSKDKTYTMYVNGIEV
FSETVDTFLPISNINGIDKATLGAVNREGKEHYLAKGSIDEISLFNKAISDQEVSTIPLSNPFQLIFQSGDSTQANYFRIPTL
YTLSSGRVLSSIDARYGGTHDSKSKINIATSYSDDNGKTWSEPIFAMKFNDYEEQLVYWPRDNKLKNSQISGSASFIDSSIVE
DKKSGKTILLADVMPAGIGNNNANKADSGFKEINGHYYLKLKKNGDNDFRYTVRENGVVYNETTNKPTNYTINDKYEVLEGGK
SLTVEQYSVDFDSGSLRERHNGKQVPMNVFYKDSLFKVTPTNYIAMTTSQNRGESWEQFKLLPPFLGEKHNGTYLCPGQGLAL
KSSNRLIFATYTSGELTYLISDDSGQTWKKSSASIPFKNATAEAQMVELRDGVIRTFFRTTTGKIAYMTSRDSGETWSKVSYI
DGIQQTSYGTQVSAIKYSQLIDGKEAVILSTPNSRSGRKGGQLVVGLVNKEDDSIDWKYHYDIDLPSYGYAYSAITELPNHHI
GVLFEKYDSWSRNELHLSNVVQYIDLEINDLTK

SeqID 213
MNRSVQERKCRYSIRKLSVGAVSMIVGAVVFGTSPVLAQEGASEQPLANETQLSGESSTLTDTEKSQPSSETELSGNKQEQER
KDKQEEKIPRDYYARDLENVETVIEKEDVETNASNGQRVDLSSELDKLKKLENATVHMEFKPDAKAPAFYNLFSVSSATKKDE
YFTMAVYNNTATLEGRGSDGKQFYNNYNDAPLKVKPGQWNSVTFTVEKPTAELPKGRVRLYVNGVLSRTSLRSGNFIKDMPDV
THVQIGATKRANNTVWGSNLQIRNLTVYNRALTPEEVQKRSQLFKRSDLEKKLPEGAALTEKTDIFESGRNGNPNKDGIKSYR
IPALLKTDKGTLIAGADERRLHSSDWGDIGMVIRRSEDNGKTWGDRVTITNLRDNPKASDPSIGSPVNIDMVLVQDPETKRIF
SIYDMFPEGKGIFGMSSQKEEAYKKIDGKTYQILYREGEKGAYTIRENGTVYTPDGKATDYRVVVDPVKPAYSDKGDLYKGDQ
LLGNIYFTTNKTSPFRIAKDSYLWMSYSDDDGKTWSAPQDITPMVKADWMKFLGVGPGTGIVLRNGPHKGRILIPVYTTNNVS
HLDGSQSSRVIYSDDHGKTWHAGEAVNDNRQVDGQKIHSSTMNNRRAQNTESTVVQLNNGDVKLFMRGLTGDLQVATSKDGGV
TWEKDIKRYPQVKDVYVQMSAIHTMHEGKEYIILSNAGGPKRENGMVHLARVEENGELTWLKHNPIQKGEFAYNSLQELGNGE
YGILYEHTEKGQNAYTLSFRKFNWEFLSKNLISPTEANRDGQRRDGQRSYWLGVVRLRSIGQQGSNPSIGKWNSDFPNPVQDLV
VCSRGRYRTGNYWYSRKHRKYASSCKSSRCQSSWRSKWQSSGASSRIYRGSWYRASCSNRRVGIFACNSYYKKRLYLQSSSCS
AGTSNRKQGEPPSFTRTNSFLPWSVYAREKERT

SeqID 214
MIQIGKIFAGRYRIVKQIGRGGMADVYLAKDLILDGEEVAVKVLRTNYQTDPIAVARFQREARAMADLDHPHIVRITDIGEED
GQQYLAMEYVAGLDLKRYIKEHYPLSNEEAVRIMGQILLAMRLAHTRGIVHRDLKPQNILLTPDGTAKVTDFGIAVAFAETSL
TQTNSMLGSVHYLSPEQARGSKATVQSDIYAMGIIFYEMLTGHIPYDGDSAVTIALQHFQKPLPSVIAENPSVPQALENVIIK
ATAKKLTNRYRSVSEMYVDLSSSLSYNRRNESKLIFDETSKADTKTLPKVSQSTLTSIPKVQAQTEHKSIKNPSQAVTEETYQ
PQAPKKHRFKMRYLILLASLVLVAASLIWILSRTPATIAIPDVAGQTVAEAKATLKKANFEIGEEKTEASEKVEEGRIIRTDP
GAGTGRKEGTKINLVVSSGKQSFQISNYVGRKSSDVIAELKEKKVPDNLIKIEEEESNESEAGTVLKQSLPEGTTYDLSKATQ
IVLTVAKKATTIQLGNYIGRNSTEVISELKQKKVPENLIKIEEEESSESEPGTIMKQSPGAGTTYDVSKPTQIVLTVAKKVTS
VAMPSYIGSSLEFTKNNLIQIVGIKEANIEVVEVTTAPAGSAEGMVVEQSPRAGEKVDLNKTRVKISIYKPKTTSATP

SeqID 215
MTKLIFMGTPDFSATVLKGLLTDDRYEILAVVTQPDRAVGRKKVIQETPVKQAAKEAGLSIYQPEKLSGSPEMEDLMKLGADG
IVTAAFGQFLPSKLLDSMDFAVNVHASLLPRHRGGAPIHYALIQGDEEAGVTIMEMVKEMDAGDMISRRSIPITDEDNVGTLF
EKLALVGRDLLLDTLPAYIAGDIKPEPQDTSQVTFSPNIKPEEEKLDWNKTNRQLFNQIRGMNPWPVAHTFLKGDRFKIYEAL
PVEGQGNPGEILSIGKKELIVATAEGALSLKQVQPAGKPKMDIASFLNGVGRTLTVGERFGD

SeqID 216
VFRRLGQDFQLRKVKKILKQINALKGKMSSLSDQELVAKTVEFRQRLSEGESLDDILVEAFAVVREADKRILGMFPYDVQVMG
AIVMHYGNVAEMNTGEGKTLTATMPVYLNAFSGEGVMVVTPNEYLSKRDAEEMGQVYRFLGLTIGVPFTEDPKKEMKAEEKKL
IYASDIIYTTNSNLGFDYLNDNLASNEEGKFLRPFNYVIIDEIDDILLDSAQTPLIIAGSPRVQSNYYAIIDTLVTTLVEGED
YIFKEEKEEVWLTTKGAKSAENFLGIDNLYKEEHASFARHLVYAIRAHKLFTKDKDYIIRGNEMVLVDKGTGRLMEMTKLQGG
LHQAIEAKEHVKLSPETRAMASITYQSLFKMFNKISGMTGTGKVAEKEFIETYNMSVVRIPTNRPRQRIDYPDNLYITLPEKV
YASLEYIKQYHAKGNPLLVFVGSVEMSQLYSSLLFREGIAHNVLNANNAAREAQIISESGQMGAVTVATSMAGRGTDIKLGKG
VAELGGLIVIGTERMESQRIDLQIRGRSGRQGDPGMSKFFVSLEDDVIKKFGPSWVHKKYKDYQVQDMTQPEVLKGRKYRKLV
EKAQHASDSAGRSARRQTLEYAESMNIQRDIVYKERNRLIDGSRDLEDVVVDIIERYTEEVAADHYASRELLFHFIVTNISFH
VKEVPDYIDVTDKTAVRSFMKQVIDKELSEKKELLNQHDLYEQFLRLSLLKAIDDNWVEQVDYLQQLSMAIGGQSASQKNPIV
EYYQEAYAGFEAMKEQIHADMVRNLLMGLVEVTPKGEIVTHFP

SeqID 217
MTETVEDKVSHSITGLDILKGIVAAGAVISGTVATQTKVFTNESAVLEKTVEKTDALATNDTVVLGTISTSNSASSTSLSASE
SASTSASESASTSASTSASTSASESASTSASTSISASSTVVGSQTAAATEATAKKVEEDRKKPASDYVASVTNVNLQSYAKRR
KRSVDSIEQLLASIKNAAVFSGNTIVNGAPAINASLNIAKSETKVYTGEGVDSVYRVPIYYKLKVTNDGSKLTFTYTVTYVNP
KTNDLGNISSMRPGYSIYNSGTSTQTMLTLGSDLGKPSGVKNYITDKNGRQVLSYNTSTMTTQGSGYTWGNGAQMNGFFAKKG

YGLTSSWTVPITGTDTSFTFTPYAARTDRIGINYFNGGGKVVESSTTSQSLSQSKSLSVSASQSASASASTSASASASTSASA
SASTSASASASTSASVSASTSASASASTSASASASTSASESASTSASASASTSASASASTSASASASTSASESASTSASASAS
TSASESASTSASASASTSASASASTSASGSASTSTSASASTSASASASTSASASASISASESASTSASESASTSTSASASTSA
SESASTSASASASTSASASASTSASASASTSASASTSASESASTSASASASTSASASASTSASASASTSASASASTSASVSAS
TSASASASTSASASASTSASESASTSASASASTSASASASTSASASASTSASASASTSASASASTSASESASTSASASASTSA
SASASTSASASASTSASASASTSASASASISASESASTSASASASTSASASASTSASASASTSASESASTSASASASTSASAS
ASTSASASASTSASASASTSASASASTSASESASTSASASASTSASESASTSASASASTSASESASTSASASASTSASASAST
SASASASTSASASASTSASASASTSASESASTSASASASTSASASASTSASASASTSASESASTSASASASTSASASASTSASAS
ASTSASASASTSASASASISASESASTSASASASTSASVSASTSASASASTSASESASTSASASASTSASESASTSASASAST
SASASASTSASASASISASESASTSASASASTSASASASTSASASASTSASESASTSTSASASTSASESASTSASASASTSAS
ASASTSASASASTSASASASTSASASTSASESASTSASASASTSASASASTSASASASTSASASASTSASASASTSASASAST
SASASASTSASASASTSASESASTSASASASTSASASASTSASASASTSASASASTSASASASTSASVSASTSASESASTSAS
ASASTSASESASTSASASASTSASESASTSASASASTSASASASTSASASASTSASASASTSASASASTSASASASTSASASA
STSASASASTSASASASTSASASASTSASASASTSASASASTSASASASISASESASTSASASASTSASASASTSASASASTS
ASASASTSASASASISASESASTSASASASTSASASASTSASASASTSASESASTSASESASTSTSASASTSASESASTSASA
ASASTSASASASTSASASASTSASASTSASESASTSASASASTSASASASTSASASASTSASASASTSASASASTSASASAST
ASASTSASASASTSASASASTSASASTSASESASTSASASASTSASASASTSASASASTSASESASTSASASASTSASASAST
SASASASTSASASASTSASASASTSASESASTSASASASTSASASASTSASASASTSASASASTSASASASTSASVSASTSAS
SASTSASASASTSASASASTSASASASTSASESASTSASASASTSASASASTSASESASTSASASASTSASASASTSASASAS
TSASASASTSASASASTSASASASTSASASASISASESASTSASASASTSASASASTSASASASTSASASASISASESASTSA
STSASESASTSTSASASTSASESASTSASASASTSASASASTSASASASTSASASTSASESASTSASASASTSASASASTSAS
ASASTSASASASTSASASASTSASVSASTSASASASTSASASASTSASESASTSASASTSASESASTSASASASTSASASAST
SASASASTSASESASTSASASASTSASASASTSASESASTSASASASTSASASASTSASASASTSASASASTSASESASTSAS
ESASTSASASASTSASASASTSASGSASTSTSASASTSASASASTSASASASISASESASTSASESASTSTSASASTSASESA
STSASASASTSASASASTSASASASTSASASTSASESASTSASASASTSASASASTSASASASTSASASASTSASVSASTSAS
ASASTSASASASTSASESASTSASASASTSASASASTSASASASTSASASASTSASESASTSASASASTSASASASTSASASA
STSASASASTSASASASISASESASTSASASASTSASASASTSASASASTSASESASTSASASASTSASASASTSASASAST
ASASASTSASASASTSASASASTSASASTSASESASTSASASASTSASESASTSASASASTSASASASTSASASASTSASAS
SASTSASASASTSASASASTSASASTSASESASTSASASASTSASASASTSASASASTSASESASTSASASASTSASASAST
ASASASTSASASASTSASASASISASESASTSASASASTSASVSASTSASASASTSASESASTSASASASTSASESASTSAS
SASTSASASASISASESASTSASASASTSASASASTSASASASTSASESASTSTSASASTSASESASTSASASASTSASASA
TSASASASTSASASASTSASESASTSASASASTSASASASTSASASASTSASASASTSASASASTSASESASTSASASAST
SASTSASASASTSASESASTSASASASTSASASASTSASASASTSASASASTSASASASTSASASASTSASVSASTSASESA
ASTSASASASTSASESASTSASASASTSASASASTSASASASTSASASASTSASASASTSASASASTSASESASTSASASAS
ASASTSASASASTSASASASTSASASASTSASASASTSASASASTSASASASTSASASASTSASASASTSASASASTSASAST
ASASASTSASASASTSASASASISASESASTSASASASTSASASASTSASVSASTSASASASTSASASASISASESASTSAS
SASTSASASASTSASASASTSASASASTSASASASISASESASTSASASASTSASASASTSASASASTSASASASTSASASA
STSASASASTSASASASTSASASASTSASASASISASESASTSASASASTSASESASTSASASASTSASASASTSASASAST
ASASTSASASASTSASASASTSASESASTSTSASASTSASESASTSASASASTSASASASTSASASASTSASASASTSASAS
SASESASTSASASASTSASASASTSASASASTSASASASTSASASASTSASASASTSASASASTSASASASTSASESASTSA
ASASTSASASASTSASASASTSASASASTSASVSASTSASESASTSASASASTSASASASTSASESASTSASASASTSASES
STSASASASTSASASASTSASASASTSASASASTSASASASTSASASASTSASASASTSASASASTSASASASTSASASAST
ASASASTSASASASTSASASASISASESASTSASASASTSASASASTSASVSASTSASASASTSASASASISASESASTSAS
SASTSASASASTSASASASTSASASASISASESASTSASASASTSASASASTSASASASTSASASASTSASASASTSASASA
TSASASASTSASASASTSASASASTSASASASTSASASASTSASASASTSASASASTSASASASTSVSNSANHSNSQVGNTS
STGKSQKELPNTGTESSIGSVLLGVLAAVTGIGLVAKRRKRDEEE

SeqID 218
MSNEKNTNTNVEKKDATVVAHEIKGELTYEDKVIQKIIGLSLENVSGLLGIDGGFFSNLKEKIVNSDDVTSGVNVEVGKTQV
VDLNVIVEYQKNVPALYSEIREIVSSEVAKMTDLEIVEINVNVVDIKTKEQHEADSVSLQDRVSDVAESTGEFTSEQFEKAK
GLGSGFSTVQEKVSEGVEAVKGAANGVVSHENTRVN

SeqID 219
MTKEKNVILTARDIVVEFDVRDKVLTAIRGVSLELVEGEVLALVGESGSGKSVLTKTFTGMLEENGRIAQGSIDYRGQDLTA
SSHKDWEQIRGAKIATIFQDPMTSLDPIKTIGSQITEVIVKHQGKTAKEAKELAIDYMNKVGIPDADRRFNEYPFQYSGGMR
RIVIAIALACRPDVLICDEPTTALDVTIQAQIIDLLKSLQNEYHFTTIFITHDLGVVASIADKVAVMYAGEIVEYGTVEEVF
DPRHPYTWSLLSSLPQLADDKGDLYSIPGTPPSLYTDLKGDAFALRSDYAMQIDFEQKAPQFSVSETHWAKTWLLHEDAPKV
KPAVIANLHDKIREKMGFAHLAD

SeqID 220

MKKNRVFATAGLVLLAAGVLAACSSSKSSDSSAPKAYGYVYTADPETLDYLISSKNSTTVVTSNGIDGLFTNDNYGNLAPAVA
EDWEVSKDGLTYTYKIRKGVKWFTSDGEEYAEVTAKDFVNGLKHAADKKSEAMYLAENSVKGLADYLSGTSTDFSTVGVKAVD
DYTLQYTLNQPEPFWNSKLTYSIFWPLNEEFETSKGSDFAKPTDPTSLLYNGPFLLKGLTAKSSVEFVKNEQYWDKENVHLDT
INLAYYDGSDQESLERNFTSGAYSYARLYPTSSNYSKVAEEYKDNIYYTQSGSGIAGLGVNIDRQSYNYTSKTTDSEKVATKK
ALLNKDFRQALNFALDRSAYSAQINGKDGAALAVRNLFVKPDFVSAGEKTFGDLVAAQLPAYGDEWKGVNLADGQDGLFNADK
AKAEFAKAKKALEADGVQFPIHLDVPVDQASKNYISRIQSFKQSVETVLGVENVVVDIQQMTSDEFLNITYYAANASSEDWDV
SGGVSWGPDYQDPSTYLDILKTTSSETTKTYLGFDNPNSPSVVQVGLKEYDKLVDEAARETSDLNVRYEKYAAAQAWLTDSSL
FIPAMASSGAAPVLSRIVPFTGASAQTGSKGSDVYFKYLKSQDKVVTKEEYEKAREKWLKEKAESNEKAQKELASHVK

SeqID 221
MEINVSKLRTDLPQVGVQPYRQVHAHSTGNPHSTVQNEADYHWRKDPELGFFSHIVGNGCIMQVGPVDNGAWDVGGGWNAETY
AAVELIESHSTKEEFMTDYRLYIELLRNLADEAGLPKTLDTGSLAGIKTHEYCTNNQPNNHSDHVDPYPYLAKWGISREQFKH
DIENGLTIETGWQKNDTGYWYVHSDGSYPKDKFEKINGTWYYFDSSGYMLADRWRKHTDGNWYWFDNSGEMATGWKKIADKWY
YFNEEGAMKTGWVKYKDTWYYLDAKEGAMVSNAFIQSADGTGWYYLKPDGTLADKPEFTVEPDGLITVK

SeqID 222
MKKKYWTLAILFFCLFNNSVTAQEIPKNLDGNITHTQTSESFSESDEKQVDYSNKNQEEVDQNKFRIQIDKTELFVTTDKHLE
KNCCKLELEPQINNDIVNSESNNLLGEDNLDNKIKENVSHLDNRGGNIEHDKDNLESSIVRKYEWDIDKVTGGGESYKLYSKS
NSKVSIAILDSGVDLQNTGLLKNLSNHSKNYVPNKGYLGKEEGEEGIISDIQDRLGHGTAVVAQIVGDDNINGVNPHVNINVY
RIFGKSSASPDWIVKAIFDAVDDGNDIINLSTGQYLMIDGEYEDGTNDFETFLKYKKAIDYANQKGVIIVAALGNDSLNVSNQ
SDLLKLISSRKKVRKPGLVVDVPSYFSSTISVGGIDRLGNLSDFSNKGDSDAIYAPAGSTLSLSELGLNNFINAEKYKEDWIF
SATLGGYTYLYGNSFAAPKVSGAIAMIIDKYKLKDQPYNYMFVKKFWKKHYQ

SeqID 223
MKKDELFEGFYLIKSADLRQTRAGKNYLAFTFQDDSGEIDGKLWDAQPHNIEAFTAGKVVHMKGRREVYNNTPQVNQITLRLP
QAGEPNDPADFKVKSPVDVKEIRDYMSQMIFKIENPVWQRIVRNLYTKYDKEFYSYPAAKTNHHAFETGLAYHTATMVRLADA
ISEVYPQLNKSLLYAGIMLHDLAKVIELTGPDQTEYTVRGNLLGHIALIDSEITKTVMELGIDDTKEEVVLLRHVILSHHGLL
EYGSPVRPRIMEAEIIHMIDNLDASMMMMSTALALVDKGEMTNKIFAMDNRSFYKPDLD

SeqID 224
VTILGKDTVQQSAKGESVTQEATPEYKLENTPGGDKGGNTGSSDANANEGGGSQAGGSAHTGSQNSAQSQASKQLATEKESAK
NAIEKAAKDKQDEIKGAPLSDKEKAELLARVEAEKQAALKEIENAKTMEDVKEAETIGVQAIAMVTVPKRPVAPNAAPKTTSA
PQATAGTMQDVTYQSPAGKQLPNTGSASSAALASLGLVVATSGFALLGRKTRRRK

SeqID 225
MNADDTVTIYDVAREAGVSMATVSRVVNGNKNVKENTRKKVLEVIDRLDYRPNAVARGLASKKTTTVGVVIPNITNGYFSSLA
KGIDDIAEMYKYNIVLANSDEDNEKEVSVVNTLFSKQVDGIIYMGYHLTDKIRSEFSRSRTPIVLAGTVDVEHQLPSVNIDYK
QATIDAVSYLAKENERIAFVSGPLVDDINGKVRLVGYKETLKKAGITYSEGLVFESKYSYDDGYALAERLISSNATAAVVTGD
ELAAGVLNGLADKGVSVPEDFEIITSDDSQISRFTRPNLTTIAQPLYDLGAISMRMLTKIMHKEELEEREVLLPHGLTERSST
RKRK

SeqID 226
MKKKLVFPNLFWWGAASSGPQTEGQYGKVHENVMDYWFKTHPEDFFDNVGPLVASNFFHTYTEDFHLMKEIGVNSFRTSIQWS
RLIKNLETGEPDPKGIAFYNAIIEEAKKNQMDLVMNLHHFDLPVELLQKYGGWESKHVVELFVKFAKTAFTCFGDKVHYWTTF
NEPMVIPEAGYLYAFHYPNLKGKGKEAVQVIYNLNLASAKVIQLYRSLELDGKIGIILNLTPAYPRSNSPEDLEASRFTDDFF
NKVFLNPAVKGTFPERLVKQLERDGVLWSHTEKELQLMKSNTVDFLGVNYYHPKRVQAQANPEEYQTPWMPDQYFKEYEWLER
RMNPYRGWEIFPKAIYDIAMIVKEEYGNIPWFISENGMGVENEARFIDENGVIDDVYRIEFYEEHLRWLHKAIEEGSHCFGYH
AWTAFDCWSWNNAYKNRYGFISVDLETQKRTIKSSGRWYRKVSDNNGFEVEIEE

SeqID 227
VENLTNFYEKYRVYLTRPRLELLAVVTIVFCAVLVFFLNIPGKGVLKLDNGTIVYDGSLVRGKMNGQGTITFQNGDQYTGGFN
NGAFNGKGTFQSKEGWTYEGDFVNGQAEGKGKLTTEQEVVYEGTFKQGVFQQK

SeqID 228
MLNKIRDYLDFAGLQYRNPDKAGAEREKMLAFRHKGQEARKVFTELAKAFQASHPEWQLQQTSQWMNQAQRLRPHFWVYLQRD
GQVTEPMMALRLYGTSTDFGISLEVSFIERKKDEQTLGKQAKVLDIPTVKGIYYLTYSNGQSQRWEANEEKRRTLREKVRSQE
VRKVLVKVDVPMTENSSEEEIVEGLLKSYSKILPYYLATRK

SeqID 229
MVQNSCWQSKSHKVKAFTLLESLLALIVISGGLLLFQAMSQLLISEVRYQQQSEQKEWLLFVDQLEVELDRSQFEKVEGNRLY
MKQDGKDIAIGKSKSDDFRKTNARGRGYQPMVYGLKSVRITEDNQLVRFHFQFQKGLEREFIYRVEKEKS

SeqID 230
MKKMMTFLKKAKVKAFTLVEMLVVLLIISVLFLLFVPNLTKQKEAVNDKGKAAVVKVVESQAELYSLEKNEDASLRKLQADGR
ITEEQAKAYKEYNDKNGGANRKVND

SeqID 231

MTSKVRKAVIPAAGLGTRFLPATKALAKEMLPIVDKPTIQFIVEEALKSGIEDILVVTGKSKRSIEDHFDSNFELEYNLKEKG
KTDLLKLVDKTTDMRLHFIRQTHPRGLGDAVLQAKAFVGNEPFVVMLGDDLMDITDEKAVPLTKQLMDDYERTHASTIAVMPV
PHDEVSAYGVIAPQGEGKDGLYSVETFVEKPAPEDAPSDLAIIGRYLLTPEIFEILEKQAPGAGNEIQLTDAIDTLNKTQRVF
AREFKGARYDVGDKFGFMKTSIDYALKHPQVKDDLKNYLIQLGKELTEKE

SeqID 232
MQNQLNELKRKMLEFFQQKQKNKKSARPGKKGSSTKKSKTLDKSVIFPAILLSIKALFNLLFVLGFLGGMLGAGIALGYGVAI
FDKVRVPQTEELVNQVKDISSISEITYSDGTVIASIESDLLRTSISSEQISENLKKAIIATEDEHFKEHKGVVPKAVIRATLG
KFVGLGSSSGGSTLTQQLIKQQVVGDAPTLARKAAEIVDALALERAMNKDEILTTYLNVAPFGRNNKGQNIAGARQAAEGIFG
VDASQLTVPQAAFLAGLPQSPITYSPYENTGELKSDEDLEIGLRRAKAVLYSMYRTGALSKDEYSQYKDYDLKQDFLPSGTVI
GISRDYLYFTTLAEAQERMYDYLAQRDNVSAKELKNEATQKFYRDLAAKEIENGGYKITTTIDQKIHSAMQSAVADYGYLLDI
GTGRVEVGNVLMDNQTGAILGFVGGRNYQENQNNHAFDTKRSPASTTKPLLAYGIAIDQGLMGSETILSNYPTNFANGNPIMY
ANSKGTGMMTLGEALNYSWNIPAYWTYRMLREKGVDVKGYMEKMGYEIPEYGIESLPMGGGIEVTVAQHTNGYQTLANNGVYF
QKHVISKIEAADGRVVYEYQDKPVQVYSKATATIMQGLLREVLSSRVTTTFKSNLTSLNPTLANADWIGKTGTTNQDENMWLM
LSTPRLTLGGWIGHDDNHSLSRRAGYSNNSNYMAHLVNAIQQASPSIWGNERFALDPSVVKSEVLKSTGQKPEKVSVEGKEVE
VTGSTVTSYWANKSGAPATSYRFAIGGSDADYQNAWSSIVGSLPTPSSSSSSSSSSSSSDSSNSSTTRPSSSRARR

SeqID 233
MSSKFMKSAAVLGTATLASLLLVACGSKTADKPADSGSSEVKELTVYVDEGYKSYIEEVAKAYEKEAGVKVTLKTGDALGGLI
KLSLDNQSGNVPDVMMAPYDRVGSLGSDGQLSEVKLSDGAKTDDTTKSLVTAANGKVYGAPAVIESLVMYYNKDLVKDAPKTI
ADLENLAKDSKYAFAGEDGKTTAFLADWTNFYYTYGLLAGNGAYVFGQNGKDAKDIGLANDGSIVGINYAKSWYEKWPKGMQI
TEGAGNLIQTQFQEGKTAAIIDGPWKAQAFKDAKVNYGVATIPTLPNGKEYAAFGGGKAWVIPQAVKNLEASQKFVDFLVATE
QQKVLYDKTNEIPANTEARSYAEGKNDELTTAVIKQFKNTQPLPNISQMSAVWDPAKNMLFDAVSGQKDAKTAANDAVTLIKI
TIKQKFGE

SeqID 234
MIDKVVRNLLLTFFFCKMTKIIIFLTTILVKKKKICYNEFKLRNRKQKGVIMWVLGPILFMIFFYSNNSKKIKKLENKIKRLF
RKEKGNAEMSRLLQEMIGKEPIITGVYIGPDNWEVVDVDEEWVKLRRVDNTGKEKFKLQRIEDIQTVEFDGE

SeqID 235
MILSKNREDGLRKFATNIRLNTLRTLNHLGFGHYGGSLSIVEVLAVLYGEIMPMTPEIFAARDRDYFILSKGHGGPALYSTLY
LNGFFDKEFLYSLNTNGTKLPSHPDRNLTPGIDMTTGSLGQGISVATGLAYGQRIRKSPFYTYAIVGDGELNEGQCWEAIQFA
SHQQLSNLIVFVDDNKKQLDGFTKDICNPGDFVEKFSAFGFESIRVKGSDIREIYEGIVQLKQSNNSSPKCIVLDTIKGQGVG
ELEEMKSNHHLRPTVEEKQMLTSVVERLSQELEETE

SeqID 236
MKKTTILSLTTAAVILAAYVPNEPILADTPSSEVIKETKVGSIIQQNNIKYKVLTVEGNIGTVQVGNGVTPVEFEAGQDGKPI
TIPTKITVGDKVFTVTEVASQAFSYYPDETGRIVYYPSSITIPSSIKKIQKKGFHGSKAKTIIFDKGSQLEKIEDRAFDFSEI
EEIELPASLEYIGTSAFSFSQKLKKLTFSSSSKLELISHEAFANLSNLEKLTLPKSVKTLGSNLFRLTTSLKHVDVEEGNESI
ASVDGVLFSKDKTQLIYYPSQKNDESYKTPKETKELASYSFNKNSYLKKLELNEGLEKIGTFAFADAIKLEEISLPNSLETII
RLAFYGNLELKELILPDNVKNFGKHVMNGLPKLKSLTIGNNINSLPSFFLSGVLDSLKEIHIKNKSTEFSVKKDTFAIPETVI
FYVTSEHIKDVLKSNLSTSNDIIVEKVDNIKQETDVAKPKKNSNQGVVGWVKDKGLWYYLNESGSMATGWVKDKGLWYYLNES
GSMATGWVKDKGLWYYLNESGSMATGWVKDKGLWYYLNESGSMATGWVKDKGLWYYLNESGSMATGWVKDKGLWYYLNESGSM
ATGWVTSGKWYYTYNSGDLLVNTTTPDGYRVNANGEWVG

SeqID 237
MVRFTGLSLKQTQAIEVLKGHISLPDVEVAVTQSDQASISIEGEEGHYQLTYRKPHQLYRALSLLVTVLAEADKVEIEEQAAY
EDLAYMVDCSRNAVLNVASAKQMIEILALMGYSTFELYMEDTYQIEGQPYFGYFRGAYSAEELQEIEAYAQQFDVTFVPCIQT
LAHLSAFVKWGVKEVQELRDVEDILLIGEEKVYDLIDGMFATLSKLKTRKVNIGMDEAHLVGLGRYLILNGVVDRSLLMCQHI
ERVLDIADKYGFHCQMWSDMFFKLMSADGQYDRDVEIPEETRVYLDRLKDRVTLVYWDYYQDSEEKYNRNFRNHHKISHDLAI
AGGAWKWIGFTPHNHFSRLVAIEANKACRANQIKEVIVTGWGDNGGETAQFSILPSLQIWAELSYRNDLDGLSAHFKTNTGLY
VEDFMQIDLANLLPDLPGNLSGINPNRYVFYQDILCPILDQHMTPEQDKPHFAQAAETLANIKEKAGNYAYLFETQAQLNAII
SSKVDVGRRIRQAYQADDKESLQQIARQELPELRSQIEDFHALFSHQWLKENKVFGLDTVDIRMGGLLQRIKRAESRIEVYLA
GQLDRIDELEVEILPFTDFYADKDFAATTANQWHTIATASTIYTT

SeqID 238
MSNSFVKLLVSQLFANLADIFFRVTIIANIYIISKSVIATSLVPILIGISSFVASLLVPLVTKRLALNRVLSLSQFGKTILLI
ILVGMPTVMQSVAPLVTYLFVVAISILDGFAAPVSYAIVPRYATDLGKANSALSMTGEAVQLIGWGLGGLLFATIGLLPTTCY
NLVLYIISSFLMLFLPNAEVEVLESETNLEILLKGWKLVARNPRLRLFVSANLLEIFSNTIWVSSIILVFVTELLNKTESYWG
YSNTAYSIGIIISGLIAFRLSEKFLAAKWEPQLFTPNLKTIQNPCLSLDPGWFLFSPNGCFLLDKKEFPLYGISVEKNTKRKI
THMNSLPNHHFQNKSFYQLSFDGGHLTQYGGLIFFQELFSQLKLKERISKYLVTNDQRRYCRYSDSDILVQFLFQLLTGYGTI
YACKELSADAYFPKLLEGGQLASQPTLSRFLSRTDEETVHSLRCLNLELVEFFLQFHQLNQLIVDIDSTHFTTYGKQEGVAYN
AHYRAHGYHPLYAFEGKTGYCFNAQLRPGNRYCSEEADSFITPVLERFNQLLFRMDSGFATPKLYDLIEKTGQYYLIKLKKNT
VLSRLGDLSLPCPQDEDLTILPHSAYSETLYQAGSWSHKRRVCQFSERKEGNLFYDVISLVTNMTSGTSQDQFQLYRGRGQAI
NPIKEMKEGFFGDKTDSSTLIKNEVRMMMSCIAYNLYLFLKHLAGGDFQTLTIKRFRHLFLHVVGKCVRTGRKQLLKLSSLYA
YSELFSALYSRIRKVNLNLPVPYEPPRRKASLMMH

SeqID 239

MFASKSERKVHYSIRKFSVGVASVVVASLVMGSVVHATENEGATQVPTSSNRANESQAEQGEQPKKLDSERDKARKEVEEYVK
KIVGESYAKSTKKRHTITVALVNELNNIKNEYLNKIVESTSESQLQILMMESRSKVDEAVSKFEKDSSSSSSSDSSTKPEASD
TAKPNKPTEPGEKVAEAKKKVEEAEKKAKDQKEEDRRNYPTITYKTLELEIAESDVEVKKAELELVKVKANEPRDEQKIKQAE
AEVESKQAEATRLKKIKTDREEABEEAKRRADAKEQGKPKGRAKRGVPGELATPDKKENDAKSSDSSVGEETLPSPSLKPEKK
VAEAEKKVEEAKKKAEDQKEEDRRNYPTNTYKTLELEIAESDVEVKKAELELVKEEAKEPRNEEKVKQAKAEVESKKAEATRL
EKIKTDRKKAEEEAKRKAAEEDKVKEKPAEQPQPAPAPKAEKPAPAPKPENPAEQPKAEKPADQQAEEDYARRSEEEYNRLTQ
QQPPKTEKPAQPSTPKTGWKQENGMWYFYNTDGSMATGWLQNNGSWYYLNSNGAMATGWLQNNGSWYYLNANGSMATGWLQNN
GSWYYLNANGSMATGWLQYNGSWYYLNANGSMATGWLQYNGSWYYLNANGDMATGWVKDGDTWYYLEASGAMKASQWFKVSDK
WYYVNGSGALAVNTTVDGYGVNANGEWVN

SeqID 240
MNYSKALNECIESAYMVAGHFGARYLESWHLLIAMSNHSYSVAGATLNDYPYEMDRLEEVALELTETDYSQDETFTELPFSRK
LQVLFDEAEYVASVVHAKVLGTEHVLYAILHDSNALATRILERAGFSYEDKKDQVKIAALRRNLEERAGWTREDLKALRQRHK
TVADKQNSMANMMGMPQTPSGGLEDYTHDLTEQARSGKLEPVIGRDKEISRMIQILSRKTKNNPVLVGDAGVGKTALALGLAQ
RIASGDVPAEMAKMRVLELDLMNVVAGTRFRGDFEERMNNIIKDIEEDGQVILFIDELHTIMGSGSGIDSTLDAANILKPALA
RGTLRTVGATTQEEYQKHIEKDAALSRRFAKVTIEEPSVADSMTILQGLKATYEKHHRVQITDEAVETAVKMAHRYLTSRHLE
DSAIDLLDEAAATVQNKAKHVKADDSDLSPADKALMDGKWKQAAQLIAKEEEVPVYKDLVTESDILTTLSRLSGIPVQKLTQI
DAKKYLNLEAELHKRVIGQDQAVSSISRAIRRNQSGIRSHKRPIGSFMFLGPTGVGKTELAKALAEVLFDDESALIRFDMSEY
MEKFAASRLNGAPPGYVGYEEGGELTEKVRNKPYSVLLFDEVEKAHPDIFNVLLQVLDDGVLTDSKGRKVDFSNTIIIMTSNI
GATALRDDKTVGFGAKDIRFDQENMEKRMFEELKKAYRPEFINRIDEKVVFHSLSSDHMQEVVKIMVKPLVASLTEKGIDLKI
QASALKLLANQGYDPEMGARPLRRTLQTEVEDKLAELLLKGDLVAGSTLKIGVKAGQLKFDIA

SeqID 241
MKILPFIARGTSYYLKMSVKKLVPFLVVGLMLAAGDSVYAYSRGNGSIARGDDYPAYYKNGSQEIDQWRMYSRQCTSFVAFRI
SNVNGFEIPAAYGNANEWGHRARREGYRVDNTPTIGSITWSTAGTYGHVAWVSNVMGDQIEIEEYNYGYTESYNKRVIKANTM
TGFIHFKDLDGGSVGNSQSSTSTGGTHYFKTKSAIKTEPLASGTVIDYYYPGEKVHYDQILEKDGYKWLSYTAYNGSYRYVQI
EAVNKNPLGNSVLSSTGGTHYFKTKSAIKTEPLVSATVIDYYYPGEKVHYDQILEKDGYKWLSYTAYNGSRRYIQLEGVTSSQ
NYQNQSGNISSYGSHSSSTVGWKKINGSWYHFKSNGSKSTGWLKDGSSWYYLKLSGEMQTGWLKENGLWYYLGSSGAMKTGWY
QVSGKWYYSYSSGALAVNTTVDGYRVNSDGERV

SeqID 242
MKVIFLADVKGKGKKGEIKEVPTGYAQNFLIKKNLAKEATAQAVGELRGKQKSEEKAHAEMIAEGKAIKAQLEAEETVVEFVI
KVGPDGRTFGSITNKKIAEELQKQFGIKIDKRHIQVQAPIRAVGLIDVPVKIYQDITSVINLRVKEG

SeqID 243
MKKKILASLLLSTVMVSQVAVLTTAHAETTDDKIAAQDNKISNLTAQQQEAQKQVDQIQEQVSAIQAEQSNLQAENDRLQAES
KKLEGEITELSKNIVSRNQSLEKQARSAQTNGAVTSYINTIVNSKSITEAISRVAAMSEIVSANNKMLEQQKADKKAISEKQV
ANNDAINTVIANQQKLADDAQALTTKQAELKAAELSLAAEKATAEGEKASLLEQKAAAEAEARAAAVAEAAYKEKRASQQQSV
LASANTNLTAQVQAVSESAAAPVRAKVRPTYSTNASSYPIGECTWGVKTLAPWAGDYWGNGAQWATSAAAAGFRTGSTPQVGA
IACWNDGGYGHVAVVTAVESTTRIQVSESNYAGNRTIGNHRGWFNPTTTSEGFVTYIYAD

SeqID 244
MVKRRIRRGTREPEKVVVPEQSSIPSYPVSVTSNQGTDVAVEPAKAVAPTTDWKQENGMWYFYNTDGSMATGWVQVNSSWYYI
NSNGSMKVNQWFQVGGKWYYVNTSGELAVNTSIDGYRVNDNGEWVR

SeqID 245
ELRRLSRLVDQELYFGCGWRLSLEWLPSMRKDSWPSNTAPRTTMVQ

SeqID 246
DCIRKQPFTRDEPNKTCRKTKPSKSYCSYRW

SeqID 247
GQRNPRRIERVIRMAETKPRISKKEG

SeqID 248
QRKLFKIFHLFQKKSGWNQKSSCLKLNLNSLNRKMTQMTKMFRSIFQPKKPLNTNFQAYNSLHQINQKISLKRRKLSEKISKS

SeqID 249
LVIIVLKIQSKSETDFIFKTWPFILLSKIIPLMVLDCQVSISWTNRETVAYSKLLAIKTLKGDYHDGQSKKIRLSHASRVRTI
SWYPHDMADSTRIMAFSRKGC

SeqID 250
ERLPAFPRSLSGRKLDQGGTKEKGSDGRSP

SeqID 251
RNCLSTWKSSSNYHTEIKRGTVRQCLGKGRFKEVYSADYAQQSYENNRKRSVKKSSLTKELKEKILHYHNQKFSPEMMVMAKQ
VNVGISTIYYWIHHGKLGLSKQDLLYPRKGKALKKQASTNFKPAGQSIEQRPEAINLRLENGHYEIDTVLLTRSKNYCLIVLI
DRKSRHQIIRLIPNKSAEVVNQALKLILKQHKILSITADNGTEFNRLFDIFSEEHIYYAHPYASWERGTNENHNRLIRR

SeqID 252
PVMTISSPTMKNMDLSTKASPSQPLQGKHGMIWSGK

SeqID 253
TSSIRIHTRKSSPNWTTTPHLALSAETN

SeqID 254
YFLPHKYARESLSLPSTNKILHRKQGS

SeqID 255
AAFKKDQINERVEKLGKLKPITINYNGKSEVIDSKEKLQELMNKAVKDEVAQI

SeqID 256
AYAHSKRSAGSGRAGGRQCLCQCQNKCRRDFKY

SeqID 257
HGRPYHKPHQPHHHGFPQQSYNLLPPKHKPTLCVRR

SeqID 258
KGKILLLPRLTTQRWQRKIRPDSRKSANNKANLDFHNSRCKSSLSDEAPNLHKNPALLVHSLSRVIAVLLELSPLQAYSIVKI
SPKEDDLIHDDAILVRFGILEVHDSPYELLLLYHTHSYRFSCSIYLS

SeqID 259
FTVSHVFLLYLSFNPRPKSMSLSFTSSKLLRPRFRTFIISASDFSVKSCTVLIPARFKQLYERTDKSSSSIVRSKIRSSDSVS
ASFITSVDLAISVRFVNKSRCSVKIRAESPKASSGIIVPFVKISRVNLSKPSLLPTRAGST

SeqID 260
LVCMKNKGCYKERNNCCH

SeqID 261
FHYLSKYFLVSAITTGDKTKRAIKFGRAIKALTISAIIQTISNSINPPNKTMSTKTTR

SeqID 262
GKKVFIKYPLSRVSSKTGPMITGRTKDKIVDKKVGCPFEKSTVKYSS

SeqID 263
SSPVFPKLVMVSGANKPRERRNFPFSSKMSFHLTFVL

SeqID 264
YLTSFSVPKIASSKVKLTRYWRSSPWRGAFGLREEPPPPKKLEKISSKPPKPPAPLKPPKPPAPPKPPLAPAAPYWS

SeqID 265
QSWRPIPDSKCYTQEKLTIPIKRRKDIKDFYHNSIQRHKNSHKSHLLDSYRLIITRLAEIVHENKILIVLILYVTNIPSRSRI
YEVNRV

SeqID 266
LFRFYRVIVLYRGWHIYLLILVNLQYVQNVFRKDRFLVRGAQPFFHGERSAGHLVLPYVL

SeqID 267
ITHPPLNPEHFVSRVFSSLGLKSYQPKDDRFLRKPSDSRHPESGNSGKWQVLNSPLVIVK

SeqID 268
TLAKAVGLMYSPPIPPKPFLGRITTDSSSI

SeqID 269
PGSPFSEISGAGFFGVAKRIFPRPPRPPWATINSCPCSIKSVKTLPVSASRTVVPCGTRTLRSSAPRPCIPLVIPFSPESAL!

SeqID 270
INSLTLATSLSKRRAPRKASKASPRMVSRLRPPDFSSPLPNLINWSNWQSRAKPAKLSSRTIIARSFDRSPSGFLGYFLYRY!
EINNCRTASPKNSKRSLCEIFKRRCSLA

SeqID 271
PIGKRNCKAECQSHHLLEKQKTFQSRKTKRYGASPEPRYRESRKPRLSQ

SeqID 272
QPLGHSKAEEHETICSHTFDNHTTETIPNQVKGRDMTSSETLPFPSKNQNQGKAKQIP

SeqID 273
PCSLPDYGLVGSGYHSCHYQSNDTRFLESHGNWRTLLYSWSWILCQEKTLFPHDLASLYPSCVRTSIHRYCLLHVKKLRNSIS
TFFFTHIDKVLVQAHIISQFWMKRTYQHIFFLGCNNLIVHCC

SeqID 274
RVKDNHLDKLVKALLKRRSSTQYYIHQLLRKMIRLYGHQQLHNNSEILVYSDYGHVDLLLLETNKIPVY

SeqID 275
QVIKIDIATTNKTESVKSQSEREKKRLTSSNILKVRGRPI

SeqID 276
AFKSSKVPSLDPSSTKTYSISVSKSGSKASRA

SeqID 277
DKTDPLARKLPDKSKPSTSFCTKSLSPVNMASLTSAKPSKTKASLGICSPADKRMTSPSTNSSGLRATS

SeqID 278
LCRLQTQARPRGSVTNLTKQNKVYRYLNYLRQTQLSAM

SeqID 279
CIQSIGNEGQCKGNSCYVGKEIHLAPISDIVGHKGKEEGDDGNDDGRQFYLFLAHLVGSAFLRSFPLLYSKGINEEGDGIGND
GRLISKDIINSTGQNGINNTKVISPFA

SeqID 280
TSTKLVIDTTTFMTFCTNNTKSSKFTNTFTKLDVGTTTRHVGCDGNGTTLTSIHDDLGFSIVVFGIQDFVRNTSCNQFLRNVV
TSFNRYCTNQDRLTLLVTSLNVFDNRFKLRFDTCIKKV

SeqID 281
ISTGVPTCSMYPLLKTAILSDKVKASS

SeqID 282
LSTMSSIKSILCSLPTHTIFSKSAISPKRGSTAI

SeqID 283
SCSYSSTNSKACSIVGLSKPTIFICVTPISAAKAISSASRPANSSTFKCVCVSKIISSNLVFYLLLYQKRGGAPNFSVSPPLF
NRELFCYLFYPILPISYSTVRDRRDWLH

SeqID 284
VTSCIVPAVACGALVVLGAALGATGLLGTVTMAMACTPIVSASFTSSIVFAFSISLRAACFSASTLAKSSAFSLSESGAPLIS
SCLSLAAFSMAFLADSFSVANCLEACD

SeqID 285
YSPFNHSILIRKTTKIINPNPKAPRMNWRSKVWSNQPVNISTNHTKSDRPIKK

SeqID 286
DYFKFRTTFTRFSTVKPYSANTFGAGAEAPKVSIPRTAPSRPTYLYQF

SeqID 287
RGRRGLCVARIKAPRLVIKPKRTIDPPTKDRYSPPLSATSLSVPKSPIISFPAKMDKNPKRKLNSKVIFNASVT

SeqID 288
TPPYTKIPAKTAIIPFISAQDFNQAQRLSG

SeqID 289
ATGAAGAAAAAAATCTTAGCGTCACTTTTATTAAGTACAGTAATGGTTTCTCAAGTAGCTGTTTTAACAACTGCGCATGCAGA
AACGACTGATGACAAAATTGCTGCTCAAGATAATAAAATTAGTAACTTAACAGCACAACAACAAGAAGCCCAAAAACAAGTTG
ACCAAATTCAGGAGCAAGTATCAGCTATTCAAGCTGAGCAGTCTAACTTGCAAGCTGAAAATGATAGATTACAAGCAGAATCT
AAGAAACTCGAGGGTGAGATTACAGAACTTTCTAAAAACATTGTTTCTCGTAACCAATCGTTGGAAAAACAAGCTCGTAGTGC
TCAAACAAATGGAGCCGTAACTAGCTATATCAATACCATTGTAAACTCAAAATCAATTACAGAAGCTATTTCACGTGTTGCTG
CAATGAGTGAAATCGTATCTGCAAACAACAAAATGTTAGAACAACAAAAGGCAGATAAAAAAGCTATTTCTGAAAAACAAGTA
GCAAATAATGATGCTATCAATACTGTAATTGCTAATCAACAAAAATTGGCTGATGATGCTCAAGCATTGACTACGAAACAGGC
AGAACTAAAAGCTGCTGAATTAAGTCTTGCTGCTGAGAAAGCGACAGCTGAAGGGGAAAAAGCAAGTCTATTAGAGCAAAAAG
CAGCAGCTGAGGCAGAGGCTCGTGCAGCTGCGGTAGCAGAAGCAGCTTATAAAGAAAAACGAGCTAGCCAACAACAATCAGTA
CTTGCTTCAGCAAACACTAACTTAACAGCTCAAGTGCAAGCAGTATCTGAATCTGCAGCGACCTGTCCGTGCAAAAGTTCG
TCCAACATACAGTACAAACGCTTCAAGTTATCCAATTGGAGAATGTACATGGGGAGTAAAAACATTGGCACCTTGGGCTGGAG
ACTACTGGGGTAATGGAGCACAGTGGGCTACAAGTGCAGCAGCAGCAGGTTTCCGTACAGGTTCAACACCTCAAGTTGGAGCA
ATTGCATGTTGGAATGATGGTGGATATGGTCACGTAGCGGTTGTTACAGCTGTTGAATCAACAACACGTATCCAAGTATCAGA

ATCAAATTATGCAGGTAATCGTACAATTGGAAATCACCGTGGATGGTTCAATCCAACAACAACTCCTGAAGGTTTTGTTACAT
ATATTTATGCAGAT

SeqID 290
ATGAAGAAAAAAATCTTAGCGTCACTTTTATTAAGTACAGTAATGGTTTCTCAAGTAGCTGTTTTAACAACTGCGCATGCAGA
AACGACTGATGACAAAATTGCTGCTCAAGATAATAAAATTAGTAACTTAACAGCACAACAACAAGAAGCCCAAAAACAAGTTG
ACCAAATTCAGGAGCAAGTATCAGCTATTCAAGCTGAGCAGTCCTAACTTGCAAGCTGAAAATGATAGATTACAAGCAGAATCI
AAGAAACTCGAGGGTGAGATTACAGAACTTTCTAAAAACATTGTTTCTCGTAACCAATCGTTGGAAAAACAAGCTCGTAGTGC
TCAAACAAATGGAGCCGTAACTAGCTATATCAATACCATTGTAAACTCAAAATCAATTACAGAAGCTATTTCACGTGTTGCTG
CAATGAGTGAAATCGTATCTGCAAACAACAAAATGTTAGAACAACAAAAGGCAGATAAAAAAGCTATTTCTGAAAAACAAGTA
GCAAATAATGATGCTATCAATACTGTAATTGCTAATCAACAAAATTGGCTGATGATGCTCAAGCATTGACTACGAAACAGGC
AGAACTAAAAGCTGCTGAATTAAGTCTTGCTGCTGAGAAAGCGACAGCTGAAGGGGAAAAAGCAAGTCTATTAGAGCAAAAAG
CAGCAGCTGAGGCAGAGGCTCGTGCAGCTGCGGTAGCAGAAGCAGCTTATAAAGAAAAACGAGCTGGCCAACAACAATCAGTA
CTTGCTTCAGCAAACACTAACTTAACAGCTCAAGTGCAAGCAGTATCTGAATCTGCAGCAGCACCTGTCCGTGCAAAAGTTCG
TCCAACATACAGTACAAACGCTTCAAGTTATCCAATTGGAGAATGTACATGGGGAGTAAAAACATTGGCACCTTGGGCTGGAC
ACTACTGGGGTAATGGAGCACAGTGGGCTACAAGTGCAGCAGCAGGTTTCCGTACAGGTTCAACACCTCAAGTTGGAGCA
ATTGCATGTTGGAATGATGGTGGATATGGTCACGTAGCGGTTGTTACAGCTGTTGAATCAACAACACGTATCCAAGTATCAGA
ATCAAATTATGCAGGTAATCGTACAATTGGAAATCACCGTGGATGGTTCAATCCAACAACAACTTCTGAAGGTTTTGTTACAT
ATATTTATGCAGAT

SeqID 291
ATGATCCAAATCGGCAAGATTTTTGCCGGACGCTATCGGATTGTCAAACAGATTGGTCGAGGAGGTATGGCGGATGTCTACCI
AGCCAAAGACTTAATCTTAGATGGGGAAGAAGTGGCAGTGAAGGTTCTGAGGACCAACTACCAGACGGACCCGATAGCTGTAC
CTCGTTTTCAGCGTGAAGCGAGAGCTATGGCAGATCTAGACCATCCTCATATCGTTCGGATAACAGATATTGGCGAGGAAGAC
GGTCAACAGTACCTAGCTATGGAGTATGTGGCTGGACTGGACCTCAAACGCTATATCAAGGAACATTATCCTCTTTCTAATGA
AGAAGCAGCCCGTATCATGGGACAAATTCTCTTGGCTATGCGCTTGGCCCATACTCGAGGAATTGTTCACAGGGACTTGAAAC
CTCAAAATATCCTCTTGACACCAGATGGGACTGCCAAGGTCACAGACTTTGGGATTGCTGTAGCCTTTGCAGAGACAAGTCTG
ACCCAGACTAACTCGATGTTGGGCTCAGTTCATTACTTGTCACCAGAGCAGGCGGGTGGTTCGAAGGCGACTGTGCAGAGTGA
TATCTATGCCATGGGGATTATTTTCTATGAGATGCTGACAGGCCATATCCCTTATGACGGGGATAGCGCGGTGACCATTGCCC
TCCAGCATTTCCAGAAACCCCTGCCGTCCGTTATTGCAGAAAATCCATCTGTACCTCAGGCTTTAGAAAATGTTATTATCAAG
GCAACTGCTAAAAAGTTGACCAATCGCTACCGCTCGGTTTCAGAGATGTATGTGGACTTGTCTAGTAGCTTGTCCTACAATCG
TAGAAATGAAAGTAAGTTAATCTTTGATGAAACGAGCAAGGCAGATACCAAGACCTTGCCGAAGGTTTCTCAGAGTACCTTGA
CATCTATTCCTAAGGTTCAAGCGCAAACAGAACACAAATCAATCAAAAACCCAAGCCAGGCTGTGACAGAGGAAACTTACCAA
CCACAAGCACCGAAAAAACATAGATTTAAGATGCGTTACCTGATTTTGTTGGCCAGCCTTGTATTGGTGGCAGCTTCTCTTAI
TTGGATACTATCCAGAACTCCTGCAACCATTGCCATTCCAGATGTGGCAGGTCAGACAGTTGCAGAGGCCAAGGCAACGCTCA
AAAAAGCCAATTTTGAGATTGGTGAGGAGAAGACAGAGGCTAGTGAAAAGGTGGAAGAAGGGCGGATTATCCGTACAGATCCI
GGCGCTGGAACTGGTCGAAAAGAAGGAACGAAAATCAATTTGGTTGTCTCATCAGGCAAGCAATCTTTCCAAATTAGTAATTA
TGTCGGTCGGAAATCCTCTGATGTCATTGCGGAATTAAAAGAGAAAAAAGTTCCAGATAATTTGATTAAAAATTGAGGAAGAAC
AGTCGAATGAGAGTGAGGCTGGAACGGTCCTGAAGCAAAGTCTACCAGAAGGTACGACCTATGACTTGAGCAAGGCAACTCAA
ATTGTCTTGACAGTAGCTAAAAAAGTTACAAGTGTTGCCATGCCGAGTTACATTGGTTCTAGCTTGGAGTTTACTAAGAACAA
TTTGATTCAAATTGTTGGGATTAAGGAAGCTAATATAGAAGTTGTAGAAGTGACGACAGCGCCTGCAGGTAGTGCAGAAGGCA
TGGTTGTTGAACAAAGTCCTAGAGCAGGTGAAAAGGTAGACCTCAATAAGACTAGAGTCAAGATTTCAATCTACAAACCTAAA
ACAACTTCAGCTACTCCT

SeqID 292
ATGATCCAAATCGGCAAGATTTTTTGCCGGACGCTATCGGATTGTCAAACAGATTGGTCGAGGAGGCATGGCGGATGTCTACCI
AGCCAAAGACTTAATCTTAGATGGGGAAGAAGTGGCAGTGAAGGTTCTGAGGACCAACTACCAGACGGACCCGATAGCTGTAC
CTCGTTTTCAGCGTGAAGCGAGAGCTATGGCAGATCTAGACCATCCTCATATCGTTCGGATAACAGATATTGGTGAGGAAGAC
GGTCAACAGTATCTTGCAATGGAGTATGTTGCTGGACTAGACCTCAAACGCTATATCAAGGAACATTATCCTCTTTCTAATGA
AGAAGCAGTCCGTATCATGGGACAAATTCTCTTGGCTATGCGCTTGGCCCATACTCGAGGAATTGTTCACAGGGACTTGAAAC
CTCAAAATATCCTTTTGACACCAGATGGGACGGCCAAGGTCACAGACTTTGGGATTGCTGTAGCCTTTGCAGAGACAAGTCTC
ACCCAGACTAACTCGATGTTGGGCTCAGTTCATTACTTGTCACCAGAGCAGGCGCGTGGTTCGAAGGCGACTGTGCAGAGTGA
TATCTATGCCATGGGGATTATTTTCTATGAGATGTTGACAGGCCATATCCCTTATGACGGGGATAGCGCGGTGACCATTGCCC
TCCAGCATTTCCAGAAACCCCTGCCGTCCGTTATTGCAGAAAATCCATCTGTACCTCAGGCTTTAGAAAATGTTATTATCAAG
GCAACTGCTAAAAAGTTGACCAATCGCTACCGCTCGGTTTCAGAGATGTATGTGGACTTGTCTAGTAGCTTGTCCTACAATCG
TAGAAATGAAAGTAAGTTAATCTTTGATGAAACGAGCAAGGCAGATACCAAGACCTTGCCGAAGGTTTCTCAGAGTACCTTGA
CATCTATTCCTAAGGTTCAAGCGCAGACAGAACACAAATCAATCAAAAACCCAAGCCAGGCTGTGACAGAGGAAACTTACCAA
CCACAAGCACCGAAAAAACATAGATTTAAGATGCGTTACCTGATTTTGTTGGCCAGCCTTGTATTGGTGGCAGCTTCTCTTAI
TTGGATACTATCCAGAACTCCTGCAACCATTGCCATTCCAGATGTGGCAGGTCAGACAGTTGCAGAGGCCAAGGCAACGCTCA
AAAAAGCCAATTTTGAGATTGGTGAGGAGAAGACAGAGGCTAGTGAAAAGGTGGAAGAAGGGCGGATTATCCGTACAGATCCI
GGCGCTGGAACTGGTCGAAAAGAAGGAACGAAAATCAATTTGGTTGTCTCATCAGGCAAACAATCCTTCCAAATTAGTAATTA
TGTCGCCGGAAATCTTCTGATGTTATCGCGGAATTAAAAGAGAAAAAAGTTCCAGATAATTTGATTAAAAATTGAGGAAGAAC
AGTCGAATGAGAGTGAGGCTGGAACGGTCCTGAAGCAAAGTCTACCAGAAGGTACGACCTATGACTTGAGCAAGGCAACTCAA
ATTGTTTTGACAGTAGCTAAAAAAGCTACGACGATTCAATTAGGGAACTATATTGGACGGAACTCTACAGAAGTAATCTCAGA
ACTCAAGCAGAAGAAGGTTCCTGAGAATTTGATTAAGATAGAGGAAGAAGAGTCCAGCGAAAGCGAACCAGGAACGATTATGA
AACAAAGTCCAGGTGCCGGAACGACTTATGATGTGAGTAAACCTACTCAAATTGTCTTGACAGTAGCTAAAAAAGTTACAAGT
GTTGCCATGCCGAGTTACATTGGTTCCAGCTTGGAGTTTACTAAGAACAATTTGATTCAAATTGTTGGGATTAAGGAAGCTAA

TATAGAAGTTGTAGAAGTGACGACAGCGCCTGCAGGTAGTGTAGAAGGCATGGTTGTTGAACAAAGTCCTAGAGCAGGTGAAA
AGGTAGACCTAAATAAGACTAGAGTCAAGATTTCAATCTACAAACCTAAAACAACTTCAGCTACTCCT

SeqID 293
ATGATCCAAATCGGCAAGATTTTTGCCGGACGCTATCGGATTGTCAAACAGATTGGTCGAGGAGGTATGGCGGATGTCTACCT
AGCCAAAGACTTAATCTTAGATGGGGAAGAAGTGGCAGTGAAGGTTCTGAGGACCAACTACCAGACGGACCCGATAGCTGTAG
CTCGTTTTCAGCGTGAAGCGAGAGCTATGGCAGATCTAGACCATCCTCATATCGTTCGGATAACAGATATTGGTGAGGAAGAC
GGTCAACAGTATCTTGCAATGGAGTATGTTGCTGGACTAGACCTCAAACGCTATATCAAGGAACATTATCCTCTTTCTAATGA
AGAAGCAGTCCGTATCATGGGACAAATCCTCCTAGCCATGCGTTTGGCCCATACCAGAGGAATTGTTCACAGGGACTTGAAAC
CTCAAAATATCCTTTTGACACCAGATGGGACTGCCAAGGTCACAGACTTTGGGATTGCTGTAGCCTTTGCAGAGACAAGTCTG
ACCCAGACTAACTCGATGTTGGGCTCAGTTCATTACTTGTCCCCAGAGCAGGCGCGTGGTTCGAAGGCGACTGTGCAGAGTGA
TATCTATGCTATGGGGATTATTTTCTATGAGATGTTGACAGGCCATATCCCTTATGACGGGGATAGCGCGGTGACCATTGCCC
TCCAGCATTTCCAGAAACCCCTGCCGTCCGTTATTGCAGAAAATCCATCGTACCTCAGGCTTTAGAAAATGTTATTATCAAG
GCAACTGCTAAAAAGTTGACCAATCGCTACCGCTCGGTTTCAGAGATGTATGTGGACTTGTCTAGTAGCTTGTCCTACAATCG
TAGAAATGAAAGTAAGTTAATCTTTGATGAAACGAGCAAGGCAGATACCAAGACCTTGCCGAAGGTTTCTCAGAGTACCTTGA
CATCTATTCCTAAGGTTCAAGCGCAGACAGAACACAAATCAATCAAAAACCCAAGCCGGGCTGTGACAGAGGAAACTTACCAA
CCACAAGCACCGAAAAAACATAGATTTAAGATGCGTTACCTGATTTTGTTGGCCAGCCTTGTATTGGTGGCAGCTTCTCTTAT
TTGGATACTATCCAGAACTCCTGCAACCATTGCCATTCCAGATGTGGCAGGTCAGACAGTTGCAGAGGCCAAGGCAACGCTCA
AAAAGCCAATTTTGAGATTGGTGAGGAGAAGACAGAGGCTAGTGAAAAGGTGGAAGAAGGGCGGATTATCCGTACAGATCCT
GGCGCTGGAACTGGTCGAAAAGAAGGAACGAAAATCAATCTGGTTGTCTCATCAGGCAAACAATCCTTCCAAATTAGTAATTA
TGTCGGCCGGAAATCTTCTGATGTTATCGCGGAATTAAAAGAGAAAAAAGTTCCAGATAATTTGATTAAAAATTGAGGAAGAAC
AGTCGAATGAGAGTGAGGCTGGAACGGTCCTGAAGCAAAGTCTACCAGAAGGTACGACCTATGACTTGAGCAAGGCAACTCAA
ATTGTTTTGACAGTAGCTAAAAAAGCTACGACGATTCAATTAGGGAACTATATTGGACGGAACTCTACAGAAGTAATCTCAGA
ACTCAAGCAGAAGAAGGTTCCTGAGAATTTGATTAAGATAGAGGAAGAAGAGTCCAGCGAAAGCGAACCAGGAACGATTATGA
AACAAAGTCCAGGTGCCGGAACGACTTATGATGTGAGTAAACCTACTCAAATTGTCTTGACAGTAGCTAAAAAAGTTACAAGT
GTTGCCATGCCGAGTTACATTGGTTCCAGCTTGGAGTTTACTAAGAACAATTTGATTCAAATTGTTGGGATTAAGGAAGCTA
TATAGAAGTTGTAGAAGTGACGACAGCGCCTGCAGGTAGTGCAGAAGGCATGGTTGTTGAACAAAGTCCTAGAGCAGGTGAAA
AGGTAGACCTCAATAAGACTAGAGTCAAGACTTCAATCTACAAACCTAAAACAACTTCAGCTACTCCT

SeqID 294
ATGATCCAAATCGGCAAGATTTTTGCCGGACGCTATCGGATTGTCAAACAGATTGGTCGAGGAGGCATGGCGGATGTCTACCT
AGCCAAAGACTTAATCTTAGATGGGGAAGAAGTGGCAGTGAAGGTTCTGAGGACCAACTACCAGACGGACCCGATAGCTGTAC
CTCGTTTTCAGCGTGAAGCGAGAGCTATGGCAGATCTAGACCATCCTCATATCGTTCGGATAACAGATATTGGTGAGGAAGAC
GGTCAACAGTATCTTGCAATGGAGTATGTTGCTGGACTAGACCTCAAACGCTATATCAAGGAACATTATCCTCTTTCTAATGA
AGAAGCAGTCCGTATCATGGGACAAATTCTCCTTGGCTATGCGCTTGGCCCATACTCGAGGAATTGTTCACAGGGACTTGAAA
CTCAAAATATCCTTTTGACACCAGATGGGACGGCCAAGGTCACAGACTTTGGGATTGCTGTAGCCTTTGCAGAGACAAGTCTC
ACCCAGACTAACTCGATGTTGGGCTCAGTTCATTACTTGTCACCAGAGCAGGCGCGTGGTTCGAAGGCGACTGTGCAGAGTGA
TATCTATGCCATGGGGATTATTTTCTATGAGATGTTGACAGGCCATATCCCTTATGACGGGGATAGCGCGGTGACCATTGCCC
TCCAGCATTTCCAGAAACCCCTGCCGTCCGTTATTGCAGAAAATCCATCTGTACCTCAGGCTTTAGAAAATGTTATTATCAGC
GCAACTGCTAAAAAGTTGACCAATCGCTATCGCTCGGTTTCAGAGATGTATGTAGACTTGTCTAGTAGCTTGTCCTACAATCC
TAGAAATGAAAGTAAGTTAATCTTTGATGAAACGAGCAAGGCAGATACCAAGACCTTGCCGAAGGTTTCTCAGAGTACCTTGA
CATCTATTCCTAAGGTTCAAGCGCAGACAGGACACAAATCAATCAAAAACCCAAGCCAGGCTGTGACAGAGGAAACTTACCAA
CCACAAGCACCGAAAAAACATAGATTTAAGATGCGTTACCTGATTTTGTTGGCCAGCCTTGTATTGGTGGCAGCTTCTCTTAT
TTGGATACTATCCAGAACTCCTGCAACCATTGCCATTCCAGATGTGGCAGGTCAGACAGTTGCAGAGGCCAAGGCAACGCTCA
AAAAGCCAATTTTGAGATTGGTGAGGAGAAGACAGAGGCTAGTGAAAAGGTGGAAGAAGGGCGGATTATCCGTACAGATCC
GGCGCTGGAACTGGTCGAAAAGAAGGAACGAAAATTAATCTGGTTGTCTCATCAGGCAAACAATCCTTCCAAATTAGTAATTA
TGTCGGCCGGAAATCTTCTGATGTTATCGCGGAATTAAAAGAGAAAAAAGTTCCAGATAATTTGATTAAAAATTGAGGAAGAAC
AGTCGAATGAGAGTGAGGCTGGAACGGTCCTGAAGCAAAGTCTACCAGAAGGTACGACCTATGACTTGAGCAAGGCAACTCAA
ATTATTTTGACAGTAGCTAAAAAAGCTACGACGATTCAATTAGGGAACTATATTGGACGGAACTCTACAGAAGTAATCTCAGA
ACTCAAGCAGAAGAAGGTTCCTGAGAATTTGATTAAGATAGAGGAAGAAGAGTCCAGCGAAAGCGAACCAGGAACGATTATGA
AACAAAGTCCAGGTGCCGGAACGACTTATGATGTGAGTAAACCTACTCAAATTGTCTTGACAGTAGCTAAAAAAGTTACAAGT
GTTGCCATGCCGAGTTACATTGGTTCCAGCTTGGAGTTTACTAAGAACAATTTGATTCAAATTGTTGGGATTAAGGAAGCTA
TATAGAAGTTGTAGAAGTGACGACAGCGCCTGCAGGTAGTGCAGAAGGCATGGTTGTTGAACAAAGTCCTAGAGCAGGTGAA
AGGTAGACCTAAATAAGACTAGAGTCAAGATTTCAATCTACAAACCTAAAACAACTTCAGCTACTCCT

SeqID 295
ATGATCCAAATCGGCAAGATTTTTGCCGGACGCTATCGGATTGTCAAACAGATTGGTCGAGGAGGCATGGCGGATGTCTACC
AGCCAAAGACTTAATCTTAGATGGGGAAGAAGTGGCAGTGAAGGTTCTGAGGACCAACTACCAGACGGACCCGATAGCTGTA
CTCGTTTTCAGCGTGAAGCGAGAGCTATGGCAGATCTAGACCATCCTCATATCGTTCGGATAACAGATATTGGTGAGGAAGA
GGTCAACAGTATCTTGCAATGGAGTATGTTGCTGGACTAGACCTCAAACGCTATATCAAGGAACATTATCCTCTTTCTAATG
AGAAGCAGTCCGTATCATGGGACAAATTCTCTTGGCTATGCGCTTGGCCCATACTCGAGGAATTGTTCACAGGGACTTGAAA
CTCAAAATATCCTTTTGACACCAGATGGGACTGCCAAGGTCACAGACTTTGGGATTGCTGTAGCCTTTGCAGAGACAAGTCT
ACCCAGACTAACTCGATGTTGGGCTCAGTTCATTACTTGTCACCAGAGCAGGCGCGTGGTTCGAAGGCGACTGTGCAGAGT
TATCTATGCCATGGGGATTATTTTCTATGAGATGTTGACAGGCCATATCCCTTATGACGGGGATAGCGCGGTGACCATTGCC
TCCAGCATTTCCAGAACCCCCTGCCGTCCGTTATTGCAGAAAATTCATCTGTACCTCAGGCTTTAGAAAATGTTATTATCAA
GCAACTGCTAAAAAGTTGACCAATCGCTATCGCTCGGTTTCAGAGATGTATGTAGACTTGTCTAGTAGCTTGTCCTACAATC
TAGAAATGAAAGTAAGTTAATCTTTGATGAAACGAGCAAGGCAGATACCAAGACCTTGCCGAAGGTTTCTCAGAGTACCTTG
CATCTATTCCTAAGGTTCAAGCGCAGACAGAACACAAATCAATCAAAAACCCAAGCCAGGCTGTGACAGAGGAAACTTACCA

CCACAAGCACCGAAAAAACATAGATTTAAGATGCGTTACCTGATTTTGTTGGCCAGCCTTGTATTGGTGGCAGCTTCTCTTAT
TTGGATACTATCCAGAACTCCTGCAACCATTGCCATTCCAGATGTGGCAGGTCAGACAGTTGCAGAGGCCAAGGCAACGCTCA
AAAAAGCCAATTTTGAGATTGGTGAGGAGAAGACAGAGGCTAGTGAAAAGGTGGAAGAAGGGCGGATTATCCGTACAGATCCT
GGCGCTGGAACTGGTCGAAAAGAAGGAACGAAAATTAATCTGGTTGTCTCATCAGGCAAACAATCCTTCCAAATTAGTAATTA
TGTCGGCCGGAAATCTTCTGATGTTATCGCGGAATTAAAAGAGAAAAAAGTTCCAGATAATTTGATTAAAAATTGAGGAAGAAG
AGTCGAATGAAAGTGAGGCTGGAACGGTCCTGAAGCAAAGTCTACCAGAAGGTACGACCTATGACTTGAGCAAGGCAACTCAA
ATTGTTTTGACAGTAGCTAAAAAAGCTACGACGATTCAATTAGGGAACTATATTGGACGGAACTCTACAGAAGTAATCTCAGA
ACTCAAGCAGAAGAAGGTTCCTGAGAATTTGATTAAGATAGAGGAAGAAGGTCCAGCGAAAGCGAACCAGGAACGATTATGA
AACAAAGTCCAGGTGCCGGAACGACTTATGTGAGTAAACCTACTCAAATTGTCTTGACAGTAGCTAAAAAAGTTACAAGT
GTTGCCATGCCGAGTTACATTGGTTCCAGCTTGGAGTTTACTAAGAACAATTTGATTCAAATTGTTGGGATTAAGGAAGCTAA
TATAGAAGTTGTAGAAGTGACGACAGCGCCTGCAGGTAGTGTAGAAGGCATGGTTGTTGAACAAAGTCCTAGAGCAGGTGAAA
AGGTAGACCTAAATAAGACTAGAGTCAAGATTTCAATCTACAAACCTAAAACAACTTCAGCTACTCCTTAA

SeqID 296
ATGTTTGCATCAAAAAGCGAAAGAAAAGTACATTATTCAATTCGTAAATTTAGTATTGGAGTAGCTAGTGTAGCTGTTGCCAG
TCTTGTTATGGGAAGTGTGGTTCATGCGACAGAGAACGAGGGAAGTACCCAAGCAGCCACTTCTTCTAATATGGCAAAGACAG
AACATAGGAAAGCTGCTAAACAAGTCGTCGATGAATATATAGAAAAAATGTTGAGGGAGATTCAACTAGATAGAAGAAAACAT
ACCCAAAATGTCGCCTTAAACATAAAGTTGAGCGCAATTAAAACGAAGTATTTGCGTGAATTAAATGTTTTAGAAGAGAAGTC
GAAAGATGAGTTGCCGTCAGAAATAAAAGCAAAGTTAGACGCAGCTTTTGAGAAGTTTAAAAAAGATACATTGAAACCAGGAC
AAAAGGTAGCAGAAGCTAAGAAGAAGGTTGAAGAAGCTAAGAAAAAAGCCGAGGATCAAAAAGAAGAAGATCGTCGTAACTAC
CCAACCAATACTTACAAAACGCTTGAACTTGAAATTGCTGAGTTCGATGTGAAAGTTAAAGAAGCGGAGCTTGAACTAGTAAA
AGAGGAAGCTAAAGAATCTCGAAACGAGGGCACAATTAAGCAAGCAAAAGAGAAAGTTGAGAGTAAAAAAGCTGAGGCTACAA
GGTTAGAAAAACATCAAGACAGATCGTAAAAAAGCAGAAGAAGAAGCTAAACGAAAAGCAGATGCTAAGTTGAAGGAAGCTAAT
GTAGCGACTTCAGATCAAGGTAAACCAAAGGGGCGGGCAAAACGAGGAGTTCCTGGAGAGCTAGCAACACCTGATAAAAAAGA
AAATGATGCGAAGTCTTCAGATTCTAGCGTAGGTGAAGAAACTCTTCCAAGCTCATCCCTGAAATCAGGAAAAAAGGTAGCAC
AAGCTGAGAAGAAGGTTGAAGAAGCTGAGAAAAAAGCCAAGGATCAAAAAGAAGAAGATCGCCGTAACTACCCAACCAATACT
TACAAAACGCTTGACCTTGAAATTGCTGAGTCCGATGTGAAAGTTAAAGAAGCGGAGCTTGAACTAGTAAAAGAGGAAGCTAA
GGAACCTCGAGACGAGGAAAAAAATTAAGCAAGCAAAAGCGAAAGTTGAGAGTAAAAAAGCTGAGGCTACAAGGTTAGAAAACA
TCAAGACAGATCGTAAAAAAGCAGAAGAAGAAGCTAAACGAAAAGCAGCAGAAGAAGATAAAGTTAAAGAAAAACCAGCTGAA
CAACCACAACCAGCGCCGGCTACTCAACCAGAAAAACCAGCTCCAAAACCAGAGAAGCCAGCTGAACAACCAAAAGCAGAAA
AACAGATGATCAACAAGCTGAAGAAGACTATGCTCGTAGATCAGAAGAAGAATATAATCGCTTGACTCAACAGCAACCGCCA
AAACTGAAAAACCAGCACAACCATCTACTCCAAAAACAGGCTGGAAACAAGAAAACGGTATGTGGTACTTCTACAATACTGAT
GGTTCAATGGCAACAGGATGGCTCCAAAACAACGGTTCATGGTACTATCTAAACGCTAATGGTGCTATGGCGACAGGATGGCT
CCAAAACAATGGTTCATGGTACTATCTAAACGCTAATGGTTCAATGGCAACAGGATGGCTCCAAAACAATGGTTCATGGTAC
ACCTAAACGCTAATGGTGCTATGGCGACAGGATGGCTCCAATACAATGGTTCATGGTACTACCTAAACAGCAATGGCGCTAT
GCGACAGGATGGCTCCAATACAATGGCTCATGGTACTACCTCAACGCTAATGGTGATATGGCGACAGGATGGCTCCAAAACA
CGGTTCATGGTACTACCTCAACGCTAATGGTGATATGGCGACAGGATGGCTCCAATACAACGGTTCATGGTATTACCTCAAC
CTAATGGTGATATGGCGACAGGTTGGGTGAAAGATGGAGATACCTGGTACTATCTTGAAGCATCAGGTGCTATGAAAGCAAG
CAATGGTTCAAAGTATCAGATAAATGGTACTATGTCAATGGCTCAGGTGCCCTTGCAGTCAACACAACTGTAGATGGCTATG
AGTCAATGCCAATGGTGAATGGGTAAACTAA

SeqID 297
ATGTTTGCATCAAAAAGCGAAAGAAAAGTACATTATTCAATTCGTAAATTTAGTGTTGGAGTAGCTAGTGTAGCTTGTTGCCA
TCTTGTTATGGGAAGTGTGGTTCATGCGACAGAGAACGAGGGAGCTACCCAAGTACCCACTTCTTCTAATAGGGCAAATGAA
GTCAGGCAGAACAAGGAGAACAACCTAAAAAACTCGATTCAGAACGAGATAAGGCAAGGAAAGAGGTCGAGGAATATGTAAA
AAAATAGTGGGTGAGAGCTATGCAAAATCAACTAAAAAGCGACATACAATTACTGTAGCTCTAGTTAACGAGTTGAACAACA
TAAGAACGAGTATTTGAATAAAATAGTTGAATCAACCTCAGAAAGCCAACTACAGATACTGATGATGGAGTCGATCAAAA
TAGATGAAGCTGTGTCTAAGTTTGAAAAGGACTCACCTTCTTCGTCAAGTTCAGACTCTTCCACTAAACCGGAAGXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXTTGCTGAGTCCGATGTGGAAGTTAAAAAAGCGGAGCTTGAACTAGTAAAA
AGGAAGCTAAGGAACCTCGAAACGAGGAAAAAGTTAAGCAAGCAAAAGCGGAAGTTGAGAGTAAAAAAGCTGAGGCTACAAG
TTAGAAAAAATCAAGACAGATCGTAAAAAAGCAGAAGAAGAAGCTAAACGAAAAGCAGCAGAAGAAGATAAAGTTAAAGAAA
ACCAGCTGAACAACCACAACCAGCGCCGGCTCCAAAAGCAGAAAAACCAGCTCCAAAACCAGAGAAGCCAGCTGAACAAC
AACCAAAAGCAGAAAAACCAGCTGATCAACAAGCTGAAGAAGACTATGCTCGTAGATCAGAAGAAGAATATAATCGCTTGAC
CAACAGCAACCGCCAAAACTGAAAAACCAGCACAACCATCTACTCCAAAAACAGGCTGGAAACAAGAAAACGGTATGTGGT
CTTCTACAATACTGATGGTTCAATGGCGACAGGATGGCTCCAAAACAATGGCTCATGGTACTACCTCAACAGCAATGGCGCT
TGGCGACAGGATGGCTCCAAAACAATGGTTCATGGTACTATCTAAACGCTAATGGTTCAATGGCAACAGGATGGCTCCAAAA
AATGGTTCATGGTACTACCTAAACGCTAATGGTTCAATGGCGACAGGATGGCTCCAATACAATGGCTCATGGTACTACCTAA
CGCTAATGGTTCAATGGCGACAGGATGGCTCCAATACAATGGCTCATGGTACTACCTAAACGCTAATGGTGATATGGCGACA
GTTGGGTGAAAGATGGAGATACCTGGTACTATCTTGAAGCATCAGGTGCTATGAAAGCAAGCCAATGGTTCAAAGTATCAGA
AAATGGTACTATGTCAATGGCTCAGGTGCCCTTGCAGTCAACACAACTGTAGATGGCTATGAGTCAATGCCAATGGTGAAT
GGTAAAC

SeqID 298
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXCTTGAAATTGCTGAGTCCGATGTGGAAGTTAAAAAAGCGGAG
TTGACTAGTAAAGAGGAAGCTAAGAAGCCTTTAAACGAGGGCACAATTAGGCAAGCAAAAGCGGAAGTTGAGAGTAAAAAAG
TGAGGCTACAAGGTTAGAAAAAAATCAAGACAGATCGTAAAAAAGCAGAAGAAGAAGCTAAACGAAGAGCAGCAGAAGAAGAT
AAGTTAAAGAAAAACCAGCTGAACAACCACAACCAGCGCCGGCCCCTCAACCAGAAAAACCAACTGAAGAGCCTGAGAATCC
GTTCCAGCTCCAAAACCAGAGAAGCCAGCTGAACAACCAAAAACCAGAGAAGCCAGCTGAACAACCAAAACCAGAGAAGCCAG

TGAACAACCAAAAGCAGAAAAAACAGATGATCAACAAGCTGAAGAAGACTATGCTCGTAGATCAGAAGAAGAATATAATCGCT
TGACTCAACAGCAACCGCAAAAACCAGAGCAACCAGCTCCTGCACCAAAAATAGGCTGGAAACAAGAAAACGGTATGTGGTAC
TTCTACAATACTGATGGTTCAATGGCGACAGGATGGCTCCAATACAATGGCTCATGGTATTACCTAAACGCTAACGGTTCAAT
GGCAACAGGTTGGGTGAAAGATGGAGATACCTGGTACTATCTTGAAGCATCAGGTGCTATGAAAGCAAGCCAATGGTTCAAAG
TATCAGATAAATGGTACTATGTCAATGGCTCAGGTGCCCTTGCAGTCAACACAACTGTAGATGGCTATGGAGTCAATGCCAAT
GGTGAATGGGTAAAC

SeqID 299
ATGTTTGCATCAAAAAGCGAAAGAAAAGTACATTATTCAATTCGTAAATTTAGTGTTGGAGTAGCTAGTGTAGCTGTTGCCAG
TCTTGTTATGGGAAGTGTGGTTCATGCGACAGAGAACGAGAGAACTACCCAAGTACCCACTTCTTCTAATAGGGGAAAGCCAG
AACGTAGGAAAGCTGCTGAACAATTCGATGAATATATAAACAAAATGATCCAATTAGATAAAAGAAAACATACCCAAAATTTA
GCCTTCAACATACAGTTGAGCAGAATTAAAACGGAGTATTTGAATGGATTAAAAGAGAAGTCGGAAGCTGAGTTGCCGTCAAA
AATAAAAGCAGAGTTAGACGCAGCTTTTTAAGCAGTTTAAAAAAGATACATTACCAACAGAACCAGAAAAAAAAGTAGCAGAAG
CTGAGAAGAAGGTTGAAGAAGCTGAGAAGAAGGTAGCAGAAGCTAAGAAAAAAGCCAAGGCTCAAAAAGAAGAAGATCACCGT
AACTACCCAACCATTACTTACAAAACGCTTGACCTTGAAATTGCTGAGTTCGATGTGAAAGTTAAAGAAGCGGAGCTTGAACT
AGTAAAAAAGGAAGCTGACGAATCTCGAAACGAGGGCACAATTAACCAAGCAAAAGCGAAAGTTGAGAGTGAAAAAGCTGAGC
CTACAAGGTTAAAAAAAAATCAAGACAGATCGTGAAAAAGCAGAAGAAGAAGCTAAACGAAGAGCAGATGCTAAAGAGCAA
GATGAATCAXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXATTGCTGAGTCCGATGTGAAAGTTAAAGAAGCGG
AGCTTGAACTAGTAAAAGAGGAAGCTAAGGAATCTCGAAACGAGGAAAAAATTAAGCAAGCAAAAGCGAAAGTTGAGAGTAAA
AAAGCTGAGGCTACAAGGTTAGAAAAAAATCAAGACAGATCGTAAAAAAGCAGAAGAAGAAGCTAAACGAAAAGCAGCAGAAGA
AGATAAAGTTAAAGAAAAACCAGCTGAACAACCACAACCAGCGCCGGCTCCAAAACCAGAGAATCCAGCTGAAGAGCCTGAGA
ATCCAGTTCCAGCTCCAAAACCAGAGAATCCAGCTGAACAACCAAAAGCAGAAAAACCAGCTGATCAACAAGCTGAAGAAGAC
TATGCTCGTAGATCAGAAGAAGAATATAATCGCTTGACTCAACAGCAACCGCCAAAACCAGAGCAACCAGCTCCTGCACCAAA
AATAGGCTGGAAACAAGAAAACGGTATGTGGTACTTCTACAATACTGATGGTTCAATGGCGACCGGATGGCTCCAAAACAATG
GCTCATGGTACTACCTCAACAGCAATGGCGCTATGGCGACAGGATGGCTCCAAAACAATGGTTCATGGTACTATCTAAACGCT
AATGGTTCAATGGCAACAGGATGGCTCCAAAACAATGGTTCATGGTACTACCTCAACGCTAATGGTGATATGGCGACAGGATC
GCTCCAATACAATGGCTCATGGTACTACCTCAACGCTAATGGTGATATGGCGACAGGATGGCTCCAATACAATGGCTCATGG
ACTACCTAAACGCTAATGGTGATATGGCGACAGGATGGCTCCAATACAATGGCTCATGGTACTATCTAAACGCTAATGGTGA
ATGGCGACAGGTTGGGTGAAAGATGGAGATACCTGGTACTATCTTGAAGCATCAGGTGCTATGAAAGCAAGCCAATGGTTCA
AGTATCAGATAAATGGTACTATGTCAATGGCTCAGGTGCCCTTGCAGTCAACACAACTGTAGACGGCTATGGAGTCAATGCC
ATGGTGAATGGGTAAAC

SeqID 300
ATGTTTGCATCAAAAAGCGAAAGAAAAGTACATTATTCAATTCGTAAATTTAGTATTGGAGTAGCTAGTGTAGCTGTTGCTAC
CTTGTTCTTAGGAGGAGTAGTCCATGCAGAAGGGGTTAGAAGTGAGAATACCCCCAAGGTTACATCTAGTGGGGATGAAGTCC
ATGAATATATAAAAAAAAAATGTTGAGTGAGATCCAATTAGATAAAAGAAAACATACCCACAATTTCGCCTTAAACCTAAAGTTC
AGCAGAATTAAAACGGAGTATTTGTATAAATTAAAAGTTAATGTTTTAGAAGAAAAGTCAAAAGCTGAGTTGACGTCAAAAA
AAAAAAAGAGGTAGACGCAGCTTTTTGAGAAGTTTAAAAAAAGATACATTGAAACTAGGAGAAAAGGTAGCAGAAGCACAGAAGA
AGGTTGAAGAAGCTAAGAAAAAAGCCAAGGATCAAAAAGAAGAAGATCACCGTAACTACCCAACCAATACTTACAAAACGCTT
GAACTTGAAATTGCTGAGTCCGATGTGAAAGTTAAAGAAGCGGAGCTTGAACTATTGAAAGAGGAAGCTAAAACTCGAAACGA
GGACACAATTAACCAAGCAAAAGCGAAAGTTAAGAGTGAACAAGCTGAGGCTACAAGGTTAAAAAAAATCAAGACAGATCGTC
AACAAGCTGAGGCTACAXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXATTGCTGAGTCCGATGTGAAAGTTA
AGAAGCGGAGCTTGAACTAGTAAAAGAGGAAGCTAAGGAACCTCGAGACGAGGAAAAAATTAAGCAAGCAAAAGCGGAAGTTC
AGAGTAAACAAGCTGAGGCTACAAGGTTAGAAAAAAATCAAGACAGATCGTAAAAAAGCAGAAGAAGAAGCTAAACGAAAAGCA
GCAGAAGAAGATAAAGTTAAAGAAAAACCAGCTGAACAACCACAACCAGCGCCGGCTCCTCAACCAGAAAAACCAACTCCAA
ACCAGAAAAACCAGCTCCAGCTCCAAAACCAGAGAATCCAGCTGAACAACCAAAAGCAGAAAAACCAGCTGATCAACAAGCT
AAGAAGACTATGCTCGTAGATCAGAAGAAGAATATAATCGCTTGACTCAACAGCAACCGCCAAAAACTGAAAAACCAGCACA
CCATCTACTCCAAAAACAGGCTGGAAACAAGAAAACGGTATGTGGTACTTCTACAATACTGATGGTTCAATGGCGACAGGAT
GCTCCAATACAATGGCTCATGGTACTACCTAAACGCTAATGGTGATATGGCGACAGGATGGCTCCAAAACAATGGTTCATGG
ACTACCTAAACGCTAATGGTGATATGGCGACAGGATGGCTCCAAAACAATGGTTCATGGTACTACCTAAACGCTAATGGTGA
ATGGCGACAGGATGGCTCCAAAACAATGGCTCATGGTACTACCTAAACGCTAATGGTGATATGGCGACAGGTTGGGTGAAAG
TGGAGATACCTGGTACTATCTTGAAGCATCAGGTGCTATGAAAGCAAGCCAATGGTTCAAAGCATCAGATAAATGGTACTAT
TCAATGGCTCAGGTGCCCTTGCAGTCAACACAACTGTAGATGGCTATGGAGTCAATGCCAATGGTGAATGGGTAAAC

SeqID 301
ATGTTTGCATCAAAAAGCGAAAGAAAAGTACATTATTCAATTCGTAAATTTAGTATTGGAGTAGCTAGTGTAGCTGTTGCCA
TCTTGTTATGGGAAGTGTGGTTCATGCGACAGAGAAGGAGGTAACTACCCAAGTACCCACTTATTCTAATATGGCAAAGACA
AACATAGGAAAGCTGCTAAACAAGTCGTCGATGAATATATAGAAAAAATGTTGAGGGAGATTCAATTAGATAGAAGAAAACA
ACCCAAAATTTCGCCTTCAACATGAAGTTGAGCGCAATTAAAACGGAGTATTTGTATGGATTAAAAGAGAAGTCGGAAGCTG
GTTGCCGTCATCGGAAGCTGAGTTGCCGTCAGAAGTAAAAAGCAAAGTTAGACGCAGCTTTTGAGCAGTTTAAAAAAGATACA
TGAAACTAGGAGAAAAGGTAGCAGAAGCTGAGAAGAAGGTTGCAGAAGCTGAGAAAAAGCCAAGGCTCAAAAAGAAGAAGAGA
CGCCGTAACTACCCAACCATTACTTACAAAACGCTTGACCTTGAAATTGCTGAGTCCGATGTGAAAGTTAAAAAAGCGGAGC
TGAACTATTGAAAGAGGAAGCTAAAACTCGAAACAAGGACACAATTAAGCAAGCAAAAGCGAAAGTTGAGAGTAAAAAAGCT
AGGCTACAAAGTTAGAAGAAATCAAGACAGATCGTAAAAAAGCAGAAGAAGAAGCTAXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXATTGCTGAGTCCGATGTGAAAGTTAAAGAAGCGGAGCTTGAACTAGTAAAAGAGGAAGCTAAGGAATC
CGAAACGAGGAAAAAGTTAAGCAAGCAAAAGCGAAAGTTGAGAGTAAAAAAGCTGAGGCTACAAGGTTAGAAAAAAATCAAGA
AGATCGTAAAAAAGCAGAAGAAGCTAAACGAAGAGCAGCAGAAGAAGATAAAGTTAAAGAAAAACCAGCTGAACAACCACAA
CAGCGCCGGCTCCTCAACCAGAAAAACCAACTGAAGAGCCTGAGAATCCAGCTCCAGCTCCAAAACCTGAGAAACCAGCTGA

```
CAACCAAAAGCAGAAAAACCAGCTGATCAACAAGCTGAAGAAGACTATGCTCGTAGATCAGAAGAAGAATATAATCGCTTGAC
TCAACAGCAACCGCCAAAAACTGAAAAACCAGCACAACCATCTACTCCAAAAACAGGCTGGAAACAAGAAAACGGTATGTGGT
ACTTCTACAATACTGATGGTTCAATGGCGACAGGATGGCTCCAAAACAATGGCTCATGGTACTACCTCAACAGCAATGGCGCT
ATGGCGACAGGATGGCTCCAATACAATGGTTCATGGTACTACCTCAACGCTAATGGTGATATGGCGACAGGATGGCTCCAAAA
CAATGGTTCATGGTACTACCTCAACGCTAATGGTGATATGGCGACAGGATGGCTCCAATACAATGGTTCATGGTACTACCTCA
ACGCTAATGGTGATATGGCGACAGGATGGCTCCAAAACAATGGCTCATGGTACTACCTAAACGCTAATGGTGATATGGCGACA
GGTTGGGTGAAAGATGGAGATACCTGGTACTATCTTGAAGCATCAGGTGCTATGAAAGCAAGCCAATGGTTCAAAGTATCAGA
TAAATGGTACTATGTCAATGGCTCAGGTGCCCTTGCAGTCAACACAACTGTAGATGGCTATGGAGTCAATGCCAATGGTGAAT
GGGTAACC
```

SeqID 302
```
ATGTTTGCATCAAAAAGCGAAAGAAAAGTACATTATTCAATTCGTAAATTTAGTATTGGAGTAGCTAGTGTAGCTGTTGCTAG
CTTGTTCTTAGGAGGAGTAGTCCATGCAGAAGGGGTTAGAAGTGAGAATACCCCCAAGGTTACATCTAGTGGGGATGAAGTCG
ATGAATATATAAAAAAAAATGTTGAGTGAGATCCAATTAGATAAAAGAAAACATACCCACAATTTCGCCTTAAACCTAAAGTTG
AGCAGAATTAAAACGGAGTATTTGTATAAAATTAAAAGTTAATGTTTTAGAAGAAAAGTCAAAAGCTGAGTTGACGTCAAAAAC
AAAAAAAGAGGTAGACGCAGCTTTTGAGAAGTTTAAAAAAAGATACATTGAAACTAGGAGAAAAGGTAGCAGAAGCTCAGAAGA
AGGTTGAAGAGCTAAGAAAAAAAGCCAAGGATCAAAAAGAAGAAGATCACCGTAACTACCCAACCAATACTTACAAAACGCTI
GAACTTGAAATTGCTGAGTCCGATGTGAAAGTTAAAGAAGCGGAGCTTGAACTATTGAAAGAGGAAGCTAAAACTCGAAACGA
GGACACAATTAACCAAGCAAAAGCGAAAGTTAAGAGTGAACAAGCTGAGGCTACAAGGTTAAAAAAAATCAAGACAGATCGTG
AACAAGCTGAGGCTACAAGGTTAGAAAACATCAAGACAGATCGTGAAAAAAGCAGAAGAAGAAGCTAAACGAAAAGCAGAAXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXCTTGAAATTGCTGAGTCCGATGTGAAAGTTAAAGAAGCGGAGCTTGAAC
TAGTAAAAGAGGAAGCTAAGGAATCTCGAAACGAGGAAAAAGTTAAGCAAGCAAAAGCGAAAGTTGAGAGTAAACAAGCTGAC
GCTACAAGGTTAGAAAAAATCAAGACAGATCGTAAAAAAGCAGAAGAAGAAGCTAAACGAAAAGCAGCAGAAGAAGATAAAG]
TAAAGAAAAACCAGCTGAACAACCACAACCAGCGCCGGCTCCTCAACCAGAAAAACCAGCTCCAGCTCCAAAACCAGAGAATC
CAGCTGAACAACCAAAAGCAGAAAAACCAGCTGATCAACAAGCTGAAGAAGACTATGCTCGTAGATCAGAAGAAGAATATAAT
CGCTTGACTCAACAGCAACCGCCAAAAACTGAAAAACCAGCACAACCATCTACTCCAAAAACAGGCTGGAAACAAGAAAACGC
TATGTGGTACTTCTACAATACTGATGGTTCAATGGCGACAGGATGGCTCCAATACAATGGCTCATGGTACTACCTAAACGCTI
ATGGTGATATGGCGACAGGATGGCTCCAAAACAATGGTTCATGGTACTACCTAAACGCTAATGGTGATATGGCGACAGGATGC
CTCCAAAACAATGGCTCATGGTACTACCTAAACGCTAATGGTGATATGGCGACAGGATGGCTCCAAAACAATGGCTCATGGTA
CTACCTAAACGCTAATGGTGATATGGCGACAGGTTGGGTGAAAGATGGAGATACCTGGTACTATCTTGAAGCATCAGGTGCTI
TGAAAGCAAGCCAATGGTTCAAAGCATCAGATAAATGGTACTATGTCAATGGCTCAGGTGCCCTTGCAGTCAACACAACTGTI
GATGGCTATGGAGTCAATGCCAATGGTGAATGGGTAAAC
```

SeqID 303
```
ATGTTTGCATCAAAAAGCGAAAGAAAAGTACATTATTCAATTCGTAAATTTAGTATTGGAGTAGCTAGTGTAGCTGTTGCCAC
TCTTTTTATGGGAAGTGTGGTTCATGCGACAGAGAAGGAGGTAACTACCCAAGTAGCCACTTCTTCTAATAAGGCAAATAAAI
GTCAGACAGAACATATGAAAGCTGCTAAACAAGTCGATGAATATATAAAAAAAAAAGCTCCAATTAGATAGAAGAAAAACATAC(
CAAAATGTCGGCTTACTCACAAAGTTGGGCGTAATTAAAACGGAGTATTTGCATGGATTAAGTGTTTCAAAAAAGAAGTCGGI
AGCTGAGTTGCCGTCAGAAATAAAAGCAAAGTTAGACGCAGCTTTTGAGCAGTTTAAAAAAAGATACATTACCAACAGAACCA(
GAAAAAAGGTAGCAGAAGCTGAGAAGAAGGTTGAAGAAGCTAAGAAAAAAGCCGAGGATCAAAAAGAAAAAGATCTCCGTAA(
TACCCAACCAATACTTACAAAACGCTTGAACTTGACATTGCTGAGTCCGATGTGGAAGTTAAAAAAGCGGAGCTTGAACTAG]
AAAAGGGAGCTACAGGAATCTCGAGACGAGAAAAAAATTAATCAAGCAAAGCGAAAAGTTGAGAATAAAAAAGCTGATGCTA(
AAGGXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXGTCCAAAACGGTATGTGGTACTTCTACAATACTGATGG!
TCAATGGCAACAGGCTGCTCCAAAACAATGGCTCATGGTACTACCTCAACAGCAATGGCGCTATGGCGACAGGATGGCTCC;
AAACAATGGCTCATGGTACTACCTCAACAGCAATGGCGCTATGGCGACAGGATGGCTCCAATACAATGGTTCATGGTACTAC(
TCAACGCTAATGGTGATATGGCGACAGGATGGTTCCAATACAATGGTTCATGGTACTACCTCAACGCTAATGGTGATATGGC(
ACAGGATGGTTCCAATACAATGGTTCATGGTACTACCTCAACGCTAATGGTGATATGGCGACAGGATGGCTCCAATACAATG(
TTCATGGTACTACCTCAACGCTAATGGTGATATGGCGACAGGATGGCTCCAATACAATGGTTCATGGTACTACCTAAACAGC]
ATGGTGCTATGGTAACAGGATGGCTCCAAAACAATGGCTCATGGTACTACCTAAACGCTAACGGTTCAATGGCAACAGATTG(
GTGAAAGATGGAGATACCTGGTACTATCTTGAAGCATCAGGTGCTATGAAAGCAAGCCAATGGTTCAAAGTATCAGATAAAT(
GTACTATGTCAATGGCTCAGGTGCCCTTGCAGTCAACACAACTGTAGATAGCTATAGAGTCAATGCCAATGGTGAATGGGTA]
AC
```

SeqID 304
```
MKKKILASLLLSTVMVSQVAVLTTAHAETTDDKIAAQDNKISNLTAQQQEAQKQVDQIQEQVSAIQAEQSNLQAENDRLQAE!
KKLEGEITELSKNIVSRNQSLEKQARSAQTNGAVTSYINTIVNSKSITEAISRVAAMSEIVSANNKMLEQQKADKKAISEKQ'
ANNDAINTVIANQQKLADDAQALTTKQAELKAAELSLAAEKATAEGEKASLLEQKAAAEAEARAAAVAEAAYKEKRASQQQS'
LASANTNLTAQVQAVSESAAAPVRAKVRPTYSTNASSYPIGECTWGVKTLAPWAGDYWGNGAQWATSAAAAGFRTGSTPQVG.
IACWNDGGYGHVAVVTAVESTTRIQVSESNYAGNRTIGNHRGWFNPTTTPEGFVTYIYAD
```

SeqID 305
```
MKKKILASLLLSTVMVSQVAVLTTAHAETTDDKIAAQDNKISNLTAQQQEAQKQVDQIQEQVSAIQAEQSNLQAENDRLQAE!
KKLEGEITELSKNIVSRNQSLEKQARSAQTNGAVTSYINTIVNSKSITEAISRVAAMSEIVSANNKMLEQQKADKKAISEKQ'
ANNDAINTVIANQQKLADDAQALTTKQAELKAAELSLAAEKATAEGEKASLLEQKAAAEAEARAAAVAEAAYKEKRAGQQQS'
LASANTNLTAQVQAVSESAAAPVRAKVRPTYSTNASSYPIGECTWGVKTLAPWAGDYWGNGAQWATSAAAAGFRTGSTPQVG.
IACWNDGGYGHVAVVTAVESTTRIQVSESNYAGNRTIGNHRGWFNPTTTSEGFVTYIYAD
```

SeqID 306

MIQIGKIFAGRYRIVKQIGRGGMADVYLAKDLILDGEEVAVKVLRTNYQTDPIAVARFQREARAMADLDHPHIVRITDIGEEL
GQQYLAMEYVAGLDLKRYIKEHYPLSNEEAARIMGQILLAMRLAHTRGIVHRDLKPQNILLTPDGTAKVTDFGIAVAFAETSI
TQTNSMLGSVHYLSPEQAGGSKATVQSDIYAMGIIFYEMLTGHIPYDGDSAVTIALQHFQKPLPSVIAENPSVPQALENVIIK
ATAKKLTNRYRSVSEMYVDLSSSLSYNRRNESKLIFDETSKADTKTLPKVSQSTLTSIPKVQAQTEHKSIKNPSQAVTEETYQ
PQAPKKHRFKMRYLILLASLVLVAASLIWILSRTPATIAIPDVAGQTVAEAKATLKKANFEIGEEKTEASEKVEEGRIIRTDI
GAGTGRKEGTKINLVVSSGKQSFQISNYVGRKSSDVIAELKEKKVPDNLIKIEEEESNESEAGTVLKQSLPEGTTYDLSKATQ
IVLTVAKKVTSVAMPSYIGSSLEFTKNNLIQIVGIKEANIEVVEVTTAPAGSAEGMVVEQSPRAGEKVDLNKTRVKISIYKPF
TTSATP

SeqID 307
MIQIGKIFAGRYRIVKQIGRGGMADVYLAKDLILDGEEVAVKVLRTNYQTDPIAVARFQREARAMADLDHPHIVRITDIGEEL
GQQYLAMEYVAGLDLKRYIKEHYPLSNEEAVRIMGQILLAMRLAHTRGIVHRDLKPQNILLTPDGTAKVTDFGIAVAFAETSI
TQTNSMLGSVHYLSPEQARGSKATVQSDIYAMGIIFYEMLTGHIPYDGDSAVTIALQHFQKPLPSVIAENPSVPQALENVIIF
ATAKKLTNRYRSVSEMYVDLSSSLSYNRRNESKLIFDETSKADTKTLPKVSQSTLTSIPKVQAQTEHKSIKNPSQAVTEETYQ
PQAPKKHRFKMRYLILLASLVLVAASLIWILSRTPATIAIPDVAGQTVAEAKATLKKANFEIGEEKTEASEKVEEGRIIRTDI
GAGTGRKEGTKINLVVSSGKQSFQISNYVGRKSSDVIAELKEKKVPDNLIKIEEEESNESEAGTVLKQSLPEGTTYDLSKATQ
IVLTVAKKATTIQLGNYIGRNSTEVISELKQKKVPENLIKIEEEESSESEPGTIMKQSPGAGTTYDVSKPTQIVLTVAKKVTS
VAMPSYIGSSLEFTKNNLIQIVGIKEANIEVVEVTTAPAGSVEGMVVEQSPRAGEKVDLNKTRVKISIYKPKTTSATP

SeqID 308
MIQIGKIFAGRYRIVKQIGRGGMADVYLAKDLILDGEEVAVKVLRTNYQTDPIAVARFQREARAMADLDHPHIVRITDIGEEI
GQQYLAMEYVAGLDLKRYIKEHYPLSNEEAVRIMGQILLAMRLAHTRGIVHRDLKPQNILLTPDGTAKVTDFGIAVAFAETSI
TQTNSMLGSVHYLSPEQARGSKATVQSDIYAMGIIFYEMLTGHIPYDGDSAVTIALQHFQKPLPSVIAENPSVPQALENVIII
ATAKKLTNRYRSVSEMYVDLSSSLSYNRRNESKLIFDETSKADTKTLPKVSQSTLTSIPKVQAQTEHKSIKNPSRAVTEETYQ
PQAPKKHRFKMRYLILLASLVLVAASLIWILSRTPATIAIPDVAGQTVAEAKATLKKANFEIGEEKTEASEKVEEGRIIRTDI
GAGTGRKEGTKINLVVSSGKQSFQISNYVGRKSSDVIAELKEKKVPDNLIKIEEEESNESEAGTVLKQSLPEGTTYDLSKATQ
IVLTVAKKATTIQLGNYIGRNSTEVISELKQKKVPENLIKIEEEESSESEPGTIMKQSPGAGTTYDVSKPTQIVLTVAKKVTS
VAMPSYIGSSLEFTKNNLIQIVGIKEANIEVVEVTTAPAGSAEGMVVEQSPRAGEKVDLNKTRVKTSIYKPKTTSATP

SeqID 309
MIQIGKIFAGRYRIVKQIGRGGMADVYLAKDLILDGEEVAVKVLRTNYQTDPIAVARFQREARAMADLDHPHIVRITDIGEEI
GQQYLAMEYVAGLDLKRYIKEHYPLSNEEAVRIMGQILLAMRLAHTRGIVHRDLKPQNILLTPDGTAKVTDFGIAVAFAETSI
TQTNSMLGSVHYLSPEQARGSKATVQSDIYAMGIIFYEMLTGHIPYDGDSAVTIALQHFQKPLPSVIAENPSVPQALENVIII
ATAKKLTNRYRSVSEMYVDLSSSLSYNRRNESKLIFDETSKADTKTLPKVSQSTLTSIPKVQAQTGHKSIKNPSQAVTEETYQ
PQAPKKHRFKMRYLILLASLVLVAASLIWILSRTPATIAIPDVAGQTVAEAKATLKKANFEIGEEKTEASEKVEEGRIIRTDI
GAGTGRKEGTKINLVVSSGKQSFQISNYVGRKSSDVIAELKEKKVPDNLIKIEEEESNESEAGTVLKQSLPEGTTYDLSKATQ
IILTVAKKATTIQLGNYIGRNSTEVISELKQKKVPENLIKIEEEESSESEPGTIMKQSPGAGTTYDVSKPTQIVLTVAKKVTS
VAMPSYIGSSLEFTKNNLIQIVGIKEANIEVVEVTTAPAGSAEGMVVEQSPRAGEKVDLNKTRVKISIYKPKTTSATP

SeqID 310
MIQIGKIFAGRYRIVKQIGRGGMADVYLAKDLILDGEEVAVKVLRTNYQTDPIAVARFQREARAMADLDHPHIVRITDIGEEl
GQQYLAMEYVAGLDLKRYIKEHYPLSNEEAVRIMGQILLAMRLAHTRGIVHRDLKPQNILLTPDGTAKVTDFGIAVAFAETSI
TQTNSMLGSVHYLSPEQARGSKATVQSDIYAMGIIFYEMLTGHIPYDGDSAVTIALQHFQNPLPSVIAENSSVPQALENVIII
ATAKKLTNRYRSVSEMYVDLSSSLSYNRRNESKLIFDETSKADTKTLPKVSQSTLTSIPKVQAQTEHKSIKNPSQAVTEETYQ
PQAPKKHRFKMRYLILLASLVLVAASLIWILSRTPATIAIPDVAGQTVAEAKATLKKANFEIGEEKTEASEKVEEGRIIRTDI
GAGTGRKEGTKINLVVSSGKQSFQISNYVGRKSSDVIAELKEKKVPDNLIKIEEEESNESEAGTVLKQSLPEGTTYDLSKATQ
IVLTVAKKATTIQLGNYIGRNSTEVISELKQKKVPENLIKIEEEESSESEPGTIMKQSPGAGTTYDVSKPTQIVLTVAKKVTS
VAMPSYIGSSLEFTKNNLIQIVGIKEANIEVVEVTTAPAGSVEGMVVEQSPRAGEKVDLNKTRVKISIYKPKTTSATP

SeqID 311
MFASKSERKVHYSIRKFSIGVASVAVASLVMGSVVHATENEGSTQAATSSNMAKTEHRKAAKQVVDEYIEKMLREIQLDRRKI
TQNVALNIKLSAIKTKYLRELNVLEEKSKDELPSEIKAKLDAAFEKFKKDTLKPGEKVAEAKKKVEEAKKKAEDQKEEDRRN
PTNTYKTLELEIAEFDVKVKEAELELVKEEAKESRNEGTIKQAKEKVESKKAEATRLENIKTDRKKAEEEAKRKADAKLKEAl
VATSDQGKPKGRAKRGVPGELATPDKKENDAKSSDSSVGEETLPSSSLKSGKKVAEAEKKVEEAEKKAKDQKEEDRRNYPTNT
YKTLDLEIAESDVKVKEAELELVKEEAKEPRDEEKIKQAKAKVESKKAEATRLENIKTDRKKAEEEAKRKAAEEDKVKEKPA:
QPQPAPATQPEKPAPKPEKPAEQPKAEKTDDQQAEEDYARRSEEEYNRLTQQQPPKTEKPAQPSTPKTGWKQENGMWYFYNTI
GSMATGWLQNNGSWYYLNANGAMATGWLQNNGSWYYLNANGSMATGWLQNNGSWYYLNANGAMATGWLQYNGSWYYLNSNGAl
ATGWLQYNGSWYYLNANGDMATGWLQNNGSWYYLNANGDMATGWLQYNGSWYYLNANGDMATGWVKDGDTWYYLEASGAMKA:
QWFKVSDKWYYVNGSGALAVNTTVDGYGVNANGEWVN

SeqID 312
MFASKSERKVHYSIRKFSVGVASVVVASLVMGSVVHATENEGATQVPTSSNRANESQAEQGEQPKKLDSERDKARKEVEEYV:
KIVGESYAKSTKKRHTITVALVNELNNNIKNEYLNKIVESTSESQLQILMMESRSKVDEAVSKFEKDSPSSSSSDSSTKPEXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXAESDVEVKKAELELVKEEAKEPRNEEKVKQAKAEV:
SKKAEATRLEKIKTDRKKAEEEAKRKAAEEDKVKEKPAEQPQPAPAPKAEKPAPAPKPENPAEQPKAEKPADQQAEEDYARR:
EEEYNRLTQQQPPKTEKPAQPSTPKTGWKQENGMWYFYNTDGSMATGWLQNNGSWYYLNSNGAMATGWLQNNGSWYYLNANG:
MATGWLQNNGSWYYLNANGSMATGWLQYNGSWYYLNANGSMATGWLQYNGSWYYLNANGDMATGWVKDGDTWYYLEASGAMK:
SQWFKVSDKWYYVNGSGALAVNTTVDGYGVNANGEWVN

SeqID 313
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXLKLLSPMWKLKKRSLTSKEEAKKPLNEGTIRQ
AKAEVESKKAEATRLEKIKTDRKKAEEEAKRRAAEEDKVKEKPAEQPQPAPAPQPEKPTEEPENPVPAPKPEKPAEQPKPEKP
AEQPKPEKPAEQPKAEKTDDQQAEEDYARRSEEEYNRLTQQQPQKPEQPAPAPKIGWKQENGMWYFYNTDGSMATGWLQYNGS
WYYLNANGSMATGWVKDGDTWYYLEASGAMKASQWFKVSDKWYYVNGSGALAVNTTVDGYGVNANGEWVN

SeqID 314
MFASKSERKVHYSIRKFSVGVASVAVASLVMGSVVHATENERTTQVPTSSNRGKPERRKAAEQFDEYINKMIQLDKRKHTQNL
AFNIQLSRIKTEYLNGLKEKSEAELPSKIKAELDAAFKQFKKDTLPTEPEKKVAEAEKKVEEAEKKVAEAKKKAKAQKEEDHR
NYPTITYKTLDLEIAEFDVKVKEAELELVKKEADESRNEGTINQAKAKVESEKAEATRLKKIKTDREKAEEEEAKRRADAKEQ
DESXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXIAESDVKVKEAELELVKEEAKESRNEEKIK
QAKAKVESKKAEATRLEKIKTDRKKAEEEAKRKAAEEDKVKEKPAEQPQPAPAPKPENPAEEPENPVPAPKPENPAEQPKAEK
PADQQAEEDYARRSEEEYNRLTQQQPPKPEQPAPAPKIGWKQENGMWYFYNTDGSMATGWLQNNGSWYYLNSNGAMATGWLQN
NGSWYYLNANGDMATGWLQYNGSWYYLNANGDMATGWLQYNGSWYYLNANGDMATGWLQYNGSWYYLNANGDMATGWVKDGDT
WYYLEASGAMKASQWFKVSDKWYYVNGSGALAVNTTVDGYGVNANGEWVN

SeqID 315
MFASKSERKVHYSIRKFSIGVASVAVASLFLGGVVHAEGVRSENTPKVTSSGDEVDEYIKKMLSEIQLDKRKHTHNFALNLKI
SRIKTEYLYKLKVNVLEEKSKAELTSKTKKEVDAAFEKFKKDTLKLGEKVAEAQKKVEEAKKKAKDQKEEDHRNYPTNTYKTI
ELEIAESDVKVKEAELELLKEEAKTRNEDTINQAKAKVKSEQAEATRLKKIKTDREQAEATXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXIAESDVKVKEAELELVKEEAKEPRDEEKIKQAKAEVESKQAEATRLEKIKTDRKK
AEEEAKRKAAEEDKVKEKPAEQPQPAPAPQPEKPTPKPEKPAPAPKPENPAEQPKAEKPADQQAEEDYARRSEEEYNRLTQQQ
PPKTEKPAQPSTPKTGWKQENGMWYFYNTDGSMATGWLQYNGSWYYLNANGDMATGWLQNNGSWYYLNANGDMATGWLQNNGS
WYYLNANGDMATGWLQNNGSWYYLNANGDMATGWVKDGDTWYYLEASGAMKASQWFKASDKWYYVNGSGALAVNTTVDGYGVN
ANGEWVN

SeqID 316
MFASKSERKVHYSIRKFSIGVASVAVASLVMGSVVHATEKEVTTQVPTYSNMAKTEHRKAAKQVVDEYIEKMLREIQLDRRKH
TQNFAFNMKLSAIKTEYLYGLKEKSEAELPSSEAELPSEVKAKLDAAFEQFKKDTLKLGEKVAEAEKKVAEAEKKAKAQKEEI
RRNYPTITYKTLDLEIAESDVEVKKAELELLKEEAKTRNKDTIKQAKAKVESKKAEATKLEEIKTDRKKAEEEAXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXIAESDVKVKEAELELVKEEAKESRNEEKVKQAKAKVESKKAE
ATRLEKIKTDRKKAEEEAKRRAAEEDKVKEKPAEQPQPAPAPQPEKPTEEPENPAPAPKPEKPAEQPKAEKPADQQAEEDYARF
SEEEYNRLTQQQPPKTEKPAQPSTPKTGWKQENGMWYFYNTDGSMATGWLQNNGSWYYLNSNGAMATGWLQYNGSWYYLNANG
DMATGWLQNNGSWYYLNANGDMATGWLQYNGSWYYLNANGDMATGWLQNNGSWYYLNANGDMATGWVKDGDTWYYLEASGAMF
ASQWFKVSDKWYYVNGSGALAVNTTVDGYGVNANGEWVN

SeqID 317
MFASKSERKVHYSIRKFSIGVASVAVASLFLGGVVHAEGVRSENTPKVTSSGDEVDEYIKKMLSEIQLDKRKHTHNFALNLKI
SRIKTEYLYKLKVNVLEEKSKAELTSKTKKEVDAAFEKFKKDTLKLGEKVAEAQKKVEEAKKKAKDQKEEDHRNYPTNTYKTI
ELEIAESDVKVKEAELELLKEEAKTRNEDTINQAKAKVKSEQAEATRLKKIKTDREQAEATRLENIKTDREKAEEEAKRKAEX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXLEIAESDVKVKEAELELVKEEAKESRNEEKVKQAF
AKVESKQAEATRLEKIKTDRKKAEEEAKRKAAEEDKVKEKPAEQPQPAPAPQPEKPAPAPKPENPAEQPKAEKPADQQAEED
ARRSEEEYNRLTQQQPPKTEKPAQPSTPKTGWKQENGMWYFYNTDGSMATGWLQYNGSWYYLNANGDMATGWLQNNGSWYYLN
ANGDMATGWLQNNGSWYYLNANGDMATGWLQNNGSWYYLNANGDMATGWVKDGDTWYYLEASGAMKASQWFKASDKWYYVNGS
GALAVNTTVDGYGVNANGEWVN

SeqID 318
MFASKSERKVHYSIRKFSIGVASVAVASLFMGSVVHATEKEVTTQVATSSNKANKSQTEHMKAAKQVDEYIKKKLQLDRRKH
QNVGLLTKLGVIKTEYLHGLSVSKKKSEAELPSEIKAKLDAAFEQFKKDTLPTEPGKKVAEAEKKVEEAKKKAEDQKEKDLRN
YPTNTYKTLELDIAESDVEVKKAELELVKGSYRNLETRKKLIKQSEKLRIKKLMLQXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXVQNGMWYFYNTDGSMATGWLQNNGSWYYLNSNGAMATGWLQNNGSWYYLNSNGAMATGWI
QYNGSWYYLNANGDMATGWFQYNGSWYYLNANGDMATGWFQYNGSWYYLNANGDMATGWFQYNGSWYYLNANGDMATGWLQYN
GSWYYLNSNGAMVTGWLQNNGSWYYLNANGSMATDWVKDGDTWYYLEASGAMKASQWFKVSDKWYYVNGSGALAVNTTVDSYI
VNANGEWVN

Note: "X" represents undefined/missing nucleotides or amino acides due t
unavailable sequencing information.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁷: C07K 14/315,
16/12, 19/00, 16/46, C12N 5/12, 15/02, A61K 39/09,
C12Q 1/68, G01N 33/569, A61P 31/04

(21) International Application Number:
PCT/EP2004/003984

(22) International Filing Date: 15 April 2004 (15.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03450087.6   15 April 2003 (15.04.2003)   EP

(71) Applicant (for all designated States except US): INTER-
CELL AG [AT/AT]; Campus Vienna Biocenter 6, A-1030
Vienna (AT).

(72) Inventors; and
(75) Inventors/Applicants (for US only): MEINKE, Andreas
[DE/AT]; Piettegasse 26/1, A-3013 Pressbaum (AT).
NAGY, Eszter [HU/AT]; Taborstrasse 9, A-1020 Vienna
(AT). HANNER, Markus [AT/AT]; Jacquingasse 5/6,
A-1030 Vienna (AT). DEWASTHALY, Shailesh [IN/AT];
Anschützgasse 23/10, A-1150 Vienna (AT). STIER-
SCHNEIDER, Ulrike [AT/AT]; Kaiserstrasse 66/2/14,
A-1070 Vienna (AT).

(74) Agent: SONN & PARTNER; Riemergasse 14, A-1010
Vienna (AT).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
—   as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
—   of inventorship (Rule 4.17(iv)) for US only

Published:
—   with international search report
—   before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
9 December 2004

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: S. PNEUMONIAE ANTIGENS

(57) Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or
a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. pneumoniae, methods for isolating
such antigens and specific uses thereof.

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7   C07K14/315   C07K16/12   C07K19/00   C07K16/46   C12N5/12
C12N15/02   A61K39/09   C12Q1/68   G01N33/569   A61P31/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7   C07K   A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBL, EMBASE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/083855 A (CHAKRAVARTI DEB NARAYAN ; RUSSELL DAVID PARRISH (US); WOOTERS JOSEPH L) 24 October 2002 (2002-10-24) page 85, line 15 – page 108, line 4 claims 1-11,25-28,59-71,96,105 see in particular SEQ ID Nos. 209 and 424.	1,2, 5-11, 14-37
X	WO 02/077021 A (CHIRON SPA ; MASIGNANI VEGA (IT); FRASER CLAIRE (US); TETTELIN HERVE () 3 October 2002 (2002-10-03) page 8, line 30 – page 34, line 40 see in particular SEQ ID Nos. 4715 and 4716. claims 1-16	1,2, 5-11, 14-37

-/--

| X | Further documents are listed in the continuation of box C. | | X | Patent family members are listed in annex. |

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
25 August 2004	25. 10. 2004

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Ulbrecht, M

Form PCT/ISA/210 (second sheet) (January 2004)

7

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HOSKINS J ET AL: "Genome of the Bacterium Streptococcus pneumoniae Strain R6" JOURNAL OF BACTERIOLOGY, WASHINGTON, DC, US, vol. 183, no. 19, October 2001 (2001-10), pages 5709-5717, XP002231307 ISSN: 0021-9193 cited in the application the whole document	1,2, 5-11, 14-37
X	-& DATABASE EMBL EBI; 7 September 2001 (2001-09-07), HOSKINS ET AL.: "Streptococcus pneumoniae R6 section 1" XP002293255 retrieved from HTTP://WWW.EBI.AC.UK Database accession no. AE008385 cited in the application the whole document	1,2, 5-11, 14-37
X	TETTELIN H ET AL: "Complete genome sequence of a virulent isolate of Streptococcus pneumoniae" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 293, no. 5529, 2001, pages 498-506, XP002218261 ISSN: 0036-8075 cited in the application the whole document	1,2, 5-11, 14-37
X	-& DATABASE EMBL EBI; 31 July 2001 (2001-07-31), TETTELIN ET AL.: "Streptococcus pneumoniae TIGR4 section 1" XP002293256 retrieved from HTTP://WWW.EBI.AC.UK Database accession no. AE007318 cited in the application the whole document	1,2, 5-11, 14-37
A	NABORS G S ET AL: "Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 18, no. 17, March 2000 (2000-03), pages 1743-1754, XP004190054 ISSN: 0264-410X the whole document	1,2, 5-11, 14-37

-/--

7

Form PCT/ISA/210 (continuation of second sheet) (January 2004)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BETHE GESINA ET AL: "The cell wall-associated serine protease PrtA: A highly conserved virulence factor of Streptococcus pneumoniae" FEMS MICROBIOLOGY LETTERS, vol. 205, no. 1, 27 November 2001 (2001-11-27), pages 99-104, XP002293235 ISSN: 0378-1097 the whole document	1,2, 5-11, 14-37
A	WIZEMANN T M ET AL: "Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection" INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 69, no. 3, March 2001 (2001-03), pages 1593-1598, XP002263818 ISSN: 0019-9567 the whole document	1,2, 5-11, 14-37
A	OVERWEG K ET AL: "The putative proteinase maturation protein A of Streptococcus pneumoniae is a conserved surface protein with potential to elicit protective immune responses" INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 68, no. 7, July 2000 (2000-07), pages 4180-4188, XP002158137 ISSN: 0019-9567 the whole document	1,2, 5-11, 14-37
A	WO 02/059148 A (CISTEM BIOTECHNOLOGIES GMBH ; AHSEN UWE (AT); ETZ HILDEGARD (AT); HAFN) 1 August 2002 (2002-08-01) the whole document	1,2, 5-11, 14-37

7

INTERNATIONAL SEARCH REPORT

Box II   Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
   because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
   because they relate to parts of the International Application that do not comply with the prescribed requirements to such
   an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III   Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple Inventions in this International application, as follows:

   see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
   searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
   of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
   covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
   restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

   see annex

Remark on Protest   ☐ The additional search fees were accompanied by the applicant's protest.

                               ☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (2)) (January 2004)

.FURTHER INFORMATION CONTINUED FROM   PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions tn this international application, as follows:

Invention 1: claims 1,2,5-11,14-37 (all partially)

> An isolated nucleic acid molecule encoding a hyperimmune serum-reactive antigen or fragment thereof as defined in claim 1, but referring only to SEQ ID No. 1; a vector comprising said nucleic acid molecule; a host cell comprising said vector; a hyperimmune serum-reactive antigen comprising the amino acid sequence of SEQ ID No. 145; a fragment of the said hyperimmune serum-reactive antigen as defined in claim 14; a method of producing the said S. pneumoniae hyperimmune serum-reactive antigen or fragment thereof; a process for producing a cell which expresses the said S. pneumoniae hyperimmune serum-reactive antigen or fragment thereof; the use of the said nucleic acid molecule or the said hyperimmune serum-reactive antigen or fragment thereof for the manufacture of a pharmaceutical preparation; an antibody, or at least an effective part thereof which binds at least to a selective part of the said hyperimmune serum-reactive antigen or fragment thereof; a hybridoma cell line which produces the said antibody; a method of producing the said antibody; the use of said antibody for the preparation of a medicament for treating or preventing S. pneumoniae infections; an antagonist which binds to the said hyperimmune serum-reactive antigen or. fragment thereof; a method of identifying an antagonist capable of binding to the said hyperimmune serum-reactive antigen or of reducing or inhibiting the interaction activity of the said hyperimmune serum-reactive antigen or fragment thereof; the use of the said hyperimmune serum-reactive antigen or fragment thereof for the isolation and/or purification and/or identification of an interaction partner; a process for in vitro diagnosing a disease or a bacterial infection based on determining the presence of the said nucleic acid sequence or the presence of the said hyperimmune serum-reactive antigen or fragment thereof; the use of said hyperimmune serum-reactive antigen or fragment thereof for the generation of a peptide binding thereto i.e. an anticaline, for the manufacture of a functional nucleic acid i.e. an aptamer or a spiegelmer, or of a functional ribonucleic acid i.e. a ribozyme, an antisense nucleic acid or a siRNA.

> ———

Inventions 2-45: claims 1,2,5-11,14-37 (all partially)

> Idem as invention 1, but each of the inventions 2-45 referring to one of the further SEQ ID Nos. mentioned in claim 1 together with its respective corresponing SEQ ID No. according to claim 11.

> ———

Inventions 46-121: claims 3-10,12,14-37 (all partially)

FURTHER INFORMATION CONTINUED FROM   PCT/ISA/ 210

Idem as invention 1, but each of the inventions 46-121
referring to one of the SEQ ID Nos. mentioned in claim 3
together with its respective corresponing SEQ ID No.
according to claim 12.

Inventions 122-133: claims 4-10,13-37 (all partially)

Idem as invention 1, but each of the inventions 122-133
referring to one of the SEQ ID Nos. mentioned in claim 4
together with its respective corresponing SEQ ID No.
according to claim 13.

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 02083855	A	24-10-2002	CA	2444133 A1	24-10-2002
			WO	02083855 A2	24-10-2002
WO 02077021	A	03-10-2002	CA	2439431 A1	03-10-2002
			EP	1373513 A2	02-01-2004
			WO	02077021 A2	03-10-2002
WO 02059148	A	01-08-2002	AT	410798 B	25-07-2003
			AT	1302001 A	15-12-2002
			BR	0207067 A	15-06-2004
			CA	2436057 A1	01-08-2002
			CZ	20032201 A3	17-03-2004
			WO	02059148 A2	01-08-2002
			EP	1355930 A2	29-10-2003
			NO	20033364 A	24-09-2003

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

❑ **BLACK BORDERS**

❑ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☑ **FADED TEXT OR DRAWING**

☑ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

❑ **SKEWED/SLANTED IMAGES**

❑ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

❑ **GRAY SCALE DOCUMENTS**

☑ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☑ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

❑ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.
As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.